[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fajhmdqA0bHW8SxLxr7iqKd9151rKhxzQQfBJZdY-pNA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":39,"phaseBuckets":90,"rows":97},"Sun Yat-sen University",[4,6],"Sun Yat-Sen University Cancer Center",1635,false,547,283,3243350,480,599,[15,18,21,24,27,30,33,36],{"name":16,"count":17},"Nasopharyngeal Carcinoma",140,{"name":19,"count":20},"Hepatocellular Carcinoma",130,{"name":22,"count":23},"Non-small Cell Lung Cancer",41,{"name":25,"count":26},"Colorectal Cancer",39,{"name":28,"count":29},"Breast Cancer",37,{"name":31,"count":32},"Cataract",30,{"name":34,"count":35},"Rectal Cancer",23,{"name":37,"count":38},"Nasopharyngeal Cancinoma (NPC)",21,[40,45,50,55,60,65,70,75,80,85],{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03869034","HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC","2020-07-20","HAIC+PD1",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT02460887","The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT","2022-04","Gemcitabine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03493048","Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM","2022-12-30","Irinotecan",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT02572141","FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","2023-03-15","Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT03561740","A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients","2023-06-15","capecitabine",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05319574","SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer","2023-06-25","Tislelizumab",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT03847857","Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage (PLACE030)","2023-07-01","Porcine Fibrin Sealant",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT04127227","Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer\u002FT-cell Lymphoma, Nasal Type","2023-07-20","sintilimab,pegaspargase,gemcitabine,oxaliplatin",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04715633","PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR\u002FMSI-H Colorectal Cancer","2023-08-30","PD-1 inhibitor plus VEGF inhibitors",{"nctId":86,"briefTitle":87,"date":88,"intervention":89},"NCT05011487","Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC","2023-09-01","Osimertinib",[91,92,93,94,95,96],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[98,127,159,224,910,1256,1602,1895,2169,2350,2484,2632,2835,3069,3236,3427,3528,3575,3629,3682,3736,3851,3941,3997,4076,4114,4163,4202,4247,4367,4414,4492,4530,4561,4601,4672,4719,4794,4849,4881,4919,4941,4963,4988,5010,5032,5059,5086,5111,5137,5216,5272,5332,5372,5406,5437,5466,5491,5513,5535,5559,5583,5601,5626,5644,5662,5680,5698,5723,5746,5772,5790,5816,5834,5858,5876,5901,5919,5945,5963,5981,6003,6028,6046,6072,6090,6115,6133,6160,6178,6196,6214,6232,6250,6274,6292,6315,6341,6359,6377,6399,6417,6443,6461,6489,6513,6531,6556,6581,6606,6624,6648,6666,6690,6716,6734,6758,6782,6800,6822,6840,6858,6876,6904,6922,6940,6958,6976,6994,7022,7046,7064,7088,7106,7124,7150,7170,7188,7206,7233,7251,7269,7287,7309,7327,7358,7390,7415,7543,7616,7686,7750,7791,7824,7905,7961,8008,8054,8087,8117,8159,8209,8241,8281,8307,8351,8377,8405,8432,8454,8482,8508,8530,8552,8579,8603,8625,8654,8682,8709,8731,8753,8814,8840,8865,8908,8946,8980,9024,9052,9082,9139,9172,9212,9254,9282,9307,9329,9360,9394,9420,9459,9481,9506,9524,9546,9564,9582,9606,9629,9647,9669,9687,9705,9730,9753,9778,9802,9827,9845,9863,9888,9906,9930,9952,9970,9988,10006,10029,10054,10078,10096,10117,10142,10160,10184,10202,10220,10244,10267,10285,10307,10331,10349,10367,10385,10408,10432,10450,10473,10491,10515,10537,10561,10579,10597,10619,10637,10655,10680,10698,10716,10734,10752,10770,10788,10806,10827,10849,10874,10892,10916,10938,10962,10987,11005,11030,11048,11071,11089,11112,11130,11148,11166,11184,11202,11220,11242,11264,11287,11305,11323,11341,11359,11382,11400,11422,11440,11458,11476,11494,11518,11536,11554,11572,11596,11614,11636,11659,11684,11708,11731,11753,11776,11800,11818,11845,11863,11881,11899,11917,11943,11961,11979,12004,12022,12040,12058,12076,12100,12121,12141,12159,12177,12195,12218,12236,12254,12276,12300,12323,12341,12359,12377,12395,12418,12436,12458,12481,12499,12524,12542,12565,12587,12609,12631,12649,12667,12685,12703,12721,12739,12757,12775,12793,12811,12832,12855,12873,12891,12909,12931,12956,12974,12996,13014,13035,13053,13071,13089,13107,13125,13143,13161,13186,13204,13222,13240,13258,13283,13301,13319,13337,13359,13381,13399,13419,13444,13462,13480,13498,13519,13537,13558,13582,13606,13631,13649,13667,13689,13707,13730,13748,13766,13795,13813,13831,13849,13867,13889,13914,13937,13955,13973,13991,14018,14040,14063,14081,14105,14123,14147,14165,14183,14201,14219,14240,14330,14356,14383,14413,14435,14463,14489,14512,14535,14559,14584,14602,14620,14643,14664,14682,14711,14753,14775,14813,14848,14870,14894,14922,14940,14963,14987,15005,15023,15049,15067,15091,15109,15133,15155,15179,15201,15225,15247,15265,15289,15313,15337,15361,15397,15431,15464,15498,15533,15567,15592,15610,15628,15650,15674,15692,15713,15741,15762,15788,15806,15824,15848,15872,15890,15908,15934,15952,15970,15992,16018,16036,16059,16080,16106,16124,16142,16160,16178,16200,16223,16241,16264,16289,16307,16330,16348,16371,16389,16415,16433,16459,16477,16495,16519,16537,16562,16580,16598,16616,16642,16660,16678,16701,16719,16737,16755,16776,16799,16824,16842,16860,16882,16905,16928,16946,16999,17025,17064,17094,17120,17151,17177,17203,17229,17251,17273,17295,17327,17357,17389,17411,17442,17466,17484,17502,17526,17544,17567,17585,17603,17626,17644,17667,17685,17703,17727,17745,17763,17784,17809,17832,17850,17868,17890,17908,17926,17944,17969,17991,18015,18033,18056,18074,18092,18110,18128,18150,18168,18193,18211,18237,18261,18279,18303,18326,18344,18365,18393,18411,18429,18447,18474,18492,18517,18535,18553,18576,18594,18617,18635,18659,18677,18698,18716,18739,18757,18779,18803,18821,18843,18867,18890,18908,18926,18948,18966,18984,19002,19020,19042,19060,19082,19104,19128,19146,19164,19187,19205,19223,19241,19259,19277,19301,19319,19337,19355,19377,19399,19424,19449,19467,19489,19507,19532,19550,19568,19589,19612,19637,19655,19676,19700,19718,19745,19763,19781,19821,19851,19877,19913,19935,19957,19979,20005,20034,20060,20082,20109,20131,20163,20185,20207,20231,20252,20275,20293,20311,20338,20356,20380,20401,20425,20446,20472,20496,20514,20532,20550,20568,20591,20615,20636,20661,20684,20702,20724,20746,20768,20793,20815,20837,20855,20873,20891,20909,20932,20954,20976,20999,21021,21046,21068,21086,21109,21134,21155,21179,21202,21220,21242,21264,21286,21308,21331,21353,21375,21397,21421,21439,21461,21485,21513,21531,21549,21573,21591,21609,21632,21650,21674,21692,21710,21732,21753,21771,21792,21817,21835,21857,21875,21898,21919,21942,21965,21988,22011,22029,22051,22072,22093,22114,22135,22157,22181,22202,22226,22247,22272,22290,22313,22334,22352,22376,22394,22417,22440,22461,22485,22503,22521,22539,22561,22582,22605,22632,22650,22668,22686,22708,22730,22752,22773,22795,22813,22831,22849,22867,22885,22907,22929,22951,22974,22999,23017,23035,23057,23078,23100,23121,23146,23168,23189,23207,23230,23252,23273,23296,23318,23336,23361,23383,23406,23428,23450,23471,23494,23516,23540,23558,23581,23599,23620,23644,23662,23680,23703,23727,23748,23769,23792,23810,23832,23854,23876,23899,23917,23939,23957,23975,23993,24011,24029,24047,24069,24087,24105,24129,24147,24169,24192,24210,24233,24255,24273,24296,24320,24344,24369,24387,24412,24430,24455,24473,24494,24517,24538,24560,24584,24607,24629,24650,24672,24693,24714,24732,24750,24768,24791,24817,24835,24853,24876,24894,24916,24938,24960,24982,25000,25022,25040,25058,25076,25094,25112,25134,25157,25178,25201,25225,25247,25269,25293,25316,25338,25361,25382,25407,25425,25456,25482,25504,25530,25548,25566,25584,25602,25624,25648,25666,25684,25775,25822,25862,25894,25920,25953,25975,25997,26024,26055,26079,26104,26133,26165,26194,26216,26239,26261,26284,26302,26326,26344,26370,26388,26406,26429,26453,26471,26495,26513,26537,26555,26577,26601,26626,26648,26673,26696,26714,26732,26755,26773,26791,26818,26841,26867,26885,26903,26921,26943,26964,26986,27007,27032,27050,27068,27086,27104,27126,27144,27165,27188,27211,27229,27251,27269,27291,27314,27332,27355,27378,27402,27423,27446,27464,27486,27514,27532,27550,27568,27586,27604,27622,27640,27663,27681,27703,27727,27745,27763,27784,27802,27820,27842,27860,27878,27896,27919,27937,27959,27977,27998,28016,28034,28056,28074,28097],{"intervention":99,"totalTrials":100,"cells":101},"vnacicizumab",1,{"EARLY_PHASE1":102,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":111,"NA":125},{"trials":103,"activeCount":104},[],0,{"trials":106,"activeCount":104},[],{"trials":108,"activeCount":104},[],{"trials":110,"activeCount":104},[],{"trials":112,"activeCount":100,"soonestReadout":118},[113],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT06770088","Vunakizumab in Adults with Spondyloarthritis","NOT_YET_RECRUITING",[95],"2026-01-10","2027-12-31","2025-01-10",880,[123],"Spondyloarthritis (SpA)",[99],{"trials":126,"activeCount":104},[],{"intervention":128,"totalTrials":100,"cells":129},"Penehyclidine hydrochloride",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":157},{"trials":131,"activeCount":104},[],{"trials":133,"activeCount":104},[],{"trials":135,"activeCount":104},[],{"trials":137,"activeCount":104},[],{"trials":139,"activeCount":100,"soonestReadout":145},[140],{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":155},"NCT06624696","Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia","RECRUITING",[95],"2026-08-31","2026-09-30","2024-11-12",204,[150,151,152,153,154],"Respiratory Hypersensitivity","Perioperative Respiratory Adverse Events","Anticholinergics","Inhalation Therapy; Complications","High Risk",[128,156],"Normal Saline",{"trials":158,"activeCount":104},[],{"intervention":160,"totalTrials":161,"cells":162},"normal saline",5,{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":193,"NA":210},{"trials":164,"activeCount":104},[],{"trials":166,"activeCount":104},[],{"trials":168,"activeCount":104},[],{"trials":170,"activeCount":104},[171,184],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":182},"NCT02987907","The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.","UNKNOWN",[94],"2019-07","2019-08","2016-08",220,[181],"HepatoCellular Carcinoma",[183,156],"Dexamethasone",{"nctId":185,"briefTitle":186,"status":174,"phases":187,"primaryCompletion":178,"completion":178,"start":188,"enrollment":189,"conditions":190,"interventions":191},"NCT01882621","Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients",[94],"2013-10",300,[22],[192,160],"Monosialoganglioside",{"trials":194,"activeCount":100,"soonestReadout":145},[195,199],{"nctId":141,"briefTitle":142,"status":143,"phases":196,"primaryCompletion":145,"completion":146,"start":147,"enrollment":148,"conditions":197,"interventions":198},[95],[150,151,152,153,154],[128,156],{"nctId":200,"briefTitle":201,"status":174,"phases":202,"primaryCompletion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT02691403","Quadratus Lumborum Block for Postoperative Analgesia After Colostomy Closure",[95],"2017-06","2016-03",50,[207],"Postoperative Pain",[209,160],"levo-bupivacaine",{"trials":211,"activeCount":104},[212],{"nctId":213,"briefTitle":214,"status":174,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT03608592","Human Umbilical Cord Mesenchymal Stem Cells (MSCs) Therapy in ARDS",[96],"2020-08-01","2020-12-01","2018-06-01",26,[221],"Acute Respiratory Distress Syndrome",[223,160],"umbilical cord derived mesenchymal stem cells (UCMSCs) suspension",{"intervention":225,"totalTrials":226,"cells":227},"Cisplatin",61,{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":245,"PHASE3":529,"PHASE4":887,"NA":889},{"trials":229,"activeCount":104},[],{"trials":231,"activeCount":100,"soonestReadout":236},[232],{"nctId":233,"briefTitle":234,"status":143,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":243},"NCT06900647","Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer",[92],"2026-06-30","2028-06-30","2025-01-01",20,[241,242],"Metastatic Breast Cancer","Recurrent Breast Cancer",[244,225,244,244,225],"Bortezomib",{"trials":246,"activeCount":528,"soonestReadout":88},[247,255,273,285,297,308,325,341,354,364,375,387,399,414,423,434,445,455,466,475,485,495,507,518],{"nctId":86,"briefTitle":87,"status":143,"phases":248,"primaryCompletion":88,"completion":249,"start":250,"enrollment":32,"conditions":251,"interventions":253},[93],"2028-09","2021-08-13",[252],"Non-Small Cell Lung Cancer",[89,225,254],"Pemetrexed",{"nctId":256,"briefTitle":257,"status":174,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":267},"NCT04974944","First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer",[93],"2023-12","2024-12","2021-07-30",172,[264,265,266],"Stage IVB Cervical Cancer","Recurrent Cervical Cancer","Persistent Cervical Cancer",[268,269,270,225,271,272],"Camrelizumab","Apatinib","Paclitaxel","Carboplatin","Bevacizumab",{"nctId":274,"briefTitle":275,"status":143,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT07325539","LDRT Combined With Toripalimab and Chemotherapy for Recurrent\u002FMetastatic NPC",[93],"2028-01-30","2030-01-30","2026-01-12",55,[37,282],"Nasopharangeal Cancer",[49,225,284],"Toripalimab",{"nctId":286,"briefTitle":287,"status":174,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":294},"NCT03668730","Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma",[93],"2021-12-31","2023-12-30","2018-10-19",215,[16],[295,225,296],"Paclitaxel liposome","5-Fluorouracil",{"nctId":298,"briefTitle":299,"status":300,"phases":301,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":307},"NCT03047265","Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","ACTIVE_NOT_RECRUITING",[93],"2025-12-01","2027-06-01","2017-02-04",164,[16],[270,225],{"nctId":309,"briefTitle":310,"status":143,"phases":311,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":315,"interventions":319},"NCT06904573","Probiotics in Advanced Urothelial Carcinoma",[93],"2027-01-01","2028-01-01",222,[316,317,318],"Advanced Urothelial Carcinoma","Probiotics","Immunotherapy",[320,321,225,49,322,323,324,284],"Probiotics Compound","Nab-paclitaxel","Disitamab vedotin","Enfortumab Vedotin","Pembrolizumab",{"nctId":326,"briefTitle":327,"status":328,"phases":329,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT04475016","TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer","COMPLETED",[93],"2022-05-06","2022-05-30","2020-08-12",29,[335],"Penile Cancer",[337,338,225,339,340],"Albumin-Bound Paclitaxel","Ifosfamide","Nimotuzumab","Triprilimab",{"nctId":342,"briefTitle":343,"status":174,"phases":344,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},"NCT05410197","Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)",[93],"2024-08-01","2025-08-01","2022-10-10",43,[350],"Advanced Biliary Tract Cancer",[352,353,49,225],"Envofolimab","Lenvatinib",{"nctId":355,"briefTitle":356,"status":143,"phases":357,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":362},"NCT06851247","GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.",[93],"2027-06","2025-01-03",47,[16],[284,363,49,225],"Anlotinib",{"nctId":365,"briefTitle":366,"status":328,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":373},"NCT03984357","Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma",[93],"2024-04-30","2025-03-30","2020-03-16",152,[16],[374,49,225],"PD-1 blocking antibody",{"nctId":376,"briefTitle":377,"status":143,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":348,"conditions":382,"interventions":384},"NCT05173246","JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma",[93],"2025-12-31","2026-12-31","2020-11-17",[383],"Esophageal Small Cell Carcinoma",[385,386,225,271],"JS001","nab-paclitaxel",{"nctId":388,"briefTitle":389,"status":328,"phases":390,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":395,"interventions":397},"NCT03175939","Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma",[93],"2008-12-31","2014-12-31","1998-04-01",263,[396],"Nasopharyngeal Cancer",[225,398],"5-FU",{"nctId":400,"briefTitle":401,"status":143,"phases":402,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":407,"interventions":409},"NCT07583511","Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study",[93],"2027-05-01","2027-12-01","2024-02-01",90,[408],"Small-cell Lung Cancer",[410,411,412,413],"Teniposide","Etoposide","serplulimab","cisplatin",{"nctId":415,"briefTitle":416,"status":300,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":23,"conditions":421,"interventions":422},"NCT05524168","SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma",[93],"2025-06-06","2026-12","2022-11-25",[16],[268,49,225],{"nctId":424,"briefTitle":425,"status":174,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":432},"NCT02421640","Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC",[93],"2017-03","2020-03","2015-03",116,[16],[433,225],"Cisplatin+TIL",{"nctId":435,"briefTitle":436,"status":328,"phases":437,"primaryCompletion":204,"completion":438,"start":439,"enrollment":205,"conditions":440,"interventions":442},"NCT02360501","Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma",[93],"2016-04","2008-01",[441],"Nasopharyngeal Neoplasms",[443,225,444],"Docetaxel","Capecitabine",{"nctId":446,"briefTitle":447,"status":174,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":430,"conditions":451,"interventions":453},"NCT00634595","Trial of E10A in Head and Neck Cancer",[93],"2010-12","2008-03",[452,16],"Head and Neck Squamous Carcinoma",[454,225,270],"E10A",{"nctId":456,"briefTitle":457,"status":174,"phases":458,"primaryCompletion":459,"completion":460,"start":429,"enrollment":461,"conditions":462,"interventions":464},"NCT02325986","Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer",[93],"2016-12","2017-12",46,[463],"Esophageal Squamous Cell Carcinoma",[465,225],"fluorouracil",{"nctId":467,"briefTitle":468,"status":143,"phases":469,"primaryCompletion":419,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT06323239","SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r\u002Fm Nasopharyngeal Carcinoma",[93],"2028-12","2024-07-15",148,[16],[284,49,225],{"nctId":476,"briefTitle":477,"status":328,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":205,"conditions":481,"interventions":482},"NCT04548440","Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients",[93],"2022-12-31","2020-08-31",[463],[483,484,225],"Sintilimab","Nab paclitaxel",{"nctId":486,"briefTitle":487,"status":174,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":494},"NCT03619824","PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma",[93],"2019-10","2024-03","2019-01",40,[441],[483,49,225],{"nctId":496,"briefTitle":497,"status":300,"phases":498,"primaryCompletion":379,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":506},"NCT05975307","Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation",[93],"2029-12-31","2023-12-01",71,[503,504,505],"Muscle-Invasive Bladder Carcinoma","Programmed Cell Death Protein 1 Inhibitor","Radiotherapy",[284,49,225,271],{"nctId":508,"briefTitle":509,"status":116,"phases":510,"primaryCompletion":511,"completion":512,"start":513,"enrollment":514,"conditions":515,"interventions":516},"NCT07110558","Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma",[93],"2029-08-14","2032-08-14","2025-08-15",59,[37],[517,225],"PD-1 antibody",{"nctId":519,"briefTitle":520,"status":174,"phases":521,"primaryCompletion":522,"completion":53,"start":523,"enrollment":29,"conditions":524,"interventions":526},"NCT03020329","Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma",[93],"2020-12-30","2016-11-14",[16,525],"Children",[295,225,527],"5-fu",11,{"trials":530,"activeCount":886,"soonestReadout":48},[531,543,558,569,579,591,604,614,622,632,642,653,665,674,685,692,704,717,729,740,750,759,769,778,786,796,803,814,824,835,846,856,867,877],{"nctId":532,"briefTitle":533,"status":328,"phases":534,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":540},"NCT01824459","S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients",[94],"2018-12-01","2013-04",576,[539],"Gastric Cancer",[541,542,225],"S-1","Oxaliplatin",{"nctId":544,"briefTitle":545,"status":116,"phases":546,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":552},"NCT03503136","Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC",[94],"2024-06","2026-06","2018-06",632,[16],[553,554,555,413,556,557],"docetaxel, nedaplatin, and capecitabine","nedaplatin","docetaxel, cisplatin, and fluorouracil","docetaxel, cisplatin, and capecitabine","docetaxel, nedaplatin, and fluorouracil",{"nctId":559,"briefTitle":560,"status":174,"phases":561,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":568},"NCT03837808","Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma",[94],"2024-02-11","2019-04-11",384,[16,441,566,567],"Nasopharyngeal Diseases","Head and Neck Neoplasm",[339,225],{"nctId":570,"briefTitle":571,"status":174,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":578},"NCT03700476","Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma",[94],"2023-02-28","2025-01","2018-12-21",425,[441],[483,49,225],{"nctId":580,"briefTitle":581,"status":328,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":589},"NCT03387774","Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients",[94],"2021-12-28","2024-01-31","2018-01-30",179,[588],"Oral Mucositis (Ulcerative) Due to Radiation",[225,590],"Ulinastatin",{"nctId":592,"briefTitle":593,"status":116,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":600},"NCT07524413","Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2030-04","2032-04","2026-04",514,[37,396],[601,602,603,225],"Becotatug Vedotin","Pucotenlimab","Gemcitabine + cisplatin",{"nctId":605,"briefTitle":606,"status":143,"phases":607,"primaryCompletion":608,"completion":609,"start":513,"enrollment":610,"conditions":611,"interventions":613},"NCT07125755","Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma",[94],"2028-08-15","2031-08-15",386,[612],"Squamous Cell Cancer of Head and Neck (SCCHN)",[225],{"nctId":615,"briefTitle":616,"status":174,"phases":617,"primaryCompletion":260,"completion":260,"start":618,"enrollment":619,"conditions":620,"interventions":621},"NCT02512315","A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma",[94],"2015-08",192,[16],[443,225],{"nctId":623,"briefTitle":624,"status":143,"phases":625,"primaryCompletion":419,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT04436965","Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition",[94],"2029-12","2021-08-16",266,[16,630],"Nutrition Therapy",[225],{"nctId":633,"briefTitle":634,"status":174,"phases":635,"primaryCompletion":636,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":641},"NCT02610010","Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma",[94],"2022-11","2025-11","2015-11",462,[16],[225],{"nctId":643,"briefTitle":644,"status":300,"phases":645,"primaryCompletion":145,"completion":646,"start":647,"enrollment":648,"conditions":649,"interventions":650},"NCT03840421","GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2028-12-31","2019-04-03",468,[16,441,566,567],[651,652,413],"gemcitabine and cisplatin","cisplatin and fluorouracil",{"nctId":654,"briefTitle":655,"status":174,"phases":656,"primaryCompletion":657,"completion":658,"start":459,"enrollment":659,"conditions":660,"interventions":663},"NCT03002064","Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients",[94],"2019-12","2020-12",358,[661,662],"Esophagus Cancer","Chemotherapy Effects",[443,664,225],"Fluorouracil",{"nctId":666,"briefTitle":667,"status":143,"phases":668,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":673},"NCT04136886","Concurrent Chemotherapy for Recurrent T3\u002FT4 Nasopharyngeal Carcinoma",[94],"2027-12","2020-01-01",346,[16],[225],{"nctId":675,"briefTitle":676,"status":116,"phases":677,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":682,"interventions":683},"NCT07373990","Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma",[94],"2028-04-30","2030-12-31","2026-01-15",418,[37,396],[684,684,603,225],"tislelizumab",{"nctId":686,"briefTitle":687,"status":174,"phases":688,"primaryCompletion":658,"completion":658,"start":638,"enrollment":179,"conditions":689,"interventions":691},"NCT02595554","Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer",[94],[690],"Cervical Carcinoma Stage IIB",[270,225],{"nctId":693,"briefTitle":694,"status":174,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":703},"NCT03071289","A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer",[94],"2025-03-31","2017-06-01",540,[700,701,702],"Cervical Cancer","Lymphocyst","Radiation Therapy",[225],{"nctId":705,"briefTitle":706,"status":143,"phases":707,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":716},"NCT05357846","PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)",[94],"2031-01-01","2031-01-31","2022-11-01",422,[713,714,715],"Squamous Cell Esophageal Carcinoma","Esophageal Cancer","Oesophageal Cancer",[483,270,225],{"nctId":718,"briefTitle":719,"status":116,"phases":720,"primaryCompletion":721,"completion":646,"start":722,"enrollment":723,"conditions":724,"interventions":728},"NCT04890522","An Open-label, Multicentre, Phase II\u002FIII RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC",[93,94],"2023-12-31","2021-07-01",622,[16,725,726,318,727],"Metastasis","Chemotherapy","Survival",[340,225,296,49],{"nctId":730,"briefTitle":731,"status":174,"phases":732,"primaryCompletion":733,"completion":346,"start":216,"enrollment":734,"conditions":735,"interventions":737},"NCT04502641","Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial",[94],"2023-08-01",160,[736],"Hypopharyngeal Cancer",[443,738,225,739],"5-fluorouracil","Platinum",{"nctId":741,"briefTitle":742,"status":143,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT06239727","Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response",[94],"2027-02-20","2030-02-20","2024-03-01",593,[16],[374,49,225,225,444],{"nctId":751,"briefTitle":752,"status":174,"phases":753,"primaryCompletion":429,"completion":429,"start":754,"enrollment":755,"conditions":756,"interventions":757},"NCT00677118","Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2006-06",506,[16],[758,225],"Cisplatin,fluorouracil",{"nctId":760,"briefTitle":761,"status":174,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":767},"NCT02465736","Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)",[94],"2025-07","2015-07",610,[463,714,715],[443,225,768,225],"Vinorelbine",{"nctId":770,"briefTitle":771,"status":116,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":777},"NCT07540390","GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.",[94],"2032-12-31","2026-05-08",442,[16],[284,363,225,49],{"nctId":779,"briefTitle":780,"status":143,"phases":781,"primaryCompletion":302,"completion":404,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT05854849","Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC",[94],"2023-05-01",244,[16],[268,49,225,269],{"nctId":787,"briefTitle":788,"status":300,"phases":789,"primaryCompletion":790,"completion":791,"start":733,"enrollment":792,"conditions":793,"interventions":794},"NCT05587374","Cadonilimab (PD-1\u002FCTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)",[94],"2027-08-01","2029-08-01",490,[16,396],[795,49,225],"Cadonilimab",{"nctId":46,"briefTitle":47,"status":300,"phases":797,"primaryCompletion":48,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":802},[94],"2025-04","2015-06",236,[16],[49,413,413],{"nctId":804,"briefTitle":805,"status":143,"phases":806,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":811,"interventions":812},"NCT06749899","QL1706 (PD-1\u002FCTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.",[94],"2028-12-01","2030-12-01","2025-05-04",580,[37,396],[813,49,225],"QL1706",{"nctId":815,"briefTitle":816,"status":174,"phases":817,"primaryCompletion":818,"start":819,"enrollment":820,"conditions":821,"interventions":822},"NCT02633176","Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma",[94],"2023-01","2015-01",120,[16],[823,225,443,444],"Cetuximab",{"nctId":825,"briefTitle":826,"status":328,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":833},"NCT01540136","Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma",[94],"2014-05","2016-07","2012-02",402,[16],[834,225],"Nedaplatin",{"nctId":836,"briefTitle":837,"status":116,"phases":838,"primaryCompletion":313,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":843},"NCT07385079","Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma",[94],"2030-01-01","2026-03-01",412,[37,396],[844,49,225,845],"Anlotinib Hydrochloride","Benmelstobart",{"nctId":847,"briefTitle":848,"status":300,"phases":849,"primaryCompletion":850,"completion":851,"start":852,"enrollment":853,"conditions":854,"interventions":855},"NCT04907370","PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma",[94],"2025-03-01","2027-03-01","2021-08-01",532,[16],[374,49,225,225],{"nctId":857,"briefTitle":858,"status":116,"phases":859,"primaryCompletion":860,"completion":861,"start":862,"enrollment":262,"conditions":863,"interventions":866},"NCT05433597","A Two-blinded, Multicentre, Phase II\u002FIII RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC",[93,94],"2024-07-01","2029-07-01","2022-07-01",[16,864,865],"TNF","Chemo-radiotherapy",[527,225,864],{"nctId":868,"briefTitle":869,"status":116,"phases":870,"primaryCompletion":871,"completion":872,"start":302,"enrollment":873,"conditions":874,"interventions":875},"NCT07238569","Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma",[94],"2029-12-01","2031-05-23",516,[37,282],[876,225,444],"Adebrelimab",{"nctId":878,"briefTitle":879,"status":328,"phases":880,"primaryCompletion":881,"completion":882,"start":638,"enrollment":883,"conditions":884,"interventions":885},"NCT02633202","Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era",[94],"2020-08-04","2021-10-11",338,[16],[225],19,{"trials":888,"activeCount":104},[],{"trials":890,"activeCount":100,"soonestReadout":895},[891,901],{"nctId":892,"briefTitle":893,"status":143,"phases":894,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":900},"NCT05352321","Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma",[96],"2025-06-01","2028-06-01","2022-06-01",264,[16],[49,225],{"nctId":902,"briefTitle":903,"status":904,"phases":905,"primaryCompletion":906,"completion":907,"start":429,"enrollment":104,"conditions":908,"interventions":909},"NCT02289807","Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy","WITHDRAWN",[96],"2020-08","2022-08",[16],[225],{"intervention":284,"totalTrials":911,"cells":912},36,{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":1139,"PHASE4":1219,"NA":1221},{"trials":914,"activeCount":104},[],{"trials":916,"activeCount":104},[],{"trials":918,"activeCount":1138,"soonestReadout":1064},[919,929,936,945,953,962,971,982,986,990,1001,1011,1022,1031,1046,1050,1060,1070,1079,1088,1099,1103,1113,1124,1128],{"nctId":920,"briefTitle":921,"status":174,"phases":922,"primaryCompletion":522,"completion":923,"start":924,"enrollment":348,"conditions":925,"interventions":928},"NCT03811379","Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy",[93],"2021-12-30","2018-11-21",[926,927],"Small Cell Carcinoma of Esophagus","Advanced Cancer",[284],{"nctId":930,"briefTitle":931,"status":143,"phases":932,"primaryCompletion":380,"completion":646,"start":746,"enrollment":17,"conditions":933,"interventions":935},"NCT06187597","Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)",[93],[934],"Locally Advanced Esophageal Squamous Cell Carcinoma",[541,284],{"nctId":937,"briefTitle":938,"status":143,"phases":939,"primaryCompletion":940,"completion":499,"start":941,"enrollment":942,"conditions":943,"interventions":944},"NCT07378306","FMD and Neoadjuvant Chemo-immunotherapy in TNBC",[93],"2029-06-30","2026-03-05",80,[28],[726,284],{"nctId":946,"briefTitle":947,"status":174,"phases":948,"primaryCompletion":381,"completion":949,"start":950,"enrollment":32,"conditions":951,"interventions":952},"NCT04169399","Toripalimab Plus Stereotactic Body Radiotherapy for HCC With PVTT",[93],"2021-01-01","2019-11-17",[19],[284],{"nctId":954,"briefTitle":955,"status":174,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":961},"NCT04170179","Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis",[93],"2021-04-01","2019-11-19",25,[19],[353,284],{"nctId":963,"briefTitle":964,"status":904,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":104,"conditions":969,"interventions":970},"NCT03919383","Phase II of Lenvatinib Plus Toripalimab for Advanced HCC",[93],"2019-12-01","2019-12-31","2019-04-15",[19],[353,284],{"nctId":972,"briefTitle":973,"status":116,"phases":974,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":979,"interventions":980},"NCT07320963","Chidamide in Combination With Toripalimab and Anlotinib in Recurrent\u002FMetastatic Nasopharyngeal Carcinoma.",[92,93],"2027-03-28","2028-03-28","2026-03-31",52,[16],[981,284,363],"Chidamide",{"nctId":274,"briefTitle":275,"status":143,"phases":983,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":984,"interventions":985},[93],[37,282],[49,225,284],{"nctId":309,"briefTitle":310,"status":143,"phases":987,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":988,"interventions":989},[93],[316,317,318],[320,321,225,49,322,323,324,284],{"nctId":991,"briefTitle":992,"status":174,"phases":993,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":997,"interventions":998},"NCT04135690","HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial",[93],"2023-12-20","2019-10-20",60,[19],[284,999,1000],"Sorafenib","systemic treatment",{"nctId":1002,"briefTitle":1003,"status":116,"phases":1004,"primaryCompletion":1005,"completion":1005,"start":1006,"enrollment":1007,"conditions":1008,"interventions":1010},"NCT06987123","TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial",[93],"2029-06-01","2025-05-18",62,[1009],"Nasopharyngeal Carcinoma (NPC)",[284,444],{"nctId":1012,"briefTitle":1013,"status":143,"phases":1014,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1021},"NCT06547203","Cetuximab, Irinotecan, Toripalimab in RAS\u002FBRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study",[93],"2026-07-30","2029-07-30","2024-07-18",34,[1020],"Colorectal Cancer Metastatic",[823,284,54],{"nctId":1023,"briefTitle":1024,"status":174,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":949,"enrollment":32,"conditions":1028,"interventions":1030},"NCT04627363","HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama",[93],"2022-06-30","2023-06-30",[19,272,1029,284,542],"Liver Neoplasms",[272,284],{"nctId":1032,"briefTitle":1033,"status":328,"phases":1034,"primaryCompletion":1035,"completion":1036,"start":1037,"enrollment":959,"conditions":1038,"interventions":1045},"NCT05060471","PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients",[93],"2024-06-21","2024-11-27","2021-10-27",[1039,1040,1041,1042,1043,1044],"Anal Canal Cancer","Anal Squamous Cell Carcinoma","Anal Cancer","Anal Canal Cancer Stage I","Anal Canal Cancer Stage II","Anal Canal Cancer Stage III",[284],{"nctId":355,"briefTitle":356,"status":143,"phases":1047,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":1048,"interventions":1049},[93],[16],[284,363,49,225],{"nctId":1051,"briefTitle":1052,"status":174,"phases":1053,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1057,"interventions":1058},"NCT04844385","Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma",[93],"2024-12-20","2021-02-20",124,[463],[284,1059,834,444],"Paclitaxel-albumin",{"nctId":1061,"briefTitle":1062,"status":300,"phases":1063,"primaryCompletion":1064,"completion":119,"start":1065,"enrollment":1066,"conditions":1067,"interventions":1069},"NCT06618014","Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)",[93],"2024-12-31","2022-01-11",51,[28,1068],"Triple Negative Breast Cancer",[284,443,271],{"nctId":1071,"briefTitle":1072,"status":143,"phases":1073,"primaryCompletion":1074,"completion":1074,"start":1075,"enrollment":1076,"conditions":1077,"interventions":1078},"NCT06912711","TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma",[93],"2029-04-20","2025-05-16",70,[16],[284,339],{"nctId":1080,"briefTitle":1081,"status":116,"phases":1082,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":1084,"conditions":1085,"interventions":1086},"NCT07555860","Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma",[93],"2026-04-20",28,[16],[601,284,268,1087],"Intensity-Modulated Radiotherapy",{"nctId":1089,"briefTitle":1090,"status":1091,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT04418648","Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy","TERMINATED",[93],"2024-05-31","2020-06-01",170,[1097],"Small Cell Lung Cancer Limited Stage",[284],{"nctId":467,"briefTitle":468,"status":143,"phases":1100,"primaryCompletion":419,"completion":470,"start":471,"enrollment":472,"conditions":1101,"interventions":1102},[93],[16],[284,49,225],{"nctId":1104,"briefTitle":1105,"status":143,"phases":1106,"primaryCompletion":1107,"completion":499,"start":1108,"enrollment":1109,"conditions":1110,"interventions":1112},"NCT03810339","Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors",[93],"2028-01-15","2019-01-15",35,[1111,927],"Solid Tumor",[284],{"nctId":1114,"briefTitle":1115,"status":116,"phases":1116,"primaryCompletion":1117,"completion":1118,"start":977,"enrollment":32,"conditions":1119,"interventions":1121},"NCT07469956","Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer",[93],"2028-01-31","2029-01-31",[1120],"Pancreatic Cancer Resectable",[1122,284,1123],"Surufatinib","mFOLFIRINOX",{"nctId":496,"briefTitle":497,"status":300,"phases":1125,"primaryCompletion":379,"completion":499,"start":500,"enrollment":501,"conditions":1126,"interventions":1127},[93],[503,504,505],[284,49,225,271],{"nctId":1129,"briefTitle":1130,"status":143,"phases":1131,"primaryCompletion":1132,"completion":1133,"start":1054,"enrollment":996,"conditions":1134,"interventions":1136},"NCT06735131","The Optimal Radioimmunotherapy Combinations for Advanced TNBC",[93],"2026-07","2027-01",[1135],"Triple-Negative Breast Cancer (TNBC)",[284,1137],"chemotherapy regimen selected by the investigator",16,{"trials":1140,"activeCount":1218,"soonestReadout":1177},[1141,1152,1160,1164,1173,1185,1196,1206],{"nctId":1142,"briefTitle":1143,"status":143,"phases":1144,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1150},"NCT07154069","Adaptive Immunotherapy for Nasopharyngeal Carcinoma",[94],"2031-09","2033-09","2025-11-13",802,[37],[444,1151,284],"Concurrent chemoradiotherapy",{"nctId":1153,"briefTitle":1154,"status":143,"phases":1155,"primaryCompletion":419,"completion":470,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1159},"NCT05340491","Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial",[94],"2022-04-01",212,[16],[284,726],{"nctId":770,"briefTitle":771,"status":116,"phases":1161,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":1162,"interventions":1163},[94],[16],[284,363,225,49],{"nctId":1165,"briefTitle":1166,"status":116,"phases":1167,"primaryCompletion":236,"completion":146,"start":236,"enrollment":1168,"conditions":1169,"interventions":1171},"NCT07371897","Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial",[94],154,[1170],"Head and Neck Squamous Cell Carcinoma HNSCC",[1172,284],"Docetaxel and Cisplatin",{"nctId":1174,"briefTitle":1175,"status":143,"phases":1176,"primaryCompletion":1177,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1184},"NCT04778956","Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma",[94],"2025-03-03","2033-03-03","2021-03-03",218,[16,1182,1183],"PD-1","Surgery",[284],{"nctId":1186,"briefTitle":1187,"status":143,"phases":1188,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1194},"NCT06201065","FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial",[94],"2025-07-26","2026-12-26","2023-12-26",200,[19],[353,284,1195],"oxaliplatin , fluorouracil, and leucovorin",{"nctId":1197,"briefTitle":1198,"status":143,"phases":1199,"primaryCompletion":646,"completion":646,"start":1200,"enrollment":1201,"conditions":1202,"interventions":1204},"NCT04365036","A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer\u002FT Cell Lymphoma, Nasal Type (ENKTL)",[94],"2020-05-03",207,[1203],"NK\u002FT Cell Lymphoma Nos",[284,1205,49,542],"Pegaspargase",{"nctId":1207,"briefTitle":1208,"status":143,"phases":1209,"primaryCompletion":1210,"completion":1211,"start":1212,"enrollment":1213,"conditions":1214,"interventions":1216},"NCT07177794","Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC",[94],"2028-05-31","2030-05-31","2025-09-10",242,[714,1215],"Chemoradiotherapy",[1217,64],"toripalimab",8,{"trials":1220,"activeCount":104},[],{"trials":1222,"activeCount":1255,"soonestReadout":1238},[1223,1234,1243],{"nctId":1224,"briefTitle":1225,"status":143,"phases":1226,"primaryCompletion":1227,"completion":1227,"start":949,"enrollment":1228,"conditions":1229,"interventions":1232},"NCT06323382","Locoregional Therapy Combined With Bevacizumab and PD1\u002FL1 Inhibitor in Advanced Hepatocellular Carcinoma",[],"2025-12-30",240,[1230,1231,272],"Advanced Hepatocellular Carcinoma","Anti-PD1\u002FPDL1 Antibody",[272,1233,69,284,483,268],"Atezolizumab",{"nctId":1235,"briefTitle":1236,"status":143,"phases":1237,"primaryCompletion":1238,"completion":1227,"start":949,"enrollment":189,"conditions":1239,"interventions":1242},"NCT06333561","HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma",[],"2024-12-30",[19,353,1240,1241],"PD-1 Inhibitor","Hepatic Arterial Infusion Chemotherapy",[353,69,284,483,268],{"nctId":1244,"briefTitle":1245,"status":328,"phases":1246,"primaryCompletion":923,"completion":73,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1252},"NCT04627012","Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma",[],"2018-01-01",600,[19,1250,1251],"Anti-PD1 Antibody","Liver Diseases",[353,1253,268,1254,284,483,69],"Opdivo","Keytruda",2,{"intervention":444,"totalTrials":29,"cells":1257},{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1465,"PHASE4":1598,"NA":1600},{"trials":1259,"activeCount":104},[],{"trials":1261,"activeCount":104},[],{"trials":1263,"activeCount":1464,"soonestReadout":1268},[1264,1273,1284,1297,1309,1321,1332,1343,1355,1359,1370,1382,1392,1396,1407,1419,1423,1433,1443,1455],{"nctId":1265,"briefTitle":1266,"status":300,"phases":1267,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":911,"conditions":1271,"interventions":1272},"NCT04940546","Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR\u002FMSS CRLM Patients",[92,93],"2023-10-30","2025-10-30","2021-06-16",[1020],[483,542,444,272],{"nctId":1274,"briefTitle":1275,"status":300,"phases":1276,"primaryCompletion":1277,"completion":1277,"start":500,"enrollment":1095,"conditions":1278,"interventions":1281},"NCT06281886","Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma",[93],"2026-12-01",[463,1279,1280],"Efficacy","Toxicity",[1282,1283,269,444],"Induction Immunotherapy-Toripalimab","Induction Chemotherapy-Albumin-paclitaxel combined with cisplatin",{"nctId":1285,"briefTitle":1286,"status":116,"phases":1287,"primaryCompletion":1288,"completion":380,"start":1083,"enrollment":1289,"conditions":1290,"interventions":1294},"NCT07549906","Neoadjuvant Iparomlimab\u002FTuvonralimab Plus CAPEOX Versus Iparomlimab\u002FTuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study",[93],"2026-07-31",45,[1291,318,1292,1293],"Colon Cancer (Stage II &Amp; III)","Beta Blocker","Neoadjuvant Chemoimmunotherapy",[1295,444,542,1296],"Iparomlimab\u002FTuvonralimab","Propranolol",{"nctId":1298,"briefTitle":1299,"status":143,"phases":1300,"primaryCompletion":1301,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1306},"NCT07392320","A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma",[93],"2031-02-10","2033-02-10","2026-02-10",142,[282],[1307,1308,444],"TP+PD1+CCRT","PD-1 Monoclonal Antibody",{"nctId":1310,"briefTitle":1311,"status":143,"phases":1312,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1320},"NCT06451211","Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer",[93],"2024-11","2027-11","2023-05-17",53,[1318,539,1319],"Stomach Neoplasms","Linitis Plastica of Stomach",[69,542,541,444],{"nctId":1322,"briefTitle":1323,"status":300,"phases":1324,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":1328,"interventions":1331},"NCT04304209","Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer",[93],"2026-10-18","2019-10-28",195,[1329,1330],"Colorectal Cancer Stage II","Colorectal Cancer Stage III",[542,444,483],{"nctId":1333,"briefTitle":1334,"status":174,"phases":1335,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":1339,"conditions":1340,"interventions":1342},"NCT01880658","Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer",[93],"2016-05","2019-05","2013-06",100,[1341],"Colorectal Neoplasms",[444],{"nctId":1344,"briefTitle":1345,"status":174,"phases":1346,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":1351,"interventions":1353},"NCT05980689","Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR\u002FMSS Locally Advanced Rectal Cancer",[93],"2024-06-30","2025-01-31","2023-10-24",33,[1352],"Locally Advanced Rectal Cancer",[1354,444],"AK104",{"nctId":1002,"briefTitle":1003,"status":116,"phases":1356,"primaryCompletion":1005,"completion":1005,"start":1006,"enrollment":1007,"conditions":1357,"interventions":1358},[93],[1009],[284,444],{"nctId":1360,"briefTitle":1361,"status":328,"phases":1362,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1369},"NCT05775900","Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS\u002FBRAF Wild-type Metastatic Colorectal Cancer",[92,93],"2025-07-31","2025-08-26","2023-02-01",24,[1368],"Metastatic Colorectal Cancer",[823,444],{"nctId":1371,"briefTitle":1372,"status":328,"phases":1373,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":1377,"interventions":1380},"NCT02004769","Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer",[93],"2016-06","2013-11",67,[1318,1378,1379],"Neoplasms Metastasis","ERBB2 Gene Amplification",[1381,443,444],"Trastuzumab",{"nctId":1383,"briefTitle":1384,"status":300,"phases":1385,"primaryCompletion":1386,"completion":1387,"start":1388,"enrollment":1389,"conditions":1390,"interventions":1391},"NCT05201859","Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma",[93],"2026-03-02","2029-03-02","2022-05-17",150,[16],[483,444],{"nctId":1051,"briefTitle":1052,"status":174,"phases":1393,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":1394,"interventions":1395},[93],[463],[284,1059,834,444],{"nctId":1397,"briefTitle":1398,"status":116,"phases":1399,"primaryCompletion":1400,"completion":237,"start":1401,"enrollment":1402,"conditions":1403,"interventions":1405},"NCT06790212","Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer",[93],"2027-08-30","2025-04-28",168,[1404],"Colon Cancer",[1406,542,444],"Ivonescimab",{"nctId":1408,"briefTitle":1409,"status":174,"phases":1410,"primaryCompletion":1411,"completion":1238,"start":1412,"enrollment":959,"conditions":1413,"interventions":1417},"NCT04301557","PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR\u002FMSI-H Locally Advanced Colorectal Cancer",[93],"2024-04-22","2020-07-31",[1414,1415,1416],"DMMR Colorectal Cancer","MSI-H Colorectal Cancer","Locally Advanced Colorectal Cancer",[1418,542,444],"PD-1 Antibody",{"nctId":435,"briefTitle":436,"status":328,"phases":1420,"primaryCompletion":204,"completion":438,"start":439,"enrollment":205,"conditions":1421,"interventions":1422},[93],[441],[443,225,444],{"nctId":1424,"briefTitle":1425,"status":174,"phases":1426,"primaryCompletion":1427,"completion":1428,"start":1429,"enrollment":1430,"conditions":1431,"interventions":1432},"NCT02027363","Maintenance Treatment With Capecitabine in Colorectal Cancer Patients",[93],"2013-12","2014-06","2010-01",245,[1341,1378],[444],{"nctId":1434,"briefTitle":1435,"status":143,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1365,"enrollment":911,"conditions":1438,"interventions":1442},"NCT05472948","Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma",[93],"2027-12-30",[1439,1440,1441],"Adenocarcinoma of Small Intestine","Appendix Carcinoma","Metastatic",[1122,483,444],{"nctId":1444,"briefTitle":1445,"status":174,"phases":1446,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":1451,"interventions":1453},"NCT04250948","Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer",[93],"2022-06-27","2024-10-05","2019-10-12",108,[539,1452],"Locally Advanced Solid Tumor",[385,542,1454,444],"S1",{"nctId":1456,"briefTitle":1457,"status":174,"phases":1458,"primaryCompletion":1459,"completion":1459,"start":1094,"enrollment":1460,"conditions":1461,"interventions":1462},"NCT04072107","EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)",[93],"2024-12-01",110,[16],[1463,444],"sintilimab",10,{"trials":1466,"activeCount":1464,"soonestReadout":63},[1467,1476,1485,1489,1495,1504,1514,1525,1533,1537,1547,1558,1562,1571,1580,1584,1588],{"nctId":1468,"briefTitle":1469,"status":143,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":1472,"enrollment":179,"conditions":1473,"interventions":1475},"NCT05044117","Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)",[94],"2026-10","2021-10-18",[1474],"Head and Neck Squamous Cell Carcinoma",[444],{"nctId":1477,"briefTitle":1478,"status":143,"phases":1479,"primaryCompletion":358,"completion":1480,"start":1481,"enrollment":1482,"conditions":1483,"interventions":1484},"NCT05342792","Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma",[94],"2029-06","2022-04-17",556,[16],[517,444],{"nctId":1142,"briefTitle":1143,"status":143,"phases":1486,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":1487,"interventions":1488},[94],[37],[444,1151,284],{"nctId":61,"briefTitle":62,"status":143,"phases":1490,"primaryCompletion":63,"completion":646,"start":1491,"enrollment":1492,"conditions":1493,"interventions":1494},[94],"2018-07-25",794,[28],[64],{"nctId":1496,"briefTitle":1497,"status":328,"phases":1498,"primaryCompletion":1499,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1503},"NCT02460419","Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma",[94],"2020-05","2015-04",104,[16],[64],{"nctId":1505,"briefTitle":1506,"status":143,"phases":1507,"primaryCompletion":1508,"completion":646,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1513},"NCT05236972","PACE: PD-1 Antibody For dMMR\u002FMSI-H Stage III Colorectal Cancer",[94],"2026-06-01","2022-01-01",323,[1512],"Colorectal Carcinoma",[483,542,64],{"nctId":1515,"briefTitle":1516,"status":174,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1523},"NCT05737563","PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC",[94],"2026-02-17","2023-02-17",380,[1522],"Esophageal Squamous Cell Carcinoma Abdominal Stage 0",[1524,54,444],"PD-1 Inhibitors",{"nctId":1526,"briefTitle":1527,"status":328,"phases":1528,"primaryCompletion":967,"completion":967,"start":1529,"enrollment":1530,"conditions":1531,"interventions":1532},"NCT01112826","Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer",[94],"2010-04-23",443,[28],[444],{"nctId":741,"briefTitle":742,"status":143,"phases":1534,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":1535,"interventions":1536},[94],[16],[374,49,225,225,444],{"nctId":1538,"briefTitle":1539,"status":116,"phases":1540,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":1544,"conditions":1545,"interventions":1546},"NCT06900218","PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma",[94],"2030-05-01","2033-05-01","2025-05-01",664,[1009],[483,444],{"nctId":1548,"briefTitle":1549,"status":143,"phases":1550,"primaryCompletion":1551,"completion":1107,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1556},"NCT06268652","Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer",[94],"2026-02-15","2024-01-15",302,[28,1555],"Refractory Breast Carcinoma",[49,444,768,1557],"Eribulin",{"nctId":815,"briefTitle":816,"status":174,"phases":1559,"primaryCompletion":818,"start":819,"enrollment":820,"conditions":1560,"interventions":1561},[94],[16],[823,225,443,444],{"nctId":1563,"briefTitle":1564,"status":328,"phases":1565,"primaryCompletion":1566,"completion":1566,"start":1567,"enrollment":394,"conditions":1568,"interventions":1569},"NCT02767661","Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer",[94],"2023-08-25","2017-07-19",[28],[444,1570],"Aromatase Inhibitor",{"nctId":1572,"briefTitle":1573,"status":174,"phases":1574,"primaryCompletion":1575,"completion":259,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1579},"NCT02958111","Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2021-12","2017-01",406,[16],[444],{"nctId":868,"briefTitle":869,"status":116,"phases":1581,"primaryCompletion":871,"completion":872,"start":302,"enrollment":873,"conditions":1582,"interventions":1583},[94],[37,282],[876,225,444],{"nctId":1207,"briefTitle":1208,"status":143,"phases":1585,"primaryCompletion":1210,"completion":1211,"start":1212,"enrollment":1213,"conditions":1586,"interventions":1587},[94],[714,1215],[1217,64],{"nctId":1589,"briefTitle":1590,"status":174,"phases":1591,"primaryCompletion":1592,"completion":490,"start":1593,"enrollment":1594,"conditions":1595,"interventions":1597},"NCT02288195","CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients",[94],"2021-03-17","2014-08-13",663,[1596],"Rectal Neoplasms",[542,64],{"trials":1599,"activeCount":104},[],{"trials":1601,"activeCount":104},[],{"intervention":483,"totalTrials":911,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1619,"PHASE3":1834,"PHASE4":1862,"NA":1864},{"trials":1605,"activeCount":104},[],{"trials":1607,"activeCount":104},[1608],{"nctId":1609,"briefTitle":1610,"status":174,"phases":1611,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1618},"NCT04400851","Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors",[92],"2021-10-10","2021-12-10","2020-08-11",18,[1617],"Pediatric Cancer",[483],{"trials":1620,"activeCount":1833,"soonestReadout":1268},[1621,1628,1632,1643,1653,1663,1673,1684,1695,1707,1717,1721,1733,1743,1751,1757,1770,1774,1784,1797,1807,1811,1815,1819,1823],{"nctId":1622,"briefTitle":1623,"status":143,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":88,"enrollment":348,"conditions":1626,"interventions":1627},"NCT06031285","Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial",[93],"2026-12-30",[19],[483],{"nctId":1265,"briefTitle":1266,"status":300,"phases":1629,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":911,"conditions":1630,"interventions":1631},[92,93],[1020],[483,542,444,272],{"nctId":1633,"briefTitle":1634,"status":116,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":1638,"conditions":1639,"interventions":1641},"NCT07487662","TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk",[93],"2028-03-17","2026-03-18",105,[1640],"Hepato Cellular Carcinoma (HCC)",[1463,1642,353],"ipilimumab N01",{"nctId":1644,"briefTitle":1645,"status":174,"phases":1646,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":32,"conditions":1650,"interventions":1652},"NCT04994210","Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL",[93],"2023-08-31","2025-08-31","2021-10-04",[1651],"Safety and Efficacy",[483,981],{"nctId":1654,"briefTitle":1655,"status":174,"phases":1656,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":492,"conditions":1659,"interventions":1661},"NCT04769908","Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis",[93],"2021-12-01","2021-02-23",[1660],"ICC",[1662,353,483],"Systemic Chemotherapy",{"nctId":1664,"briefTitle":1665,"status":174,"phases":1666,"primaryCompletion":1667,"completion":1668,"start":1657,"enrollment":29,"conditions":1669,"interventions":1670},"NCT05008666","Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH",[93],"2022-11-30","2023-04-30",[1651],[483,981,1671,1672],"Azacitidine","L-DEP",{"nctId":1674,"briefTitle":1675,"status":174,"phases":1676,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":1680,"conditions":1681,"interventions":1683},"NCT04831710","Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL",[93],"2022-04-15","2023-04-15","2021-04-15",83,[1682],"Angioimmunoblastic T-cell Lymphoma",[483,981],{"nctId":1685,"briefTitle":1686,"status":116,"phases":1687,"primaryCompletion":1688,"completion":1689,"start":1690,"enrollment":360,"conditions":1691,"interventions":1693},"NCT07574528","A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I\u002FII Extranodal NK\u002FT-Cell Lymphoma",[93],"2028-03-06","2031-05-06","2026-05-06",[1692],"NKTCL",[483,1205,1694],"Selinexor",{"nctId":1696,"briefTitle":1697,"status":328,"phases":1698,"primaryCompletion":923,"completion":923,"start":1699,"enrollment":280,"conditions":1700,"interventions":1706},"NCT03936452","Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK\u002FT Cell Lymphoma",[93],"2019-04-28",[1701,1702,363,1703,483,1704,1705,505],"Natural Killer\u002FT-Cell Lymphoma, Nasal and Nasal-Type","Early Stage","Peg-aspargase","Phase Two","Open",[483],{"nctId":1708,"briefTitle":1709,"status":300,"phases":1710,"primaryCompletion":379,"completion":380,"start":1711,"enrollment":1712,"conditions":1713,"interventions":1715},"NCT05481476","Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer",[93],"2022-12-12",32,[1714],"Pancreatic Neoplasms",[1122,483,1716],"AG",{"nctId":1322,"briefTitle":1323,"status":300,"phases":1718,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":1719,"interventions":1720},[93],[1329,1330],[542,444,483],{"nctId":1722,"briefTitle":1723,"status":174,"phases":1724,"primaryCompletion":1725,"completion":259,"start":1726,"enrollment":1727,"conditions":1728,"interventions":1731},"NCT04724239","Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR\u002FMSS Colorectal Carcinoma",[93],"2022-07-26","2021-03-11",48,[1729,1730],"Advanced Microsatellite Stable Colorectal Cancer","Metastatic Microsatellite-stable Colorectal Cancer",[483,981,1732],"IBI305",{"nctId":1734,"briefTitle":1735,"status":904,"phases":1736,"primaryCompletion":949,"completion":1737,"start":1738,"enrollment":104,"conditions":1739,"interventions":1741},"NCT04398927","Systemic Chemotherapy Plus PD-1 for Metastasis ICC",[93],"2021-02-01","2020-05-01",[1660,1740],"Metastatic Cancer",[1742,483],"Folfirinox",{"nctId":1744,"briefTitle":1745,"status":143,"phases":1746,"primaryCompletion":678,"completion":1747,"start":1748,"enrollment":17,"conditions":1749,"interventions":1750},"NCT06313190","Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)",[93],"2030-04-30","2024-04-05",[19],[483],{"nctId":1752,"briefTitle":1753,"status":904,"phases":1754,"primaryCompletion":1737,"completion":1737,"start":217,"enrollment":104,"conditions":1755,"interventions":1756},"NCT04682249","Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC",[93],[1660],[1662,483,269],{"nctId":1758,"briefTitle":1759,"status":143,"phases":1760,"primaryCompletion":380,"completion":119,"start":1761,"enrollment":820,"conditions":1762,"interventions":1764},"NCT06013618","Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory\u002F Relapsed Neuroblastoma",[93],"2023-06-19",[1763],"Neuroblastoma",[1765,1766,54,1767,1768,1769,483],"Naxitamab monotherapy","GM-CSF","Temozolomide","Naxitamab in combination therapy","GM-CSF with combination regimen",{"nctId":1383,"briefTitle":1384,"status":300,"phases":1771,"primaryCompletion":1386,"completion":1387,"start":1388,"enrollment":1389,"conditions":1772,"interventions":1773},[93],[16],[483,444],{"nctId":1775,"briefTitle":1776,"status":143,"phases":1777,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":1018,"conditions":1781,"interventions":1783},"NCT07518602","Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma",[93],"2028-03-27","2028-09-27","2026-03-27",[1782],"Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)",[981,483,272],{"nctId":1785,"briefTitle":1786,"status":143,"phases":1787,"primaryCompletion":1788,"completion":1789,"start":1790,"enrollment":32,"conditions":1791,"interventions":1795},"NCT07077512","Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed\u002FRefractory B-cell Lymphoma",[93],"2027-01-15","2027-07-15","2025-09-15",[1792,1793,1794],"Large B Cell Diffuse Lymphoma","Mantle Cell Lymphoma (MCL)","Follicular Lymphoma ( FL)",[1796,483],"Autoleucel",{"nctId":1798,"briefTitle":1799,"status":143,"phases":1800,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":29,"conditions":1804,"interventions":1806},"NCT05170503","Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma",[93],"2026-01-01","2029-01-01","2021-12-29",[1805],"Esophagogastric Junction Adenocarcinoma",[483],{"nctId":1434,"briefTitle":1435,"status":143,"phases":1808,"primaryCompletion":1437,"completion":1437,"start":1365,"enrollment":911,"conditions":1809,"interventions":1810},[93],[1439,1440,1441],[1122,483,444],{"nctId":476,"briefTitle":477,"status":328,"phases":1812,"primaryCompletion":479,"completion":479,"start":480,"enrollment":205,"conditions":1813,"interventions":1814},[93],[463],[483,484,225],{"nctId":486,"briefTitle":487,"status":174,"phases":1816,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":1817,"interventions":1818},[93],[441],[483,49,225],{"nctId":1456,"briefTitle":1457,"status":174,"phases":1820,"primaryCompletion":1459,"completion":1459,"start":1094,"enrollment":1460,"conditions":1821,"interventions":1822},[93],[16],[1463,444],{"nctId":1824,"briefTitle":1825,"status":174,"phases":1826,"primaryCompletion":1827,"completion":1827,"start":1828,"enrollment":996,"conditions":1829,"interventions":1832},"NCT04213170","Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer",[93],"2022-12","2019-04-29",[1830,1831,483,272],"Brain Metastases","Non Small Cell Lung Cancer",[1463],13,{"trials":1835,"activeCount":1861,"soonestReadout":1508},[1836,1840,1844,1848,1852],{"nctId":570,"briefTitle":571,"status":174,"phases":1837,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":1838,"interventions":1839},[94],[441],[483,49,225],{"nctId":1505,"briefTitle":1506,"status":143,"phases":1841,"primaryCompletion":1508,"completion":646,"start":1509,"enrollment":1510,"conditions":1842,"interventions":1843},[94],[1512],[483,542,64],{"nctId":705,"briefTitle":706,"status":143,"phases":1845,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":1846,"interventions":1847},[94],[713,714,715],[483,270,225],{"nctId":1538,"briefTitle":1539,"status":116,"phases":1849,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":1544,"conditions":1850,"interventions":1851},[94],[1009],[483,444],{"nctId":1853,"briefTitle":1854,"status":174,"phases":1855,"primaryCompletion":259,"completion":260,"start":658,"enrollment":1856,"conditions":1857,"interventions":1860},"NCT04682210","Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection",[94],246,[1858,1859,318],"HCC","Adjuvant Therapy",[483,272],3,{"trials":1863,"activeCount":104},[],{"trials":1865,"activeCount":1861,"soonestReadout":1238},[1866,1870,1879,1883,1891],{"nctId":1224,"briefTitle":1225,"status":143,"phases":1867,"primaryCompletion":1227,"completion":1227,"start":949,"enrollment":1228,"conditions":1868,"interventions":1869},[],[1230,1231,272],[272,1233,69,284,483,268],{"nctId":1871,"briefTitle":1872,"status":143,"phases":1873,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":32,"conditions":1877,"interventions":1878},"NCT06070636","bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma",[96],"2025-01-30","2025-06-30","2024-05-20",[1251,19,318,353,483],[353,483],{"nctId":1235,"briefTitle":1236,"status":143,"phases":1880,"primaryCompletion":1238,"completion":1227,"start":949,"enrollment":189,"conditions":1881,"interventions":1882},[],[19,353,1240,1241],[353,69,284,483,268],{"nctId":1884,"briefTitle":1885,"status":328,"phases":1886,"primaryCompletion":923,"completion":53,"start":949,"enrollment":32,"conditions":1887,"interventions":1890},"NCT04618367","HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT",[96],[1888,1029,483,1889],"Carcinoma, Hepatocellular","Portal Vein Tumor Thrombus",[353,483],{"nctId":1244,"briefTitle":1245,"status":328,"phases":1892,"primaryCompletion":923,"completion":73,"start":1247,"enrollment":1248,"conditions":1893,"interventions":1894},[],[19,1250,1251],[353,1253,268,1254,284,483,69],{"intervention":272,"totalTrials":32,"cells":1896},{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":2090,"PHASE4":2140,"NA":2142},{"trials":1898,"activeCount":104},[],{"trials":1900,"activeCount":104},[],{"trials":1902,"activeCount":2089,"soonestReadout":1268},[1903,1911,1915,1926,1930,1938,1948,1959,1968,1976,1983,1994,2005,2013,2021,2030,2034,2049,2053,2062,2071,2081],{"nctId":1904,"briefTitle":1905,"status":174,"phases":1906,"primaryCompletion":1907,"completion":1459,"start":1908,"enrollment":492,"conditions":1909,"interventions":1910},"NCT05886465","HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial",[93],"2024-06-01","2023-05-24",[19],[1233,272],{"nctId":1265,"briefTitle":1266,"status":300,"phases":1912,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":911,"conditions":1913,"interventions":1914},[92,93],[1020],[483,542,444,272],{"nctId":1916,"briefTitle":1917,"status":116,"phases":1918,"primaryCompletion":1005,"completion":1919,"start":1508,"enrollment":1920,"conditions":1921,"interventions":1923},"NCT07621497","FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)",[93],"2030-06-01",229,[1922],"Metastatic Colorectal Cancer (CRC)",[542,296,1924,1925,272,823],"Levofolinic Acid For","Calcium Folinate",{"nctId":256,"briefTitle":257,"status":174,"phases":1927,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":1928,"interventions":1929},[93],[264,265,266],[268,269,270,225,271,272],{"nctId":1931,"briefTitle":1932,"status":174,"phases":1933,"primaryCompletion":1934,"start":828,"enrollment":1366,"conditions":1935,"interventions":1937},"NCT02139579","Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer",[93],"2015-12",[1936],"Lung, Carcinoma",[272],{"nctId":1939,"briefTitle":1940,"status":116,"phases":1941,"primaryCompletion":1942,"completion":646,"start":1943,"enrollment":20,"conditions":1944,"interventions":1945},"NCT07021950","AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS\u002FpMMR Metastatic Colorectal Cancer",[93],"2027-10-31","2025-08-10",[25,1406],[1946,1947,272],"AK112","FOLFIRI",{"nctId":1949,"briefTitle":1950,"status":174,"phases":1951,"primaryCompletion":1952,"completion":1952,"start":1953,"enrollment":1954,"conditions":1955,"interventions":1957},"NCT03905317","Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene",[93],"2022-02","2019-03-01",66,[1956],"Lung Adenocarcinoma",[272,1958],"concurrent chemotherapy",{"nctId":1960,"briefTitle":1961,"status":300,"phases":1962,"primaryCompletion":1963,"completion":419,"start":1964,"enrollment":360,"conditions":1965,"interventions":1966},"NCT05491811","Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation",[93],"2024-08-31","2022-08-01",[252],[1967,272],"Ensartinib",{"nctId":1969,"briefTitle":1970,"status":143,"phases":1971,"primaryCompletion":499,"completion":499,"start":1953,"enrollment":911,"conditions":1972,"interventions":1974},"NCT03872661","Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC",[93],[1973],"Lung Cancer Stage III",[1975,272,254,271],"IBI308",{"nctId":1977,"briefTitle":1978,"status":174,"phases":1979,"primaryCompletion":438,"completion":459,"start":1980,"enrollment":942,"conditions":1981,"interventions":1982},"NCT02250599","Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma",[93],"2014-08",[441],[270,272,271],{"nctId":1984,"briefTitle":1985,"status":143,"phases":1986,"primaryCompletion":236,"completion":380,"start":1064,"enrollment":1987,"conditions":1988,"interventions":1991},"NCT06764680","Oral Chemotherapy, Targeted Therapy and Immunotherapy With\u002FWithout Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS\u002FpMMR Colorectal Cancer",[93],57,[1020,726,1989,318,1990],"Targeted Therapy","Radiotherapy, Intensity-Modulated",[1992,272,1993],"Trifluorouracil tepidopyrimidine","Sindilizumab",{"nctId":1995,"briefTitle":1996,"status":116,"phases":1997,"primaryCompletion":1998,"completion":1999,"start":2000,"enrollment":2001,"conditions":2002,"interventions":2003},"NCT06434090","Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer",[92,93],"2025-06-05","2026-07-01","2024-06-05",74,[25],[2004,272],"Liposomal irinotecan",{"nctId":2006,"briefTitle":2007,"status":143,"phases":2008,"primaryCompletion":1238,"completion":1238,"start":1509,"enrollment":430,"conditions":2009,"interventions":2011},"NCT05468242","Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy",[93],[2010],"Stage III Non-small Cell Lung Cancer",[2012,272,69],"Neoadjuvant chemo-immunotherapy",{"nctId":2014,"briefTitle":2015,"status":143,"phases":2016,"primaryCompletion":119,"completion":679,"start":895,"enrollment":2017,"conditions":2018,"interventions":2019},"NCT07012954","ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine\u002FTipiracil in RAS\u002FBRAF Wild-Type mCRC",[92,93],64,[1020],[823,2020,272],"trifluridine\u002Ftipiracil",{"nctId":2022,"briefTitle":2023,"status":143,"phases":2024,"primaryCompletion":380,"completion":380,"start":2025,"enrollment":996,"conditions":2026,"interventions":2028},"NCT06433869","The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites",[93],"2023-12-14",[2027],"Malignant Ascites",[412,272,2029],"rmhTNF-NC",{"nctId":1023,"briefTitle":1024,"status":174,"phases":2031,"primaryCompletion":1026,"completion":1027,"start":949,"enrollment":32,"conditions":2032,"interventions":2033},[93],[19,272,1029,284,542],[272,284],{"nctId":2035,"briefTitle":2036,"status":116,"phases":2037,"primaryCompletion":1348,"completion":2038,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2047},"NCT06063070","First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer",[93],"2027-10-30","2023-10-18",44,[2042,2043,2044,2045,2046],"Ovarian Cancer","High Grade Serous Adenocarcinoma of Ovary","High Grade Endometrioid Ovarian Cancer","Primary Peritoneal Cancer","Fallopian-tube Cancer",[2048,272],"Fluzoparib",{"nctId":1775,"briefTitle":1776,"status":143,"phases":2050,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":1018,"conditions":2051,"interventions":2052},[93],[1782],[981,483,272],{"nctId":2054,"briefTitle":2055,"status":328,"phases":2056,"primaryCompletion":1613,"completion":2057,"start":2058,"enrollment":2059,"conditions":2060,"interventions":2061},"NCT03904563","Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma",[93],"2022-12-15","2019-01-01",27,[1956],[272,1958],{"nctId":2063,"briefTitle":2064,"status":143,"phases":2065,"primaryCompletion":2066,"completion":237,"start":895,"enrollment":239,"conditions":2067,"interventions":2069},"NCT07150247","Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer",[93],"2027-06-30",[2068],"BRAF V600 Colorectal Cancer",[2070,272,296,54],"Iparomlimab and Tuvonralimab",{"nctId":2072,"briefTitle":2073,"status":143,"phases":2074,"primaryCompletion":380,"completion":380,"start":2075,"enrollment":2076,"conditions":2077,"interventions":2078},"NCT05727163","FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients",[93],"2022-07-29",194,[1020],[183,2079,542,2080,664,54,272,542,2080,664],"Anisodamine","Leucovorin",{"nctId":2082,"briefTitle":2083,"status":174,"phases":2084,"primaryCompletion":799,"completion":428,"start":2085,"enrollment":1289,"conditions":2086,"interventions":2087},"NCT01818973","Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer",[93],"2013-03",[34],[2088,542,272],"Xeloda",14,{"trials":2091,"activeCount":1861,"soonestReadout":380},[2092,2101,2118,2127,2136],{"nctId":2093,"briefTitle":2094,"status":143,"phases":2095,"primaryCompletion":380,"completion":499,"start":405,"enrollment":2096,"conditions":2097,"interventions":2099},"NCT06280495","Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS\u002FBRAF WT, pMMR\u002FMSS CRC Patients",[93,94],156,[25,2098],"Liver Metastases",[542,664,2100,272],"Serplulimab",{"nctId":2102,"briefTitle":2103,"status":174,"phases":2104,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":2109,"interventions":2114},"NCT03303495","A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC",[94],"2017-12-31","2018-12-31","2011-11-14",280,[1341,2110,2111,2112,2113],"Neoplasm Metastasis","Intestinal Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms",[272,2115,2116,398,2117],"CPT-11","5-FU Bolus","l-LV",{"nctId":2119,"briefTitle":2120,"status":143,"phases":2121,"primaryCompletion":2122,"completion":2122,"start":1875,"enrollment":2123,"conditions":2124,"interventions":2126},"NCT07058428","FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma",[94],"2028-12-30",258,[2125],"Multiple Brain Metastases in Lung Adenocarcinoma",[272],{"nctId":2128,"briefTitle":2129,"status":143,"phases":2130,"primaryCompletion":2131,"completion":2131,"start":2132,"enrollment":179,"conditions":2133,"interventions":2135},"NCT07481786","Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases",[94],"2029-09-15","2026-03-20",[1956,1830,1990,272,2134],"Whole-Brain Radiotherapy",[272],{"nctId":1853,"briefTitle":1854,"status":174,"phases":2137,"primaryCompletion":259,"completion":260,"start":658,"enrollment":1856,"conditions":2138,"interventions":2139},[94],[1858,1859,318],[483,272],{"trials":2141,"activeCount":104},[],{"trials":2143,"activeCount":1255,"soonestReadout":1227},[2144,2148,2160],{"nctId":1224,"briefTitle":1225,"status":143,"phases":2145,"primaryCompletion":1227,"completion":1227,"start":949,"enrollment":1228,"conditions":2146,"interventions":2147},[],[1230,1231,272],[272,1233,69,284,483,268],{"nctId":2149,"briefTitle":2150,"status":143,"phases":2151,"primaryCompletion":2152,"completion":2153,"start":2154,"enrollment":942,"conditions":2155,"interventions":2159},"NCT06265350","Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases",[96],"2026-01-30","2027-01-30","2024-02-02",[19,2156,2157,795,272,2158],"Liver Cancer Stage IV","Pulmonary Metastases","Cryoablation",[795,272],{"nctId":2161,"briefTitle":2162,"status":174,"phases":2163,"primaryCompletion":2164,"start":2165,"enrollment":1248,"conditions":2166,"interventions":2167},"NCT01912443","Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer",[],"2017-08","2013-08",[1368],[2168],"bevacizumab",{"intervention":49,"totalTrials":32,"cells":2170},{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2273,"PHASE4":2334,"NA":2336},{"trials":2172,"activeCount":104},[],{"trials":2174,"activeCount":104},[],{"trials":2176,"activeCount":2272,"soonestReadout":418},[2177,2189,2198,2202,2212,2216,2220,2224,2228,2240,2244,2252,2256,2260,2268],{"nctId":2178,"briefTitle":2179,"status":174,"phases":2180,"primaryCompletion":2181,"completion":2182,"start":2183,"enrollment":2184,"conditions":2185,"interventions":2187},"NCT06233864","A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer",[93],"2025-04-17","2026-04-17","2024-04-17",63,[2186],"Pancreatic Cancer",[2188,49],"Disitamab Vedotin",{"nctId":2190,"briefTitle":2191,"status":174,"phases":2192,"primaryCompletion":259,"completion":259,"start":2193,"enrollment":1109,"conditions":2194,"interventions":2196},"NCT02705508","PEG-ASP, Etoposide and Gemcitabine for Natural Killer\u002FT Lymphoma",[93],"2016-02",[2195],"Treatment Refusal",[49,2197,1205],"etoposide",{"nctId":274,"briefTitle":275,"status":143,"phases":2199,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":2200,"interventions":2201},[93],[37,282],[49,225,284],{"nctId":2203,"briefTitle":2204,"status":904,"phases":2205,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":104,"conditions":2209,"interventions":2211},"NCT02428764","Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma",[93],"2025-10-01","2027-10-01","2015-04-01",[2210],"Lung Cancer",[339,49,271],{"nctId":309,"briefTitle":310,"status":143,"phases":2213,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":2214,"interventions":2215},[93],[316,317,318],[320,321,225,49,322,323,324,284],{"nctId":342,"briefTitle":343,"status":174,"phases":2217,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":2218,"interventions":2219},[93],[350],[352,353,49,225],{"nctId":355,"briefTitle":356,"status":143,"phases":2221,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":2222,"interventions":2223},[93],[16],[284,363,49,225],{"nctId":365,"briefTitle":366,"status":328,"phases":2225,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":2226,"interventions":2227},[93],[16],[374,49,225],{"nctId":2229,"briefTitle":2230,"status":1091,"phases":2231,"primaryCompletion":2232,"completion":1576,"start":2233,"enrollment":205,"conditions":2234,"interventions":2236},"NCT02533323","P-Gemox Regimen as First-line Chemotherapy in NK\u002FT Lymphoma Patiens",[93],"2016-09","2012-01",[2235],"Lymphoma, Extranodal NK-T-Cell",[2237,2238,2239],"gemcitabine","oxaliplatin","pegaspargase",{"nctId":415,"briefTitle":416,"status":300,"phases":2241,"primaryCompletion":418,"completion":419,"start":420,"enrollment":23,"conditions":2242,"interventions":2243},[93],[16],[268,49,225],{"nctId":2245,"briefTitle":2246,"status":174,"phases":2247,"primaryCompletion":618,"completion":906,"start":2165,"enrollment":32,"conditions":2248,"interventions":2250},"NCT01921790","Avastin+ GemAOD As First-Line Treatment in NK\u002FT Cell Lymphoma",[93],[2249],"Extranodal NK\u002FT-cell Lymphoma, Nasal Type",[2251,49,542,1205,183],"Avastin",{"nctId":467,"briefTitle":468,"status":143,"phases":2253,"primaryCompletion":419,"completion":470,"start":471,"enrollment":472,"conditions":2254,"interventions":2255},[93],[16],[284,49,225],{"nctId":486,"briefTitle":487,"status":174,"phases":2257,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":2258,"interventions":2259},[93],[441],[483,49,225],{"nctId":2261,"briefTitle":2262,"status":174,"phases":2263,"primaryCompletion":459,"completion":2264,"start":1375,"enrollment":32,"conditions":2265,"interventions":2266},"NCT01991158","GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK\u002FT Cell Lymphoma",[93],"2020-11",[2249],[2267,49,1205,183],"High dose of methotrexate",{"nctId":496,"briefTitle":497,"status":300,"phases":2269,"primaryCompletion":379,"completion":499,"start":500,"enrollment":501,"conditions":2270,"interventions":2271},[93],[503,504,505],[284,49,225,271],6,{"trials":2274,"activeCount":528,"soonestReadout":48},[2275,2279,2283,2287,2291,2295,2299,2310,2314,2318,2322,2326,2330],{"nctId":570,"briefTitle":571,"status":174,"phases":2276,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":2277,"interventions":2278},[94],[441],[483,49,225],{"nctId":718,"briefTitle":719,"status":116,"phases":2280,"primaryCompletion":721,"completion":646,"start":722,"enrollment":723,"conditions":2281,"interventions":2282},[93,94],[16,725,726,318,727],[340,225,296,49],{"nctId":741,"briefTitle":742,"status":143,"phases":2284,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":2285,"interventions":2286},[94],[16],[374,49,225,225,444],{"nctId":770,"briefTitle":771,"status":116,"phases":2288,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":2289,"interventions":2290},[94],[16],[284,363,225,49],{"nctId":779,"briefTitle":780,"status":143,"phases":2292,"primaryCompletion":302,"completion":404,"start":782,"enrollment":783,"conditions":2293,"interventions":2294},[94],[16],[268,49,225,269],{"nctId":787,"briefTitle":788,"status":300,"phases":2296,"primaryCompletion":790,"completion":791,"start":733,"enrollment":792,"conditions":2297,"interventions":2298},[94],[16,396],[795,49,225],{"nctId":2300,"briefTitle":2301,"status":1091,"phases":2302,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":2304,"interventions":2305},"NCT02359162","Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK\u002FT-cell Lymphoma With Early Stage",[94],"2015-05",[2235],[49,542,1205,411,2306,2307,2308,2309],"Vincristine","Doxorubicin","Cyclophosphamide","Prednisone",{"nctId":46,"briefTitle":47,"status":300,"phases":2311,"primaryCompletion":48,"completion":798,"start":799,"enrollment":800,"conditions":2312,"interventions":2313},[94],[16],[49,413,413],{"nctId":1548,"briefTitle":1549,"status":143,"phases":2315,"primaryCompletion":1551,"completion":1107,"start":1552,"enrollment":1553,"conditions":2316,"interventions":2317},[94],[28,1555],[49,444,768,1557],{"nctId":804,"briefTitle":805,"status":143,"phases":2319,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":2320,"interventions":2321},[94],[37,396],[813,49,225],{"nctId":836,"briefTitle":837,"status":116,"phases":2323,"primaryCompletion":313,"completion":839,"start":840,"enrollment":841,"conditions":2324,"interventions":2325},[94],[37,396],[844,49,225,845],{"nctId":847,"briefTitle":848,"status":300,"phases":2327,"primaryCompletion":850,"completion":851,"start":852,"enrollment":853,"conditions":2328,"interventions":2329},[94],[16],[374,49,225,225],{"nctId":1197,"briefTitle":1198,"status":143,"phases":2331,"primaryCompletion":646,"completion":646,"start":1200,"enrollment":1201,"conditions":2332,"interventions":2333},[94],[1203],[284,1205,49,542],{"trials":2335,"activeCount":104},[],{"trials":2337,"activeCount":100,"soonestReadout":895},[2338,2346],{"nctId":2339,"briefTitle":2340,"status":174,"phases":2341,"primaryCompletion":259,"completion":259,"start":2342,"enrollment":1339,"conditions":2343,"interventions":2345},"NCT04365049","Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma",[],"2020-04-01",[2344],"PDAC - Pancreatic Ductal Adenocarcinoma",[321,49,268],{"nctId":892,"briefTitle":893,"status":143,"phases":2347,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":2348,"interventions":2349},[96],[16],[49,225],{"intervention":69,"totalTrials":1138,"cells":2351},{"EARLY_PHASE1":2352,"PHASE1":2354,"PHASE2":2356,"PHASE3":2440,"PHASE4":2468,"NA":2470},{"trials":2353,"activeCount":104},[],{"trials":2355,"activeCount":104},[],{"trials":2357,"activeCount":2439,"soonestReadout":68},[2358,2362,2373,2381,2385,2394,2403,2413,2423,2432],{"nctId":1310,"briefTitle":1311,"status":143,"phases":2359,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":2360,"interventions":2361},[93],[1318,539,1319],[69,542,541,444],{"nctId":2363,"briefTitle":2364,"status":143,"phases":2365,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":942,"conditions":2368,"interventions":2371},"NCT07086456","Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer",[93],"2029-07-19","2025-07-20",[1122,69,2369,2370,22],"Concurrent Chemoradiotherapy","Consolidation Therapy",[1122,69,2372],"Concurrent Chemotherapy",{"nctId":2374,"briefTitle":2375,"status":143,"phases":2376,"primaryCompletion":1277,"completion":404,"start":217,"enrollment":942,"conditions":2377,"interventions":2379},"NCT04615143","Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC",[93],[2378],"Recurrent Hepatocellular Carcinoma",[69,2380],"Tislelizumab combined with Levatinib",{"nctId":2006,"briefTitle":2007,"status":143,"phases":2382,"primaryCompletion":1238,"completion":1238,"start":1509,"enrollment":430,"conditions":2383,"interventions":2384},[93],[2010],[2012,272,69],{"nctId":2386,"briefTitle":2387,"status":143,"phases":2388,"primaryCompletion":119,"completion":499,"start":2389,"enrollment":1366,"conditions":2390,"interventions":2393},"NCT06673693","Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma",[93],"2025-04-15",[2391,2392],"Head and Neck Squamous Cell Carcinoma (HNSCC)","HNSCC",[69],{"nctId":2395,"briefTitle":2396,"status":116,"phases":2397,"primaryCompletion":2398,"completion":2398,"start":1508,"enrollment":734,"conditions":2399,"interventions":2401},"NCT07609121","Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC",[93],"2029-05-31",[2400],"NSCLC (Non-small Cell Lung Cancer)",[2402,69,1122],"Concurrent chemotherapy",{"nctId":2404,"briefTitle":2405,"status":116,"phases":2406,"primaryCompletion":2407,"completion":2408,"start":2409,"enrollment":29,"conditions":2410,"interventions":2411},"NCT07388758","Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[93],"2028-02","2029-02","2026-02",[1009],[69,2412],"Scipibaimab",{"nctId":2414,"briefTitle":2415,"status":300,"phases":2416,"primaryCompletion":2417,"completion":1288,"start":2418,"enrollment":2419,"conditions":2420,"interventions":2421},"NCT05520619","Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)",[93],"2025-11-10","2022-09-15",114,[463,934],[2422,684],"Paclitaxel, Cisplatin",{"nctId":2424,"briefTitle":2425,"status":174,"phases":2426,"primaryCompletion":782,"completion":1543,"start":2427,"enrollment":32,"conditions":2428,"interventions":2431},"NCT04843267","A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET\u002FCT",[93],"2021-05-01",[2429,2430],"Hodgkin Lymphoma","Chemotherapy Effect",[69],{"nctId":66,"briefTitle":67,"status":300,"phases":2433,"primaryCompletion":68,"completion":2434,"start":2435,"enrollment":461,"conditions":2436,"interventions":2438},[93],"2026-05-31","2022-04-24",[2437],"Carcinoma, Non-Small-Cell Lung",[69],9,{"trials":2441,"activeCount":1861,"soonestReadout":2446},[2442,2452,2464],{"nctId":2443,"briefTitle":2444,"status":300,"phases":2445,"primaryCompletion":2446,"completion":2447,"start":2448,"enrollment":2449,"conditions":2450,"interventions":2451},"NCT05211232","Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma",[94],"2026-06-02","2028-06-02","2022-06-10",450,[16],[69],{"nctId":2453,"briefTitle":2454,"status":143,"phases":2455,"primaryCompletion":2456,"completion":2457,"start":2458,"enrollment":2459,"conditions":2460,"interventions":2462},"NCT06520683","Adjuvant PD-1 Blockade for High-risk Stage-II DMMR\u002FMSI-H Colorectal Cancer",[94],"2027-11-01","2030-11-01","2024-11-01",180,[25,2461],"Microsatellite Instability High",[69,2463],"Adjuvant chemotherapy",{"nctId":675,"briefTitle":676,"status":116,"phases":2465,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":2466,"interventions":2467},[94],[37,396],[684,684,603,225],{"trials":2469,"activeCount":104},[],{"trials":2471,"activeCount":1255,"soonestReadout":1238},[2472,2476,2480],{"nctId":1224,"briefTitle":1225,"status":143,"phases":2473,"primaryCompletion":1227,"completion":1227,"start":949,"enrollment":1228,"conditions":2474,"interventions":2475},[],[1230,1231,272],[272,1233,69,284,483,268],{"nctId":1235,"briefTitle":1236,"status":143,"phases":2477,"primaryCompletion":1238,"completion":1227,"start":949,"enrollment":189,"conditions":2478,"interventions":2479},[],[19,353,1240,1241],[353,69,284,483,268],{"nctId":1244,"briefTitle":1245,"status":328,"phases":2481,"primaryCompletion":923,"completion":73,"start":1247,"enrollment":1248,"conditions":2482,"interventions":2483},[],[19,1250,1251],[353,1253,268,1254,284,483,69],{"intervention":542,"totalTrials":959,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2564,"PHASE4":2628,"NA":2630},{"trials":2487,"activeCount":104},[],{"trials":2489,"activeCount":104},[],{"trials":2491,"activeCount":1218,"soonestReadout":53},[2492,2496,2505,2509,2513,2517,2521,2530,2534,2538,2542,2546,2552,2556,2560],{"nctId":1265,"briefTitle":1266,"status":300,"phases":2493,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":911,"conditions":2494,"interventions":2495},[92,93],[1020],[483,542,444,272],{"nctId":2497,"briefTitle":2498,"status":328,"phases":2499,"primaryCompletion":522,"completion":53,"start":2500,"enrollment":996,"conditions":2501,"interventions":2503},"NCT03493061","A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM",[93],"2018-02-01",[2502,2098],"Colo-rectal Cancer",[54,542,2504],"Floxuridine",{"nctId":1916,"briefTitle":1917,"status":116,"phases":2506,"primaryCompletion":1005,"completion":1919,"start":1508,"enrollment":1920,"conditions":2507,"interventions":2508},[93],[1922],[542,296,1924,1925,272,823],{"nctId":1285,"briefTitle":1286,"status":116,"phases":2510,"primaryCompletion":1288,"completion":380,"start":1083,"enrollment":1289,"conditions":2511,"interventions":2512},[93],[1291,318,1292,1293],[1295,444,542,1296],{"nctId":1310,"briefTitle":1311,"status":143,"phases":2514,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":2515,"interventions":2516},[93],[1318,539,1319],[69,542,541,444],{"nctId":1322,"briefTitle":1323,"status":300,"phases":2518,"primaryCompletion":1325,"completion":1325,"start":1326,"enrollment":1327,"conditions":2519,"interventions":2520},[93],[1329,1330],[542,444,483],{"nctId":2522,"briefTitle":2523,"status":174,"phases":2524,"primaryCompletion":2525,"completion":2526,"start":1500,"enrollment":1084,"conditions":2527,"interventions":2528},"NCT02426450","RFA Combined With Oxaliplatin + 5-FluoroUracil\u002FLeucoVorin (5-FU\u002FLV) (FOLFOX4) for Recurrent HCC",[93],"2015-10","2017-04",[19],[542,2529],"5-Fluorouracil\u002FLeucovorin",{"nctId":2229,"briefTitle":2230,"status":1091,"phases":2531,"primaryCompletion":2232,"completion":1576,"start":2233,"enrollment":205,"conditions":2532,"interventions":2533},[93],[2235],[2237,2238,2239],{"nctId":1397,"briefTitle":1398,"status":116,"phases":2535,"primaryCompletion":1400,"completion":237,"start":1401,"enrollment":1402,"conditions":2536,"interventions":2537},[93],[1404],[1406,542,444],{"nctId":1408,"briefTitle":1409,"status":174,"phases":2539,"primaryCompletion":1411,"completion":1238,"start":1412,"enrollment":959,"conditions":2540,"interventions":2541},[93],[1414,1415,1416],[1418,542,444],{"nctId":2245,"briefTitle":2246,"status":174,"phases":2543,"primaryCompletion":618,"completion":906,"start":2165,"enrollment":32,"conditions":2544,"interventions":2545},[93],[2249],[2251,49,542,1205,183],{"nctId":51,"briefTitle":52,"status":300,"phases":2547,"primaryCompletion":53,"completion":548,"start":2548,"enrollment":2549,"conditions":2550,"interventions":2551},[93],"2018-04-15",146,[25,2098],[54,823,738,542,2080],{"nctId":2072,"briefTitle":2073,"status":143,"phases":2553,"primaryCompletion":380,"completion":380,"start":2075,"enrollment":2076,"conditions":2554,"interventions":2555},[93],[1020],[183,2079,542,2080,664,54,272,542,2080,664],{"nctId":1444,"briefTitle":1445,"status":174,"phases":2557,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":2558,"interventions":2559},[93],[539,1452],[385,542,1454,444],{"nctId":2082,"briefTitle":2083,"status":174,"phases":2561,"primaryCompletion":799,"completion":428,"start":2085,"enrollment":1289,"conditions":2562,"interventions":2563},[93],[34],[2088,542,272],{"trials":2565,"activeCount":2627,"soonestReadout":1227},[2566,2570,2574,2581,2585,2595,2607,2615,2619,2623],{"nctId":532,"briefTitle":533,"status":328,"phases":2567,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":2568,"interventions":2569},[94],[539],[541,542,225],{"nctId":2093,"briefTitle":2094,"status":143,"phases":2571,"primaryCompletion":380,"completion":499,"start":405,"enrollment":2096,"conditions":2572,"interventions":2573},[93,94],[25,2098],[542,664,2100,272],{"nctId":2575,"briefTitle":2576,"status":174,"phases":2577,"primaryCompletion":828,"completion":203,"start":2578,"enrollment":1192,"conditions":2579,"interventions":2580},"NCT01566942","FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer",[94],"2012-06",[25],[542,54],{"nctId":1505,"briefTitle":1506,"status":143,"phases":2582,"primaryCompletion":1508,"completion":646,"start":1509,"enrollment":1510,"conditions":2583,"interventions":2584},[94],[1512],[483,542,64],{"nctId":2586,"briefTitle":2587,"status":143,"phases":2588,"primaryCompletion":1227,"completion":2589,"start":2590,"enrollment":2591,"conditions":2592,"interventions":2593},"NCT06441565","Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer",[93,94],"2029-12-30","2024-05-24",84,[25],[2594,664,542],"Fruquintinib",{"nctId":2596,"briefTitle":2597,"status":1091,"phases":2598,"primaryCompletion":2599,"completion":2599,"start":2600,"enrollment":2601,"conditions":2602,"interventions":2604},"NCT03500874","Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM",[94],"2021-08-31","2018-05-28",92,[25,2098,2603],"HAI",[2605,542,2080,2606,54],"FUDR","5FU",{"nctId":2608,"briefTitle":2609,"status":1091,"phases":2610,"primaryCompletion":2611,"completion":479,"start":289,"enrollment":2601,"conditions":2612,"interventions":2613},"NCT03678428","FUDR\u002FOxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM",[94],"2022-10-31",[1368,2098],[54,2614,2504,2080,398,542],"Oxaliplatin HAI",{"nctId":2300,"briefTitle":2301,"status":1091,"phases":2616,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":2617,"interventions":2618},[94],[2235],[49,542,1205,411,2306,2307,2308,2309],{"nctId":1197,"briefTitle":1198,"status":143,"phases":2620,"primaryCompletion":646,"completion":646,"start":1200,"enrollment":1201,"conditions":2621,"interventions":2622},[94],[1203],[284,1205,49,542],{"nctId":1589,"briefTitle":1590,"status":174,"phases":2624,"primaryCompletion":1592,"completion":490,"start":1593,"enrollment":1594,"conditions":2625,"interventions":2626},[94],[1596],[542,64],4,{"trials":2629,"activeCount":104},[],{"trials":2631,"activeCount":104},[],{"intervention":2402,"totalTrials":35,"cells":2633},{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2656,"PHASE3":2782,"PHASE4":2824,"NA":2826},{"trials":2635,"activeCount":104},[],{"trials":2637,"activeCount":100,"soonestReadout":1269},[2638,2649],{"nctId":2639,"briefTitle":2640,"status":328,"phases":2641,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":1615,"conditions":2645,"interventions":2647},"NCT04951063","Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC",[92],"2023-03-31","2023-09-30","2021-06-01",[2646],"Locally Advanced Lung Carcinoma",[2402,2648],"Consolidation immunotherapy",{"nctId":2650,"briefTitle":2651,"status":300,"phases":2652,"primaryCompletion":1269,"completion":1269,"start":1647,"enrollment":1615,"conditions":2653,"interventions":2654},"NCT06020885","Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.",[92],[463],[2655,2402],"Induction chemo-immunotherapy",{"trials":2657,"activeCount":2272,"soonestReadout":2679},[2658,2667,2671,2675,2686,2695,2706,2716,2720,2729,2738,2745,2749,2757,2766,2774],{"nctId":2659,"briefTitle":2660,"status":174,"phases":2661,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":1109,"conditions":2664,"interventions":2666},"NCT04275687","Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer",[93],"2025-02-01","2020-03-01",[2665],"Loco-regionally Recurrent NSCLC After Thoracic Radiotherapy",[2402],{"nctId":2363,"briefTitle":2364,"status":143,"phases":2668,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":942,"conditions":2669,"interventions":2670},[93],[1122,69,2369,2370,22],[1122,69,2372],{"nctId":1949,"briefTitle":1950,"status":174,"phases":2672,"primaryCompletion":1952,"completion":1952,"start":1953,"enrollment":1954,"conditions":2673,"interventions":2674},[93],[1956],[272,1958],{"nctId":2676,"briefTitle":2677,"status":300,"phases":2678,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":2419,"conditions":2681,"interventions":2682},"NCT06139419","The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC",[93],"2026-08-30","2023-07-25",[22],[2683,1958,2684,2685],"induction chemo-immunotherapy","Immunotheapy consolidation","Thymosin Alpha1",{"nctId":2687,"briefTitle":2688,"status":1091,"phases":2689,"primaryCompletion":2690,"completion":2690,"start":2691,"enrollment":978,"conditions":2692,"interventions":2693},"NCT03661567","Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer",[93],"2021-09-10","2018-08-09",[22],[1958,2694],"Methylprednisolone",{"nctId":2696,"briefTitle":2697,"status":143,"phases":2698,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":2701,"conditions":2702,"interventions":2704},"NCT06912074","Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma",[93],"2029-04-04","2025-04-05",134,[2703],"Esophageal Squamous Cell Carcinoma (ESCC)",[2705,2372],"Induction chemoimmunotherapy",{"nctId":2707,"briefTitle":2708,"status":143,"phases":2709,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":2710,"conditions":2711,"interventions":2713},"NCT07086469","Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma",[93],69,[284,1122,2712,1215,463],"Neoadjuvant Immunochemotherapy",[2714,2715,2372],"Neoadjuvant immunochemotherapy","Surufatinib Administration",{"nctId":2395,"briefTitle":2396,"status":116,"phases":2717,"primaryCompletion":2398,"completion":2398,"start":1508,"enrollment":734,"conditions":2718,"interventions":2719},[93],[2400],[2402,69,1122],{"nctId":2721,"briefTitle":2722,"status":174,"phases":2723,"primaryCompletion":2724,"completion":2724,"start":1247,"enrollment":2725,"conditions":2726,"interventions":2727},"NCT03290820","Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients",[93],"2024-09-30",184,[16],[2402,2728],"Aspirin",{"nctId":2730,"briefTitle":2731,"status":143,"phases":2732,"primaryCompletion":2733,"completion":2733,"start":2734,"enrollment":1289,"conditions":2735,"interventions":2737},"NCT06730308","Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma",[93],"2028-11-19","2024-11-20",[2736],"Thymoma",[2402,2694],{"nctId":2739,"briefTitle":2740,"status":328,"phases":2741,"primaryCompletion":428,"completion":428,"start":618,"enrollment":2742,"conditions":2743,"interventions":2744},"NCT02573506","Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer",[93],99,[22],[2402],{"nctId":2054,"briefTitle":2055,"status":328,"phases":2746,"primaryCompletion":1613,"completion":2057,"start":2058,"enrollment":2059,"conditions":2747,"interventions":2748},[93],[1956],[272,1958],{"nctId":2750,"briefTitle":2751,"status":328,"phases":2752,"primaryCompletion":2753,"completion":2753,"start":1953,"enrollment":2754,"conditions":2755,"interventions":2756},"NCT03900117","Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLC",[93],"2022-06-20",77,[22],[1958],{"nctId":2758,"briefTitle":2759,"status":328,"phases":2760,"primaryCompletion":2761,"completion":721,"start":2762,"enrollment":1501,"conditions":2763,"interventions":2764},"NCT04212052","Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer",[93],"2023-01-01","2020-07-01",[22],[1958,2765],"consolidation immunotherapy",{"nctId":2767,"briefTitle":2768,"status":174,"phases":2769,"primaryCompletion":2770,"completion":2771,"start":618,"enrollment":1987,"conditions":2772,"interventions":2773},"NCT03006575","Study of Split-course Chemoradiotherapy For Postoperative Locoregional Recurrence Of Non-small Cell Lung Cancer",[93],"2020-06","2021-07",[22],[1958],{"nctId":2775,"briefTitle":2776,"status":328,"phases":2777,"primaryCompletion":2778,"completion":2778,"start":2691,"enrollment":2710,"conditions":2779,"interventions":2780},"NCT03659578","Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer",[93],"2021-09-30",[22],[2402,2781],"thymosin alpha 1",{"trials":2783,"activeCount":2627,"soonestReadout":2798},[2784,2794,2807,2814],{"nctId":2785,"briefTitle":2786,"status":143,"phases":2787,"primaryCompletion":940,"completion":940,"start":2788,"enrollment":2789,"conditions":2790,"interventions":2792},"NCT07052669","Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC",[94],"2025-07-01",311,[2791],"Locally Advanced Non-Small Cell Lung Cancer",[2372,1958,2793],"Consolidative immunotherapy",{"nctId":2795,"briefTitle":2796,"status":143,"phases":2797,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2804},"NCT06675214","Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.",[94],"2027-07-31","2030-07-31","2024-07-30",586,[16,2803],"De-escalation Therapy",[2805,2806,2372],"Full course of PD-1\u002FPD-L1 blockades","Cisplatin-based induction chemotherapy",{"nctId":2808,"briefTitle":2809,"status":143,"phases":2810,"primaryCompletion":2811,"completion":2811,"start":345,"enrollment":792,"conditions":2812,"interventions":2813},"NCT06545747","Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI",[94],"2028-07-31",[22],[2402,2793],{"nctId":2815,"briefTitle":2816,"status":143,"phases":2817,"primaryCompletion":2818,"completion":2819,"start":2820,"enrollment":2821,"conditions":2822,"interventions":2823},"NCT06092957","Reduced-dose RT With\u002FWithout CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy",[94],"2029-10-30","2031-10-30","2023-10-09",504,[16,2803],[2806,2805,2372],{"trials":2825,"activeCount":104},[],{"trials":2827,"activeCount":100,"soonestReadout":379},[2828],{"nctId":2829,"briefTitle":2830,"status":116,"phases":2831,"primaryCompletion":379,"completion":646,"start":1667,"enrollment":800,"conditions":2832,"interventions":2833},"NCT05622474","A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy",[96],[16],[2834,2402],"Induction chemotherapy plus Concurrent chemotherapy",{"intervention":353,"totalTrials":2836,"cells":2837},31,{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2842,"PHASE3":2907,"PHASE4":2978,"NA":2980},{"trials":2839,"activeCount":104},[],{"trials":2841,"activeCount":104},[],{"trials":2843,"activeCount":1861,"soonestReadout":2856},[2844,2848,2852,2862,2866,2870,2878,2882,2890,2899],{"nctId":1633,"briefTitle":1634,"status":116,"phases":2845,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":1638,"conditions":2846,"interventions":2847},[93],[1640],[1463,1642,353],{"nctId":1654,"briefTitle":1655,"status":174,"phases":2849,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":492,"conditions":2850,"interventions":2851},[93],[1660],[1662,353,483],{"nctId":2853,"briefTitle":2854,"status":300,"phases":2855,"primaryCompletion":2856,"completion":236,"start":2857,"enrollment":32,"conditions":2858,"interventions":2860},"NCT05824468","Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer",[93],"2024-07-20","2023-05-10",[700,2859],"Cervical Carcinoma",[2861,353],"Zimberelimab",{"nctId":954,"briefTitle":955,"status":174,"phases":2863,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":2864,"interventions":2865},[93],[19],[353,284],{"nctId":963,"briefTitle":964,"status":904,"phases":2867,"primaryCompletion":966,"completion":967,"start":968,"enrollment":104,"conditions":2868,"interventions":2869},[93],[19],[353,284],{"nctId":2871,"briefTitle":2872,"status":904,"phases":2873,"primaryCompletion":657,"completion":657,"start":2874,"enrollment":104,"conditions":2875,"interventions":2877},"NCT03801499","Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma",[93],"2018-09-01",[2876],"Intrahepatic Cholangiocarcinoma",[353],{"nctId":342,"briefTitle":343,"status":174,"phases":2879,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":2880,"interventions":2881},[93],[350],[352,353,49,225],{"nctId":2883,"briefTitle":2884,"status":904,"phases":2885,"primaryCompletion":2886,"completion":966,"start":2887,"enrollment":104,"conditions":2888,"interventions":2889},"NCT03746249","Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC",[93],"2019-08-01","2018-12-17",[19],[353,517],{"nctId":2891,"briefTitle":2892,"status":300,"phases":2893,"primaryCompletion":1363,"completion":236,"start":2894,"enrollment":1712,"conditions":2895,"interventions":2898},"NCT05824481","Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer",[93],"2023-05-08",[2896,2897],"Endometrial Cancer","Endometrial Adenocarcinoma",[795,353],{"nctId":2900,"briefTitle":2901,"status":904,"phases":2902,"primaryCompletion":949,"completion":949,"start":2903,"enrollment":104,"conditions":2904,"interventions":2905},"NCT03803254","HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC",[93],"2019-01-03",[19],[2906,353,517],"Folfox Protocol",{"trials":2908,"activeCount":1255,"soonestReadout":1189},[2909,2917,2927,2934,2941,2949,2957,2961,2970],{"nctId":2910,"briefTitle":2911,"status":174,"phases":2912,"primaryCompletion":479,"completion":479,"start":1247,"enrollment":2913,"conditions":2914,"interventions":2915},"NCT04053985","The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)",[94],206,[19],[2916,353],"TAI combine lenvatinib",{"nctId":2918,"briefTitle":2919,"status":174,"phases":2920,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":2924,"conditions":2925,"interventions":2926},"NCT05220020","TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate\u002FAdvanced Liver Cancer",[94],"2024-02-28","2025-02-28","2022-05-18",299,[19],[353],{"nctId":2928,"briefTitle":2929,"status":904,"phases":2930,"primaryCompletion":1509,"completion":1509,"start":2058,"enrollment":104,"conditions":2931,"interventions":2932},"NCT03791918","Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria",[94],[19],[353,517,2933],"TACE Drug Protocol",{"nctId":2935,"briefTitle":2936,"status":904,"phases":2937,"primaryCompletion":949,"completion":2644,"start":2938,"enrollment":104,"conditions":2939,"interventions":2940},"NCT03744247","Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC",[94],"2019-04-21",[19],[353,517],{"nctId":2942,"briefTitle":2943,"status":174,"phases":2944,"primaryCompletion":479,"completion":479,"start":2945,"enrollment":2946,"conditions":2947,"interventions":2948},"NCT04053972","The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.",[94],"2018-01-31",377,[19],[353],{"nctId":2950,"briefTitle":2951,"status":174,"phases":2952,"primaryCompletion":1657,"completion":1657,"start":2953,"enrollment":2954,"conditions":2955,"interventions":2956},"NCT03775395","HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC",[94],"2018-12-12",250,[19],[353,999],{"nctId":1186,"briefTitle":1187,"status":143,"phases":2958,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":2959,"interventions":2960},[94],[19],[353,284,1195],{"nctId":2962,"briefTitle":2963,"status":116,"phases":2964,"primaryCompletion":2965,"completion":2965,"start":2966,"enrollment":2967,"conditions":2968,"interventions":2969},"NCT05718232","SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)",[94],"2027-02","2023-03",136,[1230],[353],{"nctId":2971,"briefTitle":2972,"status":174,"phases":2973,"primaryCompletion":1678,"completion":63,"start":2974,"enrollment":2975,"conditions":2976,"interventions":2977},"NCT03905967","TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC",[94],"2019-06-16",336,[1230],[353],{"trials":2979,"activeCount":104},[],{"trials":2981,"activeCount":2272,"soonestReadout":1238},[2982,2990,2994,2998,3011,3020,3027,3038,3045,3055,3059,3065],{"nctId":2983,"briefTitle":2984,"status":143,"phases":2985,"primaryCompletion":1227,"completion":2679,"start":2986,"enrollment":1712,"conditions":2987,"interventions":2989},"NCT06740370","TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma",[96],"2024-12-13",[19,2988,1250,353],"Transcatheter Arterial Chemoembolization",[353,1524],{"nctId":1871,"briefTitle":1872,"status":143,"phases":2991,"primaryCompletion":1874,"completion":1875,"start":1876,"enrollment":32,"conditions":2992,"interventions":2993},[96],[1251,19,318,353,483],[353,483],{"nctId":1235,"briefTitle":1236,"status":143,"phases":2995,"primaryCompletion":1238,"completion":1227,"start":949,"enrollment":189,"conditions":2996,"interventions":2997},[],[19,353,1240,1241],[353,69,284,483,268],{"nctId":2999,"briefTitle":3000,"status":174,"phases":3001,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":1192,"conditions":3004,"interventions":3010},"NCT05889949","Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma",[],"2023-05-31","2019-06-01",[3005,3006,3007,3008,3009],"Radiomics","Hepatocellular Carcinoma (HCC)","Transcatheter Arterial Chemoembolization (TACE)","Microvascular Invasion (MVI)","Multi-kinase Inhibitors (MKI)",[999,353],{"nctId":3012,"briefTitle":3013,"status":328,"phases":3014,"primaryCompletion":346,"completion":3015,"start":670,"enrollment":1192,"conditions":3016,"interventions":3018},"NCT07537985","Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment",[96],"2025-12-25",[3017],"Hepatocellulcar Carcinoma",[353,3019,1240],"Regorafenib",{"nctId":3021,"briefTitle":3022,"status":904,"phases":3023,"primaryCompletion":2966,"completion":2966,"start":3024,"enrollment":104,"conditions":3025,"interventions":3026},"NCT05592197","Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT",[96],"2018-10-01",[1230],[353],{"nctId":3028,"briefTitle":3029,"status":143,"phases":3030,"primaryCompletion":2788,"completion":3031,"start":862,"enrollment":3032,"conditions":3033,"interventions":3037},"NCT05444478","Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma",[96],"2027-07-01",274,[19,3034,3035,353,3036],"Microwave Ablation","Liver Cancer","Recurrent Tumor",[353],{"nctId":3039,"briefTitle":3040,"status":328,"phases":3041,"primaryCompletion":746,"completion":1876,"start":500,"enrollment":3042,"conditions":3043,"interventions":3044},"NCT06435013","Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC",[],208,[19,353],[353],{"nctId":3046,"briefTitle":3047,"status":143,"phases":3048,"primaryCompletion":1277,"completion":1400,"start":3049,"enrollment":3050,"conditions":3051,"interventions":3053},"NCT06622031","TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT",[96],"2024-10-01",42,[19,1889,3052],"Systemic Therapy",[353,3054],"PD-1 inhibitor",{"nctId":1884,"briefTitle":1885,"status":328,"phases":3056,"primaryCompletion":923,"completion":53,"start":949,"enrollment":32,"conditions":3057,"interventions":3058},[96],[1888,1029,483,1889],[353,483],{"nctId":3060,"briefTitle":3061,"status":143,"phases":3062,"primaryCompletion":1875,"completion":1227,"start":1876,"enrollment":492,"conditions":3063,"interventions":3064},"NCT06061276","bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC",[96],[1251,19,318,268,353],[353,268],{"nctId":1244,"briefTitle":1245,"status":328,"phases":3066,"primaryCompletion":923,"completion":73,"start":1247,"enrollment":1248,"conditions":3067,"interventions":3068},[],[19,1250,1251],[353,1253,268,1254,284,483,69],{"intervention":268,"totalTrials":35,"cells":3070},{"EARLY_PHASE1":3071,"PHASE1":3073,"PHASE2":3075,"PHASE3":3183,"PHASE4":3212,"NA":3214},{"trials":3072,"activeCount":104},[],{"trials":3074,"activeCount":104},[],{"trials":3076,"activeCount":1861,"soonestReadout":418},[3077,3081,3094,3103,3112,3120,3129,3135,3143,3152,3156,3162,3166,3172],{"nctId":256,"briefTitle":257,"status":174,"phases":3078,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":3079,"interventions":3080},[93],[264,265,266],[268,269,270,225,271,272],{"nctId":3082,"briefTitle":3083,"status":174,"phases":3084,"primaryCompletion":3085,"completion":3085,"start":3086,"enrollment":1987,"conditions":3087,"interventions":3092},"NCT05114707","Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses",[93],"2024-04-16","2021-04-16",[3088,3089,268,3090,3091,2372],"Nasal Cavity Cancer","Paranasal Sinus Cancer","Induction Chemotherapy","Intensity Modulated Radiotherapy",[3093],"camrelizumab",{"nctId":3095,"briefTitle":3096,"status":174,"phases":3097,"primaryCompletion":1026,"completion":3098,"start":3099,"enrollment":1007,"conditions":3100,"interventions":3101},"NCT04167774","A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC",[93],"2022-09-30","2019-07-30",[252],[268,3102],"nb-Paclitaxel",{"nctId":3104,"briefTitle":3105,"status":174,"phases":3106,"primaryCompletion":3107,"completion":53,"start":3108,"enrollment":1289,"conditions":3109,"interventions":3111},"NCT04211090","Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC",[93],"2022-08-30","2020-01-15",[3110,1830],"Non-squamous Non-small-cell Lung Cancer",[268,254,271],{"nctId":3113,"briefTitle":3114,"status":143,"phases":3115,"primaryCompletion":380,"completion":303,"start":3116,"enrollment":32,"conditions":3117,"interventions":3118},"NCT07238881","Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment",[93],"2025-11-05",[3017],[3119,3119,268],"Dalpiciclib Isetionate",{"nctId":3121,"briefTitle":3122,"status":174,"phases":3123,"primaryCompletion":3124,"completion":3125,"start":3126,"enrollment":2059,"conditions":3127,"interventions":3128},"NCT04547088","Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[93],"2022-10","2023-10","2020-09",[16],[268,269],{"nctId":3130,"briefTitle":3131,"status":174,"phases":3132,"primaryCompletion":860,"completion":2788,"start":216,"enrollment":205,"conditions":3133,"interventions":3134},"NCT04454905","Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study",[93],[2876],[268,269],{"nctId":3136,"briefTitle":3137,"status":174,"phases":3138,"primaryCompletion":3139,"completion":1711,"start":3140,"enrollment":35,"conditions":3141,"interventions":3142},"NCT04539600","Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer",[93],"2022-07-31","2020-11-01",[736,318,3090],[268],{"nctId":3144,"briefTitle":3145,"status":174,"phases":3146,"primaryCompletion":3147,"completion":260,"start":897,"enrollment":32,"conditions":3148,"interventions":3151},"NCT05093140","Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL",[93],"2023-06",[3149,3150],"Primary Extranodal Lymphoma","DLBCL",[268],{"nctId":415,"briefTitle":416,"status":300,"phases":3153,"primaryCompletion":418,"completion":419,"start":420,"enrollment":23,"conditions":3154,"interventions":3155},[93],[16],[268,49,225],{"nctId":3157,"briefTitle":3158,"status":174,"phases":3159,"primaryCompletion":3124,"completion":3125,"start":3126,"enrollment":959,"conditions":3160,"interventions":3161},"NCT04548271","Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[93],[16],[268,269],{"nctId":1080,"briefTitle":1081,"status":116,"phases":3163,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":1084,"conditions":3164,"interventions":3165},[93],[16],[601,284,268,1087],{"nctId":3167,"briefTitle":3168,"status":174,"phases":3169,"primaryCompletion":966,"completion":1094,"start":535,"enrollment":205,"conditions":3170,"interventions":3171},"NCT03912857","Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer",[93],[1368],[268],{"nctId":3173,"briefTitle":3174,"status":174,"phases":3175,"primaryCompletion":3176,"completion":3177,"start":3178,"enrollment":3179,"conditions":3180,"interventions":3182},"NCT05222035","PD-1 Inhibitor Plus G-CSF in Recurrent\u002FMetastatic NPC With First-line Treatment Failure",[93],"2022-12-24","2023-06-01","2022-01-24",68,[1240,3181],"G-CSF",[268,3181],{"trials":3184,"activeCount":1861,"soonestReadout":302},[3185,3192,3200,3204],{"nctId":3186,"briefTitle":3187,"status":143,"phases":3188,"primaryCompletion":303,"completion":896,"start":2644,"enrollment":3189,"conditions":3190,"interventions":3191},"NCT04944914","Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma",[94],188,[16],[3093],{"nctId":3193,"briefTitle":3194,"status":174,"phases":3195,"primaryCompletion":3196,"completion":2409,"start":3197,"enrollment":2449,"conditions":3198,"interventions":3199},"NCT03427827","PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2024-02-06","2018-07-02",[441],[268],{"nctId":779,"briefTitle":780,"status":143,"phases":3201,"primaryCompletion":302,"completion":404,"start":782,"enrollment":783,"conditions":3202,"interventions":3203},[94],[16],[268,49,225,269],{"nctId":3205,"briefTitle":3206,"status":300,"phases":3207,"primaryCompletion":1999,"completion":1999,"start":3208,"enrollment":3209,"conditions":3210,"interventions":3211},"NCT05198609","Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial",[94],"2022-01-17",214,[19],[268,269],{"trials":3213,"activeCount":104},[],{"trials":3215,"activeCount":1861,"soonestReadout":1238},[3216,3220,3224,3228,3232],{"nctId":1224,"briefTitle":1225,"status":143,"phases":3217,"primaryCompletion":1227,"completion":1227,"start":949,"enrollment":1228,"conditions":3218,"interventions":3219},[],[1230,1231,272],[272,1233,69,284,483,268],{"nctId":1235,"briefTitle":1236,"status":143,"phases":3221,"primaryCompletion":1238,"completion":1227,"start":949,"enrollment":189,"conditions":3222,"interventions":3223},[],[19,353,1240,1241],[353,69,284,483,268],{"nctId":2339,"briefTitle":2340,"status":174,"phases":3225,"primaryCompletion":259,"completion":259,"start":2342,"enrollment":1339,"conditions":3226,"interventions":3227},[],[2344],[321,49,268],{"nctId":3060,"briefTitle":3061,"status":143,"phases":3229,"primaryCompletion":1875,"completion":1227,"start":1876,"enrollment":492,"conditions":3230,"interventions":3231},[96],[1251,19,318,268,353],[353,268],{"nctId":1244,"briefTitle":1245,"status":328,"phases":3233,"primaryCompletion":923,"completion":73,"start":1247,"enrollment":1248,"conditions":3234,"interventions":3235},[],[19,1250,1251],[353,1253,268,1254,284,483,69],{"intervention":726,"totalTrials":239,"cells":3237},{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3319,"PHASE4":3404,"NA":3406},{"trials":3239,"activeCount":104},[],{"trials":3241,"activeCount":104},[],{"trials":3243,"activeCount":1861,"soonestReadout":3301},[3244,3248,3257,3267,3276,3287,3297,3307],{"nctId":937,"briefTitle":938,"status":143,"phases":3245,"primaryCompletion":940,"completion":499,"start":941,"enrollment":942,"conditions":3246,"interventions":3247},[93],[28],[726,284],{"nctId":3249,"briefTitle":3250,"status":174,"phases":3251,"primaryCompletion":547,"completion":547,"start":1094,"enrollment":2601,"conditions":3252,"interventions":3256},"NCT04333927","Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer",[93],[3253,3254,3255],"Biliary Tract Cancer","Extrahepatic Cholangiocarcinoma","Gallbladder Cancer",[726],{"nctId":3258,"briefTitle":3259,"status":904,"phases":3260,"primaryCompletion":3261,"completion":3262,"start":1156,"enrollment":104,"conditions":3263,"interventions":3266},"NCT05481775","Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer",[93],"2025-04-01","2025-09-30",[3264,3265],"Locally Advanced Non-small Cell Lung Cancer","Efficacy and Safety",[363,726,318],{"nctId":3268,"briefTitle":3269,"status":328,"phases":3270,"primaryCompletion":3261,"completion":895,"start":3271,"enrollment":3272,"conditions":3273,"interventions":3275},"NCT07304388","HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC",[93],"2023-02-10",96,[3274],"Intrahepatic Cholangiocarcinoma (Icc)",[726],{"nctId":3277,"briefTitle":3278,"status":143,"phases":3279,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":360,"conditions":3282,"interventions":3284},"NCT06719700","Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer",[93],"2028-11-29","2024-11-30",[284,1122,1215,3283],"Limited-stage Small Cell Lung Cancer (LS-SCLC)",[726,318,3285,3286],"Angio-immuno kinase inhibitor","Consolidation Therapy with Toripalimab and Surufatinib",{"nctId":3288,"briefTitle":3289,"status":174,"phases":3290,"primaryCompletion":1934,"completion":1934,"start":3291,"enrollment":239,"conditions":3292,"interventions":3294},"NCT01899066","Efficacy Study of Lucentis in the Treatment of Retinoblastoma",[93],"2013-07",[3293],"Retinoblastoma",[3295,3296],"Lucentis, chemotherapy","chemotherapy",{"nctId":3298,"briefTitle":3299,"status":300,"phases":3300,"primaryCompletion":3301,"completion":3302,"start":3303,"enrollment":3179,"conditions":3304,"interventions":3306},"NCT03930498","Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma",[93],"2023-11-22","2026-05","2020-03-12",[3305],"Recurrent Nasopharyngeal Carcinoma",[374,726],{"nctId":3308,"briefTitle":3309,"status":174,"phases":3310,"primaryCompletion":3311,"completion":3312,"start":3313,"enrollment":2591,"conditions":3314,"interventions":3315},"NCT05549466","Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R\u002FM NPC",[93],"2023-09-20","2025-09-20","2022-10-08",[16],[3316,3317,3318,726],"Apatinib, Camrelizumab, Chemotherapy","Apatinib, Camrelizumab","Camrelizumab, Chemotherapy",{"trials":3320,"activeCount":2627,"soonestReadout":3261},[3321,3328,3339,3347,3351,3361,3368,3378,3386,3395],{"nctId":3322,"briefTitle":3323,"status":328,"phases":3324,"primaryCompletion":522,"completion":522,"start":1576,"enrollment":775,"conditions":3325,"interventions":3326},"NCT02969681","Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer",[94],[1341],[3327,726],"ascorbic acid",{"nctId":3329,"briefTitle":3330,"status":174,"phases":3331,"primaryCompletion":3332,"completion":2233,"start":3333,"enrollment":406,"conditions":3334,"interventions":3335},"NCT01048463","Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor",[94],"2011-12","2009-12",[539,25,726],[3336,3337,3338,726],"Nutriall","LDEPA","HDEPA",{"nctId":3340,"briefTitle":3341,"status":174,"phases":3342,"primaryCompletion":2526,"completion":460,"start":439,"enrollment":1520,"conditions":3343,"interventions":3346},"NCT01788137","A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients",[94],[3344,3345,154],"T-cell Lymphoma Adults","Previously Untreated",[3296,3296],{"nctId":1153,"briefTitle":1154,"status":143,"phases":3348,"primaryCompletion":419,"completion":470,"start":1156,"enrollment":1157,"conditions":3349,"interventions":3350},[94],[16],[284,726],{"nctId":3352,"briefTitle":3353,"status":174,"phases":3354,"primaryCompletion":3355,"completion":3356,"start":1247,"enrollment":3357,"conditions":3358,"interventions":3360},"NCT03344068","Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma",[93,94],"2020-12-31","2021-03-31",408,[16,3359],"Nutritional Support",[726],{"nctId":3362,"briefTitle":3363,"status":174,"phases":3364,"primaryCompletion":710,"completion":302,"start":3365,"enrollment":820,"conditions":3366,"interventions":3367},"NCT03399253","Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor",[93,94],"2017-12-10",[539],[3296],{"nctId":3369,"briefTitle":3370,"status":300,"phases":3371,"primaryCompletion":3261,"completion":3372,"start":3373,"enrollment":3374,"conditions":3375,"interventions":3377},"NCT05780372","Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma",[94],"2028-04","2023-08-08",474,[16,3376],"Radiotherapy; Complications",[726],{"nctId":3379,"briefTitle":3380,"status":174,"phases":3381,"primaryCompletion":1934,"completion":1934,"start":3382,"enrollment":205,"conditions":3383,"interventions":3384},"NCT02137928","Carboplatin Periocular Injection for Retinoblastoma",[94],"2006-01",[3293],[3385,3296],"carboplatin periocular",{"nctId":3387,"briefTitle":3388,"status":143,"phases":3389,"primaryCompletion":3390,"completion":3390,"start":3391,"enrollment":3392,"conditions":3393,"interventions":3394},"NCT06516133","Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma",[94],"2030-12","2024-05-17",494,[16],[726,726],{"nctId":3396,"briefTitle":3397,"status":143,"phases":3398,"primaryCompletion":669,"completion":626,"start":3399,"enrollment":1520,"conditions":3400,"interventions":3402},"NCT05941741","IC Plus Low-dose Radiation Plus Cadonilimab in LANPC",[94],"2024-01-10",[16,3401,505,726],"Immune Checkpoint Inhibitor",[726,3403],"Immune checkpoint inhibitor",{"trials":3405,"activeCount":104},[],{"trials":3407,"activeCount":1255,"soonestReadout":3421},[3408,3417],{"nctId":3409,"briefTitle":3410,"status":3411,"phases":3412,"primaryCompletion":679,"completion":3413,"start":1509,"enrollment":3414,"conditions":3415,"interventions":3416},"NCT05338866","Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator","ENROLLING_BY_INVITATION",[],"2033-12-31",58,[34],[726],{"nctId":3418,"briefTitle":3419,"status":143,"phases":3420,"primaryCompletion":3421,"completion":3421,"start":3422,"enrollment":3423,"conditions":3424,"interventions":3426},"NCT04174079","Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinoma",[96],"2029-05","2019-12-11",232,[3425],"Thoracic Esophageal Squamous Cell Carcinoma",[3296],{"intervention":271,"totalTrials":2089,"cells":3428},{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3501,"PHASE4":3524,"NA":3526},{"trials":3430,"activeCount":104},[],{"trials":3432,"activeCount":104},[],{"trials":3434,"activeCount":161,"soonestReadout":1064},[3435,3444,3448,3452,3461,3465,3469,3473,3480,3484,3493,3497],{"nctId":3436,"briefTitle":3437,"status":904,"phases":3438,"primaryCompletion":3439,"completion":3440,"start":3441,"enrollment":104,"conditions":3442,"interventions":3443},"NCT03164694","APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC",[93],"2025-05-20","2027-05-20","2017-05-20",[2210],[269,254,271],{"nctId":256,"briefTitle":257,"status":174,"phases":3445,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":3446,"interventions":3447},[93],[264,265,266],[268,269,270,225,271,272],{"nctId":3104,"briefTitle":3105,"status":174,"phases":3449,"primaryCompletion":3107,"completion":53,"start":3108,"enrollment":1289,"conditions":3450,"interventions":3451},[93],[3110,1830],[268,254,271],{"nctId":3453,"briefTitle":3454,"status":174,"phases":3455,"primaryCompletion":3355,"completion":289,"start":3456,"enrollment":898,"conditions":3457,"interventions":3459},"NCT03910634","IMRT With Carboplatin Versus IMRT With Carboplatin and Fluorouracil for Eldly Esophageal Cancer Patients",[93],"2019-04-09",[714,3458],"Radiotherapy Side Effect",[664,3460],"carboplatin",{"nctId":2203,"briefTitle":2204,"status":904,"phases":3462,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":104,"conditions":3463,"interventions":3464},[93],[2210],[339,49,271],{"nctId":1969,"briefTitle":1970,"status":143,"phases":3466,"primaryCompletion":499,"completion":499,"start":1953,"enrollment":911,"conditions":3467,"interventions":3468},[93],[1973],[1975,272,254,271],{"nctId":1977,"briefTitle":1978,"status":174,"phases":3470,"primaryCompletion":438,"completion":459,"start":1980,"enrollment":942,"conditions":3471,"interventions":3472},[93],[441],[270,272,271],{"nctId":3474,"briefTitle":3475,"status":904,"phases":3476,"primaryCompletion":302,"completion":1277,"start":3477,"enrollment":104,"conditions":3478,"interventions":3479},"NCT03623776","Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.",[93],"2019-02-01",[3265],[385,254,271],{"nctId":376,"briefTitle":377,"status":143,"phases":3481,"primaryCompletion":379,"completion":380,"start":381,"enrollment":348,"conditions":3482,"interventions":3483},[93],[383],[385,386,225,271],{"nctId":3485,"briefTitle":3486,"status":116,"phases":3487,"primaryCompletion":3262,"completion":119,"start":746,"enrollment":3488,"conditions":3489,"interventions":3491},"NCT06297811","Myeloprotection With Trilaciclib in Pan-cancer Population",[93],132,[252,28,2896,700,3490],"Head And Neck Squamous Cell Carcinomas",[3492,270,271],"Trilaciclib",{"nctId":1061,"briefTitle":1062,"status":300,"phases":3494,"primaryCompletion":1064,"completion":119,"start":1065,"enrollment":1066,"conditions":3495,"interventions":3496},[93],[28,1068],[284,443,271],{"nctId":496,"briefTitle":497,"status":300,"phases":3498,"primaryCompletion":379,"completion":499,"start":500,"enrollment":501,"conditions":3499,"interventions":3500},[93],[503,504,505],[284,49,225,271],{"trials":3502,"activeCount":100,"soonestReadout":3517},[3503,3513],{"nctId":3504,"briefTitle":3505,"status":174,"phases":3506,"primaryCompletion":1374,"completion":1374,"start":3507,"enrollment":3508,"conditions":3509,"interventions":3510},"NCT02755311","Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma",[94],"2014-03",198,[19],[3460,3511,3512],"lipiodol","epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil",{"nctId":3514,"briefTitle":3515,"status":143,"phases":3516,"primaryCompletion":3517,"completion":3518,"start":3519,"enrollment":2108,"conditions":3520,"interventions":3523},"NCT05367206","Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial",[94],"2024-03-31","2027-03-31","2022-03-14",[700,3521,3522],"Neoadjuvant Chemotherapy","Bulky Neoplasm",[337,271],{"trials":3525,"activeCount":104},[],{"trials":3527,"activeCount":104},[],{"intervention":374,"totalTrials":2272,"cells":3529},{"EARLY_PHASE1":3530,"PHASE1":3532,"PHASE2":3534,"PHASE3":3554,"PHASE4":3571,"NA":3573},{"trials":3531,"activeCount":104},[],{"trials":3533,"activeCount":104},[],{"trials":3535,"activeCount":1255,"soonestReadout":3301},[3536,3540,3550],{"nctId":365,"briefTitle":366,"status":328,"phases":3537,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":3538,"interventions":3539},[93],[16],[374,49,225],{"nctId":3541,"briefTitle":3542,"status":116,"phases":3543,"primaryCompletion":419,"completion":419,"start":3544,"enrollment":2913,"conditions":3545,"interventions":3546},"NCT04605562","Umbrella Biomarker-Guided Therapy in NPC",[93],"2022-06",[16],[3547,3548,374,3549],"GP+DDP","Palbociclib","Galunisertib",{"nctId":3298,"briefTitle":3299,"status":300,"phases":3551,"primaryCompletion":3301,"completion":3302,"start":3303,"enrollment":3179,"conditions":3552,"interventions":3553},[93],[3305],[374,726],{"trials":3555,"activeCount":1861,"soonestReadout":850},[3556,3563,3567],{"nctId":3557,"briefTitle":3558,"status":143,"phases":3559,"primaryCompletion":419,"completion":470,"start":2663,"enrollment":1157,"conditions":3560,"interventions":3561},"NCT03907826","PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients",[94],[3305],[374,3562],"GP",{"nctId":741,"briefTitle":742,"status":143,"phases":3564,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":3565,"interventions":3566},[94],[16],[374,49,225,225,444],{"nctId":847,"briefTitle":848,"status":300,"phases":3568,"primaryCompletion":850,"completion":851,"start":852,"enrollment":853,"conditions":3569,"interventions":3570},[94],[16],[374,49,225,225],{"trials":3572,"activeCount":104},[],{"trials":3574,"activeCount":104},[],{"intervention":601,"totalTrials":161,"cells":3576},{"EARLY_PHASE1":3577,"PHASE1":3579,"PHASE2":3598,"PHASE3":3619,"PHASE4":3625,"NA":3627},{"trials":3578,"activeCount":104},[],{"trials":3580,"activeCount":100,"soonestReadout":3585},[3581],{"nctId":3582,"briefTitle":3583,"status":143,"phases":3584,"primaryCompletion":3585,"completion":3586,"start":3587,"enrollment":1066,"conditions":3588,"interventions":3597},"NCT07584499","Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed\u002FRefractory or Metastatic Solid Tumors",[92],"2027-05-30","2028-05-30","2026-05-30",[3589,16,3590,3591,1763,3592,3593,3594,3595,3596],"Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent\u002FMetastatic (R\u002FM)","Lymphoepithelial Carcinoma","Rhabdomyosarcoma","Medulloblastoma","Wilms Tumor","Atypical Teratoid\u002FRhabdoid Tumors","Diffuse Intrinsic Pontine Gliomas","Other EGFR-positive Pediatric Solid Tumors Deemed Eligible by the Investigator",[601],{"trials":3599,"activeCount":1861,"soonestReadout":1314},[3600,3609,3615],{"nctId":3601,"briefTitle":3602,"status":143,"phases":3603,"primaryCompletion":3604,"completion":3605,"start":1303,"enrollment":514,"conditions":3606,"interventions":3607},"NCT07496190","Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy",[93],"2032-02-10","2034-02-10",[37],[3608,3608],"Becotatug vedotin",{"nctId":3610,"briefTitle":3611,"status":116,"phases":3612,"primaryCompletion":1314,"completion":3421,"start":3302,"enrollment":3050,"conditions":3613,"interventions":3614},"NCT07589049","Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study",[93],[1474],[601,602],{"nctId":1080,"briefTitle":1081,"status":116,"phases":3616,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":1084,"conditions":3617,"interventions":3618},[93],[16],[601,284,268,1087],{"trials":3620,"activeCount":100,"soonestReadout":595},[3621],{"nctId":592,"briefTitle":593,"status":116,"phases":3622,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":3623,"interventions":3624},[94],[37,396],[601,602,603,225],{"trials":3626,"activeCount":104},[],{"trials":3628,"activeCount":104},[],{"intervention":602,"totalTrials":161,"cells":3630},{"EARLY_PHASE1":3631,"PHASE1":3633,"PHASE2":3635,"PHASE3":3672,"PHASE4":3678,"NA":3680},{"trials":3632,"activeCount":104},[],{"trials":3634,"activeCount":104},[],{"trials":3636,"activeCount":2627,"soonestReadout":3641},[3637,3647,3658,3668],{"nctId":3638,"briefTitle":3639,"status":143,"phases":3640,"primaryCompletion":3641,"completion":3642,"start":3643,"enrollment":3644,"conditions":3645,"interventions":3646},"NCT06456892","Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen",[92,93],"2026-06-06","2026-12-06","2024-06-06",82,[3591,1617],[602],{"nctId":3648,"briefTitle":3649,"status":143,"phases":3650,"primaryCompletion":3651,"completion":3652,"start":3653,"enrollment":205,"conditions":3654,"interventions":3656},"NCT07448142","Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer",[93],"2027-09-01","2032-09-01","2026-03-15",[3655],"Colorectal Cancer (CRC)",[602,3657],"CAPEOX\u002FXELOX",{"nctId":3659,"briefTitle":3660,"status":116,"phases":3661,"primaryCompletion":3662,"completion":646,"start":3663,"enrollment":911,"conditions":3664,"interventions":3665},"NCT07353827","FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma",[93],"2027-08-31","2026-02-01",[3274,1241],[3666,602,3667],"Donafenib","FOLFOX",{"nctId":3610,"briefTitle":3611,"status":116,"phases":3669,"primaryCompletion":1314,"completion":3421,"start":3302,"enrollment":3050,"conditions":3670,"interventions":3671},[93],[1474],[601,602],{"trials":3673,"activeCount":100,"soonestReadout":595},[3674],{"nctId":592,"briefTitle":593,"status":116,"phases":3675,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":3676,"interventions":3677},[94],[37,396],[601,602,603,225],{"trials":3679,"activeCount":104},[],{"trials":3681,"activeCount":104},[],{"intervention":795,"totalTrials":2272,"cells":3683},{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3688,"PHASE3":3722,"PHASE4":3728,"NA":3730},{"trials":3685,"activeCount":104},[],{"trials":3687,"activeCount":104},[],{"trials":3689,"activeCount":1861,"soonestReadout":1363},[3690,3701,3709,3713],{"nctId":3691,"briefTitle":3692,"status":143,"phases":3693,"primaryCompletion":3694,"completion":807,"start":3695,"enrollment":1084,"conditions":3696,"interventions":3700},"NCT05426005","Cadonilimab for PD-1\u002FPD-L1 Blockade-refractory, MSI-H\u002FdMMR, Advanced Colorectal Cancer",[92,93],"2026-09-01","2023-02-07",[3697,3698,3699],"Colorectal Cancer Stage IV","Mismatch Repair-deficient (dMMR)","Microsatellite Instability-high (MSI-H)",[795],{"nctId":3702,"briefTitle":3703,"status":174,"phases":3704,"primaryCompletion":238,"completion":238,"start":2761,"enrollment":3705,"conditions":3706,"interventions":3708},"NCT05578430","AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)",[93],54,[3707],"Resectable Hepatocellular Carcinoma",[795],{"nctId":2891,"briefTitle":2892,"status":300,"phases":3710,"primaryCompletion":1363,"completion":236,"start":2894,"enrollment":1712,"conditions":3711,"interventions":3712},[93],[2896,2897],[795,353],{"nctId":3714,"briefTitle":3715,"status":300,"phases":3716,"primaryCompletion":3717,"completion":119,"start":3718,"enrollment":461,"conditions":3719,"interventions":3720},"NCT06143748","Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)",[93],"2026-06-10","2024-03-02",[661],[795,3721],"Paclitaxel and cisplatin",{"trials":3723,"activeCount":100,"soonestReadout":790},[3724],{"nctId":787,"briefTitle":788,"status":300,"phases":3725,"primaryCompletion":790,"completion":791,"start":733,"enrollment":792,"conditions":3726,"interventions":3727},[94],[16,396],[795,49,225],{"trials":3729,"activeCount":104},[],{"trials":3731,"activeCount":100,"soonestReadout":2152},[3732],{"nctId":2149,"briefTitle":2150,"status":143,"phases":3733,"primaryCompletion":2152,"completion":2153,"start":2154,"enrollment":942,"conditions":3734,"interventions":3735},[96],[19,2156,2157,795,272,2158],[795,272],{"intervention":443,"totalTrials":3737,"cells":3738},15,{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3751,"PHASE3":3796,"PHASE4":3847,"NA":3849},{"trials":3740,"activeCount":104},[],{"trials":3742,"activeCount":104},[3743],{"nctId":3744,"briefTitle":3745,"status":328,"phases":3746,"primaryCompletion":657,"completion":1499,"start":3747,"enrollment":3748,"conditions":3749,"interventions":3750},"NCT02964455","Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma",[92],"2016-11",12,[463],[443,834],{"trials":3752,"activeCount":1861,"soonestReadout":2643},[3753,3764,3768,3772,3776,3786],{"nctId":3754,"briefTitle":3755,"status":174,"phases":3756,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":20,"conditions":3760,"interventions":3761},"NCT02610556","Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma",[93],"2020-01","2022-01","2016-01",[16],[3762,443,3763],"Cisplatin 2","Cisplatin 1",{"nctId":1371,"briefTitle":1372,"status":328,"phases":3765,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":3766,"interventions":3767},[93],[1318,1378,1379],[1381,443,444],{"nctId":435,"briefTitle":436,"status":328,"phases":3769,"primaryCompletion":204,"completion":438,"start":439,"enrollment":205,"conditions":3770,"interventions":3771},[93],[441],[443,225,444],{"nctId":1061,"briefTitle":1062,"status":300,"phases":3773,"primaryCompletion":1064,"completion":119,"start":1065,"enrollment":1066,"conditions":3774,"interventions":3775},[93],[28,1068],[284,443,271],{"nctId":3777,"briefTitle":3778,"status":3411,"phases":3779,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":3050,"conditions":3780,"interventions":3783},"NCT07618624","BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression",[93],[3781,3782],"Recurrent Head and Neck Squamous Cell Carcinoma","Head and Neck Cancer",[3784,823,443,3785],"Finotonlimab","Platinum-based Chemotherapy",{"nctId":3787,"briefTitle":3788,"status":300,"phases":3789,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":3791,"interventions":3792},"NCT04172259","ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC",[93],"2019-01-10",[28,3521],[3793,2308,1381,443,3794,3795,270,1059],"Doxorubicin liposome","Epirubicin","Pertuzumab",{"trials":3797,"activeCount":100,"soonestReadout":895},[3798,3802,3806,3814,3818,3822,3834,3838],{"nctId":615,"briefTitle":616,"status":174,"phases":3799,"primaryCompletion":260,"completion":260,"start":618,"enrollment":619,"conditions":3800,"interventions":3801},[94],[16],[443,225],{"nctId":654,"briefTitle":655,"status":174,"phases":3803,"primaryCompletion":657,"completion":658,"start":459,"enrollment":659,"conditions":3804,"interventions":3805},[94],[661,662],[443,664,225],{"nctId":3807,"briefTitle":3808,"status":174,"phases":3809,"primaryCompletion":3758,"completion":3810,"start":3759,"enrollment":3811,"conditions":3812,"interventions":3813},"NCT02621970","Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma",[94],"2024-01",534,[16],[3763,3762,443,2088],{"nctId":730,"briefTitle":731,"status":174,"phases":3815,"primaryCompletion":733,"completion":346,"start":216,"enrollment":734,"conditions":3816,"interventions":3817},[94],[736],[443,738,225,739],{"nctId":760,"briefTitle":761,"status":174,"phases":3819,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":3820,"interventions":3821},[94],[463,714,715],[443,225,768,225],{"nctId":3823,"briefTitle":3824,"status":143,"phases":3825,"primaryCompletion":895,"completion":303,"start":3826,"enrollment":3827,"conditions":3828,"interventions":3831},"NCT05430399","Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer",[94],"2022-06-21",349,[3829,3830],"Breast Neoplasms","Locally Advanced or Metastatic Breast Cancer",[3832,3833],"utidelone","docetaxel",{"nctId":815,"briefTitle":816,"status":174,"phases":3835,"primaryCompletion":818,"start":819,"enrollment":820,"conditions":3836,"interventions":3837},[94],[16],[823,225,443,444],{"nctId":3839,"briefTitle":3840,"status":174,"phases":3841,"primaryCompletion":3842,"completion":3843,"start":178,"enrollment":3844,"conditions":3845,"interventions":3846},"NCT02786641","Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2018-08","2021-08",235,[16],[443,3763,2088,3762],{"trials":3848,"activeCount":104},[],{"trials":3850,"activeCount":104},[],{"intervention":517,"totalTrials":1833,"cells":3852},{"EARLY_PHASE1":3853,"PHASE1":3855,"PHASE2":3857,"PHASE3":3915,"PHASE4":3937,"NA":3939},{"trials":3854,"activeCount":104},[],{"trials":3856,"activeCount":104},[],{"trials":3858,"activeCount":1861,"soonestReadout":1064},[3859,3866,3872,3880,3891,3899,3903,3907,3911],{"nctId":3860,"briefTitle":3861,"status":904,"phases":3862,"primaryCompletion":217,"completion":1657,"start":3863,"enrollment":104,"conditions":3864,"interventions":3865},"NCT03780634","HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC",[93],"2019-04-01",[19],[517,999],{"nctId":3867,"briefTitle":3868,"status":300,"phases":3869,"primaryCompletion":1064,"completion":380,"start":949,"enrollment":32,"conditions":3870,"interventions":3871},"NCT04833387","PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR\u002FMSS Rectal Cancer",[93],[1512],[517],{"nctId":3873,"briefTitle":3874,"status":328,"phases":3875,"primaryCompletion":3355,"completion":3355,"start":535,"enrollment":2272,"conditions":3876,"interventions":3879},"NCT03755440","PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.",[93],[3877,3878],"Gastric Cancer Stage IV","EBV",[517],{"nctId":3881,"briefTitle":3882,"status":143,"phases":3883,"primaryCompletion":358,"completion":1480,"start":3884,"enrollment":472,"conditions":3885,"interventions":3888},"NCT06802835","EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R\u002FM Nasopharyngeal Carcinoma",[92,93],"2025-07-09",[37,3886,3887],"Recurrent Nasopharynx Carcinoma","Metastatic Nasopharyngeal Carcinoma",[3889,517,3890],"EGFR Antibody","Gemcitabine, Cisplatin",{"nctId":3892,"briefTitle":3893,"status":904,"phases":3894,"primaryCompletion":966,"completion":1094,"start":3895,"enrollment":104,"conditions":3896,"interventions":3897},"NCT03782831","TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC",[93],"2018-12-11",[19],[517,3898],"Placebos",{"nctId":2883,"briefTitle":2884,"status":904,"phases":3900,"primaryCompletion":2886,"completion":966,"start":2887,"enrollment":104,"conditions":3901,"interventions":3902},[93],[19],[353,517],{"nctId":1408,"briefTitle":1409,"status":174,"phases":3904,"primaryCompletion":1411,"completion":1238,"start":1412,"enrollment":959,"conditions":3905,"interventions":3906},[93],[1414,1415,1416],[1418,542,444],{"nctId":508,"briefTitle":509,"status":116,"phases":3908,"primaryCompletion":511,"completion":512,"start":513,"enrollment":514,"conditions":3909,"interventions":3910},[93],[37],[517,225],{"nctId":2900,"briefTitle":2901,"status":904,"phases":3912,"primaryCompletion":949,"completion":949,"start":2903,"enrollment":104,"conditions":3913,"interventions":3914},[93],[19],[2906,353,517],{"trials":3916,"activeCount":100,"soonestReadout":358},[3917,3925,3929,3933],{"nctId":3918,"briefTitle":3919,"status":174,"phases":3920,"primaryCompletion":721,"completion":379,"start":3140,"enrollment":3921,"conditions":3922,"interventions":3924},"NCT04711434","PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients",[94],260,[3923],"Lynch Syndrome",[1418],{"nctId":1477,"briefTitle":1478,"status":143,"phases":3926,"primaryCompletion":358,"completion":1480,"start":1481,"enrollment":1482,"conditions":3927,"interventions":3928},[94],[16],[517,444],{"nctId":2928,"briefTitle":2929,"status":904,"phases":3930,"primaryCompletion":1509,"completion":1509,"start":2058,"enrollment":104,"conditions":3931,"interventions":3932},[94],[19],[353,517,2933],{"nctId":2935,"briefTitle":2936,"status":904,"phases":3934,"primaryCompletion":949,"completion":2644,"start":2938,"enrollment":104,"conditions":3935,"interventions":3936},[94],[19],[353,517],{"trials":3938,"activeCount":104},[],{"trials":3940,"activeCount":104},[],{"intervention":270,"totalTrials":2439,"cells":3942},{"EARLY_PHASE1":3943,"PHASE1":3945,"PHASE2":3947,"PHASE3":3983,"PHASE4":3993,"NA":3995},{"trials":3944,"activeCount":104},[],{"trials":3946,"activeCount":104},[],{"trials":3948,"activeCount":1861,"soonestReadout":2643},[3949,3959,3963,3967,3971,3975,3979],{"nctId":3950,"briefTitle":3951,"status":904,"phases":3952,"primaryCompletion":3953,"completion":3954,"start":3955,"enrollment":104,"conditions":3956,"interventions":3958},"NCT02985333","Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma",[93],"2018-12","2019-06","2014-01",[3957],"Relapse\u002FRefractory Multiple Myeloma",[270,2308,183],{"nctId":256,"briefTitle":257,"status":174,"phases":3960,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":3961,"interventions":3962},[93],[264,265,266],[268,269,270,225,271,272],{"nctId":298,"briefTitle":299,"status":300,"phases":3964,"primaryCompletion":302,"completion":303,"start":304,"enrollment":305,"conditions":3965,"interventions":3966},[93],[16],[270,225],{"nctId":1977,"briefTitle":1978,"status":174,"phases":3968,"primaryCompletion":438,"completion":459,"start":1980,"enrollment":942,"conditions":3969,"interventions":3970},[93],[441],[270,272,271],{"nctId":3485,"briefTitle":3486,"status":116,"phases":3972,"primaryCompletion":3262,"completion":119,"start":746,"enrollment":3488,"conditions":3973,"interventions":3974},[93],[252,28,2896,700,3490],[3492,270,271],{"nctId":446,"briefTitle":447,"status":174,"phases":3976,"primaryCompletion":449,"completion":449,"start":450,"enrollment":430,"conditions":3977,"interventions":3978},[93],[452,16],[454,225,270],{"nctId":3787,"briefTitle":3788,"status":300,"phases":3980,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":3981,"interventions":3982},[93],[28,3521],[3793,2308,1381,443,3794,3795,270,1059],{"trials":3984,"activeCount":100,"soonestReadout":708},[3985,3989],{"nctId":686,"briefTitle":687,"status":174,"phases":3986,"primaryCompletion":658,"completion":658,"start":638,"enrollment":179,"conditions":3987,"interventions":3988},[94],[690],[270,225],{"nctId":705,"briefTitle":706,"status":143,"phases":3990,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":3991,"interventions":3992},[94],[713,714,715],[483,270,225],{"trials":3994,"activeCount":104},[],{"trials":3996,"activeCount":104},[],{"intervention":1767,"totalTrials":3998,"cells":3999},7,{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4013,"PHASE3":4027,"PHASE4":4072,"NA":4074},{"trials":4001,"activeCount":104},[],{"trials":4003,"activeCount":100,"soonestReadout":4008},[4004],{"nctId":4005,"briefTitle":4006,"status":143,"phases":4007,"primaryCompletion":4008,"completion":4009,"start":1509,"enrollment":26,"conditions":4010,"interventions":4012},"NCT06760117","UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R\u002FR Solid Tumors",[92],"2025-06","2025-12",[4011],"Pediatric Solid Tumor",[54,1767,2306],{"trials":4014,"activeCount":1255,"soonestReadout":380},[4015,4019],{"nctId":1758,"briefTitle":1759,"status":143,"phases":4016,"primaryCompletion":380,"completion":119,"start":1761,"enrollment":820,"conditions":4017,"interventions":4018},[93],[1763],[1765,1766,54,1767,1768,1769,483],{"nctId":4020,"briefTitle":4021,"status":300,"phases":4022,"primaryCompletion":380,"completion":380,"start":4023,"enrollment":1389,"conditions":4024,"interventions":4026},"NCT04959500","Newly Diagnosed Glioblastoma",[93],"2021-07-21",[4025],"Glioblastoma",[844,1767],{"trials":4028,"activeCount":100,"soonestReadout":4043},[4029,4039,4052,4063],{"nctId":4030,"briefTitle":4031,"status":174,"phases":4032,"primaryCompletion":4033,"completion":302,"start":4034,"enrollment":4035,"conditions":4036,"interventions":4038},"NCT05600491","A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme",[94],"2022-12-01","2015-11-08",78,[4037,4025],"Anaplastic Oligoastrocytoma",[1767],{"nctId":4040,"briefTitle":4041,"status":143,"phases":4042,"primaryCompletion":4043,"completion":4044,"start":4045,"enrollment":4046,"conditions":4047,"interventions":4051},"NCT01649830","Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma",[94],"2025-08","2026-08","2012-07",290,[4048,4049,4050],"Astrocytoma","Oligodendroglioma","Oligodendroastrocytoma",[1767],{"nctId":4053,"briefTitle":4054,"status":1091,"phases":4055,"start":4056,"enrollment":4057,"conditions":4058,"interventions":4062},"NCT00897377","Treatment Strategy for Low-grade Gliomas",[94],"2007-12",500,[4059,4060,4061],"Astrocytomas","Oligodendrogliomas","Oligoastrocytoma",[1767],{"nctId":4064,"briefTitle":4065,"status":174,"phases":4066,"primaryCompletion":460,"completion":657,"start":4067,"enrollment":189,"conditions":4068,"interventions":4070},"NCT01765088","A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas",[94],"2012-09",[4037,4069,4025],"Anaplastic Astrocytoma",[1767,4071],"α-IFN",{"trials":4073,"activeCount":104},[],{"trials":4075,"activeCount":104},[],{"intervention":296,"totalTrials":2272,"cells":4077},{"EARLY_PHASE1":4078,"PHASE1":4080,"PHASE2":4082,"PHASE3":4100,"PHASE4":4110,"NA":4112},{"trials":4079,"activeCount":104},[],{"trials":4081,"activeCount":104},[],{"trials":4083,"activeCount":1861,"soonestReadout":53},[4084,4088,4092,4096],{"nctId":1916,"briefTitle":1917,"status":116,"phases":4085,"primaryCompletion":1005,"completion":1919,"start":1508,"enrollment":1920,"conditions":4086,"interventions":4087},[93],[1922],[542,296,1924,1925,272,823],{"nctId":286,"briefTitle":287,"status":174,"phases":4089,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":4090,"interventions":4091},[93],[16],[295,225,296],{"nctId":51,"briefTitle":52,"status":300,"phases":4093,"primaryCompletion":53,"completion":548,"start":2548,"enrollment":2549,"conditions":4094,"interventions":4095},[93],[25,2098],[54,823,738,542,2080],{"nctId":2063,"briefTitle":2064,"status":143,"phases":4097,"primaryCompletion":2066,"completion":237,"start":895,"enrollment":239,"conditions":4098,"interventions":4099},[93],[2068],[2070,272,296,54],{"trials":4101,"activeCount":100,"soonestReadout":721},[4102,4106],{"nctId":718,"briefTitle":719,"status":116,"phases":4103,"primaryCompletion":721,"completion":646,"start":722,"enrollment":723,"conditions":4104,"interventions":4105},[93,94],[16,725,726,318,727],[340,225,296,49],{"nctId":730,"briefTitle":731,"status":174,"phases":4107,"primaryCompletion":733,"completion":346,"start":216,"enrollment":734,"conditions":4108,"interventions":4109},[94],[736],[443,738,225,739],{"trials":4111,"activeCount":104},[],{"trials":4113,"activeCount":104},[],{"intervention":876,"totalTrials":2627,"cells":4115},{"EARLY_PHASE1":4116,"PHASE1":4118,"PHASE2":4120,"PHASE3":4153,"PHASE4":4159,"NA":4161},{"trials":4117,"activeCount":104},[],{"trials":4119,"activeCount":104},[],{"trials":4121,"activeCount":1861,"soonestReadout":4146},[4122,4134,4142],{"nctId":4123,"briefTitle":4124,"status":143,"phases":4125,"primaryCompletion":4126,"completion":4127,"start":4128,"enrollment":3272,"conditions":4129,"interventions":4132},"NCT07241793","Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la\u002FmUC)",[93],"2028-07-01","2031-07-01","2025-11-20",[4130,316,4131],"Urothelial Carcinoma","Urothelial Carcinoma Recurrent",[876,4133],"Trastuzumab Rezetecan",{"nctId":4135,"briefTitle":4136,"status":143,"phases":4137,"primaryCompletion":4138,"completion":4138,"start":4139,"enrollment":205,"conditions":4140,"interventions":4141},"NCT06349889","Adebrelimab and Chemoradiotherapy in High-risk LANPC",[93],"2028-05-01","2024-07-23",[16,396],[876],{"nctId":4143,"briefTitle":4144,"status":143,"phases":4145,"primaryCompletion":4146,"completion":4147,"start":4148,"enrollment":4149,"conditions":4150,"interventions":4151},"NCT06455410","GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma",[93],"2026-06-18","2028-06-18","2024-06-18",216,[16],[3562,876,4152],"concurrent chemoradiotherapy",{"trials":4154,"activeCount":100,"soonestReadout":871},[4155],{"nctId":868,"briefTitle":869,"status":116,"phases":4156,"primaryCompletion":871,"completion":872,"start":302,"enrollment":873,"conditions":4157,"interventions":4158},[94],[37,282],[876,225,444],{"trials":4160,"activeCount":104},[],{"trials":4162,"activeCount":104},[],{"intervention":2100,"totalTrials":2627,"cells":4164},{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4169,"PHASE3":4179,"PHASE4":4198,"NA":4200},{"trials":4166,"activeCount":104},[],{"trials":4168,"activeCount":104},[],{"trials":4170,"activeCount":1255,"soonestReadout":380},[4171,4175],{"nctId":2022,"briefTitle":2023,"status":143,"phases":4172,"primaryCompletion":380,"completion":380,"start":2025,"enrollment":996,"conditions":4173,"interventions":4174},[93],[2027],[412,272,2029],{"nctId":400,"briefTitle":401,"status":143,"phases":4176,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":4177,"interventions":4178},[93],[408],[410,411,412,413],{"trials":4180,"activeCount":1255,"soonestReadout":380},[4181,4185],{"nctId":2093,"briefTitle":2094,"status":143,"phases":4182,"primaryCompletion":380,"completion":499,"start":405,"enrollment":2096,"conditions":4183,"interventions":4184},[93,94],[25,2098],[542,664,2100,272],{"nctId":4186,"briefTitle":4187,"status":116,"phases":4188,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":4191,"conditions":4192,"interventions":4195},"NCT07277842","PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer",[94],"2028-12-29","2025-12-29",382,[4193,4194],"Locally Advanced Low Rectal Adenocarcinoma","pMMR (Microsatellite Stable Rectal Cancer)",[2100,4196,4197],"FOLFOXIRI chemotherapy","CAPOX chemotherapy",{"trials":4199,"activeCount":104},[],{"trials":4201,"activeCount":104},[],{"intervention":2594,"totalTrials":2627,"cells":4203},{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4237,"PHASE4":4243,"NA":4245},{"trials":4205,"activeCount":104},[],{"trials":4207,"activeCount":104},[],{"trials":4209,"activeCount":1861,"soonestReadout":345},[4210,4220,4230],{"nctId":4211,"briefTitle":4212,"status":116,"phases":4213,"primaryCompletion":4214,"completion":4215,"start":4216,"enrollment":4217,"conditions":4218,"interventions":4219},"NCT07170982","Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer",[93],"2027-10-15","2029-10-15","2025-10-15",128,[2896],[2594],{"nctId":4221,"briefTitle":4222,"status":143,"phases":4223,"primaryCompletion":302,"completion":1999,"start":4224,"enrollment":911,"conditions":4225,"interventions":4229},"NCT06446154","Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma",[93],"2024-12-27",[19,4226,4227,4228],"Immune Checkpoint Inhibitors","Anti-angiogenic Therapy","Second-line Treatment",[2594],{"nctId":4231,"briefTitle":4232,"status":143,"phases":4233,"primaryCompletion":345,"completion":4234,"start":782,"enrollment":2017,"conditions":4235,"interventions":4236},"NCT06018714","Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study",[93],"2026-08-01",[1020],[2594],{"trials":4238,"activeCount":100,"soonestReadout":1227},[4239],{"nctId":2586,"briefTitle":2587,"status":143,"phases":4240,"primaryCompletion":1227,"completion":2589,"start":2590,"enrollment":2591,"conditions":4241,"interventions":4242},[93,94],[25],[2594,664,542],{"trials":4244,"activeCount":104},[],{"trials":4246,"activeCount":104},[],{"intervention":269,"totalTrials":4248,"cells":4249},17,{"EARLY_PHASE1":4250,"PHASE1":4252,"PHASE2":4254,"PHASE3":4328,"PHASE4":4354,"NA":4365},{"trials":4251,"activeCount":104},[],{"trials":4253,"activeCount":104},[],{"trials":4255,"activeCount":100,"soonestReadout":1277},[4256,4263,4271,4275,4279,4283,4287,4291,4300,4308,4312,4324],{"nctId":4257,"briefTitle":4258,"status":174,"phases":4259,"primaryCompletion":1953,"completion":1953,"start":4260,"enrollment":26,"conditions":4261,"interventions":4262},"NCT03144856","Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers",[93],"2017-02-22",[3253],[269],{"nctId":4264,"briefTitle":4265,"status":174,"phases":4266,"primaryCompletion":4267,"completion":4267,"start":4268,"enrollment":1460,"conditions":4269,"interventions":4270},"NCT03144843","Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.",[93],"2020-01-31","2017-01-13",[539],[269,3898],{"nctId":1274,"briefTitle":1275,"status":300,"phases":4272,"primaryCompletion":1277,"completion":1277,"start":500,"enrollment":1095,"conditions":4273,"interventions":4274},[93],[463,1279,1280],[1282,1283,269,444],{"nctId":3436,"briefTitle":3437,"status":904,"phases":4276,"primaryCompletion":3439,"completion":3440,"start":3441,"enrollment":104,"conditions":4277,"interventions":4278},[93],[2210],[269,254,271],{"nctId":256,"briefTitle":257,"status":174,"phases":4280,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":4281,"interventions":4282},[93],[264,265,266],[268,269,270,225,271,272],{"nctId":3121,"briefTitle":3122,"status":174,"phases":4284,"primaryCompletion":3124,"completion":3125,"start":3126,"enrollment":2059,"conditions":4285,"interventions":4286},[93],[16],[268,269],{"nctId":1752,"briefTitle":1753,"status":904,"phases":4288,"primaryCompletion":1737,"completion":1737,"start":217,"enrollment":104,"conditions":4289,"interventions":4290},[93],[1660],[1662,483,269],{"nctId":4292,"briefTitle":4293,"status":1091,"phases":4294,"primaryCompletion":4295,"completion":4296,"start":4297,"enrollment":959,"conditions":4298,"interventions":4299},"NCT02874651","ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy",[93],"2018-11-29","2020-08-27","2016-10",[441],[269],{"nctId":4301,"briefTitle":4302,"status":328,"phases":4303,"primaryCompletion":2105,"completion":4304,"start":4305,"enrollment":1109,"conditions":4306,"interventions":4307},"NCT02867956","Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer",[93],"2019-09-10","2016-08-10",[2042],[269,411],{"nctId":3130,"briefTitle":3131,"status":174,"phases":4309,"primaryCompletion":860,"completion":2788,"start":216,"enrollment":205,"conditions":4310,"interventions":4311},[93],[2876],[268,269],{"nctId":4313,"briefTitle":4314,"status":328,"phases":4315,"primaryCompletion":4316,"completion":4317,"start":4318,"enrollment":1289,"conditions":4319,"interventions":4322},"NCT03816553","SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer",[93],"2020-04-30","2022-08-31","2019-01-19",[4320,4321],"Recurrent Cervical Carcinoma","Metastatic Cervical Cancer",[4323,269],"SHR-1210",{"nctId":3157,"briefTitle":3158,"status":174,"phases":4325,"primaryCompletion":3124,"completion":3125,"start":3126,"enrollment":959,"conditions":4326,"interventions":4327},[93],[16],[268,269],{"trials":4329,"activeCount":1255,"soonestReadout":302},[4330,4338,4342,4346],{"nctId":4331,"briefTitle":4332,"status":174,"phases":4333,"primaryCompletion":536,"completion":3507,"start":4334,"enrollment":12,"conditions":4335,"interventions":4336},"NCT01287962","Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer",[94],"2011-04",[22],[4337],"apatinib",{"nctId":779,"briefTitle":780,"status":143,"phases":4339,"primaryCompletion":302,"completion":404,"start":782,"enrollment":783,"conditions":4340,"interventions":4341},[94],[16],[268,49,225,269],{"nctId":3205,"briefTitle":3206,"status":300,"phases":4343,"primaryCompletion":1999,"completion":1999,"start":3208,"enrollment":3209,"conditions":4344,"interventions":4345},[94],[19],[268,269],{"nctId":4347,"briefTitle":4348,"status":174,"phases":4349,"primaryCompletion":259,"completion":259,"start":1374,"enrollment":1856,"conditions":4350,"interventions":4352},"NCT02824458","A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations",[94],[4351],"EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors",[269,4353],"Gefitinib",{"trials":4355,"activeCount":104},[4356],{"nctId":4357,"briefTitle":4358,"status":174,"phases":4359,"primaryCompletion":658,"completion":1575,"start":4360,"enrollment":4361,"conditions":4362,"interventions":4364},"NCT03475589","Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations",[95],"2018-02-26",217,[4363],"Stage IV Cancer",[4337],{"trials":4366,"activeCount":104},[],{"intervention":664,"totalTrials":3998,"cells":4368},{"EARLY_PHASE1":4369,"PHASE1":4371,"PHASE2":4373,"PHASE3":4387,"PHASE4":4410,"NA":4412},{"trials":4370,"activeCount":104},[],{"trials":4372,"activeCount":104},[],{"trials":4374,"activeCount":100,"soonestReadout":380},[4375,4379,4383],{"nctId":3453,"briefTitle":3454,"status":174,"phases":4376,"primaryCompletion":3355,"completion":289,"start":3456,"enrollment":898,"conditions":4377,"interventions":4378},[93],[714,3458],[664,3460],{"nctId":456,"briefTitle":457,"status":174,"phases":4380,"primaryCompletion":459,"completion":460,"start":429,"enrollment":461,"conditions":4381,"interventions":4382},[93],[463],[465,225],{"nctId":2072,"briefTitle":2073,"status":143,"phases":4384,"primaryCompletion":380,"completion":380,"start":2075,"enrollment":2076,"conditions":4385,"interventions":4386},[93],[1020],[183,2079,542,2080,664,54,272,542,2080,664],{"trials":4388,"activeCount":1255,"soonestReadout":1227},[4389,4393,4397,4401],{"nctId":2093,"briefTitle":2094,"status":143,"phases":4390,"primaryCompletion":380,"completion":499,"start":405,"enrollment":2096,"conditions":4391,"interventions":4392},[93,94],[25,2098],[542,664,2100,272],{"nctId":654,"briefTitle":655,"status":174,"phases":4394,"primaryCompletion":657,"completion":658,"start":459,"enrollment":659,"conditions":4395,"interventions":4396},[94],[661,662],[443,664,225],{"nctId":2586,"briefTitle":2587,"status":143,"phases":4398,"primaryCompletion":1227,"completion":2589,"start":2590,"enrollment":2591,"conditions":4399,"interventions":4400},[93,94],[25],[2594,664,542],{"nctId":4402,"briefTitle":4403,"status":174,"phases":4404,"primaryCompletion":203,"completion":2770,"start":4405,"enrollment":4406,"conditions":4407,"interventions":4408},"NCT01211210","Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer",[93,94],"2010-06",495,[34],[465,4409,4409],"fluorouracil, oxaliplatin",{"trials":4411,"activeCount":104},[],{"trials":4413,"activeCount":104},[],{"intervention":4415,"totalTrials":3998,"cells":4416},"mFOLFOX6",{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4453,"PHASE4":4488,"NA":4490},{"trials":4418,"activeCount":104},[],{"trials":4420,"activeCount":104},[],{"trials":4422,"activeCount":1255,"soonestReadout":379},[4423,4435,4447],{"nctId":4424,"briefTitle":4425,"status":116,"phases":4426,"primaryCompletion":4427,"completion":4428,"start":4429,"enrollment":4430,"conditions":4431,"interventions":4433},"NCT06890624","mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer",[93],"2029-10-01","2031-10-01","2026-10-01",138,[4432],"Colon Cancer (Stage II &Amp;Amp; III)",[4434,4415],"cmFOLFOXIRI plus PD-1 inhibitor",{"nctId":4436,"briefTitle":4437,"status":143,"phases":4438,"primaryCompletion":379,"completion":4439,"start":4440,"enrollment":4441,"conditions":4442,"interventions":4443},"NCT05571644","Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer",[93],"2027-08-15","2023-07-10",143,[25],[4444,4415,4445,4446],"mFOLFOXIRI + Cadonilimab","mFOLFOXIRI","mFOLFOXIRI+AK104+fruquintinib",{"nctId":4448,"briefTitle":4449,"status":174,"phases":4450,"primaryCompletion":1337,"completion":906,"start":829,"enrollment":1192,"conditions":4451,"interventions":4452},"NCT02887313","FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study",[93],[34],[4415],{"trials":4454,"activeCount":100,"soonestReadout":4481},[4455,4462,4469,4477],{"nctId":4456,"briefTitle":4457,"status":174,"phases":4458,"primaryCompletion":479,"completion":1064,"start":4459,"enrollment":4046,"conditions":4460,"interventions":4461},"NCT03192618","The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.",[94],"2017-07-01",[19],[4415],{"nctId":4463,"briefTitle":4464,"status":174,"phases":4465,"primaryCompletion":460,"completion":657,"start":4466,"enrollment":1192,"conditions":4467,"interventions":4468},"NCT03015675","IV Ascorbic Acid in Advanced Gastric Cancer",[94],"2017-03-12",[539],[3327,4415],{"nctId":4470,"briefTitle":4471,"status":174,"phases":4472,"primaryCompletion":479,"completion":1064,"start":4459,"enrollment":4473,"conditions":4474,"interventions":4475},"NCT03192644","The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.",[94],162,[19],[4476,4415],"epidoxorubicin and cisplatin and lipiodol",{"nctId":4478,"briefTitle":4479,"status":116,"phases":4480,"primaryCompletion":4481,"completion":4482,"start":895,"enrollment":4483,"conditions":4484,"interventions":4485},"NCT06959693","A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS\u002FBRAF Wild-Type Metastatic Colorectal Cancer (mCRC)",[93,94],"2028-09-30","2030-06-30",590,[1922],[4486,4487,4415],"Cetuxima-β","Envafolimab",{"trials":4489,"activeCount":104},[],{"trials":4491,"activeCount":104},[],{"intervention":363,"totalTrials":161,"cells":4493},{"EARLY_PHASE1":4494,"PHASE1":4496,"PHASE2":4498,"PHASE3":4520,"PHASE4":4526,"NA":4528},{"trials":4495,"activeCount":104},[],{"trials":4497,"activeCount":104},[],{"trials":4499,"activeCount":1255,"soonestReadout":975},[4500,4504,4508,4512],{"nctId":972,"briefTitle":973,"status":116,"phases":4501,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":4502,"interventions":4503},[92,93],[16],[981,284,363],{"nctId":3258,"briefTitle":3259,"status":904,"phases":4505,"primaryCompletion":3261,"completion":3262,"start":1156,"enrollment":104,"conditions":4506,"interventions":4507},[93],[3264,3265],[363,726,318],{"nctId":355,"briefTitle":356,"status":143,"phases":4509,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":4510,"interventions":4511},[93],[16],[284,363,49,225],{"nctId":4513,"briefTitle":4514,"status":328,"phases":4515,"primaryCompletion":4516,"completion":4517,"start":1828,"enrollment":26,"conditions":4518,"interventions":4519},"NCT03906058","Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy",[93],"2021-02-27","2022-04-30",[16],[363],{"trials":4521,"activeCount":100,"soonestReadout":773},[4522],{"nctId":770,"briefTitle":771,"status":116,"phases":4523,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":4524,"interventions":4525},[94],[16],[284,363,225,49],{"trials":4527,"activeCount":104},[],{"trials":4529,"activeCount":104},[],{"intervention":2793,"totalTrials":1861,"cells":4531},{"EARLY_PHASE1":4532,"PHASE1":4534,"PHASE2":4536,"PHASE3":4538,"PHASE4":4557,"NA":4559},{"trials":4533,"activeCount":104},[],{"trials":4535,"activeCount":104},[],{"trials":4537,"activeCount":104},[],{"trials":4539,"activeCount":1861,"soonestReadout":2811},[4540,4544,4548],{"nctId":2785,"briefTitle":2786,"status":143,"phases":4541,"primaryCompletion":940,"completion":940,"start":2788,"enrollment":2789,"conditions":4542,"interventions":4543},[94],[2791],[2372,1958,2793],{"nctId":2808,"briefTitle":2809,"status":143,"phases":4545,"primaryCompletion":2811,"completion":2811,"start":345,"enrollment":792,"conditions":4546,"interventions":4547},[94],[22],[2402,2793],{"nctId":4549,"briefTitle":4550,"status":143,"phases":4551,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":4552,"conditions":4553,"interventions":4555},"NCT06734702","Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer",[94],497,[4554,2369,318,2791],"Neoadjuvant Therapy",[4556,2793],"Neoadjuvant therapy",{"trials":4558,"activeCount":104},[],{"trials":4560,"activeCount":104},[],{"intervention":4562,"totalTrials":1861,"cells":4563},"CAPOX",{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4568,"PHASE3":4586,"PHASE4":4597,"NA":4599},{"trials":4565,"activeCount":104},[],{"trials":4567,"activeCount":104},[],{"trials":4569,"activeCount":1255,"soonestReadout":2434},[4570,4578],{"nctId":4571,"briefTitle":4572,"status":116,"phases":4573,"primaryCompletion":1508,"completion":807,"start":3261,"enrollment":406,"conditions":4574,"interventions":4576},"NCT06919510","A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR\u002FMSS Locally Advanced Rectal Cancer",[93],[4575],"Rectal Adenocarcinoma",[4577,4562],"lvonescimab",{"nctId":4579,"briefTitle":4580,"status":116,"phases":4581,"primaryCompletion":2434,"completion":4582,"start":4583,"enrollment":29,"conditions":4584,"interventions":4585},"NCT07297030","SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer",[93],"2029-05-01","2025-12-20",[34],[4562,318],{"trials":4587,"activeCount":100,"soonestReadout":4592},[4588],{"nctId":4589,"briefTitle":4590,"status":143,"phases":4591,"primaryCompletion":4592,"completion":4593,"start":1083,"enrollment":1482,"conditions":4594,"interventions":4595},"NCT07528209","Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer",[94],"2032-04-20","2034-04-20",[34,4194],[4596,4562],"Pucotenlimab combine with CAPOX",{"trials":4598,"activeCount":104},[],{"trials":4600,"activeCount":104},[],{"intervention":2463,"totalTrials":3998,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4607,"PHASE3":4609,"PHASE4":4658,"NA":4660},{"trials":4604,"activeCount":104},[],{"trials":4606,"activeCount":104},[],{"trials":4608,"activeCount":104},[],{"trials":4610,"activeCount":1255,"soonestReadout":260},[4611,4617,4626,4630,4640,4650],{"nctId":4612,"briefTitle":4613,"status":174,"phases":4614,"primaryCompletion":658,"completion":1575,"start":3759,"enrollment":4046,"conditions":4615,"interventions":4616},"NCT02738697","Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection",[94],[1888],[2463],{"nctId":4618,"briefTitle":4619,"status":328,"phases":4620,"primaryCompletion":658,"completion":658,"start":4621,"enrollment":4622,"conditions":4623,"interventions":4624},"NCT01137123","Improve the Treatment of Thoracic Esophageal Cancer",[94],"2010-04",301,[3425],[4625],"adjuvant chemotherapy",{"nctId":2453,"briefTitle":2454,"status":143,"phases":4627,"primaryCompletion":2456,"completion":2457,"start":2458,"enrollment":2459,"conditions":4628,"interventions":4629},[94],[25,2461],[69,2463],{"nctId":4631,"briefTitle":4632,"status":143,"phases":4633,"primaryCompletion":260,"completion":419,"start":1657,"enrollment":4634,"conditions":4635,"interventions":4638},"NCT05194878","Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers",[94],840,[4636,4637],"Colon Cancer Stage II","Colon Cancer Stage III",[4639,4625],"neoadjuvant chemotherapyI",{"nctId":4641,"briefTitle":4642,"status":174,"phases":4643,"primaryCompletion":489,"start":4644,"enrollment":4645,"conditions":4646,"interventions":4648},"NCT02280278","Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy",[94],"2014-10",550,[4647],"Stage III Colon Cancer",[2463,4649],"Cytokine-induced killer cell immunotherapy",{"nctId":4651,"briefTitle":4652,"status":328,"phases":4653,"primaryCompletion":4008,"completion":4008,"start":1338,"enrollment":4654,"conditions":4655,"interventions":4656},"NCT01815853","Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer",[94],620,[539],[3521,4657],"Adjuvant Chemotherapy",{"trials":4659,"activeCount":104},[],{"trials":4661,"activeCount":100,"soonestReadout":4666},[4662],{"nctId":4663,"briefTitle":4664,"status":116,"phases":4665,"primaryCompletion":4666,"completion":2798,"start":4667,"enrollment":1339,"conditions":4668,"interventions":4671},"NCT07413146","Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial",[96],"2027-02-28","2026-02-24",[4669,4670,3521,1291],"Minimal Residual Disease","Immunoscore",[3521,2463],{"intervention":844,"totalTrials":161,"cells":4673},{"EARLY_PHASE1":4674,"PHASE1":4676,"PHASE2":4678,"PHASE3":4692,"PHASE4":4707,"NA":4717},{"trials":4675,"activeCount":104},[],{"trials":4677,"activeCount":104},[],{"trials":4679,"activeCount":100,"soonestReadout":380},[4680,4688],{"nctId":4681,"briefTitle":4682,"status":174,"phases":4683,"primaryCompletion":290,"completion":4684,"start":563,"enrollment":1727,"conditions":4685,"interventions":4687},"NCT03890068","Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma",[93],"2024-05-30",[4686],"Soft Tissue Sarcoma",[844],{"nctId":4020,"briefTitle":4021,"status":300,"phases":4689,"primaryCompletion":380,"completion":380,"start":4023,"enrollment":1389,"conditions":4690,"interventions":4691},[93],[4025],[844,1767],{"trials":4693,"activeCount":100,"soonestReadout":313},[4694,4703],{"nctId":4695,"briefTitle":4696,"status":174,"phases":4697,"primaryCompletion":658,"completion":1827,"start":4698,"enrollment":4699,"conditions":4700,"interventions":4702},"NCT04028778","Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC",[94],"2019-04-10",310,[4701],"Lung Cancer, Nonsmall Cell",[4353,844],{"nctId":836,"briefTitle":837,"status":116,"phases":4704,"primaryCompletion":313,"completion":839,"start":840,"enrollment":841,"conditions":4705,"interventions":4706},[94],[37,396],[844,49,225,845],{"trials":4708,"activeCount":104},[4709],{"nctId":4710,"briefTitle":4711,"status":174,"phases":4712,"primaryCompletion":479,"completion":479,"start":4713,"enrollment":32,"conditions":4714,"interventions":4715},"NCT04507035","Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy",[95],"2020-09-01",[3782],[4716],"Anlotinib hydrochloride",{"trials":4718,"activeCount":104},[],{"intervention":1205,"totalTrials":1464,"cells":4720},{"EARLY_PHASE1":4721,"PHASE1":4723,"PHASE2":4725,"PHASE3":4780,"PHASE4":4790,"NA":4792},{"trials":4722,"activeCount":104},[],{"trials":4724,"activeCount":104},[],{"trials":4726,"activeCount":100,"soonestReadout":1688},[4727,4731,4735,4744,4759,4768,4772,4776],{"nctId":1685,"briefTitle":1686,"status":116,"phases":4728,"primaryCompletion":1688,"completion":1689,"start":1690,"enrollment":360,"conditions":4729,"interventions":4730},[93],[1692],[483,1205,1694],{"nctId":2190,"briefTitle":2191,"status":174,"phases":4732,"primaryCompletion":259,"completion":259,"start":2193,"enrollment":1109,"conditions":4733,"interventions":4734},[93],[2195],[49,2197,1205],{"nctId":4736,"briefTitle":4737,"status":174,"phases":4738,"primaryCompletion":4739,"completion":1064,"start":4740,"enrollment":32,"conditions":4741,"interventions":4742},"NCT04676789","Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL",[93],"2024-09-01","2021-09-01",[2249],[1205,4743],"Anti-PD-1 monoclonal antibody",{"nctId":4745,"briefTitle":4746,"status":174,"phases":4747,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":4748,"interventions":4750},"NCT02660762","Modified MRCUKALLⅫ\u002FECOGE2993 Regimen for ALL",[93],[4749],"Leukaemia,Lymphoblastic",[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],"Daunorubicin","Intrathecal Methotrexate","Cytarabine","6-Mercaptopurine","Methotrexate","dexamethasone","thioguanine","intrathecal cytarabine",{"nctId":4760,"briefTitle":4761,"status":174,"phases":4762,"primaryCompletion":967,"completion":3355,"start":4763,"enrollment":205,"conditions":4764,"interventions":4766},"NCT03318419","Cladribine in Combination With GAP in Patients With Refractory\u002FRelapsed Acute Lymphoblastic Leukemia",[93],"2016-01-01",[4765],"Acute Lymphoblastic Leukemia",[4767,3181,4753,1205],"Cladribine",{"nctId":2229,"briefTitle":2230,"status":1091,"phases":4769,"primaryCompletion":2232,"completion":1576,"start":2233,"enrollment":205,"conditions":4770,"interventions":4771},[93],[2235],[2237,2238,2239],{"nctId":2245,"briefTitle":2246,"status":174,"phases":4773,"primaryCompletion":618,"completion":906,"start":2165,"enrollment":32,"conditions":4774,"interventions":4775},[93],[2249],[2251,49,542,1205,183],{"nctId":2261,"briefTitle":2262,"status":174,"phases":4777,"primaryCompletion":459,"completion":2264,"start":1375,"enrollment":32,"conditions":4778,"interventions":4779},[93],[2249],[2267,49,1205,183],{"trials":4781,"activeCount":100,"soonestReadout":646},[4782,4786],{"nctId":2300,"briefTitle":2301,"status":1091,"phases":4783,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":4784,"interventions":4785},[94],[2235],[49,542,1205,411,2306,2307,2308,2309],{"nctId":1197,"briefTitle":1198,"status":143,"phases":4787,"primaryCompletion":646,"completion":646,"start":1200,"enrollment":1201,"conditions":4788,"interventions":4789},[94],[1203],[284,1205,49,542],{"trials":4791,"activeCount":104},[],{"trials":4793,"activeCount":104},[],{"intervention":398,"totalTrials":3998,"cells":4795},{"EARLY_PHASE1":4796,"PHASE1":4798,"PHASE2":4800,"PHASE3":4820,"PHASE4":4845,"NA":4847},{"trials":4797,"activeCount":104},[],{"trials":4799,"activeCount":104},[],{"trials":4801,"activeCount":104},[4802,4806,4816],{"nctId":388,"briefTitle":389,"status":328,"phases":4803,"primaryCompletion":391,"completion":392,"start":393,"enrollment":394,"conditions":4804,"interventions":4805},[93],[396],[225,398],{"nctId":4807,"briefTitle":4808,"status":174,"phases":4809,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":29,"conditions":4812,"interventions":4814},"NCT02229045","Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer",[93],"2014-12","2010-11",[4813],"Gastric Caner",[4815,398],"Albumin Bound Paclitaxel",{"nctId":519,"briefTitle":520,"status":174,"phases":4817,"primaryCompletion":522,"completion":53,"start":523,"enrollment":29,"conditions":4818,"interventions":4819},[93],[16,525],[295,225,527],{"trials":4821,"activeCount":1255,"soonestReadout":860},[4822,4833,4837,4841],{"nctId":4823,"briefTitle":4824,"status":116,"phases":4825,"primaryCompletion":379,"completion":871,"start":4826,"enrollment":3488,"conditions":4827,"interventions":4830},"NCT05780294","A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC",[94],"2023-04-01",[16,4828,726,4829],"Leucogen","Myelosuppression",[527,4831,4832],"Lobaplatin","leucogen",{"nctId":2608,"briefTitle":2609,"status":1091,"phases":4834,"primaryCompletion":2611,"completion":479,"start":289,"enrollment":2601,"conditions":4835,"interventions":4836},[94],[1368,2098],[54,2614,2504,2080,398,542],{"nctId":2102,"briefTitle":2103,"status":174,"phases":4838,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":4839,"interventions":4840},[94],[1341,2110,2111,2112,2113],[272,2115,2116,398,2117],{"nctId":857,"briefTitle":858,"status":116,"phases":4842,"primaryCompletion":860,"completion":861,"start":862,"enrollment":262,"conditions":4843,"interventions":4844},[93,94],[16,864,865],[527,225,864],{"trials":4846,"activeCount":104},[],{"trials":4848,"activeCount":104},[],{"intervention":4152,"totalTrials":1861,"cells":4850},{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4855,"PHASE3":4871,"PHASE4":4877,"NA":4879},{"trials":4852,"activeCount":104},[],{"trials":4854,"activeCount":104},[],{"trials":4856,"activeCount":100,"soonestReadout":4146},[4857,4861],{"nctId":4143,"briefTitle":4144,"status":143,"phases":4858,"primaryCompletion":4146,"completion":4147,"start":4148,"enrollment":4149,"conditions":4859,"interventions":4860},[93],[16],[3562,876,4152],{"nctId":4862,"briefTitle":4863,"status":174,"phases":4864,"primaryCompletion":4865,"completion":4865,"start":4866,"enrollment":1987,"conditions":4867,"interventions":4869},"NCT03663764","Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor",[93],"2023-08","2018-08-13",[4868],"Thymoma and Thymic Carcinoma",[4870,4152],"Thymosin a1",{"trials":4872,"activeCount":100,"soonestReadout":1145},[4873],{"nctId":1142,"briefTitle":1143,"status":143,"phases":4874,"primaryCompletion":1145,"completion":1146,"start":1147,"enrollment":1148,"conditions":4875,"interventions":4876},[94],[37],[444,1151,284],{"trials":4878,"activeCount":104},[],{"trials":4880,"activeCount":104},[],{"intervention":4882,"totalTrials":1861,"cells":4883},"Almonertinib",{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4906,"PHASE4":4915,"NA":4917},{"trials":4885,"activeCount":104},[],{"trials":4887,"activeCount":104},[],{"trials":4889,"activeCount":100,"soonestReadout":4901},[4890,4897],{"nctId":4891,"briefTitle":4892,"status":174,"phases":4893,"primaryCompletion":721,"completion":721,"start":3355,"enrollment":492,"conditions":4894,"interventions":4896},"NCT04785742","Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR",[93],[4895],"Safety of Almonertinib",[4882],{"nctId":4898,"briefTitle":4899,"status":143,"phases":4900,"primaryCompletion":4901,"completion":4901,"start":4902,"enrollment":501,"conditions":4903,"interventions":4905},"NCT06947811","A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations",[92,93],"2027-03","2025-06-09",[4904],"EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4\u002F6 Inhibitor",[4882,3548],{"trials":4907,"activeCount":100,"soonestReadout":646},[4908],{"nctId":4909,"briefTitle":4910,"status":143,"phases":4911,"primaryCompletion":646,"completion":499,"start":58,"enrollment":3423,"conditions":4912,"interventions":4914},"NCT05768490","Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases",[94],[1830,505,4913],"EGFR Activating Mutation",[4882],{"trials":4916,"activeCount":104},[],{"trials":4918,"activeCount":104},[],{"intervention":603,"totalTrials":1255,"cells":4920},{"EARLY_PHASE1":4921,"PHASE1":4923,"PHASE2":4925,"PHASE3":4927,"PHASE4":4937,"NA":4939},{"trials":4922,"activeCount":104},[],{"trials":4924,"activeCount":104},[],{"trials":4926,"activeCount":104},[],{"trials":4928,"activeCount":1255,"soonestReadout":678},[4929,4933],{"nctId":592,"briefTitle":593,"status":116,"phases":4930,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":4931,"interventions":4932},[94],[37,396],[601,602,603,225],{"nctId":675,"briefTitle":676,"status":116,"phases":4934,"primaryCompletion":678,"completion":679,"start":680,"enrollment":681,"conditions":4935,"interventions":4936},[94],[37,396],[684,684,603,225],{"trials":4938,"activeCount":104},[],{"trials":4940,"activeCount":104},[],{"intervention":3562,"totalTrials":1255,"cells":4942},{"EARLY_PHASE1":4943,"PHASE1":4945,"PHASE2":4947,"PHASE3":4953,"PHASE4":4959,"NA":4961},{"trials":4944,"activeCount":104},[],{"trials":4946,"activeCount":104},[],{"trials":4948,"activeCount":100,"soonestReadout":4146},[4949],{"nctId":4143,"briefTitle":4144,"status":143,"phases":4950,"primaryCompletion":4146,"completion":4147,"start":4148,"enrollment":4149,"conditions":4951,"interventions":4952},[93],[16],[3562,876,4152],{"trials":4954,"activeCount":100,"soonestReadout":419},[4955],{"nctId":3557,"briefTitle":3558,"status":143,"phases":4956,"primaryCompletion":419,"completion":470,"start":2663,"enrollment":1157,"conditions":4957,"interventions":4958},[94],[3305],[374,3562],{"trials":4960,"activeCount":104},[],{"trials":4962,"activeCount":104},[],{"intervention":1557,"totalTrials":1255,"cells":4964},{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4978,"PHASE4":4984,"NA":4986},{"trials":4966,"activeCount":104},[],{"trials":4968,"activeCount":104},[],{"trials":4970,"activeCount":100,"soonestReadout":1277},[4971],{"nctId":4972,"briefTitle":4973,"status":116,"phases":4974,"primaryCompletion":1277,"completion":1277,"start":4975,"enrollment":333,"conditions":4976,"interventions":4977},"NCT07255612","Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)",[93],"2026-11-04",[28],[3492,1557],{"trials":4979,"activeCount":100,"soonestReadout":1551},[4980],{"nctId":1548,"briefTitle":1549,"status":143,"phases":4981,"primaryCompletion":1551,"completion":1107,"start":1552,"enrollment":1553,"conditions":4982,"interventions":4983},[94],[28,1555],[49,444,768,1557],{"trials":4985,"activeCount":104},[],{"trials":4987,"activeCount":104},[],{"intervention":2805,"totalTrials":1255,"cells":4989},{"EARLY_PHASE1":4990,"PHASE1":4992,"PHASE2":4994,"PHASE3":4996,"PHASE4":5006,"NA":5008},{"trials":4991,"activeCount":104},[],{"trials":4993,"activeCount":104},[],{"trials":4995,"activeCount":104},[],{"trials":4997,"activeCount":1255,"soonestReadout":2798},[4998,5002],{"nctId":2795,"briefTitle":2796,"status":143,"phases":4999,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":5000,"interventions":5001},[94],[16,2803],[2805,2806,2372],{"nctId":2815,"briefTitle":2816,"status":143,"phases":5003,"primaryCompletion":2818,"completion":2819,"start":2820,"enrollment":2821,"conditions":5004,"interventions":5005},[94],[16,2803],[2806,2805,2372],{"trials":5007,"activeCount":104},[],{"trials":5009,"activeCount":104},[],{"intervention":2806,"totalTrials":1255,"cells":5011},{"EARLY_PHASE1":5012,"PHASE1":5014,"PHASE2":5016,"PHASE3":5018,"PHASE4":5028,"NA":5030},{"trials":5013,"activeCount":104},[],{"trials":5015,"activeCount":104},[],{"trials":5017,"activeCount":104},[],{"trials":5019,"activeCount":1255,"soonestReadout":2798},[5020,5024],{"nctId":2795,"briefTitle":2796,"status":143,"phases":5021,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":5022,"interventions":5023},[94],[16,2803],[2805,2806,2372],{"nctId":2815,"briefTitle":2816,"status":143,"phases":5025,"primaryCompletion":2818,"completion":2819,"start":2820,"enrollment":2821,"conditions":5026,"interventions":5027},[94],[16,2803],[2806,2805,2372],{"trials":5029,"activeCount":104},[],{"trials":5031,"activeCount":104},[],{"intervention":845,"totalTrials":1255,"cells":5033},{"EARLY_PHASE1":5034,"PHASE1":5036,"PHASE2":5038,"PHASE3":5049,"PHASE4":5055,"NA":5057},{"trials":5035,"activeCount":104},[],{"trials":5037,"activeCount":104},[],{"trials":5039,"activeCount":100,"soonestReadout":419},[5040],{"nctId":5041,"briefTitle":5042,"status":143,"phases":5043,"primaryCompletion":419,"completion":470,"start":5044,"enrollment":360,"conditions":5045,"interventions":5047},"NCT06733051","Phase II Study of Golidocitinib and Benmelstobart in Patients with R\u002FR ENKTL (JACKPOT50)",[93],"2024-01-27",[5046],"Natural Killer T-cell Lymphoma",[5048,845],"Golidocitinib",{"trials":5050,"activeCount":100,"soonestReadout":313},[5051],{"nctId":836,"briefTitle":837,"status":116,"phases":5052,"primaryCompletion":313,"completion":839,"start":840,"enrollment":841,"conditions":5053,"interventions":5054},[94],[37,396],[844,49,225,845],{"trials":5056,"activeCount":104},[],{"trials":5058,"activeCount":104},[],{"intervention":4556,"totalTrials":1255,"cells":5060},{"EARLY_PHASE1":5061,"PHASE1":5063,"PHASE2":5065,"PHASE3":5076,"PHASE4":5082,"NA":5084},{"trials":5062,"activeCount":104},[],{"trials":5064,"activeCount":104},[],{"trials":5066,"activeCount":100,"soonestReadout":2589},[5067],{"nctId":5068,"briefTitle":5069,"status":143,"phases":5070,"primaryCompletion":2589,"completion":2589,"start":1801,"enrollment":5071,"conditions":5072,"interventions":5074},"NCT07103395","A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer",[93],56,[5073],"Lung Cancer (NSCLC)",[4556,5075],"Consolidative therapy",{"trials":5077,"activeCount":100,"soonestReadout":3280},[5078],{"nctId":4549,"briefTitle":4550,"status":143,"phases":5079,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":4552,"conditions":5080,"interventions":5081},[94],[4554,2369,318,2791],[4556,2793],{"trials":5083,"activeCount":104},[],{"trials":5085,"activeCount":104},[],{"intervention":4487,"totalTrials":1255,"cells":5087},{"EARLY_PHASE1":5088,"PHASE1":5090,"PHASE2":5092,"PHASE3":5101,"PHASE4":5107,"NA":5109},{"trials":5089,"activeCount":104},[],{"trials":5091,"activeCount":104},[],{"trials":5093,"activeCount":100,"soonestReadout":860},[5094],{"nctId":5095,"briefTitle":5096,"status":143,"phases":5097,"primaryCompletion":860,"completion":1999,"start":73,"enrollment":280,"conditions":5098,"interventions":5099},"NCT06014372","Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer",[93],[1404,4554,318],[4487,5100],"CAPEOX",{"trials":5102,"activeCount":100,"soonestReadout":4481},[5103],{"nctId":4478,"briefTitle":4479,"status":116,"phases":5104,"primaryCompletion":4481,"completion":4482,"start":895,"enrollment":4483,"conditions":5105,"interventions":5106},[93,94],[1922],[4486,4487,4415],{"trials":5108,"activeCount":104},[],{"trials":5110,"activeCount":104},[],{"intervention":813,"totalTrials":1255,"cells":5112},{"EARLY_PHASE1":5113,"PHASE1":5115,"PHASE2":5117,"PHASE3":5127,"PHASE4":5133,"NA":5135},{"trials":5114,"activeCount":104},[],{"trials":5116,"activeCount":104},[],{"trials":5118,"activeCount":100,"soonestReadout":403},[5119],{"nctId":5120,"briefTitle":5121,"status":143,"phases":5122,"primaryCompletion":403,"completion":4138,"start":5123,"enrollment":1289,"conditions":5124,"interventions":5126},"NCT06939855","QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma",[93],"2025-09-28",[5125],"Bone and Soft Tissue Tumors",[813],{"trials":5128,"activeCount":100,"soonestReadout":807},[5129],{"nctId":804,"briefTitle":805,"status":143,"phases":5130,"primaryCompletion":807,"completion":808,"start":809,"enrollment":810,"conditions":5131,"interventions":5132},[94],[37,396],[813,49,225],{"trials":5134,"activeCount":104},[],{"trials":5136,"activeCount":104},[],{"intervention":5138,"totalTrials":3998,"cells":5139},"Entecavir",{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5192,"PHASE4":5203,"NA":5205},{"trials":5141,"activeCount":104},[],{"trials":5143,"activeCount":104},[],{"trials":5145,"activeCount":100,"soonestReadout":419},[5146,5157,5167,5177,5186],{"nctId":5147,"briefTitle":5148,"status":328,"phases":5149,"primaryCompletion":5150,"completion":449,"start":5151,"enrollment":1450,"conditions":5152,"interventions":5154},"NCT01254994","The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure",[93],"2009-07","2007-08",[5153],"Liver Failure",[5155,5156],"entecavir","Traditional comprehensive medical treatment",{"nctId":5158,"briefTitle":5159,"status":174,"phases":5160,"primaryCompletion":368,"completion":1064,"start":5161,"enrollment":5162,"conditions":5163,"interventions":5165},"NCT05382351","Antiviral Therapy for Patients With Chronic Hepatitis B Infection",[93],"2022-05-10",238,[5164],"Chronic Hepatitis B Virus Infection",[5138,5166],"Entecavir combined with Tenofovir Amibufenamide",{"nctId":5168,"briefTitle":5169,"status":300,"phases":5170,"primaryCompletion":419,"completion":5171,"start":5172,"enrollment":2591,"conditions":5173,"interventions":5176},"NCT05453435","Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)",[93],"2027-05","2022-07-15",[5174,5175],"Resolved Hepatitis B","CD20 Positive B-cell Lymphoma",[5138],{"nctId":5178,"briefTitle":5179,"status":174,"phases":5180,"primaryCompletion":5181,"completion":5182,"start":5183,"enrollment":205,"conditions":5184,"interventions":5185},"NCT02777814","Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers",[93],"2018-10","2019-11","2015-05-01",[1341],[5138],{"nctId":5187,"briefTitle":5188,"status":174,"phases":5189,"primaryCompletion":460,"completion":549,"start":799,"enrollment":205,"conditions":5190,"interventions":5191},"NCT02777801","Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers",[93],[1318],[5138],{"trials":5193,"activeCount":100,"soonestReadout":5198},[5194],{"nctId":5195,"briefTitle":5196,"status":143,"phases":5197,"primaryCompletion":5198,"completion":3440,"start":5199,"enrollment":2967,"conditions":5200,"interventions":5202},"NCT06966232","Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers",[94],"2027-05-15","2025-05-15",[5201],"Gastrointestinal Cancers",[5138],{"trials":5204,"activeCount":104},[],{"trials":5206,"activeCount":104},[5207],{"nctId":5208,"briefTitle":5209,"status":174,"phases":5210,"primaryCompletion":5211,"completion":5211,"start":4045,"enrollment":996,"conditions":5212,"interventions":5214},"NCT01599130","Efficacy of Peg-interferon α-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss",[96],"2014-04",[5213],"Hepatitis B",[5138,5215],"Peginterferon alfa-2a",{"intervention":651,"totalTrials":161,"cells":5217},{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5224,"PHASE4":5258,"NA":5260},{"trials":5219,"activeCount":104},[],{"trials":5221,"activeCount":104},[],{"trials":5223,"activeCount":104},[],{"trials":5225,"activeCount":1255,"soonestReadout":145},[5226,5230,5240,5247],{"nctId":643,"briefTitle":644,"status":300,"phases":5227,"primaryCompletion":145,"completion":646,"start":647,"enrollment":648,"conditions":5228,"interventions":5229},[94],[16,441,566,567],[651,652,413],{"nctId":5231,"briefTitle":5232,"status":143,"phases":5233,"primaryCompletion":5234,"completion":5235,"start":5236,"enrollment":5237,"conditions":5238,"interventions":5239},"NCT05979961","Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma",[94],"2026-09","2029-09","2023-09-07",454,[16],[651],{"nctId":5241,"briefTitle":5242,"status":174,"phases":5243,"primaryCompletion":5244,"completion":2264,"start":1375,"enrollment":12,"conditions":5245,"interventions":5246},"NCT01872962","Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2018-11",[16],[651],{"nctId":5248,"briefTitle":5249,"status":328,"phases":5250,"primaryCompletion":5251,"completion":5252,"start":5253,"enrollment":5254,"conditions":5255,"interventions":5256},"NCT01528618","Effect and Safety Study of GP\u002FFP Regimens in Advanced Nasopharyngeal Carcinoma",[94],"2016-04-10","2020-12-20","2012-02-21",362,[441],[651,5257],"5-Fluorouracil and cisplatin",{"trials":5259,"activeCount":104},[],{"trials":5261,"activeCount":104},[5262],{"nctId":5263,"briefTitle":5264,"status":174,"phases":5265,"primaryCompletion":658,"completion":1827,"start":1934,"enrollment":610,"conditions":5266,"interventions":5267},"NCT02627807","Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma",[96],[441],[5268,5269,5270,5271],"Gemcitabine and cisplatin","Docetaxel and cisplatin","Cisplatin 100mg\u002Fm² concurrent chemotherapy","Cisplatin 80mg\u002Fm² concurrent chemotherapy",{"intervention":5273,"totalTrials":161,"cells":5274},"FOLFOXIRI",{"EARLY_PHASE1":5275,"PHASE1":5277,"PHASE2":5279,"PHASE3":5315,"PHASE4":5328,"NA":5330},{"trials":5276,"activeCount":104},[],{"trials":5278,"activeCount":104},[],{"trials":5280,"activeCount":104},[5281,5290,5299,5307],{"nctId":5282,"briefTitle":5283,"status":328,"phases":5284,"primaryCompletion":5285,"completion":5286,"start":5287,"enrollment":1339,"conditions":5288,"interventions":5289},"NCT02217020","Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer",[93],"2016-09-15","2017-08-15","2014-08-15",[34],[5273],{"nctId":5291,"briefTitle":5292,"status":328,"phases":5293,"primaryCompletion":657,"completion":657,"start":5294,"enrollment":5295,"conditions":5296,"interventions":5297},"NCT02063529","FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer",[93],"2014-02",101,[1368],[5298,5273],"FOLFOXIRI + Cetuximab",{"nctId":5300,"briefTitle":5301,"status":174,"phases":5302,"primaryCompletion":5303,"completion":5304,"start":5211,"enrollment":4473,"conditions":5305,"interventions":5306},"NCT02128425","FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer",[93],"2017-02","2018-04",[1368],[5273,3667],{"nctId":5308,"briefTitle":5309,"status":328,"phases":5310,"primaryCompletion":1247,"completion":670,"start":5311,"enrollment":4430,"conditions":5312,"interventions":5313},"NCT02350530","FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type",[93],"2015-01-01",[1368],[5314,5273],"FOLFOXIRI + Bevacizumab",{"trials":5316,"activeCount":100,"soonestReadout":5321},[5317],{"nctId":5318,"briefTitle":5319,"status":143,"phases":5320,"primaryCompletion":5321,"completion":5322,"start":5323,"enrollment":5324,"conditions":5325,"interventions":5326},"NCT03671252","Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation",[94],"2025-09-25","2028-09-25","2018-11-16",776,[34],[5273,5327],"XELOX",{"trials":5329,"activeCount":104},[],{"trials":5331,"activeCount":104},[],{"intervention":834,"totalTrials":161,"cells":5333},{"EARLY_PHASE1":5334,"PHASE1":5336,"PHASE2":5342,"PHASE3":5358,"PHASE4":5368,"NA":5370},{"trials":5335,"activeCount":104},[],{"trials":5337,"activeCount":104},[5338],{"nctId":3744,"briefTitle":3745,"status":328,"phases":5339,"primaryCompletion":657,"completion":1499,"start":3747,"enrollment":3748,"conditions":5340,"interventions":5341},[92],[463],[443,834],{"trials":5343,"activeCount":104},[5344,5348],{"nctId":1051,"briefTitle":1052,"status":174,"phases":5345,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":5346,"interventions":5347},[93],[463],[284,1059,834,444],{"nctId":5349,"briefTitle":5350,"status":328,"phases":5351,"primaryCompletion":5352,"completion":3759,"start":1429,"enrollment":5353,"conditions":5354,"interventions":5356},"NCT02861690","Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma",[93],"2015-09",72,[5355],"Esophageal Carcinoma",[5357,834],"Liposomal Paclitaxel",{"trials":5359,"activeCount":100,"soonestReadout":547},[5360,5364],{"nctId":544,"briefTitle":545,"status":116,"phases":5361,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":5362,"interventions":5363},[94],[16],[553,554,555,413,556,557],{"nctId":825,"briefTitle":826,"status":328,"phases":5365,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":5366,"interventions":5367},[94],[16],[834,225],{"trials":5369,"activeCount":104},[],{"trials":5371,"activeCount":104},[],{"intervention":768,"totalTrials":1861,"cells":5373},{"EARLY_PHASE1":5374,"PHASE1":5376,"PHASE2":5378,"PHASE3":5392,"PHASE4":5402,"NA":5404},{"trials":5375,"activeCount":104},[],{"trials":5377,"activeCount":104},[],{"trials":5379,"activeCount":104},[5380],{"nctId":5381,"briefTitle":5382,"status":174,"phases":5383,"primaryCompletion":5384,"completion":923,"start":5385,"enrollment":5386,"conditions":5387,"interventions":5388},"NCT03997539","A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer",[93],"2021-06-30","2019-08-15",256,[241],[5389,5390,5391],"Pyrotinib","Treatment of physician's choice","vinorelbine",{"trials":5393,"activeCount":100,"soonestReadout":1551},[5394,5398],{"nctId":760,"briefTitle":761,"status":174,"phases":5395,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":5396,"interventions":5397},[94],[463,714,715],[443,225,768,225],{"nctId":1548,"briefTitle":1549,"status":143,"phases":5399,"primaryCompletion":1551,"completion":1107,"start":1552,"enrollment":1553,"conditions":5400,"interventions":5401},[94],[28,1555],[49,444,768,1557],{"trials":5403,"activeCount":104},[],{"trials":5405,"activeCount":104},[],{"intervention":74,"totalTrials":1255,"cells":5407},{"EARLY_PHASE1":5408,"PHASE1":5410,"PHASE2":5412,"PHASE3":5424,"PHASE4":5433,"NA":5435},{"trials":5409,"activeCount":104},[],{"trials":5411,"activeCount":104},[],{"trials":5413,"activeCount":104},[5414],{"nctId":5415,"briefTitle":5416,"status":328,"phases":5417,"primaryCompletion":5418,"completion":5419,"start":218,"enrollment":1987,"conditions":5420,"interventions":5423},"NCT03529266","Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma.",[93],"2019-03-31","2021-08-22",[714,5421,5422],"Gastroesophageal Junction Cancer","Anastomotic Leak",[74],{"trials":5425,"activeCount":100,"soonestReadout":73},[5426],{"nctId":71,"briefTitle":72,"status":300,"phases":5427,"primaryCompletion":73,"completion":379,"start":5428,"enrollment":5429,"conditions":5430,"interventions":5432},[94],"2019-02-21",360,[5431],"Esophageal Anastomotic Leak",[74],{"trials":5434,"activeCount":104},[],{"trials":5436,"activeCount":104},[],{"intervention":5438,"totalTrials":1255,"cells":5439},"3 cycles chemotherapy",{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5444,"PHASE3":5446,"PHASE4":5462,"NA":5464},{"trials":5441,"activeCount":104},[],{"trials":5443,"activeCount":104},[],{"trials":5445,"activeCount":104},[],{"trials":5447,"activeCount":100,"soonestReadout":679},[5448,5454],{"nctId":5449,"briefTitle":5450,"status":143,"phases":5451,"primaryCompletion":679,"completion":679,"start":3140,"enrollment":4057,"conditions":5452,"interventions":5453},"NCT05080010","Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma",[94],[3293],[5438],{"nctId":5455,"briefTitle":5456,"status":174,"phases":5457,"primaryCompletion":5458,"completion":5458,"start":2165,"enrollment":586,"conditions":5459,"interventions":5460},"NCT01906814","Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation",[94],"2024-04",[3293],[5438,5461],"6 cycles chemotherapy",{"trials":5463,"activeCount":104},[],{"trials":5465,"activeCount":104},[],{"intervention":4831,"totalTrials":1255,"cells":5467},{"EARLY_PHASE1":5468,"PHASE1":5470,"PHASE2":5472,"PHASE3":5481,"PHASE4":5487,"NA":5489},{"trials":5469,"activeCount":104},[],{"trials":5471,"activeCount":104},[],{"trials":5473,"activeCount":104},[5474],{"nctId":5475,"briefTitle":5476,"status":174,"phases":5477,"primaryCompletion":657,"completion":1575,"start":5478,"enrollment":996,"conditions":5479,"interventions":5480},"NCT03210389","A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.",[93],"2017-07",[3305],[4831],{"trials":5482,"activeCount":100,"soonestReadout":379},[5483],{"nctId":4823,"briefTitle":4824,"status":116,"phases":5484,"primaryCompletion":379,"completion":871,"start":4826,"enrollment":3488,"conditions":5485,"interventions":5486},[94],[16,4828,726,4829],[527,4831,4832],{"trials":5488,"activeCount":104},[],{"trials":5490,"activeCount":104},[],{"intervention":337,"totalTrials":1255,"cells":5492},{"EARLY_PHASE1":5493,"PHASE1":5495,"PHASE2":5497,"PHASE3":5503,"PHASE4":5509,"NA":5511},{"trials":5494,"activeCount":104},[],{"trials":5496,"activeCount":104},[],{"trials":5498,"activeCount":104},[5499],{"nctId":326,"briefTitle":327,"status":328,"phases":5500,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":5501,"interventions":5502},[93],[335],[337,338,225,339,340],{"trials":5504,"activeCount":100,"soonestReadout":3517},[5505],{"nctId":3514,"briefTitle":3515,"status":143,"phases":5506,"primaryCompletion":3517,"completion":3518,"start":3519,"enrollment":2108,"conditions":5507,"interventions":5508},[94],[700,3521,3522],[337,271],{"trials":5510,"activeCount":104},[],{"trials":5512,"activeCount":104},[],{"intervention":340,"totalTrials":1255,"cells":5514},{"EARLY_PHASE1":5515,"PHASE1":5517,"PHASE2":5519,"PHASE3":5525,"PHASE4":5531,"NA":5533},{"trials":5516,"activeCount":104},[],{"trials":5518,"activeCount":104},[],{"trials":5520,"activeCount":104},[5521],{"nctId":326,"briefTitle":327,"status":328,"phases":5522,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":5523,"interventions":5524},[93],[335],[337,338,225,339,340],{"trials":5526,"activeCount":100,"soonestReadout":721},[5527],{"nctId":718,"briefTitle":719,"status":116,"phases":5528,"primaryCompletion":721,"completion":646,"start":722,"enrollment":723,"conditions":5529,"interventions":5530},[93,94],[16,725,726,318,727],[340,225,296,49],{"trials":5532,"activeCount":104},[],{"trials":5534,"activeCount":104},[],{"intervention":5536,"totalTrials":100,"cells":5537},"First line therapy",{"EARLY_PHASE1":5538,"PHASE1":5540,"PHASE2":5542,"PHASE3":5544,"PHASE4":5555,"NA":5557},{"trials":5539,"activeCount":104},[],{"trials":5541,"activeCount":104},[],{"trials":5543,"activeCount":104},[],{"trials":5545,"activeCount":100,"soonestReadout":679},[5546],{"nctId":5547,"briefTitle":5548,"status":116,"phases":5549,"primaryCompletion":679,"completion":5550,"start":238,"enrollment":5551,"conditions":5552,"interventions":5554},"NCT06739317","SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.",[93,94],"2031-06-30",398,[5553],"Unresectable Hepatocellular Carcinoma (HCC)",[5536,5536],{"trials":5556,"activeCount":104},[],{"trials":5558,"activeCount":104},[],{"intervention":5560,"totalTrials":100,"cells":5561},"Gemcitabine and carboplatin plus antibiotic",{"EARLY_PHASE1":5562,"PHASE1":5564,"PHASE2":5566,"PHASE3":5568,"PHASE4":5579,"NA":5581},{"trials":5563,"activeCount":104},[],{"trials":5565,"activeCount":104},[],{"trials":5567,"activeCount":104},[],{"trials":5569,"activeCount":100,"soonestReadout":548},[5570],{"nctId":5571,"briefTitle":5572,"status":143,"phases":5573,"primaryCompletion":548,"completion":1132,"start":5574,"enrollment":5575,"conditions":5576,"interventions":5577},"NCT04722978","Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer",[94],"2021-04-20",228,[1068],[5560,5578],"Gemcitabine combined with carboplatin plus placebo",{"trials":5580,"activeCount":104},[],{"trials":5582,"activeCount":104},[],{"intervention":5578,"totalTrials":100,"cells":5584},{"EARLY_PHASE1":5585,"PHASE1":5587,"PHASE2":5589,"PHASE3":5591,"PHASE4":5597,"NA":5599},{"trials":5586,"activeCount":104},[],{"trials":5588,"activeCount":104},[],{"trials":5590,"activeCount":104},[],{"trials":5592,"activeCount":100,"soonestReadout":548},[5593],{"nctId":5571,"briefTitle":5572,"status":143,"phases":5594,"primaryCompletion":548,"completion":1132,"start":5574,"enrollment":5575,"conditions":5595,"interventions":5596},[94],[1068],[5560,5578],{"trials":5598,"activeCount":104},[],{"trials":5600,"activeCount":104},[],{"intervention":5602,"totalTrials":100,"cells":5603},"Regorafenib and DIBIRI",{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5608,"PHASE3":5610,"PHASE4":5622,"NA":5624},{"trials":5605,"activeCount":104},[],{"trials":5607,"activeCount":104},[],{"trials":5609,"activeCount":104},[],{"trials":5611,"activeCount":100,"soonestReadout":3518},[5612],{"nctId":5613,"briefTitle":5614,"status":143,"phases":5615,"primaryCompletion":3518,"completion":5616,"start":5617,"enrollment":5618,"conditions":5619,"interventions":5621},"NCT05794971","Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases",[94],"2028-03-31","2023-06-10",126,[5620,3019],"Colorectal Cancer Liver Metastases",[5602,3019],{"trials":5623,"activeCount":104},[],{"trials":5625,"activeCount":104},[],{"intervention":553,"totalTrials":100,"cells":5627},{"EARLY_PHASE1":5628,"PHASE1":5630,"PHASE2":5632,"PHASE3":5634,"PHASE4":5640,"NA":5642},{"trials":5629,"activeCount":104},[],{"trials":5631,"activeCount":104},[],{"trials":5633,"activeCount":104},[],{"trials":5635,"activeCount":100,"soonestReadout":547},[5636],{"nctId":544,"briefTitle":545,"status":116,"phases":5637,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":5638,"interventions":5639},[94],[16],[553,554,555,413,556,557],{"trials":5641,"activeCount":104},[],{"trials":5643,"activeCount":104},[],{"intervention":555,"totalTrials":100,"cells":5645},{"EARLY_PHASE1":5646,"PHASE1":5648,"PHASE2":5650,"PHASE3":5652,"PHASE4":5658,"NA":5660},{"trials":5647,"activeCount":104},[],{"trials":5649,"activeCount":104},[],{"trials":5651,"activeCount":104},[],{"trials":5653,"activeCount":100,"soonestReadout":547},[5654],{"nctId":544,"briefTitle":545,"status":116,"phases":5655,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":5656,"interventions":5657},[94],[16],[553,554,555,413,556,557],{"trials":5659,"activeCount":104},[],{"trials":5661,"activeCount":104},[],{"intervention":556,"totalTrials":100,"cells":5663},{"EARLY_PHASE1":5664,"PHASE1":5666,"PHASE2":5668,"PHASE3":5670,"PHASE4":5676,"NA":5678},{"trials":5665,"activeCount":104},[],{"trials":5667,"activeCount":104},[],{"trials":5669,"activeCount":104},[],{"trials":5671,"activeCount":100,"soonestReadout":547},[5672],{"nctId":544,"briefTitle":545,"status":116,"phases":5673,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":5674,"interventions":5675},[94],[16],[553,554,555,413,556,557],{"trials":5677,"activeCount":104},[],{"trials":5679,"activeCount":104},[],{"intervention":557,"totalTrials":100,"cells":5681},{"EARLY_PHASE1":5682,"PHASE1":5684,"PHASE2":5686,"PHASE3":5688,"PHASE4":5694,"NA":5696},{"trials":5683,"activeCount":104},[],{"trials":5685,"activeCount":104},[],{"trials":5687,"activeCount":104},[],{"trials":5689,"activeCount":100,"soonestReadout":547},[5690],{"nctId":544,"briefTitle":545,"status":116,"phases":5691,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":5692,"interventions":5693},[94],[16],[553,554,555,413,556,557],{"trials":5695,"activeCount":104},[],{"trials":5697,"activeCount":104},[],{"intervention":5699,"totalTrials":100,"cells":5700},"Adjuvant immunotherapy",{"EARLY_PHASE1":5701,"PHASE1":5703,"PHASE2":5705,"PHASE3":5707,"PHASE4":5719,"NA":5721},{"trials":5702,"activeCount":104},[],{"trials":5704,"activeCount":104},[],{"trials":5706,"activeCount":104},[],{"trials":5708,"activeCount":100,"soonestReadout":5713},[5709],{"nctId":5710,"briefTitle":5711,"status":143,"phases":5712,"primaryCompletion":5713,"completion":5713,"start":5714,"enrollment":5715,"conditions":5716,"interventions":5718},"NCT05877872","Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma",[94],"2029-03-30","2023-05-20",424,[16,5717],"De-escaltion Therapy",[5699],{"trials":5720,"activeCount":104},[],{"trials":5722,"activeCount":104},[],{"intervention":5724,"totalTrials":100,"cells":5725},"Gemcitabine, Vinorelbine, Eribulin, or Utidelone",{"EARLY_PHASE1":5726,"PHASE1":5728,"PHASE2":5730,"PHASE3":5732,"PHASE4":5742,"NA":5744},{"trials":5727,"activeCount":104},[],{"trials":5729,"activeCount":104},[],{"trials":5731,"activeCount":104},[],{"trials":5733,"activeCount":100,"soonestReadout":5738},[5734],{"nctId":5735,"briefTitle":5736,"status":143,"phases":5737,"primaryCompletion":5738,"completion":5739,"start":1790,"enrollment":619,"conditions":5740,"interventions":5741},"NCT07088263","Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer",[94],"2027-07-24","2028-06-24",[3829],[5724],{"trials":5743,"activeCount":104},[],{"trials":5745,"activeCount":104},[],{"intervention":5747,"totalTrials":100,"cells":5748},"Toripalimab plus concurrent chemo-radiotherapy",{"EARLY_PHASE1":5749,"PHASE1":5751,"PHASE2":5753,"PHASE3":5755,"PHASE4":5768,"NA":5770},{"trials":5750,"activeCount":104},[],{"trials":5752,"activeCount":104},[],{"trials":5754,"activeCount":104},[],{"trials":5756,"activeCount":100,"soonestReadout":763},[5757],{"nctId":5758,"briefTitle":5759,"status":143,"phases":5760,"primaryCompletion":763,"completion":5761,"start":5762,"enrollment":5763,"conditions":5764,"interventions":5766},"NCT04453813","Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma",[94],"2027-07","2020-07-03",226,[16,726,505,5765],"PD-1 Treatment",[5747,5767],"Concurrent chemo-radiotherapy",{"trials":5769,"activeCount":104},[],{"trials":5771,"activeCount":104},[],{"intervention":5767,"totalTrials":100,"cells":5773},{"EARLY_PHASE1":5774,"PHASE1":5776,"PHASE2":5778,"PHASE3":5780,"PHASE4":5786,"NA":5788},{"trials":5775,"activeCount":104},[],{"trials":5777,"activeCount":104},[],{"trials":5779,"activeCount":104},[],{"trials":5781,"activeCount":100,"soonestReadout":763},[5782],{"nctId":5758,"briefTitle":5759,"status":143,"phases":5783,"primaryCompletion":763,"completion":5761,"start":5762,"enrollment":5763,"conditions":5784,"interventions":5785},[94],[16,726,505,5765],[5747,5767],{"trials":5787,"activeCount":104},[],{"trials":5789,"activeCount":104},[],{"intervention":5791,"totalTrials":100,"cells":5792},"Phosphate-containing Replacement Fluid",{"EARLY_PHASE1":5793,"PHASE1":5795,"PHASE2":5797,"PHASE3":5799,"PHASE4":5812,"NA":5814},{"trials":5794,"activeCount":104},[],{"trials":5796,"activeCount":104},[],{"trials":5798,"activeCount":104},[],{"trials":5800,"activeCount":100,"soonestReadout":119},[5801],{"nctId":5802,"briefTitle":5803,"status":116,"phases":5804,"primaryCompletion":119,"completion":237,"start":5805,"enrollment":179,"conditions":5806,"interventions":5810},"NCT07550894","Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT",[94],"2026-05-01",[5807,5808,5809],"Acute Kidney Injury","Sepsis","Critically Ill Patients Requiring Continuous Renal Replacement Therapy",[5791,5811],"Standard Phosphate-free Replacement Fluid",{"trials":5813,"activeCount":104},[],{"trials":5815,"activeCount":104},[],{"intervention":5811,"totalTrials":100,"cells":5817},{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5822,"PHASE3":5824,"PHASE4":5830,"NA":5832},{"trials":5819,"activeCount":104},[],{"trials":5821,"activeCount":104},[],{"trials":5823,"activeCount":104},[],{"trials":5825,"activeCount":100,"soonestReadout":119},[5826],{"nctId":5802,"briefTitle":5803,"status":116,"phases":5827,"primaryCompletion":119,"completion":237,"start":5805,"enrollment":179,"conditions":5828,"interventions":5829},[94],[5807,5808,5809],[5791,5811],{"trials":5831,"activeCount":104},[],{"trials":5833,"activeCount":104},[],{"intervention":5835,"totalTrials":100,"cells":5836},"TPF+CCRT",{"EARLY_PHASE1":5837,"PHASE1":5839,"PHASE2":5841,"PHASE3":5843,"PHASE4":5854,"NA":5856},{"trials":5838,"activeCount":104},[],{"trials":5840,"activeCount":104},[],{"trials":5842,"activeCount":104},[],{"trials":5844,"activeCount":100,"soonestReadout":721},[5845],{"nctId":5846,"briefTitle":5847,"status":300,"phases":5848,"primaryCompletion":721,"completion":380,"start":5849,"enrollment":5850,"conditions":5851,"interventions":5852},"NCT03306121","TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma",[94],"2017-11-13",322,[16],[5835,5853],"CCRT+ PF",{"trials":5855,"activeCount":104},[],{"trials":5857,"activeCount":104},[],{"intervention":5853,"totalTrials":100,"cells":5859},{"EARLY_PHASE1":5860,"PHASE1":5862,"PHASE2":5864,"PHASE3":5866,"PHASE4":5872,"NA":5874},{"trials":5861,"activeCount":104},[],{"trials":5863,"activeCount":104},[],{"trials":5865,"activeCount":104},[],{"trials":5867,"activeCount":100,"soonestReadout":721},[5868],{"nctId":5846,"briefTitle":5847,"status":300,"phases":5869,"primaryCompletion":721,"completion":380,"start":5849,"enrollment":5850,"conditions":5870,"interventions":5871},[94],[16],[5835,5853],{"trials":5873,"activeCount":104},[],{"trials":5875,"activeCount":104},[],{"intervention":5877,"totalTrials":100,"cells":5878},"TPC chemotherapy",{"EARLY_PHASE1":5879,"PHASE1":5881,"PHASE2":5883,"PHASE3":5885,"PHASE4":5897,"NA":5899},{"trials":5880,"activeCount":104},[],{"trials":5882,"activeCount":104},[],{"trials":5884,"activeCount":104},[],{"trials":5886,"activeCount":100,"soonestReadout":5891},[5887],{"nctId":5888,"briefTitle":5889,"status":300,"phases":5890,"primaryCompletion":5891,"completion":5892,"start":5893,"enrollment":2591,"conditions":5894,"interventions":5895},"NCT06664983","TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma",[94],"2025-10-21","2026-10-21","2024-10-21",[37],[5877,5896],"cadonilimab combined TPC chemotherapy",{"trials":5898,"activeCount":104},[],{"trials":5900,"activeCount":104},[],{"intervention":5896,"totalTrials":100,"cells":5902},{"EARLY_PHASE1":5903,"PHASE1":5905,"PHASE2":5907,"PHASE3":5909,"PHASE4":5915,"NA":5917},{"trials":5904,"activeCount":104},[],{"trials":5906,"activeCount":104},[],{"trials":5908,"activeCount":104},[],{"trials":5910,"activeCount":100,"soonestReadout":5891},[5911],{"nctId":5888,"briefTitle":5889,"status":300,"phases":5912,"primaryCompletion":5891,"completion":5892,"start":5893,"enrollment":2591,"conditions":5913,"interventions":5914},[94],[37],[5877,5896],{"trials":5916,"activeCount":104},[],{"trials":5918,"activeCount":104},[],{"intervention":5920,"totalTrials":100,"cells":5921},"Gargle with 2.5% sodium bicarbonate solution during radiotherapy",{"EARLY_PHASE1":5922,"PHASE1":5924,"PHASE2":5926,"PHASE3":5928,"PHASE4":5941,"NA":5943},{"trials":5923,"activeCount":104},[],{"trials":5925,"activeCount":104},[],{"trials":5927,"activeCount":104},[],{"trials":5929,"activeCount":100,"soonestReadout":5934},[5930],{"nctId":5931,"briefTitle":5932,"status":143,"phases":5933,"primaryCompletion":5934,"completion":5935,"start":5936,"enrollment":5937,"conditions":5938,"interventions":5939},"NCT06854510","Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.",[93,94],"2026-01","2030-02","2025-02-21",196,[37],[5920,5940],"Gargle with 0.9% sodium chloride solution during radiotherapy",{"trials":5942,"activeCount":104},[],{"trials":5944,"activeCount":104},[],{"intervention":5940,"totalTrials":100,"cells":5946},{"EARLY_PHASE1":5947,"PHASE1":5949,"PHASE2":5951,"PHASE3":5953,"PHASE4":5959,"NA":5961},{"trials":5948,"activeCount":104},[],{"trials":5950,"activeCount":104},[],{"trials":5952,"activeCount":104},[],{"trials":5954,"activeCount":100,"soonestReadout":5934},[5955],{"nctId":5931,"briefTitle":5932,"status":143,"phases":5956,"primaryCompletion":5934,"completion":5935,"start":5936,"enrollment":5937,"conditions":5957,"interventions":5958},[93,94],[37],[5920,5940],{"trials":5960,"activeCount":104},[],{"trials":5962,"activeCount":104},[],{"intervention":4639,"totalTrials":100,"cells":5964},{"EARLY_PHASE1":5965,"PHASE1":5967,"PHASE2":5969,"PHASE3":5971,"PHASE4":5977,"NA":5979},{"trials":5966,"activeCount":104},[],{"trials":5968,"activeCount":104},[],{"trials":5970,"activeCount":104},[],{"trials":5972,"activeCount":100,"soonestReadout":260},[5973],{"nctId":4631,"briefTitle":4632,"status":143,"phases":5974,"primaryCompletion":260,"completion":419,"start":1657,"enrollment":4634,"conditions":5975,"interventions":5976},[94],[4636,4637],[4639,4625],{"trials":5978,"activeCount":104},[],{"trials":5980,"activeCount":104},[],{"intervention":5982,"totalTrials":100,"cells":5983},"Sugemalimab",{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":5988,"PHASE3":5990,"PHASE4":5999,"NA":6001},{"trials":5985,"activeCount":104},[],{"trials":5987,"activeCount":104},[],{"trials":5989,"activeCount":104},[],{"trials":5991,"activeCount":100,"soonestReadout":379},[5992],{"nctId":5993,"briefTitle":5994,"status":143,"phases":5995,"primaryCompletion":379,"completion":3518,"start":73,"enrollment":671,"conditions":5996,"interventions":5998},"NCT05623267","Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT",[93,94],[5997],"Limited Stage Small Cell Lung Cancer",[5982],{"trials":6000,"activeCount":104},[],{"trials":6002,"activeCount":104},[],{"intervention":6004,"totalTrials":100,"cells":6005},"TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy",{"EARLY_PHASE1":6006,"PHASE1":6008,"PHASE2":6010,"PHASE3":6012,"PHASE4":6024,"NA":6026},{"trials":6007,"activeCount":104},[],{"trials":6009,"activeCount":104},[],{"trials":6011,"activeCount":104},[],{"trials":6013,"activeCount":100,"soonestReadout":839},[6014],{"nctId":6015,"briefTitle":6016,"status":143,"phases":6017,"primaryCompletion":839,"completion":6018,"start":6019,"enrollment":6020,"conditions":6021,"interventions":6022},"NCT06712888","Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2032-01-01","2025-02-17",466,[1009],[6004,6023],"GP plus placebo induction therapy",{"trials":6025,"activeCount":104},[],{"trials":6027,"activeCount":104},[],{"intervention":6023,"totalTrials":100,"cells":6029},{"EARLY_PHASE1":6030,"PHASE1":6032,"PHASE2":6034,"PHASE3":6036,"PHASE4":6042,"NA":6044},{"trials":6031,"activeCount":104},[],{"trials":6033,"activeCount":104},[],{"trials":6035,"activeCount":104},[],{"trials":6037,"activeCount":100,"soonestReadout":839},[6038],{"nctId":6015,"briefTitle":6016,"status":143,"phases":6039,"primaryCompletion":839,"completion":6018,"start":6019,"enrollment":6020,"conditions":6040,"interventions":6041},[94],[1009],[6004,6023],{"trials":6043,"activeCount":104},[],{"trials":6045,"activeCount":104},[],{"intervention":6047,"totalTrials":100,"cells":6048},"RT plus Nimotuzumab",{"EARLY_PHASE1":6049,"PHASE1":6051,"PHASE2":6053,"PHASE3":6055,"PHASE4":6068,"NA":6070},{"trials":6050,"activeCount":104},[],{"trials":6052,"activeCount":104},[],{"trials":6054,"activeCount":104},[],{"trials":6056,"activeCount":100,"soonestReadout":6061},[6057],{"nctId":6058,"briefTitle":6059,"status":300,"phases":6060,"primaryCompletion":6061,"completion":6062,"start":6063,"enrollment":6064,"conditions":6065,"interventions":6066},"NCT04456322","Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma",[94],"2024-05-11","2027-05-11","2020-08-17",381,[16],[6047,6067],"RT plus Cisplatin",{"trials":6069,"activeCount":104},[],{"trials":6071,"activeCount":104},[],{"intervention":6067,"totalTrials":100,"cells":6073},{"EARLY_PHASE1":6074,"PHASE1":6076,"PHASE2":6078,"PHASE3":6080,"PHASE4":6086,"NA":6088},{"trials":6075,"activeCount":104},[],{"trials":6077,"activeCount":104},[],{"trials":6079,"activeCount":104},[],{"trials":6081,"activeCount":100,"soonestReadout":6061},[6082],{"nctId":6058,"briefTitle":6059,"status":300,"phases":6083,"primaryCompletion":6061,"completion":6062,"start":6063,"enrollment":6064,"conditions":6084,"interventions":6085},[94],[16],[6047,6067],{"trials":6087,"activeCount":104},[],{"trials":6089,"activeCount":104},[],{"intervention":6091,"totalTrials":100,"cells":6092},"CNG Chemotherapy",{"EARLY_PHASE1":6093,"PHASE1":6095,"PHASE2":6097,"PHASE3":6099,"PHASE4":6111,"NA":6113},{"trials":6094,"activeCount":104},[],{"trials":6096,"activeCount":104},[],{"trials":6098,"activeCount":104},[],{"trials":6100,"activeCount":100,"soonestReadout":6105},[6101],{"nctId":6102,"briefTitle":6103,"status":116,"phases":6104,"primaryCompletion":6105,"completion":6105,"start":6106,"enrollment":6107,"conditions":6108,"interventions":6109},"NCT03529279","CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy",[94],"2026-06-12","2018-06-12",1324,[16],[6091,6110],"NCCN Chemotherapy",{"trials":6112,"activeCount":104},[],{"trials":6114,"activeCount":104},[],{"intervention":6110,"totalTrials":100,"cells":6116},{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6123,"PHASE4":6129,"NA":6131},{"trials":6118,"activeCount":104},[],{"trials":6120,"activeCount":104},[],{"trials":6122,"activeCount":104},[],{"trials":6124,"activeCount":100,"soonestReadout":6105},[6125],{"nctId":6102,"briefTitle":6103,"status":116,"phases":6126,"primaryCompletion":6105,"completion":6105,"start":6106,"enrollment":6107,"conditions":6127,"interventions":6128},[94],[16],[6091,6110],{"trials":6130,"activeCount":104},[],{"trials":6132,"activeCount":104},[],{"intervention":6134,"totalTrials":100,"cells":6135},"Taxane plus Intermittent Capecitabine",{"EARLY_PHASE1":6136,"PHASE1":6138,"PHASE2":6140,"PHASE3":6142,"PHASE4":6156,"NA":6158},{"trials":6137,"activeCount":104},[],{"trials":6139,"activeCount":104},[],{"trials":6141,"activeCount":104},[],{"trials":6143,"activeCount":100,"soonestReadout":851},[6144],{"nctId":6145,"briefTitle":6146,"status":116,"phases":6147,"primaryCompletion":851,"completion":6148,"start":6149,"enrollment":6150,"conditions":6151,"interventions":6152},"NCT05172518","Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer",[94],"2030-03-01","2022-03-01",512,[3829,3830],[6134,6153,6154,6155],"Utidelone plus Intermittent Capecitabine","Taxane plus Metronomic Capecitabine","Utidelone plus Metronomic Capecitabine",{"trials":6157,"activeCount":104},[],{"trials":6159,"activeCount":104},[],{"intervention":6153,"totalTrials":100,"cells":6161},{"EARLY_PHASE1":6162,"PHASE1":6164,"PHASE2":6166,"PHASE3":6168,"PHASE4":6174,"NA":6176},{"trials":6163,"activeCount":104},[],{"trials":6165,"activeCount":104},[],{"trials":6167,"activeCount":104},[],{"trials":6169,"activeCount":100,"soonestReadout":851},[6170],{"nctId":6145,"briefTitle":6146,"status":116,"phases":6171,"primaryCompletion":851,"completion":6148,"start":6149,"enrollment":6150,"conditions":6172,"interventions":6173},[94],[3829,3830],[6134,6153,6154,6155],{"trials":6175,"activeCount":104},[],{"trials":6177,"activeCount":104},[],{"intervention":6154,"totalTrials":100,"cells":6179},{"EARLY_PHASE1":6180,"PHASE1":6182,"PHASE2":6184,"PHASE3":6186,"PHASE4":6192,"NA":6194},{"trials":6181,"activeCount":104},[],{"trials":6183,"activeCount":104},[],{"trials":6185,"activeCount":104},[],{"trials":6187,"activeCount":100,"soonestReadout":851},[6188],{"nctId":6145,"briefTitle":6146,"status":116,"phases":6189,"primaryCompletion":851,"completion":6148,"start":6149,"enrollment":6150,"conditions":6190,"interventions":6191},[94],[3829,3830],[6134,6153,6154,6155],{"trials":6193,"activeCount":104},[],{"trials":6195,"activeCount":104},[],{"intervention":6155,"totalTrials":100,"cells":6197},{"EARLY_PHASE1":6198,"PHASE1":6200,"PHASE2":6202,"PHASE3":6204,"PHASE4":6210,"NA":6212},{"trials":6199,"activeCount":104},[],{"trials":6201,"activeCount":104},[],{"trials":6203,"activeCount":104},[],{"trials":6205,"activeCount":100,"soonestReadout":851},[6206],{"nctId":6145,"briefTitle":6146,"status":116,"phases":6207,"primaryCompletion":851,"completion":6148,"start":6149,"enrollment":6150,"conditions":6208,"interventions":6209},[94],[3829,3830],[6134,6153,6154,6155],{"trials":6211,"activeCount":104},[],{"trials":6213,"activeCount":104},[],{"intervention":5327,"totalTrials":100,"cells":6215},{"EARLY_PHASE1":6216,"PHASE1":6218,"PHASE2":6220,"PHASE3":6222,"PHASE4":6228,"NA":6230},{"trials":6217,"activeCount":104},[],{"trials":6219,"activeCount":104},[],{"trials":6221,"activeCount":104},[],{"trials":6223,"activeCount":100,"soonestReadout":5321},[6224],{"nctId":5318,"briefTitle":5319,"status":143,"phases":6225,"primaryCompletion":5321,"completion":5322,"start":5323,"enrollment":5324,"conditions":6226,"interventions":6227},[94],[34],[5273,5327],{"trials":6229,"activeCount":104},[],{"trials":6231,"activeCount":104},[],{"intervention":652,"totalTrials":100,"cells":6233},{"EARLY_PHASE1":6234,"PHASE1":6236,"PHASE2":6238,"PHASE3":6240,"PHASE4":6246,"NA":6248},{"trials":6235,"activeCount":104},[],{"trials":6237,"activeCount":104},[],{"trials":6239,"activeCount":104},[],{"trials":6241,"activeCount":100,"soonestReadout":145},[6242],{"nctId":643,"briefTitle":644,"status":300,"phases":6243,"primaryCompletion":145,"completion":646,"start":647,"enrollment":648,"conditions":6244,"interventions":6245},[94],[16,441,566,567],[651,652,413],{"trials":6247,"activeCount":104},[],{"trials":6249,"activeCount":104},[],{"intervention":6251,"totalTrials":100,"cells":6252},"Neoadjuvant treatment of SBRT plus chemoimmunotherapy followed by surgery and postoperative radiotherapy or chemoradiotherapy",{"EARLY_PHASE1":6253,"PHASE1":6255,"PHASE2":6257,"PHASE3":6259,"PHASE4":6270,"NA":6272},{"trials":6254,"activeCount":104},[],{"trials":6256,"activeCount":104},[],{"trials":6258,"activeCount":104},[],{"trials":6260,"activeCount":100,"soonestReadout":646},[6261],{"nctId":6262,"briefTitle":6263,"status":116,"phases":6264,"primaryCompletion":646,"completion":679,"start":4667,"enrollment":2725,"conditions":6265,"interventions":6268},"NCT07402538","Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma",[94],[6266,6267],"Oral Cancer","Oropharyngeal Cancer",[6251,6269],"Surgery and postoperative radiotherapy or chemoradiotherapy",{"trials":6271,"activeCount":104},[],{"trials":6273,"activeCount":104},[],{"intervention":6269,"totalTrials":100,"cells":6275},{"EARLY_PHASE1":6276,"PHASE1":6278,"PHASE2":6280,"PHASE3":6282,"PHASE4":6288,"NA":6290},{"trials":6277,"activeCount":104},[],{"trials":6279,"activeCount":104},[],{"trials":6281,"activeCount":104},[],{"trials":6283,"activeCount":100,"soonestReadout":646},[6284],{"nctId":6262,"briefTitle":6263,"status":116,"phases":6285,"primaryCompletion":646,"completion":679,"start":4667,"enrollment":2725,"conditions":6286,"interventions":6287},[94],[6266,6267],[6251,6269],{"trials":6289,"activeCount":104},[],{"trials":6291,"activeCount":104},[],{"intervention":6293,"totalTrials":100,"cells":6294},"Palliative Chemotherapy",{"EARLY_PHASE1":6295,"PHASE1":6297,"PHASE2":6299,"PHASE3":6301,"PHASE4":6311,"NA":6313},{"trials":6296,"activeCount":104},[],{"trials":6298,"activeCount":104},[],{"trials":6300,"activeCount":104},[],{"trials":6302,"activeCount":100,"soonestReadout":940},[6303],{"nctId":6304,"briefTitle":6305,"status":143,"phases":6306,"primaryCompletion":940,"completion":940,"start":1552,"enrollment":6307,"conditions":6308,"interventions":6310},"NCT06208371","Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM",[94],117,[6309],"Colorectal Neoplasms Malignant",[6293],{"trials":6312,"activeCount":104},[],{"trials":6314,"activeCount":104},[],{"intervention":6316,"totalTrials":100,"cells":6317},"Albumin-bound Paclitaxel + Tegafur Gimeracil Oteracil (S-1) + Anlotinib",{"EARLY_PHASE1":6318,"PHASE1":6320,"PHASE2":6322,"PHASE3":6324,"PHASE4":6337,"NA":6339},{"trials":6319,"activeCount":104},[],{"trials":6321,"activeCount":104},[],{"trials":6323,"activeCount":104},[],{"trials":6325,"activeCount":100,"soonestReadout":6330},[6326],{"nctId":6327,"briefTitle":6328,"status":116,"phases":6329,"primaryCompletion":6330,"completion":6330,"start":6331,"enrollment":2913,"conditions":6332,"interventions":6335},"NCT06662877","Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment",[93,94],"2029-09-01","2024-11-25",[3253,6333,726,6334],"Second Line Treatment","Tyrosine Kinase Inhibitor",[6316,6336],"Oxaliplatin + Leucovorin + Fluorouracil",{"trials":6338,"activeCount":104},[],{"trials":6340,"activeCount":104},[],{"intervention":6336,"totalTrials":100,"cells":6342},{"EARLY_PHASE1":6343,"PHASE1":6345,"PHASE2":6347,"PHASE3":6349,"PHASE4":6355,"NA":6357},{"trials":6344,"activeCount":104},[],{"trials":6346,"activeCount":104},[],{"trials":6348,"activeCount":104},[],{"trials":6350,"activeCount":100,"soonestReadout":6330},[6351],{"nctId":6327,"briefTitle":6328,"status":116,"phases":6352,"primaryCompletion":6330,"completion":6330,"start":6331,"enrollment":2913,"conditions":6353,"interventions":6354},[93,94],[3253,6333,726,6334],[6316,6336],{"trials":6356,"activeCount":104},[],{"trials":6358,"activeCount":104},[],{"intervention":4832,"totalTrials":100,"cells":6360},{"EARLY_PHASE1":6361,"PHASE1":6363,"PHASE2":6365,"PHASE3":6367,"PHASE4":6373,"NA":6375},{"trials":6362,"activeCount":104},[],{"trials":6364,"activeCount":104},[],{"trials":6366,"activeCount":104},[],{"trials":6368,"activeCount":100,"soonestReadout":379},[6369],{"nctId":4823,"briefTitle":4824,"status":116,"phases":6370,"primaryCompletion":379,"completion":871,"start":4826,"enrollment":3488,"conditions":6371,"interventions":6372},[94],[16,4828,726,4829],[527,4831,4832],{"trials":6374,"activeCount":104},[],{"trials":6376,"activeCount":104},[],{"intervention":6378,"totalTrials":100,"cells":6379},"Experimental dose: modified XELOX + sintilimab",{"EARLY_PHASE1":6380,"PHASE1":6382,"PHASE2":6384,"PHASE3":6386,"PHASE4":6395,"NA":6397},{"trials":6381,"activeCount":104},[],{"trials":6383,"activeCount":104},[],{"trials":6385,"activeCount":104},[],{"trials":6387,"activeCount":100,"soonestReadout":419},[6388],{"nctId":6389,"briefTitle":6390,"status":143,"phases":6391,"primaryCompletion":419,"completion":470,"start":1668,"enrollment":698,"conditions":6392,"interventions":6393},"NCT05918094","Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric\u002FGastroesophageal Junction Adenocarcinoma",[94],[539],[6378,6394],"Standard dose: standard XELOX + sintilimab",{"trials":6396,"activeCount":104},[],{"trials":6398,"activeCount":104},[],{"intervention":6394,"totalTrials":100,"cells":6400},{"EARLY_PHASE1":6401,"PHASE1":6403,"PHASE2":6405,"PHASE3":6407,"PHASE4":6413,"NA":6415},{"trials":6402,"activeCount":104},[],{"trials":6404,"activeCount":104},[],{"trials":6406,"activeCount":104},[],{"trials":6408,"activeCount":100,"soonestReadout":419},[6409],{"nctId":6389,"briefTitle":6390,"status":143,"phases":6410,"primaryCompletion":419,"completion":470,"start":1668,"enrollment":698,"conditions":6411,"interventions":6412},[94],[539],[6378,6394],{"trials":6414,"activeCount":104},[],{"trials":6416,"activeCount":104},[],{"intervention":6418,"totalTrials":100,"cells":6419},"Xinlikang",{"EARLY_PHASE1":6420,"PHASE1":6422,"PHASE2":6424,"PHASE3":6426,"PHASE4":6439,"NA":6441},{"trials":6421,"activeCount":104},[],{"trials":6423,"activeCount":104},[],{"trials":6425,"activeCount":104},[],{"trials":6427,"activeCount":100,"soonestReadout":6432},[6428],{"nctId":6429,"briefTitle":6430,"status":143,"phases":6431,"primaryCompletion":6432,"completion":6433,"start":6434,"enrollment":942,"conditions":6435,"interventions":6437},"NCT07084662","Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma",[93,94],"2028-08-01","2030-08-01","2025-09-11",[6436],"Diffuse Large B-Cell Lymphoma (DLBCL)",[6418,6438],"mimic",{"trials":6440,"activeCount":104},[],{"trials":6442,"activeCount":104},[],{"intervention":6438,"totalTrials":100,"cells":6444},{"EARLY_PHASE1":6445,"PHASE1":6447,"PHASE2":6449,"PHASE3":6451,"PHASE4":6457,"NA":6459},{"trials":6446,"activeCount":104},[],{"trials":6448,"activeCount":104},[],{"trials":6450,"activeCount":104},[],{"trials":6452,"activeCount":100,"soonestReadout":6432},[6453],{"nctId":6429,"briefTitle":6430,"status":143,"phases":6454,"primaryCompletion":6432,"completion":6433,"start":6434,"enrollment":942,"conditions":6455,"interventions":6456},[93,94],[6436],[6418,6438],{"trials":6458,"activeCount":104},[],{"trials":6460,"activeCount":104},[],{"intervention":6462,"totalTrials":100,"cells":6463},"axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib",{"EARLY_PHASE1":6464,"PHASE1":6466,"PHASE2":6468,"PHASE3":6470,"PHASE4":6485,"NA":6487},{"trials":6465,"activeCount":104},[],{"trials":6467,"activeCount":104},[],{"trials":6469,"activeCount":104},[],{"trials":6471,"activeCount":100,"soonestReadout":6476},[6472],{"nctId":6473,"briefTitle":6474,"status":143,"phases":6475,"primaryCompletion":6476,"completion":6477,"start":6478,"enrollment":6479,"conditions":6480,"interventions":6484},"NCT06726421","Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)",[94],"2030-09-30","2033-09-30","2024-09-18",252,[6481,6482,6483],"Renal Cell Carcinoma (Kidney Cancer)","Kidney Cancer Metastatic","Renal Cell Carcinoma Metastatic",[6462],{"trials":6486,"activeCount":104},[],{"trials":6488,"activeCount":104},[],{"intervention":6490,"totalTrials":100,"cells":6491},"Experimental drug",{"EARLY_PHASE1":6492,"PHASE1":6494,"PHASE2":6496,"PHASE3":6498,"PHASE4":6509,"NA":6511},{"trials":6493,"activeCount":104},[],{"trials":6495,"activeCount":104},[],{"trials":6497,"activeCount":104},[],{"trials":6499,"activeCount":100,"soonestReadout":5934},[6500],{"nctId":6501,"briefTitle":6502,"status":143,"phases":6503,"primaryCompletion":5934,"completion":1133,"start":6504,"enrollment":6505,"conditions":6506,"interventions":6507},"NCT05768503","Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS\u002FpMMR mCRC",[94],"2023-03-01",176,[1730],[6490,6508],"Control Rx",{"trials":6510,"activeCount":104},[],{"trials":6512,"activeCount":104},[],{"intervention":6508,"totalTrials":100,"cells":6514},{"EARLY_PHASE1":6515,"PHASE1":6517,"PHASE2":6519,"PHASE3":6521,"PHASE4":6527,"NA":6529},{"trials":6516,"activeCount":104},[],{"trials":6518,"activeCount":104},[],{"trials":6520,"activeCount":104},[],{"trials":6522,"activeCount":100,"soonestReadout":5934},[6523],{"nctId":6501,"briefTitle":6502,"status":143,"phases":6524,"primaryCompletion":5934,"completion":1133,"start":6504,"enrollment":6505,"conditions":6525,"interventions":6526},[94],[1730],[6490,6508],{"trials":6528,"activeCount":104},[],{"trials":6530,"activeCount":104},[],{"intervention":6532,"totalTrials":100,"cells":6533},"Drug：Cisplatin",{"EARLY_PHASE1":6534,"PHASE1":6536,"PHASE2":6538,"PHASE3":6540,"PHASE4":6552,"NA":6554},{"trials":6535,"activeCount":104},[],{"trials":6537,"activeCount":104},[],{"trials":6539,"activeCount":104},[],{"trials":6541,"activeCount":100,"soonestReadout":6546},[6542],{"nctId":6543,"briefTitle":6544,"status":143,"phases":6545,"primaryCompletion":6546,"completion":6547,"start":6548,"enrollment":711,"conditions":6549,"interventions":6551},"NCT06492460","2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma",[94],"2029-09-20","2033-07-17","2024-09-20",[6550],"Squamous Cell Carcinoma of Head and Neck",[6532],{"trials":6553,"activeCount":104},[],{"trials":6555,"activeCount":104},[],{"intervention":6557,"totalTrials":100,"cells":6558},"Megestrol Acetate + Trastuzumab Deruxtecan",{"EARLY_PHASE1":6559,"PHASE1":6561,"PHASE2":6563,"PHASE3":6565,"PHASE4":6577,"NA":6579},{"trials":6560,"activeCount":104},[],{"trials":6562,"activeCount":104},[],{"trials":6564,"activeCount":104},[],{"trials":6566,"activeCount":100,"soonestReadout":6571},[6567],{"nctId":6568,"briefTitle":6569,"status":116,"phases":6570,"primaryCompletion":6571,"completion":6572,"start":5805,"enrollment":3488,"conditions":6573,"interventions":6576},"NCT07543536","Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer",[94],"2029-04-01","2031-04-01",[6574,6575],"Advanced\u002FMetastatic Breast Cancer","HER2+, Low, or Ultralow Advanced\u002FMetastatic Breast Cancer",[6557],{"trials":6578,"activeCount":104},[],{"trials":6580,"activeCount":104},[],{"intervention":6582,"totalTrials":100,"cells":6583},"Nintedanib",{"EARLY_PHASE1":6584,"PHASE1":6586,"PHASE2":6588,"PHASE3":6590,"PHASE4":6602,"NA":6604},{"trials":6585,"activeCount":104},[],{"trials":6587,"activeCount":104},[],{"trials":6589,"activeCount":104},[],{"trials":6591,"activeCount":100,"soonestReadout":236},[6592],{"nctId":6593,"briefTitle":6594,"status":116,"phases":6595,"primaryCompletion":236,"completion":2066,"start":6596,"enrollment":6597,"conditions":6598,"interventions":6600},"NCT07162961","Nintedanib for Improving Reproductive Outcomes in Adenomyosis",[94],"2025-09-01",328,[6599],"Adenomyosis of Uterus",[6582,6601],"Progesterone",{"trials":6603,"activeCount":104},[],{"trials":6605,"activeCount":104},[],{"intervention":6601,"totalTrials":100,"cells":6607},{"EARLY_PHASE1":6608,"PHASE1":6610,"PHASE2":6612,"PHASE3":6614,"PHASE4":6620,"NA":6622},{"trials":6609,"activeCount":104},[],{"trials":6611,"activeCount":104},[],{"trials":6613,"activeCount":104},[],{"trials":6615,"activeCount":100,"soonestReadout":236},[6616],{"nctId":6593,"briefTitle":6594,"status":116,"phases":6617,"primaryCompletion":236,"completion":2066,"start":6596,"enrollment":6597,"conditions":6618,"interventions":6619},[94],[6599],[6582,6601],{"trials":6621,"activeCount":104},[],{"trials":6623,"activeCount":104},[],{"intervention":6625,"totalTrials":100,"cells":6626},"Camrelizumab combined GP chemotherapy",{"EARLY_PHASE1":6627,"PHASE1":6629,"PHASE2":6631,"PHASE3":6633,"PHASE4":6644,"NA":6646},{"trials":6628,"activeCount":104},[],{"trials":6630,"activeCount":104},[],{"trials":6632,"activeCount":104},[],{"trials":6634,"activeCount":100,"soonestReadout":6639},[6635],{"nctId":6636,"briefTitle":6637,"status":143,"phases":6638,"primaryCompletion":6639,"completion":6640,"start":1036,"enrollment":1213,"conditions":6641,"interventions":6642},"NCT06669611","Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[94],"2027-11-20","2029-11-20",[37],[6625,6643],"Camrelizumab combined TPC chemotherapy",{"trials":6645,"activeCount":104},[],{"trials":6647,"activeCount":104},[],{"intervention":6643,"totalTrials":100,"cells":6649},{"EARLY_PHASE1":6650,"PHASE1":6652,"PHASE2":6654,"PHASE3":6656,"PHASE4":6662,"NA":6664},{"trials":6651,"activeCount":104},[],{"trials":6653,"activeCount":104},[],{"trials":6655,"activeCount":104},[],{"trials":6657,"activeCount":100,"soonestReadout":6639},[6658],{"nctId":6636,"briefTitle":6637,"status":143,"phases":6659,"primaryCompletion":6639,"completion":6640,"start":1036,"enrollment":1213,"conditions":6660,"interventions":6661},[94],[37],[6625,6643],{"trials":6663,"activeCount":104},[],{"trials":6665,"activeCount":104},[],{"intervention":6667,"totalTrials":100,"cells":6668},"Houyanqing Oral Liquid",{"EARLY_PHASE1":6669,"PHASE1":6671,"PHASE2":6673,"PHASE3":6675,"PHASE4":6686,"NA":6688},{"trials":6670,"activeCount":104},[],{"trials":6672,"activeCount":104},[],{"trials":6674,"activeCount":104},[],{"trials":6676,"activeCount":100,"soonestReadout":6681},[6677],{"nctId":6678,"briefTitle":6679,"status":143,"phases":6680,"primaryCompletion":6681,"completion":4439,"start":6682,"enrollment":610,"conditions":6683,"interventions":6685},"NCT07311772","Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid",[94],"2027-03-15","2025-12-16",[37,6684],"Radiation-induced Oral Mucositis",[6667],{"trials":6687,"activeCount":104},[],{"trials":6689,"activeCount":104},[],{"intervention":6691,"totalTrials":100,"cells":6692},"induction chemotherapy",{"EARLY_PHASE1":6693,"PHASE1":6695,"PHASE2":6697,"PHASE3":6699,"PHASE4":6712,"NA":6714},{"trials":6694,"activeCount":104},[],{"trials":6696,"activeCount":104},[],{"trials":6698,"activeCount":104},[],{"trials":6700,"activeCount":100,"soonestReadout":6705},[6701],{"nctId":6702,"briefTitle":6703,"status":300,"phases":6704,"primaryCompletion":6705,"completion":6706,"start":6707,"enrollment":6708,"conditions":6709,"interventions":6710},"NCT05304468","Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain",[94],"2026-10-29","2029-10-29","2022-05-11",452,[16],[6691,6711],"cisplatin concurrent chemotherapy",{"trials":6713,"activeCount":104},[],{"trials":6715,"activeCount":104},[],{"intervention":6711,"totalTrials":100,"cells":6717},{"EARLY_PHASE1":6718,"PHASE1":6720,"PHASE2":6722,"PHASE3":6724,"PHASE4":6730,"NA":6732},{"trials":6719,"activeCount":104},[],{"trials":6721,"activeCount":104},[],{"trials":6723,"activeCount":104},[],{"trials":6725,"activeCount":100,"soonestReadout":6705},[6726],{"nctId":6702,"briefTitle":6703,"status":300,"phases":6727,"primaryCompletion":6705,"completion":6706,"start":6707,"enrollment":6708,"conditions":6728,"interventions":6729},[94],[16],[6691,6711],{"trials":6731,"activeCount":104},[],{"trials":6733,"activeCount":104},[],{"intervention":6735,"totalTrials":100,"cells":6736},"Multiple cardiovascular drugs related to \"Golden Triangle\"",{"EARLY_PHASE1":6737,"PHASE1":6739,"PHASE2":6741,"PHASE3":6743,"PHASE4":6754,"NA":6756},{"trials":6738,"activeCount":104},[],{"trials":6740,"activeCount":104},[],{"trials":6742,"activeCount":104},[],{"trials":6744,"activeCount":100,"soonestReadout":6749},[6745],{"nctId":6746,"briefTitle":6747,"status":143,"phases":6748,"primaryCompletion":6749,"completion":1999,"start":2644,"enrollment":6750,"conditions":6751,"interventions":6753},"NCT04980716","Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients",[94],"2026-01-31",524,[22,6752],"Cardiovascular Complication",[6735],{"trials":6755,"activeCount":104},[],{"trials":6757,"activeCount":104},[],{"intervention":6759,"totalTrials":100,"cells":6760},"Group A",{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6765,"PHASE3":6767,"PHASE4":6778,"NA":6780},{"trials":6762,"activeCount":104},[],{"trials":6764,"activeCount":104},[],{"trials":6766,"activeCount":104},[],{"trials":6768,"activeCount":100,"soonestReadout":646},[6769],{"nctId":6770,"briefTitle":6771,"status":116,"phases":6772,"primaryCompletion":646,"completion":679,"start":895,"enrollment":6773,"conditions":6774,"interventions":6776},"NCT06946628","New Triple Therapy in Newly Diagnosed Type 2 Diabetes",[94],296,[6775],"Diabetes Mellitus",[6759,6777],"Group B",{"trials":6779,"activeCount":104},[],{"trials":6781,"activeCount":104},[],{"intervention":6777,"totalTrials":100,"cells":6783},{"EARLY_PHASE1":6784,"PHASE1":6786,"PHASE2":6788,"PHASE3":6790,"PHASE4":6796,"NA":6798},{"trials":6785,"activeCount":104},[],{"trials":6787,"activeCount":104},[],{"trials":6789,"activeCount":104},[],{"trials":6791,"activeCount":100,"soonestReadout":646},[6792],{"nctId":6770,"briefTitle":6771,"status":116,"phases":6793,"primaryCompletion":646,"completion":679,"start":895,"enrollment":6773,"conditions":6794,"interventions":6795},[94],[6775],[6759,6777],{"trials":6797,"activeCount":104},[],{"trials":6799,"activeCount":104},[],{"intervention":6801,"totalTrials":100,"cells":6802},"FOLFOX 2d",{"EARLY_PHASE1":6803,"PHASE1":6805,"PHASE2":6807,"PHASE3":6809,"PHASE4":6818,"NA":6820},{"trials":6804,"activeCount":104},[],{"trials":6806,"activeCount":104},[],{"trials":6808,"activeCount":104},[],{"trials":6810,"activeCount":100,"soonestReadout":2788},[6811],{"nctId":6812,"briefTitle":6813,"status":143,"phases":6814,"primaryCompletion":2788,"completion":4429,"start":1725,"enrollment":189,"conditions":6815,"interventions":6816},"NCT05476432","HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study",[94],[19],[6801,6817],"FOLFOX 1d",{"trials":6819,"activeCount":104},[],{"trials":6821,"activeCount":104},[],{"intervention":6817,"totalTrials":100,"cells":6823},{"EARLY_PHASE1":6824,"PHASE1":6826,"PHASE2":6828,"PHASE3":6830,"PHASE4":6836,"NA":6838},{"trials":6825,"activeCount":104},[],{"trials":6827,"activeCount":104},[],{"trials":6829,"activeCount":104},[],{"trials":6831,"activeCount":100,"soonestReadout":2788},[6832],{"nctId":6812,"briefTitle":6813,"status":143,"phases":6833,"primaryCompletion":2788,"completion":4429,"start":1725,"enrollment":189,"conditions":6834,"interventions":6835},[94],[19],[6801,6817],{"trials":6837,"activeCount":104},[],{"trials":6839,"activeCount":104},[],{"intervention":3832,"totalTrials":100,"cells":6841},{"EARLY_PHASE1":6842,"PHASE1":6844,"PHASE2":6846,"PHASE3":6848,"PHASE4":6854,"NA":6856},{"trials":6843,"activeCount":104},[],{"trials":6845,"activeCount":104},[],{"trials":6847,"activeCount":104},[],{"trials":6849,"activeCount":100,"soonestReadout":895},[6850],{"nctId":3823,"briefTitle":3824,"status":143,"phases":6851,"primaryCompletion":895,"completion":303,"start":3826,"enrollment":3827,"conditions":6852,"interventions":6853},[94],[3829,3830],[3832,3833],{"trials":6855,"activeCount":104},[],{"trials":6857,"activeCount":104},[],{"intervention":4596,"totalTrials":100,"cells":6859},{"EARLY_PHASE1":6860,"PHASE1":6862,"PHASE2":6864,"PHASE3":6866,"PHASE4":6872,"NA":6874},{"trials":6861,"activeCount":104},[],{"trials":6863,"activeCount":104},[],{"trials":6865,"activeCount":104},[],{"trials":6867,"activeCount":100,"soonestReadout":4592},[6868],{"nctId":4589,"briefTitle":4590,"status":143,"phases":6869,"primaryCompletion":4592,"completion":4593,"start":1083,"enrollment":1482,"conditions":6870,"interventions":6871},[94],[34,4194],[4596,4562],{"trials":6873,"activeCount":104},[],{"trials":6875,"activeCount":104},[],{"intervention":6877,"totalTrials":100,"cells":6878},"Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU",{"EARLY_PHASE1":6879,"PHASE1":6881,"PHASE2":6883,"PHASE3":6885,"PHASE4":6900,"NA":6902},{"trials":6880,"activeCount":104},[],{"trials":6882,"activeCount":104},[],{"trials":6884,"activeCount":104},[],{"trials":6886,"activeCount":100,"soonestReadout":5761},[6887],{"nctId":6888,"briefTitle":6889,"status":143,"phases":6890,"primaryCompletion":5761,"completion":6891,"start":6892,"enrollment":698,"conditions":6893,"interventions":6895},"NCT06041477","Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC",[94],"2030-07","2023-10-31",[19,2430,6894],"Chemotherapeutic Toxicity",[6877,6896,6897,6898,6899],"Concurrent Lenvatinib","Concurrent PD-1 antibody","Sequential Lenvatinib","Sequential PD-1 antibody",{"trials":6901,"activeCount":104},[],{"trials":6903,"activeCount":104},[],{"intervention":6896,"totalTrials":100,"cells":6905},{"EARLY_PHASE1":6906,"PHASE1":6908,"PHASE2":6910,"PHASE3":6912,"PHASE4":6918,"NA":6920},{"trials":6907,"activeCount":104},[],{"trials":6909,"activeCount":104},[],{"trials":6911,"activeCount":104},[],{"trials":6913,"activeCount":100,"soonestReadout":5761},[6914],{"nctId":6888,"briefTitle":6889,"status":143,"phases":6915,"primaryCompletion":5761,"completion":6891,"start":6892,"enrollment":698,"conditions":6916,"interventions":6917},[94],[19,2430,6894],[6877,6896,6897,6898,6899],{"trials":6919,"activeCount":104},[],{"trials":6921,"activeCount":104},[],{"intervention":6897,"totalTrials":100,"cells":6923},{"EARLY_PHASE1":6924,"PHASE1":6926,"PHASE2":6928,"PHASE3":6930,"PHASE4":6936,"NA":6938},{"trials":6925,"activeCount":104},[],{"trials":6927,"activeCount":104},[],{"trials":6929,"activeCount":104},[],{"trials":6931,"activeCount":100,"soonestReadout":5761},[6932],{"nctId":6888,"briefTitle":6889,"status":143,"phases":6933,"primaryCompletion":5761,"completion":6891,"start":6892,"enrollment":698,"conditions":6934,"interventions":6935},[94],[19,2430,6894],[6877,6896,6897,6898,6899],{"trials":6937,"activeCount":104},[],{"trials":6939,"activeCount":104},[],{"intervention":6898,"totalTrials":100,"cells":6941},{"EARLY_PHASE1":6942,"PHASE1":6944,"PHASE2":6946,"PHASE3":6948,"PHASE4":6954,"NA":6956},{"trials":6943,"activeCount":104},[],{"trials":6945,"activeCount":104},[],{"trials":6947,"activeCount":104},[],{"trials":6949,"activeCount":100,"soonestReadout":5761},[6950],{"nctId":6888,"briefTitle":6889,"status":143,"phases":6951,"primaryCompletion":5761,"completion":6891,"start":6892,"enrollment":698,"conditions":6952,"interventions":6953},[94],[19,2430,6894],[6877,6896,6897,6898,6899],{"trials":6955,"activeCount":104},[],{"trials":6957,"activeCount":104},[],{"intervention":6899,"totalTrials":100,"cells":6959},{"EARLY_PHASE1":6960,"PHASE1":6962,"PHASE2":6964,"PHASE3":6966,"PHASE4":6972,"NA":6974},{"trials":6961,"activeCount":104},[],{"trials":6963,"activeCount":104},[],{"trials":6965,"activeCount":104},[],{"trials":6967,"activeCount":100,"soonestReadout":5761},[6968],{"nctId":6888,"briefTitle":6889,"status":143,"phases":6969,"primaryCompletion":5761,"completion":6891,"start":6892,"enrollment":698,"conditions":6970,"interventions":6971},[94],[19,2430,6894],[6877,6896,6897,6898,6899],{"trials":6973,"activeCount":104},[],{"trials":6975,"activeCount":104},[],{"intervention":4486,"totalTrials":100,"cells":6977},{"EARLY_PHASE1":6978,"PHASE1":6980,"PHASE2":6982,"PHASE3":6984,"PHASE4":6990,"NA":6992},{"trials":6979,"activeCount":104},[],{"trials":6981,"activeCount":104},[],{"trials":6983,"activeCount":104},[],{"trials":6985,"activeCount":100,"soonestReadout":4481},[6986],{"nctId":4478,"briefTitle":4479,"status":116,"phases":6987,"primaryCompletion":4481,"completion":4482,"start":895,"enrollment":4483,"conditions":6988,"interventions":6989},[93,94],[1922],[4486,4487,4415],{"trials":6991,"activeCount":104},[],{"trials":6993,"activeCount":104},[],{"intervention":6995,"totalTrials":100,"cells":6996},"Androgen Deprivation Therapy",{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7003,"PHASE4":7018,"NA":7020},{"trials":6998,"activeCount":104},[],{"trials":7000,"activeCount":104},[],{"trials":7002,"activeCount":104},[],{"trials":7004,"activeCount":100,"soonestReadout":3413},[7005],{"nctId":7006,"briefTitle":7007,"status":300,"phases":7008,"primaryCompletion":3413,"completion":7009,"start":7010,"enrollment":7011,"conditions":7012,"interventions":7017},"NCT07477626","Radiotherapy After Prostatectomy for Node Positive Prostate Cancer",[94],"2038-12-31","2026-01-06",372,[7013,7014,7015,6995,7016],"Prostate Cancer (Post Prostatectomy)","Radiotherapy; Image-Guided","Prostate Cancer Non-Metastatic","Lymph Node Positive",[6995],{"trials":7019,"activeCount":104},[],{"trials":7021,"activeCount":104},[],{"intervention":7023,"totalTrials":100,"cells":7024},"Camrelizumab plus chemo-radiotherapy",{"EARLY_PHASE1":7025,"PHASE1":7027,"PHASE2":7029,"PHASE3":7031,"PHASE4":7042,"NA":7044},{"trials":7026,"activeCount":104},[],{"trials":7028,"activeCount":104},[],{"trials":7030,"activeCount":104},[],{"trials":7032,"activeCount":100,"soonestReadout":5234},[7033],{"nctId":7034,"briefTitle":7035,"status":143,"phases":7036,"primaryCompletion":5234,"completion":249,"start":4713,"enrollment":7037,"conditions":7038,"interventions":7040},"NCT04453826","Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma",[94],388,[396,726,505,7039],"PD-1 Therapy",[7023,7041],"Chemo-radiotherapy alone",{"trials":7043,"activeCount":104},[],{"trials":7045,"activeCount":104},[],{"intervention":7041,"totalTrials":100,"cells":7047},{"EARLY_PHASE1":7048,"PHASE1":7050,"PHASE2":7052,"PHASE3":7054,"PHASE4":7060,"NA":7062},{"trials":7049,"activeCount":104},[],{"trials":7051,"activeCount":104},[],{"trials":7053,"activeCount":104},[],{"trials":7055,"activeCount":100,"soonestReadout":5234},[7056],{"nctId":7034,"briefTitle":7035,"status":143,"phases":7057,"primaryCompletion":5234,"completion":249,"start":4713,"enrollment":7037,"conditions":7058,"interventions":7059},[94],[396,726,505,7039],[7023,7041],{"trials":7061,"activeCount":104},[],{"trials":7063,"activeCount":104},[],{"intervention":7065,"totalTrials":100,"cells":7066},"GP\u002FPFLL+AK104",{"EARLY_PHASE1":7067,"PHASE1":7069,"PHASE2":7071,"PHASE3":7073,"PHASE4":7084,"NA":7086},{"trials":7068,"activeCount":104},[],{"trials":7070,"activeCount":104},[],{"trials":7072,"activeCount":104},[],{"trials":7074,"activeCount":100,"soonestReadout":3663},[7075],{"nctId":7076,"briefTitle":7077,"status":143,"phases":7078,"primaryCompletion":3663,"completion":7079,"start":405,"enrollment":189,"conditions":7080,"interventions":7082},"NCT06241599","A Multi-center, Randomized, Double-blind, Phase II\u002FIII Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)",[93,94],"2029-02-01",[7081],"Recurrent or Metastatic Nasopharyngeal Carcinoma",[7065,7083],"GP\u002FPFLL+placebo",{"trials":7085,"activeCount":104},[],{"trials":7087,"activeCount":104},[],{"intervention":7083,"totalTrials":100,"cells":7089},{"EARLY_PHASE1":7090,"PHASE1":7092,"PHASE2":7094,"PHASE3":7096,"PHASE4":7102,"NA":7104},{"trials":7091,"activeCount":104},[],{"trials":7093,"activeCount":104},[],{"trials":7095,"activeCount":104},[],{"trials":7097,"activeCount":100,"soonestReadout":3663},[7098],{"nctId":7076,"briefTitle":7077,"status":143,"phases":7099,"primaryCompletion":3663,"completion":7079,"start":405,"enrollment":189,"conditions":7100,"interventions":7101},[93,94],[7081],[7065,7083],{"trials":7103,"activeCount":104},[],{"trials":7105,"activeCount":104},[],{"intervention":1195,"totalTrials":100,"cells":7107},{"EARLY_PHASE1":7108,"PHASE1":7110,"PHASE2":7112,"PHASE3":7114,"PHASE4":7120,"NA":7122},{"trials":7109,"activeCount":104},[],{"trials":7111,"activeCount":104},[],{"trials":7113,"activeCount":104},[],{"trials":7115,"activeCount":100,"soonestReadout":1189},[7116],{"nctId":1186,"briefTitle":1187,"status":143,"phases":7117,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":7118,"interventions":7119},[94],[19],[353,284,1195],{"trials":7121,"activeCount":104},[],{"trials":7123,"activeCount":104},[],{"intervention":7125,"totalTrials":100,"cells":7126},"Etoposide + carboplatin; Etoposide + cisplatin",{"EARLY_PHASE1":7127,"PHASE1":7129,"PHASE2":7131,"PHASE3":7133,"PHASE4":7146,"NA":7148},{"trials":7128,"activeCount":104},[],{"trials":7130,"activeCount":104},[],{"trials":7132,"activeCount":104},[],{"trials":7134,"activeCount":100,"soonestReadout":119},[7135],{"nctId":7136,"briefTitle":7137,"status":143,"phases":7138,"primaryCompletion":119,"completion":773,"start":7139,"enrollment":7140,"conditions":7141,"interventions":7145},"NCT07008716","Omitting CTV for Primary Tumor in LS-SCLC",[94],"2025-06-03",852,[7142,7143,3458,7144],"SCLC, Limited Stage","Radiation Exposure","Progression",[7125],{"trials":7147,"activeCount":104},[],{"trials":7149,"activeCount":104},[],{"intervention":59,"totalTrials":100,"cells":7151},{"EARLY_PHASE1":7152,"PHASE1":7154,"PHASE2":7156,"PHASE3":7158,"PHASE4":7166,"NA":7168},{"trials":7153,"activeCount":104},[],{"trials":7155,"activeCount":104},[],{"trials":7157,"activeCount":104},[],{"trials":7159,"activeCount":100,"soonestReadout":58},[7160],{"nctId":56,"briefTitle":57,"status":300,"phases":7161,"primaryCompletion":58,"completion":6572,"start":5311,"enrollment":7162,"conditions":7163,"interventions":7164},[94],738,[1404],[59,7165],"Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens",{"trials":7167,"activeCount":104},[],{"trials":7169,"activeCount":104},[],{"intervention":7165,"totalTrials":100,"cells":7171},{"EARLY_PHASE1":7172,"PHASE1":7174,"PHASE2":7176,"PHASE3":7178,"PHASE4":7184,"NA":7186},{"trials":7173,"activeCount":104},[],{"trials":7175,"activeCount":104},[],{"trials":7177,"activeCount":104},[],{"trials":7179,"activeCount":100,"soonestReadout":58},[7180],{"nctId":56,"briefTitle":57,"status":300,"phases":7181,"primaryCompletion":58,"completion":6572,"start":5311,"enrollment":7162,"conditions":7182,"interventions":7183},[94],[1404],[59,7165],{"trials":7185,"activeCount":104},[],{"trials":7187,"activeCount":104},[],{"intervention":864,"totalTrials":100,"cells":7189},{"EARLY_PHASE1":7190,"PHASE1":7192,"PHASE2":7194,"PHASE3":7196,"PHASE4":7202,"NA":7204},{"trials":7191,"activeCount":104},[],{"trials":7193,"activeCount":104},[],{"trials":7195,"activeCount":104},[],{"trials":7197,"activeCount":100,"soonestReadout":860},[7198],{"nctId":857,"briefTitle":858,"status":116,"phases":7199,"primaryCompletion":860,"completion":861,"start":862,"enrollment":262,"conditions":7200,"interventions":7201},[93,94],[16,864,865],[527,225,864],{"trials":7203,"activeCount":104},[],{"trials":7205,"activeCount":104},[],{"intervention":7207,"totalTrials":100,"cells":7208},"Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine",{"EARLY_PHASE1":7209,"PHASE1":7211,"PHASE2":7213,"PHASE3":7215,"PHASE4":7229,"NA":7231},{"trials":7210,"activeCount":104},[],{"trials":7212,"activeCount":104},[],{"trials":7214,"activeCount":104},[],{"trials":7216,"activeCount":100,"soonestReadout":7221},[7217],{"nctId":7218,"briefTitle":7219,"status":116,"phases":7220,"primaryCompletion":7221,"completion":7222,"start":7223,"enrollment":7224,"conditions":7225,"interventions":7227},"NCT06561763","TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma",[94],"2028-08-20","2031-08-20","2024-08-20",416,[7226],"High Risk Locally Advanced Nasopharyngeal Carcinoma",[7207,7228],"Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine",{"trials":7230,"activeCount":104},[],{"trials":7232,"activeCount":104},[],{"intervention":7228,"totalTrials":100,"cells":7234},{"EARLY_PHASE1":7235,"PHASE1":7237,"PHASE2":7239,"PHASE3":7241,"PHASE4":7247,"NA":7249},{"trials":7236,"activeCount":104},[],{"trials":7238,"activeCount":104},[],{"trials":7240,"activeCount":104},[],{"trials":7242,"activeCount":100,"soonestReadout":7221},[7243],{"nctId":7218,"briefTitle":7219,"status":116,"phases":7244,"primaryCompletion":7221,"completion":7222,"start":7223,"enrollment":7224,"conditions":7245,"interventions":7246},[94],[7226],[7207,7228],{"trials":7248,"activeCount":104},[],{"trials":7250,"activeCount":104},[],{"intervention":4196,"totalTrials":100,"cells":7252},{"EARLY_PHASE1":7253,"PHASE1":7255,"PHASE2":7257,"PHASE3":7259,"PHASE4":7265,"NA":7267},{"trials":7254,"activeCount":104},[],{"trials":7256,"activeCount":104},[],{"trials":7258,"activeCount":104},[],{"trials":7260,"activeCount":100,"soonestReadout":4189},[7261],{"nctId":4186,"briefTitle":4187,"status":116,"phases":7262,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":4191,"conditions":7263,"interventions":7264},[94],[4193,4194],[2100,4196,4197],{"trials":7266,"activeCount":104},[],{"trials":7268,"activeCount":104},[],{"intervention":4197,"totalTrials":100,"cells":7270},{"EARLY_PHASE1":7271,"PHASE1":7273,"PHASE2":7275,"PHASE3":7277,"PHASE4":7283,"NA":7285},{"trials":7272,"activeCount":104},[],{"trials":7274,"activeCount":104},[],{"trials":7276,"activeCount":104},[],{"trials":7278,"activeCount":100,"soonestReadout":4189},[7279],{"nctId":4186,"briefTitle":4187,"status":116,"phases":7280,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":4191,"conditions":7281,"interventions":7282},[94],[4193,4194],[2100,4196,4197],{"trials":7284,"activeCount":104},[],{"trials":7286,"activeCount":104},[],{"intervention":7288,"totalTrials":100,"cells":7289},"Topotecan",{"EARLY_PHASE1":7290,"PHASE1":7292,"PHASE2":7294,"PHASE3":7296,"PHASE4":7305,"NA":7307},{"trials":7291,"activeCount":104},[],{"trials":7293,"activeCount":104},[],{"trials":7295,"activeCount":104},[],{"trials":7297,"activeCount":100,"soonestReadout":1238},[7298],{"nctId":7299,"briefTitle":7300,"status":143,"phases":7301,"primaryCompletion":1238,"completion":1437,"start":1726,"enrollment":205,"conditions":7302,"interventions":7303},"NCT04799002","Topotecan and Melphalan for Retinoblastoma",[94],[3293,2430],[7288,7304],"Melphalan",{"trials":7306,"activeCount":104},[],{"trials":7308,"activeCount":104},[],{"intervention":7304,"totalTrials":100,"cells":7310},{"EARLY_PHASE1":7311,"PHASE1":7313,"PHASE2":7315,"PHASE3":7317,"PHASE4":7323,"NA":7325},{"trials":7312,"activeCount":104},[],{"trials":7314,"activeCount":104},[],{"trials":7316,"activeCount":104},[],{"trials":7318,"activeCount":100,"soonestReadout":1238},[7319],{"nctId":7299,"briefTitle":7300,"status":143,"phases":7320,"primaryCompletion":1238,"completion":1437,"start":1726,"enrollment":205,"conditions":7321,"interventions":7322},[94],[3293,2430],[7288,7304],{"trials":7324,"activeCount":104},[],{"trials":7326,"activeCount":104},[],{"intervention":3019,"totalTrials":1861,"cells":7328},{"EARLY_PHASE1":7329,"PHASE1":7331,"PHASE2":7333,"PHASE3":7344,"PHASE4":7350,"NA":7352},{"trials":7330,"activeCount":104},[],{"trials":7332,"activeCount":104},[],{"trials":7334,"activeCount":104},[7335],{"nctId":7336,"briefTitle":7337,"status":174,"phases":7338,"primaryCompletion":1738,"completion":7339,"start":7340,"enrollment":2040,"conditions":7341,"interventions":7342},"NCT03946917","JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer",[92,93],"2021-11-20","2019-03-12",[25],[385,7343],"regorafenib",{"trials":7345,"activeCount":100,"soonestReadout":3518},[7346],{"nctId":5613,"briefTitle":5614,"status":143,"phases":7347,"primaryCompletion":3518,"completion":5616,"start":5617,"enrollment":5618,"conditions":7348,"interventions":7349},[94],[5620,3019],[5602,3019],{"trials":7351,"activeCount":104},[],{"trials":7353,"activeCount":104},[7354],{"nctId":3012,"briefTitle":3013,"status":328,"phases":7355,"primaryCompletion":346,"completion":3015,"start":670,"enrollment":1192,"conditions":7356,"interventions":7357},[96],[3017],[353,3019,1240],{"intervention":7359,"totalTrials":1861,"cells":7360},"docetaxel and cisplatin",{"EARLY_PHASE1":7361,"PHASE1":7363,"PHASE2":7365,"PHASE3":7376,"PHASE4":7382,"NA":7384},{"trials":7362,"activeCount":104},[],{"trials":7364,"activeCount":104},[],{"trials":7366,"activeCount":104},[7367],{"nctId":7368,"briefTitle":7369,"status":328,"phases":7370,"primaryCompletion":2770,"completion":7371,"start":618,"enrollment":7372,"conditions":7373,"interventions":7375},"NCT02577341","Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer",[93],"2020-10",122,[7374],"Non-small-cell Lung Cancer",[339,7359],{"trials":7377,"activeCount":100,"soonestReadout":236},[7378],{"nctId":1165,"briefTitle":1166,"status":116,"phases":7379,"primaryCompletion":236,"completion":146,"start":236,"enrollment":1168,"conditions":7380,"interventions":7381},[94],[1170],[1172,284],{"trials":7383,"activeCount":104},[],{"trials":7385,"activeCount":104},[7386],{"nctId":5263,"briefTitle":5264,"status":174,"phases":7387,"primaryCompletion":658,"completion":1827,"start":1934,"enrollment":610,"conditions":7388,"interventions":7389},[96],[441],[5268,5269,5270,5271],{"intervention":3403,"totalTrials":1255,"cells":7391},{"EARLY_PHASE1":7392,"PHASE1":7394,"PHASE2":7396,"PHASE3":7398,"PHASE4":7404,"NA":7406},{"trials":7393,"activeCount":104},[],{"trials":7395,"activeCount":104},[],{"trials":7397,"activeCount":104},[],{"trials":7399,"activeCount":100,"soonestReadout":669},[7400],{"nctId":3396,"briefTitle":3397,"status":143,"phases":7401,"primaryCompletion":669,"completion":626,"start":3399,"enrollment":1520,"conditions":7402,"interventions":7403},[94],[16,3401,505,726],[726,3403],{"trials":7405,"activeCount":104},[],{"trials":7407,"activeCount":104},[7408],{"nctId":7409,"briefTitle":7410,"status":174,"phases":7411,"primaryCompletion":850,"completion":6596,"start":6504,"enrollment":1339,"conditions":7412,"interventions":7414},"NCT05609695","Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs \u002F Locoregional Therapy in the Treatment of Hepatocellular Carcinoma",[],[7413],"Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs \u002F Locoregional Therapy for Hepatocellular Carcinoma",[3403],{"intervention":981,"totalTrials":1138,"cells":7416},{"EARLY_PHASE1":7417,"PHASE1":7419,"PHASE2":7421,"PHASE3":7537,"PHASE4":7539,"NA":7541},{"trials":7418,"activeCount":104},[],{"trials":7420,"activeCount":104},[],{"trials":7422,"activeCount":2439,"soonestReadout":7506},[7423,7433,7437,7445,7455,7459,7463,7467,7475,7479,7487,7498,7502,7510,7519,7528],{"nctId":7424,"briefTitle":7425,"status":174,"phases":7426,"primaryCompletion":217,"completion":3355,"start":7427,"enrollment":7428,"conditions":7429,"interventions":7431},"NCT03321890","Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",[93],"2017-03-07",102,[7430],"Peripheral T-cell Lymphoma",[981,7432,2308,2197,4755],"prednisone",{"nctId":1644,"briefTitle":1645,"status":174,"phases":7434,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":32,"conditions":7435,"interventions":7436},[93],[1651],[483,981],{"nctId":7438,"briefTitle":7439,"status":116,"phases":7440,"primaryCompletion":3651,"completion":6330,"start":1790,"enrollment":3705,"conditions":7441,"interventions":7443},"NCT07139353","Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma",[92,93],[7442],"Peripheral T Cells Lymphoma (PTCL)",[7444,981],"Linperlisib",{"nctId":7446,"briefTitle":7447,"status":116,"phases":7448,"primaryCompletion":3586,"completion":7449,"start":3587,"enrollment":1066,"conditions":7450,"interventions":7452},"NCT07601607","Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma",[92,93],"2028-11-30",[7451],"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R\u002FR DLBCL)",[7453,981,7454],"Lisaftoclax","rituximab",{"nctId":1664,"briefTitle":1665,"status":174,"phases":7456,"primaryCompletion":1667,"completion":1668,"start":1657,"enrollment":29,"conditions":7457,"interventions":7458},[93],[1651],[483,981,1671,1672],{"nctId":1674,"briefTitle":1675,"status":174,"phases":7460,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":1680,"conditions":7461,"interventions":7462},[93],[1682],[483,981],{"nctId":972,"briefTitle":973,"status":116,"phases":7464,"primaryCompletion":975,"completion":976,"start":977,"enrollment":978,"conditions":7465,"interventions":7466},[92,93],[16],[981,284,363],{"nctId":7468,"briefTitle":7469,"status":174,"phases":7470,"primaryCompletion":289,"completion":289,"start":7471,"enrollment":1339,"conditions":7472,"interventions":7474},"NCT03245905","Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL",[93],"2017-08-20",[7473],"Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)",[981],{"nctId":1722,"briefTitle":1723,"status":174,"phases":7476,"primaryCompletion":1725,"completion":259,"start":1726,"enrollment":1727,"conditions":7477,"interventions":7478},[93],[1729,1730],[483,981,1732],{"nctId":7480,"briefTitle":7481,"status":116,"phases":7482,"primaryCompletion":313,"completion":839,"start":1801,"enrollment":996,"conditions":7483,"interventions":7485},"NCT07339527","EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas",[92,93],[7484],"Mature T-cell and NK-cell Lymphoma",[7486,5048,981],"Zeprumetostat",{"nctId":7488,"briefTitle":7489,"status":116,"phases":7490,"primaryCompletion":7491,"completion":6572,"start":7492,"enrollment":3179,"conditions":7493,"interventions":7495},"NCT07415980","Phase Ib\u002FII Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL",[92,93],"2028-04-01","2026-04-01",[7494],"Double Expressor DLBCL",[7496,7497,981],"Polatuzumab Vedotin","Rituximab",{"nctId":1775,"briefTitle":1776,"status":143,"phases":7499,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":1018,"conditions":7500,"interventions":7501},[93],[1782],[981,483,272],{"nctId":7503,"briefTitle":7504,"status":300,"phases":7505,"primaryCompletion":7506,"completion":1269,"start":949,"enrollment":1289,"conditions":7507,"interventions":7509},"NCT04562311","Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma",[93],"2024-08-30",[7508],"Bladder Cancer Stage IV",[981],{"nctId":7511,"briefTitle":7512,"status":143,"phases":7513,"primaryCompletion":4739,"completion":3694,"start":7514,"enrollment":360,"conditions":7515,"interventions":7517},"NCT05572983","Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype",[93],"2022-09-01",[7516],"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype",[7518,981],"Chidamide combined with CHOP",{"nctId":7520,"briefTitle":7521,"status":143,"phases":7522,"primaryCompletion":790,"completion":791,"start":7523,"enrollment":5295,"conditions":7524,"interventions":7526},"NCT07093710","Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma",[92,93],"2025-08-27",[7525],"Peripheral T Cell Lymphoma",[5048,7527,981],"Mitoxantrone Hydrochloride Liposome",{"nctId":7529,"briefTitle":7530,"status":174,"phases":7531,"primaryCompletion":7532,"completion":7533,"start":2548,"enrollment":1954,"conditions":7534,"interventions":7536},"NCT03494634","Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors",[93],"2019-09-30","2020-09-30",[7535],"Experimental Tumor",[981],{"trials":7538,"activeCount":104},[],{"trials":7540,"activeCount":104},[],{"trials":7542,"activeCount":104},[],{"intervention":54,"totalTrials":1833,"cells":7544},{"EARLY_PHASE1":7545,"PHASE1":7547,"PHASE2":7560,"PHASE3":7594,"PHASE4":7612,"NA":7614},{"trials":7546,"activeCount":104},[],{"trials":7548,"activeCount":1255,"soonestReadout":4739},[7549,7553],{"nctId":4005,"briefTitle":4006,"status":143,"phases":7550,"primaryCompletion":4008,"completion":4009,"start":1509,"enrollment":26,"conditions":7551,"interventions":7552},[92],[4011],[54,1767,2306],{"nctId":7554,"briefTitle":7555,"status":300,"phases":7556,"primaryCompletion":4739,"completion":895,"start":7557,"enrollment":3179,"conditions":7558,"interventions":7559},"NCT05620862","Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors",[92],"2022-10-25",[4011],[7527,54,2306],{"trials":7561,"activeCount":161,"soonestReadout":53},[7562,7570,7574,7578,7582,7586,7590],{"nctId":7563,"briefTitle":7564,"status":328,"phases":7565,"primaryCompletion":289,"completion":289,"start":7566,"enrollment":29,"conditions":7567,"interventions":7568},"NCT04790448","Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer",[92,93],"2020-07-27",[1020],[823,54,7569],"Vemurafenib",{"nctId":2497,"briefTitle":2498,"status":328,"phases":7571,"primaryCompletion":522,"completion":53,"start":2500,"enrollment":996,"conditions":7572,"interventions":7573},[93],[2502,2098],[54,542,2504],{"nctId":1012,"briefTitle":1013,"status":143,"phases":7575,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":7576,"interventions":7577},[93],[1020],[823,284,54],{"nctId":1758,"briefTitle":1759,"status":143,"phases":7579,"primaryCompletion":380,"completion":119,"start":1761,"enrollment":820,"conditions":7580,"interventions":7581},[93],[1763],[1765,1766,54,1767,1768,1769,483],{"nctId":51,"briefTitle":52,"status":300,"phases":7583,"primaryCompletion":53,"completion":548,"start":2548,"enrollment":2549,"conditions":7584,"interventions":7585},[93],[25,2098],[54,823,738,542,2080],{"nctId":2063,"briefTitle":2064,"status":143,"phases":7587,"primaryCompletion":2066,"completion":237,"start":895,"enrollment":239,"conditions":7588,"interventions":7589},[93],[2068],[2070,272,296,54],{"nctId":2072,"briefTitle":2073,"status":143,"phases":7591,"primaryCompletion":380,"completion":380,"start":2075,"enrollment":2076,"conditions":7592,"interventions":7593},[93],[1020],[183,2079,542,2080,664,54,272,542,2080,664],{"trials":7595,"activeCount":104},[7596,7600,7604,7608],{"nctId":2575,"briefTitle":2576,"status":174,"phases":7597,"primaryCompletion":828,"completion":203,"start":2578,"enrollment":1192,"conditions":7598,"interventions":7599},[94],[25],[542,54],{"nctId":1515,"briefTitle":1516,"status":174,"phases":7601,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":7602,"interventions":7603},[94],[1522],[1524,54,444],{"nctId":2596,"briefTitle":2597,"status":1091,"phases":7605,"primaryCompletion":2599,"completion":2599,"start":2600,"enrollment":2601,"conditions":7606,"interventions":7607},[94],[25,2098,2603],[2605,542,2080,2606,54],{"nctId":2608,"briefTitle":2609,"status":1091,"phases":7609,"primaryCompletion":2611,"completion":479,"start":289,"enrollment":2601,"conditions":7610,"interventions":7611},[94],[1368,2098],[54,2614,2504,2080,398,542],{"trials":7613,"activeCount":104},[],{"trials":7615,"activeCount":104},[],{"intervention":823,"totalTrials":528,"cells":7617},{"EARLY_PHASE1":7618,"PHASE1":7620,"PHASE2":7622,"PHASE3":7668,"PHASE4":7682,"NA":7684},{"trials":7619,"activeCount":104},[],{"trials":7621,"activeCount":104},[],{"trials":7623,"activeCount":161,"soonestReadout":53},[7624,7628,7632,7640,7644,7648,7652,7656,7660],{"nctId":7563,"briefTitle":7564,"status":328,"phases":7625,"primaryCompletion":289,"completion":289,"start":7566,"enrollment":29,"conditions":7626,"interventions":7627},[92,93],[1020],[823,54,7569],{"nctId":1916,"briefTitle":1917,"status":116,"phases":7629,"primaryCompletion":1005,"completion":1919,"start":1508,"enrollment":1920,"conditions":7630,"interventions":7631},[93],[1922],[542,296,1924,1925,272,823],{"nctId":7633,"briefTitle":7634,"status":328,"phases":7635,"primaryCompletion":2578,"completion":7636,"start":7637,"enrollment":996,"conditions":7638,"interventions":7639},"NCT01271439","Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma",[93],"2012-12","2010-09",[16],[823],{"nctId":1012,"briefTitle":1013,"status":143,"phases":7641,"primaryCompletion":1015,"completion":1016,"start":1017,"enrollment":1018,"conditions":7642,"interventions":7643},[93],[1020],[823,284,54],{"nctId":2014,"briefTitle":2015,"status":143,"phases":7645,"primaryCompletion":119,"completion":679,"start":895,"enrollment":2017,"conditions":7646,"interventions":7647},[92,93],[1020],[823,2020,272],{"nctId":1360,"briefTitle":1361,"status":328,"phases":7649,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":7650,"interventions":7651},[92,93],[1368],[823,444],{"nctId":3777,"briefTitle":3778,"status":3411,"phases":7653,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":3050,"conditions":7654,"interventions":7655},[93],[3781,3782],[3784,823,443,3785],{"nctId":51,"briefTitle":52,"status":300,"phases":7657,"primaryCompletion":53,"completion":548,"start":2548,"enrollment":2549,"conditions":7658,"interventions":7659},[93],[25,2098],[54,823,738,542,2080],{"nctId":7661,"briefTitle":7662,"status":174,"phases":7663,"primaryCompletion":1064,"completion":379,"start":733,"enrollment":1350,"conditions":7664,"interventions":7666},"NCT06118047","Crisaborole Ointment for Skin Toxicity Induced by Cetuximab",[93],[1368,823,7665],"Skin Toxicity",[7667,823],"Crisaborole Ointment",{"trials":7669,"activeCount":104},[7670,7678],{"nctId":7671,"briefTitle":7672,"status":174,"phases":7673,"primaryCompletion":479,"completion":7506,"start":7674,"enrollment":942,"conditions":7675,"interventions":7676},"NCT04262635","Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer",[94],"2021-09-24",[25],[7677,823],"Cetuximab, Capecitabine",{"nctId":815,"briefTitle":816,"status":174,"phases":7679,"primaryCompletion":818,"start":819,"enrollment":820,"conditions":7680,"interventions":7681},[94],[16],[823,225,443,444],{"trials":7683,"activeCount":104},[],{"trials":7685,"activeCount":104},[],{"intervention":1122,"totalTrials":1218,"cells":7687},{"EARLY_PHASE1":7688,"PHASE1":7690,"PHASE2":7692,"PHASE3":7744,"PHASE4":7746,"NA":7748},{"trials":7689,"activeCount":104},[],{"trials":7691,"activeCount":104},[],{"trials":7693,"activeCount":161,"soonestReadout":379},[7694,7706,7710,7714,7718,7726,7730,7740],{"nctId":7695,"briefTitle":7696,"status":328,"phases":7697,"primaryCompletion":7698,"completion":6749,"start":7699,"enrollment":333,"conditions":7700,"interventions":7704},"NCT05494580","Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer",[92,93],"2024-06-20","2022-09-22",[2042,7701,7702,7703,2045],"Ovarian Carcinoma","Platinum-resistant Ovarian Cancer","Fallopian Tube Carcinosarcoma",[7705,1122],"Pamiparib",{"nctId":2363,"briefTitle":2364,"status":143,"phases":7707,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":942,"conditions":7708,"interventions":7709},[93],[1122,69,2369,2370,22],[1122,69,2372],{"nctId":1708,"briefTitle":1709,"status":300,"phases":7711,"primaryCompletion":379,"completion":380,"start":1711,"enrollment":1712,"conditions":7712,"interventions":7713},[93],[1714],[1122,483,1716],{"nctId":2395,"briefTitle":2396,"status":116,"phases":7715,"primaryCompletion":2398,"completion":2398,"start":1508,"enrollment":734,"conditions":7716,"interventions":7717},[93],[2400],[2402,69,1122],{"nctId":7719,"briefTitle":7720,"status":174,"phases":7721,"primaryCompletion":7722,"completion":7722,"start":1613,"enrollment":360,"conditions":7723,"interventions":7725},"NCT05106777","Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma",[93],"2023-12-10",[7724],"Sarcoma",[1122],{"nctId":1434,"briefTitle":1435,"status":143,"phases":7727,"primaryCompletion":1437,"completion":1437,"start":1365,"enrollment":911,"conditions":7728,"interventions":7729},[93],[1439,1440,1441],[1122,483,444],{"nctId":7731,"briefTitle":7732,"status":328,"phases":7733,"primaryCompletion":696,"completion":7734,"start":7735,"enrollment":7736,"conditions":7737,"interventions":7738},"NCT05481463","Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer",[93],"2025-05-10","2023-01-30",22,[1714],[1122,7739],"TAS-102",{"nctId":1114,"briefTitle":1115,"status":116,"phases":7741,"primaryCompletion":1117,"completion":1118,"start":977,"enrollment":32,"conditions":7742,"interventions":7743},[93],[1120],[1122,284,1123],{"trials":7745,"activeCount":104},[],{"trials":7747,"activeCount":104},[],{"trials":7749,"activeCount":104},[],{"intervention":7497,"totalTrials":2627,"cells":7751},{"EARLY_PHASE1":7752,"PHASE1":7754,"PHASE2":7756,"PHASE3":7785,"PHASE4":7787,"NA":7789},{"trials":7753,"activeCount":104},[],{"trials":7755,"activeCount":104},[],{"trials":7757,"activeCount":2627,"soonestReadout":7491},[7758,7762,7771,7775],{"nctId":7446,"briefTitle":7447,"status":116,"phases":7759,"primaryCompletion":3586,"completion":7449,"start":3587,"enrollment":1066,"conditions":7760,"interventions":7761},[92,93],[7451],[7453,981,7454],{"nctId":7763,"briefTitle":7764,"status":143,"phases":7765,"primaryCompletion":1302,"completion":7766,"start":7767,"enrollment":205,"conditions":7768,"interventions":7769},"NCT06846489","Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma",[93],"2033-02-20","2025-04-14",[1793],[7770,7497],"Acalabrutinib",{"nctId":7488,"briefTitle":7489,"status":116,"phases":7772,"primaryCompletion":7491,"completion":6572,"start":7492,"enrollment":3179,"conditions":7773,"interventions":7774},[92,93],[7494],[7496,7497,981],{"nctId":7776,"briefTitle":7777,"status":143,"phases":7778,"primaryCompletion":7779,"completion":4481,"start":7780,"enrollment":3050,"conditions":7781,"interventions":7783},"NCT06647732","Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)",[93],"2028-08-31","2024-10-30",[7782],"Mucosa-associated Lymphoid Tissue Lymphoma (MALT)",[7784,7497],"Zanubrutinib",{"trials":7786,"activeCount":104},[],{"trials":7788,"activeCount":104},[],{"trials":7790,"activeCount":104},[],{"intervention":5048,"totalTrials":2627,"cells":7792},{"EARLY_PHASE1":7793,"PHASE1":7795,"PHASE2":7797,"PHASE3":7818,"PHASE4":7820,"NA":7822},{"trials":7794,"activeCount":104},[],{"trials":7796,"activeCount":104},[],{"trials":7798,"activeCount":2627,"soonestReadout":419},[7799,7803,7810,7814],{"nctId":7480,"briefTitle":7481,"status":116,"phases":7800,"primaryCompletion":313,"completion":839,"start":1801,"enrollment":996,"conditions":7801,"interventions":7802},[92,93],[7484],[7486,5048,981],{"nctId":7804,"briefTitle":7805,"status":116,"phases":7806,"primaryCompletion":470,"completion":470,"start":763,"enrollment":1109,"conditions":7807,"interventions":7808},"NCT07032532","Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)",[93],[7525],[5048,7809],"Golidocitinib plus CHOP",{"nctId":5041,"briefTitle":5042,"status":143,"phases":7811,"primaryCompletion":419,"completion":470,"start":5044,"enrollment":360,"conditions":7812,"interventions":7813},[93],[5046],[5048,845],{"nctId":7520,"briefTitle":7521,"status":143,"phases":7815,"primaryCompletion":790,"completion":791,"start":7523,"enrollment":5295,"conditions":7816,"interventions":7817},[92,93],[7525],[5048,7527,981],{"trials":7819,"activeCount":104},[],{"trials":7821,"activeCount":104},[],{"trials":7823,"activeCount":104},[],{"intervention":2308,"totalTrials":1464,"cells":7825},{"EARLY_PHASE1":7826,"PHASE1":7839,"PHASE2":7851,"PHASE3":7877,"PHASE4":7891,"NA":7893},{"trials":7827,"activeCount":100,"soonestReadout":7832},[7828],{"nctId":7829,"briefTitle":7830,"status":116,"phases":7831,"primaryCompletion":7832,"completion":7079,"start":3663,"enrollment":959,"conditions":7833,"interventions":7836},"NCT07342738","TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors",[91],"2028-02-01",[7834,7835,1111],"KRAS G12V","KRAS G12D",[7837,7838,2308],"TCR-T cells","Fludarabine",{"trials":7840,"activeCount":100,"soonestReadout":7845},[7841],{"nctId":7842,"briefTitle":7843,"status":143,"phases":7844,"primaryCompletion":7845,"completion":7846,"start":7847,"enrollment":2439,"conditions":7848,"interventions":7849},"NCT06898385","A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation",[92],"2027-03-27","2027-09-27","2025-03-27",[2186],[7850,7838,2308],"IX001 TCR-T",{"trials":7852,"activeCount":1255,"soonestReadout":2643},[7853,7857,7861,7865,7873],{"nctId":7424,"briefTitle":7425,"status":174,"phases":7854,"primaryCompletion":217,"completion":3355,"start":7427,"enrollment":7428,"conditions":7855,"interventions":7856},[93],[7430],[981,7432,2308,2197,4755],{"nctId":3950,"briefTitle":3951,"status":904,"phases":7858,"primaryCompletion":3953,"completion":3954,"start":3955,"enrollment":104,"conditions":7859,"interventions":7860},[93],[3957],[270,2308,183],{"nctId":4745,"briefTitle":4746,"status":174,"phases":7862,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":7863,"interventions":7864},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"nctId":7866,"briefTitle":7867,"status":143,"phases":7868,"primaryCompletion":7869,"completion":6148,"start":850,"enrollment":1501,"conditions":7870,"interventions":7872},"NCT06854250","Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer",[93],"2029-03-01",[7871],"Metastatic Prostate Cancer",[2308],{"nctId":3787,"briefTitle":3788,"status":300,"phases":7874,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":7875,"interventions":7876},[93],[28,3521],[3793,2308,1381,443,3794,3795,270,1059],{"trials":7878,"activeCount":104},[7879,7883],{"nctId":2300,"briefTitle":2301,"status":1091,"phases":7880,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":7881,"interventions":7882},[94],[2235],[49,542,1205,411,2306,2307,2308,2309],{"nctId":7884,"briefTitle":7885,"status":174,"phases":7886,"primaryCompletion":5304,"completion":7887,"start":1500,"enrollment":800,"conditions":7888,"interventions":7890},"NCT02362165","CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma",[94],"2018-05",[7889],"Multiple Myeloma",[2308,244,183,2307],{"trials":7892,"activeCount":104},[],{"trials":7894,"activeCount":104},[7895],{"nctId":7896,"briefTitle":7897,"status":328,"phases":7898,"primaryCompletion":2578,"completion":2578,"start":7899,"enrollment":314,"conditions":7900,"interventions":7903},"NCT01060410","Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment",[],"2010-05",[7901,7902],"Lupus Erythematosus, Systemic","Adverse Effects",[7904,2308],"Polymorphism Analysis",{"intervention":541,"totalTrials":3998,"cells":7906},{"EARLY_PHASE1":7907,"PHASE1":7909,"PHASE2":7911,"PHASE3":7951,"PHASE4":7957,"NA":7959},{"trials":7908,"activeCount":104},[],{"trials":7910,"activeCount":104},[],{"trials":7912,"activeCount":1861,"soonestReadout":1313},[7913,7921,7925,7929,7937,7944],{"nctId":7914,"briefTitle":7915,"status":328,"phases":7916,"primaryCompletion":3291,"completion":3507,"start":7917,"enrollment":26,"conditions":7918,"interventions":7919},"NCT02090153","Study of S-1 Plus LV for Advanced Gastric Cancer",[93],"2011-07",[539],[541,7920],"LV",{"nctId":930,"briefTitle":931,"status":143,"phases":7922,"primaryCompletion":380,"completion":646,"start":746,"enrollment":17,"conditions":7923,"interventions":7924},[93],[934],[541,284],{"nctId":1310,"briefTitle":1311,"status":143,"phases":7926,"primaryCompletion":1313,"completion":1314,"start":1315,"enrollment":1316,"conditions":7927,"interventions":7928},[93],[1318,539,1319],[69,542,541,444],{"nctId":7930,"briefTitle":7931,"status":143,"phases":7932,"primaryCompletion":7933,"completion":1942,"start":2458,"enrollment":5071,"conditions":7934,"interventions":7935},"NCT06657690","Irinotecan Liposome Combined with S-1 in PD-1\u002FL1 Inhibitor Refractory Recurrent or Metastatic NPC",[93],"2026-10-31",[7081],[7936,541],"Irinotecan liposome",{"nctId":7938,"briefTitle":7939,"status":328,"phases":7940,"primaryCompletion":5303,"completion":5303,"start":830,"enrollment":7941,"conditions":7942,"interventions":7943},"NCT02229058","Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer",[93],73,[539],[4815,541],{"nctId":7945,"briefTitle":7946,"status":328,"phases":7947,"primaryCompletion":906,"completion":906,"start":764,"enrollment":3050,"conditions":7948,"interventions":7949},"NCT02606916","Radiotherapy Combined With S-1\u002FDDP for Elderly Esophageal Squamous Cell Cancer.",[93],[463],[7950,541],"DDP",{"trials":7952,"activeCount":104},[7953],{"nctId":532,"briefTitle":533,"status":328,"phases":7954,"primaryCompletion":535,"completion":535,"start":536,"enrollment":537,"conditions":7955,"interventions":7956},[94],[539],[541,542,225],{"trials":7958,"activeCount":104},[],{"trials":7960,"activeCount":104},[],{"intervention":318,"totalTrials":161,"cells":7962},{"EARLY_PHASE1":7963,"PHASE1":7965,"PHASE2":7967,"PHASE3":7993,"PHASE4":7995,"NA":7997},{"trials":7964,"activeCount":104},[],{"trials":7966,"activeCount":104},[],{"trials":7968,"activeCount":1861,"soonestReadout":2434},[7969,7973,7977,7989],{"nctId":3258,"briefTitle":3259,"status":904,"phases":7970,"primaryCompletion":3261,"completion":3262,"start":1156,"enrollment":104,"conditions":7971,"interventions":7972},[93],[3264,3265],[363,726,318],{"nctId":3277,"briefTitle":3278,"status":143,"phases":7974,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":360,"conditions":7975,"interventions":7976},[93],[284,1122,1215,3283],[726,318,3285,3286],{"nctId":7978,"briefTitle":7979,"status":116,"phases":7980,"primaryCompletion":7981,"completion":7982,"start":2417,"enrollment":26,"conditions":7983,"interventions":7987},"NCT07231575","Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC",[93],"2027-11-30","2032-05-30",[7984,7985,7986],"Neoadjuvant Immunotherapy","NSCLC","Chemo-free Therapy",[318,7988],"antiangiogenesis therapy",{"nctId":4579,"briefTitle":4580,"status":116,"phases":7990,"primaryCompletion":2434,"completion":4582,"start":4583,"enrollment":29,"conditions":7991,"interventions":7992},[93],[34],[4562,318],{"trials":7994,"activeCount":104},[],{"trials":7996,"activeCount":104},[],{"trials":7998,"activeCount":104},[7999],{"nctId":8000,"briefTitle":8001,"status":328,"phases":8002,"primaryCompletion":746,"completion":8003,"start":8004,"enrollment":8005,"conditions":8006,"interventions":8007},"NCT06292052","Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness",[],"2024-04-01","2017-01-01",209,[2210],[318],{"intervention":3667,"totalTrials":161,"cells":8009},{"EARLY_PHASE1":8010,"PHASE1":8012,"PHASE2":8014,"PHASE3":8032,"PHASE4":8042,"NA":8044},{"trials":8011,"activeCount":104},[],{"trials":8013,"activeCount":104},[],{"trials":8015,"activeCount":1255,"soonestReadout":1277},[8016,8020,8024],{"nctId":3659,"briefTitle":3660,"status":116,"phases":8017,"primaryCompletion":3662,"completion":646,"start":3663,"enrollment":911,"conditions":8018,"interventions":8019},[93],[3274,1241],[3666,602,3667],{"nctId":5300,"briefTitle":5301,"status":174,"phases":8021,"primaryCompletion":5303,"completion":5304,"start":5211,"enrollment":4473,"conditions":8022,"interventions":8023},[93],[1368],[5273,3667],{"nctId":8025,"briefTitle":8026,"status":143,"phases":8027,"primaryCompletion":1277,"completion":851,"start":8028,"enrollment":32,"conditions":8029,"interventions":8030},"NCT07192185","Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab",[93],"2025-09-17",[3006],[3667,8031],"Atezolizumab & Bevacizumab",{"trials":8033,"activeCount":104},[8034],{"nctId":8035,"briefTitle":8036,"status":174,"phases":8037,"primaryCompletion":8038,"completion":8038,"start":8039,"enrollment":6479,"conditions":8040,"interventions":8041},"NCT03469479","Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria",[94],"2023-03-02","2018-03-02",[19],[3667],{"trials":8043,"activeCount":104},[],{"trials":8045,"activeCount":100,"soonestReadout":8050},[8046],{"nctId":8047,"briefTitle":8048,"status":143,"phases":8049,"primaryCompletion":8050,"completion":1325,"start":8051,"enrollment":1339,"conditions":8052,"interventions":8053},"NCT05718492","A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents",[96],"2025-10-18","2022-10-18",[19],[3667],{"intervention":321,"totalTrials":2627,"cells":8055},{"EARLY_PHASE1":8056,"PHASE1":8058,"PHASE2":8067,"PHASE3":8077,"PHASE4":8079,"NA":8081},{"trials":8057,"activeCount":104},[],{"trials":8059,"activeCount":100,"soonestReadout":346},[8060],{"nctId":8061,"briefTitle":8062,"status":143,"phases":8063,"primaryCompletion":346,"completion":790,"start":8064,"enrollment":1366,"conditions":8065,"interventions":8066},"NCT06611150","Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma",[92],"2024-08-02",[1009],[321],{"trials":8068,"activeCount":1255,"soonestReadout":379},[8069,8073],{"nctId":309,"briefTitle":310,"status":143,"phases":8070,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":8071,"interventions":8072},[93],[316,317,318],[320,321,225,49,322,323,324,284],{"nctId":376,"briefTitle":377,"status":143,"phases":8074,"primaryCompletion":379,"completion":380,"start":381,"enrollment":348,"conditions":8075,"interventions":8076},[93],[383],[385,386,225,271],{"trials":8078,"activeCount":104},[],{"trials":8080,"activeCount":104},[],{"trials":8082,"activeCount":104},[8083],{"nctId":2339,"briefTitle":2340,"status":174,"phases":8084,"primaryCompletion":259,"completion":259,"start":2342,"enrollment":1339,"conditions":8085,"interventions":8086},[],[2344],[321,49,268],{"intervention":2080,"totalTrials":2627,"cells":8088},{"EARLY_PHASE1":8089,"PHASE1":8091,"PHASE2":8093,"PHASE3":8103,"PHASE4":8113,"NA":8115},{"trials":8090,"activeCount":104},[],{"trials":8092,"activeCount":104},[],{"trials":8094,"activeCount":1255,"soonestReadout":53},[8095,8099],{"nctId":51,"briefTitle":52,"status":300,"phases":8096,"primaryCompletion":53,"completion":548,"start":2548,"enrollment":2549,"conditions":8097,"interventions":8098},[93],[25,2098],[54,823,738,542,2080],{"nctId":2072,"briefTitle":2073,"status":143,"phases":8100,"primaryCompletion":380,"completion":380,"start":2075,"enrollment":2076,"conditions":8101,"interventions":8102},[93],[1020],[183,2079,542,2080,664,54,272,542,2080,664],{"trials":8104,"activeCount":104},[8105,8109],{"nctId":2596,"briefTitle":2597,"status":1091,"phases":8106,"primaryCompletion":2599,"completion":2599,"start":2600,"enrollment":2601,"conditions":8107,"interventions":8108},[94],[25,2098,2603],[2605,542,2080,2606,54],{"nctId":2608,"briefTitle":2609,"status":1091,"phases":8110,"primaryCompletion":2611,"completion":479,"start":289,"enrollment":2601,"conditions":8111,"interventions":8112},[94],[1368,2098],[54,2614,2504,2080,398,542],{"trials":8114,"activeCount":104},[],{"trials":8116,"activeCount":104},[],{"intervention":254,"totalTrials":2272,"cells":8118},{"EARLY_PHASE1":8119,"PHASE1":8121,"PHASE2":8123,"PHASE3":8153,"PHASE4":8155,"NA":8157},{"trials":8120,"activeCount":104},[],{"trials":8122,"activeCount":104},[],{"trials":8124,"activeCount":1255,"soonestReadout":88},[8125,8129,8133,8137,8141,8145],{"nctId":86,"briefTitle":87,"status":143,"phases":8126,"primaryCompletion":88,"completion":249,"start":250,"enrollment":32,"conditions":8127,"interventions":8128},[93],[252],[89,225,254],{"nctId":3436,"briefTitle":3437,"status":904,"phases":8130,"primaryCompletion":3439,"completion":3440,"start":3441,"enrollment":104,"conditions":8131,"interventions":8132},[93],[2210],[269,254,271],{"nctId":3104,"briefTitle":3105,"status":174,"phases":8134,"primaryCompletion":3107,"completion":53,"start":3108,"enrollment":1289,"conditions":8135,"interventions":8136},[93],[3110,1830],[268,254,271],{"nctId":1969,"briefTitle":1970,"status":143,"phases":8138,"primaryCompletion":499,"completion":499,"start":1953,"enrollment":911,"conditions":8139,"interventions":8140},[93],[1973],[1975,272,254,271],{"nctId":3474,"briefTitle":3475,"status":904,"phases":8142,"primaryCompletion":302,"completion":1277,"start":3477,"enrollment":104,"conditions":8143,"interventions":8144},[93],[3265],[385,254,271],{"nctId":8146,"briefTitle":8147,"status":328,"phases":8148,"primaryCompletion":8149,"completion":2233,"start":8150,"enrollment":1109,"conditions":8151,"interventions":8152},"NCT00630149","Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy",[93],"2011-11","2007-11",[441],[254],{"trials":8154,"activeCount":104},[],{"trials":8156,"activeCount":104},[],{"trials":8158,"activeCount":104},[],{"intervention":5389,"totalTrials":2627,"cells":8160},{"EARLY_PHASE1":8161,"PHASE1":8163,"PHASE2":8165,"PHASE3":8203,"PHASE4":8205,"NA":8207},{"trials":8162,"activeCount":104},[],{"trials":8164,"activeCount":104},[],{"trials":8166,"activeCount":1255,"soonestReadout":2456},[8167,8171,8182,8196],{"nctId":5381,"briefTitle":5382,"status":174,"phases":8168,"primaryCompletion":5384,"completion":923,"start":5385,"enrollment":5386,"conditions":8169,"interventions":8170},[93],[241],[5389,5390,5391],{"nctId":8172,"briefTitle":8173,"status":143,"phases":8174,"primaryCompletion":8175,"completion":8176,"start":1508,"enrollment":1987,"conditions":8177,"interventions":8179},"NCT07610720","Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer",[93],"2028-11-01","2029-11-01",[6574,8178],"HER2-Positive Metastatic Breast Cancer",[8180,1381,3795,5389,8181],"Dalpiciclib","Endocrine Therapy 1",{"nctId":8183,"briefTitle":8184,"status":143,"phases":8185,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":8186,"interventions":8188},"NCT06563999","Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.",[93],[1973,8187],"Mutation",[8189,8190,8191,8192,8193,5389,8194,8195,1967],"Sunvozertinib","Crizotinib","Pralsetinib","Larotrectinib","Savolitinib","Dabrafenib+Trametinib","Glecirasib",{"nctId":8197,"briefTitle":8198,"status":174,"phases":8199,"primaryCompletion":1737,"completion":2662,"start":8200,"enrollment":2059,"conditions":8201,"interventions":8202},"NCT04255056","Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and Pertuzumab",[93],"2020-02-01",[28],[5389],{"trials":8204,"activeCount":104},[],{"trials":8206,"activeCount":104},[],{"trials":8208,"activeCount":104},[],{"intervention":2188,"totalTrials":1861,"cells":8210},{"EARLY_PHASE1":8211,"PHASE1":8213,"PHASE2":8215,"PHASE3":8235,"PHASE4":8237,"NA":8239},{"trials":8212,"activeCount":104},[],{"trials":8214,"activeCount":104},[],{"trials":8216,"activeCount":1255,"soonestReadout":5805},[8217,8221,8225],{"nctId":2178,"briefTitle":2179,"status":174,"phases":8218,"primaryCompletion":2181,"completion":2182,"start":2183,"enrollment":2184,"conditions":8219,"interventions":8220},[93],[2186],[2188,49],{"nctId":309,"briefTitle":310,"status":143,"phases":8222,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":8223,"interventions":8224},[93],[316,317,318],[320,321,225,49,322,323,324,284],{"nctId":8226,"briefTitle":8227,"status":116,"phases":8228,"primaryCompletion":5805,"completion":4582,"start":8229,"enrollment":32,"conditions":8230,"interventions":8233},"NCT06957561","Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer",[92,93],"2025-04-30",[8231,8232],"Bladder Cancer","Muscle-invasive Bladder Cancer",[2188,8234],"Ivonescimab（AK112，a PD-1\u002FVEGF bispecific antibody）",{"trials":8236,"activeCount":104},[],{"trials":8238,"activeCount":104},[],{"trials":8240,"activeCount":104},[],{"intervention":8242,"totalTrials":1861,"cells":8243},"R-CHOP Protocol",{"EARLY_PHASE1":8244,"PHASE1":8246,"PHASE2":8248,"PHASE3":8275,"PHASE4":8277,"NA":8279},{"trials":8245,"activeCount":104},[],{"trials":8247,"activeCount":104},[],{"trials":8249,"activeCount":1255,"soonestReadout":8262},[8250,8258,8267],{"nctId":8251,"briefTitle":8252,"status":174,"phases":8253,"primaryCompletion":1064,"completion":8254,"start":710,"enrollment":3705,"conditions":8255,"interventions":8257},"NCT05577364","Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients",[92,93],"2026-02-28",[8256],"EBV-Positive Diffuse Large B-Cell Lymphoma, Nos",[1694,8242],{"nctId":8259,"briefTitle":8260,"status":143,"phases":8261,"primaryCompletion":8262,"completion":851,"start":2458,"enrollment":26,"conditions":8263,"interventions":8265},"NCT06647940","Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）",[93],"2026-11-01",[8264],"Diffuse Large B Cell Lymphoma (DLBCL)",[8266,8242],"Orelabrutinib Oral",{"nctId":8268,"briefTitle":8269,"status":143,"phases":8270,"primaryCompletion":1133,"completion":3372,"start":345,"enrollment":3050,"conditions":8271,"interventions":8273},"NCT06517511","Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)",[93],[8272],"Diffuse Large B Cell Lymphoma",[8274,8242],"Selinexor Oral Tablet [Xpovio]",{"trials":8276,"activeCount":104},[],{"trials":8278,"activeCount":104},[],{"trials":8280,"activeCount":104},[],{"intervention":1381,"totalTrials":1861,"cells":8282},{"EARLY_PHASE1":8283,"PHASE1":8285,"PHASE2":8287,"PHASE3":8301,"PHASE4":8303,"NA":8305},{"trials":8284,"activeCount":104},[],{"trials":8286,"activeCount":104},[],{"trials":8288,"activeCount":1255,"soonestReadout":2643},[8289,8293,8297],{"nctId":8172,"briefTitle":8173,"status":143,"phases":8290,"primaryCompletion":8175,"completion":8176,"start":1508,"enrollment":1987,"conditions":8291,"interventions":8292},[93],[6574,8178],[8180,1381,3795,5389,8181],{"nctId":1371,"briefTitle":1372,"status":328,"phases":8294,"primaryCompletion":1374,"completion":1374,"start":1375,"enrollment":1376,"conditions":8295,"interventions":8296},[93],[1318,1378,1379],[1381,443,444],{"nctId":3787,"briefTitle":3788,"status":300,"phases":8298,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":8299,"interventions":8300},[93],[28,3521],[3793,2308,1381,443,3794,3795,270,1059],{"trials":8302,"activeCount":104},[],{"trials":8304,"activeCount":104},[],{"trials":8306,"activeCount":104},[],{"intervention":8308,"totalTrials":1861,"cells":8309},"Bendamustine",{"EARLY_PHASE1":8310,"PHASE1":8312,"PHASE2":8314,"PHASE3":8345,"PHASE4":8347,"NA":8349},{"trials":8311,"activeCount":104},[],{"trials":8313,"activeCount":104},[],{"trials":8315,"activeCount":1255,"soonestReadout":7832},[8316,8325,8335],{"nctId":8317,"briefTitle":8318,"status":116,"phases":8319,"primaryCompletion":7832,"completion":8320,"start":2662,"enrollment":205,"conditions":8321,"interventions":8323},"NCT06757894","Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma",[93],"2034-02-01",[8322],"Follicular Lymphoma (FL)",[8324,8308],"Zuberitamab",{"nctId":8326,"briefTitle":8327,"status":116,"phases":8328,"primaryCompletion":2457,"completion":2457,"start":1543,"enrollment":8329,"conditions":8330,"interventions":8332},"NCT06961500","Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A",[93],133,[8331],"Follicular Lymphoma Grade 3A",[8333,8334,8308],"Obinutuzumab","CHOP",{"nctId":8336,"briefTitle":8337,"status":174,"phases":8338,"primaryCompletion":1952,"completion":8339,"start":8340,"enrollment":5071,"conditions":8341,"interventions":8343},"NCT04762745","The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma",[92,93],"2023-02","2021-02",[8342],"Relapsed, Refractory, Multiple Myeloma",[8344,8308,183,8344,8308,183,8344,8308,183,8344,8308,183],"Pomalidomide",{"trials":8346,"activeCount":104},[],{"trials":8348,"activeCount":104},[],{"trials":8350,"activeCount":104},[],{"intervention":1946,"totalTrials":1255,"cells":8352},{"EARLY_PHASE1":8353,"PHASE1":8355,"PHASE2":8357,"PHASE3":8371,"PHASE4":8373,"NA":8375},{"trials":8354,"activeCount":104},[],{"trials":8356,"activeCount":104},[],{"trials":8358,"activeCount":1255,"soonestReadout":1942},[8359,8367],{"nctId":8360,"briefTitle":8361,"status":116,"phases":8362,"primaryCompletion":404,"completion":404,"start":8363,"enrollment":280,"conditions":8364,"interventions":8366},"NCT06684873","A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)",[93],"2024-11-02",[7985,8365],"Brain Metastasases",[1946],{"nctId":1939,"briefTitle":1940,"status":116,"phases":8368,"primaryCompletion":1942,"completion":646,"start":1943,"enrollment":20,"conditions":8369,"interventions":8370},[93],[25,1406],[1946,1947,272],{"trials":8372,"activeCount":104},[],{"trials":8374,"activeCount":104},[],{"trials":8376,"activeCount":104},[],{"intervention":7453,"totalTrials":1255,"cells":8378},{"EARLY_PHASE1":8379,"PHASE1":8381,"PHASE2":8383,"PHASE3":8399,"PHASE4":8401,"NA":8403},{"trials":8380,"activeCount":104},[],{"trials":8382,"activeCount":104},[],{"trials":8384,"activeCount":1255,"soonestReadout":3586},[8385,8389],{"nctId":7446,"briefTitle":7447,"status":116,"phases":8386,"primaryCompletion":3586,"completion":7449,"start":3587,"enrollment":1066,"conditions":8387,"interventions":8388},[92,93],[7451],[7453,981,7454],{"nctId":8390,"briefTitle":8391,"status":116,"phases":8392,"primaryCompletion":8393,"completion":8394,"start":8254,"enrollment":7372,"conditions":8395,"interventions":8396},"NCT07398638","Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib\u002FII Study",[92,93],"2029-02-28","2031-02-28",[8264],[8397,8398,7453],"R-CHOP","POLA-R-CHP",{"trials":8400,"activeCount":104},[],{"trials":8402,"activeCount":104},[],{"trials":8404,"activeCount":104},[],{"intervention":5075,"totalTrials":1255,"cells":8406},{"EARLY_PHASE1":8407,"PHASE1":8409,"PHASE2":8411,"PHASE3":8426,"PHASE4":8428,"NA":8430},{"trials":8408,"activeCount":104},[],{"trials":8410,"activeCount":104},[],{"trials":8412,"activeCount":1255,"soonestReadout":8417},[8413,8422],{"nctId":8414,"briefTitle":8415,"status":116,"phases":8416,"primaryCompletion":8417,"completion":8417,"start":2206,"enrollment":5071,"conditions":8418,"interventions":8420},"NCT07103408","A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer",[93],"2029-09-30",[8419],"Small-Cell Lung Cancer (SCLC)",[8421,5075],"Immuno-chemotherapy",{"nctId":5068,"briefTitle":5069,"status":143,"phases":8423,"primaryCompletion":2589,"completion":2589,"start":1801,"enrollment":5071,"conditions":8424,"interventions":8425},[93],[5073],[4556,5075],{"trials":8427,"activeCount":104},[],{"trials":8429,"activeCount":104},[],{"trials":8431,"activeCount":104},[],{"intervention":3492,"totalTrials":1255,"cells":8433},{"EARLY_PHASE1":8434,"PHASE1":8436,"PHASE2":8438,"PHASE3":8448,"PHASE4":8450,"NA":8452},{"trials":8435,"activeCount":104},[],{"trials":8437,"activeCount":104},[],{"trials":8439,"activeCount":1255,"soonestReadout":3262},[8440,8444],{"nctId":4972,"briefTitle":4973,"status":116,"phases":8441,"primaryCompletion":1277,"completion":1277,"start":4975,"enrollment":333,"conditions":8442,"interventions":8443},[93],[28],[3492,1557],{"nctId":3485,"briefTitle":3486,"status":116,"phases":8445,"primaryCompletion":3262,"completion":119,"start":746,"enrollment":3488,"conditions":8446,"interventions":8447},[93],[252,28,2896,700,3490],[3492,270,271],{"trials":8449,"activeCount":104},[],{"trials":8451,"activeCount":104},[],{"trials":8453,"activeCount":104},[],{"intervention":1406,"totalTrials":1255,"cells":8455},{"EARLY_PHASE1":8456,"PHASE1":8458,"PHASE2":8460,"PHASE3":8476,"PHASE4":8478,"NA":8480},{"trials":8457,"activeCount":104},[],{"trials":8459,"activeCount":104},[],{"trials":8461,"activeCount":1255,"soonestReadout":1400},[8462,8472],{"nctId":8463,"briefTitle":8464,"status":116,"phases":8465,"primaryCompletion":8466,"completion":8467,"start":8468,"enrollment":2184,"conditions":8469,"interventions":8471},"NCT07204548","The IVO-LUNG Study",[93],"2027-10","2029-10","2025-10",[8470],"Non Small Cell Lung Cancer (Stage III)",[1406],{"nctId":1397,"briefTitle":1398,"status":116,"phases":8473,"primaryCompletion":1400,"completion":237,"start":1401,"enrollment":1402,"conditions":8474,"interventions":8475},[93],[1404],[1406,542,444],{"trials":8477,"activeCount":104},[],{"trials":8479,"activeCount":104},[],{"trials":8481,"activeCount":104},[],{"intervention":8397,"totalTrials":1255,"cells":8483},{"EARLY_PHASE1":8484,"PHASE1":8486,"PHASE2":8488,"PHASE3":8502,"PHASE4":8504,"NA":8506},{"trials":8485,"activeCount":104},[],{"trials":8487,"activeCount":104},[],{"trials":8489,"activeCount":1255,"soonestReadout":380},[8490,8494],{"nctId":8390,"briefTitle":8391,"status":116,"phases":8491,"primaryCompletion":8393,"completion":8394,"start":8254,"enrollment":7372,"conditions":8492,"interventions":8493},[92,93],[8264],[8397,8398,7453],{"nctId":8495,"briefTitle":8496,"status":116,"phases":8497,"primaryCompletion":380,"completion":646,"start":941,"enrollment":996,"conditions":8498,"interventions":8500},"NCT07494565","Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL",[93],[6436,8499],"CD5 Positive",[8501,8397],"Celecoxib Combined with R-CHOP",{"trials":8503,"activeCount":104},[],{"trials":8505,"activeCount":104},[],{"trials":8507,"activeCount":104},[],{"intervention":1967,"totalTrials":1255,"cells":8509},{"EARLY_PHASE1":8510,"PHASE1":8512,"PHASE2":8514,"PHASE3":8524,"PHASE4":8526,"NA":8528},{"trials":8511,"activeCount":104},[],{"trials":8513,"activeCount":104},[],{"trials":8515,"activeCount":1255,"soonestReadout":1963},[8516,8520],{"nctId":1960,"briefTitle":1961,"status":300,"phases":8517,"primaryCompletion":1963,"completion":419,"start":1964,"enrollment":360,"conditions":8518,"interventions":8519},[93],[252],[1967,272],{"nctId":8183,"briefTitle":8184,"status":143,"phases":8521,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":8522,"interventions":8523},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":8525,"activeCount":104},[],{"trials":8527,"activeCount":104},[],{"trials":8529,"activeCount":104},[],{"intervention":2683,"totalTrials":1255,"cells":8531},{"EARLY_PHASE1":8532,"PHASE1":8534,"PHASE2":8540,"PHASE3":8546,"PHASE4":8548,"NA":8550},{"trials":8533,"activeCount":104},[],{"trials":8535,"activeCount":100,"soonestReadout":1269},[8536],{"nctId":2650,"briefTitle":2651,"status":300,"phases":8537,"primaryCompletion":1269,"completion":1269,"start":1647,"enrollment":1615,"conditions":8538,"interventions":8539},[92],[463],[2655,2402],{"trials":8541,"activeCount":100,"soonestReadout":2679},[8542],{"nctId":2676,"briefTitle":2677,"status":300,"phases":8543,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":2419,"conditions":8544,"interventions":8545},[93],[22],[2683,1958,2684,2685],{"trials":8547,"activeCount":104},[],{"trials":8549,"activeCount":104},[],{"trials":8551,"activeCount":104},[],{"intervention":2020,"totalTrials":1255,"cells":8553},{"EARLY_PHASE1":8554,"PHASE1":8556,"PHASE2":8558,"PHASE3":8573,"PHASE4":8575,"NA":8577},{"trials":8555,"activeCount":104},[],{"trials":8557,"activeCount":104},[],{"trials":8559,"activeCount":1255,"soonestReadout":119},[8560,8564],{"nctId":2014,"briefTitle":2015,"status":143,"phases":8561,"primaryCompletion":119,"completion":679,"start":895,"enrollment":2017,"conditions":8562,"interventions":8563},[92,93],[1020],[823,2020,272],{"nctId":8565,"briefTitle":8566,"status":143,"phases":8567,"primaryCompletion":646,"completion":646,"start":8568,"enrollment":8569,"conditions":8570,"interventions":8571},"NCT05965531","Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy",[93],"2024-01-01",65,[34],[8572],"Trifluridine\u002FTipiracil",{"trials":8574,"activeCount":104},[],{"trials":8576,"activeCount":104},[],{"trials":8578,"activeCount":104},[],{"intervention":8234,"totalTrials":1255,"cells":8580},{"EARLY_PHASE1":8581,"PHASE1":8583,"PHASE2":8585,"PHASE3":8597,"PHASE4":8599,"NA":8601},{"trials":8582,"activeCount":104},[],{"trials":8584,"activeCount":104},[],{"trials":8586,"activeCount":1255,"soonestReadout":5805},[8587,8593],{"nctId":8588,"briefTitle":8589,"status":116,"phases":8590,"primaryCompletion":145,"completion":237,"start":346,"enrollment":1727,"conditions":8591,"interventions":8592},"NCT07064902","Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma",[93],[1009],[8234],{"nctId":8226,"briefTitle":8227,"status":116,"phases":8594,"primaryCompletion":5805,"completion":4582,"start":8229,"enrollment":32,"conditions":8595,"interventions":8596},[92,93],[8231,8232],[2188,8234],{"trials":8598,"activeCount":104},[],{"trials":8600,"activeCount":104},[],{"trials":8602,"activeCount":104},[],{"intervention":3795,"totalTrials":1255,"cells":8604},{"EARLY_PHASE1":8605,"PHASE1":8607,"PHASE2":8609,"PHASE3":8619,"PHASE4":8621,"NA":8623},{"trials":8606,"activeCount":104},[],{"trials":8608,"activeCount":104},[],{"trials":8610,"activeCount":1255,"soonestReadout":2643},[8611,8615],{"nctId":8172,"briefTitle":8173,"status":143,"phases":8612,"primaryCompletion":8175,"completion":8176,"start":1508,"enrollment":1987,"conditions":8613,"interventions":8614},[93],[6574,8178],[8180,1381,3795,5389,8181],{"nctId":3787,"briefTitle":3788,"status":300,"phases":8616,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":8617,"interventions":8618},[93],[28,3521],[3793,2308,1381,443,3794,3795,270,1059],{"trials":8620,"activeCount":104},[],{"trials":8622,"activeCount":104},[],{"trials":8624,"activeCount":104},[],{"intervention":8266,"totalTrials":1255,"cells":8626},{"EARLY_PHASE1":8627,"PHASE1":8629,"PHASE2":8631,"PHASE3":8648,"PHASE4":8650,"NA":8652},{"trials":8628,"activeCount":104},[],{"trials":8630,"activeCount":104},[],{"trials":8632,"activeCount":1255,"soonestReadout":4044},[8633,8637],{"nctId":8259,"briefTitle":8260,"status":143,"phases":8634,"primaryCompletion":8262,"completion":851,"start":2458,"enrollment":26,"conditions":8635,"interventions":8636},[93],[8264],[8266,8242],{"nctId":8638,"briefTitle":8639,"status":143,"phases":8640,"primaryCompletion":4044,"completion":8641,"start":852,"enrollment":1712,"conditions":8642,"interventions":8645},"NCT04989621","Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)",[93],"2028-08",[8643,8644],"Follicular Lymphoma","Relapsed and Refractory Follicular Lymphoma",[8646,8647],"Orelabrutinib and Rituximab","Orelabrutinib",{"trials":8649,"activeCount":104},[],{"trials":8651,"activeCount":104},[],{"trials":8653,"activeCount":104},[],{"intervention":2070,"totalTrials":1255,"cells":8655},{"EARLY_PHASE1":8656,"PHASE1":8658,"PHASE2":8660,"PHASE3":8676,"PHASE4":8678,"NA":8680},{"trials":8657,"activeCount":104},[],{"trials":8659,"activeCount":104},[],{"trials":8661,"activeCount":1255,"soonestReadout":2066},[8662,8672],{"nctId":8663,"briefTitle":8664,"status":143,"phases":8665,"primaryCompletion":8666,"completion":8667,"start":8668,"enrollment":23,"conditions":8669,"interventions":8671},"NCT07101744","Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial",[93],"2028-07-16","2030-07-16","2025-10-17",[1009,8670],"First-line Treatment Failure Nasopharyngeal Carcinoma",[2070],{"nctId":2063,"briefTitle":2064,"status":143,"phases":8673,"primaryCompletion":2066,"completion":237,"start":895,"enrollment":239,"conditions":8674,"interventions":8675},[93],[2068],[2070,272,296,54],{"trials":8677,"activeCount":104},[],{"trials":8679,"activeCount":104},[],{"trials":8681,"activeCount":104},[],{"intervention":1766,"totalTrials":1255,"cells":8683},{"EARLY_PHASE1":8684,"PHASE1":8686,"PHASE2":8688,"PHASE3":8703,"PHASE4":8705,"NA":8707},{"trials":8685,"activeCount":104},[],{"trials":8687,"activeCount":104},[],{"trials":8689,"activeCount":1255,"soonestReadout":8698},[8690,8694],{"nctId":1758,"briefTitle":1759,"status":143,"phases":8691,"primaryCompletion":380,"completion":119,"start":1761,"enrollment":820,"conditions":8692,"interventions":8693},[93],[1763],[1765,1766,54,1767,1768,1769,483],{"nctId":8695,"briefTitle":8696,"status":143,"phases":8697,"primaryCompletion":8698,"completion":8699,"start":8700,"enrollment":4430,"conditions":8701,"interventions":8702},"NCT06472739","The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy",[93],"2024-08-15","2024-11-15","2023-09-15",[1766],[1766],{"trials":8704,"activeCount":104},[],{"trials":8706,"activeCount":104},[],{"trials":8708,"activeCount":104},[],{"intervention":3548,"totalTrials":1255,"cells":8710},{"EARLY_PHASE1":8711,"PHASE1":8713,"PHASE2":8715,"PHASE3":8725,"PHASE4":8727,"NA":8729},{"trials":8712,"activeCount":104},[],{"trials":8714,"activeCount":104},[],{"trials":8716,"activeCount":1255,"soonestReadout":419},[8717,8721],{"nctId":3541,"briefTitle":3542,"status":116,"phases":8718,"primaryCompletion":419,"completion":419,"start":3544,"enrollment":2913,"conditions":8719,"interventions":8720},[93],[16],[3547,3548,374,3549],{"nctId":4898,"briefTitle":4899,"status":143,"phases":8722,"primaryCompletion":4901,"completion":4901,"start":4902,"enrollment":501,"conditions":8723,"interventions":8724},[92,93],[4904],[4882,3548],{"trials":8726,"activeCount":104},[],{"trials":8728,"activeCount":104},[],{"trials":8730,"activeCount":104},[],{"intervention":7527,"totalTrials":1255,"cells":8732},{"EARLY_PHASE1":8733,"PHASE1":8735,"PHASE2":8741,"PHASE3":8747,"PHASE4":8749,"NA":8751},{"trials":8734,"activeCount":104},[],{"trials":8736,"activeCount":100,"soonestReadout":4739},[8737],{"nctId":7554,"briefTitle":7555,"status":300,"phases":8738,"primaryCompletion":4739,"completion":895,"start":7557,"enrollment":3179,"conditions":8739,"interventions":8740},[92],[4011],[7527,54,2306],{"trials":8742,"activeCount":100,"soonestReadout":790},[8743],{"nctId":7520,"briefTitle":7521,"status":143,"phases":8744,"primaryCompletion":790,"completion":791,"start":7523,"enrollment":5295,"conditions":8745,"interventions":8746},[92,93],[7525],[5048,7527,981],{"trials":8748,"activeCount":104},[],{"trials":8750,"activeCount":104},[],{"trials":8752,"activeCount":104},[],{"intervention":3054,"totalTrials":3998,"cells":8754},{"EARLY_PHASE1":8755,"PHASE1":8757,"PHASE2":8759,"PHASE3":8800,"PHASE4":8802,"NA":8804},{"trials":8756,"activeCount":104},[],{"trials":8758,"activeCount":104},[],{"trials":8760,"activeCount":100,"soonestReadout":8765},[8761,8771,8779,8785,8791],{"nctId":8762,"briefTitle":8763,"status":143,"phases":8764,"primaryCompletion":8765,"completion":8766,"start":7734,"enrollment":1680,"conditions":8767,"interventions":8769},"NCT06977074","PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC",[93],"2028-05-10","2030-05-10",[8768],"Non-small Cell Lung Cancer (NSCLC)",[3054,8770],"Platinum Doublet",{"nctId":8772,"briefTitle":8773,"status":174,"phases":8774,"primaryCompletion":260,"completion":260,"start":8775,"enrollment":1366,"conditions":8776,"interventions":8778},"NCT05994456","Neoadjuvant Toripalimab for dMMR\u002FMSI-H Gastric Cancer",[93],"2023-03-09",[8777],"Gastric or Gastroesophageal Junction Adenocarcinoma",[3054],{"nctId":8780,"briefTitle":8781,"status":174,"phases":8782,"primaryCompletion":53,"completion":53,"start":5574,"enrollment":942,"conditions":8783,"interventions":8784},"NCT04814030","Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial",[93],[19],[3054],{"nctId":8786,"briefTitle":8787,"status":174,"phases":8788,"primaryCompletion":53,"completion":290,"start":5574,"enrollment":1987,"conditions":8789,"interventions":8790},"NCT04814043","PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial",[93],[19],[3054],{"nctId":8792,"briefTitle":8793,"status":174,"phases":8794,"primaryCompletion":798,"completion":798,"start":957,"enrollment":3050,"conditions":8795,"interventions":8798},"NCT04624984","PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed\u002FRefractory CHL",[93],[8796,8797],"Classical Hodgkin Lymphoma","Refractory or Relapsed Classical Hodgkin Lymphoma",[3054,8799],"PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome",{"trials":8801,"activeCount":104},[],{"trials":8803,"activeCount":104},[],{"trials":8805,"activeCount":100,"soonestReadout":1277},[8806,8810],{"nctId":3012,"briefTitle":3013,"status":328,"phases":8807,"primaryCompletion":346,"completion":3015,"start":670,"enrollment":1192,"conditions":8808,"interventions":8809},[96],[3017],[353,3019,1240],{"nctId":3046,"briefTitle":3047,"status":143,"phases":8811,"primaryCompletion":1277,"completion":1400,"start":3049,"enrollment":3050,"conditions":8812,"interventions":8813},[96],[19,1889,3052],[353,3054],{"intervention":2685,"totalTrials":1255,"cells":8815},{"EARLY_PHASE1":8816,"PHASE1":8818,"PHASE2":8820,"PHASE3":8826,"PHASE4":8828,"NA":8830},{"trials":8817,"activeCount":104},[],{"trials":8819,"activeCount":104},[],{"trials":8821,"activeCount":100,"soonestReadout":2679},[8822],{"nctId":2676,"briefTitle":2677,"status":300,"phases":8823,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":2419,"conditions":8824,"interventions":8825},[93],[22],[2683,1958,2684,2685],{"trials":8827,"activeCount":104},[],{"trials":8829,"activeCount":104},[],{"trials":8831,"activeCount":100,"soonestReadout":380},[8832],{"nctId":8833,"briefTitle":8834,"status":116,"phases":8835,"primaryCompletion":380,"completion":3518,"start":722,"enrollment":8836,"conditions":8837,"interventions":8839},"NCT04901104","Long-term Prognosis of Patients With Sepsis After Immunotherapy",[],900,[8838],"Long-term Effects of Thymosin Alpha 1 Treatment",[2685],{"intervention":3666,"totalTrials":1255,"cells":8841},{"EARLY_PHASE1":8842,"PHASE1":8844,"PHASE2":8846,"PHASE3":8852,"PHASE4":8854,"NA":8856},{"trials":8843,"activeCount":104},[],{"trials":8845,"activeCount":104},[],{"trials":8847,"activeCount":100,"soonestReadout":3662},[8848],{"nctId":3659,"briefTitle":3660,"status":116,"phases":8849,"primaryCompletion":3662,"completion":646,"start":3663,"enrollment":911,"conditions":8850,"interventions":8851},[93],[3274,1241],[3666,602,3667],{"trials":8853,"activeCount":104},[],{"trials":8855,"activeCount":104},[],{"trials":8857,"activeCount":100,"soonestReadout":4429},[8858],{"nctId":8859,"briefTitle":8860,"status":143,"phases":8861,"primaryCompletion":4429,"completion":8862,"start":3049,"enrollment":1450,"conditions":8863,"interventions":8864},"NCT06609876","Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC",[96],"2028-10-01",[19,3034,3666,3036],[3666],{"intervention":8866,"totalTrials":1861,"cells":8867},"Metformin",{"EARLY_PHASE1":8868,"PHASE1":8870,"PHASE2":8872,"PHASE3":8889,"PHASE4":8891,"NA":8906},{"trials":8869,"activeCount":104},[],{"trials":8871,"activeCount":104},[],{"trials":8873,"activeCount":100,"soonestReadout":8886},[8874,8882],{"nctId":8875,"briefTitle":8876,"status":174,"phases":8877,"primaryCompletion":368,"completion":1963,"start":8878,"enrollment":8879,"conditions":8880,"interventions":8881},"NCT04926155","The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer",[93],"2021-06-23",234,[7871],[8866],{"nctId":8883,"briefTitle":8884,"status":116,"phases":8885,"primaryCompletion":8886,"completion":3662,"start":1270,"enrollment":628,"conditions":8887,"interventions":8888},"NCT04925063","The Effect of Metformin in Patients With Newly Diagnosed mHSPC",[93],"2027-04-30",[7871],[8866],{"trials":8890,"activeCount":104},[],{"trials":8892,"activeCount":104},[8893],{"nctId":8894,"briefTitle":8895,"status":174,"phases":8896,"primaryCompletion":8897,"completion":1238,"start":8898,"enrollment":8899,"conditions":8900,"interventions":8902},"NCT06127433","The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes",[95],"2024-05-01","2023-03-07",210,[8901],"Insulin Pump，Continuous Glucose Monitoring Technology",[8903,8866,8904,8905],"Insulin Glargine","Dapagliflozin","Insulin aspart",{"trials":8907,"activeCount":104},[],{"intervention":411,"totalTrials":2272,"cells":8909},{"EARLY_PHASE1":8910,"PHASE1":8912,"PHASE2":8914,"PHASE3":8936,"PHASE4":8942,"NA":8944},{"trials":8911,"activeCount":104},[],{"trials":8913,"activeCount":104},[],{"trials":8915,"activeCount":100,"soonestReadout":403},[8916,8920,8924,8928,8932],{"nctId":7424,"briefTitle":7425,"status":174,"phases":8917,"primaryCompletion":217,"completion":3355,"start":7427,"enrollment":7428,"conditions":8918,"interventions":8919},[93],[7430],[981,7432,2308,2197,4755],{"nctId":2190,"briefTitle":2191,"status":174,"phases":8921,"primaryCompletion":259,"completion":259,"start":2193,"enrollment":1109,"conditions":8922,"interventions":8923},[93],[2195],[49,2197,1205],{"nctId":4745,"briefTitle":4746,"status":174,"phases":8925,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":8926,"interventions":8927},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"nctId":4301,"briefTitle":4302,"status":328,"phases":8929,"primaryCompletion":2105,"completion":4304,"start":4305,"enrollment":1109,"conditions":8930,"interventions":8931},[93],[2042],[269,411],{"nctId":400,"briefTitle":401,"status":143,"phases":8933,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":8934,"interventions":8935},[93],[408],[410,411,412,413],{"trials":8937,"activeCount":104},[8938],{"nctId":2300,"briefTitle":2301,"status":1091,"phases":8939,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":8940,"interventions":8941},[94],[2235],[49,542,1205,411,2306,2307,2308,2309],{"trials":8943,"activeCount":104},[],{"trials":8945,"activeCount":104},[],{"intervention":339,"totalTrials":161,"cells":8947},{"EARLY_PHASE1":8948,"PHASE1":8950,"PHASE2":8952,"PHASE3":8970,"PHASE4":8976,"NA":8978},{"trials":8949,"activeCount":104},[],{"trials":8951,"activeCount":104},[],{"trials":8953,"activeCount":100,"soonestReadout":1074},[8954,8958,8962,8966],{"nctId":7368,"briefTitle":7369,"status":328,"phases":8955,"primaryCompletion":2770,"completion":7371,"start":618,"enrollment":7372,"conditions":8956,"interventions":8957},[93],[7374],[339,7359],{"nctId":2203,"briefTitle":2204,"status":904,"phases":8959,"primaryCompletion":2206,"completion":2207,"start":2208,"enrollment":104,"conditions":8960,"interventions":8961},[93],[2210],[339,49,271],{"nctId":326,"briefTitle":327,"status":328,"phases":8963,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":8964,"interventions":8965},[93],[335],[337,338,225,339,340],{"nctId":1071,"briefTitle":1072,"status":143,"phases":8967,"primaryCompletion":1074,"completion":1074,"start":1075,"enrollment":1076,"conditions":8968,"interventions":8969},[93],[16],[284,339],{"trials":8971,"activeCount":104},[8972],{"nctId":559,"briefTitle":560,"status":174,"phases":8973,"primaryCompletion":562,"completion":562,"start":563,"enrollment":564,"conditions":8974,"interventions":8975},[94],[16,441,566,567],[339,225],{"trials":8977,"activeCount":104},[],{"trials":8979,"activeCount":104},[],{"intervention":2694,"totalTrials":2627,"cells":8981},{"EARLY_PHASE1":8982,"PHASE1":8984,"PHASE2":8986,"PHASE3":9006,"PHASE4":9020,"NA":9022},{"trials":8983,"activeCount":104},[],{"trials":8985,"activeCount":104},[],{"trials":8987,"activeCount":100,"soonestReadout":2733},[8988,8992,8996],{"nctId":2687,"briefTitle":2688,"status":1091,"phases":8989,"primaryCompletion":2690,"completion":2690,"start":2691,"enrollment":978,"conditions":8990,"interventions":8991},[93],[22],[1958,2694],{"nctId":2730,"briefTitle":2731,"status":143,"phases":8993,"primaryCompletion":2733,"completion":2733,"start":2734,"enrollment":1289,"conditions":8994,"interventions":8995},[93],[2736],[2402,2694],{"nctId":8997,"briefTitle":8998,"status":174,"phases":8999,"primaryCompletion":459,"completion":459,"start":1428,"enrollment":2459,"conditions":9000,"interventions":9005},"NCT02160132","A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.",[93],[9001,9002,9003,9004],"Glomerulonephritis, IGA","Peripapillary Crescent","Necrosis","Steroid Nephropathy",[2694,2694],{"trials":9007,"activeCount":104},[9008],{"nctId":9009,"briefTitle":9010,"status":328,"phases":9011,"primaryCompletion":1337,"completion":1337,"start":9012,"enrollment":9013,"conditions":9014,"interventions":9016},"NCT00657059","Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)",[94],"2007-09",151,[9015],"IgA Nephropathy",[9017,9018,9019],"irbesartan","methylprednisolone","mycophenolate mofetil",{"trials":9021,"activeCount":104},[],{"trials":9023,"activeCount":104},[],{"intervention":2422,"totalTrials":1255,"cells":9025},{"EARLY_PHASE1":9026,"PHASE1":9028,"PHASE2":9030,"PHASE3":9036,"PHASE4":9048,"NA":9050},{"trials":9027,"activeCount":104},[],{"trials":9029,"activeCount":104},[],{"trials":9031,"activeCount":100,"soonestReadout":2417},[9032],{"nctId":2414,"briefTitle":2415,"status":300,"phases":9033,"primaryCompletion":2417,"completion":1288,"start":2418,"enrollment":2419,"conditions":9034,"interventions":9035},[93],[463,934],[2422,684],{"trials":9037,"activeCount":104},[9038],{"nctId":9039,"briefTitle":9040,"status":174,"phases":9041,"primaryCompletion":850,"completion":850,"start":9042,"enrollment":9043,"conditions":9044,"interventions":9047},"NCT03468010","A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement)",[94],"2018-03-01",432,[700,4657,9045,9046],"Radiation","Lymph Node Metastases",[2422],{"trials":9049,"activeCount":104},[],{"trials":9051,"activeCount":104},[],{"intervention":385,"totalTrials":2627,"cells":9053},{"EARLY_PHASE1":9054,"PHASE1":9056,"PHASE2":9058,"PHASE3":9076,"PHASE4":9078,"NA":9080},{"trials":9055,"activeCount":104},[],{"trials":9057,"activeCount":104},[],{"trials":9059,"activeCount":100,"soonestReadout":379},[9060,9064,9068,9072],{"nctId":7336,"briefTitle":7337,"status":174,"phases":9061,"primaryCompletion":1738,"completion":7339,"start":7340,"enrollment":2040,"conditions":9062,"interventions":9063},[92,93],[25],[385,7343],{"nctId":3474,"briefTitle":3475,"status":904,"phases":9065,"primaryCompletion":302,"completion":1277,"start":3477,"enrollment":104,"conditions":9066,"interventions":9067},[93],[3265],[385,254,271],{"nctId":376,"briefTitle":377,"status":143,"phases":9069,"primaryCompletion":379,"completion":380,"start":381,"enrollment":348,"conditions":9070,"interventions":9071},[93],[383],[385,386,225,271],{"nctId":1444,"briefTitle":1445,"status":174,"phases":9073,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":9074,"interventions":9075},[93],[539,1452],[385,542,1454,444],{"trials":9077,"activeCount":104},[],{"trials":9079,"activeCount":104},[],{"trials":9081,"activeCount":104},[],{"intervention":9083,"totalTrials":2627,"cells":9084},"Icotinib",{"EARLY_PHASE1":9085,"PHASE1":9087,"PHASE2":9089,"PHASE3":9133,"PHASE4":9135,"NA":9137},{"trials":9086,"activeCount":104},[],{"trials":9088,"activeCount":104},[],{"trials":9090,"activeCount":100,"soonestReadout":1015},[9091,9098,9112,9125],{"nctId":9092,"briefTitle":9093,"status":1091,"phases":9094,"primaryCompletion":9095,"completion":9095,"start":819,"enrollment":219,"conditions":9096,"interventions":9097},"NCT02362230","Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy",[93],"2020-12-15",[241],[9083],{"nctId":9099,"briefTitle":9100,"status":328,"phases":9101,"primaryCompletion":658,"completion":9102,"start":819,"enrollment":4217,"conditions":9103,"interventions":9111},"NCT02264210","Icotinib for Completed Resected IB NSCLC With EGFR Mutation",[93],"2022-07",[9104,9105,9106,9107,9108,9109,9110],"Lung Neoplasms","Squamous Cell Lung Cancer","Adenocarcinoma of the Lung","Adenosquamous Cell Lung Cancer","Large Cell Lung Cancer","Bronchial Neoplasms","Stage IB Non-small Cell Lung Cancer",[9083],{"nctId":9113,"briefTitle":9114,"status":143,"phases":9115,"primaryCompletion":1015,"completion":9116,"start":9117,"enrollment":35,"conditions":9118,"interventions":9123},"NCT06517953","Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations",[93],"2027-12-24","2024-07-17",[9119,9120,9121,9122],"Non-small Cell Lung Cancer Metastatic","EGFR G719X","EGFR L861Q","EGFR S768I",[9083,9124],"Befotertinib",{"nctId":9126,"briefTitle":9127,"status":174,"phases":9128,"primaryCompletion":2106,"completion":1337,"start":1934,"enrollment":9129,"conditions":9130,"interventions":9131},"NCT03151161","Intermittent and Maintenance of Icotinib in Combination With Pemetrexed\u002FCarboplatin Compared With Icotinib Single Drug in Ⅲb\u002FIV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation",[93],118,[1936],[9132,9083],"Icotinib,Pemetrexed,Carboplatin",{"trials":9134,"activeCount":104},[],{"trials":9136,"activeCount":104},[],{"trials":9138,"activeCount":104},[],{"intervention":1742,"totalTrials":1861,"cells":9140},{"EARLY_PHASE1":9141,"PHASE1":9143,"PHASE2":9145,"PHASE3":9166,"PHASE4":9168,"NA":9170},{"trials":9142,"activeCount":104},[],{"trials":9144,"activeCount":104},[],{"trials":9146,"activeCount":100,"soonestReadout":1064},[9147,9154,9158],{"nctId":9148,"briefTitle":9149,"status":143,"phases":9150,"primaryCompletion":1064,"completion":379,"start":9151,"enrollment":942,"conditions":9152,"interventions":9153},"NCT04084496","mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients",[93],"2019-09-01",[2186],[1742],{"nctId":1734,"briefTitle":1735,"status":904,"phases":9155,"primaryCompletion":949,"completion":1737,"start":1738,"enrollment":104,"conditions":9156,"interventions":9157},[93],[1660,1740],[1742,483],{"nctId":9159,"briefTitle":9160,"status":174,"phases":9161,"primaryCompletion":966,"completion":966,"start":9162,"enrollment":1339,"conditions":9163,"interventions":9164},"NCT03812783","HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC",[93],"2018-11-05",[19],[2906,999,9165],"FOLFIRINOX",{"trials":9167,"activeCount":104},[],{"trials":9169,"activeCount":104},[],{"trials":9171,"activeCount":104},[],{"intervention":9173,"totalTrials":1861,"cells":9174},"Furmonertinib",{"EARLY_PHASE1":9175,"PHASE1":9177,"PHASE2":9179,"PHASE3":9206,"PHASE4":9208,"NA":9210},{"trials":9176,"activeCount":104},[],{"trials":9178,"activeCount":104},[],{"trials":9180,"activeCount":100,"soonestReadout":2922},[9181,9188,9197],{"nctId":9182,"briefTitle":9183,"status":174,"phases":9184,"primaryCompletion":584,"completion":1093,"start":2644,"enrollment":2017,"conditions":9185,"interventions":9187},"NCT04970693","A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression",[93],[22,9186],"Oligoprogressive",[9173],{"nctId":9189,"briefTitle":9190,"status":143,"phases":9191,"primaryCompletion":2922,"completion":9192,"start":330,"enrollment":2108,"conditions":9193,"interventions":9194},"NCT05334277","Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA",[93],"2028-02-29",[22],[9173,9173,9195,9196],"Furmonertinib\u002FPemetrexed\u002FCarboplatin","Furmonertinib\u002FPemetrexed\u002FCarboplatin\u002FBevacizumab",{"nctId":9198,"briefTitle":9199,"status":328,"phases":9200,"primaryCompletion":9201,"completion":9202,"start":8568,"enrollment":461,"conditions":9203,"interventions":9204},"NCT06812871","High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis",[93],"2025-10-20","2026-03-30",[9119],[9205],"furmonertinib",{"trials":9207,"activeCount":104},[],{"trials":9209,"activeCount":104},[],{"trials":9211,"activeCount":104},[],{"intervention":9213,"totalTrials":1861,"cells":9214},"minocycline",{"EARLY_PHASE1":9215,"PHASE1":9217,"PHASE2":9219,"PHASE3":9248,"PHASE4":9250,"NA":9252},{"trials":9216,"activeCount":104},[],{"trials":9218,"activeCount":104},[],{"trials":9220,"activeCount":100,"soonestReadout":379},[9221,9230,9241],{"nctId":9222,"briefTitle":9223,"status":143,"phases":9224,"primaryCompletion":379,"completion":380,"start":1657,"enrollment":1464,"conditions":9225,"interventions":9229},"NCT05474729","Minocycline for Chronic Autoimmune Uveitis",[92,93],[9226,9227,9228],"Minocycline","Uveitis","Retinal Degeneration",[9213],{"nctId":9231,"briefTitle":9232,"status":328,"phases":9233,"primaryCompletion":9234,"completion":500,"start":9235,"enrollment":1109,"conditions":9236,"interventions":9240},"NCT04068207","Minocycline Treatment in Retinitis Pigmentosa",[93],"2023-01-31","2019-08-25",[9237,9238,9239],"Retinitis Pigmentosa","Inherited Retinal Dystrophy","Retina Disorder",[9226],{"nctId":9242,"briefTitle":9243,"status":174,"phases":9244,"primaryCompletion":1907,"completion":895,"start":2058,"enrollment":161,"conditions":9245,"interventions":9247},"NCT05474950","Minocycline Treatment for Cystoid Macular Edema",[92,93],[9226,9246],"Cystoid Macular Edema",[9213],{"trials":9249,"activeCount":104},[],{"trials":9251,"activeCount":104},[],{"trials":9253,"activeCount":104},[],{"intervention":89,"totalTrials":1255,"cells":9255},{"EARLY_PHASE1":9256,"PHASE1":9258,"PHASE2":9260,"PHASE3":9276,"PHASE4":9278,"NA":9280},{"trials":9257,"activeCount":104},[],{"trials":9259,"activeCount":104},[],{"trials":9261,"activeCount":100,"soonestReadout":88},[9262,9266],{"nctId":86,"briefTitle":87,"status":143,"phases":9263,"primaryCompletion":88,"completion":249,"start":250,"enrollment":32,"conditions":9264,"interventions":9265},[93],[252],[89,225,254],{"nctId":9267,"briefTitle":9268,"status":174,"phases":9269,"primaryCompletion":8003,"completion":9270,"start":9271,"enrollment":9272,"conditions":9273,"interventions":9275},"NCT04829019","Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI",[93],"2025-10-31","2021-04-07",88,[9274],"Neurocognitive",[89],{"trials":9277,"activeCount":104},[],{"trials":9279,"activeCount":104},[],{"trials":9281,"activeCount":104},[],{"intervention":1308,"totalTrials":1255,"cells":9283},{"EARLY_PHASE1":9284,"PHASE1":9286,"PHASE2":9288,"PHASE3":9301,"PHASE4":9303,"NA":9305},{"trials":9285,"activeCount":104},[],{"trials":9287,"activeCount":104},[],{"trials":9289,"activeCount":100,"soonestReadout":1301},[9290,9294],{"nctId":1298,"briefTitle":1299,"status":143,"phases":9291,"primaryCompletion":1301,"completion":1302,"start":1303,"enrollment":1304,"conditions":9292,"interventions":9293},[93],[282],[1307,1308,444],{"nctId":9295,"briefTitle":9296,"status":174,"phases":9297,"primaryCompletion":721,"completion":1347,"start":9095,"enrollment":32,"conditions":9298,"interventions":9299},"NCT04652440","Ablation Combined With PD-1 in HCC: Phase II Study",[92,93],[19],[9300],"PD-1 monoclonal antibody",{"trials":9302,"activeCount":104},[],{"trials":9304,"activeCount":104},[],{"trials":9306,"activeCount":104},[],{"intervention":1694,"totalTrials":1255,"cells":9308},{"EARLY_PHASE1":9309,"PHASE1":9311,"PHASE2":9313,"PHASE3":9323,"PHASE4":9325,"NA":9327},{"trials":9310,"activeCount":104},[],{"trials":9312,"activeCount":104},[],{"trials":9314,"activeCount":100,"soonestReadout":1688},[9315,9319],{"nctId":1685,"briefTitle":1686,"status":116,"phases":9316,"primaryCompletion":1688,"completion":1689,"start":1690,"enrollment":360,"conditions":9317,"interventions":9318},[93],[1692],[483,1205,1694],{"nctId":8251,"briefTitle":8252,"status":174,"phases":9320,"primaryCompletion":1064,"completion":8254,"start":710,"enrollment":3705,"conditions":9321,"interventions":9322},[92,93],[8256],[1694,8242],{"trials":9324,"activeCount":104},[],{"trials":9326,"activeCount":104},[],{"trials":9328,"activeCount":104},[],{"intervention":9330,"totalTrials":1255,"cells":9331},"Fulvestrant",{"EARLY_PHASE1":9332,"PHASE1":9334,"PHASE2":9336,"PHASE3":9354,"PHASE4":9356,"NA":9358},{"trials":9333,"activeCount":104},[],{"trials":9335,"activeCount":104},[],{"trials":9337,"activeCount":100,"soonestReadout":9342},[9338,9347],{"nctId":9339,"briefTitle":9340,"status":116,"phases":9341,"primaryCompletion":9342,"completion":2122,"start":9343,"enrollment":205,"conditions":9344,"interventions":9345},"NCT07235618","A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer",[93],"2028-01","2026-01-05",[3830],[9346,9330],"Entinostat",{"nctId":9348,"briefTitle":9349,"status":174,"phases":9350,"primaryCompletion":438,"completion":3953,"start":1375,"enrollment":3414,"conditions":9351,"interventions":9352},"NCT02000193","Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer",[93],[28],[9353],"fulvestrant",{"trials":9355,"activeCount":104},[],{"trials":9357,"activeCount":104},[],{"trials":9359,"activeCount":104},[],{"intervention":9361,"totalTrials":1255,"cells":9362},"Hetrombopag",{"EARLY_PHASE1":9363,"PHASE1":9365,"PHASE2":9367,"PHASE3":9388,"PHASE4":9390,"NA":9392},{"trials":9364,"activeCount":104},[],{"trials":9366,"activeCount":104},[],{"trials":9368,"activeCount":100,"soonestReadout":9381},[9369,9377],{"nctId":9370,"briefTitle":9371,"status":174,"phases":9372,"primaryCompletion":1543,"completion":346,"start":9373,"enrollment":406,"conditions":9374,"interventions":9376},"NCT05969158","Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma",[93],"2023-09-04",[9375],"Chemotherapy-Induced Thrombocytopenia",[9361],{"nctId":9378,"briefTitle":9379,"status":116,"phases":9380,"primaryCompletion":9381,"completion":9382,"start":6749,"enrollment":148,"conditions":9383,"interventions":9385},"NCT07334093","A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.",[93],"2027-11-15","2027-12-15",[9384],"Cancer Therapy-induced Thrombocytopenia (CTIT)",[9386,9387],"rhTPO + hetrombopag","hetrombopag",{"trials":9389,"activeCount":104},[],{"trials":9391,"activeCount":104},[],{"trials":9393,"activeCount":104},[],{"intervention":324,"totalTrials":1255,"cells":9395},{"EARLY_PHASE1":9396,"PHASE1":9398,"PHASE2":9408,"PHASE3":9414,"PHASE4":9416,"NA":9418},{"trials":9397,"activeCount":104},[],{"trials":9399,"activeCount":104},[9400],{"nctId":9401,"briefTitle":9402,"status":328,"phases":9403,"primaryCompletion":1737,"completion":1737,"start":9404,"enrollment":1350,"conditions":9405,"interventions":9406},"NCT05226728","Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer",[92],"2018-10-10",[22],[9407],"pembrolizumab",{"trials":9409,"activeCount":100,"soonestReadout":312},[9410],{"nctId":309,"briefTitle":310,"status":143,"phases":9411,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":9412,"interventions":9413},[93],[316,317,318],[320,321,225,49,322,323,324,284],{"trials":9415,"activeCount":104},[],{"trials":9417,"activeCount":104},[],{"trials":9419,"activeCount":104},[],{"intervention":9421,"totalTrials":1255,"cells":9422},"maintenance therapy",{"EARLY_PHASE1":9423,"PHASE1":9425,"PHASE2":9427,"PHASE3":9453,"PHASE4":9455,"NA":9457},{"trials":9424,"activeCount":104},[],{"trials":9426,"activeCount":104},[],{"trials":9428,"activeCount":100,"soonestReadout":303},[9429,9439],{"nctId":9430,"briefTitle":9431,"status":116,"phases":9432,"primaryCompletion":303,"completion":896,"start":4667,"enrollment":1056,"conditions":9433,"interventions":9437},"NCT07405736","Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer",[93],[1020,9434,9435,3655,9436],"Peritoneal (Metastatic) Cancer","Peritoneal Metastasis","MSS Metastatic Colorectal Cancer",[9438,9421],"maintenance therapy plus lubiprostone",{"nctId":9440,"briefTitle":9441,"status":174,"phases":9442,"primaryCompletion":9443,"completion":9443,"start":429,"enrollment":205,"conditions":9444,"interventions":9446},"NCT02396043","Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma",[93],"2025-03",[9445],"Lymphoma, Lymphoblastic",[9447,9448,9449,9421,9450,9451,9452],"induction phase1","induction phase2","protocol M","reinduction phase1","reinduction phase2","Intrathecal",{"trials":9454,"activeCount":104},[],{"trials":9456,"activeCount":104},[],{"trials":9458,"activeCount":104},[],{"intervention":1059,"totalTrials":1255,"cells":9460},{"EARLY_PHASE1":9461,"PHASE1":9463,"PHASE2":9465,"PHASE3":9475,"PHASE4":9477,"NA":9479},{"trials":9462,"activeCount":104},[],{"trials":9464,"activeCount":104},[],{"trials":9466,"activeCount":100,"soonestReadout":2643},[9467,9471],{"nctId":1051,"briefTitle":1052,"status":174,"phases":9468,"primaryCompletion":1054,"completion":1054,"start":1055,"enrollment":1056,"conditions":9469,"interventions":9470},[93],[463],[284,1059,834,444],{"nctId":3787,"briefTitle":3788,"status":300,"phases":9472,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":9473,"interventions":9474},[93],[28,3521],[3793,2308,1381,443,3794,3795,270,1059],{"trials":9476,"activeCount":104},[],{"trials":9478,"activeCount":104},[],{"trials":9480,"activeCount":104},[],{"intervention":9482,"totalTrials":100,"cells":9483},"SBRT+Toripalimab Plus Docetaxel and Cisplatin",{"EARLY_PHASE1":9484,"PHASE1":9486,"PHASE2":9488,"PHASE3":9500,"PHASE4":9502,"NA":9504},{"trials":9485,"activeCount":104},[],{"trials":9487,"activeCount":104},[],{"trials":9489,"activeCount":100,"soonestReadout":6434},[9490],{"nctId":9491,"briefTitle":9492,"status":143,"phases":9493,"primaryCompletion":6434,"completion":9494,"start":9495,"enrollment":1109,"conditions":9496,"interventions":9499},"NCT06611137","SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx",[93],"2027-09-11","2024-09-11",[9497,9498],"Laryngeal Cancer","Hypopharynx Cancer",[9482],{"trials":9501,"activeCount":104},[],{"trials":9503,"activeCount":104},[],{"trials":9505,"activeCount":104},[],{"intervention":8770,"totalTrials":100,"cells":9507},{"EARLY_PHASE1":9508,"PHASE1":9510,"PHASE2":9512,"PHASE3":9518,"PHASE4":9520,"NA":9522},{"trials":9509,"activeCount":104},[],{"trials":9511,"activeCount":104},[],{"trials":9513,"activeCount":100,"soonestReadout":8765},[9514],{"nctId":8762,"briefTitle":8763,"status":143,"phases":9515,"primaryCompletion":8765,"completion":8766,"start":7734,"enrollment":1680,"conditions":9516,"interventions":9517},[93],[8768],[3054,8770],{"trials":9519,"activeCount":104},[],{"trials":9521,"activeCount":104},[],{"trials":9523,"activeCount":104},[],{"intervention":9525,"totalTrials":100,"cells":9526},"CCRT+Nimotuzumab",{"EARLY_PHASE1":9527,"PHASE1":9529,"PHASE2":9531,"PHASE3":9540,"PHASE4":9542,"NA":9544},{"trials":9528,"activeCount":104},[],{"trials":9530,"activeCount":104},[],{"trials":9532,"activeCount":100,"soonestReadout":1963},[9533],{"nctId":9534,"briefTitle":9535,"status":300,"phases":9536,"primaryCompletion":1963,"completion":419,"start":4267,"enrollment":1856,"conditions":9537,"interventions":9538},"NCT04223024","Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma",[93],[16],[9525,9539],"CCRT alone",{"trials":9541,"activeCount":104},[],{"trials":9543,"activeCount":104},[],{"trials":9545,"activeCount":104},[],{"intervention":9539,"totalTrials":100,"cells":9547},{"EARLY_PHASE1":9548,"PHASE1":9550,"PHASE2":9552,"PHASE3":9558,"PHASE4":9560,"NA":9562},{"trials":9549,"activeCount":104},[],{"trials":9551,"activeCount":104},[],{"trials":9553,"activeCount":100,"soonestReadout":1963},[9554],{"nctId":9534,"briefTitle":9535,"status":300,"phases":9555,"primaryCompletion":1963,"completion":419,"start":4267,"enrollment":1856,"conditions":9556,"interventions":9557},[93],[16],[9525,9539],{"trials":9559,"activeCount":104},[],{"trials":9561,"activeCount":104},[],{"trials":9563,"activeCount":104},[],{"intervention":4133,"totalTrials":100,"cells":9565},{"EARLY_PHASE1":9566,"PHASE1":9568,"PHASE2":9570,"PHASE3":9576,"PHASE4":9578,"NA":9580},{"trials":9567,"activeCount":104},[],{"trials":9569,"activeCount":104},[],{"trials":9571,"activeCount":100,"soonestReadout":4126},[9572],{"nctId":4123,"briefTitle":4124,"status":143,"phases":9573,"primaryCompletion":4126,"completion":4127,"start":4128,"enrollment":3272,"conditions":9574,"interventions":9575},[93],[4130,316,4131],[876,4133],{"trials":9577,"activeCount":104},[],{"trials":9579,"activeCount":104},[],{"trials":9581,"activeCount":104},[],{"intervention":9583,"totalTrials":100,"cells":9584},"Triprolizumab",{"EARLY_PHASE1":9585,"PHASE1":9587,"PHASE2":9589,"PHASE3":9600,"PHASE4":9602,"NA":9604},{"trials":9586,"activeCount":104},[],{"trials":9588,"activeCount":104},[],{"trials":9590,"activeCount":100,"soonestReadout":9595},[9591],{"nctId":9592,"briefTitle":9593,"status":143,"phases":9594,"primaryCompletion":9595,"completion":9595,"start":9596,"enrollment":1615,"conditions":9597,"interventions":9599},"NCT06587802","Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma",[93],"2027-03-14","2025-03-14",[9598],"Adrenocortical Carcinoma",[9583],{"trials":9601,"activeCount":104},[],{"trials":9603,"activeCount":104},[],{"trials":9605,"activeCount":104},[],{"intervention":9607,"totalTrials":100,"cells":9608},"Eribulin in Combination with Anlotinib",{"EARLY_PHASE1":9609,"PHASE1":9611,"PHASE2":9613,"PHASE3":9623,"PHASE4":9625,"NA":9627},{"trials":9610,"activeCount":104},[],{"trials":9612,"activeCount":104},[],{"trials":9614,"activeCount":100,"soonestReadout":1747},[9615],{"nctId":9616,"briefTitle":9617,"status":143,"phases":9618,"primaryCompletion":1747,"completion":9619,"start":7492,"enrollment":978,"conditions":9620,"interventions":9622},"NCT07520760","A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent\u002FMetastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates",[93],"2035-04-30",[9621],"HER 2 Negative Breast Cancer",[9607],{"trials":9624,"activeCount":104},[],{"trials":9626,"activeCount":104},[],{"trials":9628,"activeCount":104},[],{"intervention":1642,"totalTrials":100,"cells":9630},{"EARLY_PHASE1":9631,"PHASE1":9633,"PHASE2":9635,"PHASE3":9641,"PHASE4":9643,"NA":9645},{"trials":9632,"activeCount":104},[],{"trials":9634,"activeCount":104},[],{"trials":9636,"activeCount":100,"soonestReadout":1636},[9637],{"nctId":1633,"briefTitle":1634,"status":116,"phases":9638,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":1638,"conditions":9639,"interventions":9640},[93],[1640],[1463,1642,353],{"trials":9642,"activeCount":104},[],{"trials":9644,"activeCount":104},[],{"trials":9646,"activeCount":104},[],{"intervention":9648,"totalTrials":100,"cells":9649},"Taurine",{"EARLY_PHASE1":9650,"PHASE1":9652,"PHASE2":9654,"PHASE3":9663,"PHASE4":9665,"NA":9667},{"trials":9651,"activeCount":104},[],{"trials":9653,"activeCount":104},[],{"trials":9655,"activeCount":100,"soonestReadout":9660},[9656],{"nctId":9657,"briefTitle":9658,"status":116,"phases":9659,"primaryCompletion":9660,"completion":5713,"start":1690,"enrollment":20,"conditions":9661,"interventions":9662},"NCT07567742","Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma",[93],"2027-03-30",[588,1009],[9648],{"trials":9664,"activeCount":104},[],{"trials":9666,"activeCount":104},[],{"trials":9668,"activeCount":104},[],{"intervention":1282,"totalTrials":100,"cells":9670},{"EARLY_PHASE1":9671,"PHASE1":9673,"PHASE2":9675,"PHASE3":9681,"PHASE4":9683,"NA":9685},{"trials":9672,"activeCount":104},[],{"trials":9674,"activeCount":104},[],{"trials":9676,"activeCount":100,"soonestReadout":1277},[9677],{"nctId":1274,"briefTitle":1275,"status":300,"phases":9678,"primaryCompletion":1277,"completion":1277,"start":500,"enrollment":1095,"conditions":9679,"interventions":9680},[93],[463,1279,1280],[1282,1283,269,444],{"trials":9682,"activeCount":104},[],{"trials":9684,"activeCount":104},[],{"trials":9686,"activeCount":104},[],{"intervention":1283,"totalTrials":100,"cells":9688},{"EARLY_PHASE1":9689,"PHASE1":9691,"PHASE2":9693,"PHASE3":9699,"PHASE4":9701,"NA":9703},{"trials":9690,"activeCount":104},[],{"trials":9692,"activeCount":104},[],{"trials":9694,"activeCount":100,"soonestReadout":1277},[9695],{"nctId":1274,"briefTitle":1275,"status":300,"phases":9696,"primaryCompletion":1277,"completion":1277,"start":500,"enrollment":1095,"conditions":9697,"interventions":9698},[93],[463,1279,1280],[1282,1283,269,444],{"trials":9700,"activeCount":104},[],{"trials":9702,"activeCount":104},[],{"trials":9704,"activeCount":104},[],{"intervention":9706,"totalTrials":100,"cells":9707},"Adebrelimab & SHR2554",{"EARLY_PHASE1":9708,"PHASE1":9710,"PHASE2":9712,"PHASE3":9724,"PHASE4":9726,"NA":9728},{"trials":9709,"activeCount":104},[],{"trials":9711,"activeCount":104},[],{"trials":9713,"activeCount":100,"soonestReadout":9718},[9714],{"nctId":9715,"briefTitle":9716,"status":116,"phases":9717,"primaryCompletion":9718,"completion":9719,"start":9720,"enrollment":492,"conditions":9721,"interventions":9723},"NCT07615283","Adebrelimab Combined With SHR2554 in Relapsed\u002FRefractory PTCL and NK\u002FT-Cell Lymphoma",[92,93],"2030-05-29","2030-10-29","2026-05-29",[9722,1692],"Relapsed or Refractory Peripheral T Cell Lymphoma",[9706],{"trials":9725,"activeCount":104},[],{"trials":9727,"activeCount":104},[],{"trials":9729,"activeCount":104},[],{"intervention":9731,"totalTrials":100,"cells":9732},"Golicitinib combined with Pomadomide",{"EARLY_PHASE1":9733,"PHASE1":9735,"PHASE2":9737,"PHASE3":9747,"PHASE4":9749,"NA":9751},{"trials":9734,"activeCount":104},[],{"trials":9736,"activeCount":104},[],{"trials":9738,"activeCount":100,"soonestReadout":419},[9739],{"nctId":9740,"briefTitle":9741,"status":143,"phases":9742,"primaryCompletion":419,"completion":419,"start":9743,"enrollment":1350,"conditions":9744,"interventions":9746},"NCT06855823","A Phase I\u002FII Study of Golidocitinib Combined with Pomalidomide in R\u002FR PTCL",[92,93],"2025-01-14",[9745],"Relapsed\u002FRefractory Peripheral T-Cell Lymphoma (R\u002FR PTCL)",[9731],{"trials":9748,"activeCount":104},[],{"trials":9750,"activeCount":104},[],{"trials":9752,"activeCount":104},[],{"intervention":9754,"totalTrials":100,"cells":9755},"Ivonescimab Combined With Chemotherapy",{"EARLY_PHASE1":9756,"PHASE1":9758,"PHASE2":9760,"PHASE3":9772,"PHASE4":9774,"NA":9776},{"trials":9757,"activeCount":104},[],{"trials":9759,"activeCount":104},[],{"trials":9761,"activeCount":100,"soonestReadout":9766},[9762],{"nctId":9763,"briefTitle":9764,"status":116,"phases":9765,"primaryCompletion":9766,"completion":9767,"start":1054,"enrollment":1366,"conditions":9768,"interventions":9771},"NCT06750952","Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial",[93],"2026-12-20","2028-12-20",[9769,9770],"Relapsed or Metastatic Thymic Cancer","First-line Treatment",[9754],{"trials":9773,"activeCount":104},[],{"trials":9775,"activeCount":104},[],{"trials":9777,"activeCount":104},[],{"intervention":9779,"totalTrials":100,"cells":9780},"Pucotenlimab combined with GP regimen",{"EARLY_PHASE1":9781,"PHASE1":9783,"PHASE2":9785,"PHASE3":9796,"PHASE4":9798,"NA":9800},{"trials":9782,"activeCount":104},[],{"trials":9784,"activeCount":104},[],{"trials":9786,"activeCount":100,"soonestReadout":1437},[9787],{"nctId":9788,"briefTitle":9789,"status":143,"phases":9790,"primaryCompletion":1437,"completion":2122,"start":5199,"enrollment":1350,"conditions":9791,"interventions":9795},"NCT06969534","Safety and Efficacy of Pucotenlimab in pLECC",[93],[9792,9793,9794],"Lymphoepithelioma-like Carcinoma","Lymphoepithelioma","Carcinoma",[9779],{"trials":9797,"activeCount":104},[],{"trials":9799,"activeCount":104},[],{"trials":9801,"activeCount":104},[],{"intervention":9803,"totalTrials":100,"cells":9804},"Docetaxel, Cisplatin, Toripalimab",{"EARLY_PHASE1":9805,"PHASE1":9807,"PHASE2":9809,"PHASE3":9821,"PHASE4":9823,"NA":9825},{"trials":9806,"activeCount":104},[],{"trials":9808,"activeCount":104},[],{"trials":9810,"activeCount":100,"soonestReadout":379},[9811],{"nctId":9812,"briefTitle":9813,"status":116,"phases":9814,"primaryCompletion":379,"completion":380,"start":9815,"enrollment":205,"conditions":9816,"interventions":9820},"NCT06861712","Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer",[93],"2025-05-06",[9817,9818,9819],"Oral Squamous Cell Carcinoma (OSCC)","Oropharyngeal Squamous Cell Carcinoma (SCC)","Stereotactic Body Radiation Therapy (SBRT)",[9803],{"trials":9822,"activeCount":104},[],{"trials":9824,"activeCount":104},[],{"trials":9826,"activeCount":104},[],{"intervention":1924,"totalTrials":100,"cells":9828},{"EARLY_PHASE1":9829,"PHASE1":9831,"PHASE2":9833,"PHASE3":9839,"PHASE4":9841,"NA":9843},{"trials":9830,"activeCount":104},[],{"trials":9832,"activeCount":104},[],{"trials":9834,"activeCount":100,"soonestReadout":1005},[9835],{"nctId":1916,"briefTitle":1917,"status":116,"phases":9836,"primaryCompletion":1005,"completion":1919,"start":1508,"enrollment":1920,"conditions":9837,"interventions":9838},[93],[1922],[542,296,1924,1925,272,823],{"trials":9840,"activeCount":104},[],{"trials":9842,"activeCount":104},[],{"trials":9844,"activeCount":104},[],{"intervention":1925,"totalTrials":100,"cells":9846},{"EARLY_PHASE1":9847,"PHASE1":9849,"PHASE2":9851,"PHASE3":9857,"PHASE4":9859,"NA":9861},{"trials":9848,"activeCount":104},[],{"trials":9850,"activeCount":104},[],{"trials":9852,"activeCount":100,"soonestReadout":1005},[9853],{"nctId":1916,"briefTitle":1917,"status":116,"phases":9854,"primaryCompletion":1005,"completion":1919,"start":1508,"enrollment":1920,"conditions":9855,"interventions":9856},[93],[1922],[542,296,1924,1925,272,823],{"trials":9858,"activeCount":104},[],{"trials":9860,"activeCount":104},[],{"trials":9862,"activeCount":104},[],{"intervention":9864,"totalTrials":100,"cells":9865},"CART therapy",{"EARLY_PHASE1":9866,"PHASE1":9868,"PHASE2":9870,"PHASE3":9882,"PHASE4":9884,"NA":9886},{"trials":9867,"activeCount":104},[],{"trials":9869,"activeCount":104},[],{"trials":9871,"activeCount":100,"soonestReadout":9876},[9872],{"nctId":9873,"briefTitle":9874,"status":143,"phases":9875,"primaryCompletion":9876,"completion":9876,"start":9877,"enrollment":1464,"conditions":9878,"interventions":9881},"NCT06836505","Safety and Efficacy of CAR-T Cell Therapy for Relapsed\u002Frefractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.",[92,93],"2027-12-12","2024-12-12",[9879,9880],"Neuroblastoma (NB)","Desmoplastic Small Round Cell Tumor (DSRCT)",[9864],{"trials":9883,"activeCount":104},[],{"trials":9885,"activeCount":104},[],{"trials":9887,"activeCount":104},[],{"intervention":7444,"totalTrials":100,"cells":9889},{"EARLY_PHASE1":9890,"PHASE1":9892,"PHASE2":9894,"PHASE3":9900,"PHASE4":9902,"NA":9904},{"trials":9891,"activeCount":104},[],{"trials":9893,"activeCount":104},[],{"trials":9895,"activeCount":100,"soonestReadout":3651},[9896],{"nctId":7438,"briefTitle":7439,"status":116,"phases":9897,"primaryCompletion":3651,"completion":6330,"start":1790,"enrollment":3705,"conditions":9898,"interventions":9899},[92,93],[7442],[7444,981],{"trials":9901,"activeCount":104},[],{"trials":9903,"activeCount":104},[],{"trials":9905,"activeCount":104},[],{"intervention":9907,"totalTrials":100,"cells":9908},"Camrelizumab, gemcitabin, cisplatin",{"EARLY_PHASE1":9909,"PHASE1":9911,"PHASE2":9913,"PHASE3":9924,"PHASE4":9926,"NA":9928},{"trials":9910,"activeCount":104},[],{"trials":9912,"activeCount":104},[],{"trials":9914,"activeCount":100,"soonestReadout":9919},[9915],{"nctId":9916,"briefTitle":9917,"status":143,"phases":9918,"primaryCompletion":9919,"completion":9920,"start":2753,"enrollment":9921,"conditions":9922,"interventions":9923},"NCT05431764","Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma",[93],"2025-06-20","2026-06-20",38,[16],[9907],{"trials":9925,"activeCount":104},[],{"trials":9927,"activeCount":104},[],{"trials":9929,"activeCount":104},[],{"intervention":9931,"totalTrials":100,"cells":9932},"Sintlimab+Rituximab follwed by R-CHOP",{"EARLY_PHASE1":9933,"PHASE1":9935,"PHASE2":9937,"PHASE3":9946,"PHASE4":9948,"NA":9950},{"trials":9934,"activeCount":104},[],{"trials":9936,"activeCount":104},[],{"trials":9938,"activeCount":100,"soonestReadout":1437},[9939],{"nctId":9940,"briefTitle":9941,"status":143,"phases":9942,"primaryCompletion":1437,"completion":2589,"start":147,"enrollment":32,"conditions":9943,"interventions":9945},"NCT06742502","Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL",[93],[9944],"Primary Mediastinal Diffuse Large B-cell Lymphoma",[9931],{"trials":9947,"activeCount":104},[],{"trials":9949,"activeCount":104},[],{"trials":9951,"activeCount":104},[],{"intervention":2861,"totalTrials":100,"cells":9953},{"EARLY_PHASE1":9954,"PHASE1":9956,"PHASE2":9958,"PHASE3":9964,"PHASE4":9966,"NA":9968},{"trials":9955,"activeCount":104},[],{"trials":9957,"activeCount":104},[],{"trials":9959,"activeCount":100,"soonestReadout":2856},[9960],{"nctId":2853,"briefTitle":2854,"status":300,"phases":9961,"primaryCompletion":2856,"completion":236,"start":2857,"enrollment":32,"conditions":9962,"interventions":9963},[93],[700,2859],[2861,353],{"trials":9965,"activeCount":104},[],{"trials":9967,"activeCount":104},[],{"trials":9969,"activeCount":104},[],{"intervention":1295,"totalTrials":100,"cells":9971},{"EARLY_PHASE1":9972,"PHASE1":9974,"PHASE2":9976,"PHASE3":9982,"PHASE4":9984,"NA":9986},{"trials":9973,"activeCount":104},[],{"trials":9975,"activeCount":104},[],{"trials":9977,"activeCount":100,"soonestReadout":1288},[9978],{"nctId":1285,"briefTitle":1286,"status":116,"phases":9979,"primaryCompletion":1288,"completion":380,"start":1083,"enrollment":1289,"conditions":9980,"interventions":9981},[93],[1291,318,1292,1293],[1295,444,542,1296],{"trials":9983,"activeCount":104},[],{"trials":9985,"activeCount":104},[],{"trials":9987,"activeCount":104},[],{"intervention":1296,"totalTrials":100,"cells":9989},{"EARLY_PHASE1":9990,"PHASE1":9992,"PHASE2":9994,"PHASE3":10000,"PHASE4":10002,"NA":10004},{"trials":9991,"activeCount":104},[],{"trials":9993,"activeCount":104},[],{"trials":9995,"activeCount":100,"soonestReadout":1288},[9996],{"nctId":1285,"briefTitle":1286,"status":116,"phases":9997,"primaryCompletion":1288,"completion":380,"start":1083,"enrollment":1289,"conditions":9998,"interventions":9999},[93],[1291,318,1292,1293],[1295,444,542,1296],{"trials":10001,"activeCount":104},[],{"trials":10003,"activeCount":104},[],{"trials":10005,"activeCount":104},[],{"intervention":10007,"totalTrials":100,"cells":10008},"Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin",{"EARLY_PHASE1":10009,"PHASE1":10011,"PHASE2":10013,"PHASE3":10023,"PHASE4":10025,"NA":10027},{"trials":10010,"activeCount":104},[],{"trials":10012,"activeCount":104},[],{"trials":10014,"activeCount":100,"soonestReadout":763},[10015],{"nctId":10016,"briefTitle":10017,"status":143,"phases":10018,"primaryCompletion":763,"completion":1132,"start":10019,"enrollment":9921,"conditions":10020,"interventions":10022},"NCT05930665","Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma",[93],"2023-11-01",[10021],"Pleural Mesothelioma",[10007],{"trials":10024,"activeCount":104},[],{"trials":10026,"activeCount":104},[],{"trials":10028,"activeCount":104},[],{"intervention":10030,"totalTrials":100,"cells":10031},"sintilimab combined with bevacizumab biosimilar",{"EARLY_PHASE1":10032,"PHASE1":10034,"PHASE2":10036,"PHASE3":10048,"PHASE4":10050,"NA":10052},{"trials":10033,"activeCount":104},[],{"trials":10035,"activeCount":104},[],{"trials":10037,"activeCount":100,"soonestReadout":10042},[10038],{"nctId":10039,"briefTitle":10040,"status":143,"phases":10041,"primaryCompletion":10042,"completion":10043,"start":10044,"enrollment":29,"conditions":10045,"interventions":10047},"NCT07324824","Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma",[93],"2029-01","2030-01","2026-01-14",[19,4554,483,10046],"Bevacizimab",[10030],{"trials":10049,"activeCount":104},[],{"trials":10051,"activeCount":104},[],{"trials":10053,"activeCount":104},[],{"intervention":10055,"totalTrials":100,"cells":10056},"GP+Toripalimab+CCRT",{"EARLY_PHASE1":10057,"PHASE1":10059,"PHASE2":10061,"PHASE3":10072,"PHASE4":10074,"NA":10076},{"trials":10058,"activeCount":104},[],{"trials":10060,"activeCount":104},[],{"trials":10062,"activeCount":100,"soonestReadout":10067},[10063],{"nctId":10064,"briefTitle":10065,"status":116,"phases":10066,"primaryCompletion":10067,"completion":10068,"start":2181,"enrollment":5353,"conditions":10069,"interventions":10070},"NCT06605131","GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma",[93],"2026-02-25","2029-02-25",[37],[10055,10071],"GP+CCRT",{"trials":10073,"activeCount":104},[],{"trials":10075,"activeCount":104},[],{"trials":10077,"activeCount":104},[],{"intervention":10071,"totalTrials":100,"cells":10079},{"EARLY_PHASE1":10080,"PHASE1":10082,"PHASE2":10084,"PHASE3":10090,"PHASE4":10092,"NA":10094},{"trials":10081,"activeCount":104},[],{"trials":10083,"activeCount":104},[],{"trials":10085,"activeCount":100,"soonestReadout":10067},[10086],{"nctId":10064,"briefTitle":10065,"status":116,"phases":10087,"primaryCompletion":10067,"completion":10068,"start":2181,"enrollment":5353,"conditions":10088,"interventions":10089},[93],[37],[10055,10071],{"trials":10091,"activeCount":104},[],{"trials":10093,"activeCount":104},[],{"trials":10095,"activeCount":104},[],{"intervention":10097,"totalTrials":100,"cells":10098},"Sintilimab plus platinum-doublet chemotherapy",{"EARLY_PHASE1":10099,"PHASE1":10101,"PHASE2":10103,"PHASE3":10111,"PHASE4":10113,"NA":10115},{"trials":10100,"activeCount":104},[],{"trials":10102,"activeCount":104},[],{"trials":10104,"activeCount":100,"soonestReadout":896},[10105],{"nctId":10106,"briefTitle":10107,"status":116,"phases":10108,"primaryCompletion":896,"completion":1005,"start":1508,"enrollment":1350,"conditions":10109,"interventions":10110},"NCT07603661","Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC",[93],[1831],[10097],{"trials":10112,"activeCount":104},[],{"trials":10114,"activeCount":104},[],{"trials":10116,"activeCount":104},[],{"intervention":10118,"totalTrials":100,"cells":10119},"lpromlimab and Tuvonralimab lpromlimab and Tuvonralimab Combined with Albumin-Bound Paclitaxel and Nedaplatin",{"EARLY_PHASE1":10120,"PHASE1":10122,"PHASE2":10124,"PHASE3":10136,"PHASE4":10138,"NA":10140},{"trials":10121,"activeCount":104},[],{"trials":10123,"activeCount":104},[],{"trials":10125,"activeCount":100,"soonestReadout":10130},[10126],{"nctId":10127,"briefTitle":10128,"status":300,"phases":10129,"primaryCompletion":10130,"completion":10131,"start":10132,"enrollment":1007,"conditions":10133,"interventions":10135},"NCT07374003","Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma",[93],"2029-06-20","2029-12-20","2025-12-17",[10134],"Locally Advanced, Resectable",[10118],{"trials":10137,"activeCount":104},[],{"trials":10139,"activeCount":104},[],{"trials":10141,"activeCount":104},[],{"intervention":1947,"totalTrials":100,"cells":10143},{"EARLY_PHASE1":10144,"PHASE1":10146,"PHASE2":10148,"PHASE3":10154,"PHASE4":10156,"NA":10158},{"trials":10145,"activeCount":104},[],{"trials":10147,"activeCount":104},[],{"trials":10149,"activeCount":100,"soonestReadout":1942},[10150],{"nctId":1939,"briefTitle":1940,"status":116,"phases":10151,"primaryCompletion":1942,"completion":646,"start":1943,"enrollment":20,"conditions":10152,"interventions":10153},[93],[25,1406],[1946,1947,272],{"trials":10155,"activeCount":104},[],{"trials":10157,"activeCount":104},[],{"trials":10159,"activeCount":104},[],{"intervention":10161,"totalTrials":100,"cells":10162},"intravenous",{"EARLY_PHASE1":10163,"PHASE1":10165,"PHASE2":10167,"PHASE3":10178,"PHASE4":10180,"NA":10182},{"trials":10164,"activeCount":104},[],{"trials":10166,"activeCount":104},[],{"trials":10168,"activeCount":100,"soonestReadout":237},[10169],{"nctId":10170,"briefTitle":10171,"status":143,"phases":10172,"primaryCompletion":237,"completion":646,"start":359,"enrollment":10173,"conditions":10174,"interventions":10176},"NCT06737913","HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma",[93],76,[10175],"Advanced Hepatocellular Carcinoma (HCC)",[10161,10161,10177],"Adebrelimab and bevacizumab maintainance treatment",{"trials":10179,"activeCount":104},[],{"trials":10181,"activeCount":104},[],{"trials":10183,"activeCount":104},[],{"intervention":10177,"totalTrials":100,"cells":10185},{"EARLY_PHASE1":10186,"PHASE1":10188,"PHASE2":10190,"PHASE3":10196,"PHASE4":10198,"NA":10200},{"trials":10187,"activeCount":104},[],{"trials":10189,"activeCount":104},[],{"trials":10191,"activeCount":100,"soonestReadout":237},[10192],{"nctId":10170,"briefTitle":10171,"status":143,"phases":10193,"primaryCompletion":237,"completion":646,"start":359,"enrollment":10173,"conditions":10194,"interventions":10195},[93],[10175],[10161,10161,10177],{"trials":10197,"activeCount":104},[],{"trials":10199,"activeCount":104},[],{"trials":10201,"activeCount":104},[],{"intervention":1307,"totalTrials":100,"cells":10203},{"EARLY_PHASE1":10204,"PHASE1":10206,"PHASE2":10208,"PHASE3":10214,"PHASE4":10216,"NA":10218},{"trials":10205,"activeCount":104},[],{"trials":10207,"activeCount":104},[],{"trials":10209,"activeCount":100,"soonestReadout":1301},[10210],{"nctId":1298,"briefTitle":1299,"status":143,"phases":10211,"primaryCompletion":1301,"completion":1302,"start":1303,"enrollment":1304,"conditions":10212,"interventions":10213},[93],[282],[1307,1308,444],{"trials":10215,"activeCount":104},[],{"trials":10217,"activeCount":104},[],{"trials":10219,"activeCount":104},[],{"intervention":10221,"totalTrials":100,"cells":10222},"Yivoximab",{"EARLY_PHASE1":10223,"PHASE1":10225,"PHASE2":10227,"PHASE3":10238,"PHASE4":10240,"NA":10242},{"trials":10224,"activeCount":104},[],{"trials":10226,"activeCount":104},[],{"trials":10228,"activeCount":100,"soonestReadout":303},[10229],{"nctId":10230,"briefTitle":10231,"status":3411,"phases":10232,"primaryCompletion":303,"completion":303,"start":10233,"enrollment":996,"conditions":10234,"interventions":10237},"NCT07488572","Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study",[93],"2025-11-01",[10235,10236],"Renal Cell Carcinoma (RCC)","Metastatic Clear Cell Renal Cell Carcinoma",[10221],{"trials":10239,"activeCount":104},[],{"trials":10241,"activeCount":104},[],{"trials":10243,"activeCount":104},[],{"intervention":10245,"totalTrials":100,"cells":10246},"AK112 + paclitaxel",{"EARLY_PHASE1":10247,"PHASE1":10249,"PHASE2":10251,"PHASE3":10261,"PHASE4":10263,"NA":10265},{"trials":10248,"activeCount":104},[],{"trials":10250,"activeCount":104},[],{"trials":10252,"activeCount":100,"soonestReadout":678},[10253],{"nctId":10254,"briefTitle":10255,"status":116,"phases":10256,"primaryCompletion":678,"completion":646,"start":513,"enrollment":1460,"conditions":10257,"interventions":10259},"NCT06904300","Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G\u002FGEJ Cancer",[93],[10258],"Gastric (Cardia, Body) Cancer",[10245,10260],"Paclitaxel ± ramucirumab",{"trials":10262,"activeCount":104},[],{"trials":10264,"activeCount":104},[],{"trials":10266,"activeCount":104},[],{"intervention":10260,"totalTrials":100,"cells":10268},{"EARLY_PHASE1":10269,"PHASE1":10271,"PHASE2":10273,"PHASE3":10279,"PHASE4":10281,"NA":10283},{"trials":10270,"activeCount":104},[],{"trials":10272,"activeCount":104},[],{"trials":10274,"activeCount":100,"soonestReadout":678},[10275],{"nctId":10254,"briefTitle":10255,"status":116,"phases":10276,"primaryCompletion":678,"completion":646,"start":513,"enrollment":1460,"conditions":10277,"interventions":10278},[93],[10258],[10245,10260],{"trials":10280,"activeCount":104},[],{"trials":10282,"activeCount":104},[],{"trials":10284,"activeCount":104},[],{"intervention":10286,"totalTrials":100,"cells":10287},"Serplulimab in combination with Fruquintinib",{"EARLY_PHASE1":10288,"PHASE1":10290,"PHASE2":10292,"PHASE3":10301,"PHASE4":10303,"NA":10305},{"trials":10289,"activeCount":104},[],{"trials":10291,"activeCount":104},[],{"trials":10293,"activeCount":100,"soonestReadout":119},[10294],{"nctId":10295,"briefTitle":10296,"status":300,"phases":10297,"primaryCompletion":119,"completion":646,"start":346,"enrollment":492,"conditions":10298,"interventions":10300},"NCT07488533","Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma",[93],[10299],"Non-Clear Cell Renal Cell Carcinoma",[10286],{"trials":10302,"activeCount":104},[],{"trials":10304,"activeCount":104},[],{"trials":10306,"activeCount":104},[],{"intervention":10308,"totalTrials":100,"cells":10309},"Volonib combined with Everolimus Formation",{"EARLY_PHASE1":10310,"PHASE1":10312,"PHASE2":10314,"PHASE3":10325,"PHASE4":10327,"NA":10329},{"trials":10311,"activeCount":104},[],{"trials":10313,"activeCount":104},[],{"trials":10315,"activeCount":100,"soonestReadout":10320},[10316],{"nctId":10317,"briefTitle":10318,"status":143,"phases":10319,"primaryCompletion":10320,"completion":10321,"start":1238,"enrollment":942,"conditions":10322,"interventions":10324},"NCT06730672","An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus",[93],"2027-12-27","2028-12-27",[10323],"Renal Cell Carcinoma Stage I",[10308],{"trials":10326,"activeCount":104},[],{"trials":10328,"activeCount":104},[],{"trials":10330,"activeCount":104},[],{"intervention":4577,"totalTrials":100,"cells":10332},{"EARLY_PHASE1":10333,"PHASE1":10335,"PHASE2":10337,"PHASE3":10343,"PHASE4":10345,"NA":10347},{"trials":10334,"activeCount":104},[],{"trials":10336,"activeCount":104},[],{"trials":10338,"activeCount":100,"soonestReadout":1508},[10339],{"nctId":4571,"briefTitle":4572,"status":116,"phases":10340,"primaryCompletion":1508,"completion":807,"start":3261,"enrollment":406,"conditions":10341,"interventions":10342},[93],[4575],[4577,4562],{"trials":10344,"activeCount":104},[],{"trials":10346,"activeCount":104},[],{"trials":10348,"activeCount":104},[],{"intervention":8421,"totalTrials":100,"cells":10350},{"EARLY_PHASE1":10351,"PHASE1":10353,"PHASE2":10355,"PHASE3":10361,"PHASE4":10363,"NA":10365},{"trials":10352,"activeCount":104},[],{"trials":10354,"activeCount":104},[],{"trials":10356,"activeCount":100,"soonestReadout":8417},[10357],{"nctId":8414,"briefTitle":8415,"status":116,"phases":10358,"primaryCompletion":8417,"completion":8417,"start":2206,"enrollment":5071,"conditions":10359,"interventions":10360},[93],[8419],[8421,5075],{"trials":10362,"activeCount":104},[],{"trials":10364,"activeCount":104},[],{"trials":10366,"activeCount":104},[],{"intervention":3119,"totalTrials":100,"cells":10368},{"EARLY_PHASE1":10369,"PHASE1":10371,"PHASE2":10373,"PHASE3":10379,"PHASE4":10381,"NA":10383},{"trials":10370,"activeCount":104},[],{"trials":10372,"activeCount":104},[],{"trials":10374,"activeCount":100,"soonestReadout":380},[10375],{"nctId":3113,"briefTitle":3114,"status":143,"phases":10376,"primaryCompletion":380,"completion":303,"start":3116,"enrollment":32,"conditions":10377,"interventions":10378},[93],[3017],[3119,3119,268],{"trials":10380,"activeCount":104},[],{"trials":10382,"activeCount":104},[],{"trials":10384,"activeCount":104},[],{"intervention":10386,"totalTrials":100,"cells":10387},"Drug: QL1706 5mg\u002Fkg, iv drip,d1,Q3W; Albumin-Bound Paclitaxel 125mg\u002Fm2, iv drip, d1、d8, Q3W; Lenvatinib 8mg, po, QD",{"EARLY_PHASE1":10388,"PHASE1":10390,"PHASE2":10392,"PHASE3":10402,"PHASE4":10404,"NA":10406},{"trials":10389,"activeCount":104},[],{"trials":10391,"activeCount":104},[],{"trials":10393,"activeCount":100,"soonestReadout":8886},[10394],{"nctId":10395,"briefTitle":10396,"status":143,"phases":10397,"primaryCompletion":8886,"completion":1437,"start":10398,"enrollment":492,"conditions":10399,"interventions":10401},"NCT07530445","Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer",[93],"2026-03-23",[10400],"Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer",[10386],{"trials":10403,"activeCount":104},[],{"trials":10405,"activeCount":104},[],{"trials":10407,"activeCount":104},[],{"intervention":10409,"totalTrials":100,"cells":10410},"Trifluridine\u002Ftipiracil plus fruquintinib",{"EARLY_PHASE1":10411,"PHASE1":10413,"PHASE2":10415,"PHASE3":10426,"PHASE4":10428,"NA":10430},{"trials":10412,"activeCount":104},[],{"trials":10414,"activeCount":104},[],{"trials":10416,"activeCount":100,"soonestReadout":2038},[10417],{"nctId":10418,"briefTitle":10419,"status":116,"phases":10420,"primaryCompletion":2038,"completion":10421,"start":302,"enrollment":800,"conditions":10422,"interventions":10424},"NCT07261709","Trifluridine\u002FTipiracil Plus Fruquintinib vs. Trifluridine\u002FTipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial",[93],"2028-03-30",[10423],"Refractory Metastatic Colorectal Cancer",[10409,10425],"trifluridine\u002Ftipiracil plus bevacizumab",{"trials":10427,"activeCount":104},[],{"trials":10429,"activeCount":104},[],{"trials":10431,"activeCount":104},[],{"intervention":10425,"totalTrials":100,"cells":10433},{"EARLY_PHASE1":10434,"PHASE1":10436,"PHASE2":10438,"PHASE3":10444,"PHASE4":10446,"NA":10448},{"trials":10435,"activeCount":104},[],{"trials":10437,"activeCount":104},[],{"trials":10439,"activeCount":100,"soonestReadout":2038},[10440],{"nctId":10418,"briefTitle":10419,"status":116,"phases":10441,"primaryCompletion":2038,"completion":10421,"start":302,"enrollment":800,"conditions":10442,"interventions":10443},[93],[10423],[10409,10425],{"trials":10445,"activeCount":104},[],{"trials":10447,"activeCount":104},[],{"trials":10449,"activeCount":104},[],{"intervention":10451,"totalTrials":100,"cells":10452},"Trastuzumab +Cetuximab β+Irinotecan",{"EARLY_PHASE1":10453,"PHASE1":10455,"PHASE2":10457,"PHASE3":10467,"PHASE4":10469,"NA":10471},{"trials":10454,"activeCount":104},[],{"trials":10456,"activeCount":104},[],{"trials":10458,"activeCount":100,"soonestReadout":1437},[10459],{"nctId":10460,"briefTitle":10461,"status":116,"phases":10462,"primaryCompletion":1437,"completion":2122,"start":10463,"enrollment":1018,"conditions":10464,"interventions":10466},"NCT07059338","Dual EGFR\u002FHER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer",[93],"2025-07-11",[10465,3655],"HER2 Positive",[10451],{"trials":10468,"activeCount":104},[],{"trials":10470,"activeCount":104},[],{"trials":10472,"activeCount":104},[],{"intervention":2380,"totalTrials":100,"cells":10474},{"EARLY_PHASE1":10475,"PHASE1":10477,"PHASE2":10479,"PHASE3":10485,"PHASE4":10487,"NA":10489},{"trials":10476,"activeCount":104},[],{"trials":10478,"activeCount":104},[],{"trials":10480,"activeCount":100,"soonestReadout":1277},[10481],{"nctId":2374,"briefTitle":2375,"status":143,"phases":10482,"primaryCompletion":1277,"completion":404,"start":217,"enrollment":942,"conditions":10483,"interventions":10484},[93],[2378],[69,2380],{"trials":10486,"activeCount":104},[],{"trials":10488,"activeCount":104},[],{"trials":10490,"activeCount":104},[],{"intervention":10492,"totalTrials":100,"cells":10493},"Pucotenlimab combination with Vorolanib",{"EARLY_PHASE1":10494,"PHASE1":10496,"PHASE2":10498,"PHASE3":10509,"PHASE4":10511,"NA":10513},{"trials":10495,"activeCount":104},[],{"trials":10497,"activeCount":104},[],{"trials":10499,"activeCount":100,"soonestReadout":380},[10500],{"nctId":10501,"briefTitle":10502,"status":143,"phases":10503,"primaryCompletion":380,"completion":380,"start":10504,"enrollment":38,"conditions":10505,"interventions":10508},"NCT07386158","Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC",[93],"2025-07-10",[10506,10507,4554],"Vorolanib","Clear Cell Renal Cell Carcinoma (ccRCC)",[10492],{"trials":10510,"activeCount":104},[],{"trials":10512,"activeCount":104},[],{"trials":10514,"activeCount":104},[],{"intervention":10516,"totalTrials":100,"cells":10517},"Linperlisib in combination with CHOP",{"EARLY_PHASE1":10518,"PHASE1":10520,"PHASE2":10522,"PHASE3":10531,"PHASE4":10533,"NA":10535},{"trials":10519,"activeCount":104},[],{"trials":10521,"activeCount":104},[],{"trials":10523,"activeCount":100,"soonestReadout":4044},[10524],{"nctId":10525,"briefTitle":10526,"status":143,"phases":10527,"primaryCompletion":4044,"completion":419,"start":10528,"enrollment":205,"conditions":10529,"interventions":10530},"NCT05949944","Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma",[92,93],"2023-08-15",[7430],[10516],{"trials":10532,"activeCount":104},[],{"trials":10534,"activeCount":104},[],{"trials":10536,"activeCount":104},[],{"intervention":10538,"totalTrials":100,"cells":10539},"Concurrent penpulimab and AVD",{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10544,"PHASE3":10555,"PHASE4":10557,"NA":10559},{"trials":10541,"activeCount":104},[],{"trials":10543,"activeCount":104},[],{"trials":10545,"activeCount":100,"soonestReadout":146},[10546],{"nctId":10547,"briefTitle":10548,"status":143,"phases":10549,"primaryCompletion":146,"completion":669,"start":10550,"enrollment":1450,"conditions":10551,"interventions":10553},"NCT05949931","Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma",[93],"2023-10-01",[10552],"Classic Hodgkin Lymphoma",[10538,10554],"Sequential penpulimab and AVD",{"trials":10556,"activeCount":104},[],{"trials":10558,"activeCount":104},[],{"trials":10560,"activeCount":104},[],{"intervention":10554,"totalTrials":100,"cells":10562},{"EARLY_PHASE1":10563,"PHASE1":10565,"PHASE2":10567,"PHASE3":10573,"PHASE4":10575,"NA":10577},{"trials":10564,"activeCount":104},[],{"trials":10566,"activeCount":104},[],{"trials":10568,"activeCount":100,"soonestReadout":146},[10569],{"nctId":10547,"briefTitle":10548,"status":143,"phases":10570,"primaryCompletion":146,"completion":669,"start":10550,"enrollment":1450,"conditions":10571,"interventions":10572},[93],[10552],[10538,10554],{"trials":10574,"activeCount":104},[],{"trials":10576,"activeCount":104},[],{"trials":10578,"activeCount":104},[],{"intervention":3657,"totalTrials":100,"cells":10580},{"EARLY_PHASE1":10581,"PHASE1":10583,"PHASE2":10585,"PHASE3":10591,"PHASE4":10593,"NA":10595},{"trials":10582,"activeCount":104},[],{"trials":10584,"activeCount":104},[],{"trials":10586,"activeCount":100,"soonestReadout":3651},[10587],{"nctId":3648,"briefTitle":3649,"status":143,"phases":10588,"primaryCompletion":3651,"completion":3652,"start":3653,"enrollment":205,"conditions":10589,"interventions":10590},[93],[3655],[602,3657],{"trials":10592,"activeCount":104},[],{"trials":10594,"activeCount":104},[],{"trials":10596,"activeCount":104},[],{"intervention":10598,"totalTrials":100,"cells":10599},"Intensified Therapy",{"EARLY_PHASE1":10600,"PHASE1":10602,"PHASE2":10604,"PHASE3":10613,"PHASE4":10615,"NA":10617},{"trials":10601,"activeCount":104},[],{"trials":10603,"activeCount":104},[],{"trials":10605,"activeCount":100,"soonestReadout":7933},[10606],{"nctId":10607,"briefTitle":10608,"status":143,"phases":10609,"primaryCompletion":7933,"completion":380,"start":9343,"enrollment":942,"conditions":10610,"interventions":10611},"NCT07501351","Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line",[93],[3017],[10598,10612],"Conversion Therapy",{"trials":10614,"activeCount":104},[],{"trials":10616,"activeCount":104},[],{"trials":10618,"activeCount":104},[],{"intervention":10612,"totalTrials":100,"cells":10620},{"EARLY_PHASE1":10621,"PHASE1":10623,"PHASE2":10625,"PHASE3":10631,"PHASE4":10633,"NA":10635},{"trials":10622,"activeCount":104},[],{"trials":10624,"activeCount":104},[],{"trials":10626,"activeCount":100,"soonestReadout":7933},[10627],{"nctId":10607,"briefTitle":10608,"status":143,"phases":10628,"primaryCompletion":7933,"completion":380,"start":9343,"enrollment":942,"conditions":10629,"interventions":10630},[93],[3017],[10598,10612],{"trials":10632,"activeCount":104},[],{"trials":10634,"activeCount":104},[],{"trials":10636,"activeCount":104},[],{"intervention":8398,"totalTrials":100,"cells":10638},{"EARLY_PHASE1":10639,"PHASE1":10641,"PHASE2":10643,"PHASE3":10649,"PHASE4":10651,"NA":10653},{"trials":10640,"activeCount":104},[],{"trials":10642,"activeCount":104},[],{"trials":10644,"activeCount":100,"soonestReadout":8393},[10645],{"nctId":8390,"briefTitle":8391,"status":116,"phases":10646,"primaryCompletion":8393,"completion":8394,"start":8254,"enrollment":7372,"conditions":10647,"interventions":10648},[92,93],[8264],[8397,8398,7453],{"trials":10650,"activeCount":104},[],{"trials":10652,"activeCount":104},[],{"trials":10654,"activeCount":104},[],{"intervention":10656,"totalTrials":100,"cells":10657},"Zanubrutinib , Thiotepa",{"EARLY_PHASE1":10658,"PHASE1":10660,"PHASE2":10662,"PHASE3":10674,"PHASE4":10676,"NA":10678},{"trials":10659,"activeCount":104},[],{"trials":10661,"activeCount":104},[],{"trials":10663,"activeCount":100,"soonestReadout":313},[10664],{"nctId":10665,"briefTitle":10666,"status":116,"phases":10667,"primaryCompletion":313,"completion":313,"start":238,"enrollment":32,"conditions":10668,"interventions":10671},"NCT06646211","High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)",[93],[10669,10670],"Primary Central Nervous System Lymphoma (PCNSL)","Non Hodgkin Lymphoma (NHL)",[10656,10672,10673],"Methotrexate , Thiotepa and Zanubrutinib","ASCT±Zanubrutinib",{"trials":10675,"activeCount":104},[],{"trials":10677,"activeCount":104},[],{"trials":10679,"activeCount":104},[],{"intervention":10672,"totalTrials":100,"cells":10681},{"EARLY_PHASE1":10682,"PHASE1":10684,"PHASE2":10686,"PHASE3":10692,"PHASE4":10694,"NA":10696},{"trials":10683,"activeCount":104},[],{"trials":10685,"activeCount":104},[],{"trials":10687,"activeCount":100,"soonestReadout":313},[10688],{"nctId":10665,"briefTitle":10666,"status":116,"phases":10689,"primaryCompletion":313,"completion":313,"start":238,"enrollment":32,"conditions":10690,"interventions":10691},[93],[10669,10670],[10656,10672,10673],{"trials":10693,"activeCount":104},[],{"trials":10695,"activeCount":104},[],{"trials":10697,"activeCount":104},[],{"intervention":10673,"totalTrials":100,"cells":10699},{"EARLY_PHASE1":10700,"PHASE1":10702,"PHASE2":10704,"PHASE3":10710,"PHASE4":10712,"NA":10714},{"trials":10701,"activeCount":104},[],{"trials":10703,"activeCount":104},[],{"trials":10705,"activeCount":100,"soonestReadout":313},[10706],{"nctId":10665,"briefTitle":10666,"status":116,"phases":10707,"primaryCompletion":313,"completion":313,"start":238,"enrollment":32,"conditions":10708,"interventions":10709},[93],[10669,10670],[10656,10672,10673],{"trials":10711,"activeCount":104},[],{"trials":10713,"activeCount":104},[],{"trials":10715,"activeCount":104},[],{"intervention":4434,"totalTrials":100,"cells":10717},{"EARLY_PHASE1":10718,"PHASE1":10720,"PHASE2":10722,"PHASE3":10728,"PHASE4":10730,"NA":10732},{"trials":10719,"activeCount":104},[],{"trials":10721,"activeCount":104},[],{"trials":10723,"activeCount":100,"soonestReadout":4427},[10724],{"nctId":4424,"briefTitle":4425,"status":116,"phases":10725,"primaryCompletion":4427,"completion":4428,"start":4429,"enrollment":4430,"conditions":10726,"interventions":10727},[93],[4432],[4434,4415],{"trials":10729,"activeCount":104},[],{"trials":10731,"activeCount":104},[],{"trials":10733,"activeCount":104},[],{"intervention":1716,"totalTrials":100,"cells":10735},{"EARLY_PHASE1":10736,"PHASE1":10738,"PHASE2":10740,"PHASE3":10746,"PHASE4":10748,"NA":10750},{"trials":10737,"activeCount":104},[],{"trials":10739,"activeCount":104},[],{"trials":10741,"activeCount":100,"soonestReadout":379},[10742],{"nctId":1708,"briefTitle":1709,"status":300,"phases":10743,"primaryCompletion":379,"completion":380,"start":1711,"enrollment":1712,"conditions":10744,"interventions":10745},[93],[1714],[1122,483,1716],{"trials":10747,"activeCount":104},[],{"trials":10749,"activeCount":104},[],{"trials":10751,"activeCount":104},[],{"intervention":3889,"totalTrials":100,"cells":10753},{"EARLY_PHASE1":10754,"PHASE1":10756,"PHASE2":10758,"PHASE3":10764,"PHASE4":10766,"NA":10768},{"trials":10755,"activeCount":104},[],{"trials":10757,"activeCount":104},[],{"trials":10759,"activeCount":100,"soonestReadout":358},[10760],{"nctId":3881,"briefTitle":3882,"status":143,"phases":10761,"primaryCompletion":358,"completion":1480,"start":3884,"enrollment":472,"conditions":10762,"interventions":10763},[92,93],[37,3886,3887],[3889,517,3890],{"trials":10765,"activeCount":104},[],{"trials":10767,"activeCount":104},[],{"trials":10769,"activeCount":104},[],{"intervention":3890,"totalTrials":100,"cells":10771},{"EARLY_PHASE1":10772,"PHASE1":10774,"PHASE2":10776,"PHASE3":10782,"PHASE4":10784,"NA":10786},{"trials":10773,"activeCount":104},[],{"trials":10775,"activeCount":104},[],{"trials":10777,"activeCount":100,"soonestReadout":358},[10778],{"nctId":3881,"briefTitle":3882,"status":143,"phases":10779,"primaryCompletion":358,"completion":1480,"start":3884,"enrollment":472,"conditions":10780,"interventions":10781},[92,93],[37,3886,3887],[3889,517,3890],{"trials":10783,"activeCount":104},[],{"trials":10785,"activeCount":104},[],{"trials":10787,"activeCount":104},[],{"intervention":9346,"totalTrials":100,"cells":10789},{"EARLY_PHASE1":10790,"PHASE1":10792,"PHASE2":10794,"PHASE3":10800,"PHASE4":10802,"NA":10804},{"trials":10791,"activeCount":104},[],{"trials":10793,"activeCount":104},[],{"trials":10795,"activeCount":100,"soonestReadout":9342},[10796],{"nctId":9339,"briefTitle":9340,"status":116,"phases":10797,"primaryCompletion":9342,"completion":2122,"start":9343,"enrollment":205,"conditions":10798,"interventions":10799},[93],[3830],[9346,9330],{"trials":10801,"activeCount":104},[],{"trials":10803,"activeCount":104},[],{"trials":10805,"activeCount":104},[],{"intervention":10807,"totalTrials":100,"cells":10808},"Paclitaxel + Ifosfamide + Cisplatin & Toripalimab",{"EARLY_PHASE1":10809,"PHASE1":10811,"PHASE2":10813,"PHASE3":10821,"PHASE4":10823,"NA":10825},{"trials":10810,"activeCount":104},[],{"trials":10812,"activeCount":104},[],{"trials":10814,"activeCount":100,"soonestReadout":303},[10815],{"nctId":10816,"briefTitle":10817,"status":143,"phases":10818,"primaryCompletion":303,"completion":404,"start":1093,"enrollment":959,"conditions":10819,"interventions":10820},"NCT06415318","TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer",[93],[335],[10807],{"trials":10822,"activeCount":104},[],{"trials":10824,"activeCount":104},[],{"trials":10826,"activeCount":104},[],{"intervention":10828,"totalTrials":100,"cells":10829},"SCR Regimen Sequential with R-CHOP and Maintenance Therapy",{"EARLY_PHASE1":10830,"PHASE1":10832,"PHASE2":10834,"PHASE3":10843,"PHASE4":10845,"NA":10847},{"trials":10831,"activeCount":104},[],{"trials":10833,"activeCount":104},[],{"trials":10835,"activeCount":100,"soonestReadout":119},[10836],{"nctId":10837,"briefTitle":10838,"status":300,"phases":10839,"primaryCompletion":119,"completion":646,"start":1269,"enrollment":32,"conditions":10840,"interventions":10842},"NCT07538180","Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC\u002FBCL2 Double-Expressor DLBCL",[93],[10841],"Newly Diagnosed MYC\u002FBCL2 Double-expressor DLBCL",[10828],{"trials":10844,"activeCount":104},[],{"trials":10846,"activeCount":104},[],{"trials":10848,"activeCount":104},[],{"intervention":10850,"totalTrials":100,"cells":10851},"Anlotinib+Cyclophosphamide+Vinorelbine",{"EARLY_PHASE1":10852,"PHASE1":10854,"PHASE2":10856,"PHASE3":10868,"PHASE4":10870,"NA":10872},{"trials":10853,"activeCount":104},[],{"trials":10855,"activeCount":104},[],{"trials":10857,"activeCount":100,"soonestReadout":10862},[10858],{"nctId":10859,"briefTitle":10860,"status":116,"phases":10861,"primaryCompletion":10862,"completion":2122,"start":2206,"enrollment":1389,"conditions":10863,"interventions":10866},"NCT07137884","Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children",[93],"2028-10-30",[10864,10865],"Rhabdomyosarcoma Recurrent","Maintenance Treatment",[10850,10867],"Cyclophosphamide+Vinorelbine",{"trials":10869,"activeCount":104},[],{"trials":10871,"activeCount":104},[],{"trials":10873,"activeCount":104},[],{"intervention":10867,"totalTrials":100,"cells":10875},{"EARLY_PHASE1":10876,"PHASE1":10878,"PHASE2":10880,"PHASE3":10886,"PHASE4":10888,"NA":10890},{"trials":10877,"activeCount":104},[],{"trials":10879,"activeCount":104},[],{"trials":10881,"activeCount":100,"soonestReadout":10862},[10882],{"nctId":10859,"briefTitle":10860,"status":116,"phases":10883,"primaryCompletion":10862,"completion":2122,"start":2206,"enrollment":1389,"conditions":10884,"interventions":10885},[93],[10864,10865],[10850,10867],{"trials":10887,"activeCount":104},[],{"trials":10889,"activeCount":104},[],{"trials":10891,"activeCount":104},[],{"intervention":10893,"totalTrials":100,"cells":10894},"Arsenous Acid plus Chemotherapy",{"EARLY_PHASE1":10895,"PHASE1":10897,"PHASE2":10899,"PHASE3":10910,"PHASE4":10912,"NA":10914},{"trials":10896,"activeCount":104},[],{"trials":10898,"activeCount":104},[],{"trials":10900,"activeCount":100,"soonestReadout":10905},[10901],{"nctId":10902,"briefTitle":10903,"status":143,"phases":10904,"primaryCompletion":10905,"completion":10906,"start":10907,"enrollment":3748,"conditions":10908,"interventions":10909},"NCT06678048","Arsenous Acid for Refractory Triple-Negative Breast Cancer",[93],"2026-04-22","2026-10-23","2024-10-23",[28],[10893],{"trials":10911,"activeCount":104},[],{"trials":10913,"activeCount":104},[],{"trials":10915,"activeCount":104},[],{"intervention":10917,"totalTrials":100,"cells":10918},"Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1",{"EARLY_PHASE1":10919,"PHASE1":10921,"PHASE2":10923,"PHASE3":10932,"PHASE4":10934,"NA":10936},{"trials":10920,"activeCount":104},[],{"trials":10922,"activeCount":104},[],{"trials":10924,"activeCount":100,"soonestReadout":3651},[10925],{"nctId":10926,"briefTitle":10927,"status":143,"phases":10928,"primaryCompletion":3651,"completion":3651,"start":4739,"enrollment":26,"conditions":10929,"interventions":10931},"NCT06467799","Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC",[93],[19,10930],"Beyond Milan Criteria",[10917],{"trials":10933,"activeCount":104},[],{"trials":10935,"activeCount":104},[],{"trials":10937,"activeCount":104},[],{"intervention":10939,"totalTrials":100,"cells":10940},"Tislelizumab Combined With Chemotherapy",{"EARLY_PHASE1":10941,"PHASE1":10943,"PHASE2":10945,"PHASE3":10956,"PHASE4":10958,"NA":10960},{"trials":10942,"activeCount":104},[],{"trials":10944,"activeCount":104},[],{"trials":10946,"activeCount":100,"soonestReadout":10951},[10947],{"nctId":10948,"briefTitle":10949,"status":116,"phases":10950,"primaryCompletion":10951,"completion":10951,"start":6548,"enrollment":1727,"conditions":10952,"interventions":10955},"NCT06614231","Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA\u002FN2 Non-small Cell Lung Cancer",[93],"2028-09-08",[10953,10954],"NSCLC, Stage IIIA","NSCLC (non-small Cell Lung Cancer)",[10939],{"trials":10957,"activeCount":104},[],{"trials":10959,"activeCount":104},[],{"trials":10961,"activeCount":104},[],{"intervention":10963,"totalTrials":100,"cells":10964},"Recaticimab and Adebrelimab",{"EARLY_PHASE1":10965,"PHASE1":10967,"PHASE2":10969,"PHASE3":10981,"PHASE4":10983,"NA":10985},{"trials":10966,"activeCount":104},[],{"trials":10968,"activeCount":104},[],{"trials":10970,"activeCount":100,"soonestReadout":10975},[10971],{"nctId":10972,"briefTitle":10973,"status":116,"phases":10974,"primaryCompletion":10975,"completion":10976,"start":10504,"enrollment":26,"conditions":10977,"interventions":10979},"NCT07062328","A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC",[93],"2026-12-10","2028-04-20",[10978],"Biliary Tract Carcinoma",[10963,10980],"GP chemotherapy",{"trials":10982,"activeCount":104},[],{"trials":10984,"activeCount":104},[],{"trials":10986,"activeCount":104},[],{"intervention":10980,"totalTrials":100,"cells":10988},{"EARLY_PHASE1":10989,"PHASE1":10991,"PHASE2":10993,"PHASE3":10999,"PHASE4":11001,"NA":11003},{"trials":10990,"activeCount":104},[],{"trials":10992,"activeCount":104},[],{"trials":10994,"activeCount":100,"soonestReadout":10975},[10995],{"nctId":10972,"briefTitle":10973,"status":116,"phases":10996,"primaryCompletion":10975,"completion":10976,"start":10504,"enrollment":26,"conditions":10997,"interventions":10998},[93],[10978],[10963,10980],{"trials":11000,"activeCount":104},[],{"trials":11002,"activeCount":104},[],{"trials":11004,"activeCount":104},[],{"intervention":11006,"totalTrials":100,"cells":11007},"Tislelizumab combined with Liposomal mitoxantrone hydrochloride",{"EARLY_PHASE1":11008,"PHASE1":11010,"PHASE2":11012,"PHASE3":11024,"PHASE4":11026,"NA":11028},{"trials":11009,"activeCount":104},[],{"trials":11011,"activeCount":104},[],{"trials":11013,"activeCount":100,"soonestReadout":8229},[11014],{"nctId":11015,"briefTitle":11016,"status":300,"phases":11017,"primaryCompletion":8229,"completion":11018,"start":11019,"enrollment":461,"conditions":11020,"interventions":11022},"NCT05464433","Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer\u002FT Cell Lymphoma",[92,93],"2025-11-30","2022-06-23",[11021],"Extranodal Natural Killer T Cell Lymphoma",[11006,11023],"Maintenance of tislelizumab",{"trials":11025,"activeCount":104},[],{"trials":11027,"activeCount":104},[],{"trials":11029,"activeCount":104},[],{"intervention":11023,"totalTrials":100,"cells":11031},{"EARLY_PHASE1":11032,"PHASE1":11034,"PHASE2":11036,"PHASE3":11042,"PHASE4":11044,"NA":11046},{"trials":11033,"activeCount":104},[],{"trials":11035,"activeCount":104},[],{"trials":11037,"activeCount":100,"soonestReadout":8229},[11038],{"nctId":11015,"briefTitle":11016,"status":300,"phases":11039,"primaryCompletion":8229,"completion":11018,"start":11019,"enrollment":461,"conditions":11040,"interventions":11041},[92,93],[11021],[11006,11023],{"trials":11043,"activeCount":104},[],{"trials":11045,"activeCount":104},[],{"trials":11047,"activeCount":104},[],{"intervention":11049,"totalTrials":100,"cells":11050},"Tunlametinib + Cetuximab β",{"EARLY_PHASE1":11051,"PHASE1":11053,"PHASE2":11055,"PHASE3":11065,"PHASE4":11067,"NA":11069},{"trials":11052,"activeCount":104},[],{"trials":11054,"activeCount":104},[],{"trials":11056,"activeCount":100,"soonestReadout":1210},[11057],{"nctId":11058,"briefTitle":11059,"status":116,"phases":11060,"primaryCompletion":1210,"completion":11061,"start":3653,"enrollment":280,"conditions":11062,"interventions":11063},"NCT07463677","Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[93],"2029-03-31",[5073],[11049,11064],"Tunlametinib + Fulzerasib",{"trials":11066,"activeCount":104},[],{"trials":11068,"activeCount":104},[],{"trials":11070,"activeCount":104},[],{"intervention":11064,"totalTrials":100,"cells":11072},{"EARLY_PHASE1":11073,"PHASE1":11075,"PHASE2":11077,"PHASE3":11083,"PHASE4":11085,"NA":11087},{"trials":11074,"activeCount":104},[],{"trials":11076,"activeCount":104},[],{"trials":11078,"activeCount":100,"soonestReadout":1210},[11079],{"nctId":11058,"briefTitle":11059,"status":116,"phases":11080,"primaryCompletion":1210,"completion":11061,"start":3653,"enrollment":280,"conditions":11081,"interventions":11082},[93],[5073],[11049,11064],{"trials":11084,"activeCount":104},[],{"trials":11086,"activeCount":104},[],{"trials":11088,"activeCount":104},[],{"intervention":11090,"totalTrials":100,"cells":11091},"Sintilimab plus chemotherapy",{"EARLY_PHASE1":11092,"PHASE1":11094,"PHASE2":11096,"PHASE3":11106,"PHASE4":11108,"NA":11110},{"trials":11093,"activeCount":104},[],{"trials":11095,"activeCount":104},[],{"trials":11097,"activeCount":100,"soonestReadout":1227},[11098],{"nctId":11099,"briefTitle":11100,"status":143,"phases":11101,"primaryCompletion":1227,"completion":1015,"start":11102,"enrollment":6505,"conditions":11103,"interventions":11104},"NCT04589754","Adriamycin and Ifosfamide Combined With Sintilimab",[93],"2021-07-26",[4686],[11090,11105],"Adriamycin-based chemotherapy",{"trials":11107,"activeCount":104},[],{"trials":11109,"activeCount":104},[],{"trials":11111,"activeCount":104},[],{"intervention":11105,"totalTrials":100,"cells":11113},{"EARLY_PHASE1":11114,"PHASE1":11116,"PHASE2":11118,"PHASE3":11124,"PHASE4":11126,"NA":11128},{"trials":11115,"activeCount":104},[],{"trials":11117,"activeCount":104},[],{"trials":11119,"activeCount":100,"soonestReadout":1227},[11120],{"nctId":11099,"briefTitle":11100,"status":143,"phases":11121,"primaryCompletion":1227,"completion":1015,"start":11102,"enrollment":6505,"conditions":11122,"interventions":11123},[93],[4686],[11090,11105],{"trials":11125,"activeCount":104},[],{"trials":11127,"activeCount":104},[],{"trials":11129,"activeCount":104},[],{"intervention":320,"totalTrials":100,"cells":11131},{"EARLY_PHASE1":11132,"PHASE1":11134,"PHASE2":11136,"PHASE3":11142,"PHASE4":11144,"NA":11146},{"trials":11133,"activeCount":104},[],{"trials":11135,"activeCount":104},[],{"trials":11137,"activeCount":100,"soonestReadout":312},[11138],{"nctId":309,"briefTitle":310,"status":143,"phases":11139,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":11140,"interventions":11141},[93],[316,317,318],[320,321,225,49,322,323,324,284],{"trials":11143,"activeCount":104},[],{"trials":11145,"activeCount":104},[],{"trials":11147,"activeCount":104},[],{"intervention":323,"totalTrials":100,"cells":11149},{"EARLY_PHASE1":11150,"PHASE1":11152,"PHASE2":11154,"PHASE3":11160,"PHASE4":11162,"NA":11164},{"trials":11151,"activeCount":104},[],{"trials":11153,"activeCount":104},[],{"trials":11155,"activeCount":100,"soonestReadout":312},[11156],{"nctId":309,"briefTitle":310,"status":143,"phases":11157,"primaryCompletion":312,"completion":313,"start":238,"enrollment":314,"conditions":11158,"interventions":11159},[93],[316,317,318],[320,321,225,49,322,323,324,284],{"trials":11161,"activeCount":104},[],{"trials":11163,"activeCount":104},[],{"trials":11165,"activeCount":104},[],{"intervention":7486,"totalTrials":100,"cells":11167},{"EARLY_PHASE1":11168,"PHASE1":11170,"PHASE2":11172,"PHASE3":11178,"PHASE4":11180,"NA":11182},{"trials":11169,"activeCount":104},[],{"trials":11171,"activeCount":104},[],{"trials":11173,"activeCount":100,"soonestReadout":313},[11174],{"nctId":7480,"briefTitle":7481,"status":116,"phases":11175,"primaryCompletion":313,"completion":839,"start":1801,"enrollment":996,"conditions":11176,"interventions":11177},[92,93],[7484],[7486,5048,981],{"trials":11179,"activeCount":104},[],{"trials":11181,"activeCount":104},[],{"trials":11183,"activeCount":104},[],{"intervention":1975,"totalTrials":100,"cells":11185},{"EARLY_PHASE1":11186,"PHASE1":11188,"PHASE2":11190,"PHASE3":11196,"PHASE4":11198,"NA":11200},{"trials":11187,"activeCount":104},[],{"trials":11189,"activeCount":104},[],{"trials":11191,"activeCount":100,"soonestReadout":499},[11192],{"nctId":1969,"briefTitle":1970,"status":143,"phases":11193,"primaryCompletion":499,"completion":499,"start":1953,"enrollment":911,"conditions":11194,"interventions":11195},[93],[1973],[1975,272,254,271],{"trials":11197,"activeCount":104},[],{"trials":11199,"activeCount":104},[],{"trials":11201,"activeCount":104},[],{"intervention":2684,"totalTrials":100,"cells":11203},{"EARLY_PHASE1":11204,"PHASE1":11206,"PHASE2":11208,"PHASE3":11214,"PHASE4":11216,"NA":11218},{"trials":11205,"activeCount":104},[],{"trials":11207,"activeCount":104},[],{"trials":11209,"activeCount":100,"soonestReadout":2679},[11210],{"nctId":2676,"briefTitle":2677,"status":300,"phases":11211,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":2419,"conditions":11212,"interventions":11213},[93],[22],[2683,1958,2684,2685],{"trials":11215,"activeCount":104},[],{"trials":11217,"activeCount":104},[],{"trials":11219,"activeCount":104},[],{"intervention":11221,"totalTrials":100,"cells":11222},"Trilaciclib+R-CHOP",{"EARLY_PHASE1":11223,"PHASE1":11225,"PHASE2":11227,"PHASE3":11236,"PHASE4":11238,"NA":11240},{"trials":11224,"activeCount":104},[],{"trials":11226,"activeCount":104},[],{"trials":11228,"activeCount":100,"soonestReadout":1238},[11229],{"nctId":11230,"briefTitle":11231,"status":143,"phases":11232,"primaryCompletion":1238,"completion":404,"start":11233,"enrollment":9921,"conditions":11234,"interventions":11235},"NCT06569485","A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients",[93],"2024-05-23",[3150],[11221],{"trials":11237,"activeCount":104},[],{"trials":11239,"activeCount":104},[],{"trials":11241,"activeCount":104},[],{"intervention":11243,"totalTrials":100,"cells":11244},"Mitoxantrone Hydrochloride Liposome & Enlonstobart",{"EARLY_PHASE1":11245,"PHASE1":11247,"PHASE2":11249,"PHASE3":11258,"PHASE4":11260,"NA":11262},{"trials":11246,"activeCount":104},[],{"trials":11248,"activeCount":104},[],{"trials":11250,"activeCount":100,"soonestReadout":380},[11251],{"nctId":11252,"briefTitle":11253,"status":116,"phases":11254,"primaryCompletion":380,"completion":119,"start":11255,"enrollment":348,"conditions":11256,"interventions":11257},"NCT07288814","Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)",[92,93],"2025-12-08",[9722],[11243],{"trials":11259,"activeCount":104},[],{"trials":11261,"activeCount":104},[],{"trials":11263,"activeCount":104},[],{"intervention":11265,"totalTrials":100,"cells":11266},"Toripalimab Combined With CAV\u002FIE chemotherapy",{"EARLY_PHASE1":11267,"PHASE1":11269,"PHASE2":11271,"PHASE3":11281,"PHASE4":11283,"NA":11285},{"trials":11268,"activeCount":104},[],{"trials":11270,"activeCount":104},[],{"trials":11272,"activeCount":100,"soonestReadout":1874},[11273],{"nctId":11274,"briefTitle":11275,"status":143,"phases":11276,"primaryCompletion":1874,"completion":236,"start":11277,"enrollment":1192,"conditions":11278,"interventions":11279},"NCT04589741","Toripalimab Combined With CAV\u002FIE Regimen",[93],"2020-10-23",[4686],[11265,11280],"CAV\u002FIE alternate chemotherapy",{"trials":11282,"activeCount":104},[],{"trials":11284,"activeCount":104},[],{"trials":11286,"activeCount":104},[],{"intervention":11280,"totalTrials":100,"cells":11288},{"EARLY_PHASE1":11289,"PHASE1":11291,"PHASE2":11293,"PHASE3":11299,"PHASE4":11301,"NA":11303},{"trials":11290,"activeCount":104},[],{"trials":11292,"activeCount":104},[],{"trials":11294,"activeCount":100,"soonestReadout":1874},[11295],{"nctId":11274,"briefTitle":11275,"status":143,"phases":11296,"primaryCompletion":1874,"completion":236,"start":11277,"enrollment":1192,"conditions":11297,"interventions":11298},[93],[4686],[11265,11280],{"trials":11300,"activeCount":104},[],{"trials":11302,"activeCount":104},[],{"trials":11304,"activeCount":104},[],{"intervention":7770,"totalTrials":100,"cells":11306},{"EARLY_PHASE1":11307,"PHASE1":11309,"PHASE2":11311,"PHASE3":11317,"PHASE4":11319,"NA":11321},{"trials":11308,"activeCount":104},[],{"trials":11310,"activeCount":104},[],{"trials":11312,"activeCount":100,"soonestReadout":1302},[11313],{"nctId":7763,"briefTitle":7764,"status":143,"phases":11314,"primaryCompletion":1302,"completion":7766,"start":7767,"enrollment":205,"conditions":11315,"interventions":11316},[93],[1793],[7770,7497],{"trials":11318,"activeCount":104},[],{"trials":11320,"activeCount":104},[],{"trials":11322,"activeCount":104},[],{"intervention":1992,"totalTrials":100,"cells":11324},{"EARLY_PHASE1":11325,"PHASE1":11327,"PHASE2":11329,"PHASE3":11335,"PHASE4":11337,"NA":11339},{"trials":11326,"activeCount":104},[],{"trials":11328,"activeCount":104},[],{"trials":11330,"activeCount":100,"soonestReadout":236},[11331],{"nctId":1984,"briefTitle":1985,"status":143,"phases":11332,"primaryCompletion":236,"completion":380,"start":1064,"enrollment":1987,"conditions":11333,"interventions":11334},[93],[1020,726,1989,318,1990],[1992,272,1993],{"trials":11336,"activeCount":104},[],{"trials":11338,"activeCount":104},[],{"trials":11340,"activeCount":104},[],{"intervention":1993,"totalTrials":100,"cells":11342},{"EARLY_PHASE1":11343,"PHASE1":11345,"PHASE2":11347,"PHASE3":11353,"PHASE4":11355,"NA":11357},{"trials":11344,"activeCount":104},[],{"trials":11346,"activeCount":104},[],{"trials":11348,"activeCount":100,"soonestReadout":236},[11349],{"nctId":1984,"briefTitle":1985,"status":143,"phases":11350,"primaryCompletion":236,"completion":380,"start":1064,"enrollment":1987,"conditions":11351,"interventions":11352},[93],[1020,726,1989,318,1990],[1992,272,1993],{"trials":11354,"activeCount":104},[],{"trials":11356,"activeCount":104},[],{"trials":11358,"activeCount":104},[],{"intervention":11360,"totalTrials":100,"cells":11361},"GP+Penpulimab+Anlotinib",{"EARLY_PHASE1":11362,"PHASE1":11364,"PHASE2":11366,"PHASE3":11376,"PHASE4":11378,"NA":11380},{"trials":11363,"activeCount":104},[],{"trials":11365,"activeCount":104},[],{"trials":11367,"activeCount":100,"soonestReadout":238},[11368],{"nctId":11369,"briefTitle":11370,"status":300,"phases":11371,"primaryCompletion":238,"completion":312,"start":11372,"enrollment":1501,"conditions":11373,"interventions":11374},"NCT05193617","Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma",[93],"2022-01-20",[16],[11360,11375],"GP+Penpulimab",{"trials":11377,"activeCount":104},[],{"trials":11379,"activeCount":104},[],{"trials":11381,"activeCount":104},[],{"intervention":11375,"totalTrials":100,"cells":11383},{"EARLY_PHASE1":11384,"PHASE1":11386,"PHASE2":11388,"PHASE3":11394,"PHASE4":11396,"NA":11398},{"trials":11385,"activeCount":104},[],{"trials":11387,"activeCount":104},[],{"trials":11389,"activeCount":100,"soonestReadout":238},[11390],{"nctId":11369,"briefTitle":11370,"status":300,"phases":11391,"primaryCompletion":238,"completion":312,"start":11372,"enrollment":1501,"conditions":11392,"interventions":11393},[93],[16],[11360,11375],{"trials":11395,"activeCount":104},[],{"trials":11397,"activeCount":104},[],{"trials":11399,"activeCount":104},[],{"intervention":11401,"totalTrials":100,"cells":11402},"Tunlametinib+PD-1 mAb",{"EARLY_PHASE1":11403,"PHASE1":11405,"PHASE2":11407,"PHASE3":11416,"PHASE4":11418,"NA":11420},{"trials":11404,"activeCount":104},[],{"trials":11406,"activeCount":104},[],{"trials":11408,"activeCount":100,"soonestReadout":678},[11409],{"nctId":11410,"briefTitle":11411,"status":116,"phases":11412,"primaryCompletion":678,"completion":678,"start":597,"enrollment":10173,"conditions":11413,"interventions":11415},"NCT07507526","A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer",[93],[11414],"Gastric Adenocarcinoma",[11401],{"trials":11417,"activeCount":104},[],{"trials":11419,"activeCount":104},[],{"trials":11421,"activeCount":104},[],{"intervention":2004,"totalTrials":100,"cells":11423},{"EARLY_PHASE1":11424,"PHASE1":11426,"PHASE2":11428,"PHASE3":11434,"PHASE4":11436,"NA":11438},{"trials":11425,"activeCount":104},[],{"trials":11427,"activeCount":104},[],{"trials":11429,"activeCount":100,"soonestReadout":1998},[11430],{"nctId":1995,"briefTitle":1996,"status":116,"phases":11431,"primaryCompletion":1998,"completion":1999,"start":2000,"enrollment":2001,"conditions":11432,"interventions":11433},[92,93],[25],[2004,272],{"trials":11435,"activeCount":104},[],{"trials":11437,"activeCount":104},[],{"trials":11439,"activeCount":104},[],{"intervention":7936,"totalTrials":100,"cells":11441},{"EARLY_PHASE1":11442,"PHASE1":11444,"PHASE2":11446,"PHASE3":11452,"PHASE4":11454,"NA":11456},{"trials":11443,"activeCount":104},[],{"trials":11445,"activeCount":104},[],{"trials":11447,"activeCount":100,"soonestReadout":7933},[11448],{"nctId":7930,"briefTitle":7931,"status":143,"phases":11449,"primaryCompletion":7933,"completion":1942,"start":2458,"enrollment":5071,"conditions":11450,"interventions":11451},[93],[7081],[7936,541],{"trials":11453,"activeCount":104},[],{"trials":11455,"activeCount":104},[],{"trials":11457,"activeCount":104},[],{"intervention":2012,"totalTrials":100,"cells":11459},{"EARLY_PHASE1":11460,"PHASE1":11462,"PHASE2":11464,"PHASE3":11470,"PHASE4":11472,"NA":11474},{"trials":11461,"activeCount":104},[],{"trials":11463,"activeCount":104},[],{"trials":11465,"activeCount":100,"soonestReadout":1238},[11466],{"nctId":2006,"briefTitle":2007,"status":143,"phases":11467,"primaryCompletion":1238,"completion":1238,"start":1509,"enrollment":430,"conditions":11468,"interventions":11469},[93],[2010],[2012,272,69],{"trials":11471,"activeCount":104},[],{"trials":11473,"activeCount":104},[],{"trials":11475,"activeCount":104},[],{"intervention":7809,"totalTrials":100,"cells":11477},{"EARLY_PHASE1":11478,"PHASE1":11480,"PHASE2":11482,"PHASE3":11488,"PHASE4":11490,"NA":11492},{"trials":11479,"activeCount":104},[],{"trials":11481,"activeCount":104},[],{"trials":11483,"activeCount":100,"soonestReadout":470},[11484],{"nctId":7804,"briefTitle":7805,"status":116,"phases":11485,"primaryCompletion":470,"completion":470,"start":763,"enrollment":1109,"conditions":11486,"interventions":11487},[93],[7525],[5048,7809],{"trials":11489,"activeCount":104},[],{"trials":11491,"activeCount":104},[],{"trials":11493,"activeCount":104},[],{"intervention":11495,"totalTrials":100,"cells":11496},"TACE-HAIC+T-B",{"EARLY_PHASE1":11497,"PHASE1":11499,"PHASE2":11501,"PHASE3":11512,"PHASE4":11514,"NA":11516},{"trials":11498,"activeCount":104},[],{"trials":11500,"activeCount":104},[],{"trials":11502,"activeCount":100,"soonestReadout":1437},[11503],{"nctId":11504,"briefTitle":11505,"status":300,"phases":11506,"primaryCompletion":1437,"completion":2122,"start":11507,"enrollment":406,"conditions":11508,"interventions":11509},"NCT07380633","Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial",[93],"2026-01-23",[3006],[11495,11510,11511],"HAIC+T-B","TACE+T-B",{"trials":11513,"activeCount":104},[],{"trials":11515,"activeCount":104},[],{"trials":11517,"activeCount":104},[],{"intervention":11510,"totalTrials":100,"cells":11519},{"EARLY_PHASE1":11520,"PHASE1":11522,"PHASE2":11524,"PHASE3":11530,"PHASE4":11532,"NA":11534},{"trials":11521,"activeCount":104},[],{"trials":11523,"activeCount":104},[],{"trials":11525,"activeCount":100,"soonestReadout":1437},[11526],{"nctId":11504,"briefTitle":11505,"status":300,"phases":11527,"primaryCompletion":1437,"completion":2122,"start":11507,"enrollment":406,"conditions":11528,"interventions":11529},[93],[3006],[11495,11510,11511],{"trials":11531,"activeCount":104},[],{"trials":11533,"activeCount":104},[],{"trials":11535,"activeCount":104},[],{"intervention":11511,"totalTrials":100,"cells":11537},{"EARLY_PHASE1":11538,"PHASE1":11540,"PHASE2":11542,"PHASE3":11548,"PHASE4":11550,"NA":11552},{"trials":11539,"activeCount":104},[],{"trials":11541,"activeCount":104},[],{"trials":11543,"activeCount":100,"soonestReadout":1437},[11544],{"nctId":11504,"briefTitle":11505,"status":300,"phases":11545,"primaryCompletion":1437,"completion":2122,"start":11507,"enrollment":406,"conditions":11546,"interventions":11547},[93],[3006],[11495,11510,11511],{"trials":11549,"activeCount":104},[],{"trials":11551,"activeCount":104},[],{"trials":11553,"activeCount":104},[],{"intervention":2705,"totalTrials":100,"cells":11555},{"EARLY_PHASE1":11556,"PHASE1":11558,"PHASE2":11560,"PHASE3":11566,"PHASE4":11568,"NA":11570},{"trials":11557,"activeCount":104},[],{"trials":11559,"activeCount":104},[],{"trials":11561,"activeCount":100,"soonestReadout":2699},[11562],{"nctId":2696,"briefTitle":2697,"status":143,"phases":11563,"primaryCompletion":2699,"completion":2699,"start":2700,"enrollment":2701,"conditions":11564,"interventions":11565},[93],[2703],[2705,2372],{"trials":11567,"activeCount":104},[],{"trials":11569,"activeCount":104},[],{"trials":11571,"activeCount":104},[],{"intervention":11573,"totalTrials":100,"cells":11574},"Sintilimab with P-GEMOX Regimen",{"EARLY_PHASE1":11575,"PHASE1":11577,"PHASE2":11579,"PHASE3":11590,"PHASE4":11592,"NA":11594},{"trials":11576,"activeCount":104},[],{"trials":11578,"activeCount":104},[],{"trials":11580,"activeCount":100,"soonestReadout":11585},[11581],{"nctId":11582,"briefTitle":11583,"status":143,"phases":11584,"primaryCompletion":11585,"completion":11585,"start":11586,"enrollment":2591,"conditions":11587,"interventions":11588},"NCT06583083","Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer\u002FT Cell Lymphoma",[93],"2026-08-28","2024-10-22",[1701],[11573,11589],"P-GEMOX Regimen",{"trials":11591,"activeCount":104},[],{"trials":11593,"activeCount":104},[],{"trials":11595,"activeCount":104},[],{"intervention":11589,"totalTrials":100,"cells":11597},{"EARLY_PHASE1":11598,"PHASE1":11600,"PHASE2":11602,"PHASE3":11608,"PHASE4":11610,"NA":11612},{"trials":11599,"activeCount":104},[],{"trials":11601,"activeCount":104},[],{"trials":11603,"activeCount":100,"soonestReadout":11585},[11604],{"nctId":11582,"briefTitle":11583,"status":143,"phases":11605,"primaryCompletion":11585,"completion":11585,"start":11586,"enrollment":2591,"conditions":11606,"interventions":11607},[93],[1701],[11573,11589],{"trials":11609,"activeCount":104},[],{"trials":11611,"activeCount":104},[],{"trials":11613,"activeCount":104},[],{"intervention":11615,"totalTrials":100,"cells":11616},"Bevacizumab combined with Sintilimab",{"EARLY_PHASE1":11617,"PHASE1":11619,"PHASE2":11621,"PHASE3":11630,"PHASE4":11632,"NA":11634},{"trials":11618,"activeCount":104},[],{"trials":11620,"activeCount":104},[],{"trials":11622,"activeCount":100,"soonestReadout":11627},[11623],{"nctId":11624,"briefTitle":11625,"status":143,"phases":11626,"primaryCompletion":11627,"completion":11627,"start":8038,"enrollment":9272,"conditions":11628,"interventions":11629},"NCT06090656","Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)",[93],"2025-07-25",[19],[11615],{"trials":11631,"activeCount":104},[],{"trials":11633,"activeCount":104},[],{"trials":11635,"activeCount":104},[],{"intervention":11637,"totalTrials":100,"cells":11638},"Neoadjuvant SBRT combined with Lenvatinib and Pucotenlimab",{"EARLY_PHASE1":11639,"PHASE1":11641,"PHASE2":11643,"PHASE3":11653,"PHASE4":11655,"NA":11657},{"trials":11640,"activeCount":104},[],{"trials":11642,"activeCount":104},[],{"trials":11644,"activeCount":100,"soonestReadout":1277},[11645],{"nctId":11646,"briefTitle":11647,"status":300,"phases":11648,"primaryCompletion":1277,"completion":1277,"start":4139,"enrollment":1109,"conditions":11649,"interventions":11652},"NCT06524466","Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma",[93],[3707,11650,11651],"Macrovascular Invasion","CNLC IIIA Stage",[11637],{"trials":11654,"activeCount":104},[],{"trials":11656,"activeCount":104},[],{"trials":11658,"activeCount":104},[],{"intervention":11660,"totalTrials":100,"cells":11661},"PD-1 monoclonal antibody combined with gemcitabine and cisplatin followed by selective radiotherapy",{"EARLY_PHASE1":11662,"PHASE1":11664,"PHASE2":11666,"PHASE3":11678,"PHASE4":11680,"NA":11682},{"trials":11663,"activeCount":104},[],{"trials":11665,"activeCount":104},[],{"trials":11667,"activeCount":100,"soonestReadout":11672},[11668],{"nctId":11669,"briefTitle":11670,"status":116,"phases":11671,"primaryCompletion":11672,"completion":11673,"start":11674,"enrollment":11675,"conditions":11676,"interventions":11677},"NCT07528183","PD-1 Monoclonal Antibody Combined With Gemcitabine and Cisplatin Followed by Selective Radiotherapy for Unresectable Locally Recurrent NPC",[93],"2032-04-10","2035-04-10","2026-04-10",86,[37],[11660],{"trials":11679,"activeCount":104},[],{"trials":11681,"activeCount":104},[],{"trials":11683,"activeCount":104},[],{"intervention":11685,"totalTrials":100,"cells":11686},"lparomlimab and Tuvonralimab Injection and regorafenib and CPAOX and short-course radiotherapy",{"EARLY_PHASE1":11687,"PHASE1":11689,"PHASE2":11691,"PHASE3":11702,"PHASE4":11704,"NA":11706},{"trials":11688,"activeCount":104},[],{"trials":11690,"activeCount":104},[],{"trials":11692,"activeCount":100,"soonestReadout":11697},[11693],{"nctId":11694,"briefTitle":11695,"status":143,"phases":11696,"primaryCompletion":11697,"completion":11698,"start":8229,"enrollment":9272,"conditions":11699,"interventions":11701},"NCT06911684","Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR\u002FMSS LARC.",[93],"2026-04-30","2031-12-31",[11700],"Rectal Cancer Patients",[11685,11685],{"trials":11703,"activeCount":104},[],{"trials":11705,"activeCount":104},[],{"trials":11707,"activeCount":104},[],{"intervention":11709,"totalTrials":100,"cells":11710},"Anlotinib and Benmelstobart",{"EARLY_PHASE1":11711,"PHASE1":11713,"PHASE2":11715,"PHASE3":11725,"PHASE4":11727,"NA":11729},{"trials":11712,"activeCount":104},[],{"trials":11714,"activeCount":104},[],{"trials":11716,"activeCount":100,"soonestReadout":403},[11717],{"nctId":11718,"briefTitle":11719,"status":116,"phases":11720,"primaryCompletion":403,"completion":11721,"start":1543,"enrollment":7736,"conditions":11722,"interventions":11724},"NCT06429397","Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma",[93],"2027-05-28",[11723],"Pheochromocytoma",[11709],{"trials":11726,"activeCount":104},[],{"trials":11728,"activeCount":104},[],{"trials":11730,"activeCount":104},[],{"intervention":11732,"totalTrials":100,"cells":11733},"The combination treatment of anlotinib, penpulimab and capecitabine.",{"EARLY_PHASE1":11734,"PHASE1":11736,"PHASE2":11738,"PHASE3":11747,"PHASE4":11749,"NA":11751},{"trials":11735,"activeCount":104},[],{"trials":11737,"activeCount":104},[],{"trials":11739,"activeCount":100,"soonestReadout":11744},[11740],{"nctId":11741,"briefTitle":11742,"status":300,"phases":11743,"primaryCompletion":11744,"completion":1999,"start":88,"enrollment":514,"conditions":11745,"interventions":11746},"NCT05807880","Anlotinib, Penpulimab and Capecitabine in Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[93],"2025-07-30",[441],[11732],{"trials":11748,"activeCount":104},[],{"trials":11750,"activeCount":104},[],{"trials":11752,"activeCount":104},[],{"intervention":11754,"totalTrials":100,"cells":11755},"irinotecan liposome (II) + temozolomide + fluzoparib",{"EARLY_PHASE1":11756,"PHASE1":11758,"PHASE2":11760,"PHASE3":11770,"PHASE4":11772,"NA":11774},{"trials":11757,"activeCount":104},[],{"trials":11759,"activeCount":104},[],{"trials":11761,"activeCount":100,"soonestReadout":11766},[11762],{"nctId":11763,"briefTitle":11764,"status":143,"phases":11765,"primaryCompletion":11766,"completion":2407,"start":2389,"enrollment":333,"conditions":11767,"interventions":11769},"NCT06827717","Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma",[93],"2027-04",[11768],"Ewing Sarcoma",[11754],{"trials":11771,"activeCount":104},[],{"trials":11773,"activeCount":104},[],{"trials":11775,"activeCount":104},[],{"intervention":11777,"totalTrials":100,"cells":11778},"Dabrafenib + Trametinib",{"EARLY_PHASE1":11779,"PHASE1":11781,"PHASE2":11783,"PHASE3":11794,"PHASE4":11796,"NA":11798},{"trials":11780,"activeCount":104},[],{"trials":11782,"activeCount":104},[],{"trials":11784,"activeCount":100,"soonestReadout":850},[11785],{"nctId":11786,"briefTitle":11787,"status":116,"phases":11788,"primaryCompletion":850,"completion":851,"start":405,"enrollment":492,"conditions":11789,"interventions":11792},"NCT06054191","Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations",[93],[7985,11790,11791],"BRAF V600 Mutation","MET Exon 14 Mutation",[11777,11793],"Capmatinib",{"trials":11795,"activeCount":104},[],{"trials":11797,"activeCount":104},[],{"trials":11799,"activeCount":104},[],{"intervention":11793,"totalTrials":100,"cells":11801},{"EARLY_PHASE1":11802,"PHASE1":11804,"PHASE2":11806,"PHASE3":11812,"PHASE4":11814,"NA":11816},{"trials":11803,"activeCount":104},[],{"trials":11805,"activeCount":104},[],{"trials":11807,"activeCount":100,"soonestReadout":850},[11808],{"nctId":11786,"briefTitle":11787,"status":116,"phases":11809,"primaryCompletion":850,"completion":851,"start":405,"enrollment":492,"conditions":11810,"interventions":11811},[93],[7985,11790,11791],[11777,11793],{"trials":11813,"activeCount":104},[],{"trials":11815,"activeCount":104},[],{"trials":11817,"activeCount":104},[],{"intervention":11819,"totalTrials":100,"cells":11820},"GP plus Toripalimab Induction chemotherapy+CCRT",{"EARLY_PHASE1":11821,"PHASE1":11823,"PHASE2":11825,"PHASE3":11839,"PHASE4":11841,"NA":11843},{"trials":11822,"activeCount":104},[],{"trials":11824,"activeCount":104},[],{"trials":11826,"activeCount":100,"soonestReadout":11831},[11827],{"nctId":11828,"briefTitle":11829,"status":143,"phases":11830,"primaryCompletion":11831,"completion":11832,"start":11833,"enrollment":11834,"conditions":11835,"interventions":11836},"NCT07362979","Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma",[93],"2029-03-12","2031-03-12","2026-03-12",243,[37],[11819,11837,11838],"TP plus Toripalimab Induction chemotherapy+CCRT","TPC plus Toripalimab Induction chemotherapy+CCRT",{"trials":11840,"activeCount":104},[],{"trials":11842,"activeCount":104},[],{"trials":11844,"activeCount":104},[],{"intervention":11837,"totalTrials":100,"cells":11846},{"EARLY_PHASE1":11847,"PHASE1":11849,"PHASE2":11851,"PHASE3":11857,"PHASE4":11859,"NA":11861},{"trials":11848,"activeCount":104},[],{"trials":11850,"activeCount":104},[],{"trials":11852,"activeCount":100,"soonestReadout":11831},[11853],{"nctId":11828,"briefTitle":11829,"status":143,"phases":11854,"primaryCompletion":11831,"completion":11832,"start":11833,"enrollment":11834,"conditions":11855,"interventions":11856},[93],[37],[11819,11837,11838],{"trials":11858,"activeCount":104},[],{"trials":11860,"activeCount":104},[],{"trials":11862,"activeCount":104},[],{"intervention":11838,"totalTrials":100,"cells":11864},{"EARLY_PHASE1":11865,"PHASE1":11867,"PHASE2":11869,"PHASE3":11875,"PHASE4":11877,"NA":11879},{"trials":11866,"activeCount":104},[],{"trials":11868,"activeCount":104},[],{"trials":11870,"activeCount":100,"soonestReadout":11831},[11871],{"nctId":11828,"briefTitle":11829,"status":143,"phases":11872,"primaryCompletion":11831,"completion":11832,"start":11833,"enrollment":11834,"conditions":11873,"interventions":11874},[93],[37],[11819,11837,11838],{"trials":11876,"activeCount":104},[],{"trials":11878,"activeCount":104},[],{"trials":11880,"activeCount":104},[],{"intervention":2029,"totalTrials":100,"cells":11882},{"EARLY_PHASE1":11883,"PHASE1":11885,"PHASE2":11887,"PHASE3":11893,"PHASE4":11895,"NA":11897},{"trials":11884,"activeCount":104},[],{"trials":11886,"activeCount":104},[],{"trials":11888,"activeCount":100,"soonestReadout":380},[11889],{"nctId":2022,"briefTitle":2023,"status":143,"phases":11890,"primaryCompletion":380,"completion":380,"start":2025,"enrollment":996,"conditions":11891,"interventions":11892},[93],[2027],[412,272,2029],{"trials":11894,"activeCount":104},[],{"trials":11896,"activeCount":104},[],{"trials":11898,"activeCount":104},[],{"intervention":7496,"totalTrials":100,"cells":11900},{"EARLY_PHASE1":11901,"PHASE1":11903,"PHASE2":11905,"PHASE3":11911,"PHASE4":11913,"NA":11915},{"trials":11902,"activeCount":104},[],{"trials":11904,"activeCount":104},[],{"trials":11906,"activeCount":100,"soonestReadout":7491},[11907],{"nctId":7488,"briefTitle":7489,"status":116,"phases":11908,"primaryCompletion":7491,"completion":6572,"start":7492,"enrollment":3179,"conditions":11909,"interventions":11910},[92,93],[7494],[7496,7497,981],{"trials":11912,"activeCount":104},[],{"trials":11914,"activeCount":104},[],{"trials":11916,"activeCount":104},[],{"intervention":11918,"totalTrials":100,"cells":11919},"Capecitabine, Oxaliplatin",{"EARLY_PHASE1":11920,"PHASE1":11922,"PHASE2":11924,"PHASE3":11937,"PHASE4":11939,"NA":11941},{"trials":11921,"activeCount":104},[],{"trials":11923,"activeCount":104},[],{"trials":11925,"activeCount":100,"soonestReadout":290},[11926],{"nctId":11927,"briefTitle":11928,"status":300,"phases":11929,"primaryCompletion":290,"completion":2066,"start":11930,"enrollment":11931,"conditions":11932,"interventions":11936},"NCT03840239","TNT to Increase the Clinical Complete Response Rate for Distal LARC",[93],"2018-12-25",98,[34,11933,11934,11935],"Rectal Cancer Stage II","Rectal Cancer Stage III","Chemoradiation",[11918],{"trials":11938,"activeCount":104},[],{"trials":11940,"activeCount":104},[],{"trials":11942,"activeCount":104},[],{"intervention":5100,"totalTrials":100,"cells":11944},{"EARLY_PHASE1":11945,"PHASE1":11947,"PHASE2":11949,"PHASE3":11955,"PHASE4":11957,"NA":11959},{"trials":11946,"activeCount":104},[],{"trials":11948,"activeCount":104},[],{"trials":11950,"activeCount":100,"soonestReadout":860},[11951],{"nctId":5095,"briefTitle":5096,"status":143,"phases":11952,"primaryCompletion":860,"completion":1999,"start":73,"enrollment":280,"conditions":11953,"interventions":11954},[93],[1404,4554,318],[4487,5100],{"trials":11956,"activeCount":104},[],{"trials":11958,"activeCount":104},[],{"trials":11960,"activeCount":104},[],{"intervention":7784,"totalTrials":100,"cells":11962},{"EARLY_PHASE1":11963,"PHASE1":11965,"PHASE2":11967,"PHASE3":11973,"PHASE4":11975,"NA":11977},{"trials":11964,"activeCount":104},[],{"trials":11966,"activeCount":104},[],{"trials":11968,"activeCount":100,"soonestReadout":7779},[11969],{"nctId":7776,"briefTitle":7777,"status":143,"phases":11970,"primaryCompletion":7779,"completion":4481,"start":7780,"enrollment":3050,"conditions":11971,"interventions":11972},[93],[7782],[7784,7497],{"trials":11974,"activeCount":104},[],{"trials":11976,"activeCount":104},[],{"trials":11978,"activeCount":104},[],{"intervention":11980,"totalTrials":100,"cells":11981},"Zanubrutinib and Rituximab",{"EARLY_PHASE1":11982,"PHASE1":11984,"PHASE2":11986,"PHASE3":11998,"PHASE4":12000,"NA":12002},{"trials":11983,"activeCount":104},[],{"trials":11985,"activeCount":104},[],{"trials":11987,"activeCount":100,"soonestReadout":260},[11988],{"nctId":11989,"briefTitle":11990,"status":300,"phases":11991,"primaryCompletion":260,"completion":419,"start":217,"enrollment":3050,"conditions":11992,"interventions":11995},"NCT04624958","Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL",[93],[11993,11994],"Mantle Cell Lymphoma","Newly-diagnosed Mantle Cell Lymphoma",[11980,11996,11997],"R-DHAOx","Zanubrutinib Maintenance",{"trials":11999,"activeCount":104},[],{"trials":12001,"activeCount":104},[],{"trials":12003,"activeCount":104},[],{"intervention":11996,"totalTrials":100,"cells":12005},{"EARLY_PHASE1":12006,"PHASE1":12008,"PHASE2":12010,"PHASE3":12016,"PHASE4":12018,"NA":12020},{"trials":12007,"activeCount":104},[],{"trials":12009,"activeCount":104},[],{"trials":12011,"activeCount":100,"soonestReadout":260},[12012],{"nctId":11989,"briefTitle":11990,"status":300,"phases":12013,"primaryCompletion":260,"completion":419,"start":217,"enrollment":3050,"conditions":12014,"interventions":12015},[93],[11993,11994],[11980,11996,11997],{"trials":12017,"activeCount":104},[],{"trials":12019,"activeCount":104},[],{"trials":12021,"activeCount":104},[],{"intervention":11997,"totalTrials":100,"cells":12023},{"EARLY_PHASE1":12024,"PHASE1":12026,"PHASE2":12028,"PHASE3":12034,"PHASE4":12036,"NA":12038},{"trials":12025,"activeCount":104},[],{"trials":12027,"activeCount":104},[],{"trials":12029,"activeCount":100,"soonestReadout":260},[12030],{"nctId":11989,"briefTitle":11990,"status":300,"phases":12031,"primaryCompletion":260,"completion":419,"start":217,"enrollment":3050,"conditions":12032,"interventions":12033},[93],[11993,11994],[11980,11996,11997],{"trials":12035,"activeCount":104},[],{"trials":12037,"activeCount":104},[],{"trials":12039,"activeCount":104},[],{"intervention":2714,"totalTrials":100,"cells":12041},{"EARLY_PHASE1":12042,"PHASE1":12044,"PHASE2":12046,"PHASE3":12052,"PHASE4":12054,"NA":12056},{"trials":12043,"activeCount":104},[],{"trials":12045,"activeCount":104},[],{"trials":12047,"activeCount":100,"soonestReadout":2366},[12048],{"nctId":2707,"briefTitle":2708,"status":143,"phases":12049,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":2710,"conditions":12050,"interventions":12051},[93],[284,1122,2712,1215,463],[2714,2715,2372],{"trials":12053,"activeCount":104},[],{"trials":12055,"activeCount":104},[],{"trials":12057,"activeCount":104},[],{"intervention":2715,"totalTrials":100,"cells":12059},{"EARLY_PHASE1":12060,"PHASE1":12062,"PHASE2":12064,"PHASE3":12070,"PHASE4":12072,"NA":12074},{"trials":12061,"activeCount":104},[],{"trials":12063,"activeCount":104},[],{"trials":12065,"activeCount":100,"soonestReadout":2366},[12066],{"nctId":2707,"briefTitle":2708,"status":143,"phases":12067,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":2710,"conditions":12068,"interventions":12069},[93],[284,1122,2712,1215,463],[2714,2715,2372],{"trials":12071,"activeCount":104},[],{"trials":12073,"activeCount":104},[],{"trials":12075,"activeCount":104},[],{"intervention":12077,"totalTrials":100,"cells":12078},"Cryoablation therapy + anti-PD-1 antibody",{"EARLY_PHASE1":12079,"PHASE1":12081,"PHASE2":12083,"PHASE3":12094,"PHASE4":12096,"NA":12098},{"trials":12080,"activeCount":104},[],{"trials":12082,"activeCount":104},[],{"trials":12084,"activeCount":100,"soonestReadout":12089},[12085],{"nctId":12086,"briefTitle":12087,"status":143,"phases":12088,"primaryCompletion":12089,"completion":7981,"start":2734,"enrollment":1987,"conditions":12090,"interventions":12093},"NCT07602049","Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma",[93],"2026-11-30",[12091,12092],"Soft Tissue Sarcoma (STS)","Osteosarcoma",[12077],{"trials":12095,"activeCount":104},[],{"trials":12097,"activeCount":104},[],{"trials":12099,"activeCount":104},[],{"intervention":12101,"totalTrials":100,"cells":12102},"RC48\u002FCarboplatin",{"EARLY_PHASE1":12103,"PHASE1":12105,"PHASE2":12107,"PHASE3":12115,"PHASE4":12117,"NA":12119},{"trials":12104,"activeCount":104},[],{"trials":12106,"activeCount":104},[],{"trials":12108,"activeCount":100,"soonestReadout":6596},[12109],{"nctId":12110,"briefTitle":12111,"status":116,"phases":12112,"primaryCompletion":6596,"completion":3694,"start":4739,"enrollment":360,"conditions":12113,"interventions":12114},"NCT06574763","Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer",[93],[2042],[12101],{"trials":12116,"activeCount":104},[],{"trials":12118,"activeCount":104},[],{"trials":12120,"activeCount":104},[],{"intervention":79,"totalTrials":100,"cells":12122},{"EARLY_PHASE1":12123,"PHASE1":12125,"PHASE2":12127,"PHASE3":12135,"PHASE4":12137,"NA":12139},{"trials":12124,"activeCount":104},[],{"trials":12126,"activeCount":104},[],{"trials":12128,"activeCount":100,"soonestReadout":78},[12129],{"nctId":76,"briefTitle":77,"status":300,"phases":12130,"primaryCompletion":78,"completion":12131,"start":12132,"enrollment":1018,"conditions":12133,"interventions":12134},[93],"2027-10-09","2019-10-09",[1203],[79],{"trials":12136,"activeCount":104},[],{"trials":12138,"activeCount":104},[],{"trials":12140,"activeCount":104},[],{"intervention":2048,"totalTrials":100,"cells":12142},{"EARLY_PHASE1":12143,"PHASE1":12145,"PHASE2":12147,"PHASE3":12153,"PHASE4":12155,"NA":12157},{"trials":12144,"activeCount":104},[],{"trials":12146,"activeCount":104},[],{"trials":12148,"activeCount":100,"soonestReadout":1348},[12149],{"nctId":2035,"briefTitle":2036,"status":116,"phases":12150,"primaryCompletion":1348,"completion":2038,"start":2039,"enrollment":2040,"conditions":12151,"interventions":12152},[93],[2042,2043,2044,2045,2046],[2048,272],{"trials":12154,"activeCount":104},[],{"trials":12156,"activeCount":104},[],{"trials":12158,"activeCount":104},[],{"intervention":8180,"totalTrials":100,"cells":12160},{"EARLY_PHASE1":12161,"PHASE1":12163,"PHASE2":12165,"PHASE3":12171,"PHASE4":12173,"NA":12175},{"trials":12162,"activeCount":104},[],{"trials":12164,"activeCount":104},[],{"trials":12166,"activeCount":100,"soonestReadout":8175},[12167],{"nctId":8172,"briefTitle":8173,"status":143,"phases":12168,"primaryCompletion":8175,"completion":8176,"start":1508,"enrollment":1987,"conditions":12169,"interventions":12170},[93],[6574,8178],[8180,1381,3795,5389,8181],{"trials":12172,"activeCount":104},[],{"trials":12174,"activeCount":104},[],{"trials":12176,"activeCount":104},[],{"intervention":8181,"totalTrials":100,"cells":12178},{"EARLY_PHASE1":12179,"PHASE1":12181,"PHASE2":12183,"PHASE3":12189,"PHASE4":12191,"NA":12193},{"trials":12180,"activeCount":104},[],{"trials":12182,"activeCount":104},[],{"trials":12184,"activeCount":100,"soonestReadout":8175},[12185],{"nctId":8172,"briefTitle":8173,"status":143,"phases":12186,"primaryCompletion":8175,"completion":8176,"start":1508,"enrollment":1987,"conditions":12187,"interventions":12188},[93],[6574,8178],[8180,1381,3795,5389,8181],{"trials":12190,"activeCount":104},[],{"trials":12192,"activeCount":104},[],{"trials":12194,"activeCount":104},[],{"intervention":12196,"totalTrials":100,"cells":12197},"Receive Abiraterone plus prednisone\u002FEnzalutamide\u002FApalutamide\u002FRezvilutamide in the evening",{"EARLY_PHASE1":12198,"PHASE1":12200,"PHASE2":12202,"PHASE3":12212,"PHASE4":12214,"NA":12216},{"trials":12199,"activeCount":104},[],{"trials":12201,"activeCount":104},[],{"trials":12203,"activeCount":100,"soonestReadout":9443},[12204],{"nctId":12205,"briefTitle":12206,"status":116,"phases":12207,"primaryCompletion":9443,"completion":4009,"start":12208,"enrollment":1076,"conditions":12209,"interventions":12211},"NCT06505278","The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy",[93],"2024-08",[12210],"Prostate Cancer",[12196],{"trials":12213,"activeCount":104},[],{"trials":12215,"activeCount":104},[],{"trials":12217,"activeCount":104},[],{"intervention":9195,"totalTrials":100,"cells":12219},{"EARLY_PHASE1":12220,"PHASE1":12222,"PHASE2":12224,"PHASE3":12230,"PHASE4":12232,"NA":12234},{"trials":12221,"activeCount":104},[],{"trials":12223,"activeCount":104},[],{"trials":12225,"activeCount":100,"soonestReadout":2922},[12226],{"nctId":9189,"briefTitle":9190,"status":143,"phases":12227,"primaryCompletion":2922,"completion":9192,"start":330,"enrollment":2108,"conditions":12228,"interventions":12229},[93],[22],[9173,9173,9195,9196],{"trials":12231,"activeCount":104},[],{"trials":12233,"activeCount":104},[],{"trials":12235,"activeCount":104},[],{"intervention":9196,"totalTrials":100,"cells":12237},{"EARLY_PHASE1":12238,"PHASE1":12240,"PHASE2":12242,"PHASE3":12248,"PHASE4":12250,"NA":12252},{"trials":12239,"activeCount":104},[],{"trials":12241,"activeCount":104},[],{"trials":12243,"activeCount":100,"soonestReadout":2922},[12244],{"nctId":9189,"briefTitle":9190,"status":143,"phases":12245,"primaryCompletion":2922,"completion":9192,"start":330,"enrollment":2108,"conditions":12246,"interventions":12247},[93],[22],[9173,9173,9195,9196],{"trials":12249,"activeCount":104},[],{"trials":12251,"activeCount":104},[],{"trials":12253,"activeCount":104},[],{"intervention":12255,"totalTrials":100,"cells":12256},"Hepatic arterial infusion chemotherapy(HAIC) combined with adebrelimab plus apatinib",{"EARLY_PHASE1":12257,"PHASE1":12259,"PHASE2":12261,"PHASE3":12270,"PHASE4":12272,"NA":12274},{"trials":12258,"activeCount":104},[],{"trials":12260,"activeCount":104},[],{"trials":12262,"activeCount":100,"soonestReadout":1801},[12263],{"nctId":12264,"briefTitle":12265,"status":116,"phases":12266,"primaryCompletion":1801,"completion":3663,"start":12267,"enrollment":1350,"conditions":12268,"interventions":12269},"NCT06482008","HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study",[93],"2024-06-19",[19],[12255],{"trials":12271,"activeCount":104},[],{"trials":12273,"activeCount":104},[],{"trials":12275,"activeCount":104},[],{"intervention":12277,"totalTrials":100,"cells":12278},"Apatinib, Irinotecan, Temozolomide",{"EARLY_PHASE1":12279,"PHASE1":12281,"PHASE2":12283,"PHASE3":12294,"PHASE4":12296,"NA":12298},{"trials":12280,"activeCount":104},[],{"trials":12282,"activeCount":104},[],{"trials":12284,"activeCount":100,"soonestReadout":12289},[12285],{"nctId":12286,"briefTitle":12287,"status":143,"phases":12288,"primaryCompletion":12289,"completion":12289,"start":12290,"enrollment":12291,"conditions":12292,"interventions":12293},"NCT05027386","Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I\u002FII，Multi-center, Clinical Study.",[92,93],"2026-02-04","2021-08-26",125,[1763],[12277],{"trials":12295,"activeCount":104},[],{"trials":12297,"activeCount":104},[],{"trials":12299,"activeCount":104},[],{"intervention":12301,"totalTrials":100,"cells":12302},"Cetuximab + Envafolimab + mFOLFOXIRI",{"EARLY_PHASE1":12303,"PHASE1":12305,"PHASE2":12307,"PHASE3":12317,"PHASE4":12319,"NA":12321},{"trials":12304,"activeCount":104},[],{"trials":12306,"activeCount":104},[],{"trials":12308,"activeCount":100,"soonestReadout":380},[12309],{"nctId":12310,"briefTitle":12311,"status":143,"phases":12312,"primaryCompletion":380,"completion":646,"start":12313,"enrollment":3508,"conditions":12314,"interventions":12315},"NCT05959356","Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS\u002FBRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer",[93],"2023-11-09",[1368],[12301,12316],"Cetuximab + mFOLFOX6",{"trials":12318,"activeCount":104},[],{"trials":12320,"activeCount":104},[],{"trials":12322,"activeCount":104},[],{"intervention":12316,"totalTrials":100,"cells":12324},{"EARLY_PHASE1":12325,"PHASE1":12327,"PHASE2":12329,"PHASE3":12335,"PHASE4":12337,"NA":12339},{"trials":12326,"activeCount":104},[],{"trials":12328,"activeCount":104},[],{"trials":12330,"activeCount":100,"soonestReadout":380},[12331],{"nctId":12310,"briefTitle":12311,"status":143,"phases":12332,"primaryCompletion":380,"completion":646,"start":12313,"enrollment":3508,"conditions":12333,"interventions":12334},[93],[1368],[12301,12316],{"trials":12336,"activeCount":104},[],{"trials":12338,"activeCount":104},[],{"trials":12340,"activeCount":104},[],{"intervention":4444,"totalTrials":100,"cells":12342},{"EARLY_PHASE1":12343,"PHASE1":12345,"PHASE2":12347,"PHASE3":12353,"PHASE4":12355,"NA":12357},{"trials":12344,"activeCount":104},[],{"trials":12346,"activeCount":104},[],{"trials":12348,"activeCount":100,"soonestReadout":379},[12349],{"nctId":4436,"briefTitle":4437,"status":143,"phases":12350,"primaryCompletion":379,"completion":4439,"start":4440,"enrollment":4441,"conditions":12351,"interventions":12352},[93],[25],[4444,4415,4445,4446],{"trials":12354,"activeCount":104},[],{"trials":12356,"activeCount":104},[],{"trials":12358,"activeCount":104},[],{"intervention":4445,"totalTrials":100,"cells":12360},{"EARLY_PHASE1":12361,"PHASE1":12363,"PHASE2":12365,"PHASE3":12371,"PHASE4":12373,"NA":12375},{"trials":12362,"activeCount":104},[],{"trials":12364,"activeCount":104},[],{"trials":12366,"activeCount":100,"soonestReadout":379},[12367],{"nctId":4436,"briefTitle":4437,"status":143,"phases":12368,"primaryCompletion":379,"completion":4439,"start":4440,"enrollment":4441,"conditions":12369,"interventions":12370},[93],[25],[4444,4415,4445,4446],{"trials":12372,"activeCount":104},[],{"trials":12374,"activeCount":104},[],{"trials":12376,"activeCount":104},[],{"intervention":4446,"totalTrials":100,"cells":12378},{"EARLY_PHASE1":12379,"PHASE1":12381,"PHASE2":12383,"PHASE3":12389,"PHASE4":12391,"NA":12393},{"trials":12380,"activeCount":104},[],{"trials":12382,"activeCount":104},[],{"trials":12384,"activeCount":100,"soonestReadout":379},[12385],{"nctId":4436,"briefTitle":4437,"status":143,"phases":12386,"primaryCompletion":379,"completion":4439,"start":4440,"enrollment":4441,"conditions":12387,"interventions":12388},[93],[25],[4444,4415,4445,4446],{"trials":12390,"activeCount":104},[],{"trials":12392,"activeCount":104},[],{"trials":12394,"activeCount":104},[],{"intervention":12396,"totalTrials":100,"cells":12397},"TPC induction chemotherapy",{"EARLY_PHASE1":12398,"PHASE1":12400,"PHASE2":12402,"PHASE3":12412,"PHASE4":12414,"NA":12416},{"trials":12399,"activeCount":104},[],{"trials":12401,"activeCount":104},[],{"trials":12403,"activeCount":100,"soonestReadout":1064},[12404],{"nctId":12405,"briefTitle":12406,"status":143,"phases":12407,"primaryCompletion":1064,"completion":646,"start":12408,"enrollment":4473,"conditions":12409,"interventions":12410},"NCT06301165","TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma",[93],"2024-03-19",[16],[12396,12411],"GP induction chemotherapy",{"trials":12413,"activeCount":104},[],{"trials":12415,"activeCount":104},[],{"trials":12417,"activeCount":104},[],{"intervention":12411,"totalTrials":100,"cells":12419},{"EARLY_PHASE1":12420,"PHASE1":12422,"PHASE2":12424,"PHASE3":12430,"PHASE4":12432,"NA":12434},{"trials":12421,"activeCount":104},[],{"trials":12423,"activeCount":104},[],{"trials":12425,"activeCount":100,"soonestReadout":1064},[12426],{"nctId":12405,"briefTitle":12406,"status":143,"phases":12427,"primaryCompletion":1064,"completion":646,"start":12408,"enrollment":4473,"conditions":12428,"interventions":12429},[93],[16],[12396,12411],{"trials":12431,"activeCount":104},[],{"trials":12433,"activeCount":104},[],{"trials":12435,"activeCount":104},[],{"intervention":12437,"totalTrials":100,"cells":12438},"Drug Combination Therapy",{"EARLY_PHASE1":12439,"PHASE1":12441,"PHASE2":12443,"PHASE3":12452,"PHASE4":12454,"NA":12456},{"trials":12440,"activeCount":104},[],{"trials":12442,"activeCount":104},[],{"trials":12444,"activeCount":100,"soonestReadout":499},[12445],{"nctId":12446,"briefTitle":12447,"status":116,"phases":12448,"primaryCompletion":499,"completion":499,"start":1801,"enrollment":32,"conditions":12449,"interventions":12451},"NCT07354984","A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[93],[12450],"Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma",[12437],{"trials":12453,"activeCount":104},[],{"trials":12455,"activeCount":104},[],{"trials":12457,"activeCount":104},[],{"intervention":12459,"totalTrials":100,"cells":12460},"QL1706 Combined With Lenvatinib",{"EARLY_PHASE1":12461,"PHASE1":12463,"PHASE2":12465,"PHASE3":12475,"PHASE4":12477,"NA":12479},{"trials":12462,"activeCount":104},[],{"trials":12464,"activeCount":104},[],{"trials":12466,"activeCount":100,"soonestReadout":119},[12467],{"nctId":12468,"briefTitle":12469,"status":143,"phases":12470,"primaryCompletion":119,"completion":646,"start":12471,"enrollment":959,"conditions":12472,"interventions":12474},"NCT07389629","Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC",[93],"2025-11-21",[2070,12473,4554],"Clear Cell Renal Cell Carcinoma",[12459],{"trials":12476,"activeCount":104},[],{"trials":12478,"activeCount":104},[],{"trials":12480,"activeCount":104},[],{"intervention":8324,"totalTrials":100,"cells":12482},{"EARLY_PHASE1":12483,"PHASE1":12485,"PHASE2":12487,"PHASE3":12493,"PHASE4":12495,"NA":12497},{"trials":12484,"activeCount":104},[],{"trials":12486,"activeCount":104},[],{"trials":12488,"activeCount":100,"soonestReadout":7832},[12489],{"nctId":8317,"briefTitle":8318,"status":116,"phases":12490,"primaryCompletion":7832,"completion":8320,"start":2662,"enrollment":205,"conditions":12491,"interventions":12492},[93],[8322],[8324,8308],{"trials":12494,"activeCount":104},[],{"trials":12496,"activeCount":104},[],{"trials":12498,"activeCount":104},[],{"intervention":12500,"totalTrials":100,"cells":12501},"Valganciclovir Hydrochloride",{"EARLY_PHASE1":12502,"PHASE1":12504,"PHASE2":12506,"PHASE3":12518,"PHASE4":12520,"NA":12522},{"trials":12503,"activeCount":104},[],{"trials":12505,"activeCount":104},[],{"trials":12507,"activeCount":100,"soonestReadout":12512},[12508],{"nctId":12509,"briefTitle":12510,"status":116,"phases":12511,"primaryCompletion":12512,"completion":12513,"start":12514,"enrollment":1464,"conditions":12515,"interventions":12516},"NCT07138989","EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[93],"2026-08-18","2031-08-18","2025-08-19",[37],[12500,12517],"gemcitabine, cisplatin, and PD-1 antibody",{"trials":12519,"activeCount":104},[],{"trials":12521,"activeCount":104},[],{"trials":12523,"activeCount":104},[],{"intervention":12517,"totalTrials":100,"cells":12525},{"EARLY_PHASE1":12526,"PHASE1":12528,"PHASE2":12530,"PHASE3":12536,"PHASE4":12538,"NA":12540},{"trials":12527,"activeCount":104},[],{"trials":12529,"activeCount":104},[],{"trials":12531,"activeCount":100,"soonestReadout":12512},[12532],{"nctId":12509,"briefTitle":12510,"status":116,"phases":12533,"primaryCompletion":12512,"completion":12513,"start":12514,"enrollment":1464,"conditions":12534,"interventions":12535},[93],[37],[12500,12517],{"trials":12537,"activeCount":104},[],{"trials":12539,"activeCount":104},[],{"trials":12541,"activeCount":104},[],{"intervention":12543,"totalTrials":100,"cells":12544},"FOLFOX-HAIC+Lenvatinib+Envolizumab",{"EARLY_PHASE1":12545,"PHASE1":12547,"PHASE2":12549,"PHASE3":12559,"PHASE4":12561,"NA":12563},{"trials":12546,"activeCount":104},[],{"trials":12548,"activeCount":104},[],{"trials":12550,"activeCount":100,"soonestReadout":1177},[12551],{"nctId":12552,"briefTitle":12553,"status":116,"phases":12554,"primaryCompletion":1177,"completion":380,"start":12555,"enrollment":1727,"conditions":12556,"interventions":12558},"NCT06143579","A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma",[93],"2023-12-15",[12557],"Potentially Resectable Hepatocellular Carcinoma",[12543],{"trials":12560,"activeCount":104},[],{"trials":12562,"activeCount":104},[],{"trials":12564,"activeCount":104},[],{"intervention":12566,"totalTrials":100,"cells":12567},"Cetuximab and irinotecan",{"EARLY_PHASE1":12568,"PHASE1":12570,"PHASE2":12572,"PHASE3":12581,"PHASE4":12583,"NA":12585},{"trials":12569,"activeCount":104},[],{"trials":12571,"activeCount":104},[],{"trials":12573,"activeCount":100,"soonestReadout":369},[12574],{"nctId":12575,"briefTitle":12576,"status":143,"phases":12577,"primaryCompletion":369,"completion":1625,"start":12578,"enrollment":3705,"conditions":12579,"interventions":12580},"NCT05962502","Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy",[93],"2023-08-24",[1368],[12566],{"trials":12582,"activeCount":104},[],{"trials":12584,"activeCount":104},[],{"trials":12586,"activeCount":104},[],{"intervention":12588,"totalTrials":100,"cells":12589},"Second-line systemic therapy",{"EARLY_PHASE1":12590,"PHASE1":12592,"PHASE2":12594,"PHASE3":12603,"PHASE4":12605,"NA":12607},{"trials":12591,"activeCount":104},[],{"trials":12593,"activeCount":104},[],{"trials":12595,"activeCount":100,"soonestReadout":7933},[12596],{"nctId":12597,"briefTitle":12598,"status":116,"phases":12599,"primaryCompletion":7933,"completion":7933,"start":3049,"enrollment":1076,"conditions":12600,"interventions":12602},"NCT06592612","Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment",[93],[19,12601],"Oligoprogression",[12588],{"trials":12604,"activeCount":104},[],{"trials":12606,"activeCount":104},[],{"trials":12608,"activeCount":104},[],{"intervention":12610,"totalTrials":100,"cells":12611},"TACE-HACI, plus atezolizumab-bevacizumab",{"EARLY_PHASE1":12612,"PHASE1":12614,"PHASE2":12616,"PHASE3":12625,"PHASE4":12627,"NA":12629},{"trials":12613,"activeCount":104},[],{"trials":12615,"activeCount":104},[],{"trials":12617,"activeCount":100,"soonestReadout":12622},[12618],{"nctId":12619,"briefTitle":12620,"status":143,"phases":12621,"primaryCompletion":12622,"completion":1227,"start":8775,"enrollment":280,"conditions":12623,"interventions":12624},"NCT05751343","Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial",[93],"2024-08-28",[19],[12610],{"trials":12626,"activeCount":104},[],{"trials":12628,"activeCount":104},[],{"trials":12630,"activeCount":104},[],{"intervention":3285,"totalTrials":100,"cells":12632},{"EARLY_PHASE1":12633,"PHASE1":12635,"PHASE2":12637,"PHASE3":12643,"PHASE4":12645,"NA":12647},{"trials":12634,"activeCount":104},[],{"trials":12636,"activeCount":104},[],{"trials":12638,"activeCount":100,"soonestReadout":3280},[12639],{"nctId":3277,"briefTitle":3278,"status":143,"phases":12640,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":360,"conditions":12641,"interventions":12642},[93],[284,1122,1215,3283],[726,318,3285,3286],{"trials":12644,"activeCount":104},[],{"trials":12646,"activeCount":104},[],{"trials":12648,"activeCount":104},[],{"intervention":3286,"totalTrials":100,"cells":12650},{"EARLY_PHASE1":12651,"PHASE1":12653,"PHASE2":12655,"PHASE3":12661,"PHASE4":12663,"NA":12665},{"trials":12652,"activeCount":104},[],{"trials":12654,"activeCount":104},[],{"trials":12656,"activeCount":100,"soonestReadout":3280},[12657],{"nctId":3277,"briefTitle":3278,"status":143,"phases":12658,"primaryCompletion":3280,"completion":3280,"start":3281,"enrollment":360,"conditions":12659,"interventions":12660},[93],[284,1122,1215,3283],[726,318,3285,3286],{"trials":12662,"activeCount":104},[],{"trials":12664,"activeCount":104},[],{"trials":12666,"activeCount":104},[],{"intervention":9438,"totalTrials":100,"cells":12668},{"EARLY_PHASE1":12669,"PHASE1":12671,"PHASE2":12673,"PHASE3":12679,"PHASE4":12681,"NA":12683},{"trials":12670,"activeCount":104},[],{"trials":12672,"activeCount":104},[],{"trials":12674,"activeCount":100,"soonestReadout":303},[12675],{"nctId":9430,"briefTitle":9431,"status":116,"phases":12676,"primaryCompletion":303,"completion":896,"start":4667,"enrollment":1056,"conditions":12677,"interventions":12678},[93],[1020,9434,9435,3655,9436],[9438,9421],{"trials":12680,"activeCount":104},[],{"trials":12682,"activeCount":104},[],{"trials":12684,"activeCount":104},[],{"intervention":7988,"totalTrials":100,"cells":12686},{"EARLY_PHASE1":12687,"PHASE1":12689,"PHASE2":12691,"PHASE3":12697,"PHASE4":12699,"NA":12701},{"trials":12688,"activeCount":104},[],{"trials":12690,"activeCount":104},[],{"trials":12692,"activeCount":100,"soonestReadout":7981},[12693],{"nctId":7978,"briefTitle":7979,"status":116,"phases":12694,"primaryCompletion":7981,"completion":7982,"start":2417,"enrollment":26,"conditions":12695,"interventions":12696},[93],[7984,7985,7986],[318,7988],{"trials":12698,"activeCount":104},[],{"trials":12700,"activeCount":104},[],{"trials":12702,"activeCount":104},[],{"intervention":1765,"totalTrials":100,"cells":12704},{"EARLY_PHASE1":12705,"PHASE1":12707,"PHASE2":12709,"PHASE3":12715,"PHASE4":12717,"NA":12719},{"trials":12706,"activeCount":104},[],{"trials":12708,"activeCount":104},[],{"trials":12710,"activeCount":100,"soonestReadout":380},[12711],{"nctId":1758,"briefTitle":1759,"status":143,"phases":12712,"primaryCompletion":380,"completion":119,"start":1761,"enrollment":820,"conditions":12713,"interventions":12714},[93],[1763],[1765,1766,54,1767,1768,1769,483],{"trials":12716,"activeCount":104},[],{"trials":12718,"activeCount":104},[],{"trials":12720,"activeCount":104},[],{"intervention":1768,"totalTrials":100,"cells":12722},{"EARLY_PHASE1":12723,"PHASE1":12725,"PHASE2":12727,"PHASE3":12733,"PHASE4":12735,"NA":12737},{"trials":12724,"activeCount":104},[],{"trials":12726,"activeCount":104},[],{"trials":12728,"activeCount":100,"soonestReadout":380},[12729],{"nctId":1758,"briefTitle":1759,"status":143,"phases":12730,"primaryCompletion":380,"completion":119,"start":1761,"enrollment":820,"conditions":12731,"interventions":12732},[93],[1763],[1765,1766,54,1767,1768,1769,483],{"trials":12734,"activeCount":104},[],{"trials":12736,"activeCount":104},[],{"trials":12738,"activeCount":104},[],{"intervention":1769,"totalTrials":100,"cells":12740},{"EARLY_PHASE1":12741,"PHASE1":12743,"PHASE2":12745,"PHASE3":12751,"PHASE4":12753,"NA":12755},{"trials":12742,"activeCount":104},[],{"trials":12744,"activeCount":104},[],{"trials":12746,"activeCount":100,"soonestReadout":380},[12747],{"nctId":1758,"briefTitle":1759,"status":143,"phases":12748,"primaryCompletion":380,"completion":119,"start":1761,"enrollment":820,"conditions":12749,"interventions":12750},[93],[1763],[1765,1766,54,1767,1768,1769,483],{"trials":12752,"activeCount":104},[],{"trials":12754,"activeCount":104},[],{"trials":12756,"activeCount":104},[],{"intervention":410,"totalTrials":100,"cells":12758},{"EARLY_PHASE1":12759,"PHASE1":12761,"PHASE2":12763,"PHASE3":12769,"PHASE4":12771,"NA":12773},{"trials":12760,"activeCount":104},[],{"trials":12762,"activeCount":104},[],{"trials":12764,"activeCount":100,"soonestReadout":403},[12765],{"nctId":400,"briefTitle":401,"status":143,"phases":12766,"primaryCompletion":403,"completion":404,"start":405,"enrollment":406,"conditions":12767,"interventions":12768},[93],[408],[410,411,412,413],{"trials":12770,"activeCount":104},[],{"trials":12772,"activeCount":104},[],{"trials":12774,"activeCount":104},[],{"intervention":2412,"totalTrials":100,"cells":12776},{"EARLY_PHASE1":12777,"PHASE1":12779,"PHASE2":12781,"PHASE3":12787,"PHASE4":12789,"NA":12791},{"trials":12778,"activeCount":104},[],{"trials":12780,"activeCount":104},[],{"trials":12782,"activeCount":100,"soonestReadout":2407},[12783],{"nctId":2404,"briefTitle":2405,"status":116,"phases":12784,"primaryCompletion":2407,"completion":2408,"start":2409,"enrollment":29,"conditions":12785,"interventions":12786},[93],[1009],[69,2412],{"trials":12788,"activeCount":104},[],{"trials":12790,"activeCount":104},[],{"trials":12792,"activeCount":104},[],{"intervention":9124,"totalTrials":100,"cells":12794},{"EARLY_PHASE1":12795,"PHASE1":12797,"PHASE2":12799,"PHASE3":12805,"PHASE4":12807,"NA":12809},{"trials":12796,"activeCount":104},[],{"trials":12798,"activeCount":104},[],{"trials":12800,"activeCount":100,"soonestReadout":1015},[12801],{"nctId":9113,"briefTitle":9114,"status":143,"phases":12802,"primaryCompletion":1015,"completion":9116,"start":9117,"enrollment":35,"conditions":12803,"interventions":12804},[93],[9119,9120,9121,9122],[9083,9124],{"trials":12806,"activeCount":104},[],{"trials":12808,"activeCount":104},[],{"trials":12810,"activeCount":104},[],{"intervention":12812,"totalTrials":100,"cells":12813},"SHR-A1811 plus AK112",{"EARLY_PHASE1":12814,"PHASE1":12816,"PHASE2":12818,"PHASE3":12826,"PHASE4":12828,"NA":12830},{"trials":12815,"activeCount":104},[],{"trials":12817,"activeCount":104},[],{"trials":12819,"activeCount":100,"soonestReadout":119},[12820],{"nctId":12821,"briefTitle":12822,"status":116,"phases":12823,"primaryCompletion":119,"completion":646,"start":11697,"enrollment":32,"conditions":12824,"interventions":12825},"NCT07489703","SHR-A1811 + AK112 in HER2-Altered Advanced\u002FMetastatic NSCLC",[93],[252],[12812],{"trials":12827,"activeCount":104},[],{"trials":12829,"activeCount":104},[],{"trials":12831,"activeCount":104},[],{"intervention":12833,"totalTrials":100,"cells":12834},"Telpegfilgrastim",{"EARLY_PHASE1":12835,"PHASE1":12837,"PHASE2":12839,"PHASE3":12849,"PHASE4":12851,"NA":12853},{"trials":12836,"activeCount":104},[],{"trials":12838,"activeCount":104},[],{"trials":12840,"activeCount":100,"soonestReadout":4009},[12841],{"nctId":12842,"briefTitle":12843,"status":143,"phases":12844,"primaryCompletion":4009,"completion":4009,"start":1459,"enrollment":12845,"conditions":12846,"interventions":12848},"NCT06857292","Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy",[93],97,[12847],"Chemotherapy-Induced Neutropenia",[12833],{"trials":12850,"activeCount":104},[],{"trials":12852,"activeCount":104},[],{"trials":12854,"activeCount":104},[],{"intervention":8274,"totalTrials":100,"cells":12856},{"EARLY_PHASE1":12857,"PHASE1":12859,"PHASE2":12861,"PHASE3":12867,"PHASE4":12869,"NA":12871},{"trials":12858,"activeCount":104},[],{"trials":12860,"activeCount":104},[],{"trials":12862,"activeCount":100,"soonestReadout":1133},[12863],{"nctId":8268,"briefTitle":8269,"status":143,"phases":12864,"primaryCompletion":1133,"completion":3372,"start":345,"enrollment":3050,"conditions":12865,"interventions":12866},[93],[8272],[8274,8242],{"trials":12868,"activeCount":104},[],{"trials":12870,"activeCount":104},[],{"trials":12872,"activeCount":104},[],{"intervention":8333,"totalTrials":100,"cells":12874},{"EARLY_PHASE1":12875,"PHASE1":12877,"PHASE2":12879,"PHASE3":12885,"PHASE4":12887,"NA":12889},{"trials":12876,"activeCount":104},[],{"trials":12878,"activeCount":104},[],{"trials":12880,"activeCount":100,"soonestReadout":2457},[12881],{"nctId":8326,"briefTitle":8327,"status":116,"phases":12882,"primaryCompletion":2457,"completion":2457,"start":1543,"enrollment":8329,"conditions":12883,"interventions":12884},[93],[8331],[8333,8334,8308],{"trials":12886,"activeCount":104},[],{"trials":12888,"activeCount":104},[],{"trials":12890,"activeCount":104},[],{"intervention":8334,"totalTrials":100,"cells":12892},{"EARLY_PHASE1":12893,"PHASE1":12895,"PHASE2":12897,"PHASE3":12903,"PHASE4":12905,"NA":12907},{"trials":12894,"activeCount":104},[],{"trials":12896,"activeCount":104},[],{"trials":12898,"activeCount":100,"soonestReadout":2457},[12899],{"nctId":8326,"briefTitle":8327,"status":116,"phases":12900,"primaryCompletion":2457,"completion":2457,"start":1543,"enrollment":8329,"conditions":12901,"interventions":12902},[93],[8331],[8333,8334,8308],{"trials":12904,"activeCount":104},[],{"trials":12906,"activeCount":104},[],{"trials":12908,"activeCount":104},[],{"intervention":12910,"totalTrials":100,"cells":12911},"Toripalimab plus celecoxib",{"EARLY_PHASE1":12912,"PHASE1":12914,"PHASE2":12916,"PHASE3":12925,"PHASE4":12927,"NA":12929},{"trials":12913,"activeCount":104},[],{"trials":12915,"activeCount":104},[],{"trials":12917,"activeCount":100,"soonestReadout":7491},[12918],{"nctId":12919,"briefTitle":12920,"status":143,"phases":12921,"primaryCompletion":7491,"completion":6572,"start":895,"enrollment":1638,"conditions":12922,"interventions":12924},"NCT06903858","Toripalimab Plus Celecoxib for dMMR\u002FMSI-H Locally Advanced Colorectal Cancer",[93],[25,2461,12923],"Mismatch Repair Deficiency",[12910],{"trials":12926,"activeCount":104},[],{"trials":12928,"activeCount":104},[],{"trials":12930,"activeCount":104},[],{"intervention":12932,"totalTrials":100,"cells":12933},"Teprotumumab N01",{"EARLY_PHASE1":12934,"PHASE1":12936,"PHASE2":12938,"PHASE3":12950,"PHASE4":12952,"NA":12954},{"trials":12935,"activeCount":104},[],{"trials":12937,"activeCount":104},[],{"trials":12939,"activeCount":100,"soonestReadout":669},[12940],{"nctId":12941,"briefTitle":12942,"status":116,"phases":12943,"primaryCompletion":669,"completion":3372,"start":4044,"enrollment":996,"conditions":12944,"interventions":12948},"NCT07594912","Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy",[93],[12945,12946,12947],"Thyroid Eye Disease, TED","Graves Ophthalmopathy","Optic Neuropathy",[12932,12949],"Intravenous Methylprednisolone",{"trials":12951,"activeCount":104},[],{"trials":12953,"activeCount":104},[],{"trials":12955,"activeCount":104},[],{"intervention":12949,"totalTrials":100,"cells":12957},{"EARLY_PHASE1":12958,"PHASE1":12960,"PHASE2":12962,"PHASE3":12968,"PHASE4":12970,"NA":12972},{"trials":12959,"activeCount":104},[],{"trials":12961,"activeCount":104},[],{"trials":12963,"activeCount":100,"soonestReadout":669},[12964],{"nctId":12941,"briefTitle":12942,"status":116,"phases":12965,"primaryCompletion":669,"completion":3372,"start":4044,"enrollment":996,"conditions":12966,"interventions":12967},[93],[12945,12946,12947],[12932,12949],{"trials":12969,"activeCount":104},[],{"trials":12971,"activeCount":104},[],{"trials":12973,"activeCount":104},[],{"intervention":12975,"totalTrials":100,"cells":12976},"Postoperative EGFR-TKI Therapy",{"EARLY_PHASE1":12977,"PHASE1":12979,"PHASE2":12981,"PHASE3":12990,"PHASE4":12992,"NA":12994},{"trials":12978,"activeCount":104},[],{"trials":12980,"activeCount":104},[],{"trials":12982,"activeCount":100,"soonestReadout":302},[12983],{"nctId":12984,"briefTitle":12985,"status":143,"phases":12986,"primaryCompletion":302,"completion":379,"start":12987,"enrollment":1712,"conditions":12988,"interventions":12989},"NCT06924398","Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）",[93],"2025-04-20",[5073],[12975],{"trials":12991,"activeCount":104},[],{"trials":12993,"activeCount":104},[],{"trials":12995,"activeCount":104},[],{"intervention":9386,"totalTrials":100,"cells":12997},{"EARLY_PHASE1":12998,"PHASE1":13000,"PHASE2":13002,"PHASE3":13008,"PHASE4":13010,"NA":13012},{"trials":12999,"activeCount":104},[],{"trials":13001,"activeCount":104},[],{"trials":13003,"activeCount":100,"soonestReadout":9381},[13004],{"nctId":9378,"briefTitle":9379,"status":116,"phases":13005,"primaryCompletion":9381,"completion":9382,"start":6749,"enrollment":148,"conditions":13006,"interventions":13007},[93],[9384],[9386,9387],{"trials":13009,"activeCount":104},[],{"trials":13011,"activeCount":104},[],{"trials":13013,"activeCount":104},[],{"intervention":13015,"totalTrials":100,"cells":13016},"QL1706 + Lenvatinib",{"EARLY_PHASE1":13017,"PHASE1":13019,"PHASE2":13021,"PHASE3":13029,"PHASE4":13031,"NA":13033},{"trials":13018,"activeCount":104},[],{"trials":13020,"activeCount":104},[],{"trials":13022,"activeCount":100,"soonestReadout":7079},[13023],{"nctId":13024,"briefTitle":13025,"status":143,"phases":13026,"primaryCompletion":7079,"completion":709,"start":11674,"enrollment":360,"conditions":13027,"interventions":13028},"NCT07384416","QL1706 Plus Lenvatinib in Previously Treated Penile Cancer",[93],[335],[13015],{"trials":13030,"activeCount":104},[],{"trials":13032,"activeCount":104},[],{"trials":13034,"activeCount":104},[],{"intervention":8189,"totalTrials":100,"cells":13036},{"EARLY_PHASE1":13037,"PHASE1":13039,"PHASE2":13041,"PHASE3":13047,"PHASE4":13049,"NA":13051},{"trials":13038,"activeCount":104},[],{"trials":13040,"activeCount":104},[],{"trials":13042,"activeCount":100,"soonestReadout":2456},[13043],{"nctId":8183,"briefTitle":8184,"status":143,"phases":13044,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":13045,"interventions":13046},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":13048,"activeCount":104},[],{"trials":13050,"activeCount":104},[],{"trials":13052,"activeCount":104},[],{"intervention":8190,"totalTrials":100,"cells":13054},{"EARLY_PHASE1":13055,"PHASE1":13057,"PHASE2":13059,"PHASE3":13065,"PHASE4":13067,"NA":13069},{"trials":13056,"activeCount":104},[],{"trials":13058,"activeCount":104},[],{"trials":13060,"activeCount":100,"soonestReadout":2456},[13061],{"nctId":8183,"briefTitle":8184,"status":143,"phases":13062,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":13063,"interventions":13064},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":13066,"activeCount":104},[],{"trials":13068,"activeCount":104},[],{"trials":13070,"activeCount":104},[],{"intervention":8191,"totalTrials":100,"cells":13072},{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13077,"PHASE3":13083,"PHASE4":13085,"NA":13087},{"trials":13074,"activeCount":104},[],{"trials":13076,"activeCount":104},[],{"trials":13078,"activeCount":100,"soonestReadout":2456},[13079],{"nctId":8183,"briefTitle":8184,"status":143,"phases":13080,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":13081,"interventions":13082},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":13084,"activeCount":104},[],{"trials":13086,"activeCount":104},[],{"trials":13088,"activeCount":104},[],{"intervention":8192,"totalTrials":100,"cells":13090},{"EARLY_PHASE1":13091,"PHASE1":13093,"PHASE2":13095,"PHASE3":13101,"PHASE4":13103,"NA":13105},{"trials":13092,"activeCount":104},[],{"trials":13094,"activeCount":104},[],{"trials":13096,"activeCount":100,"soonestReadout":2456},[13097],{"nctId":8183,"briefTitle":8184,"status":143,"phases":13098,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":13099,"interventions":13100},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":13102,"activeCount":104},[],{"trials":13104,"activeCount":104},[],{"trials":13106,"activeCount":104},[],{"intervention":8193,"totalTrials":100,"cells":13108},{"EARLY_PHASE1":13109,"PHASE1":13111,"PHASE2":13113,"PHASE3":13119,"PHASE4":13121,"NA":13123},{"trials":13110,"activeCount":104},[],{"trials":13112,"activeCount":104},[],{"trials":13114,"activeCount":100,"soonestReadout":2456},[13115],{"nctId":8183,"briefTitle":8184,"status":143,"phases":13116,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":13117,"interventions":13118},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":13120,"activeCount":104},[],{"trials":13122,"activeCount":104},[],{"trials":13124,"activeCount":104},[],{"intervention":8194,"totalTrials":100,"cells":13126},{"EARLY_PHASE1":13127,"PHASE1":13129,"PHASE2":13131,"PHASE3":13137,"PHASE4":13139,"NA":13141},{"trials":13128,"activeCount":104},[],{"trials":13130,"activeCount":104},[],{"trials":13132,"activeCount":100,"soonestReadout":2456},[13133],{"nctId":8183,"briefTitle":8184,"status":143,"phases":13134,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":13135,"interventions":13136},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":13138,"activeCount":104},[],{"trials":13140,"activeCount":104},[],{"trials":13142,"activeCount":104},[],{"intervention":8195,"totalTrials":100,"cells":13144},{"EARLY_PHASE1":13145,"PHASE1":13147,"PHASE2":13149,"PHASE3":13155,"PHASE4":13157,"NA":13159},{"trials":13146,"activeCount":104},[],{"trials":13148,"activeCount":104},[],{"trials":13150,"activeCount":100,"soonestReadout":2456},[13151],{"nctId":8183,"briefTitle":8184,"status":143,"phases":13152,"primaryCompletion":2456,"completion":8176,"start":2458,"enrollment":820,"conditions":13153,"interventions":13154},[93],[1973,8187],[8189,8190,8191,8192,8193,5389,8194,8195,1967],{"trials":13156,"activeCount":104},[],{"trials":13158,"activeCount":104},[],{"trials":13160,"activeCount":104},[],{"intervention":13162,"totalTrials":100,"cells":13163},"Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy",{"EARLY_PHASE1":13164,"PHASE1":13166,"PHASE2":13168,"PHASE3":13180,"PHASE4":13182,"NA":13184},{"trials":13165,"activeCount":104},[],{"trials":13167,"activeCount":104},[],{"trials":13169,"activeCount":100,"soonestReadout":13174},[13170],{"nctId":13171,"briefTitle":13172,"status":116,"phases":13173,"primaryCompletion":13174,"completion":6546,"start":3312,"enrollment":1954,"conditions":13175,"interventions":13179},"NCT07175636","QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer",[93],"2026-09-20",[13176,13177,13178],"Locally Advanced Rectal Cancer (LARC)","Mismatch Repair-Proficient (pMMR) Rectal Cancer","Non-metastatic Rectal Cancer",[13162],{"trials":13181,"activeCount":104},[],{"trials":13183,"activeCount":104},[],{"trials":13185,"activeCount":104},[],{"intervention":8501,"totalTrials":100,"cells":13187},{"EARLY_PHASE1":13188,"PHASE1":13190,"PHASE2":13192,"PHASE3":13198,"PHASE4":13200,"NA":13202},{"trials":13189,"activeCount":104},[],{"trials":13191,"activeCount":104},[],{"trials":13193,"activeCount":100,"soonestReadout":380},[13194],{"nctId":8495,"briefTitle":8496,"status":116,"phases":13195,"primaryCompletion":380,"completion":646,"start":941,"enrollment":996,"conditions":13196,"interventions":13197},[93],[6436,8499],[8501,8397],{"trials":13199,"activeCount":104},[],{"trials":13201,"activeCount":104},[],{"trials":13203,"activeCount":104},[],{"intervention":1796,"totalTrials":100,"cells":13205},{"EARLY_PHASE1":13206,"PHASE1":13208,"PHASE2":13210,"PHASE3":13216,"PHASE4":13218,"NA":13220},{"trials":13207,"activeCount":104},[],{"trials":13209,"activeCount":104},[],{"trials":13211,"activeCount":100,"soonestReadout":1788},[13212],{"nctId":1785,"briefTitle":1786,"status":143,"phases":13213,"primaryCompletion":1788,"completion":1789,"start":1790,"enrollment":32,"conditions":13214,"interventions":13215},[93],[1792,1793,1794],[1796,483],{"trials":13217,"activeCount":104},[],{"trials":13219,"activeCount":104},[],{"trials":13221,"activeCount":104},[],{"intervention":3784,"totalTrials":100,"cells":13223},{"EARLY_PHASE1":13224,"PHASE1":13226,"PHASE2":13228,"PHASE3":13234,"PHASE4":13236,"NA":13238},{"trials":13225,"activeCount":104},[],{"trials":13227,"activeCount":104},[],{"trials":13229,"activeCount":100,"soonestReadout":119},[13230],{"nctId":3777,"briefTitle":3778,"status":3411,"phases":13231,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":3050,"conditions":13232,"interventions":13233},[93],[3781,3782],[3784,823,443,3785],{"trials":13235,"activeCount":104},[],{"trials":13237,"activeCount":104},[],{"trials":13239,"activeCount":104},[],{"intervention":3785,"totalTrials":100,"cells":13241},{"EARLY_PHASE1":13242,"PHASE1":13244,"PHASE2":13246,"PHASE3":13252,"PHASE4":13254,"NA":13256},{"trials":13243,"activeCount":104},[],{"trials":13245,"activeCount":104},[],{"trials":13247,"activeCount":100,"soonestReadout":119},[13248],{"nctId":3777,"briefTitle":3778,"status":3411,"phases":13249,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":3050,"conditions":13250,"interventions":13251},[93],[3781,3782],[3784,823,443,3785],{"trials":13253,"activeCount":104},[],{"trials":13255,"activeCount":104},[],{"trials":13257,"activeCount":104},[],{"intervention":13259,"totalTrials":100,"cells":13260},"SBRT+chemoimmunotherapy",{"EARLY_PHASE1":13261,"PHASE1":13263,"PHASE2":13265,"PHASE3":13277,"PHASE4":13279,"NA":13281},{"trials":13262,"activeCount":104},[],{"trials":13264,"activeCount":104},[],{"trials":13266,"activeCount":100,"soonestReadout":13271},[13267],{"nctId":13268,"briefTitle":13269,"status":143,"phases":13270,"primaryCompletion":13271,"completion":13272,"start":13273,"enrollment":959,"conditions":13274,"interventions":13276},"NCT06219980","SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx",[93],"2025-12-07","2026-12-07","2023-12-07",[13275],"SBRT",[13259],{"trials":13278,"activeCount":104},[],{"trials":13280,"activeCount":104},[],{"trials":13282,"activeCount":104},[],{"intervention":1087,"totalTrials":100,"cells":13284},{"EARLY_PHASE1":13285,"PHASE1":13287,"PHASE2":13289,"PHASE3":13295,"PHASE4":13297,"NA":13299},{"trials":13286,"activeCount":104},[],{"trials":13288,"activeCount":104},[],{"trials":13290,"activeCount":100,"soonestReadout":119},[13291],{"nctId":1080,"briefTitle":1081,"status":116,"phases":13292,"primaryCompletion":119,"completion":499,"start":1083,"enrollment":1084,"conditions":13293,"interventions":13294},[93],[16],[601,284,268,1087],{"trials":13296,"activeCount":104},[],{"trials":13298,"activeCount":104},[],{"trials":13300,"activeCount":104},[],{"intervention":3547,"totalTrials":100,"cells":13302},{"EARLY_PHASE1":13303,"PHASE1":13305,"PHASE2":13307,"PHASE3":13313,"PHASE4":13315,"NA":13317},{"trials":13304,"activeCount":104},[],{"trials":13306,"activeCount":104},[],{"trials":13308,"activeCount":100,"soonestReadout":419},[13309],{"nctId":3541,"briefTitle":3542,"status":116,"phases":13310,"primaryCompletion":419,"completion":419,"start":3544,"enrollment":2913,"conditions":13311,"interventions":13312},[93],[16],[3547,3548,374,3549],{"trials":13314,"activeCount":104},[],{"trials":13316,"activeCount":104},[],{"trials":13318,"activeCount":104},[],{"intervention":3549,"totalTrials":100,"cells":13320},{"EARLY_PHASE1":13321,"PHASE1":13323,"PHASE2":13325,"PHASE3":13331,"PHASE4":13333,"NA":13335},{"trials":13322,"activeCount":104},[],{"trials":13324,"activeCount":104},[],{"trials":13326,"activeCount":100,"soonestReadout":419},[13327],{"nctId":3541,"briefTitle":3542,"status":116,"phases":13328,"primaryCompletion":419,"completion":419,"start":3544,"enrollment":2913,"conditions":13329,"interventions":13330},[93],[16],[3547,3548,374,3549],{"trials":13332,"activeCount":104},[],{"trials":13334,"activeCount":104},[],{"trials":13336,"activeCount":104},[],{"intervention":13338,"totalTrials":100,"cells":13339},"Lucanisatuzumab plus tagolimumab",{"EARLY_PHASE1":13340,"PHASE1":13342,"PHASE2":13344,"PHASE3":13353,"PHASE4":13355,"NA":13357},{"trials":13341,"activeCount":104},[],{"trials":13343,"activeCount":104},[],{"trials":13345,"activeCount":100,"soonestReadout":13350},[13346],{"nctId":13347,"briefTitle":13348,"status":143,"phases":13349,"primaryCompletion":13350,"completion":2122,"start":1147,"enrollment":1109,"conditions":13351,"interventions":13352},"NCT07258108","Sac-TMT Plus KL-A167 in PD-L1+, HR+\u002FHER2- Metastatic Breast Cancer After CDK4\u002F6 Inhibitors",[93],"2027-07-30",[28],[13338],{"trials":13354,"activeCount":104},[],{"trials":13356,"activeCount":104},[],{"trials":13358,"activeCount":104},[],{"intervention":13360,"totalTrials":100,"cells":13361},"Toripalimab+Chemotherapy",{"EARLY_PHASE1":13362,"PHASE1":13364,"PHASE2":13366,"PHASE3":13375,"PHASE4":13377,"NA":13379},{"trials":13363,"activeCount":104},[],{"trials":13365,"activeCount":104},[],{"trials":13367,"activeCount":100,"soonestReadout":1277},[13368],{"nctId":13369,"briefTitle":13370,"status":143,"phases":13371,"primaryCompletion":1277,"completion":871,"start":1459,"enrollment":942,"conditions":13372,"interventions":13373},"NCT06426511","ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC",[93],[4701],[13360,13374],"Toripalimab+Chemotherapy followed by consolidation toripalimab",{"trials":13376,"activeCount":104},[],{"trials":13378,"activeCount":104},[],{"trials":13380,"activeCount":104},[],{"intervention":13374,"totalTrials":100,"cells":13382},{"EARLY_PHASE1":13383,"PHASE1":13385,"PHASE2":13387,"PHASE3":13393,"PHASE4":13395,"NA":13397},{"trials":13384,"activeCount":104},[],{"trials":13386,"activeCount":104},[],{"trials":13388,"activeCount":100,"soonestReadout":1277},[13389],{"nctId":13369,"briefTitle":13370,"status":143,"phases":13390,"primaryCompletion":1277,"completion":871,"start":1459,"enrollment":942,"conditions":13391,"interventions":13392},[93],[4701],[13360,13374],{"trials":13394,"activeCount":104},[],{"trials":13396,"activeCount":104},[],{"trials":13398,"activeCount":104},[],{"intervention":44,"totalTrials":100,"cells":13400},{"EARLY_PHASE1":13401,"PHASE1":13403,"PHASE2":13405,"PHASE3":13413,"PHASE4":13415,"NA":13417},{"trials":13402,"activeCount":104},[],{"trials":13404,"activeCount":104},[],{"trials":13406,"activeCount":100,"soonestReadout":43},[13407],{"nctId":41,"briefTitle":42,"status":300,"phases":13408,"primaryCompletion":43,"completion":379,"start":13409,"enrollment":492,"conditions":13410,"interventions":13411},[93],"2019-03-25",[19],[44,13412],"HAIC",{"trials":13414,"activeCount":104},[],{"trials":13416,"activeCount":104},[],{"trials":13418,"activeCount":104},[],{"intervention":13420,"totalTrials":100,"cells":13421},"Very low-risk group",{"EARLY_PHASE1":13422,"PHASE1":13424,"PHASE2":13426,"PHASE3":13438,"PHASE4":13440,"NA":13442},{"trials":13423,"activeCount":104},[],{"trials":13425,"activeCount":104},[],{"trials":13427,"activeCount":100,"soonestReadout":1437},[13428],{"nctId":13429,"briefTitle":13430,"status":143,"phases":13431,"primaryCompletion":1437,"completion":646,"start":8878,"enrollment":1339,"conditions":13432,"interventions":13434},"NCT07300449","A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents",[93],[13433],"Hepatoblastoma",[13420,13435,13436,13437],"Low-risk group","Intermediate-risk group","High-risk group",{"trials":13439,"activeCount":104},[],{"trials":13441,"activeCount":104},[],{"trials":13443,"activeCount":104},[],{"intervention":13435,"totalTrials":100,"cells":13445},{"EARLY_PHASE1":13446,"PHASE1":13448,"PHASE2":13450,"PHASE3":13456,"PHASE4":13458,"NA":13460},{"trials":13447,"activeCount":104},[],{"trials":13449,"activeCount":104},[],{"trials":13451,"activeCount":100,"soonestReadout":1437},[13452],{"nctId":13429,"briefTitle":13430,"status":143,"phases":13453,"primaryCompletion":1437,"completion":646,"start":8878,"enrollment":1339,"conditions":13454,"interventions":13455},[93],[13433],[13420,13435,13436,13437],{"trials":13457,"activeCount":104},[],{"trials":13459,"activeCount":104},[],{"trials":13461,"activeCount":104},[],{"intervention":13436,"totalTrials":100,"cells":13463},{"EARLY_PHASE1":13464,"PHASE1":13466,"PHASE2":13468,"PHASE3":13474,"PHASE4":13476,"NA":13478},{"trials":13465,"activeCount":104},[],{"trials":13467,"activeCount":104},[],{"trials":13469,"activeCount":100,"soonestReadout":1437},[13470],{"nctId":13429,"briefTitle":13430,"status":143,"phases":13471,"primaryCompletion":1437,"completion":646,"start":8878,"enrollment":1339,"conditions":13472,"interventions":13473},[93],[13433],[13420,13435,13436,13437],{"trials":13475,"activeCount":104},[],{"trials":13477,"activeCount":104},[],{"trials":13479,"activeCount":104},[],{"intervention":13437,"totalTrials":100,"cells":13481},{"EARLY_PHASE1":13482,"PHASE1":13484,"PHASE2":13486,"PHASE3":13492,"PHASE4":13494,"NA":13496},{"trials":13483,"activeCount":104},[],{"trials":13485,"activeCount":104},[],{"trials":13487,"activeCount":100,"soonestReadout":1437},[13488],{"nctId":13429,"briefTitle":13430,"status":143,"phases":13489,"primaryCompletion":1437,"completion":646,"start":8878,"enrollment":1339,"conditions":13490,"interventions":13491},[93],[13433],[13420,13435,13436,13437],{"trials":13493,"activeCount":104},[],{"trials":13495,"activeCount":104},[],{"trials":13497,"activeCount":104},[],{"intervention":13499,"totalTrials":100,"cells":13500},"Sotoclax in combination with zanubrutinib and rituximab regimen",{"EARLY_PHASE1":13501,"PHASE1":13503,"PHASE2":13505,"PHASE3":13513,"PHASE4":13515,"NA":13517},{"trials":13502,"activeCount":104},[],{"trials":13504,"activeCount":104},[],{"trials":13506,"activeCount":100,"soonestReadout":10421},[13507],{"nctId":13508,"briefTitle":13509,"status":116,"phases":13510,"primaryCompletion":10421,"completion":8417,"start":3694,"enrollment":978,"conditions":13511,"interventions":13512},"NCT07550855","Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma",[93],[8322],[13499],{"trials":13514,"activeCount":104},[],{"trials":13516,"activeCount":104},[],{"trials":13518,"activeCount":104},[],{"intervention":7518,"totalTrials":100,"cells":13520},{"EARLY_PHASE1":13521,"PHASE1":13523,"PHASE2":13525,"PHASE3":13531,"PHASE4":13533,"NA":13535},{"trials":13522,"activeCount":104},[],{"trials":13524,"activeCount":104},[],{"trials":13526,"activeCount":100,"soonestReadout":4739},[13527],{"nctId":7511,"briefTitle":7512,"status":143,"phases":13528,"primaryCompletion":4739,"completion":3694,"start":7514,"enrollment":360,"conditions":13529,"interventions":13530},[93],[7516],[7518,981],{"trials":13532,"activeCount":104},[],{"trials":13534,"activeCount":104},[],{"trials":13536,"activeCount":104},[],{"intervention":13538,"totalTrials":100,"cells":13539},"4 cycles",{"EARLY_PHASE1":13540,"PHASE1":13542,"PHASE2":13544,"PHASE3":13552,"PHASE4":13554,"NA":13556},{"trials":13541,"activeCount":104},[],{"trials":13543,"activeCount":104},[],{"trials":13545,"activeCount":100,"soonestReadout":1471},[13546],{"nctId":13547,"briefTitle":13548,"status":116,"phases":13549,"primaryCompletion":1471,"completion":669,"start":4043,"enrollment":1954,"conditions":13550,"interventions":13551},"NCT07129161","Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC",[93],[2437],[13538,13538],{"trials":13553,"activeCount":104},[],{"trials":13555,"activeCount":104},[],{"trials":13557,"activeCount":104},[],{"intervention":13559,"totalTrials":100,"cells":13560},"Envafolimab Plus Chemoradiotherapy",{"EARLY_PHASE1":13561,"PHASE1":13563,"PHASE2":13565,"PHASE3":13576,"PHASE4":13578,"NA":13580},{"trials":13562,"activeCount":104},[],{"trials":13564,"activeCount":104},[],{"trials":13566,"activeCount":100,"soonestReadout":1508},[13567],{"nctId":13568,"briefTitle":13569,"status":143,"phases":13570,"primaryCompletion":1508,"completion":380,"start":13571,"enrollment":911,"conditions":13572,"interventions":13575},"NCT05397769","Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.",[93],"2022-06-08",[13573,4487,3090,13574],"Locally Advanced Nasopharyngeal Carcinoma","PD-L1",[13559],{"trials":13577,"activeCount":104},[],{"trials":13579,"activeCount":104},[],{"trials":13581,"activeCount":104},[],{"intervention":13583,"totalTrials":100,"cells":13584},"Paclitaxel Polymersomes Combined with Carboplatin and Adebelimab",{"EARLY_PHASE1":13585,"PHASE1":13587,"PHASE2":13589,"PHASE3":13600,"PHASE4":13602,"NA":13604},{"trials":13586,"activeCount":104},[],{"trials":13588,"activeCount":104},[],{"trials":13590,"activeCount":100,"soonestReadout":13595},[13591],{"nctId":13592,"briefTitle":13593,"status":143,"phases":13594,"primaryCompletion":13595,"completion":13595,"start":13596,"enrollment":1712,"conditions":13597,"interventions":13599},"NCT07336979","Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma",[93],"2027-03-20","2025-03-20",[13598],"Resectable Mucosal Melanoma",[13583],{"trials":13601,"activeCount":104},[],{"trials":13603,"activeCount":104},[],{"trials":13605,"activeCount":104},[],{"intervention":13607,"totalTrials":100,"cells":13608},"Garsorasib, Benmelstobart, Anlotinib",{"EARLY_PHASE1":13609,"PHASE1":13611,"PHASE2":13613,"PHASE3":13625,"PHASE4":13627,"NA":13629},{"trials":13610,"activeCount":104},[],{"trials":13612,"activeCount":104},[],{"trials":13614,"activeCount":100,"soonestReadout":10862},[13615],{"nctId":13616,"briefTitle":13617,"status":116,"phases":13618,"primaryCompletion":10862,"completion":2122,"start":13619,"enrollment":2710,"conditions":13620,"interventions":13622},"NCT07294261","Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC",[93],"2025-12-23",[13621],"Local Advanced or Metastatic NSCLC",[13607,13623,13624],"Benmelstobart, Anlotinib","Garsorasib, Cetuximab Beta",{"trials":13626,"activeCount":104},[],{"trials":13628,"activeCount":104},[],{"trials":13630,"activeCount":104},[],{"intervention":13623,"totalTrials":100,"cells":13632},{"EARLY_PHASE1":13633,"PHASE1":13635,"PHASE2":13637,"PHASE3":13643,"PHASE4":13645,"NA":13647},{"trials":13634,"activeCount":104},[],{"trials":13636,"activeCount":104},[],{"trials":13638,"activeCount":100,"soonestReadout":10862},[13639],{"nctId":13616,"briefTitle":13617,"status":116,"phases":13640,"primaryCompletion":10862,"completion":2122,"start":13619,"enrollment":2710,"conditions":13641,"interventions":13642},[93],[13621],[13607,13623,13624],{"trials":13644,"activeCount":104},[],{"trials":13646,"activeCount":104},[],{"trials":13648,"activeCount":104},[],{"intervention":13624,"totalTrials":100,"cells":13650},{"EARLY_PHASE1":13651,"PHASE1":13653,"PHASE2":13655,"PHASE3":13661,"PHASE4":13663,"NA":13665},{"trials":13652,"activeCount":104},[],{"trials":13654,"activeCount":104},[],{"trials":13656,"activeCount":100,"soonestReadout":10862},[13657],{"nctId":13616,"briefTitle":13617,"status":116,"phases":13658,"primaryCompletion":10862,"completion":2122,"start":13619,"enrollment":2710,"conditions":13659,"interventions":13660},[93],[13621],[13607,13623,13624],{"trials":13662,"activeCount":104},[],{"trials":13664,"activeCount":104},[],{"trials":13666,"activeCount":104},[],{"intervention":13668,"totalTrials":100,"cells":13669},"Sodium Fluoride",{"EARLY_PHASE1":13670,"PHASE1":13672,"PHASE2":13674,"PHASE3":13683,"PHASE4":13685,"NA":13687},{"trials":13671,"activeCount":104},[],{"trials":13673,"activeCount":104},[],{"trials":13675,"activeCount":100,"soonestReadout":3281},[13676],{"nctId":13677,"briefTitle":13678,"status":116,"phases":13679,"primaryCompletion":3281,"completion":380,"start":12555,"enrollment":13680,"conditions":13681,"interventions":13682},"NCT06174012","The Effect of Sodium Fluoride Application on the Prevention of Radiation Caries in NPC Patients",[93],135,[13668],[13668],{"trials":13684,"activeCount":104},[],{"trials":13686,"activeCount":104},[],{"trials":13688,"activeCount":104},[],{"intervention":84,"totalTrials":100,"cells":13690},{"EARLY_PHASE1":13691,"PHASE1":13693,"PHASE2":13695,"PHASE3":13701,"PHASE4":13703,"NA":13705},{"trials":13692,"activeCount":104},[],{"trials":13694,"activeCount":104},[],{"trials":13696,"activeCount":100,"soonestReadout":83},[13697],{"nctId":81,"briefTitle":82,"status":300,"phases":13698,"primaryCompletion":83,"completion":1363,"start":217,"enrollment":1316,"conditions":13699,"interventions":13700},[93],[25,2461],[84],{"trials":13702,"activeCount":104},[],{"trials":13704,"activeCount":104},[],{"trials":13706,"activeCount":104},[],{"intervention":13708,"totalTrials":100,"cells":13709},"Bone marrow mesenchymal stem cells",{"EARLY_PHASE1":13710,"PHASE1":13712,"PHASE2":13714,"PHASE3":13724,"PHASE4":13726,"NA":13728},{"trials":13711,"activeCount":104},[],{"trials":13713,"activeCount":104},[],{"trials":13715,"activeCount":100,"soonestReadout":9270},[13716],{"nctId":13717,"briefTitle":13718,"status":143,"phases":13719,"primaryCompletion":9270,"completion":6749,"start":6504,"enrollment":406,"conditions":13720,"interventions":13722},"NCT06740149","Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients",[92,93],[13721],"Acute-On-Chronic Liver Failure",[13708,13723,13708,13708],"Solvent of CG-BM1",{"trials":13725,"activeCount":104},[],{"trials":13727,"activeCount":104},[],{"trials":13729,"activeCount":104},[],{"intervention":13723,"totalTrials":100,"cells":13731},{"EARLY_PHASE1":13732,"PHASE1":13734,"PHASE2":13736,"PHASE3":13742,"PHASE4":13744,"NA":13746},{"trials":13733,"activeCount":104},[],{"trials":13735,"activeCount":104},[],{"trials":13737,"activeCount":100,"soonestReadout":9270},[13738],{"nctId":13717,"briefTitle":13718,"status":143,"phases":13739,"primaryCompletion":9270,"completion":6749,"start":6504,"enrollment":406,"conditions":13740,"interventions":13741},[92,93],[13721],[13708,13723,13708,13708],{"trials":13743,"activeCount":104},[],{"trials":13745,"activeCount":104},[],{"trials":13747,"activeCount":104},[],{"intervention":2079,"totalTrials":100,"cells":13749},{"EARLY_PHASE1":13750,"PHASE1":13752,"PHASE2":13754,"PHASE3":13760,"PHASE4":13762,"NA":13764},{"trials":13751,"activeCount":104},[],{"trials":13753,"activeCount":104},[],{"trials":13755,"activeCount":100,"soonestReadout":380},[13756],{"nctId":2072,"briefTitle":2073,"status":143,"phases":13757,"primaryCompletion":380,"completion":380,"start":2075,"enrollment":2076,"conditions":13758,"interventions":13759},[93],[1020],[183,2079,542,2080,664,54,272,542,2080,664],{"trials":13761,"activeCount":104},[],{"trials":13763,"activeCount":104},[],{"trials":13765,"activeCount":104},[],{"intervention":13767,"totalTrials":100,"cells":13768},"Neoadjuvant toripalimab plus celecoxib for 6 cycles",{"EARLY_PHASE1":13769,"PHASE1":13771,"PHASE2":13773,"PHASE3":13789,"PHASE4":13791,"NA":13793},{"trials":13770,"activeCount":104},[],{"trials":13772,"activeCount":104},[],{"trials":13774,"activeCount":100,"soonestReadout":13779},[13775],{"nctId":13776,"briefTitle":13777,"status":143,"phases":13778,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":13782,"conditions":13783,"interventions":13784},"NCT03926338","Neoadjuvant Toripalimab With or Without Celecoxib in dMMR\u002FMSI-H Colorectal Cancer",[93],"2027-04-01","2030-04-01","2019-05-10",270,[25,3698,3699,4554],[13767,13785,13786,13787,13788],"Neoadjuvant toripalimab monotherapy for 6 cycles","Neoadjuvant toripalimab plus celecoxib for 12 cycles","Neoadjuvant toripalimab monotherapy for 12 cycles","Toripalimab plus celecoxib as neoadjuvant or definitive therapy",{"trials":13790,"activeCount":104},[],{"trials":13792,"activeCount":104},[],{"trials":13794,"activeCount":104},[],{"intervention":13785,"totalTrials":100,"cells":13796},{"EARLY_PHASE1":13797,"PHASE1":13799,"PHASE2":13801,"PHASE3":13807,"PHASE4":13809,"NA":13811},{"trials":13798,"activeCount":104},[],{"trials":13800,"activeCount":104},[],{"trials":13802,"activeCount":100,"soonestReadout":13779},[13803],{"nctId":13776,"briefTitle":13777,"status":143,"phases":13804,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":13782,"conditions":13805,"interventions":13806},[93],[25,3698,3699,4554],[13767,13785,13786,13787,13788],{"trials":13808,"activeCount":104},[],{"trials":13810,"activeCount":104},[],{"trials":13812,"activeCount":104},[],{"intervention":13786,"totalTrials":100,"cells":13814},{"EARLY_PHASE1":13815,"PHASE1":13817,"PHASE2":13819,"PHASE3":13825,"PHASE4":13827,"NA":13829},{"trials":13816,"activeCount":104},[],{"trials":13818,"activeCount":104},[],{"trials":13820,"activeCount":100,"soonestReadout":13779},[13821],{"nctId":13776,"briefTitle":13777,"status":143,"phases":13822,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":13782,"conditions":13823,"interventions":13824},[93],[25,3698,3699,4554],[13767,13785,13786,13787,13788],{"trials":13826,"activeCount":104},[],{"trials":13828,"activeCount":104},[],{"trials":13830,"activeCount":104},[],{"intervention":13787,"totalTrials":100,"cells":13832},{"EARLY_PHASE1":13833,"PHASE1":13835,"PHASE2":13837,"PHASE3":13843,"PHASE4":13845,"NA":13847},{"trials":13834,"activeCount":104},[],{"trials":13836,"activeCount":104},[],{"trials":13838,"activeCount":100,"soonestReadout":13779},[13839],{"nctId":13776,"briefTitle":13777,"status":143,"phases":13840,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":13782,"conditions":13841,"interventions":13842},[93],[25,3698,3699,4554],[13767,13785,13786,13787,13788],{"trials":13844,"activeCount":104},[],{"trials":13846,"activeCount":104},[],{"trials":13848,"activeCount":104},[],{"intervention":13788,"totalTrials":100,"cells":13850},{"EARLY_PHASE1":13851,"PHASE1":13853,"PHASE2":13855,"PHASE3":13861,"PHASE4":13863,"NA":13865},{"trials":13852,"activeCount":104},[],{"trials":13854,"activeCount":104},[],{"trials":13856,"activeCount":100,"soonestReadout":13779},[13857],{"nctId":13776,"briefTitle":13777,"status":143,"phases":13858,"primaryCompletion":13779,"completion":13780,"start":13781,"enrollment":13782,"conditions":13859,"interventions":13860},[93],[25,3698,3699,4554],[13767,13785,13786,13787,13788],{"trials":13862,"activeCount":104},[],{"trials":13864,"activeCount":104},[],{"trials":13866,"activeCount":104},[],{"intervention":13868,"totalTrials":100,"cells":13869},"Zimberelimab 240mg",{"EARLY_PHASE1":13870,"PHASE1":13872,"PHASE2":13874,"PHASE3":13883,"PHASE4":13885,"NA":13887},{"trials":13871,"activeCount":104},[],{"trials":13873,"activeCount":104},[],{"trials":13875,"activeCount":100,"soonestReadout":1875},[13876],{"nctId":13877,"briefTitle":13878,"status":143,"phases":13879,"primaryCompletion":1875,"completion":236,"start":13880,"enrollment":3705,"conditions":13881,"interventions":13882},"NCT05900765","A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma",[93],"2023-06-14",[8796],[13868],{"trials":13884,"activeCount":104},[],{"trials":13886,"activeCount":104},[],{"trials":13888,"activeCount":104},[],{"intervention":13890,"totalTrials":100,"cells":13891},"Tislelizumab Nab paclitaxel",{"EARLY_PHASE1":13892,"PHASE1":13894,"PHASE2":13896,"PHASE3":13908,"PHASE4":13910,"NA":13912},{"trials":13893,"activeCount":104},[],{"trials":13895,"activeCount":104},[],{"trials":13897,"activeCount":100,"soonestReadout":13902},[13898],{"nctId":13899,"briefTitle":13900,"status":116,"phases":13901,"primaryCompletion":13902,"completion":6546,"start":3312,"enrollment":1366,"conditions":13903,"interventions":13907},"NCT07145931","Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base",[93],"2027-09-20",[13904,13905,1293,13906],"Head and Neck Cancer Squamous Cell Carcinoma","Skull Base--Cancer","Objective Response Rate",[13890],{"trials":13909,"activeCount":104},[],{"trials":13911,"activeCount":104},[],{"trials":13913,"activeCount":104},[],{"intervention":13915,"totalTrials":100,"cells":13916},"Sintilimab in combination with AVD chemotherapy",{"EARLY_PHASE1":13917,"PHASE1":13919,"PHASE2":13921,"PHASE3":13931,"PHASE4":13933,"NA":13935},{"trials":13918,"activeCount":104},[],{"trials":13920,"activeCount":104},[],{"trials":13922,"activeCount":100,"soonestReadout":13927},[13923],{"nctId":13924,"briefTitle":13925,"status":143,"phases":13926,"primaryCompletion":13927,"completion":13928,"start":10907,"enrollment":7941,"conditions":13929,"interventions":13930},"NCT06848569","Sintilimab Plus AVD in Pediatric Low\u002FModerate Risk Hodgkin Lymphoma: A Phase II Study",[93],"2027-10-23","2031-10-23",[8796],[13915],{"trials":13932,"activeCount":104},[],{"trials":13934,"activeCount":104},[],{"trials":13936,"activeCount":104},[],{"intervention":3793,"totalTrials":100,"cells":13938},{"EARLY_PHASE1":13939,"PHASE1":13941,"PHASE2":13943,"PHASE3":13949,"PHASE4":13951,"NA":13953},{"trials":13940,"activeCount":104},[],{"trials":13942,"activeCount":104},[],{"trials":13944,"activeCount":100,"soonestReadout":2643},[13945],{"nctId":3787,"briefTitle":3788,"status":300,"phases":13946,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":13947,"interventions":13948},[93],[28,3521],[3793,2308,1381,443,3794,3795,270,1059],{"trials":13950,"activeCount":104},[],{"trials":13952,"activeCount":104},[],{"trials":13954,"activeCount":104},[],{"intervention":3794,"totalTrials":100,"cells":13956},{"EARLY_PHASE1":13957,"PHASE1":13959,"PHASE2":13961,"PHASE3":13967,"PHASE4":13969,"NA":13971},{"trials":13958,"activeCount":104},[],{"trials":13960,"activeCount":104},[],{"trials":13962,"activeCount":100,"soonestReadout":2643},[13963],{"nctId":3787,"briefTitle":3788,"status":300,"phases":13964,"primaryCompletion":2643,"completion":146,"start":3790,"enrollment":2096,"conditions":13965,"interventions":13966},[93],[28,3521],[3793,2308,1381,443,3794,3795,270,1059],{"trials":13968,"activeCount":104},[],{"trials":13970,"activeCount":104},[],{"trials":13972,"activeCount":104},[],{"intervention":3721,"totalTrials":100,"cells":13974},{"EARLY_PHASE1":13975,"PHASE1":13977,"PHASE2":13979,"PHASE3":13985,"PHASE4":13987,"NA":13989},{"trials":13976,"activeCount":104},[],{"trials":13978,"activeCount":104},[],{"trials":13980,"activeCount":100,"soonestReadout":3717},[13981],{"nctId":3714,"briefTitle":3715,"status":300,"phases":13982,"primaryCompletion":3717,"completion":119,"start":3718,"enrollment":461,"conditions":13983,"interventions":13984},[93],[661],[795,3721],{"trials":13986,"activeCount":104},[],{"trials":13988,"activeCount":104},[],{"trials":13990,"activeCount":104},[],{"intervention":13992,"totalTrials":100,"cells":13993},"Sacituzumab tirumotecan",{"EARLY_PHASE1":13994,"PHASE1":13996,"PHASE2":13998,"PHASE3":14012,"PHASE4":14014,"NA":14016},{"trials":13995,"activeCount":104},[],{"trials":13997,"activeCount":104},[],{"trials":13999,"activeCount":100,"soonestReadout":14004},[14000],{"nctId":14001,"briefTitle":14002,"status":116,"phases":14003,"primaryCompletion":14004,"completion":14005,"start":14006,"enrollment":9921,"conditions":14007,"interventions":14011},"NCT07343453","A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors",[93],"2027-12-22","2029-12-22","2025-12-22",[14008,14009,14010],"Thymic Epithelial Tumors","Advanced Stage","Second-line Therapy",[13992],{"trials":14013,"activeCount":104},[],{"trials":14015,"activeCount":104},[],{"trials":14017,"activeCount":104},[],{"intervention":14019,"totalTrials":100,"cells":14020},"Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab",{"EARLY_PHASE1":14021,"PHASE1":14023,"PHASE2":14025,"PHASE3":14034,"PHASE4":14036,"NA":14038},{"trials":14022,"activeCount":104},[],{"trials":14024,"activeCount":104},[],{"trials":14026,"activeCount":100,"soonestReadout":646},[14027],{"nctId":14028,"briefTitle":14029,"status":116,"phases":14030,"primaryCompletion":646,"completion":499,"start":14031,"enrollment":4035,"conditions":14032,"interventions":14033},"NCT07196540","IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx",[93],"2025-09-26",[2113],[14019],{"trials":14035,"activeCount":104},[],{"trials":14037,"activeCount":104},[],{"trials":14039,"activeCount":104},[],{"intervention":14041,"totalTrials":100,"cells":14042},"Doxorubicin Hydrochloride Liposome+Irinotecan",{"EARLY_PHASE1":14043,"PHASE1":14045,"PHASE2":14047,"PHASE3":14057,"PHASE4":14059,"NA":14061},{"trials":14044,"activeCount":104},[],{"trials":14046,"activeCount":104},[],{"trials":14048,"activeCount":100,"soonestReadout":236},[14049],{"nctId":14050,"briefTitle":14051,"status":143,"phases":14052,"primaryCompletion":236,"completion":1288,"start":290,"enrollment":9272,"conditions":14053,"interventions":14055},"NCT05457829","Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study",[93],[14054],"Rhabdomyosarcoma, Child",[14041,14056],"Temozolomide+Irinotecan+Vincristine",{"trials":14058,"activeCount":104},[],{"trials":14060,"activeCount":104},[],{"trials":14062,"activeCount":104},[],{"intervention":14056,"totalTrials":100,"cells":14064},{"EARLY_PHASE1":14065,"PHASE1":14067,"PHASE2":14069,"PHASE3":14075,"PHASE4":14077,"NA":14079},{"trials":14066,"activeCount":104},[],{"trials":14068,"activeCount":104},[],{"trials":14070,"activeCount":100,"soonestReadout":236},[14071],{"nctId":14050,"briefTitle":14051,"status":143,"phases":14072,"primaryCompletion":236,"completion":1288,"start":290,"enrollment":9272,"conditions":14073,"interventions":14074},[93],[14054],[14041,14056],{"trials":14076,"activeCount":104},[],{"trials":14078,"activeCount":104},[],{"trials":14080,"activeCount":104},[],{"intervention":14082,"totalTrials":100,"cells":14083},"Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine",{"EARLY_PHASE1":14084,"PHASE1":14086,"PHASE2":14088,"PHASE3":14099,"PHASE4":14101,"NA":14103},{"trials":14085,"activeCount":104},[],{"trials":14087,"activeCount":104},[],{"trials":14089,"activeCount":100,"soonestReadout":14094},[14090],{"nctId":14091,"briefTitle":14092,"status":116,"phases":14093,"primaryCompletion":14094,"completion":10906,"start":14094,"enrollment":205,"conditions":14095,"interventions":14097},"NCT05988372","Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)",[93],"2023-10-23",[14096],"Locally Advanced Pancreatic Cancer",[14082,14098],"Albumin-paclitaxel + Gemcitabine",{"trials":14100,"activeCount":104},[],{"trials":14102,"activeCount":104},[],{"trials":14104,"activeCount":104},[],{"intervention":14098,"totalTrials":100,"cells":14106},{"EARLY_PHASE1":14107,"PHASE1":14109,"PHASE2":14111,"PHASE3":14117,"PHASE4":14119,"NA":14121},{"trials":14108,"activeCount":104},[],{"trials":14110,"activeCount":104},[],{"trials":14112,"activeCount":100,"soonestReadout":14094},[14113],{"nctId":14091,"briefTitle":14092,"status":116,"phases":14114,"primaryCompletion":14094,"completion":10906,"start":14094,"enrollment":205,"conditions":14115,"interventions":14116},[93],[14096],[14082,14098],{"trials":14118,"activeCount":104},[],{"trials":14120,"activeCount":104},[],{"trials":14122,"activeCount":104},[],{"intervention":14124,"totalTrials":100,"cells":14125},"R-CMOP Regimen",{"EARLY_PHASE1":14126,"PHASE1":14128,"PHASE2":14130,"PHASE3":14141,"PHASE4":14143,"NA":14145},{"trials":14127,"activeCount":104},[],{"trials":14129,"activeCount":104},[],{"trials":14131,"activeCount":100,"soonestReadout":7779},[14132],{"nctId":14133,"briefTitle":14134,"status":143,"phases":14135,"primaryCompletion":7779,"completion":7449,"start":120,"enrollment":14136,"conditions":14137,"interventions":14139},"NCT06760039","Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL",[92,93],112,[14138],"Diffuse Large B-Cell Lymphoma",[14124,14140],"R-CHOP Regimen",{"trials":14142,"activeCount":104},[],{"trials":14144,"activeCount":104},[],{"trials":14146,"activeCount":104},[],{"intervention":14140,"totalTrials":100,"cells":14148},{"EARLY_PHASE1":14149,"PHASE1":14151,"PHASE2":14153,"PHASE3":14159,"PHASE4":14161,"NA":14163},{"trials":14150,"activeCount":104},[],{"trials":14152,"activeCount":104},[],{"trials":14154,"activeCount":100,"soonestReadout":7779},[14155],{"nctId":14133,"briefTitle":14134,"status":143,"phases":14156,"primaryCompletion":7779,"completion":7449,"start":120,"enrollment":14136,"conditions":14157,"interventions":14158},[92,93],[14138],[14124,14140],{"trials":14160,"activeCount":104},[],{"trials":14162,"activeCount":104},[],{"trials":14164,"activeCount":104},[],{"intervention":8646,"totalTrials":100,"cells":14166},{"EARLY_PHASE1":14167,"PHASE1":14169,"PHASE2":14171,"PHASE3":14177,"PHASE4":14179,"NA":14181},{"trials":14168,"activeCount":104},[],{"trials":14170,"activeCount":104},[],{"trials":14172,"activeCount":100,"soonestReadout":4044},[14173],{"nctId":8638,"briefTitle":8639,"status":143,"phases":14174,"primaryCompletion":4044,"completion":8641,"start":852,"enrollment":1712,"conditions":14175,"interventions":14176},[93],[8643,8644],[8646,8647],{"trials":14178,"activeCount":104},[],{"trials":14180,"activeCount":104},[],{"trials":14182,"activeCount":104},[],{"intervention":1123,"totalTrials":100,"cells":14184},{"EARLY_PHASE1":14185,"PHASE1":14187,"PHASE2":14189,"PHASE3":14195,"PHASE4":14197,"NA":14199},{"trials":14186,"activeCount":104},[],{"trials":14188,"activeCount":104},[],{"trials":14190,"activeCount":100,"soonestReadout":1117},[14191],{"nctId":1114,"briefTitle":1115,"status":116,"phases":14192,"primaryCompletion":1117,"completion":1118,"start":977,"enrollment":32,"conditions":14193,"interventions":14194},[93],[1120],[1122,284,1123],{"trials":14196,"activeCount":104},[],{"trials":14198,"activeCount":104},[],{"trials":14200,"activeCount":104},[],{"intervention":1137,"totalTrials":100,"cells":14202},{"EARLY_PHASE1":14203,"PHASE1":14205,"PHASE2":14207,"PHASE3":14213,"PHASE4":14215,"NA":14217},{"trials":14204,"activeCount":104},[],{"trials":14206,"activeCount":104},[],{"trials":14208,"activeCount":100,"soonestReadout":1132},[14209],{"nctId":1129,"briefTitle":1130,"status":143,"phases":14210,"primaryCompletion":1132,"completion":1133,"start":1054,"enrollment":996,"conditions":14211,"interventions":14212},[93],[1135],[284,1137],{"trials":14214,"activeCount":104},[],{"trials":14216,"activeCount":104},[],{"trials":14218,"activeCount":104},[],{"intervention":14220,"totalTrials":100,"cells":14221},"Serplulimab + FOLFOXIRI",{"EARLY_PHASE1":14222,"PHASE1":14224,"PHASE2":14226,"PHASE3":14234,"PHASE4":14236,"NA":14238},{"trials":14223,"activeCount":104},[],{"trials":14225,"activeCount":104},[],{"trials":14227,"activeCount":100,"soonestReadout":4739},[14228],{"nctId":14229,"briefTitle":14230,"status":116,"phases":14231,"primaryCompletion":4739,"completion":3651,"start":10019,"enrollment":1316,"conditions":14232,"interventions":14233},"NCT06099951","Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy",[93],[25],[14220],{"trials":14235,"activeCount":104},[],{"trials":14237,"activeCount":104},[],{"trials":14239,"activeCount":104},[],{"intervention":183,"totalTrials":1833,"cells":14241},{"EARLY_PHASE1":14242,"PHASE1":14244,"PHASE2":14246,"PHASE3":14298,"PHASE4":14320,"NA":14322},{"trials":14243,"activeCount":104},[],{"trials":14245,"activeCount":104},[],{"trials":14247,"activeCount":100,"soonestReadout":380},[14248,14252,14260,14264,14272,14276,14280,14290,14294],{"nctId":3950,"briefTitle":3951,"status":904,"phases":14249,"primaryCompletion":3953,"completion":3954,"start":3955,"enrollment":104,"conditions":14250,"interventions":14251},[93],[3957],[270,2308,183],{"nctId":14253,"briefTitle":14254,"status":904,"phases":14255,"primaryCompletion":3953,"completion":657,"start":459,"enrollment":104,"conditions":14256,"interventions":14257},"NCT02986451","Clarithromycin,Lenalidomide and Dexamethasone for Relapsed\u002FRefractory Myeloma",[93],[3957],[14258,14259,183],"clarithromycin","Lenalidomide",{"nctId":4745,"briefTitle":4746,"status":174,"phases":14261,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":14262,"interventions":14263},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"nctId":14265,"briefTitle":14266,"status":174,"phases":14267,"primaryCompletion":549,"completion":549,"start":178,"enrollment":1192,"conditions":14268,"interventions":14270},"NCT02846493","Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome",[93],[14269],"Ovarian Hyperstimulation Syndrome",[14271,4756],"bromocriptine",{"nctId":2245,"briefTitle":2246,"status":174,"phases":14273,"primaryCompletion":618,"completion":906,"start":2165,"enrollment":32,"conditions":14274,"interventions":14275},[93],[2249],[2251,49,542,1205,183],{"nctId":2072,"briefTitle":2073,"status":143,"phases":14277,"primaryCompletion":380,"completion":380,"start":2075,"enrollment":2076,"conditions":14278,"interventions":14279},[93],[1020],[183,2079,542,2080,664,54,272,542,2080,664],{"nctId":14281,"briefTitle":14282,"status":174,"phases":14283,"primaryCompletion":1227,"completion":1227,"start":14284,"enrollment":205,"conditions":14285,"interventions":14288},"NCT03641456","VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma",[93],"2020-09-25",[14286,14287,154],"Myeloma","Newly Diagnosed",[14289,14259,183],"bortezomib",{"nctId":2261,"briefTitle":2262,"status":174,"phases":14291,"primaryCompletion":459,"completion":2264,"start":1375,"enrollment":32,"conditions":14292,"interventions":14293},[93],[2249],[2267,49,1205,183],{"nctId":8336,"briefTitle":8337,"status":174,"phases":14295,"primaryCompletion":1952,"completion":8339,"start":8340,"enrollment":5071,"conditions":14296,"interventions":14297},[92,93],[8342],[8344,8308,183,8344,8308,183,8344,8308,183,8344,8308,183],{"trials":14299,"activeCount":104},[14300,14312,14316],{"nctId":14301,"briefTitle":14302,"status":328,"phases":14303,"primaryCompletion":14304,"completion":1094,"start":14305,"enrollment":14306,"conditions":14307,"interventions":14309},"NCT03674294","Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy",[94],"2020-03-31","2015-08-04",248,[2112,14308],"Chemotherapy-induced Nausea and Vomiting",[14310,14311,183],"Aprepitant","Palonosetron",{"nctId":172,"briefTitle":173,"status":174,"phases":14313,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":14314,"interventions":14315},[94],[181],[183,156],{"nctId":7884,"briefTitle":7885,"status":174,"phases":14317,"primaryCompletion":5304,"completion":7887,"start":1500,"enrollment":800,"conditions":14318,"interventions":14319},[94],[7889],[2308,244,183,2307],{"trials":14321,"activeCount":104},[],{"trials":14323,"activeCount":104},[14324],{"nctId":14325,"briefTitle":14326,"status":174,"phases":14327,"primaryCompletion":491,"completion":491,"start":3955,"enrollment":205,"conditions":14328,"interventions":14329},"NCT02644720","Neural Compensation, Visual Function and Visual Quality After Monofocal or Multifocal Intraocular Lens Implantation",[96],[31],[183],{"intervention":8031,"totalTrials":1255,"cells":14331},{"EARLY_PHASE1":14332,"PHASE1":14334,"PHASE2":14336,"PHASE3":14342,"PHASE4":14344,"NA":14346},{"trials":14333,"activeCount":104},[],{"trials":14335,"activeCount":104},[],{"trials":14337,"activeCount":100,"soonestReadout":1277},[14338],{"nctId":8025,"briefTitle":8026,"status":143,"phases":14339,"primaryCompletion":1277,"completion":851,"start":8028,"enrollment":32,"conditions":14340,"interventions":14341},[93],[3006],[3667,8031],{"trials":14343,"activeCount":104},[],{"trials":14345,"activeCount":104},[],{"trials":14347,"activeCount":104},[14348],{"nctId":14349,"briefTitle":14350,"status":328,"phases":14351,"primaryCompletion":14352,"completion":2417,"start":14353,"enrollment":189,"conditions":14354,"interventions":14355},"NCT07272265","The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study",[96],"2025-05-31","2020-10-28",[3006],[8031],{"intervention":13412,"totalTrials":1255,"cells":14357},{"EARLY_PHASE1":14358,"PHASE1":14360,"PHASE2":14362,"PHASE3":14368,"PHASE4":14370,"NA":14372},{"trials":14359,"activeCount":104},[],{"trials":14361,"activeCount":104},[],{"trials":14363,"activeCount":100,"soonestReadout":43},[14364],{"nctId":41,"briefTitle":42,"status":300,"phases":14365,"primaryCompletion":43,"completion":379,"start":13409,"enrollment":492,"conditions":14366,"interventions":14367},[93],[19],[44,13412],{"trials":14369,"activeCount":104},[],{"trials":14371,"activeCount":104},[],{"trials":14373,"activeCount":104},[14374],{"nctId":14375,"briefTitle":14376,"status":174,"phases":14377,"primaryCompletion":290,"completion":1238,"start":14378,"enrollment":1228,"conditions":14379,"interventions":14381},"NCT03591705","TACE-HAIC vs. HAIC for Potentially Resectable HCC",[96],"2018-07-06",[14380,19],"Potentially Resection",[14382,13412],"TACE-HAIC",{"intervention":2306,"totalTrials":2627,"cells":14384},{"EARLY_PHASE1":14385,"PHASE1":14387,"PHASE2":14397,"PHASE3":14403,"PHASE4":14409,"NA":14411},{"trials":14386,"activeCount":104},[],{"trials":14388,"activeCount":1255,"soonestReadout":4739},[14389,14393],{"nctId":4005,"briefTitle":4006,"status":143,"phases":14390,"primaryCompletion":4008,"completion":4009,"start":1509,"enrollment":26,"conditions":14391,"interventions":14392},[92],[4011],[54,1767,2306],{"nctId":7554,"briefTitle":7555,"status":300,"phases":14394,"primaryCompletion":4739,"completion":895,"start":7557,"enrollment":3179,"conditions":14395,"interventions":14396},[92],[4011],[7527,54,2306],{"trials":14398,"activeCount":104},[14399],{"nctId":4745,"briefTitle":4746,"status":174,"phases":14400,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":14401,"interventions":14402},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":14404,"activeCount":104},[14405],{"nctId":2300,"briefTitle":2301,"status":1091,"phases":14406,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":14407,"interventions":14408},[94],[2235],[49,542,1205,411,2306,2307,2308,2309],{"trials":14410,"activeCount":104},[],{"trials":14412,"activeCount":104},[],{"intervention":7838,"totalTrials":1255,"cells":14414},{"EARLY_PHASE1":14415,"PHASE1":14421,"PHASE2":14427,"PHASE3":14429,"PHASE4":14431,"NA":14433},{"trials":14416,"activeCount":100,"soonestReadout":7832},[14417],{"nctId":7829,"briefTitle":7830,"status":116,"phases":14418,"primaryCompletion":7832,"completion":7079,"start":3663,"enrollment":959,"conditions":14419,"interventions":14420},[91],[7834,7835,1111],[7837,7838,2308],{"trials":14422,"activeCount":100,"soonestReadout":7845},[14423],{"nctId":7842,"briefTitle":7843,"status":143,"phases":14424,"primaryCompletion":7845,"completion":7846,"start":7847,"enrollment":2439,"conditions":14425,"interventions":14426},[92],[2186],[7850,7838,2308],{"trials":14428,"activeCount":104},[],{"trials":14430,"activeCount":104},[],{"trials":14432,"activeCount":104},[],{"trials":14434,"activeCount":104},[],{"intervention":14436,"totalTrials":1255,"cells":14437},"umbilical cord blood NK cells",{"EARLY_PHASE1":14438,"PHASE1":14440,"PHASE2":14449,"PHASE3":14451,"PHASE4":14453,"NA":14455},{"trials":14439,"activeCount":104},[],{"trials":14441,"activeCount":100,"soonestReadout":12089},[14442],{"nctId":14443,"briefTitle":14444,"status":143,"phases":14445,"primaryCompletion":12089,"completion":14446,"start":2458,"enrollment":32,"conditions":14447,"interventions":14448},"NCT06631391","Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R\u002FR Neuroblastoma.",[92],"2029-11-30",[1763],[14436],{"trials":14450,"activeCount":104},[],{"trials":14452,"activeCount":104},[],{"trials":14454,"activeCount":104},[],{"trials":14456,"activeCount":100,"soonestReadout":3663},[14457],{"nctId":14458,"briefTitle":14459,"status":143,"phases":14460,"primaryCompletion":3663,"completion":7832,"start":2458,"enrollment":492,"conditions":14461,"interventions":14462},"NCT06848582","Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study",[96],[12091],[14436],{"intervention":244,"totalTrials":1861,"cells":14464},{"EARLY_PHASE1":14465,"PHASE1":14467,"PHASE2":14473,"PHASE3":14479,"PHASE4":14485,"NA":14487},{"trials":14466,"activeCount":104},[],{"trials":14468,"activeCount":100,"soonestReadout":236},[14469],{"nctId":233,"briefTitle":234,"status":143,"phases":14470,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":14471,"interventions":14472},[92],[241,242],[244,225,244,244,225],{"trials":14474,"activeCount":104},[14475],{"nctId":14281,"briefTitle":14282,"status":174,"phases":14476,"primaryCompletion":1227,"completion":1227,"start":14284,"enrollment":205,"conditions":14477,"interventions":14478},[93],[14286,14287,154],[14289,14259,183],{"trials":14480,"activeCount":104},[14481],{"nctId":7884,"briefTitle":7885,"status":174,"phases":14482,"primaryCompletion":5304,"completion":7887,"start":1500,"enrollment":800,"conditions":14483,"interventions":14484},[94],[7889],[2308,244,183,2307],{"trials":14486,"activeCount":104},[],{"trials":14488,"activeCount":104},[],{"intervention":14490,"totalTrials":100,"cells":14491},"WGc-043",{"EARLY_PHASE1":14492,"PHASE1":14494,"PHASE2":14504,"PHASE3":14506,"PHASE4":14508,"NA":14510},{"trials":14493,"activeCount":104},[],{"trials":14495,"activeCount":100,"soonestReadout":2066},[14496],{"nctId":14497,"briefTitle":14498,"status":116,"phases":14499,"primaryCompletion":2066,"completion":237,"start":14500,"enrollment":2017,"conditions":14501,"interventions":14503},"NCT07028047","Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study",[92],"2025-06-23",[14502],"Advanced EBV-positive Malignant Solid Tumors",[14490],{"trials":14505,"activeCount":104},[],{"trials":14507,"activeCount":104},[],{"trials":14509,"activeCount":104},[],{"trials":14511,"activeCount":104},[],{"intervention":14513,"totalTrials":100,"cells":14514},"Sintilimab and Linperlisib Combination Treatment",{"EARLY_PHASE1":14515,"PHASE1":14517,"PHASE2":14527,"PHASE3":14529,"PHASE4":14531,"NA":14533},{"trials":14516,"activeCount":104},[],{"trials":14518,"activeCount":100,"soonestReadout":6749},[14519],{"nctId":14520,"briefTitle":14521,"status":143,"phases":14522,"primaryCompletion":6749,"completion":14523,"start":5936,"enrollment":3748,"conditions":14524,"interventions":14526},"NCT06793956","Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer\u002FT Cell Lymphoma",[92],"2030-01-31",[14525],"Extranodal Natural Killer\u002FT Cell Lymphoma",[14513],{"trials":14528,"activeCount":104},[],{"trials":14530,"activeCount":104},[],{"trials":14532,"activeCount":104},[],{"trials":14534,"activeCount":104},[],{"intervention":14536,"totalTrials":100,"cells":14537},"WTX212A",{"EARLY_PHASE1":14538,"PHASE1":14540,"PHASE2":14551,"PHASE3":14553,"PHASE4":14555,"NA":14557},{"trials":14539,"activeCount":104},[],{"trials":14541,"activeCount":100,"soonestReadout":4666},[14542],{"nctId":14543,"briefTitle":14544,"status":143,"phases":14545,"primaryCompletion":4666,"completion":1400,"start":14546,"enrollment":3748,"conditions":14547,"interventions":14550},"NCT07269899","A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors",[92],"2025-11-25",[14548,14549],"Solid Tumor Cancer","Cancer",[14536],{"trials":14552,"activeCount":104},[],{"trials":14554,"activeCount":104},[],{"trials":14556,"activeCount":104},[],{"trials":14558,"activeCount":104},[],{"intervention":14560,"totalTrials":100,"cells":14561},"4mg\u002Fml KDR2-2 suspension eyedrop",{"EARLY_PHASE1":14562,"PHASE1":14564,"PHASE2":14576,"PHASE3":14578,"PHASE4":14580,"NA":14582},{"trials":14563,"activeCount":104},[],{"trials":14565,"activeCount":100,"soonestReadout":1064},[14566],{"nctId":14567,"briefTitle":14568,"status":300,"phases":14569,"primaryCompletion":1064,"completion":1064,"start":14570,"enrollment":492,"conditions":14571,"interventions":14574},"NCT04844619","KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial",[92],"2021-04-19",[14572,14573],"Neovascular Glaucoma","Neovascularization",[14560,14575],"16mg\u002Fml KDR2-2 suspension eyedrop",{"trials":14577,"activeCount":104},[],{"trials":14579,"activeCount":104},[],{"trials":14581,"activeCount":104},[],{"trials":14583,"activeCount":104},[],{"intervention":14575,"totalTrials":100,"cells":14585},{"EARLY_PHASE1":14586,"PHASE1":14588,"PHASE2":14594,"PHASE3":14596,"PHASE4":14598,"NA":14600},{"trials":14587,"activeCount":104},[],{"trials":14589,"activeCount":100,"soonestReadout":1064},[14590],{"nctId":14567,"briefTitle":14568,"status":300,"phases":14591,"primaryCompletion":1064,"completion":1064,"start":14570,"enrollment":492,"conditions":14592,"interventions":14593},[92],[14572,14573],[14560,14575],{"trials":14595,"activeCount":104},[],{"trials":14597,"activeCount":104},[],{"trials":14599,"activeCount":104},[],{"trials":14601,"activeCount":104},[],{"intervention":7850,"totalTrials":100,"cells":14603},{"EARLY_PHASE1":14604,"PHASE1":14606,"PHASE2":14612,"PHASE3":14614,"PHASE4":14616,"NA":14618},{"trials":14605,"activeCount":104},[],{"trials":14607,"activeCount":100,"soonestReadout":7845},[14608],{"nctId":7842,"briefTitle":7843,"status":143,"phases":14609,"primaryCompletion":7845,"completion":7846,"start":7847,"enrollment":2439,"conditions":14610,"interventions":14611},[92],[2186],[7850,7838,2308],{"trials":14613,"activeCount":104},[],{"trials":14615,"activeCount":104},[],{"trials":14617,"activeCount":104},[],{"trials":14619,"activeCount":104},[],{"intervention":14621,"totalTrials":100,"cells":14622},"GDMT",{"EARLY_PHASE1":14623,"PHASE1":14633,"PHASE2":14635,"PHASE3":14637,"PHASE4":14639,"NA":14641},{"trials":14624,"activeCount":100,"soonestReadout":14629},[14625],{"nctId":14626,"briefTitle":14627,"status":116,"phases":14628,"primaryCompletion":14629,"completion":6476,"start":2206,"enrollment":189,"conditions":14630,"interventions":14632},"NCT07197021","Transcatheter Edge-to-Edge Repair In Moderate and Exertional-Induced Severe MR (TIMER)",[91],"2027-09-30",[14631],"Mitral Regurgitation Functional",[14621],{"trials":14634,"activeCount":104},[],{"trials":14636,"activeCount":104},[],{"trials":14638,"activeCount":104},[],{"trials":14640,"activeCount":104},[],{"trials":14642,"activeCount":104},[],{"intervention":14644,"totalTrials":100,"cells":14645},"KSD-101",{"EARLY_PHASE1":14646,"PHASE1":14654,"PHASE2":14656,"PHASE3":14658,"PHASE4":14660,"NA":14662},{"trials":14647,"activeCount":100,"soonestReadout":379},[14648],{"nctId":14649,"briefTitle":14650,"status":116,"phases":14651,"primaryCompletion":379,"completion":380,"start":8897,"enrollment":3748,"conditions":14652,"interventions":14653},"NCT06370026","KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial",[91],[16],[14644],{"trials":14655,"activeCount":104},[],{"trials":14657,"activeCount":104},[],{"trials":14659,"activeCount":104},[],{"trials":14661,"activeCount":104},[],{"trials":14663,"activeCount":104},[],{"intervention":7837,"totalTrials":100,"cells":14665},{"EARLY_PHASE1":14666,"PHASE1":14672,"PHASE2":14674,"PHASE3":14676,"PHASE4":14678,"NA":14680},{"trials":14667,"activeCount":100,"soonestReadout":7832},[14668],{"nctId":7829,"briefTitle":7830,"status":116,"phases":14669,"primaryCompletion":7832,"completion":7079,"start":3663,"enrollment":959,"conditions":14670,"interventions":14671},[91],[7834,7835,1111],[7837,7838,2308],{"trials":14673,"activeCount":104},[],{"trials":14675,"activeCount":104},[],{"trials":14677,"activeCount":104},[],{"trials":14679,"activeCount":104},[],{"trials":14681,"activeCount":104},[],{"intervention":1524,"totalTrials":1861,"cells":14683},{"EARLY_PHASE1":14684,"PHASE1":14686,"PHASE2":14688,"PHASE3":14690,"PHASE4":14696,"NA":14698},{"trials":14685,"activeCount":104},[],{"trials":14687,"activeCount":104},[],{"trials":14689,"activeCount":104},[],{"trials":14691,"activeCount":104},[14692],{"nctId":1515,"briefTitle":1516,"status":174,"phases":14693,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":14694,"interventions":14695},[94],[1522],[1524,54,444],{"trials":14697,"activeCount":104},[],{"trials":14699,"activeCount":100,"soonestReadout":1227},[14700,14704],{"nctId":2983,"briefTitle":2984,"status":143,"phases":14701,"primaryCompletion":1227,"completion":2679,"start":2986,"enrollment":1712,"conditions":14702,"interventions":14703},[96],[19,2988,1250,353],[353,1524],{"nctId":14705,"briefTitle":14706,"status":328,"phases":14707,"primaryCompletion":1027,"completion":1238,"start":14708,"enrollment":2096,"conditions":14709,"interventions":14710},"NCT06980350","Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy",[],"2018-07-01",[25],[1524],{"intervention":14712,"totalTrials":1861,"cells":14713},"Simvastatin",{"EARLY_PHASE1":14714,"PHASE1":14716,"PHASE2":14718,"PHASE3":14720,"PHASE4":14722,"NA":14724},{"trials":14715,"activeCount":104},[],{"trials":14717,"activeCount":104},[],{"trials":14719,"activeCount":104},[],{"trials":14721,"activeCount":104},[],{"trials":14723,"activeCount":104},[],{"trials":14725,"activeCount":100,"soonestReadout":260},[14726,14737,14746],{"nctId":14727,"briefTitle":14728,"status":328,"phases":14729,"primaryCompletion":14730,"completion":4045,"start":7637,"enrollment":9013,"conditions":14731,"interventions":14736},"NCT01178710","Effect of Simvastatin on Cardiac Function",[96],"2011-06",[14732,14733,14734,14735],"Rheumatic Heart Disease","Congenital Heart Disease","Aneurysm","Heart Valve Disease",[14712],{"nctId":14738,"briefTitle":14739,"status":143,"phases":14740,"primaryCompletion":260,"completion":419,"start":14741,"enrollment":14742,"conditions":14743,"interventions":14744},"NCT01653223","Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery",[96],"2013-01",369,[14733,14735],[14745],"simvastatin",{"nctId":14747,"briefTitle":14748,"status":328,"phases":14749,"primaryCompletion":5181,"completion":3757,"start":7899,"enrollment":1389,"conditions":14750,"interventions":14752},"NCT01106495","Effect of Enhanced External Counterpulsation (EECP) on Subclinical Atherosclerosis",[96],[14751],"Atherosclerosis",[14712],{"intervention":1233,"totalTrials":1255,"cells":14754},{"EARLY_PHASE1":14755,"PHASE1":14757,"PHASE2":14759,"PHASE3":14765,"PHASE4":14767,"NA":14769},{"trials":14756,"activeCount":104},[],{"trials":14758,"activeCount":104},[],{"trials":14760,"activeCount":104},[14761],{"nctId":1904,"briefTitle":1905,"status":174,"phases":14762,"primaryCompletion":1907,"completion":1459,"start":1908,"enrollment":492,"conditions":14763,"interventions":14764},[93],[19],[1233,272],{"trials":14766,"activeCount":104},[],{"trials":14768,"activeCount":104},[],{"trials":14770,"activeCount":100,"soonestReadout":1227},[14771],{"nctId":1224,"briefTitle":1225,"status":143,"phases":14772,"primaryCompletion":1227,"completion":1227,"start":949,"enrollment":1228,"conditions":14773,"interventions":14774},[],[1230,1231,272],[272,1233,69,284,483,268],{"intervention":14776,"totalTrials":1255,"cells":14777},"Doxycycline Hyclate",{"EARLY_PHASE1":14778,"PHASE1":14780,"PHASE2":14782,"PHASE3":14800,"PHASE4":14802,"NA":14804},{"trials":14779,"activeCount":104},[],{"trials":14781,"activeCount":104},[],{"trials":14783,"activeCount":104},[14784],{"nctId":14785,"briefTitle":14786,"status":174,"phases":14787,"primaryCompletion":9102,"completion":9102,"start":14788,"enrollment":1339,"conditions":14789,"interventions":14798},"NCT02203682","Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy",[93],"2014-07",[12946,14790,14791,14792,14793,14794,14795,14796,14797],"Graves Disease","Thyroid-associated Ophthalmopathy","Thyroid Diseases","Endocrine System Diseases","Eye Diseases, Hereditary","Hyperthyroidism","Autoimmune Diseases","Immune System Diseases",[14799],"Doxycycline hyclate",{"trials":14801,"activeCount":104},[],{"trials":14803,"activeCount":104},[],{"trials":14805,"activeCount":100,"soonestReadout":302},[14806],{"nctId":14807,"briefTitle":14808,"status":143,"phases":14809,"primaryCompletion":302,"completion":1277,"start":1509,"enrollment":239,"conditions":14810,"interventions":14812},"NCT05112211","Multi-model Image of Doxycycline in TAO",[96],[14811],"Thyroid Associated Ophthalmopathy",[14776],{"intervention":14814,"totalTrials":1255,"cells":14815},"Health education",{"EARLY_PHASE1":14816,"PHASE1":14818,"PHASE2":14820,"PHASE3":14822,"PHASE4":14824,"NA":14826},{"trials":14817,"activeCount":104},[],{"trials":14819,"activeCount":104},[],{"trials":14821,"activeCount":104},[],{"trials":14823,"activeCount":104},[],{"trials":14825,"activeCount":104},[],{"trials":14827,"activeCount":100,"soonestReadout":1508},[14828,14838],{"nctId":14829,"briefTitle":14830,"status":116,"phases":14831,"primaryCompletion":1508,"completion":1508,"start":14832,"enrollment":14833,"conditions":14834,"interventions":14837},"NCT07002021","Effectiveness Evaluation of the \"Mosquito-Free Campus\" Initiative on Dengue Fever Prevention and Control: A Cluster Randomized Controlled Trial",[96],"2025-06-15",3940,[14835,14836],"Dengue","Infection Prevention",[14814],{"nctId":14839,"briefTitle":14840,"status":174,"phases":14841,"primaryCompletion":1347,"completion":1347,"start":14842,"enrollment":14843,"conditions":14844,"interventions":14847},"NCT06048406","Effect of Health Education on Promoting Influenza Vaccination Health Literacy",[96],"2023-09-11",3036,[14845,14846],"Vaccination; Infection","Influenza",[14814],{"intervention":3521,"totalTrials":1255,"cells":14849},{"EARLY_PHASE1":14850,"PHASE1":14852,"PHASE2":14854,"PHASE3":14856,"PHASE4":14862,"NA":14864},{"trials":14851,"activeCount":104},[],{"trials":14853,"activeCount":104},[],{"trials":14855,"activeCount":104},[],{"trials":14857,"activeCount":104},[14858],{"nctId":4651,"briefTitle":4652,"status":328,"phases":14859,"primaryCompletion":4008,"completion":4008,"start":1338,"enrollment":4654,"conditions":14860,"interventions":14861},[94],[539],[3521,4657],{"trials":14863,"activeCount":104},[],{"trials":14865,"activeCount":100,"soonestReadout":4666},[14866],{"nctId":4663,"briefTitle":4664,"status":116,"phases":14867,"primaryCompletion":4666,"completion":2798,"start":4667,"enrollment":1339,"conditions":14868,"interventions":14869},[96],[4669,4670,3521,1291],[3521,2463],{"intervention":14871,"totalTrials":100,"cells":14872},"Metformin Hydrochloride and Empagliflozin tables",{"EARLY_PHASE1":14873,"PHASE1":14875,"PHASE2":14877,"PHASE3":14879,"PHASE4":14881,"NA":14883},{"trials":14874,"activeCount":104},[],{"trials":14876,"activeCount":104},[],{"trials":14878,"activeCount":104},[],{"trials":14880,"activeCount":104},[],{"trials":14882,"activeCount":104},[],{"trials":14884,"activeCount":100,"soonestReadout":379},[14885],{"nctId":14886,"briefTitle":14887,"status":300,"phases":14888,"primaryCompletion":379,"completion":379,"start":14889,"enrollment":14890,"conditions":14891,"interventions":14893},"NCT07003191","Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes",[],"2023-08-02",2600,[14892],"Type 2 Diabetes",[14871],{"intervention":14895,"totalTrials":100,"cells":14896},"Fruquintinib+Paclitaxel",{"EARLY_PHASE1":14897,"PHASE1":14899,"PHASE2":14901,"PHASE3":14903,"PHASE4":14905,"NA":14907},{"trials":14898,"activeCount":104},[],{"trials":14900,"activeCount":104},[],{"trials":14902,"activeCount":104},[],{"trials":14904,"activeCount":104},[],{"trials":14906,"activeCount":104},[],{"trials":14908,"activeCount":100,"soonestReadout":14913},[14909],{"nctId":14910,"briefTitle":14911,"status":116,"phases":14912,"primaryCompletion":14913,"completion":380,"start":14914,"enrollment":14915,"conditions":14916,"interventions":14920},"NCT07144995","MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G\u002FGEJ Adenocarcinoma",[],"2026-08-05","2025-09-05",1143,[14917,14918,2594,14919],"Advanced Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Ramucirumab",[14895,14921],"Ramucirumab+Paclitaxel",{"intervention":14921,"totalTrials":100,"cells":14923},{"EARLY_PHASE1":14924,"PHASE1":14926,"PHASE2":14928,"PHASE3":14930,"PHASE4":14932,"NA":14934},{"trials":14925,"activeCount":104},[],{"trials":14927,"activeCount":104},[],{"trials":14929,"activeCount":104},[],{"trials":14931,"activeCount":104},[],{"trials":14933,"activeCount":104},[],{"trials":14935,"activeCount":100,"soonestReadout":14913},[14936],{"nctId":14910,"briefTitle":14911,"status":116,"phases":14937,"primaryCompletion":14913,"completion":380,"start":14914,"enrollment":14915,"conditions":14938,"interventions":14939},[],[14917,14918,2594,14919],[14895,14921],{"intervention":14941,"totalTrials":100,"cells":14942},"Lenvatinb",{"EARLY_PHASE1":14943,"PHASE1":14945,"PHASE2":14947,"PHASE3":14949,"PHASE4":14951,"NA":14953},{"trials":14944,"activeCount":104},[],{"trials":14946,"activeCount":104},[],{"trials":14948,"activeCount":104},[],{"trials":14950,"activeCount":104},[],{"trials":14952,"activeCount":104},[],{"trials":14954,"activeCount":100,"soonestReadout":4429},[14955],{"nctId":14956,"briefTitle":14957,"status":143,"phases":14958,"primaryCompletion":4429,"completion":10862,"start":3049,"enrollment":430,"conditions":14959,"interventions":14962},"NCT06609850","The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma",[96],[2378,353,14960,14961,3052],"Local Therapy","Ablation",[14941],{"intervention":14964,"totalTrials":100,"cells":14965},"AIs",{"EARLY_PHASE1":14966,"PHASE1":14968,"PHASE2":14970,"PHASE3":14972,"PHASE4":14974,"NA":14976},{"trials":14967,"activeCount":104},[],{"trials":14969,"activeCount":104},[],{"trials":14971,"activeCount":104},[],{"trials":14973,"activeCount":104},[],{"trials":14975,"activeCount":104},[],{"trials":14977,"activeCount":100,"soonestReadout":1963},[14978],{"nctId":14979,"briefTitle":14980,"status":143,"phases":14981,"primaryCompletion":1963,"completion":145,"start":88,"enrollment":14982,"conditions":14983,"interventions":14984},"NCT06195202","Serum Estradiol (E2) Levels in Breast Cancer Patients During Endocrine Therapy by High Performance Liquid Chromatography-tandem Mass Spectrometry (LC-MS \u002FMS)",[],2000,[28],[14964,14985,14986],"OFS+AIs","FUL",{"intervention":14985,"totalTrials":100,"cells":14988},{"EARLY_PHASE1":14989,"PHASE1":14991,"PHASE2":14993,"PHASE3":14995,"PHASE4":14997,"NA":14999},{"trials":14990,"activeCount":104},[],{"trials":14992,"activeCount":104},[],{"trials":14994,"activeCount":104},[],{"trials":14996,"activeCount":104},[],{"trials":14998,"activeCount":104},[],{"trials":15000,"activeCount":100,"soonestReadout":1963},[15001],{"nctId":14979,"briefTitle":14980,"status":143,"phases":15002,"primaryCompletion":1963,"completion":145,"start":88,"enrollment":14982,"conditions":15003,"interventions":15004},[],[28],[14964,14985,14986],{"intervention":14986,"totalTrials":100,"cells":15006},{"EARLY_PHASE1":15007,"PHASE1":15009,"PHASE2":15011,"PHASE3":15013,"PHASE4":15015,"NA":15017},{"trials":15008,"activeCount":104},[],{"trials":15010,"activeCount":104},[],{"trials":15012,"activeCount":104},[],{"trials":15014,"activeCount":104},[],{"trials":15016,"activeCount":104},[],{"trials":15018,"activeCount":100,"soonestReadout":1963},[15019],{"nctId":14979,"briefTitle":14980,"status":143,"phases":15020,"primaryCompletion":1963,"completion":145,"start":88,"enrollment":14982,"conditions":15021,"interventions":15022},[],[28],[14964,14985,14986],{"intervention":15024,"totalTrials":100,"cells":15025},"SCA Induction followed by Response-Adapted Therapy",{"EARLY_PHASE1":15026,"PHASE1":15028,"PHASE2":15030,"PHASE3":15032,"PHASE4":15034,"NA":15036},{"trials":15027,"activeCount":104},[],{"trials":15029,"activeCount":104},[],{"trials":15031,"activeCount":104},[],{"trials":15033,"activeCount":104},[],{"trials":15035,"activeCount":104},[],{"trials":15037,"activeCount":100,"soonestReadout":1005},[15038],{"nctId":15039,"briefTitle":15040,"status":116,"phases":15041,"primaryCompletion":1005,"completion":1005,"start":1508,"enrollment":32,"conditions":15042,"interventions":15048},"NCT07542912","Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK\u002FT-Cell Lymphoma",[96],[15043,15044,15045,15046,15047],"Complete Remission Rate， CRR","Progression Free Survival","Overall Survival","Adverse Event","Duration of Response",[15024],{"intervention":2834,"totalTrials":100,"cells":15050},{"EARLY_PHASE1":15051,"PHASE1":15053,"PHASE2":15055,"PHASE3":15057,"PHASE4":15059,"NA":15061},{"trials":15052,"activeCount":104},[],{"trials":15054,"activeCount":104},[],{"trials":15056,"activeCount":104},[],{"trials":15058,"activeCount":104},[],{"trials":15060,"activeCount":104},[],{"trials":15062,"activeCount":100,"soonestReadout":379},[15063],{"nctId":2829,"briefTitle":2830,"status":116,"phases":15064,"primaryCompletion":379,"completion":646,"start":1667,"enrollment":800,"conditions":15065,"interventions":15066},[96],[16],[2834,2402],{"intervention":15068,"totalTrials":100,"cells":15069},"CSII in the prediction model group",{"EARLY_PHASE1":15070,"PHASE1":15072,"PHASE2":15074,"PHASE3":15076,"PHASE4":15078,"NA":15080},{"trials":15071,"activeCount":104},[],{"trials":15073,"activeCount":104},[],{"trials":15075,"activeCount":104},[],{"trials":15077,"activeCount":104},[],{"trials":15079,"activeCount":104},[],{"trials":15081,"activeCount":100,"soonestReadout":548},[15082],{"nctId":15083,"briefTitle":15084,"status":143,"phases":15085,"primaryCompletion":548,"completion":548,"start":15086,"enrollment":15087,"conditions":15088,"interventions":15089},"NCT07066891","Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm",[96],"2025-07-15",400,[6775,14892],[15068,15090],"CSII in the empirical group",{"intervention":15090,"totalTrials":100,"cells":15092},{"EARLY_PHASE1":15093,"PHASE1":15095,"PHASE2":15097,"PHASE3":15099,"PHASE4":15101,"NA":15103},{"trials":15094,"activeCount":104},[],{"trials":15096,"activeCount":104},[],{"trials":15098,"activeCount":104},[],{"trials":15100,"activeCount":104},[],{"trials":15102,"activeCount":104},[],{"trials":15104,"activeCount":100,"soonestReadout":548},[15105],{"nctId":15083,"briefTitle":15084,"status":143,"phases":15106,"primaryCompletion":548,"completion":548,"start":15086,"enrollment":15087,"conditions":15107,"interventions":15108},[96],[6775,14892],[15068,15090],{"intervention":15110,"totalTrials":100,"cells":15111},"cisplatin-based chemotherapy",{"EARLY_PHASE1":15112,"PHASE1":15114,"PHASE2":15116,"PHASE3":15118,"PHASE4":15120,"NA":15122},{"trials":15113,"activeCount":104},[],{"trials":15115,"activeCount":104},[],{"trials":15117,"activeCount":104},[],{"trials":15119,"activeCount":104},[],{"trials":15121,"activeCount":104},[],{"trials":15123,"activeCount":100,"soonestReadout":380},[15124],{"nctId":15125,"briefTitle":15126,"status":143,"phases":15127,"primaryCompletion":380,"completion":119,"start":2342,"enrollment":205,"conditions":15128,"interventions":15132},"NCT04544969","Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC",[],[15129,16,15130,15131],"Circulating Tumor Cell","Distant Metastases.Clinical","Effects of Chemotherapy",[15110],{"intervention":15134,"totalTrials":100,"cells":15135},"Trastuzumab Deruxtecan",{"EARLY_PHASE1":15136,"PHASE1":15138,"PHASE2":15140,"PHASE3":15142,"PHASE4":15144,"NA":15146},{"trials":15137,"activeCount":104},[],{"trials":15139,"activeCount":104},[],{"trials":15141,"activeCount":104},[],{"trials":15143,"activeCount":104},[],{"trials":15145,"activeCount":104},[],{"trials":15147,"activeCount":100,"soonestReadout":1132},[15148],{"nctId":15149,"briefTitle":15150,"status":143,"phases":15151,"primaryCompletion":1132,"completion":1132,"start":347,"enrollment":15152,"conditions":15153,"interventions":15154},"NCT06551220","Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns",[],800,[241],[15134],{"intervention":15156,"totalTrials":100,"cells":15157},"cisplatin-based chemoradiotherapy combined with immunotherapy",{"EARLY_PHASE1":15158,"PHASE1":15160,"PHASE2":15162,"PHASE3":15164,"PHASE4":15166,"NA":15168},{"trials":15159,"activeCount":104},[],{"trials":15161,"activeCount":104},[],{"trials":15163,"activeCount":104},[],{"trials":15165,"activeCount":104},[],{"trials":15167,"activeCount":104},[],{"trials":15169,"activeCount":100,"soonestReadout":419},[15170],{"nctId":15171,"briefTitle":15172,"status":143,"phases":15173,"primaryCompletion":419,"completion":470,"start":471,"enrollment":205,"conditions":15174,"interventions":15178},"NCT06197776","Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r\u002Fm NPC",[],[15175,16,15176,15177],"Multi-omics Technique","Recurrent and Metastatic Nasopharyngeal Carcinoma","Efficacy of Chemoradiotherapy and Immunotherapy",[15156],{"intervention":15180,"totalTrials":100,"cells":15181},"Pediatric lymphoma protocol",{"EARLY_PHASE1":15182,"PHASE1":15184,"PHASE2":15186,"PHASE3":15188,"PHASE4":15190,"NA":15192},{"trials":15183,"activeCount":104},[],{"trials":15185,"activeCount":104},[],{"trials":15187,"activeCount":104},[],{"trials":15189,"activeCount":104},[],{"trials":15191,"activeCount":104},[],{"trials":15193,"activeCount":100,"soonestReadout":1508},[15194],{"nctId":15195,"briefTitle":15196,"status":143,"phases":15197,"primaryCompletion":1508,"completion":1508,"start":1657,"enrollment":996,"conditions":15198,"interventions":15200},"NCT04957901","The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study",[],[15199],"Lymphoma",[15180],{"intervention":15202,"totalTrials":100,"cells":15203},"Pucotenlimab ,Lenvatinib",{"EARLY_PHASE1":15204,"PHASE1":15206,"PHASE2":15208,"PHASE3":15210,"PHASE4":15212,"NA":15214},{"trials":15205,"activeCount":104},[],{"trials":15207,"activeCount":104},[],{"trials":15209,"activeCount":104},[],{"trials":15211,"activeCount":104},[],{"trials":15213,"activeCount":104},[],{"trials":15215,"activeCount":100,"soonestReadout":15220},[15216],{"nctId":15217,"briefTitle":15218,"status":143,"phases":15219,"primaryCompletion":15220,"completion":15221,"start":15222,"enrollment":1366,"conditions":15223,"interventions":15224},"NCT07188311","Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed\u002FRefractory Hepatoblastoma in Children",[96],"2027-04-10","2027-12-10","2025-04-10",[13433,1617],[15202],{"intervention":15226,"totalTrials":100,"cells":15227},"The arm will receive combination therapy (entecavir 0.5 mg once daily plus TAF 25 mg once daily); after HBV DNA becomes undetectable, the combination group will switch to TAF monotherapy.",{"EARLY_PHASE1":15228,"PHASE1":15230,"PHASE2":15232,"PHASE3":15234,"PHASE4":15236,"NA":15238},{"trials":15229,"activeCount":104},[],{"trials":15231,"activeCount":104},[],{"trials":15233,"activeCount":104},[],{"trials":15235,"activeCount":104},[],{"trials":15237,"activeCount":104},[],{"trials":15239,"activeCount":100,"soonestReadout":14629},[15240],{"nctId":15241,"briefTitle":15242,"status":116,"phases":15243,"primaryCompletion":14629,"completion":4481,"start":302,"enrollment":820,"conditions":15244,"interventions":15245},"NCT07253220","TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma",[96],[5213,3006],[15226,15246],"TAF monotherapy",{"intervention":15246,"totalTrials":100,"cells":15248},{"EARLY_PHASE1":15249,"PHASE1":15251,"PHASE2":15253,"PHASE3":15255,"PHASE4":15257,"NA":15259},{"trials":15250,"activeCount":104},[],{"trials":15252,"activeCount":104},[],{"trials":15254,"activeCount":104},[],{"trials":15256,"activeCount":104},[],{"trials":15258,"activeCount":104},[],{"trials":15260,"activeCount":100,"soonestReadout":14629},[15261],{"nctId":15241,"briefTitle":15242,"status":116,"phases":15262,"primaryCompletion":14629,"completion":4481,"start":302,"enrollment":820,"conditions":15263,"interventions":15264},[96],[5213,3006],[15226,15246],{"intervention":15266,"totalTrials":100,"cells":15267},"system therapy",{"EARLY_PHASE1":15268,"PHASE1":15270,"PHASE2":15272,"PHASE3":15274,"PHASE4":15276,"NA":15278},{"trials":15269,"activeCount":104},[],{"trials":15271,"activeCount":104},[],{"trials":15273,"activeCount":104},[],{"trials":15275,"activeCount":104},[],{"trials":15277,"activeCount":104},[],{"trials":15279,"activeCount":100,"soonestReadout":1875},[15280],{"nctId":15281,"briefTitle":15282,"status":143,"phases":15283,"primaryCompletion":1875,"completion":1227,"start":15284,"enrollment":15285,"conditions":15286,"interventions":15288},"NCT06644430","Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma",[],"2024-10-04",470,[1230,2210,15287,14961,3052],"Oligometastasis",[15266],{"intervention":15290,"totalTrials":100,"cells":15291},"Genome-wide genotyping",{"EARLY_PHASE1":15292,"PHASE1":15294,"PHASE2":15296,"PHASE3":15298,"PHASE4":15300,"NA":15302},{"trials":15293,"activeCount":104},[],{"trials":15295,"activeCount":104},[],{"trials":15297,"activeCount":104},[],{"trials":15299,"activeCount":104},[],{"trials":15301,"activeCount":104},[],{"trials":15303,"activeCount":100,"soonestReadout":1875},[15304],{"nctId":15305,"briefTitle":15306,"status":143,"phases":15307,"primaryCompletion":1875,"completion":679,"start":15308,"enrollment":15309,"conditions":15310,"interventions":15312},"NCT06801977","The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study",[],"2002-01-01",10000,[15311],"Primary Pulmonary Lymphoepithelioma-like Carcinoma",[15290],{"intervention":15314,"totalTrials":100,"cells":15315},"Assigned Interventions: IOP-lowering eye drops",{"EARLY_PHASE1":15316,"PHASE1":15318,"PHASE2":15320,"PHASE3":15322,"PHASE4":15324,"NA":15326},{"trials":15317,"activeCount":104},[],{"trials":15319,"activeCount":104},[],{"trials":15321,"activeCount":104},[],{"trials":15323,"activeCount":104},[],{"trials":15325,"activeCount":104},[],{"trials":15327,"activeCount":100,"soonestReadout":15332},[15328],{"nctId":15329,"briefTitle":15330,"status":300,"phases":15331,"primaryCompletion":15332,"completion":7449,"start":3177,"enrollment":371,"conditions":15333,"interventions":15336},"NCT05850936","Effect of IOP Lowering on Progressive HM",[96],"2026-11-20",[15334,15335],"High Myopia","Intraocular Pressure",[15314],{"intervention":15338,"totalTrials":100,"cells":15339},"ultrasound scanning",{"EARLY_PHASE1":15340,"PHASE1":15342,"PHASE2":15344,"PHASE3":15346,"PHASE4":15348,"NA":15350},{"trials":15341,"activeCount":104},[],{"trials":15343,"activeCount":104},[],{"trials":15345,"activeCount":104},[],{"trials":15347,"activeCount":104},[],{"trials":15349,"activeCount":104},[],{"trials":15351,"activeCount":100,"soonestReadout":1227},[15352],{"nctId":15353,"briefTitle":15354,"status":3411,"phases":15355,"primaryCompletion":1227,"completion":1437,"start":923,"enrollment":15356,"conditions":15357,"interventions":15360},"NCT07178015","A Cohort Study on Cardiovascular and Cerebrovascular Outcomes",[],855,[15358,15359],"Stroke","Atheroscleroses",[15338],{"intervention":8904,"totalTrials":1861,"cells":15362},{"EARLY_PHASE1":15363,"PHASE1":15365,"PHASE2":15367,"PHASE3":15369,"PHASE4":15371,"NA":15395},{"trials":15364,"activeCount":104},[],{"trials":15366,"activeCount":104},[],{"trials":15368,"activeCount":104},[],{"trials":15370,"activeCount":104},[],{"trials":15372,"activeCount":104},[15373,15381,15391],{"nctId":15374,"briefTitle":15375,"status":174,"phases":15376,"primaryCompletion":1027,"completion":15377,"start":1156,"enrollment":11931,"conditions":15378,"interventions":15380},"NCT05606718","Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling",[95],"2023-07-31",[15379],"Functional Mitral Regurgitation",[8904],{"nctId":15382,"briefTitle":15383,"status":174,"phases":15384,"primaryCompletion":10907,"completion":15385,"start":15386,"enrollment":15387,"conditions":15388,"interventions":15389},"NCT05848102","Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)",[95],"2025-04-23","2022-12-23",166,[15379],[15390],"dapagliflozin",{"nctId":8894,"briefTitle":8895,"status":174,"phases":15392,"primaryCompletion":8897,"completion":1238,"start":8898,"enrollment":8899,"conditions":15393,"interventions":15394},[95],[8901],[8903,8866,8904,8905],{"trials":15396,"activeCount":104},[],{"intervention":14310,"totalTrials":1861,"cells":15398},{"EARLY_PHASE1":15399,"PHASE1":15401,"PHASE2":15403,"PHASE3":15413,"PHASE4":15419,"NA":15429},{"trials":15400,"activeCount":104},[],{"trials":15402,"activeCount":104},[],{"trials":15404,"activeCount":104},[15405],{"nctId":15406,"briefTitle":15407,"status":328,"phases":15408,"primaryCompletion":15409,"completion":217,"start":1934,"enrollment":4430,"conditions":15410,"interventions":15411},"NCT02646020","Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment",[93],"2020-10-01",[22],[14310,15412],"Desloratadine",{"trials":15414,"activeCount":104},[15415],{"nctId":14301,"briefTitle":14302,"status":328,"phases":15416,"primaryCompletion":14304,"completion":1094,"start":14305,"enrollment":14306,"conditions":15417,"interventions":15418},[94],[2112,14308],[14310,14311,183],{"trials":15420,"activeCount":104},[15421],{"nctId":15422,"briefTitle":15423,"status":174,"phases":15424,"primaryCompletion":2525,"completion":1934,"start":1500,"enrollment":15425,"conditions":15426,"interventions":15428},"NCT02347878","Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)",[95],85,[15427,15199],"Leukemia",[14310],{"trials":15430,"activeCount":104},[],{"intervention":15432,"totalTrials":1255,"cells":15433},"CSII",{"EARLY_PHASE1":15434,"PHASE1":15436,"PHASE2":15438,"PHASE3":15440,"PHASE4":15442,"NA":15462},{"trials":15435,"activeCount":104},[],{"trials":15437,"activeCount":104},[],{"trials":15439,"activeCount":104},[],{"trials":15441,"activeCount":104},[],{"trials":15443,"activeCount":104},[15444,15454],{"nctId":15445,"briefTitle":15446,"status":328,"phases":15447,"primaryCompletion":3953,"completion":3953,"start":15448,"enrollment":898,"conditions":15449,"interventions":15451},"NCT01471808","Effects of Different Early Intensive Therapies on Long-term β-cell Function",[95],"2011-10",[15450],"Diabetes Mellitus, Type 2",[15432,15452,15453],"CSII, Metformin, Pioglitazone","CSII, Sitagliptin",{"nctId":15455,"briefTitle":15456,"status":174,"phases":15457,"primaryCompletion":4810,"completion":1934,"start":15458,"enrollment":1339,"conditions":15459,"interventions":15460},"NCT01790308","Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function",[95],"2013-02",[15450],[15432,15461],"Liraglutide",{"trials":15463,"activeCount":104},[],{"intervention":15465,"totalTrials":1255,"cells":15466},"25mg etanercept",{"EARLY_PHASE1":15467,"PHASE1":15469,"PHASE2":15471,"PHASE3":15473,"PHASE4":15475,"NA":15496},{"trials":15468,"activeCount":104},[],{"trials":15470,"activeCount":104},[],{"trials":15472,"activeCount":104},[],{"trials":15474,"activeCount":104},[],{"trials":15476,"activeCount":104},[15477,15488],{"nctId":15478,"briefTitle":15479,"status":328,"phases":15480,"primaryCompletion":15481,"completion":15482,"start":15483,"enrollment":1389,"conditions":15484,"interventions":15486},"NCT02364479","Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein",[95],"2016-07-28","2016-08-28","2014-02-10",[15485],"Spondyloarthritis",[15487,15465],"50mg Yisaipu",{"nctId":15489,"briefTitle":15490,"status":328,"phases":15491,"primaryCompletion":2232,"completion":5181,"start":5211,"enrollment":3272,"conditions":15492,"interventions":15494},"NCT02960035","A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis",[95],[15493],"Spondyloarthropathy",[15495,15465],"50mg etanercept",{"trials":15497,"activeCount":104},[],{"intervention":15499,"totalTrials":1255,"cells":15500},"propofol",{"EARLY_PHASE1":15501,"PHASE1":15503,"PHASE2":15505,"PHASE3":15507,"PHASE4":15518,"NA":15531},{"trials":15502,"activeCount":104},[],{"trials":15504,"activeCount":104},[],{"trials":15506,"activeCount":104},[],{"trials":15508,"activeCount":104},[15509],{"nctId":15510,"briefTitle":15511,"status":328,"phases":15512,"primaryCompletion":15513,"completion":7780,"start":7698,"enrollment":9272,"conditions":15514,"interventions":15516},"NCT06714669","Comparison of General Anesthesia Hemodynamics Between R and P in Patients Undergoing Laparoscopic Hepatectomy",[94],"2024-10-20",[15515],"Hypotension During Surgery",[15499,15517],"Remimazolam",{"trials":15519,"activeCount":104},[15520],{"nctId":15521,"briefTitle":15522,"status":328,"phases":15523,"primaryCompletion":15524,"completion":15524,"start":2085,"enrollment":15525,"conditions":15526,"interventions":15528},"NCT01809041","Comparison of Intravenous Anesthetics to Volatile Anesthetics on Postoperative Cognitive Dysfunction",[95],"2019-04",684,[15527],"Intra-abdominal and Intrapelvic Surgery",[15529,15499,15530],"Sevoflurane","remifentanil",{"trials":15532,"activeCount":104},[],{"intervention":15534,"totalTrials":1255,"cells":15535},"zometa",{"EARLY_PHASE1":15536,"PHASE1":15538,"PHASE2":15540,"PHASE3":15552,"PHASE4":15554,"NA":15565},{"trials":15537,"activeCount":104},[],{"trials":15539,"activeCount":104},[],{"trials":15541,"activeCount":104},[15542],{"nctId":15543,"briefTitle":15544,"status":328,"phases":15545,"primaryCompletion":15546,"completion":15547,"start":15548,"enrollment":996,"conditions":15549,"interventions":15550},"NCT00697619","To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer",[93],"2009-01","2009-09","2005-09",[396],[15551],"Zometa",{"trials":15553,"activeCount":104},[],{"trials":15555,"activeCount":104},[15556],{"nctId":15557,"briefTitle":15558,"status":328,"phases":15559,"primaryCompletion":2085,"completion":2085,"start":15560,"enrollment":2096,"conditions":15561,"interventions":15564},"NCT00762346","Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis",[95],"2008-09",[1831,15562,15563],"Bone Metastases","High NTX Level",[15534],{"trials":15566,"activeCount":104},[],{"intervention":3385,"totalTrials":1255,"cells":15568},{"EARLY_PHASE1":15569,"PHASE1":15571,"PHASE2":15573,"PHASE3":15575,"PHASE4":15581,"NA":15590},{"trials":15570,"activeCount":104},[],{"trials":15572,"activeCount":104},[],{"trials":15574,"activeCount":104},[],{"trials":15576,"activeCount":104},[15577],{"nctId":3379,"briefTitle":3380,"status":174,"phases":15578,"primaryCompletion":1934,"completion":1934,"start":3382,"enrollment":205,"conditions":15579,"interventions":15580},[94],[3293],[3385,3296],{"trials":15582,"activeCount":104},[15583],{"nctId":15584,"briefTitle":15585,"status":328,"phases":15586,"primaryCompletion":5211,"completion":5211,"start":15546,"enrollment":219,"conditions":15587,"interventions":15588},"NCT02319486","CEV With\u002FWithout Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma",[95],[3293],[3385,15589],"CEV chemotherapy",{"trials":15591,"activeCount":104},[],{"intervention":15452,"totalTrials":100,"cells":15593},{"EARLY_PHASE1":15594,"PHASE1":15596,"PHASE2":15598,"PHASE3":15600,"PHASE4":15602,"NA":15608},{"trials":15595,"activeCount":104},[],{"trials":15597,"activeCount":104},[],{"trials":15599,"activeCount":104},[],{"trials":15601,"activeCount":104},[],{"trials":15603,"activeCount":104},[15604],{"nctId":15445,"briefTitle":15446,"status":328,"phases":15605,"primaryCompletion":3953,"completion":3953,"start":15448,"enrollment":898,"conditions":15606,"interventions":15607},[95],[15450],[15432,15452,15453],{"trials":15609,"activeCount":104},[],{"intervention":15453,"totalTrials":100,"cells":15611},{"EARLY_PHASE1":15612,"PHASE1":15614,"PHASE2":15616,"PHASE3":15618,"PHASE4":15620,"NA":15626},{"trials":15613,"activeCount":104},[],{"trials":15615,"activeCount":104},[],{"trials":15617,"activeCount":104},[],{"trials":15619,"activeCount":104},[],{"trials":15621,"activeCount":104},[15622],{"nctId":15445,"briefTitle":15446,"status":328,"phases":15623,"primaryCompletion":3953,"completion":3953,"start":15448,"enrollment":898,"conditions":15624,"interventions":15625},[95],[15450],[15432,15452,15453],{"trials":15627,"activeCount":104},[],{"intervention":15629,"totalTrials":100,"cells":15630},"Terlipressin",{"EARLY_PHASE1":15631,"PHASE1":15633,"PHASE2":15635,"PHASE3":15637,"PHASE4":15639,"NA":15648},{"trials":15632,"activeCount":104},[],{"trials":15634,"activeCount":104},[],{"trials":15636,"activeCount":104},[],{"trials":15638,"activeCount":104},[],{"trials":15640,"activeCount":104},[15641],{"nctId":15642,"briefTitle":15643,"status":174,"phases":15644,"primaryCompletion":5478,"completion":460,"start":764,"enrollment":32,"conditions":15645,"interventions":15647},"NCT02489864","The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure",[95],[15646],"Hepatorenal Syndrome",[15629],{"trials":15649,"activeCount":104},[],{"intervention":15651,"totalTrials":100,"cells":15652},"CSII,ALA,MET,RSG",{"EARLY_PHASE1":15653,"PHASE1":15655,"PHASE2":15657,"PHASE3":15659,"PHASE4":15661,"NA":15672},{"trials":15654,"activeCount":104},[],{"trials":15656,"activeCount":104},[],{"trials":15658,"activeCount":104},[],{"trials":15660,"activeCount":104},[],{"trials":15662,"activeCount":104},[15663],{"nctId":15664,"briefTitle":15665,"status":15666,"phases":15667,"primaryCompletion":1337,"completion":1575,"start":15668,"enrollment":15087,"conditions":15669,"interventions":15671},"NCT00948324","Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes","SUSPENDED",[95],"2008-06",[15670],"Type 2 Diabetes Mellitus",[15651],{"trials":15673,"activeCount":104},[],{"intervention":15487,"totalTrials":100,"cells":15675},{"EARLY_PHASE1":15676,"PHASE1":15678,"PHASE2":15680,"PHASE3":15682,"PHASE4":15684,"NA":15690},{"trials":15677,"activeCount":104},[],{"trials":15679,"activeCount":104},[],{"trials":15681,"activeCount":104},[],{"trials":15683,"activeCount":104},[],{"trials":15685,"activeCount":104},[15686],{"nctId":15478,"briefTitle":15479,"status":328,"phases":15687,"primaryCompletion":15481,"completion":15482,"start":15483,"enrollment":1389,"conditions":15688,"interventions":15689},[95],[15485],[15487,15465],{"trials":15691,"activeCount":104},[],{"intervention":15693,"totalTrials":100,"cells":15694},"Celecoxib",{"EARLY_PHASE1":15695,"PHASE1":15697,"PHASE2":15699,"PHASE3":15701,"PHASE4":15703,"NA":15711},{"trials":15696,"activeCount":104},[],{"trials":15698,"activeCount":104},[],{"trials":15700,"activeCount":104},[],{"trials":15702,"activeCount":104},[],{"trials":15704,"activeCount":104},[15705],{"nctId":15706,"briefTitle":15707,"status":328,"phases":15708,"primaryCompletion":829,"completion":829,"start":764,"enrollment":430,"conditions":15709,"interventions":15710},"NCT02961998","Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail",[95],[19],[15693,999],{"trials":15712,"activeCount":104},[],{"intervention":15714,"totalTrials":100,"cells":15715},"lidocaine cream",{"EARLY_PHASE1":15716,"PHASE1":15718,"PHASE2":15720,"PHASE3":15722,"PHASE4":15724,"NA":15739},{"trials":15717,"activeCount":104},[],{"trials":15719,"activeCount":104},[],{"trials":15721,"activeCount":104},[],{"trials":15723,"activeCount":104},[],{"trials":15725,"activeCount":104},[15726],{"nctId":15727,"briefTitle":15728,"status":904,"phases":15729,"primaryCompletion":15730,"completion":15730,"start":5199,"enrollment":104,"conditions":15731,"interventions":15738},"NCT06967064","The Application of Lidocaine Cream on Oral Secretions of LMA Removal During the Recovery Period in Ophthalmic Surgical Patients Under General Anesthesia",[95],"2025-05-22",[15732,15733,15734,15735,15736,15737],"Airway Complication of Anaesthesia","Laryngeal Mask Airway Removal","Anesthesia Emergence","Secretion; Excess, Salivation","Ophthalmic Surgery","General Anesthesia",[15714],{"trials":15740,"activeCount":104},[],{"intervention":15742,"totalTrials":100,"cells":15743},"lamivudine or entecavir",{"EARLY_PHASE1":15744,"PHASE1":15746,"PHASE2":15748,"PHASE3":15750,"PHASE4":15752,"NA":15760},{"trials":15745,"activeCount":104},[],{"trials":15747,"activeCount":104},[],{"trials":15749,"activeCount":104},[],{"trials":15751,"activeCount":104},[],{"trials":15753,"activeCount":104},[15754],{"nctId":15755,"briefTitle":15756,"status":174,"phases":15757,"primaryCompletion":3333,"completion":449,"start":8150,"enrollment":1192,"conditions":15758,"interventions":15759},"NCT00555334","Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma",[95],[19,3035],[15742],{"trials":15761,"activeCount":104},[],{"intervention":15763,"totalTrials":100,"cells":15764},"antiviral treatment",{"EARLY_PHASE1":15765,"PHASE1":15767,"PHASE2":15769,"PHASE3":15771,"PHASE4":15773,"NA":15786},{"trials":15766,"activeCount":104},[],{"trials":15768,"activeCount":104},[],{"trials":15770,"activeCount":104},[],{"trials":15772,"activeCount":104},[],{"trials":15774,"activeCount":104},[15775],{"nctId":15776,"briefTitle":15777,"status":174,"phases":15778,"primaryCompletion":15779,"completion":15780,"start":15781,"enrollment":1192,"conditions":15782,"interventions":15785},"NCT00768157","Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma",[95],"2009-08","2010-08","2007-04",[19,15783,15784],"Hepatitis B Virus","Recurrence",[15763],{"trials":15787,"activeCount":104},[],{"intervention":15529,"totalTrials":100,"cells":15789},{"EARLY_PHASE1":15790,"PHASE1":15792,"PHASE2":15794,"PHASE3":15796,"PHASE4":15798,"NA":15804},{"trials":15791,"activeCount":104},[],{"trials":15793,"activeCount":104},[],{"trials":15795,"activeCount":104},[],{"trials":15797,"activeCount":104},[],{"trials":15799,"activeCount":104},[15800],{"nctId":15521,"briefTitle":15522,"status":328,"phases":15801,"primaryCompletion":15524,"completion":15524,"start":2085,"enrollment":15525,"conditions":15802,"interventions":15803},[95],[15527],[15529,15499,15530],{"trials":15805,"activeCount":104},[],{"intervention":15530,"totalTrials":100,"cells":15807},{"EARLY_PHASE1":15808,"PHASE1":15810,"PHASE2":15812,"PHASE3":15814,"PHASE4":15816,"NA":15822},{"trials":15809,"activeCount":104},[],{"trials":15811,"activeCount":104},[],{"trials":15813,"activeCount":104},[],{"trials":15815,"activeCount":104},[],{"trials":15817,"activeCount":104},[15818],{"nctId":15521,"briefTitle":15522,"status":328,"phases":15819,"primaryCompletion":15524,"completion":15524,"start":2085,"enrollment":15525,"conditions":15820,"interventions":15821},[95],[15527],[15529,15499,15530],{"trials":15823,"activeCount":104},[],{"intervention":15825,"totalTrials":100,"cells":15826},"Febuxostat",{"EARLY_PHASE1":15827,"PHASE1":15829,"PHASE2":15831,"PHASE3":15833,"PHASE4":15835,"NA":15846},{"trials":15828,"activeCount":104},[],{"trials":15830,"activeCount":104},[],{"trials":15832,"activeCount":104},[],{"trials":15834,"activeCount":104},[],{"trials":15836,"activeCount":104},[15837],{"nctId":15838,"briefTitle":15839,"status":174,"phases":15840,"primaryCompletion":479,"completion":479,"start":15841,"enrollment":15842,"conditions":15843,"interventions":15845},"NCT03200210","Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients",[95],"2017-07-11",548,[15844],"Hyperuricemia",[15825],{"trials":15847,"activeCount":104},[],{"intervention":15849,"totalTrials":100,"cells":15850},"High-dose multi-vitamins with minerals",{"EARLY_PHASE1":15851,"PHASE1":15853,"PHASE2":15855,"PHASE3":15857,"PHASE4":15859,"NA":15870},{"trials":15852,"activeCount":104},[],{"trials":15854,"activeCount":104},[],{"trials":15856,"activeCount":104},[],{"trials":15858,"activeCount":104},[],{"trials":15860,"activeCount":104},[15861],{"nctId":15862,"briefTitle":15863,"status":174,"phases":15864,"primaryCompletion":15865,"completion":5304,"start":1576,"enrollment":1192,"conditions":15866,"interventions":15867},"NCT03218709","The Intervention of Multi-vitamin With Minerals to Hyperuricemia",[95],"2018-01",[15844],[15849,15868,15869],"Low-dose multi-vitamins with minerals","Hypouricemic",{"trials":15871,"activeCount":104},[],{"intervention":15868,"totalTrials":100,"cells":15873},{"EARLY_PHASE1":15874,"PHASE1":15876,"PHASE2":15878,"PHASE3":15880,"PHASE4":15882,"NA":15888},{"trials":15875,"activeCount":104},[],{"trials":15877,"activeCount":104},[],{"trials":15879,"activeCount":104},[],{"trials":15881,"activeCount":104},[],{"trials":15883,"activeCount":104},[15884],{"nctId":15862,"briefTitle":15863,"status":174,"phases":15885,"primaryCompletion":15865,"completion":5304,"start":1576,"enrollment":1192,"conditions":15886,"interventions":15887},[95],[15844],[15849,15868,15869],{"trials":15889,"activeCount":104},[],{"intervention":15869,"totalTrials":100,"cells":15891},{"EARLY_PHASE1":15892,"PHASE1":15894,"PHASE2":15896,"PHASE3":15898,"PHASE4":15900,"NA":15906},{"trials":15893,"activeCount":104},[],{"trials":15895,"activeCount":104},[],{"trials":15897,"activeCount":104},[],{"trials":15899,"activeCount":104},[],{"trials":15901,"activeCount":104},[15902],{"nctId":15862,"briefTitle":15863,"status":174,"phases":15903,"primaryCompletion":15865,"completion":5304,"start":1576,"enrollment":1192,"conditions":15904,"interventions":15905},[95],[15844],[15849,15868,15869],{"trials":15907,"activeCount":104},[],{"intervention":15909,"totalTrials":100,"cells":15910},"Fengshigutong Capsule plus Imrecoxib",{"EARLY_PHASE1":15911,"PHASE1":15913,"PHASE2":15915,"PHASE3":15917,"PHASE4":15919,"NA":15932},{"trials":15912,"activeCount":104},[],{"trials":15914,"activeCount":104},[],{"trials":15916,"activeCount":104},[],{"trials":15918,"activeCount":104},[],{"trials":15920,"activeCount":104},[15921],{"nctId":15922,"briefTitle":15923,"status":174,"phases":15924,"primaryCompletion":15925,"completion":15925,"start":15926,"enrollment":2459,"conditions":15927,"interventions":15929},"NCT03932006","A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis",[95],"2019-05-31","2016-06-30",[15928],"Ankylosing Spondylitis",[15909,15930,15931],"Fengshigutong","Imrecoxib",{"trials":15933,"activeCount":104},[],{"intervention":15930,"totalTrials":100,"cells":15935},{"EARLY_PHASE1":15936,"PHASE1":15938,"PHASE2":15940,"PHASE3":15942,"PHASE4":15944,"NA":15950},{"trials":15937,"activeCount":104},[],{"trials":15939,"activeCount":104},[],{"trials":15941,"activeCount":104},[],{"trials":15943,"activeCount":104},[],{"trials":15945,"activeCount":104},[15946],{"nctId":15922,"briefTitle":15923,"status":174,"phases":15947,"primaryCompletion":15925,"completion":15925,"start":15926,"enrollment":2459,"conditions":15948,"interventions":15949},[95],[15928],[15909,15930,15931],{"trials":15951,"activeCount":104},[],{"intervention":15931,"totalTrials":100,"cells":15953},{"EARLY_PHASE1":15954,"PHASE1":15956,"PHASE2":15958,"PHASE3":15960,"PHASE4":15962,"NA":15968},{"trials":15955,"activeCount":104},[],{"trials":15957,"activeCount":104},[],{"trials":15959,"activeCount":104},[],{"trials":15961,"activeCount":104},[],{"trials":15963,"activeCount":104},[15964],{"nctId":15922,"briefTitle":15923,"status":174,"phases":15965,"primaryCompletion":15925,"completion":15925,"start":15926,"enrollment":2459,"conditions":15966,"interventions":15967},[95],[15928],[15909,15930,15931],{"trials":15969,"activeCount":104},[],{"intervention":15971,"totalTrials":100,"cells":15972},"0.3% Sodium Hyaluronate",{"EARLY_PHASE1":15973,"PHASE1":15975,"PHASE2":15977,"PHASE3":15979,"PHASE4":15981,"NA":15990},{"trials":15974,"activeCount":104},[],{"trials":15976,"activeCount":104},[],{"trials":15978,"activeCount":104},[],{"trials":15980,"activeCount":104},[],{"trials":15982,"activeCount":104},[15983],{"nctId":15984,"briefTitle":15985,"status":174,"phases":15986,"primaryCompletion":204,"completion":204,"start":5352,"enrollment":996,"conditions":15987,"interventions":15989},"NCT02595606","0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients",[95],[15988,6775],"Dry Eye Syndromes",[15971],{"trials":15991,"activeCount":104},[],{"intervention":15993,"totalTrials":100,"cells":15994},"intravenous use of sulodexide followed by oral use",{"EARLY_PHASE1":15995,"PHASE1":15997,"PHASE2":15999,"PHASE3":16001,"PHASE4":16003,"NA":16016},{"trials":15996,"activeCount":104},[],{"trials":15998,"activeCount":104},[],{"trials":16000,"activeCount":104},[],{"trials":16002,"activeCount":104},[],{"trials":16004,"activeCount":104},[16005],{"nctId":16006,"briefTitle":16007,"status":174,"phases":16008,"primaryCompletion":16009,"completion":16009,"start":16010,"enrollment":942,"conditions":16011,"interventions":16014},"NCT01316068","Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients",[95],"2012-08","2011-03",[16012,16013],"Diabetic Nephropathy","Albuminuria",[15993,16015],"use of sulodexide orally only",{"trials":16017,"activeCount":104},[],{"intervention":16015,"totalTrials":100,"cells":16019},{"EARLY_PHASE1":16020,"PHASE1":16022,"PHASE2":16024,"PHASE3":16026,"PHASE4":16028,"NA":16034},{"trials":16021,"activeCount":104},[],{"trials":16023,"activeCount":104},[],{"trials":16025,"activeCount":104},[],{"trials":16027,"activeCount":104},[],{"trials":16029,"activeCount":104},[16030],{"nctId":16006,"briefTitle":16007,"status":174,"phases":16031,"primaryCompletion":16009,"completion":16009,"start":16010,"enrollment":942,"conditions":16032,"interventions":16033},[95],[16012,16013],[15993,16015],{"trials":16035,"activeCount":104},[],{"intervention":16037,"totalTrials":100,"cells":16038},"Luspatercept Injectable Product",{"EARLY_PHASE1":16039,"PHASE1":16041,"PHASE2":16043,"PHASE3":16045,"PHASE4":16047,"NA":16057},{"trials":16040,"activeCount":104},[],{"trials":16042,"activeCount":104},[],{"trials":16044,"activeCount":104},[],{"trials":16046,"activeCount":104},[],{"trials":16048,"activeCount":104},[16049],{"nctId":16050,"briefTitle":16051,"status":174,"phases":16052,"primaryCompletion":573,"completion":1668,"start":9102,"enrollment":239,"conditions":16053,"interventions":16056},"NCT05462548","The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study",[95],[16054,16055],"Thalassemia Major","Transfusion-dependent Anemia",[16037],{"trials":16058,"activeCount":104},[],{"intervention":16060,"totalTrials":100,"cells":16061},"Lithium Carbonate",{"EARLY_PHASE1":16062,"PHASE1":16064,"PHASE2":16066,"PHASE3":16068,"PHASE4":16070,"NA":16078},{"trials":16063,"activeCount":104},[],{"trials":16065,"activeCount":104},[],{"trials":16067,"activeCount":104},[],{"trials":16069,"activeCount":104},[],{"trials":16071,"activeCount":104},[16072],{"nctId":16073,"briefTitle":16074,"status":174,"phases":16075,"primaryCompletion":259,"completion":259,"start":14741,"enrollment":15087,"conditions":16076,"interventions":16077},"NCT01669369","Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma",[95],[12092],[16060],{"trials":16079,"activeCount":104},[],{"intervention":16081,"totalTrials":100,"cells":16082},"lamivudine",{"EARLY_PHASE1":16083,"PHASE1":16085,"PHASE2":16087,"PHASE3":16089,"PHASE4":16091,"NA":16104},{"trials":16084,"activeCount":104},[],{"trials":16086,"activeCount":104},[],{"trials":16088,"activeCount":104},[],{"trials":16090,"activeCount":104},[],{"trials":16092,"activeCount":104},[16093],{"nctId":16094,"briefTitle":16095,"status":174,"phases":16096,"primaryCompletion":1576,"completion":1576,"start":16097,"enrollment":1248,"conditions":16098,"interventions":16100},"NCT00810524","Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection",[95],"2007-01",[16099],"Hepatitis B, Chronic",[16081,16101,16102,16103],"Telbivudine","Enticavir","Adefovir Dipivoxil",{"trials":16105,"activeCount":104},[],{"intervention":16101,"totalTrials":100,"cells":16107},{"EARLY_PHASE1":16108,"PHASE1":16110,"PHASE2":16112,"PHASE3":16114,"PHASE4":16116,"NA":16122},{"trials":16109,"activeCount":104},[],{"trials":16111,"activeCount":104},[],{"trials":16113,"activeCount":104},[],{"trials":16115,"activeCount":104},[],{"trials":16117,"activeCount":104},[16118],{"nctId":16094,"briefTitle":16095,"status":174,"phases":16119,"primaryCompletion":1576,"completion":1576,"start":16097,"enrollment":1248,"conditions":16120,"interventions":16121},[95],[16099],[16081,16101,16102,16103],{"trials":16123,"activeCount":104},[],{"intervention":16102,"totalTrials":100,"cells":16125},{"EARLY_PHASE1":16126,"PHASE1":16128,"PHASE2":16130,"PHASE3":16132,"PHASE4":16134,"NA":16140},{"trials":16127,"activeCount":104},[],{"trials":16129,"activeCount":104},[],{"trials":16131,"activeCount":104},[],{"trials":16133,"activeCount":104},[],{"trials":16135,"activeCount":104},[16136],{"nctId":16094,"briefTitle":16095,"status":174,"phases":16137,"primaryCompletion":1576,"completion":1576,"start":16097,"enrollment":1248,"conditions":16138,"interventions":16139},[95],[16099],[16081,16101,16102,16103],{"trials":16141,"activeCount":104},[],{"intervention":16103,"totalTrials":100,"cells":16143},{"EARLY_PHASE1":16144,"PHASE1":16146,"PHASE2":16148,"PHASE3":16150,"PHASE4":16152,"NA":16158},{"trials":16145,"activeCount":104},[],{"trials":16147,"activeCount":104},[],{"trials":16149,"activeCount":104},[],{"trials":16151,"activeCount":104},[],{"trials":16153,"activeCount":104},[16154],{"nctId":16094,"briefTitle":16095,"status":174,"phases":16155,"primaryCompletion":1576,"completion":1576,"start":16097,"enrollment":1248,"conditions":16156,"interventions":16157},[95],[16099],[16081,16101,16102,16103],{"trials":16159,"activeCount":104},[],{"intervention":209,"totalTrials":100,"cells":16161},{"EARLY_PHASE1":16162,"PHASE1":16164,"PHASE2":16166,"PHASE3":16168,"PHASE4":16170,"NA":16176},{"trials":16163,"activeCount":104},[],{"trials":16165,"activeCount":104},[],{"trials":16167,"activeCount":104},[],{"trials":16169,"activeCount":104},[],{"trials":16171,"activeCount":104},[16172],{"nctId":200,"briefTitle":201,"status":174,"phases":16173,"primaryCompletion":203,"start":204,"enrollment":205,"conditions":16174,"interventions":16175},[95],[207],[209,160],{"trials":16177,"activeCount":104},[],{"intervention":16179,"totalTrials":100,"cells":16180},"Total Glucosides Paeony",{"EARLY_PHASE1":16181,"PHASE1":16183,"PHASE2":16185,"PHASE3":16187,"PHASE4":16189,"NA":16198},{"trials":16182,"activeCount":104},[],{"trials":16184,"activeCount":104},[],{"trials":16186,"activeCount":104},[],{"trials":16188,"activeCount":104},[],{"trials":16190,"activeCount":104},[16191],{"nctId":16192,"briefTitle":16193,"status":328,"phases":16194,"primaryCompletion":16195,"completion":16195,"start":8149,"enrollment":9921,"conditions":16196,"interventions":16197},"NCT01517620","Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy",[95],"2012-11",[15928],[16179],{"trials":16199,"activeCount":104},[],{"intervention":16201,"totalTrials":100,"cells":16202},"Etanercept",{"EARLY_PHASE1":16203,"PHASE1":16205,"PHASE2":16207,"PHASE3":16209,"PHASE4":16211,"NA":16221},{"trials":16204,"activeCount":104},[],{"trials":16206,"activeCount":104},[],{"trials":16208,"activeCount":104},[],{"trials":16210,"activeCount":104},[],{"trials":16212,"activeCount":104},[16213],{"nctId":16214,"briefTitle":16215,"status":328,"phases":16216,"primaryCompletion":7637,"completion":7637,"start":16217,"enrollment":1109,"conditions":16218,"interventions":16220},"NCT02915354","Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study",[95],"2007-07",[16219,15784],"Spondylitis, Ankylosing",[16201],{"trials":16222,"activeCount":104},[],{"intervention":15495,"totalTrials":100,"cells":16224},{"EARLY_PHASE1":16225,"PHASE1":16227,"PHASE2":16229,"PHASE3":16231,"PHASE4":16233,"NA":16239},{"trials":16226,"activeCount":104},[],{"trials":16228,"activeCount":104},[],{"trials":16230,"activeCount":104},[],{"trials":16232,"activeCount":104},[],{"trials":16234,"activeCount":104},[16235],{"nctId":15489,"briefTitle":15490,"status":328,"phases":16236,"primaryCompletion":2232,"completion":5181,"start":5211,"enrollment":3272,"conditions":16237,"interventions":16238},[95],[15493],[15495,15465],{"trials":16240,"activeCount":104},[],{"intervention":16242,"totalTrials":100,"cells":16243},"Insulin LISPRO",{"EARLY_PHASE1":16244,"PHASE1":16246,"PHASE2":16248,"PHASE3":16250,"PHASE4":16252,"NA":16262},{"trials":16245,"activeCount":104},[],{"trials":16247,"activeCount":104},[],{"trials":16249,"activeCount":104},[],{"trials":16251,"activeCount":104},[],{"trials":16253,"activeCount":104},[16254],{"nctId":16255,"briefTitle":16256,"status":328,"phases":16257,"primaryCompletion":16258,"completion":16258,"start":16259,"enrollment":1376,"conditions":16260,"interventions":16261},"NCT03509324","Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes",[95],"2015-06-30","2015-03-01",[15450],[16242],{"trials":16263,"activeCount":104},[],{"intervention":16265,"totalTrials":100,"cells":16266},"CSII with formula-based initial insulin regimen",{"EARLY_PHASE1":16267,"PHASE1":16269,"PHASE2":16271,"PHASE3":16273,"PHASE4":16275,"NA":16287},{"trials":16268,"activeCount":104},[],{"trials":16270,"activeCount":104},[],{"trials":16272,"activeCount":104},[],{"trials":16274,"activeCount":104},[],{"trials":16276,"activeCount":104},[16277],{"nctId":16278,"briefTitle":16279,"status":174,"phases":16280,"primaryCompletion":3124,"completion":3124,"start":16281,"enrollment":5071,"conditions":16282,"interventions":16285},"NCT05084079","Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in SIIT",[95],"2021-11",[6775,15450,16283,16284,14793],"Glucose Metabolism Disorders","Metabolic Disease",[16265,16286],"CSII with weight-based initial insulin regimen",{"trials":16288,"activeCount":104},[],{"intervention":16286,"totalTrials":100,"cells":16290},{"EARLY_PHASE1":16291,"PHASE1":16293,"PHASE2":16295,"PHASE3":16297,"PHASE4":16299,"NA":16305},{"trials":16292,"activeCount":104},[],{"trials":16294,"activeCount":104},[],{"trials":16296,"activeCount":104},[],{"trials":16298,"activeCount":104},[],{"trials":16300,"activeCount":104},[16301],{"nctId":16278,"briefTitle":16279,"status":174,"phases":16302,"primaryCompletion":3124,"completion":3124,"start":16281,"enrollment":5071,"conditions":16303,"interventions":16304},[95],[6775,15450,16283,16284,14793],[16265,16286],{"trials":16306,"activeCount":104},[],{"intervention":16308,"totalTrials":100,"cells":16309},"6-mercaptopurine, Methotrexate",{"EARLY_PHASE1":16310,"PHASE1":16312,"PHASE2":16314,"PHASE3":16316,"PHASE4":16318,"NA":16328},{"trials":16311,"activeCount":104},[],{"trials":16313,"activeCount":104},[],{"trials":16315,"activeCount":104},[],{"trials":16317,"activeCount":104},[],{"trials":16319,"activeCount":104},[16320],{"nctId":16321,"briefTitle":16322,"status":174,"phases":16323,"primaryCompletion":1427,"completion":3953,"start":16324,"enrollment":1248,"conditions":16325,"interventions":16326},"NCT00846703","The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia",[95],"2008-07",[4765],[16308,16327],"6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone",{"trials":16329,"activeCount":104},[],{"intervention":16327,"totalTrials":100,"cells":16331},{"EARLY_PHASE1":16332,"PHASE1":16334,"PHASE2":16336,"PHASE3":16338,"PHASE4":16340,"NA":16346},{"trials":16333,"activeCount":104},[],{"trials":16335,"activeCount":104},[],{"trials":16337,"activeCount":104},[],{"trials":16339,"activeCount":104},[],{"trials":16341,"activeCount":104},[16342],{"nctId":16321,"briefTitle":16322,"status":174,"phases":16343,"primaryCompletion":1427,"completion":3953,"start":16324,"enrollment":1248,"conditions":16344,"interventions":16345},[95],[4765],[16308,16327],{"trials":16347,"activeCount":104},[],{"intervention":16349,"totalTrials":100,"cells":16350},"Tamoxifen",{"EARLY_PHASE1":16351,"PHASE1":16353,"PHASE2":16355,"PHASE3":16357,"PHASE4":16359,"NA":16369},{"trials":16352,"activeCount":104},[],{"trials":16354,"activeCount":104},[],{"trials":16356,"activeCount":104},[],{"trials":16358,"activeCount":104},[],{"trials":16360,"activeCount":104},[16361],{"nctId":16362,"briefTitle":16363,"status":174,"phases":16364,"primaryCompletion":657,"completion":2770,"start":427,"enrollment":1339,"conditions":16365,"interventions":16367},"NCT03060304","The Effect of Tamoxifen on Clinical Outcome in Women With Thin Endometrium Undergoing Frozen Thawed Cycle.",[95],[16366],"Endometrium",[16349,16368],"estradiol valerate",{"trials":16370,"activeCount":104},[],{"intervention":16368,"totalTrials":100,"cells":16372},{"EARLY_PHASE1":16373,"PHASE1":16375,"PHASE2":16377,"PHASE3":16379,"PHASE4":16381,"NA":16387},{"trials":16374,"activeCount":104},[],{"trials":16376,"activeCount":104},[],{"trials":16378,"activeCount":104},[],{"trials":16380,"activeCount":104},[],{"trials":16382,"activeCount":104},[16383],{"nctId":16362,"briefTitle":16363,"status":174,"phases":16384,"primaryCompletion":657,"completion":2770,"start":427,"enrollment":1339,"conditions":16385,"interventions":16386},[95],[16366],[16349,16368],{"trials":16388,"activeCount":104},[],{"intervention":16390,"totalTrials":100,"cells":16391},"Simplified intensive insulin therapy regimen",{"EARLY_PHASE1":16392,"PHASE1":16394,"PHASE2":16396,"PHASE3":16398,"PHASE4":16400,"NA":16413},{"trials":16393,"activeCount":104},[],{"trials":16395,"activeCount":104},[],{"trials":16397,"activeCount":104},[],{"trials":16399,"activeCount":104},[],{"trials":16401,"activeCount":104},[16402],{"nctId":16403,"briefTitle":16404,"status":174,"phases":16405,"primaryCompletion":289,"completion":479,"start":3003,"enrollment":16406,"conditions":16407,"interventions":16411},"NCT03972982","Effects of Structured Simplified Short-term Intensive Insulin Therapy on Long-term Glycemic Remission",[95],330,[16408,16409,16410],"Newly Diagnosed Type 2 Diabetes","Simplified Short-term Intensive Insulin Therapy","Glycemic Remission",[16390,16412],"Traditional Short-term Intensive insulin therapy",{"trials":16414,"activeCount":104},[],{"intervention":16412,"totalTrials":100,"cells":16416},{"EARLY_PHASE1":16417,"PHASE1":16419,"PHASE2":16421,"PHASE3":16423,"PHASE4":16425,"NA":16431},{"trials":16418,"activeCount":104},[],{"trials":16420,"activeCount":104},[],{"trials":16422,"activeCount":104},[],{"trials":16424,"activeCount":104},[],{"trials":16426,"activeCount":104},[16427],{"nctId":16403,"briefTitle":16404,"status":174,"phases":16428,"primaryCompletion":289,"completion":479,"start":3003,"enrollment":16406,"conditions":16429,"interventions":16430},[95],[16408,16409,16410],[16390,16412],{"trials":16432,"activeCount":104},[],{"intervention":16434,"totalTrials":100,"cells":16435},"MTX",{"EARLY_PHASE1":16436,"PHASE1":16438,"PHASE2":16440,"PHASE3":16442,"PHASE4":16444,"NA":16457},{"trials":16437,"activeCount":104},[],{"trials":16439,"activeCount":104},[],{"trials":16441,"activeCount":104},[],{"trials":16443,"activeCount":104},[],{"trials":16445,"activeCount":104},[16446],{"nctId":16447,"briefTitle":16448,"status":174,"phases":16449,"primaryCompletion":16450,"completion":16450,"start":16451,"enrollment":734,"conditions":16452,"interventions":16454},"NCT04066803","Optimal MTX Dose With Folic Acid Randomized Case-control Trial",[95],"2020-07-30","2018-08-01",[16453],"Rheumatoid Arthritis",[16434,16455,16456],"Folic Acid","DMARDs",{"trials":16458,"activeCount":104},[],{"intervention":16455,"totalTrials":100,"cells":16460},{"EARLY_PHASE1":16461,"PHASE1":16463,"PHASE2":16465,"PHASE3":16467,"PHASE4":16469,"NA":16475},{"trials":16462,"activeCount":104},[],{"trials":16464,"activeCount":104},[],{"trials":16466,"activeCount":104},[],{"trials":16468,"activeCount":104},[],{"trials":16470,"activeCount":104},[16471],{"nctId":16447,"briefTitle":16448,"status":174,"phases":16472,"primaryCompletion":16450,"completion":16450,"start":16451,"enrollment":734,"conditions":16473,"interventions":16474},[95],[16453],[16434,16455,16456],{"trials":16476,"activeCount":104},[],{"intervention":16456,"totalTrials":100,"cells":16478},{"EARLY_PHASE1":16479,"PHASE1":16481,"PHASE2":16483,"PHASE3":16485,"PHASE4":16487,"NA":16493},{"trials":16480,"activeCount":104},[],{"trials":16482,"activeCount":104},[],{"trials":16484,"activeCount":104},[],{"trials":16486,"activeCount":104},[],{"trials":16488,"activeCount":104},[16489],{"nctId":16447,"briefTitle":16448,"status":174,"phases":16490,"primaryCompletion":16450,"completion":16450,"start":16451,"enrollment":734,"conditions":16491,"interventions":16492},[95],[16453],[16434,16455,16456],{"trials":16494,"activeCount":104},[],{"intervention":16496,"totalTrials":100,"cells":16497},"Loxoprofen sodium hydrogel patch",{"EARLY_PHASE1":16498,"PHASE1":16500,"PHASE2":16502,"PHASE3":16504,"PHASE4":16506,"NA":16517},{"trials":16499,"activeCount":104},[],{"trials":16501,"activeCount":104},[],{"trials":16503,"activeCount":104},[],{"trials":16505,"activeCount":104},[],{"trials":16507,"activeCount":104},[16508],{"nctId":16509,"briefTitle":16510,"status":328,"phases":16511,"primaryCompletion":16512,"completion":16512,"start":16513,"enrollment":1076,"conditions":16514,"interventions":16515},"NCT03800797","Efficacy and Safety of Loxoprofen Hydrogel Patch in Patients With Ankylosing Spondylitis",[95],"2015-12-10","2015-05-25",[15928],[16496,16516],"Loxoprofen sodium",{"trials":16518,"activeCount":104},[],{"intervention":16516,"totalTrials":100,"cells":16520},{"EARLY_PHASE1":16521,"PHASE1":16523,"PHASE2":16525,"PHASE3":16527,"PHASE4":16529,"NA":16535},{"trials":16522,"activeCount":104},[],{"trials":16524,"activeCount":104},[],{"trials":16526,"activeCount":104},[],{"trials":16528,"activeCount":104},[],{"trials":16530,"activeCount":104},[16531],{"nctId":16509,"briefTitle":16510,"status":328,"phases":16532,"primaryCompletion":16512,"completion":16512,"start":16513,"enrollment":1076,"conditions":16533,"interventions":16534},[95],[15928],[16496,16516],{"trials":16536,"activeCount":104},[],{"intervention":16538,"totalTrials":100,"cells":16539},"CSII followed by Lina+MET",{"EARLY_PHASE1":16540,"PHASE1":16542,"PHASE2":16544,"PHASE3":16546,"PHASE4":16548,"NA":16560},{"trials":16541,"activeCount":104},[],{"trials":16543,"activeCount":104},[],{"trials":16545,"activeCount":104},[],{"trials":16547,"activeCount":104},[],{"trials":16549,"activeCount":104},[16550],{"nctId":16551,"briefTitle":16552,"status":328,"phases":16553,"primaryCompletion":479,"completion":479,"start":16554,"enrollment":841,"conditions":16555,"interventions":16556},"NCT03194945","Effects of Sequential Treatment Based on Lina\u002FMET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes",[95],"2017-11-01",[15670],[16538,16557,16558,16559],"CSII followed by Lina","CSII followed by MET","CSII alone",{"trials":16561,"activeCount":104},[],{"intervention":16557,"totalTrials":100,"cells":16563},{"EARLY_PHASE1":16564,"PHASE1":16566,"PHASE2":16568,"PHASE3":16570,"PHASE4":16572,"NA":16578},{"trials":16565,"activeCount":104},[],{"trials":16567,"activeCount":104},[],{"trials":16569,"activeCount":104},[],{"trials":16571,"activeCount":104},[],{"trials":16573,"activeCount":104},[16574],{"nctId":16551,"briefTitle":16552,"status":328,"phases":16575,"primaryCompletion":479,"completion":479,"start":16554,"enrollment":841,"conditions":16576,"interventions":16577},[95],[15670],[16538,16557,16558,16559],{"trials":16579,"activeCount":104},[],{"intervention":16558,"totalTrials":100,"cells":16581},{"EARLY_PHASE1":16582,"PHASE1":16584,"PHASE2":16586,"PHASE3":16588,"PHASE4":16590,"NA":16596},{"trials":16583,"activeCount":104},[],{"trials":16585,"activeCount":104},[],{"trials":16587,"activeCount":104},[],{"trials":16589,"activeCount":104},[],{"trials":16591,"activeCount":104},[16592],{"nctId":16551,"briefTitle":16552,"status":328,"phases":16593,"primaryCompletion":479,"completion":479,"start":16554,"enrollment":841,"conditions":16594,"interventions":16595},[95],[15670],[16538,16557,16558,16559],{"trials":16597,"activeCount":104},[],{"intervention":16559,"totalTrials":100,"cells":16599},{"EARLY_PHASE1":16600,"PHASE1":16602,"PHASE2":16604,"PHASE3":16606,"PHASE4":16608,"NA":16614},{"trials":16601,"activeCount":104},[],{"trials":16603,"activeCount":104},[],{"trials":16605,"activeCount":104},[],{"trials":16607,"activeCount":104},[],{"trials":16609,"activeCount":104},[16610],{"nctId":16551,"briefTitle":16552,"status":328,"phases":16611,"primaryCompletion":479,"completion":479,"start":16554,"enrollment":841,"conditions":16612,"interventions":16613},[95],[15670],[16538,16557,16558,16559],{"trials":16615,"activeCount":104},[],{"intervention":16617,"totalTrials":100,"cells":16618},"celebrex",{"EARLY_PHASE1":16619,"PHASE1":16621,"PHASE2":16623,"PHASE3":16625,"PHASE4":16627,"NA":16640},{"trials":16620,"activeCount":104},[],{"trials":16622,"activeCount":104},[],{"trials":16624,"activeCount":104},[],{"trials":16626,"activeCount":104},[],{"trials":16628,"activeCount":104},[16629],{"nctId":16630,"briefTitle":16631,"status":328,"phases":16632,"primaryCompletion":16633,"completion":16634,"start":16635,"enrollment":1389,"conditions":16636,"interventions":16637},"NCT01934933","Etanercept and Celecoxib Alone\u002FCombined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis",[95],"2015-09-23","2017-01-30","2014-09-24",[15928],[16617,16638,16639],"Enbrel","Enbrel plus Celebrex",{"trials":16641,"activeCount":104},[],{"intervention":16638,"totalTrials":100,"cells":16643},{"EARLY_PHASE1":16644,"PHASE1":16646,"PHASE2":16648,"PHASE3":16650,"PHASE4":16652,"NA":16658},{"trials":16645,"activeCount":104},[],{"trials":16647,"activeCount":104},[],{"trials":16649,"activeCount":104},[],{"trials":16651,"activeCount":104},[],{"trials":16653,"activeCount":104},[16654],{"nctId":16630,"briefTitle":16631,"status":328,"phases":16655,"primaryCompletion":16633,"completion":16634,"start":16635,"enrollment":1389,"conditions":16656,"interventions":16657},[95],[15928],[16617,16638,16639],{"trials":16659,"activeCount":104},[],{"intervention":16639,"totalTrials":100,"cells":16661},{"EARLY_PHASE1":16662,"PHASE1":16664,"PHASE2":16666,"PHASE3":16668,"PHASE4":16670,"NA":16676},{"trials":16663,"activeCount":104},[],{"trials":16665,"activeCount":104},[],{"trials":16667,"activeCount":104},[],{"trials":16669,"activeCount":104},[],{"trials":16671,"activeCount":104},[16672],{"nctId":16630,"briefTitle":16631,"status":328,"phases":16673,"primaryCompletion":16633,"completion":16634,"start":16635,"enrollment":1389,"conditions":16674,"interventions":16675},[95],[15928],[16617,16638,16639],{"trials":16677,"activeCount":104},[],{"intervention":16679,"totalTrials":100,"cells":16680},"Artesunate",{"EARLY_PHASE1":16681,"PHASE1":16683,"PHASE2":16685,"PHASE3":16687,"PHASE4":16689,"NA":16699},{"trials":16682,"activeCount":104},[],{"trials":16684,"activeCount":104},[],{"trials":16686,"activeCount":104},[],{"trials":16688,"activeCount":104},[],{"trials":16690,"activeCount":104},[16691],{"nctId":16692,"briefTitle":16693,"status":174,"phases":16694,"primaryCompletion":3098,"completion":3098,"start":16695,"enrollment":406,"conditions":16696,"interventions":16698},"NCT03214731","Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis",[95],"2019-01-16",[16697],"Lupus Nephritis",[16679],{"trials":16700,"activeCount":104},[],{"intervention":8903,"totalTrials":100,"cells":16702},{"EARLY_PHASE1":16703,"PHASE1":16705,"PHASE2":16707,"PHASE3":16709,"PHASE4":16711,"NA":16717},{"trials":16704,"activeCount":104},[],{"trials":16706,"activeCount":104},[],{"trials":16708,"activeCount":104},[],{"trials":16710,"activeCount":104},[],{"trials":16712,"activeCount":104},[16713],{"nctId":8894,"briefTitle":8895,"status":174,"phases":16714,"primaryCompletion":8897,"completion":1238,"start":8898,"enrollment":8899,"conditions":16715,"interventions":16716},[95],[8901],[8903,8866,8904,8905],{"trials":16718,"activeCount":104},[],{"intervention":8905,"totalTrials":100,"cells":16720},{"EARLY_PHASE1":16721,"PHASE1":16723,"PHASE2":16725,"PHASE3":16727,"PHASE4":16729,"NA":16735},{"trials":16722,"activeCount":104},[],{"trials":16724,"activeCount":104},[],{"trials":16726,"activeCount":104},[],{"trials":16728,"activeCount":104},[],{"trials":16730,"activeCount":104},[16731],{"nctId":8894,"briefTitle":8895,"status":174,"phases":16732,"primaryCompletion":8897,"completion":1238,"start":8898,"enrollment":8899,"conditions":16733,"interventions":16734},[95],[8901],[8903,8866,8904,8905],{"trials":16736,"activeCount":104},[],{"intervention":15461,"totalTrials":100,"cells":16738},{"EARLY_PHASE1":16739,"PHASE1":16741,"PHASE2":16743,"PHASE3":16745,"PHASE4":16747,"NA":16753},{"trials":16740,"activeCount":104},[],{"trials":16742,"activeCount":104},[],{"trials":16744,"activeCount":104},[],{"trials":16746,"activeCount":104},[],{"trials":16748,"activeCount":104},[16749],{"nctId":15455,"briefTitle":15456,"status":174,"phases":16750,"primaryCompletion":4810,"completion":1934,"start":15458,"enrollment":1339,"conditions":16751,"interventions":16752},[95],[15450],[15432,15461],{"trials":16754,"activeCount":104},[],{"intervention":16756,"totalTrials":100,"cells":16757},"Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.",{"EARLY_PHASE1":16758,"PHASE1":16760,"PHASE2":16762,"PHASE3":16764,"PHASE4":16766,"NA":16774},{"trials":16759,"activeCount":104},[],{"trials":16761,"activeCount":104},[],{"trials":16763,"activeCount":104},[],{"trials":16765,"activeCount":104},[],{"trials":16767,"activeCount":104},[16768],{"nctId":16769,"briefTitle":16770,"status":174,"phases":16771,"primaryCompletion":764,"completion":829,"start":3291,"enrollment":1192,"conditions":16772,"interventions":16773},"NCT01894269","Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication",[95],[19],[16756],{"trials":16775,"activeCount":104},[],{"intervention":16777,"totalTrials":100,"cells":16778},"Pioglitazone + Metformin",{"EARLY_PHASE1":16779,"PHASE1":16781,"PHASE2":16783,"PHASE3":16785,"PHASE4":16787,"NA":16797},{"trials":16780,"activeCount":104},[],{"trials":16782,"activeCount":104},[],{"trials":16784,"activeCount":104},[],{"trials":16786,"activeCount":104},[],{"trials":16788,"activeCount":104},[16789],{"nctId":16790,"briefTitle":16791,"status":174,"phases":16792,"primaryCompletion":16793,"completion":2106,"start":16794,"enrollment":205,"conditions":16795,"interventions":16796},"NCT03196362","Impacts of PIO\u002FMET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes",[95],"2018-09-30","2016-12-01",[15670],[16777],{"trials":16798,"activeCount":104},[],{"intervention":16800,"totalTrials":100,"cells":16801},"Liraglutide combined with metformin",{"EARLY_PHASE1":16802,"PHASE1":16804,"PHASE2":16806,"PHASE3":16808,"PHASE4":16810,"NA":16822},{"trials":16803,"activeCount":104},[],{"trials":16805,"activeCount":104},[],{"trials":16807,"activeCount":104},[],{"trials":16809,"activeCount":104},[],{"trials":16811,"activeCount":104},[16812],{"nctId":16813,"briefTitle":16814,"status":328,"phases":16815,"primaryCompletion":2526,"completion":2526,"start":1980,"enrollment":16816,"conditions":16817,"interventions":16819},"NCT02147925","Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects",[95],75,[16818],"Non-alcoholic Fatty Liver Disease",[16800,16820,16821],"Insulin glargine combined with metformin","Sitagliptin combined with metformin",{"trials":16823,"activeCount":104},[],{"intervention":16820,"totalTrials":100,"cells":16825},{"EARLY_PHASE1":16826,"PHASE1":16828,"PHASE2":16830,"PHASE3":16832,"PHASE4":16834,"NA":16840},{"trials":16827,"activeCount":104},[],{"trials":16829,"activeCount":104},[],{"trials":16831,"activeCount":104},[],{"trials":16833,"activeCount":104},[],{"trials":16835,"activeCount":104},[16836],{"nctId":16813,"briefTitle":16814,"status":328,"phases":16837,"primaryCompletion":2526,"completion":2526,"start":1980,"enrollment":16816,"conditions":16838,"interventions":16839},[95],[16818],[16800,16820,16821],{"trials":16841,"activeCount":104},[],{"intervention":16821,"totalTrials":100,"cells":16843},{"EARLY_PHASE1":16844,"PHASE1":16846,"PHASE2":16848,"PHASE3":16850,"PHASE4":16852,"NA":16858},{"trials":16845,"activeCount":104},[],{"trials":16847,"activeCount":104},[],{"trials":16849,"activeCount":104},[],{"trials":16851,"activeCount":104},[],{"trials":16853,"activeCount":104},[16854],{"nctId":16813,"briefTitle":16814,"status":328,"phases":16855,"primaryCompletion":2526,"completion":2526,"start":1980,"enrollment":16816,"conditions":16856,"interventions":16857},[95],[16818],[16800,16820,16821],{"trials":16859,"activeCount":104},[],{"intervention":16861,"totalTrials":100,"cells":16862},"Ketorolac Tromethamine",{"EARLY_PHASE1":16863,"PHASE1":16865,"PHASE2":16867,"PHASE3":16869,"PHASE4":16871,"NA":16880},{"trials":16864,"activeCount":104},[],{"trials":16866,"activeCount":104},[],{"trials":16868,"activeCount":104},[],{"trials":16870,"activeCount":104},[],{"trials":16872,"activeCount":104},[16873],{"nctId":16874,"briefTitle":16875,"status":328,"phases":16876,"primaryCompletion":4644,"completion":4644,"start":14788,"enrollment":7941,"conditions":16877,"interventions":16879},"NCT02729285","Preoperative Ketorolac for Pain Control in Scleral Buckle Surgery",[95],[16878],"Pain",[16861],{"trials":16881,"activeCount":104},[],{"intervention":16883,"totalTrials":100,"cells":16884},"Growth Hormone",{"EARLY_PHASE1":16885,"PHASE1":16887,"PHASE2":16889,"PHASE3":16891,"PHASE4":16893,"NA":16903},{"trials":16886,"activeCount":104},[],{"trials":16888,"activeCount":104},[],{"trials":16890,"activeCount":104},[],{"trials":16892,"activeCount":104},[],{"trials":16894,"activeCount":104},[16895],{"nctId":16896,"briefTitle":16897,"status":174,"phases":16898,"primaryCompletion":177,"completion":16899,"start":427,"enrollment":942,"conditions":16900,"interventions":16902},"NCT03027843","The Effect of Growth Hormone in Assisted Reproductive Technology Clinical Outcome of Poor Responder",[95],"2020-04",[16901],"Low Ovarian Reserve",[16883],{"trials":16904,"activeCount":104},[],{"intervention":16906,"totalTrials":100,"cells":16907},"bisphosphates",{"EARLY_PHASE1":16908,"PHASE1":16910,"PHASE2":16912,"PHASE3":16914,"PHASE4":16916,"NA":16926},{"trials":16909,"activeCount":104},[],{"trials":16911,"activeCount":104},[],{"trials":16913,"activeCount":104},[],{"trials":16915,"activeCount":104},[],{"trials":16917,"activeCount":104},[16918],{"nctId":16919,"briefTitle":16920,"status":328,"phases":16921,"primaryCompletion":16922,"completion":16922,"start":16923,"enrollment":9043,"conditions":16924,"interventions":16925},"NCT00765687","Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates",[95],"2012-05","2008-08",[22,15562],[16906],{"trials":16927,"activeCount":104},[],{"intervention":15589,"totalTrials":100,"cells":16929},{"EARLY_PHASE1":16930,"PHASE1":16932,"PHASE2":16934,"PHASE3":16936,"PHASE4":16938,"NA":16944},{"trials":16931,"activeCount":104},[],{"trials":16933,"activeCount":104},[],{"trials":16935,"activeCount":104},[],{"trials":16937,"activeCount":104},[],{"trials":16939,"activeCount":104},[16940],{"nctId":15584,"briefTitle":15585,"status":328,"phases":16941,"primaryCompletion":5211,"completion":5211,"start":15546,"enrollment":219,"conditions":16942,"interventions":16943},[95],[3293],[3385,15589],{"trials":16945,"activeCount":104},[],{"intervention":2906,"totalTrials":2272,"cells":16947},{"EARLY_PHASE1":16948,"PHASE1":16950,"PHASE2":16952,"PHASE3":16978,"PHASE4":16995,"NA":16997},{"trials":16949,"activeCount":104},[],{"trials":16951,"activeCount":104},[],{"trials":16953,"activeCount":104},[16954,16964,16968,16974],{"nctId":16955,"briefTitle":16956,"status":328,"phases":16957,"primaryCompletion":16958,"completion":16959,"start":16960,"enrollment":16961,"conditions":16962,"interventions":16963},"NCT03048123","HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A\u002FB",[93],"2016-10-01","2017-01-24","2015-10-01",79,[19],[2906,2933],{"nctId":9159,"briefTitle":9160,"status":174,"phases":16965,"primaryCompletion":966,"completion":966,"start":9162,"enrollment":1339,"conditions":16966,"interventions":16967},[93],[19],[2906,999,9165],{"nctId":16969,"briefTitle":16970,"status":328,"phases":16971,"primaryCompletion":2526,"completion":2526,"start":799,"enrollment":1109,"conditions":16972,"interventions":16973},"NCT02981498","Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma",[93],[19],[2906],{"nctId":2900,"briefTitle":2901,"status":904,"phases":16975,"primaryCompletion":949,"completion":949,"start":2903,"enrollment":104,"conditions":16976,"interventions":16977},[93],[19],[2906,353,517],{"trials":16979,"activeCount":104},[16980,16988],{"nctId":16981,"briefTitle":16982,"status":328,"phases":16983,"primaryCompletion":16984,"completion":16984,"start":16958,"enrollment":16985,"conditions":16986,"interventions":16987},"NCT02973685","HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A\u002FB.",[94],"2020-11-28",315,[181],[2906,2933],{"nctId":16989,"briefTitle":16990,"status":328,"phases":16991,"primaryCompletion":5478,"completion":3842,"start":1336,"enrollment":16992,"conditions":16993,"interventions":16994},"NCT02774187","Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC",[94],247,[19],[999,2906],{"trials":16996,"activeCount":104},[],{"trials":16998,"activeCount":104},[],{"intervention":2309,"totalTrials":1861,"cells":17000},{"EARLY_PHASE1":17001,"PHASE1":17003,"PHASE2":17005,"PHASE3":17015,"PHASE4":17021,"NA":17023},{"trials":17002,"activeCount":104},[],{"trials":17004,"activeCount":104},[],{"trials":17006,"activeCount":104},[17007,17011],{"nctId":7424,"briefTitle":7425,"status":174,"phases":17008,"primaryCompletion":217,"completion":3355,"start":7427,"enrollment":7428,"conditions":17009,"interventions":17010},[93],[7430],[981,7432,2308,2197,4755],{"nctId":4745,"briefTitle":4746,"status":174,"phases":17012,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":17013,"interventions":17014},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":17016,"activeCount":104},[17017],{"nctId":2300,"briefTitle":2301,"status":1091,"phases":17018,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":17019,"interventions":17020},[94],[2235],[49,542,1205,411,2306,2307,2308,2309],{"trials":17022,"activeCount":104},[],{"trials":17024,"activeCount":104},[],{"intervention":17026,"totalTrials":1861,"cells":17027},"HAIC of FOLFOX",{"EARLY_PHASE1":17028,"PHASE1":17030,"PHASE2":17032,"PHASE3":17049,"PHASE4":17060,"NA":17062},{"trials":17029,"activeCount":104},[],{"trials":17031,"activeCount":104},[],{"trials":17033,"activeCount":104},[17034,17041],{"nctId":17035,"briefTitle":17036,"status":904,"phases":17037,"primaryCompletion":17038,"completion":17038,"start":218,"enrollment":104,"conditions":17039,"interventions":17040},"NCT03722498","Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE",[93],"2021-03-22",[19],[17026,999],{"nctId":17042,"briefTitle":17043,"status":174,"phases":17044,"primaryCompletion":9151,"completion":9151,"start":17045,"enrollment":1389,"conditions":17046,"interventions":17047},"NCT03812770","Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC",[93],"2018-08-04",[19],[999,17026,17048],"HAIC of OXA",{"trials":17050,"activeCount":104},[17051],{"nctId":17052,"briefTitle":17053,"status":174,"phases":17054,"primaryCompletion":17055,"completion":17056,"start":17057,"enrollment":189,"conditions":17058,"interventions":17059},"NCT03468231","HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC",[94],"2019-09-09","2020-03-09","2018-03-09",[19],[999,17026,17048],{"trials":17061,"activeCount":104},[],{"trials":17063,"activeCount":104},[],{"intervention":3898,"totalTrials":1861,"cells":17065},{"EARLY_PHASE1":17066,"PHASE1":17068,"PHASE2":17070,"PHASE3":17080,"PHASE4":17090,"NA":17092},{"trials":17067,"activeCount":104},[],{"trials":17069,"activeCount":104},[],{"trials":17071,"activeCount":104},[17072,17076],{"nctId":4264,"briefTitle":4265,"status":174,"phases":17073,"primaryCompletion":4267,"completion":4267,"start":4268,"enrollment":1460,"conditions":17074,"interventions":17075},[93],[539],[269,3898],{"nctId":3892,"briefTitle":3893,"status":904,"phases":17077,"primaryCompletion":966,"completion":1094,"start":3895,"enrollment":104,"conditions":17078,"interventions":17079},[93],[19],[517,3898],{"trials":17081,"activeCount":104},[17082],{"nctId":17083,"briefTitle":17084,"status":174,"phases":17085,"primaryCompletion":10550,"completion":10550,"start":3024,"enrollment":17086,"conditions":17087,"interventions":17088},"NCT03780049","HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B",[94],304,[19],[17089,3898],"H101",{"trials":17091,"activeCount":104},[],{"trials":17093,"activeCount":104},[],{"intervention":2933,"totalTrials":1861,"cells":17095},{"EARLY_PHASE1":17096,"PHASE1":17098,"PHASE2":17100,"PHASE3":17106,"PHASE4":17116,"NA":17118},{"trials":17097,"activeCount":104},[],{"trials":17099,"activeCount":104},[],{"trials":17101,"activeCount":104},[17102],{"nctId":16955,"briefTitle":16956,"status":328,"phases":17103,"primaryCompletion":16958,"completion":16959,"start":16960,"enrollment":16961,"conditions":17104,"interventions":17105},[93],[19],[2906,2933],{"trials":17107,"activeCount":104},[17108,17112],{"nctId":16981,"briefTitle":16982,"status":328,"phases":17109,"primaryCompletion":16984,"completion":16984,"start":16958,"enrollment":16985,"conditions":17110,"interventions":17111},[94],[181],[2906,2933],{"nctId":2928,"briefTitle":2929,"status":904,"phases":17113,"primaryCompletion":1509,"completion":1509,"start":2058,"enrollment":104,"conditions":17114,"interventions":17115},[94],[19],[353,517,2933],{"trials":17117,"activeCount":104},[],{"trials":17119,"activeCount":104},[],{"intervention":4353,"totalTrials":1861,"cells":17121},{"EARLY_PHASE1":17122,"PHASE1":17124,"PHASE2":17126,"PHASE3":17128,"PHASE4":17147,"NA":17149},{"trials":17123,"activeCount":104},[],{"trials":17125,"activeCount":104},[],{"trials":17127,"activeCount":104},[],{"trials":17129,"activeCount":104},[17130,17139,17143],{"nctId":17131,"briefTitle":17132,"status":174,"phases":17133,"primaryCompletion":5934,"completion":5934,"start":17134,"enrollment":4483,"conditions":17135,"interventions":17137},"NCT03203590","Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients",[94],"2017-09",[17136],"2-year Disease-Free Survival",[17138,4353],"Oral Navelbine + Carboplatin",{"nctId":4695,"briefTitle":4696,"status":174,"phases":17140,"primaryCompletion":658,"completion":1827,"start":4698,"enrollment":4699,"conditions":17141,"interventions":17142},[94],[4701],[4353,844],{"nctId":4347,"briefTitle":4348,"status":174,"phases":17144,"primaryCompletion":259,"completion":259,"start":1374,"enrollment":1856,"conditions":17145,"interventions":17146},[94],[4351],[269,4353],{"trials":17148,"activeCount":104},[],{"trials":17150,"activeCount":104},[],{"intervention":3762,"totalTrials":1861,"cells":17152},{"EARLY_PHASE1":17153,"PHASE1":17155,"PHASE2":17157,"PHASE3":17163,"PHASE4":17173,"NA":17175},{"trials":17154,"activeCount":104},[],{"trials":17156,"activeCount":104},[],{"trials":17158,"activeCount":104},[17159],{"nctId":3754,"briefTitle":3755,"status":174,"phases":17160,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":20,"conditions":17161,"interventions":17162},[93],[16],[3762,443,3763],{"trials":17164,"activeCount":104},[17165,17169],{"nctId":3807,"briefTitle":3808,"status":174,"phases":17166,"primaryCompletion":3758,"completion":3810,"start":3759,"enrollment":3811,"conditions":17167,"interventions":17168},[94],[16],[3763,3762,443,2088],{"nctId":3839,"briefTitle":3840,"status":174,"phases":17170,"primaryCompletion":3842,"completion":3843,"start":178,"enrollment":3844,"conditions":17171,"interventions":17172},[94],[16],[443,3763,2088,3762],{"trials":17174,"activeCount":104},[],{"trials":17176,"activeCount":104},[],{"intervention":3763,"totalTrials":1861,"cells":17178},{"EARLY_PHASE1":17179,"PHASE1":17181,"PHASE2":17183,"PHASE3":17189,"PHASE4":17199,"NA":17201},{"trials":17180,"activeCount":104},[],{"trials":17182,"activeCount":104},[],{"trials":17184,"activeCount":104},[17185],{"nctId":3754,"briefTitle":3755,"status":174,"phases":17186,"primaryCompletion":3757,"completion":3758,"start":3759,"enrollment":20,"conditions":17187,"interventions":17188},[93],[16],[3762,443,3763],{"trials":17190,"activeCount":104},[17191,17195],{"nctId":3807,"briefTitle":3808,"status":174,"phases":17192,"primaryCompletion":3758,"completion":3810,"start":3759,"enrollment":3811,"conditions":17193,"interventions":17194},[94],[16],[3763,3762,443,2088],{"nctId":3839,"briefTitle":3840,"status":174,"phases":17196,"primaryCompletion":3842,"completion":3843,"start":178,"enrollment":3844,"conditions":17197,"interventions":17198},[94],[16],[443,3763,2088,3762],{"trials":17200,"activeCount":104},[],{"trials":17202,"activeCount":104},[],{"intervention":2088,"totalTrials":1861,"cells":17204},{"EARLY_PHASE1":17205,"PHASE1":17207,"PHASE2":17209,"PHASE3":17215,"PHASE4":17225,"NA":17227},{"trials":17206,"activeCount":104},[],{"trials":17208,"activeCount":104},[],{"trials":17210,"activeCount":104},[17211],{"nctId":2082,"briefTitle":2083,"status":174,"phases":17212,"primaryCompletion":799,"completion":428,"start":2085,"enrollment":1289,"conditions":17213,"interventions":17214},[93],[34],[2088,542,272],{"trials":17216,"activeCount":104},[17217,17221],{"nctId":3807,"briefTitle":3808,"status":174,"phases":17218,"primaryCompletion":3758,"completion":3810,"start":3759,"enrollment":3811,"conditions":17219,"interventions":17220},[94],[16],[3763,3762,443,2088],{"nctId":3839,"briefTitle":3840,"status":174,"phases":17222,"primaryCompletion":3842,"completion":3843,"start":178,"enrollment":3844,"conditions":17223,"interventions":17224},[94],[16],[443,3763,2088,3762],{"trials":17226,"activeCount":104},[],{"trials":17228,"activeCount":104},[],{"intervention":3327,"totalTrials":1255,"cells":17230},{"EARLY_PHASE1":17231,"PHASE1":17233,"PHASE2":17235,"PHASE3":17237,"PHASE4":17247,"NA":17249},{"trials":17232,"activeCount":104},[],{"trials":17234,"activeCount":104},[],{"trials":17236,"activeCount":104},[],{"trials":17238,"activeCount":104},[17239,17243],{"nctId":3322,"briefTitle":3323,"status":328,"phases":17240,"primaryCompletion":522,"completion":522,"start":1576,"enrollment":775,"conditions":17241,"interventions":17242},[94],[1341],[3327,726],{"nctId":4463,"briefTitle":4464,"status":174,"phases":17244,"primaryCompletion":460,"completion":657,"start":4466,"enrollment":1192,"conditions":17245,"interventions":17246},[94],[539],[3327,4415],{"trials":17248,"activeCount":104},[],{"trials":17250,"activeCount":104},[],{"intervention":17048,"totalTrials":1255,"cells":17252},{"EARLY_PHASE1":17253,"PHASE1":17255,"PHASE2":17257,"PHASE3":17263,"PHASE4":17269,"NA":17271},{"trials":17254,"activeCount":104},[],{"trials":17256,"activeCount":104},[],{"trials":17258,"activeCount":104},[17259],{"nctId":17042,"briefTitle":17043,"status":174,"phases":17260,"primaryCompletion":9151,"completion":9151,"start":17045,"enrollment":1389,"conditions":17261,"interventions":17262},[93],[19],[999,17026,17048],{"trials":17264,"activeCount":104},[17265],{"nctId":17052,"briefTitle":17053,"status":174,"phases":17266,"primaryCompletion":17055,"completion":17056,"start":17057,"enrollment":189,"conditions":17267,"interventions":17268},[94],[19],[999,17026,17048],{"trials":17270,"activeCount":104},[],{"trials":17272,"activeCount":104},[],{"intervention":2504,"totalTrials":1255,"cells":17274},{"EARLY_PHASE1":17275,"PHASE1":17277,"PHASE2":17279,"PHASE3":17285,"PHASE4":17291,"NA":17293},{"trials":17276,"activeCount":104},[],{"trials":17278,"activeCount":104},[],{"trials":17280,"activeCount":104},[17281],{"nctId":2497,"briefTitle":2498,"status":328,"phases":17282,"primaryCompletion":522,"completion":53,"start":2500,"enrollment":996,"conditions":17283,"interventions":17284},[93],[2502,2098],[54,542,2504],{"trials":17286,"activeCount":104},[17287],{"nctId":2608,"briefTitle":2609,"status":1091,"phases":17288,"primaryCompletion":2611,"completion":479,"start":289,"enrollment":2601,"conditions":17289,"interventions":17290},[94],[1368,2098],[54,2614,2504,2080,398,542],{"trials":17292,"activeCount":104},[],{"trials":17294,"activeCount":104},[],{"intervention":17296,"totalTrials":1255,"cells":17297},"Doxycycline",{"EARLY_PHASE1":17298,"PHASE1":17300,"PHASE2":17302,"PHASE3":17312,"PHASE4":17323,"NA":17325},{"trials":17299,"activeCount":104},[],{"trials":17301,"activeCount":104},[],{"trials":17303,"activeCount":104},[17304],{"nctId":17305,"briefTitle":17306,"status":328,"phases":17307,"primaryCompletion":1375,"completion":1375,"start":17308,"enrollment":2089,"conditions":17309,"interventions":17311},"NCT01727973","Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy",[92,93],"2012-10",[12946,14790,17310,14792,14793,14794,14795,14796,14797],"Eye Diseases",[17296],{"trials":17313,"activeCount":104},[17314],{"nctId":17315,"briefTitle":17316,"status":174,"phases":17317,"primaryCompletion":17318,"completion":17318,"start":17319,"enrollment":492,"conditions":17320,"interventions":17322},"NCT01886560","Low Dose Doxycycline in the Treatment of Corneal Burn",[93,94],"2014-09","2013-09",[17321],"Eye Burns",[17296],{"trials":17324,"activeCount":104},[],{"trials":17326,"activeCount":104},[],{"intervention":17328,"totalTrials":1255,"cells":17329},"Tacrolimus Sustained-release",{"EARLY_PHASE1":17330,"PHASE1":17332,"PHASE2":17334,"PHASE3":17336,"PHASE4":17353,"NA":17355},{"trials":17331,"activeCount":104},[],{"trials":17333,"activeCount":104},[],{"trials":17335,"activeCount":104},[],{"trials":17337,"activeCount":104},[17338,17346],{"nctId":17339,"briefTitle":17340,"status":328,"phases":17341,"primaryCompletion":15448,"completion":15448,"start":17342,"enrollment":239,"conditions":17343,"interventions":17345},"NCT01328834","Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis",[94],"2011-01",[17344],"Nephritis, Lupus",[17328],{"nctId":17347,"briefTitle":17348,"status":328,"phases":17349,"primaryCompletion":15448,"completion":15448,"start":17342,"enrollment":239,"conditions":17350,"interventions":17352},"NCT01309477","The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)",[94],[17351],"Nephrotic Syndrome",[17328],{"trials":17354,"activeCount":104},[],{"trials":17356,"activeCount":104},[],{"intervention":17358,"totalTrials":1255,"cells":17359},"Ganglioside-Monosialic Acid",{"EARLY_PHASE1":17360,"PHASE1":17362,"PHASE2":17364,"PHASE3":17366,"PHASE4":17385,"NA":17387},{"trials":17361,"activeCount":104},[],{"trials":17363,"activeCount":104},[],{"trials":17365,"activeCount":104},[],{"trials":17367,"activeCount":104},[17368,17378],{"nctId":17369,"briefTitle":17370,"status":1091,"phases":17371,"primaryCompletion":17372,"completion":17372,"start":17373,"enrollment":10173,"conditions":17374,"interventions":17376},"NCT05239663","GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer",[94],"2024-07-31","2022-02-08",[17375,28],"Chemotherapy-Related Cognitive Impairment",[17358,17377],"250ml normal saline",{"nctId":17379,"briefTitle":17380,"status":328,"phases":17381,"primaryCompletion":3747,"completion":459,"start":2303,"enrollment":2913,"conditions":17382,"interventions":17383},"NCT02468739","Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer",[94],[28],[17384],"Ganglioside-monosialic acid",{"trials":17386,"activeCount":104},[],{"trials":17388,"activeCount":104},[],{"intervention":2307,"totalTrials":1255,"cells":17390},{"EARLY_PHASE1":17391,"PHASE1":17393,"PHASE2":17395,"PHASE3":17397,"PHASE4":17407,"NA":17409},{"trials":17392,"activeCount":104},[],{"trials":17394,"activeCount":104},[],{"trials":17396,"activeCount":104},[],{"trials":17398,"activeCount":104},[17399,17403],{"nctId":2300,"briefTitle":2301,"status":1091,"phases":17400,"primaryCompletion":203,"completion":203,"start":2303,"enrollment":205,"conditions":17401,"interventions":17402},[94],[2235],[49,542,1205,411,2306,2307,2308,2309],{"nctId":7884,"briefTitle":7885,"status":174,"phases":17404,"primaryCompletion":5304,"completion":7887,"start":1500,"enrollment":800,"conditions":17405,"interventions":17406},[94],[7889],[2308,244,183,2307],{"trials":17408,"activeCount":104},[],{"trials":17410,"activeCount":104},[],{"intervention":17412,"totalTrials":1255,"cells":17413},"Hepatic Arterial Infusion combined with Apatinib and Camrelizumab",{"EARLY_PHASE1":17414,"PHASE1":17416,"PHASE2":17418,"PHASE3":17428,"PHASE4":17438,"NA":17440},{"trials":17415,"activeCount":104},[],{"trials":17417,"activeCount":104},[],{"trials":17419,"activeCount":104},[17420],{"nctId":17421,"briefTitle":17422,"status":174,"phases":17423,"primaryCompletion":721,"completion":379,"start":17424,"enrollment":360,"conditions":17425,"interventions":17427},"NCT04191889","A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification",[93],"2020-04-13",[17426],"C-staged Hepatocellular Carcinoma in BCLC Classification",[17412],{"trials":17429,"activeCount":104},[17430],{"nctId":17431,"briefTitle":17432,"status":174,"phases":17433,"primaryCompletion":2458,"completion":895,"start":17434,"enrollment":17,"conditions":17435,"interventions":17436},"NCT05313282","A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification",[94],"2022-06-15",[17426],[17412,17437],"Apatinib combined with Camrelizumab",{"trials":17439,"activeCount":104},[],{"trials":17441,"activeCount":104},[],{"intervention":17443,"totalTrials":100,"cells":17444},"TACE regimen",{"EARLY_PHASE1":17445,"PHASE1":17447,"PHASE2":17449,"PHASE3":17451,"PHASE4":17462,"NA":17464},{"trials":17446,"activeCount":104},[],{"trials":17448,"activeCount":104},[],{"trials":17450,"activeCount":104},[],{"trials":17452,"activeCount":104},[17453],{"nctId":17454,"briefTitle":17455,"status":328,"phases":17456,"primaryCompletion":7371,"completion":17457,"start":178,"enrollment":3209,"conditions":17458,"interventions":17459},"NCT02856126","HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC",[94],"2024-07",[19],[17443,17460,17461],"HAIC Regimen","Oral Sorafenib",{"trials":17463,"activeCount":104},[],{"trials":17465,"activeCount":104},[],{"intervention":17460,"totalTrials":100,"cells":17467},{"EARLY_PHASE1":17468,"PHASE1":17470,"PHASE2":17472,"PHASE3":17474,"PHASE4":17480,"NA":17482},{"trials":17469,"activeCount":104},[],{"trials":17471,"activeCount":104},[],{"trials":17473,"activeCount":104},[],{"trials":17475,"activeCount":104},[17476],{"nctId":17454,"briefTitle":17455,"status":328,"phases":17477,"primaryCompletion":7371,"completion":17457,"start":178,"enrollment":3209,"conditions":17478,"interventions":17479},[94],[19],[17443,17460,17461],{"trials":17481,"activeCount":104},[],{"trials":17483,"activeCount":104},[],{"intervention":17461,"totalTrials":100,"cells":17485},{"EARLY_PHASE1":17486,"PHASE1":17488,"PHASE2":17490,"PHASE3":17492,"PHASE4":17498,"NA":17500},{"trials":17487,"activeCount":104},[],{"trials":17489,"activeCount":104},[],{"trials":17491,"activeCount":104},[],{"trials":17493,"activeCount":104},[17494],{"nctId":17454,"briefTitle":17455,"status":328,"phases":17495,"primaryCompletion":7371,"completion":17457,"start":178,"enrollment":3209,"conditions":17496,"interventions":17497},[94],[19],[17443,17460,17461],{"trials":17499,"activeCount":104},[],{"trials":17501,"activeCount":104},[],{"intervention":17503,"totalTrials":100,"cells":17504},"Liposome doxorubicin",{"EARLY_PHASE1":17505,"PHASE1":17507,"PHASE2":17509,"PHASE3":17511,"PHASE4":17522,"NA":17524},{"trials":17506,"activeCount":104},[],{"trials":17508,"activeCount":104},[],{"trials":17510,"activeCount":104},[],{"trials":17512,"activeCount":104},[17513],{"nctId":17514,"briefTitle":17515,"status":174,"phases":17516,"primaryCompletion":4033,"completion":6504,"start":17517,"enrollment":5353,"conditions":17518,"interventions":17520},"NCT05561036","A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor",[94],"2020-09-29",[17519],"Desmoid Tumor",[17503,17521],"Saline Solution",{"trials":17523,"activeCount":104},[],{"trials":17525,"activeCount":104},[],{"intervention":17521,"totalTrials":100,"cells":17527},{"EARLY_PHASE1":17528,"PHASE1":17530,"PHASE2":17532,"PHASE3":17534,"PHASE4":17540,"NA":17542},{"trials":17529,"activeCount":104},[],{"trials":17531,"activeCount":104},[],{"trials":17533,"activeCount":104},[],{"trials":17535,"activeCount":104},[17536],{"nctId":17514,"briefTitle":17515,"status":174,"phases":17537,"primaryCompletion":4033,"completion":6504,"start":17517,"enrollment":5353,"conditions":17538,"interventions":17539},[94],[17519],[17503,17521],{"trials":17541,"activeCount":104},[],{"trials":17543,"activeCount":104},[],{"intervention":17545,"totalTrials":100,"cells":17546},"HAIC of 130 mg\u002Fm² Oxaliplatin, and 5-fu",{"EARLY_PHASE1":17547,"PHASE1":17549,"PHASE2":17551,"PHASE3":17553,"PHASE4":17563,"NA":17565},{"trials":17548,"activeCount":104},[],{"trials":17550,"activeCount":104},[],{"trials":17552,"activeCount":104},[],{"trials":17554,"activeCount":104},[17555],{"nctId":17556,"briefTitle":17557,"status":174,"phases":17558,"primaryCompletion":4033,"completion":4033,"start":522,"enrollment":15087,"conditions":17559,"interventions":17560},"NCT04687163","Sorafenib or Lenvatinib Plus HAIC of 130 mg\u002Fm² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg\u002Fm² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial",[94],[19],[17545,17561,17562],"HAIC of 85 mg\u002Fm² Oxaliplatin, and 5-fu","TKI",{"trials":17564,"activeCount":104},[],{"trials":17566,"activeCount":104},[],{"intervention":17561,"totalTrials":100,"cells":17568},{"EARLY_PHASE1":17569,"PHASE1":17571,"PHASE2":17573,"PHASE3":17575,"PHASE4":17581,"NA":17583},{"trials":17570,"activeCount":104},[],{"trials":17572,"activeCount":104},[],{"trials":17574,"activeCount":104},[],{"trials":17576,"activeCount":104},[17577],{"nctId":17556,"briefTitle":17557,"status":174,"phases":17578,"primaryCompletion":4033,"completion":4033,"start":522,"enrollment":15087,"conditions":17579,"interventions":17580},[94],[19],[17545,17561,17562],{"trials":17582,"activeCount":104},[],{"trials":17584,"activeCount":104},[],{"intervention":17562,"totalTrials":100,"cells":17586},{"EARLY_PHASE1":17587,"PHASE1":17589,"PHASE2":17591,"PHASE3":17593,"PHASE4":17599,"NA":17601},{"trials":17588,"activeCount":104},[],{"trials":17590,"activeCount":104},[],{"trials":17592,"activeCount":104},[],{"trials":17594,"activeCount":104},[17595],{"nctId":17556,"briefTitle":17557,"status":174,"phases":17596,"primaryCompletion":4033,"completion":4033,"start":522,"enrollment":15087,"conditions":17597,"interventions":17598},[94],[19],[17545,17561,17562],{"trials":17600,"activeCount":104},[],{"trials":17602,"activeCount":104},[],{"intervention":17604,"totalTrials":100,"cells":17605},"Mega Resveratrol®",{"EARLY_PHASE1":17606,"PHASE1":17608,"PHASE2":17610,"PHASE3":17612,"PHASE4":17622,"NA":17624},{"trials":17607,"activeCount":104},[],{"trials":17609,"activeCount":104},[],{"trials":17611,"activeCount":104},[],{"trials":17613,"activeCount":104},[17614],{"nctId":17615,"briefTitle":17616,"status":328,"phases":17617,"primaryCompletion":331,"completion":3098,"start":2427,"enrollment":1402,"conditions":17618,"interventions":17620},"NCT04886297","A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder",[94],[17619],"Dyslipidemias",[17604,17621],"Mega Resveratrol® Placebo",{"trials":17623,"activeCount":104},[],{"trials":17625,"activeCount":104},[],{"intervention":17621,"totalTrials":100,"cells":17627},{"EARLY_PHASE1":17628,"PHASE1":17630,"PHASE2":17632,"PHASE3":17634,"PHASE4":17640,"NA":17642},{"trials":17629,"activeCount":104},[],{"trials":17631,"activeCount":104},[],{"trials":17633,"activeCount":104},[],{"trials":17635,"activeCount":104},[17636],{"nctId":17615,"briefTitle":17616,"status":328,"phases":17637,"primaryCompletion":331,"completion":3098,"start":2427,"enrollment":1402,"conditions":17638,"interventions":17639},[94],[17619],[17604,17621],{"trials":17641,"activeCount":104},[],{"trials":17643,"activeCount":104},[],{"intervention":17645,"totalTrials":100,"cells":17646},"Pemetrexed\u002FPlatinum",{"EARLY_PHASE1":17647,"PHASE1":17649,"PHASE2":17651,"PHASE3":17653,"PHASE4":17663,"NA":17665},{"trials":17648,"activeCount":104},[],{"trials":17650,"activeCount":104},[],{"trials":17652,"activeCount":104},[],{"trials":17654,"activeCount":104},[17655],{"nctId":17656,"briefTitle":17657,"status":328,"phases":17658,"primaryCompletion":259,"completion":260,"start":3759,"enrollment":734,"conditions":17659,"interventions":17661},"NCT01951482","Pemetrexed\u002FPlatinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR\u002FALK Negative Non-Squamous Non-small Cell Lung Cancer",[94],[17660,1830,272],"Non Squamous Non-small Cell Lung Cancer",[17645,17662],"Bevacizumab and Pemetrexed\u002Fplatinum",{"trials":17664,"activeCount":104},[],{"trials":17666,"activeCount":104},[],{"intervention":17662,"totalTrials":100,"cells":17668},{"EARLY_PHASE1":17669,"PHASE1":17671,"PHASE2":17673,"PHASE3":17675,"PHASE4":17681,"NA":17683},{"trials":17670,"activeCount":104},[],{"trials":17672,"activeCount":104},[],{"trials":17674,"activeCount":104},[],{"trials":17676,"activeCount":104},[17677],{"nctId":17656,"briefTitle":17657,"status":328,"phases":17678,"primaryCompletion":259,"completion":260,"start":3759,"enrollment":734,"conditions":17679,"interventions":17680},[94],[17660,1830,272],[17645,17662],{"trials":17682,"activeCount":104},[],{"trials":17684,"activeCount":104},[],{"intervention":17089,"totalTrials":100,"cells":17686},{"EARLY_PHASE1":17687,"PHASE1":17689,"PHASE2":17691,"PHASE3":17693,"PHASE4":17699,"NA":17701},{"trials":17688,"activeCount":104},[],{"trials":17690,"activeCount":104},[],{"trials":17692,"activeCount":104},[],{"trials":17694,"activeCount":104},[17695],{"nctId":17083,"briefTitle":17084,"status":174,"phases":17696,"primaryCompletion":10550,"completion":10550,"start":3024,"enrollment":17086,"conditions":17697,"interventions":17698},[94],[19],[17089,3898],{"trials":17700,"activeCount":104},[],{"trials":17702,"activeCount":104},[],{"intervention":17704,"totalTrials":100,"cells":17705},"cisplatin and pemetrexed",{"EARLY_PHASE1":17706,"PHASE1":17708,"PHASE2":17710,"PHASE3":17712,"PHASE4":17723,"NA":17725},{"trials":17707,"activeCount":104},[],{"trials":17709,"activeCount":104},[],{"trials":17711,"activeCount":104},[],{"trials":17713,"activeCount":104},[17714],{"nctId":17715,"briefTitle":17716,"status":174,"phases":17717,"primaryCompletion":3544,"completion":1827,"start":618,"enrollment":17718,"conditions":17719,"interventions":17721},"NCT02607592","A Prospective Multi-center Phase III Randomized Controlled Trial",[94],293,[17720],"Carcinoma，Non-Small-Cell Lung",[17704,17722],"nedaplatin+pemetrexed",{"trials":17724,"activeCount":104},[],{"trials":17726,"activeCount":104},[],{"intervention":17722,"totalTrials":100,"cells":17728},{"EARLY_PHASE1":17729,"PHASE1":17731,"PHASE2":17733,"PHASE3":17735,"PHASE4":17741,"NA":17743},{"trials":17730,"activeCount":104},[],{"trials":17732,"activeCount":104},[],{"trials":17734,"activeCount":104},[],{"trials":17736,"activeCount":104},[17737],{"nctId":17715,"briefTitle":17716,"status":174,"phases":17738,"primaryCompletion":3544,"completion":1827,"start":618,"enrollment":17718,"conditions":17739,"interventions":17740},[94],[17720],[17704,17722],{"trials":17742,"activeCount":104},[],{"trials":17744,"activeCount":104},[],{"intervention":590,"totalTrials":100,"cells":17746},{"EARLY_PHASE1":17747,"PHASE1":17749,"PHASE2":17751,"PHASE3":17753,"PHASE4":17759,"NA":17761},{"trials":17748,"activeCount":104},[],{"trials":17750,"activeCount":104},[],{"trials":17752,"activeCount":104},[],{"trials":17754,"activeCount":104},[17755],{"nctId":580,"briefTitle":581,"status":328,"phases":17756,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":17757,"interventions":17758},[94],[588],[225,590],{"trials":17760,"activeCount":104},[],{"trials":17762,"activeCount":104},[],{"intervention":17764,"totalTrials":100,"cells":17765},"ADVAGRAF",{"EARLY_PHASE1":17766,"PHASE1":17768,"PHASE2":17770,"PHASE3":17772,"PHASE4":17780,"NA":17782},{"trials":17767,"activeCount":104},[],{"trials":17769,"activeCount":104},[],{"trials":17771,"activeCount":104},[],{"trials":17773,"activeCount":104},[17774],{"nctId":17775,"briefTitle":17776,"status":904,"phases":17777,"primaryCompletion":7636,"completion":7636,"start":17342,"enrollment":104,"conditions":17778,"interventions":17779},"NCT01288664","Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis",[94],[16697],[17764],{"trials":17781,"activeCount":104},[],{"trials":17783,"activeCount":104},[],{"intervention":17785,"totalTrials":100,"cells":17786},"NACT",{"EARLY_PHASE1":17787,"PHASE1":17789,"PHASE2":17791,"PHASE3":17793,"PHASE4":17805,"NA":17807},{"trials":17788,"activeCount":104},[],{"trials":17790,"activeCount":104},[],{"trials":17792,"activeCount":104},[],{"trials":17794,"activeCount":104},[17795],{"nctId":17796,"briefTitle":17797,"status":174,"phases":17798,"primaryCompletion":1827,"completion":1827,"start":1934,"enrollment":17799,"conditions":17800,"interventions":17804},"NCT02629718","Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer",[94],700,[17801,17802,17803],"PFS","OS","Quality of Life",[17785],{"trials":17806,"activeCount":104},[],{"trials":17808,"activeCount":104},[],{"intervention":17810,"totalTrials":100,"cells":17811},"Prednisolone",{"EARLY_PHASE1":17812,"PHASE1":17814,"PHASE2":17816,"PHASE3":17818,"PHASE4":17828,"NA":17830},{"trials":17813,"activeCount":104},[],{"trials":17815,"activeCount":104},[],{"trials":17817,"activeCount":104},[],{"trials":17819,"activeCount":104},[17820],{"nctId":17821,"briefTitle":17822,"status":174,"phases":17823,"primaryCompletion":3747,"completion":3747,"start":1336,"enrollment":16816,"conditions":17824,"interventions":17826},"NCT02662283","Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy",[93,94],[17825],"IGA Nephropathy",[17810,17827],"Reh-acteoside",{"trials":17829,"activeCount":104},[],{"trials":17831,"activeCount":104},[],{"intervention":17827,"totalTrials":100,"cells":17833},{"EARLY_PHASE1":17834,"PHASE1":17836,"PHASE2":17838,"PHASE3":17840,"PHASE4":17846,"NA":17848},{"trials":17835,"activeCount":104},[],{"trials":17837,"activeCount":104},[],{"trials":17839,"activeCount":104},[],{"trials":17841,"activeCount":104},[17842],{"nctId":17821,"briefTitle":17822,"status":174,"phases":17843,"primaryCompletion":3747,"completion":3747,"start":1336,"enrollment":16816,"conditions":17844,"interventions":17845},[93,94],[17825],[17810,17827],{"trials":17847,"activeCount":104},[],{"trials":17849,"activeCount":104},[],{"intervention":17138,"totalTrials":100,"cells":17851},{"EARLY_PHASE1":17852,"PHASE1":17854,"PHASE2":17856,"PHASE3":17858,"PHASE4":17864,"NA":17866},{"trials":17853,"activeCount":104},[],{"trials":17855,"activeCount":104},[],{"trials":17857,"activeCount":104},[],{"trials":17859,"activeCount":104},[17860],{"nctId":17131,"briefTitle":17132,"status":174,"phases":17861,"primaryCompletion":5934,"completion":5934,"start":17134,"enrollment":4483,"conditions":17862,"interventions":17863},[94],[17136],[17138,4353],{"trials":17865,"activeCount":104},[],{"trials":17867,"activeCount":104},[],{"intervention":17869,"totalTrials":100,"cells":17870},"Docetaxel, cisplatin and fluorouracil",{"EARLY_PHASE1":17871,"PHASE1":17873,"PHASE2":17875,"PHASE3":17877,"PHASE4":17886,"NA":17888},{"trials":17872,"activeCount":104},[],{"trials":17874,"activeCount":104},[],{"trials":17876,"activeCount":104},[],{"trials":17878,"activeCount":104},[17879],{"nctId":17880,"briefTitle":17881,"status":174,"phases":17882,"primaryCompletion":438,"completion":5304,"start":17342,"enrollment":17883,"conditions":17884,"interventions":17885},"NCT01245959","Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma",[94],476,[16],[17869],{"trials":17887,"activeCount":104},[],{"trials":17889,"activeCount":104},[],{"intervention":14311,"totalTrials":100,"cells":17891},{"EARLY_PHASE1":17892,"PHASE1":17894,"PHASE2":17896,"PHASE3":17898,"PHASE4":17904,"NA":17906},{"trials":17893,"activeCount":104},[],{"trials":17895,"activeCount":104},[],{"trials":17897,"activeCount":104},[],{"trials":17899,"activeCount":104},[17900],{"nctId":14301,"briefTitle":14302,"status":328,"phases":17901,"primaryCompletion":14304,"completion":1094,"start":14305,"enrollment":14306,"conditions":17902,"interventions":17903},[94],[2112,14308],[14310,14311,183],{"trials":17905,"activeCount":104},[],{"trials":17907,"activeCount":104},[],{"intervention":17377,"totalTrials":100,"cells":17909},{"EARLY_PHASE1":17910,"PHASE1":17912,"PHASE2":17914,"PHASE3":17916,"PHASE4":17922,"NA":17924},{"trials":17911,"activeCount":104},[],{"trials":17913,"activeCount":104},[],{"trials":17915,"activeCount":104},[],{"trials":17917,"activeCount":104},[17918],{"nctId":17369,"briefTitle":17370,"status":1091,"phases":17919,"primaryCompletion":17372,"completion":17372,"start":17373,"enrollment":10173,"conditions":17920,"interventions":17921},[94],[17375,28],[17358,17377],{"trials":17923,"activeCount":104},[],{"trials":17925,"activeCount":104},[],{"intervention":2916,"totalTrials":100,"cells":17927},{"EARLY_PHASE1":17928,"PHASE1":17930,"PHASE2":17932,"PHASE3":17934,"PHASE4":17940,"NA":17942},{"trials":17929,"activeCount":104},[],{"trials":17931,"activeCount":104},[],{"trials":17933,"activeCount":104},[],{"trials":17935,"activeCount":104},[17936],{"nctId":2910,"briefTitle":2911,"status":174,"phases":17937,"primaryCompletion":479,"completion":479,"start":1247,"enrollment":2913,"conditions":17938,"interventions":17939},[94],[19],[2916,353],{"trials":17941,"activeCount":104},[],{"trials":17943,"activeCount":104},[],{"intervention":17945,"totalTrials":100,"cells":17946},"Monosialotetrahexosyl ganglioside",{"EARLY_PHASE1":17947,"PHASE1":17949,"PHASE2":17951,"PHASE3":17953,"PHASE4":17965,"NA":17967},{"trials":17948,"activeCount":104},[],{"trials":17950,"activeCount":104},[],{"trials":17952,"activeCount":104},[],{"trials":17954,"activeCount":104},[17955],{"nctId":17956,"briefTitle":17957,"status":1091,"phases":17958,"primaryCompletion":17372,"completion":17372,"start":17959,"enrollment":1066,"conditions":17960,"interventions":17963},"NCT04395339","GM1 Prophylaxis for WBRT Related Cognitive Dysfunction",[94],"2020-05-15",[1830,3458,17961,17962,28],"Cognitive Impairment","Gangliosidosis, GM1",[17945,17964],"Control",{"trials":17966,"activeCount":104},[],{"trials":17968,"activeCount":104},[],{"intervention":17970,"totalTrials":100,"cells":17971},"Cytokine-Induced Killer Cells",{"EARLY_PHASE1":17972,"PHASE1":17974,"PHASE2":17976,"PHASE3":17978,"PHASE4":17987,"NA":17989},{"trials":17973,"activeCount":104},[],{"trials":17975,"activeCount":104},[],{"trials":17977,"activeCount":104},[],{"trials":17979,"activeCount":104},[17980],{"nctId":17981,"briefTitle":17982,"status":328,"phases":17983,"primaryCompletion":17318,"completion":4810,"start":17984,"enrollment":1192,"conditions":17985,"interventions":17986},"NCT01749865","CIK Treatment for HCC Patient Underwent Radical Resection",[94],"2008-10",[1888],[17970],{"trials":17988,"activeCount":104},[],{"trials":17990,"activeCount":104},[],{"intervention":17992,"totalTrials":100,"cells":17993},"Liposomal Bupivacaine",{"EARLY_PHASE1":17994,"PHASE1":17996,"PHASE2":17998,"PHASE3":18000,"PHASE4":18011,"NA":18013},{"trials":17995,"activeCount":104},[],{"trials":17997,"activeCount":104},[],{"trials":17999,"activeCount":104},[],{"trials":18001,"activeCount":104},[18002],{"nctId":18003,"briefTitle":18004,"status":174,"phases":18005,"primaryCompletion":1876,"completion":547,"start":10019,"enrollment":2001,"conditions":18006,"interventions":18010},"NCT06430112","Liposomal Bupivacaine vs Ropivacaine for TAPBs",[94],[18007,18008,17992,18009],"Abdominal Tumor","Postoperative Analgesia","Ropivacaine",[17992,18009],{"trials":18012,"activeCount":104},[],{"trials":18014,"activeCount":104},[],{"intervention":18009,"totalTrials":100,"cells":18016},{"EARLY_PHASE1":18017,"PHASE1":18019,"PHASE2":18021,"PHASE3":18023,"PHASE4":18029,"NA":18031},{"trials":18018,"activeCount":104},[],{"trials":18020,"activeCount":104},[],{"trials":18022,"activeCount":104},[],{"trials":18024,"activeCount":104},[18025],{"nctId":18003,"briefTitle":18004,"status":174,"phases":18026,"primaryCompletion":1876,"completion":547,"start":10019,"enrollment":2001,"conditions":18027,"interventions":18028},[94],[18007,18008,17992,18009],[17992,18009],{"trials":18030,"activeCount":104},[],{"trials":18032,"activeCount":104},[],{"intervention":18034,"totalTrials":100,"cells":18035},"Prednisone+placebo of Doxycycline",{"EARLY_PHASE1":18036,"PHASE1":18038,"PHASE2":18040,"PHASE3":18042,"PHASE4":18052,"NA":18054},{"trials":18037,"activeCount":104},[],{"trials":18039,"activeCount":104},[],{"trials":18041,"activeCount":104},[],{"trials":18043,"activeCount":104},[18044],{"nctId":18045,"briefTitle":18046,"status":174,"phases":18047,"primaryCompletion":3759,"completion":3759,"start":16195,"enrollment":2549,"conditions":18048,"interventions":18050},"NCT01809444","Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy",[93,94],[18049],"Thyroid Associated Opthalmopathies",[18034,18051],"Doxycycline+placebo of Prednisone",{"trials":18053,"activeCount":104},[],{"trials":18055,"activeCount":104},[],{"intervention":18051,"totalTrials":100,"cells":18057},{"EARLY_PHASE1":18058,"PHASE1":18060,"PHASE2":18062,"PHASE3":18064,"PHASE4":18070,"NA":18072},{"trials":18059,"activeCount":104},[],{"trials":18061,"activeCount":104},[],{"trials":18063,"activeCount":104},[],{"trials":18065,"activeCount":104},[18066],{"nctId":18045,"briefTitle":18046,"status":174,"phases":18067,"primaryCompletion":3759,"completion":3759,"start":16195,"enrollment":2549,"conditions":18068,"interventions":18069},[93,94],[18049],[18034,18051],{"trials":18071,"activeCount":104},[],{"trials":18073,"activeCount":104},[],{"intervention":3336,"totalTrials":100,"cells":18075},{"EARLY_PHASE1":18076,"PHASE1":18078,"PHASE2":18080,"PHASE3":18082,"PHASE4":18088,"NA":18090},{"trials":18077,"activeCount":104},[],{"trials":18079,"activeCount":104},[],{"trials":18081,"activeCount":104},[],{"trials":18083,"activeCount":104},[18084],{"nctId":3329,"briefTitle":3330,"status":174,"phases":18085,"primaryCompletion":3332,"completion":2233,"start":3333,"enrollment":406,"conditions":18086,"interventions":18087},[94],[539,25,726],[3336,3337,3338,726],{"trials":18089,"activeCount":104},[],{"trials":18091,"activeCount":104},[],{"intervention":3337,"totalTrials":100,"cells":18093},{"EARLY_PHASE1":18094,"PHASE1":18096,"PHASE2":18098,"PHASE3":18100,"PHASE4":18106,"NA":18108},{"trials":18095,"activeCount":104},[],{"trials":18097,"activeCount":104},[],{"trials":18099,"activeCount":104},[],{"trials":18101,"activeCount":104},[18102],{"nctId":3329,"briefTitle":3330,"status":174,"phases":18103,"primaryCompletion":3332,"completion":2233,"start":3333,"enrollment":406,"conditions":18104,"interventions":18105},[94],[539,25,726],[3336,3337,3338,726],{"trials":18107,"activeCount":104},[],{"trials":18109,"activeCount":104},[],{"intervention":3338,"totalTrials":100,"cells":18111},{"EARLY_PHASE1":18112,"PHASE1":18114,"PHASE2":18116,"PHASE3":18118,"PHASE4":18124,"NA":18126},{"trials":18113,"activeCount":104},[],{"trials":18115,"activeCount":104},[],{"trials":18117,"activeCount":104},[],{"trials":18119,"activeCount":104},[18120],{"nctId":3329,"briefTitle":3330,"status":174,"phases":18121,"primaryCompletion":3332,"completion":2233,"start":3333,"enrollment":406,"conditions":18122,"interventions":18123},[94],[539,25,726],[3336,3337,3338,726],{"trials":18125,"activeCount":104},[],{"trials":18127,"activeCount":104},[],{"intervention":18129,"totalTrials":100,"cells":18130},"Inductive chemotherapy + concurrent cisplatin and IMRT",{"EARLY_PHASE1":18131,"PHASE1":18133,"PHASE2":18135,"PHASE3":18137,"PHASE4":18146,"NA":18148},{"trials":18132,"activeCount":104},[],{"trials":18134,"activeCount":104},[],{"trials":18136,"activeCount":104},[],{"trials":18138,"activeCount":104},[18139],{"nctId":18140,"briefTitle":18141,"status":174,"phases":18142,"primaryCompletion":459,"completion":459,"start":3291,"enrollment":189,"conditions":18143,"interventions":18144},"NCT01854203","Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC",[93,94],[16],[18129,18145],"Inductive chemotherapy + IMRT",{"trials":18147,"activeCount":104},[],{"trials":18149,"activeCount":104},[],{"intervention":18145,"totalTrials":100,"cells":18151},{"EARLY_PHASE1":18152,"PHASE1":18154,"PHASE2":18156,"PHASE3":18158,"PHASE4":18164,"NA":18166},{"trials":18153,"activeCount":104},[],{"trials":18155,"activeCount":104},[],{"trials":18157,"activeCount":104},[],{"trials":18159,"activeCount":104},[18160],{"nctId":18140,"briefTitle":18141,"status":174,"phases":18161,"primaryCompletion":459,"completion":459,"start":3291,"enrollment":189,"conditions":18162,"interventions":18163},[93,94],[16],[18129,18145],{"trials":18165,"activeCount":104},[],{"trials":18167,"activeCount":104},[],{"intervention":18169,"totalTrials":100,"cells":18170},"Endocrine therapy combined with trastuzumab",{"EARLY_PHASE1":18171,"PHASE1":18173,"PHASE2":18175,"PHASE3":18177,"PHASE4":18189,"NA":18191},{"trials":18172,"activeCount":104},[],{"trials":18174,"activeCount":104},[],{"trials":18176,"activeCount":104},[],{"trials":18178,"activeCount":104},[18179],{"nctId":18180,"briefTitle":18181,"status":328,"phases":18182,"primaryCompletion":18183,"completion":18183,"start":18184,"enrollment":18185,"conditions":18186,"interventions":18187},"NCT01950182","Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer",[94],"2020-05-31","2013-09-16",392,[28],[18169,18188],"Chemotherapy combined with trastuzumab",{"trials":18190,"activeCount":104},[],{"trials":18192,"activeCount":104},[],{"intervention":18188,"totalTrials":100,"cells":18194},{"EARLY_PHASE1":18195,"PHASE1":18197,"PHASE2":18199,"PHASE3":18201,"PHASE4":18207,"NA":18209},{"trials":18196,"activeCount":104},[],{"trials":18198,"activeCount":104},[],{"trials":18200,"activeCount":104},[],{"trials":18202,"activeCount":104},[18203],{"nctId":18180,"briefTitle":18181,"status":328,"phases":18204,"primaryCompletion":18183,"completion":18183,"start":18184,"enrollment":18185,"conditions":18205,"interventions":18206},[94],[28],[18169,18188],{"trials":18208,"activeCount":104},[],{"trials":18210,"activeCount":104},[],{"intervention":18212,"totalTrials":100,"cells":18213},"Celecoxib 200mg oral",{"EARLY_PHASE1":18214,"PHASE1":18216,"PHASE2":18218,"PHASE3":18220,"PHASE4":18233,"NA":18235},{"trials":18215,"activeCount":104},[],{"trials":18217,"activeCount":104},[],{"trials":18219,"activeCount":104},[],{"trials":18221,"activeCount":104},[18222],{"nctId":18223,"briefTitle":18224,"status":328,"phases":18225,"primaryCompletion":18226,"completion":18226,"start":2232,"enrollment":18227,"conditions":18228,"interventions":18230},"NCT03059238","Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure",[94],"2019-03",213,[3035,18229],"Pain Postoperative",[18212,18231,18232],"parecoxib sodium","controlled-release oxycodone",{"trials":18234,"activeCount":104},[],{"trials":18236,"activeCount":104},[],{"intervention":18238,"totalTrials":100,"cells":18239},"CCRT+GP",{"EARLY_PHASE1":18240,"PHASE1":18242,"PHASE2":18244,"PHASE3":18246,"PHASE4":18257,"NA":18259},{"trials":18241,"activeCount":104},[],{"trials":18243,"activeCount":104},[],{"trials":18245,"activeCount":104},[],{"trials":18247,"activeCount":104},[18248],{"nctId":18249,"briefTitle":18250,"status":174,"phases":18251,"primaryCompletion":18252,"completion":379,"start":18253,"enrollment":4149,"conditions":18254,"interventions":18255},"NCT03321539","Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma",[94],"2022-12-25","2017-10-30",[16],[18238,18256],"CCRT+PF",{"trials":18258,"activeCount":104},[],{"trials":18260,"activeCount":104},[],{"intervention":18256,"totalTrials":100,"cells":18262},{"EARLY_PHASE1":18263,"PHASE1":18265,"PHASE2":18267,"PHASE3":18269,"PHASE4":18275,"NA":18277},{"trials":18264,"activeCount":104},[],{"trials":18266,"activeCount":104},[],{"trials":18268,"activeCount":104},[],{"trials":18270,"activeCount":104},[18271],{"nctId":18249,"briefTitle":18250,"status":174,"phases":18272,"primaryCompletion":18252,"completion":379,"start":18253,"enrollment":4149,"conditions":18273,"interventions":18274},[94],[16],[18238,18256],{"trials":18276,"activeCount":104},[],{"trials":18278,"activeCount":104},[],{"intervention":18280,"totalTrials":100,"cells":18281},"olanzapine plus fosaprepitant-based triple regimen",{"EARLY_PHASE1":18282,"PHASE1":18284,"PHASE2":18286,"PHASE3":18288,"PHASE4":18299,"NA":18301},{"trials":18283,"activeCount":104},[],{"trials":18285,"activeCount":104},[],{"trials":18287,"activeCount":104},[],{"trials":18289,"activeCount":104},[18290],{"nctId":18291,"briefTitle":18292,"status":174,"phases":18293,"primaryCompletion":1737,"completion":18294,"start":15409,"enrollment":18295,"conditions":18296,"interventions":18298},"NCT04536558","Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study",[94],"2021-03-30",352,[18297],"Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy",[18280],{"trials":18300,"activeCount":104},[],{"trials":18302,"activeCount":104},[],{"intervention":18304,"totalTrials":100,"cells":18305},"Gefitinib and Pemetrexed\u002Fplatinum",{"EARLY_PHASE1":18306,"PHASE1":18308,"PHASE2":18310,"PHASE3":18312,"PHASE4":18322,"NA":18324},{"trials":18307,"activeCount":104},[],{"trials":18309,"activeCount":104},[],{"trials":18311,"activeCount":104},[],{"trials":18313,"activeCount":104},[18314],{"nctId":18315,"briefTitle":18316,"status":174,"phases":18317,"primaryCompletion":3544,"completion":1827,"start":3759,"enrollment":734,"conditions":18318,"interventions":18320},"NCT01951469","Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer",[94],[22,1830,18319],"EGFR Mutation",[18304,18321],"Gefitinib mono-therapy",{"trials":18323,"activeCount":104},[],{"trials":18325,"activeCount":104},[],{"intervention":18321,"totalTrials":100,"cells":18327},{"EARLY_PHASE1":18328,"PHASE1":18330,"PHASE2":18332,"PHASE3":18334,"PHASE4":18340,"NA":18342},{"trials":18329,"activeCount":104},[],{"trials":18331,"activeCount":104},[],{"trials":18333,"activeCount":104},[],{"trials":18335,"activeCount":104},[18336],{"nctId":18315,"briefTitle":18316,"status":174,"phases":18337,"primaryCompletion":3544,"completion":1827,"start":3759,"enrollment":734,"conditions":18338,"interventions":18339},[94],[22,1830,18319],[18304,18321],{"trials":18341,"activeCount":104},[],{"trials":18343,"activeCount":104},[],{"intervention":18345,"totalTrials":100,"cells":18346},"cytokine-induced killer cell (CIK) treatment",{"EARLY_PHASE1":18347,"PHASE1":18349,"PHASE2":18351,"PHASE3":18353,"PHASE4":18361,"NA":18363},{"trials":18348,"activeCount":104},[],{"trials":18350,"activeCount":104},[],{"trials":18352,"activeCount":104},[],{"trials":18354,"activeCount":104},[18355],{"nctId":18356,"briefTitle":18357,"status":328,"phases":18358,"primaryCompletion":17318,"completion":4810,"start":15668,"enrollment":1192,"conditions":18359,"interventions":18360},"NCT00769106","Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer",[94],[19],[18345],{"trials":18362,"activeCount":104},[],{"trials":18364,"activeCount":104},[],{"intervention":18366,"totalTrials":100,"cells":18367},"cyclophosphamide or azathioprine",{"EARLY_PHASE1":18368,"PHASE1":18370,"PHASE2":18372,"PHASE3":18374,"PHASE4":18389,"NA":18391},{"trials":18369,"activeCount":104},[],{"trials":18371,"activeCount":104},[],{"trials":18373,"activeCount":104},[],{"trials":18375,"activeCount":104},[18376],{"nctId":18377,"briefTitle":18378,"status":328,"phases":18379,"primaryCompletion":15560,"completion":15560,"start":18380,"enrollment":18381,"conditions":18382,"interventions":18387},"NCT00615173","Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis",[94],"2006-07",81,[18383,16697,18384,18385,18386],"Kidney Diseases","Tacrolimus","Induction Phase","Maintenance Phase",[18388,18366],"tacrolimus",{"trials":18390,"activeCount":104},[],{"trials":18392,"activeCount":104},[],{"intervention":7677,"totalTrials":100,"cells":18394},{"EARLY_PHASE1":18395,"PHASE1":18397,"PHASE2":18399,"PHASE3":18401,"PHASE4":18407,"NA":18409},{"trials":18396,"activeCount":104},[],{"trials":18398,"activeCount":104},[],{"trials":18400,"activeCount":104},[],{"trials":18402,"activeCount":104},[18403],{"nctId":7671,"briefTitle":7672,"status":174,"phases":18404,"primaryCompletion":479,"completion":7506,"start":7674,"enrollment":942,"conditions":18405,"interventions":18406},[94],[25],[7677,823],{"trials":18408,"activeCount":104},[],{"trials":18410,"activeCount":104},[],{"intervention":2605,"totalTrials":100,"cells":18412},{"EARLY_PHASE1":18413,"PHASE1":18415,"PHASE2":18417,"PHASE3":18419,"PHASE4":18425,"NA":18427},{"trials":18414,"activeCount":104},[],{"trials":18416,"activeCount":104},[],{"trials":18418,"activeCount":104},[],{"trials":18420,"activeCount":104},[18421],{"nctId":2596,"briefTitle":2597,"status":1091,"phases":18422,"primaryCompletion":2599,"completion":2599,"start":2600,"enrollment":2601,"conditions":18423,"interventions":18424},[94],[25,2098,2603],[2605,542,2080,2606,54],{"trials":18426,"activeCount":104},[],{"trials":18428,"activeCount":104},[],{"intervention":2606,"totalTrials":100,"cells":18430},{"EARLY_PHASE1":18431,"PHASE1":18433,"PHASE2":18435,"PHASE3":18437,"PHASE4":18443,"NA":18445},{"trials":18432,"activeCount":104},[],{"trials":18434,"activeCount":104},[],{"trials":18436,"activeCount":104},[],{"trials":18438,"activeCount":104},[18439],{"nctId":2596,"briefTitle":2597,"status":1091,"phases":18440,"primaryCompletion":2599,"completion":2599,"start":2600,"enrollment":2601,"conditions":18441,"interventions":18442},[94],[25,2098,2603],[2605,542,2080,2606,54],{"trials":18444,"activeCount":104},[],{"trials":18446,"activeCount":104},[],{"intervention":18448,"totalTrials":100,"cells":18449},"FOLFOX regimen",{"EARLY_PHASE1":18450,"PHASE1":18452,"PHASE2":18454,"PHASE3":18456,"PHASE4":18470,"NA":18472},{"trials":18451,"activeCount":104},[],{"trials":18453,"activeCount":104},[],{"trials":18455,"activeCount":104},[],{"trials":18457,"activeCount":104},[18458],{"nctId":18459,"briefTitle":18460,"status":328,"phases":18461,"primaryCompletion":18462,"completion":18463,"start":18464,"enrollment":18465,"conditions":18466,"interventions":18468},"NCT03164382","Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil\u002FLeucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma",[94],"2020-10-31","2020-11-30","2017-03-01",262,[3035,18467],"Hepatic Carcinoma",[18448,18469],"Sorafenib 200Mg Tab",{"trials":18471,"activeCount":104},[],{"trials":18473,"activeCount":104},[],{"intervention":18469,"totalTrials":100,"cells":18475},{"EARLY_PHASE1":18476,"PHASE1":18478,"PHASE2":18480,"PHASE3":18482,"PHASE4":18488,"NA":18490},{"trials":18477,"activeCount":104},[],{"trials":18479,"activeCount":104},[],{"trials":18481,"activeCount":104},[],{"trials":18483,"activeCount":104},[18484],{"nctId":18459,"briefTitle":18460,"status":328,"phases":18485,"primaryCompletion":18462,"completion":18463,"start":18464,"enrollment":18465,"conditions":18486,"interventions":18487},[94],[3035,18467],[18448,18469],{"trials":18489,"activeCount":104},[],{"trials":18491,"activeCount":104},[],{"intervention":18493,"totalTrials":100,"cells":18494},"standard adjuvant chemotherapy plus moxifloxacin",{"EARLY_PHASE1":18495,"PHASE1":18497,"PHASE2":18499,"PHASE3":18501,"PHASE4":18513,"NA":18515},{"trials":18496,"activeCount":104},[],{"trials":18498,"activeCount":104},[],{"trials":18500,"activeCount":104},[],{"trials":18502,"activeCount":104},[18503],{"nctId":18504,"briefTitle":18505,"status":328,"phases":18506,"primaryCompletion":18507,"completion":18507,"start":18508,"enrollment":18509,"conditions":18510,"interventions":18511},"NCT05114720","Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer",[94],"2025-11-27","2021-11-11",559,[28],[18493,18512],"standard adjuvant chemotherapy plus placebo",{"trials":18514,"activeCount":104},[],{"trials":18516,"activeCount":104},[],{"intervention":18512,"totalTrials":100,"cells":18518},{"EARLY_PHASE1":18519,"PHASE1":18521,"PHASE2":18523,"PHASE3":18525,"PHASE4":18531,"NA":18533},{"trials":18520,"activeCount":104},[],{"trials":18522,"activeCount":104},[],{"trials":18524,"activeCount":104},[],{"trials":18526,"activeCount":104},[18527],{"nctId":18504,"briefTitle":18505,"status":328,"phases":18528,"primaryCompletion":18507,"completion":18507,"start":18508,"enrollment":18509,"conditions":18529,"interventions":18530},[94],[28],[18493,18512],{"trials":18532,"activeCount":104},[],{"trials":18534,"activeCount":104},[],{"intervention":4409,"totalTrials":100,"cells":18536},{"EARLY_PHASE1":18537,"PHASE1":18539,"PHASE2":18541,"PHASE3":18543,"PHASE4":18549,"NA":18551},{"trials":18538,"activeCount":104},[],{"trials":18540,"activeCount":104},[],{"trials":18542,"activeCount":104},[],{"trials":18544,"activeCount":104},[18545],{"nctId":4402,"briefTitle":4403,"status":174,"phases":18546,"primaryCompletion":203,"completion":2770,"start":4405,"enrollment":4406,"conditions":18547,"interventions":18548},[93,94],[34],[465,4409,4409],{"trials":18550,"activeCount":104},[],{"trials":18552,"activeCount":104},[],{"intervention":18554,"totalTrials":100,"cells":18555},"Steroid nasal spray",{"EARLY_PHASE1":18556,"PHASE1":18558,"PHASE2":18560,"PHASE3":18562,"PHASE4":18572,"NA":18574},{"trials":18557,"activeCount":104},[],{"trials":18559,"activeCount":104},[],{"trials":18561,"activeCount":104},[],{"trials":18563,"activeCount":104},[18564],{"nctId":18565,"briefTitle":18566,"status":174,"phases":18567,"primaryCompletion":721,"completion":860,"start":18568,"enrollment":1402,"conditions":18569,"interventions":18571},"NCT05757479","Steroid-Eluting Stent Implant for the Treatment of Radiation-Related Sinusitis",[94],"2023-02-11",[18570],"Radiation-Induced Mucositis",[18554],{"trials":18573,"activeCount":104},[],{"trials":18575,"activeCount":104},[],{"intervention":739,"totalTrials":100,"cells":18577},{"EARLY_PHASE1":18578,"PHASE1":18580,"PHASE2":18582,"PHASE3":18584,"PHASE4":18590,"NA":18592},{"trials":18579,"activeCount":104},[],{"trials":18581,"activeCount":104},[],{"trials":18583,"activeCount":104},[],{"trials":18585,"activeCount":104},[18586],{"nctId":730,"briefTitle":731,"status":174,"phases":18587,"primaryCompletion":733,"completion":346,"start":216,"enrollment":734,"conditions":18588,"interventions":18589},[94],[736],[443,738,225,739],{"trials":18591,"activeCount":104},[],{"trials":18593,"activeCount":104},[],{"intervention":18595,"totalTrials":100,"cells":18596},"Tripterygium",{"EARLY_PHASE1":18597,"PHASE1":18599,"PHASE2":18601,"PHASE3":18603,"PHASE4":18613,"NA":18615},{"trials":18598,"activeCount":104},[],{"trials":18600,"activeCount":104},[],{"trials":18602,"activeCount":104},[],{"trials":18604,"activeCount":104},[18605],{"nctId":18606,"briefTitle":18607,"status":174,"phases":18608,"primaryCompletion":5150,"completion":15779,"start":17984,"enrollment":942,"conditions":18609,"interventions":18611},"NCT00889694","Clinical Study of Tripterygium Capsule to Treat Early Ankylosing Spondylitis",[93,94],[18610],"Early Ankylosing Spondylitis",[18595,18612],"Sulfasalazine",{"trials":18614,"activeCount":104},[],{"trials":18616,"activeCount":104},[],{"intervention":18612,"totalTrials":100,"cells":18618},{"EARLY_PHASE1":18619,"PHASE1":18621,"PHASE2":18623,"PHASE3":18625,"PHASE4":18631,"NA":18633},{"trials":18620,"activeCount":104},[],{"trials":18622,"activeCount":104},[],{"trials":18624,"activeCount":104},[],{"trials":18626,"activeCount":104},[18627],{"nctId":18606,"briefTitle":18607,"status":174,"phases":18628,"primaryCompletion":5150,"completion":15779,"start":17984,"enrollment":942,"conditions":18629,"interventions":18630},[93,94],[18610],[18595,18612],{"trials":18632,"activeCount":104},[],{"trials":18634,"activeCount":104},[],{"intervention":18636,"totalTrials":100,"cells":18637},"oxaliplatin+capecitabine",{"EARLY_PHASE1":18638,"PHASE1":18640,"PHASE2":18642,"PHASE3":18644,"PHASE4":18655,"NA":18657},{"trials":18639,"activeCount":104},[],{"trials":18641,"activeCount":104},[],{"trials":18643,"activeCount":104},[],{"trials":18645,"activeCount":104},[18646],{"nctId":18647,"briefTitle":18648,"status":1091,"phases":18649,"primaryCompletion":331,"completion":18650,"start":18651,"enrollment":18652,"conditions":18653,"interventions":18654},"NCT03970694","Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer",[94],"2022-06-05","2019-05-11",49,[1404],[18636],{"trials":18656,"activeCount":104},[],{"trials":18658,"activeCount":104},[],{"intervention":758,"totalTrials":100,"cells":18660},{"EARLY_PHASE1":18661,"PHASE1":18663,"PHASE2":18665,"PHASE3":18667,"PHASE4":18673,"NA":18675},{"trials":18662,"activeCount":104},[],{"trials":18664,"activeCount":104},[],{"trials":18666,"activeCount":104},[],{"trials":18668,"activeCount":104},[18669],{"nctId":751,"briefTitle":752,"status":174,"phases":18670,"primaryCompletion":429,"completion":429,"start":754,"enrollment":755,"conditions":18671,"interventions":18672},[94],[16],[758,225],{"trials":18674,"activeCount":104},[],{"trials":18676,"activeCount":104},[],{"intervention":18678,"totalTrials":100,"cells":18679},"thalidomide",{"EARLY_PHASE1":18680,"PHASE1":18682,"PHASE2":18684,"PHASE3":18686,"PHASE4":18694,"NA":18696},{"trials":18681,"activeCount":104},[],{"trials":18683,"activeCount":104},[],{"trials":18685,"activeCount":104},[],{"trials":18687,"activeCount":104},[18688],{"nctId":18689,"briefTitle":18690,"status":174,"phases":18691,"primaryCompletion":5150,"completion":7917,"start":16324,"enrollment":1192,"conditions":18692,"interventions":18693},"NCT00728078","Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma",[93,94],[19,3035],[18678],{"trials":18695,"activeCount":104},[],{"trials":18697,"activeCount":104},[],{"intervention":4649,"totalTrials":100,"cells":18699},{"EARLY_PHASE1":18700,"PHASE1":18702,"PHASE2":18704,"PHASE3":18706,"PHASE4":18712,"NA":18714},{"trials":18701,"activeCount":104},[],{"trials":18703,"activeCount":104},[],{"trials":18705,"activeCount":104},[],{"trials":18707,"activeCount":104},[18708],{"nctId":4641,"briefTitle":4642,"status":174,"phases":18709,"primaryCompletion":489,"start":4644,"enrollment":4645,"conditions":18710,"interventions":18711},[94],[4647],[2463,4649],{"trials":18713,"activeCount":104},[],{"trials":18715,"activeCount":104},[],{"intervention":18717,"totalTrials":100,"cells":18718},"mFOLFOXIRI adjuvant chemotherapy",{"EARLY_PHASE1":18719,"PHASE1":18721,"PHASE2":18723,"PHASE3":18725,"PHASE4":18735,"NA":18737},{"trials":18720,"activeCount":104},[],{"trials":18722,"activeCount":104},[],{"trials":18724,"activeCount":104},[],{"trials":18726,"activeCount":104},[18727],{"nctId":18728,"briefTitle":18729,"status":174,"phases":18730,"primaryCompletion":2662,"completion":2662,"start":2342,"enrollment":18731,"conditions":18732,"interventions":18733},"NCT04338191","mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer",[94],638,[25],[18717,18734],"mFOLFOX6 adjuvant chemotherapy",{"trials":18736,"activeCount":104},[],{"trials":18738,"activeCount":104},[],{"intervention":18734,"totalTrials":100,"cells":18740},{"EARLY_PHASE1":18741,"PHASE1":18743,"PHASE2":18745,"PHASE3":18747,"PHASE4":18753,"NA":18755},{"trials":18742,"activeCount":104},[],{"trials":18744,"activeCount":104},[],{"trials":18746,"activeCount":104},[],{"trials":18748,"activeCount":104},[18749],{"nctId":18728,"briefTitle":18729,"status":174,"phases":18750,"primaryCompletion":2662,"completion":2662,"start":2342,"enrollment":18731,"conditions":18751,"interventions":18752},[94],[25],[18717,18734],{"trials":18754,"activeCount":104},[],{"trials":18756,"activeCount":104},[],{"intervention":18758,"totalTrials":100,"cells":18759},"EGFR-TKI",{"EARLY_PHASE1":18760,"PHASE1":18762,"PHASE2":18764,"PHASE3":18766,"PHASE4":18775,"NA":18777},{"trials":18761,"activeCount":104},[],{"trials":18763,"activeCount":104},[],{"trials":18765,"activeCount":104},[],{"trials":18767,"activeCount":104},[18768],{"nctId":18769,"briefTitle":18770,"status":174,"phases":18771,"primaryCompletion":1575,"completion":1827,"start":618,"enrollment":18772,"conditions":18773,"interventions":18774},"NCT02714010","EGFR-TKI Concurrent With\u002FWithout WBRT in Brain Metastasis From NSCLC",[94],601,[252],[18758],{"trials":18776,"activeCount":104},[],{"trials":18778,"activeCount":104},[],{"intervention":18780,"totalTrials":100,"cells":18781},"Aprepitant+Tropisetron",{"EARLY_PHASE1":18782,"PHASE1":18784,"PHASE2":18786,"PHASE3":18788,"PHASE4":18799,"NA":18801},{"trials":18783,"activeCount":104},[],{"trials":18785,"activeCount":104},[],{"trials":18787,"activeCount":104},[],{"trials":18789,"activeCount":104},[18790],{"nctId":18791,"briefTitle":18792,"status":328,"phases":18793,"primaryCompletion":18794,"completion":967,"start":18795,"enrollment":16985,"conditions":18796,"interventions":18797},"NCT02909478","Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer",[94],"2019-10-23","2017-09-01",[14308,25],[18780,18798],"Dexamethasone+Tropisetron",{"trials":18800,"activeCount":104},[],{"trials":18802,"activeCount":104},[],{"intervention":18798,"totalTrials":100,"cells":18804},{"EARLY_PHASE1":18805,"PHASE1":18807,"PHASE2":18809,"PHASE3":18811,"PHASE4":18817,"NA":18819},{"trials":18806,"activeCount":104},[],{"trials":18808,"activeCount":104},[],{"trials":18810,"activeCount":104},[],{"trials":18812,"activeCount":104},[18813],{"nctId":18791,"briefTitle":18792,"status":328,"phases":18814,"primaryCompletion":18794,"completion":967,"start":18795,"enrollment":16985,"conditions":18815,"interventions":18816},[94],[14308,25],[18780,18798],{"trials":18818,"activeCount":104},[],{"trials":18820,"activeCount":104},[],{"intervention":18822,"totalTrials":100,"cells":18823},"Induction chemotherapy, Chemoradiotherapy and gap chemotherapy",{"EARLY_PHASE1":18824,"PHASE1":18826,"PHASE2":18828,"PHASE3":18830,"PHASE4":18839,"NA":18841},{"trials":18825,"activeCount":104},[],{"trials":18827,"activeCount":104},[],{"trials":18829,"activeCount":104},[],{"trials":18831,"activeCount":104},[18832],{"nctId":18833,"briefTitle":18834,"status":174,"phases":18835,"primaryCompletion":658,"completion":4009,"start":3955,"enrollment":1482,"conditions":18836,"interventions":18838},"NCT02031939","Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer",[94],[18837],"Advanced Rectal Cancer",[18822],{"trials":18840,"activeCount":104},[],{"trials":18842,"activeCount":104},[],{"intervention":18844,"totalTrials":100,"cells":18845},"postoperative antimicrobial prophylaxis",{"EARLY_PHASE1":18846,"PHASE1":18848,"PHASE2":18850,"PHASE3":18852,"PHASE4":18863,"NA":18865},{"trials":18847,"activeCount":104},[],{"trials":18849,"activeCount":104},[],{"trials":18851,"activeCount":104},[],{"trials":18853,"activeCount":104},[18854],{"nctId":18855,"briefTitle":18856,"status":15666,"phases":18857,"primaryCompletion":18858,"completion":2771,"start":3126,"enrollment":18859,"conditions":18860,"interventions":18862},"NCT03990974","Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection",[94],"2021-06",458,[19,18861],"Postoperative Infection",[18844],{"trials":18864,"activeCount":104},[],{"trials":18866,"activeCount":104},[],{"intervention":18868,"totalTrials":100,"cells":18869},"Medox® Anthocyanin",{"EARLY_PHASE1":18870,"PHASE1":18872,"PHASE2":18874,"PHASE3":18876,"PHASE4":18886,"NA":18888},{"trials":18871,"activeCount":104},[],{"trials":18873,"activeCount":104},[],{"trials":18875,"activeCount":104},[],{"trials":18877,"activeCount":104},[18878],{"nctId":18879,"briefTitle":18880,"status":328,"phases":18881,"primaryCompletion":18882,"completion":18882,"start":3024,"enrollment":18883,"conditions":18884,"interventions":18885},"NCT03415503","Dietary Anthocyanins Improve Lipid Metabolism in a Dose - Dependent Manner",[94],"2019-10-01",169,[17619],[18868],{"trials":18887,"activeCount":104},[],{"trials":18889,"activeCount":104},[],{"intervention":2614,"totalTrials":100,"cells":18891},{"EARLY_PHASE1":18892,"PHASE1":18894,"PHASE2":18896,"PHASE3":18898,"PHASE4":18904,"NA":18906},{"trials":18893,"activeCount":104},[],{"trials":18895,"activeCount":104},[],{"trials":18897,"activeCount":104},[],{"trials":18899,"activeCount":104},[18900],{"nctId":2608,"briefTitle":2609,"status":1091,"phases":18901,"primaryCompletion":2611,"completion":479,"start":289,"enrollment":2601,"conditions":18902,"interventions":18903},[94],[1368,2098],[54,2614,2504,2080,398,542],{"trials":18905,"activeCount":104},[],{"trials":18907,"activeCount":104},[],{"intervention":4476,"totalTrials":100,"cells":18909},{"EARLY_PHASE1":18910,"PHASE1":18912,"PHASE2":18914,"PHASE3":18916,"PHASE4":18922,"NA":18924},{"trials":18911,"activeCount":104},[],{"trials":18913,"activeCount":104},[],{"trials":18915,"activeCount":104},[],{"trials":18917,"activeCount":104},[18918],{"nctId":4470,"briefTitle":4471,"status":174,"phases":18919,"primaryCompletion":479,"completion":1064,"start":4459,"enrollment":4473,"conditions":18920,"interventions":18921},[94],[19],[4476,4415],{"trials":18923,"activeCount":104},[],{"trials":18925,"activeCount":104},[],{"intervention":18927,"totalTrials":100,"cells":18928},"2400 mg\u002Fm² 5-fu",{"EARLY_PHASE1":18929,"PHASE1":18931,"PHASE2":18933,"PHASE3":18935,"PHASE4":18944,"NA":18946},{"trials":18930,"activeCount":104},[],{"trials":18932,"activeCount":104},[],{"trials":18934,"activeCount":104},[],{"trials":18936,"activeCount":104},[18937],{"nctId":18938,"briefTitle":18939,"status":174,"phases":18940,"primaryCompletion":4033,"completion":4033,"start":1953,"enrollment":15087,"conditions":18941,"interventions":18942},"NCT04667351","HAIC of Oxaliplatin, and 2400 mg\u002Fm² 5-fu vs HAIC of Oxaliplatin, and 1200 mg\u002Fm² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial",[94],[181],[18927,18943],"1200 mg\u002Fm² 5-fu",{"trials":18945,"activeCount":104},[],{"trials":18947,"activeCount":104},[],{"intervention":18943,"totalTrials":100,"cells":18949},{"EARLY_PHASE1":18950,"PHASE1":18952,"PHASE2":18954,"PHASE3":18956,"PHASE4":18962,"NA":18964},{"trials":18951,"activeCount":104},[],{"trials":18953,"activeCount":104},[],{"trials":18955,"activeCount":104},[],{"trials":18957,"activeCount":104},[18958],{"nctId":18938,"briefTitle":18939,"status":174,"phases":18959,"primaryCompletion":4033,"completion":4033,"start":1953,"enrollment":15087,"conditions":18960,"interventions":18961},[94],[181],[18927,18943],{"trials":18963,"activeCount":104},[],{"trials":18965,"activeCount":104},[],{"intervention":2115,"totalTrials":100,"cells":18967},{"EARLY_PHASE1":18968,"PHASE1":18970,"PHASE2":18972,"PHASE3":18974,"PHASE4":18980,"NA":18982},{"trials":18969,"activeCount":104},[],{"trials":18971,"activeCount":104},[],{"trials":18973,"activeCount":104},[],{"trials":18975,"activeCount":104},[18976],{"nctId":2102,"briefTitle":2103,"status":174,"phases":18977,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":18978,"interventions":18979},[94],[1341,2110,2111,2112,2113],[272,2115,2116,398,2117],{"trials":18981,"activeCount":104},[],{"trials":18983,"activeCount":104},[],{"intervention":2116,"totalTrials":100,"cells":18985},{"EARLY_PHASE1":18986,"PHASE1":18988,"PHASE2":18990,"PHASE3":18992,"PHASE4":18998,"NA":19000},{"trials":18987,"activeCount":104},[],{"trials":18989,"activeCount":104},[],{"trials":18991,"activeCount":104},[],{"trials":18993,"activeCount":104},[18994],{"nctId":2102,"briefTitle":2103,"status":174,"phases":18995,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":18996,"interventions":18997},[94],[1341,2110,2111,2112,2113],[272,2115,2116,398,2117],{"trials":18999,"activeCount":104},[],{"trials":19001,"activeCount":104},[],{"intervention":2117,"totalTrials":100,"cells":19003},{"EARLY_PHASE1":19004,"PHASE1":19006,"PHASE2":19008,"PHASE3":19010,"PHASE4":19016,"NA":19018},{"trials":19005,"activeCount":104},[],{"trials":19007,"activeCount":104},[],{"trials":19009,"activeCount":104},[],{"trials":19011,"activeCount":104},[19012],{"nctId":2102,"briefTitle":2103,"status":174,"phases":19013,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":19014,"interventions":19015},[94],[1341,2110,2111,2112,2113],[272,2115,2116,398,2117],{"trials":19017,"activeCount":104},[],{"trials":19019,"activeCount":104},[],{"intervention":19021,"totalTrials":100,"cells":19022},"intra-operative 5-FU chemotherapy",{"EARLY_PHASE1":19023,"PHASE1":19025,"PHASE2":19027,"PHASE3":19029,"PHASE4":19038,"NA":19040},{"trials":19024,"activeCount":104},[],{"trials":19026,"activeCount":104},[],{"trials":19028,"activeCount":104},[],{"trials":19030,"activeCount":104},[19031],{"nctId":19032,"briefTitle":19033,"status":174,"phases":19034,"primaryCompletion":657,"completion":657,"start":16010,"enrollment":19035,"conditions":19036,"interventions":19037},"NCT01465451","Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and Safety",[94],695,[25],[19021],{"trials":19039,"activeCount":104},[],{"trials":19041,"activeCount":104},[],{"intervention":15517,"totalTrials":100,"cells":19043},{"EARLY_PHASE1":19044,"PHASE1":19046,"PHASE2":19048,"PHASE3":19050,"PHASE4":19056,"NA":19058},{"trials":19045,"activeCount":104},[],{"trials":19047,"activeCount":104},[],{"trials":19049,"activeCount":104},[],{"trials":19051,"activeCount":104},[19052],{"nctId":15510,"briefTitle":15511,"status":328,"phases":19053,"primaryCompletion":15513,"completion":7780,"start":7698,"enrollment":9272,"conditions":19054,"interventions":19055},[94],[15515],[15499,15517],{"trials":19057,"activeCount":104},[],{"trials":19059,"activeCount":104},[],{"intervention":19061,"totalTrials":100,"cells":19062},"neoadjuvant chemotherapy plus concurrent chemoradiotherapy",{"EARLY_PHASE1":19063,"PHASE1":19065,"PHASE2":19067,"PHASE3":19069,"PHASE4":19078,"NA":19080},{"trials":19064,"activeCount":104},[],{"trials":19066,"activeCount":104},[],{"trials":19068,"activeCount":104},[],{"trials":19070,"activeCount":104},[19071],{"nctId":19072,"briefTitle":19073,"status":174,"phases":19074,"primaryCompletion":19075,"completion":203,"start":15668,"enrollment":15087,"conditions":19076,"interventions":19077},"NCT00705627","A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma",[94],"2015-02",[16],[19061],{"trials":19079,"activeCount":104},[],{"trials":19081,"activeCount":104},[],{"intervention":19083,"totalTrials":100,"cells":19084},"β-elemene",{"EARLY_PHASE1":19085,"PHASE1":19087,"PHASE2":19089,"PHASE3":19091,"PHASE4":19100,"NA":19102},{"trials":19086,"activeCount":104},[],{"trials":19088,"activeCount":104},[],{"trials":19090,"activeCount":104},[],{"trials":19092,"activeCount":104},[19093],{"nctId":19094,"briefTitle":19095,"status":174,"phases":19096,"primaryCompletion":16899,"completion":19097,"start":1500,"enrollment":1339,"conditions":19098,"interventions":19099},"NCT02629757","A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas",[94],"2023-05",[4037,4069,4025],[19083],{"trials":19101,"activeCount":104},[],{"trials":19103,"activeCount":104},[],{"intervention":19105,"totalTrials":100,"cells":19106},"IMRT combine with cisplatin concurrent chemotherapy",{"EARLY_PHASE1":19107,"PHASE1":19109,"PHASE2":19111,"PHASE3":19113,"PHASE4":19124,"NA":19126},{"trials":19108,"activeCount":104},[],{"trials":19110,"activeCount":104},[],{"trials":19112,"activeCount":104},[],{"trials":19114,"activeCount":104},[19115],{"nctId":19116,"briefTitle":19117,"status":328,"phases":19118,"primaryCompletion":7557,"completion":4009,"start":4268,"enrollment":19119,"conditions":19120,"interventions":19122},"NCT02973386","Prognostic Analysis of Concurrent Chemoradiotherapy With\u002FWithout Adjuvant Chemotherapy for Locally Advanced NPC Patients",[94],294,[19121],"Local Advanced High Risk Nasopharyngeal Carcinoma",[19105,19123],"IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy",{"trials":19125,"activeCount":104},[],{"trials":19127,"activeCount":104},[],{"intervention":19123,"totalTrials":100,"cells":19129},{"EARLY_PHASE1":19130,"PHASE1":19132,"PHASE2":19134,"PHASE3":19136,"PHASE4":19142,"NA":19144},{"trials":19131,"activeCount":104},[],{"trials":19133,"activeCount":104},[],{"trials":19135,"activeCount":104},[],{"trials":19137,"activeCount":104},[19138],{"nctId":19116,"briefTitle":19117,"status":328,"phases":19139,"primaryCompletion":7557,"completion":4009,"start":4268,"enrollment":19119,"conditions":19140,"interventions":19141},[94],[19121],[19105,19123],{"trials":19143,"activeCount":104},[],{"trials":19145,"activeCount":104},[],{"intervention":5257,"totalTrials":100,"cells":19147},{"EARLY_PHASE1":19148,"PHASE1":19150,"PHASE2":19152,"PHASE3":19154,"PHASE4":19160,"NA":19162},{"trials":19149,"activeCount":104},[],{"trials":19151,"activeCount":104},[],{"trials":19153,"activeCount":104},[],{"trials":19155,"activeCount":104},[19156],{"nctId":5248,"briefTitle":5249,"status":328,"phases":19157,"primaryCompletion":5251,"completion":5252,"start":5253,"enrollment":5254,"conditions":19158,"interventions":19159},[94],[441],[651,5257],{"trials":19161,"activeCount":104},[],{"trials":19163,"activeCount":104},[],{"intervention":19165,"totalTrials":100,"cells":19166},"Neurotropin",{"EARLY_PHASE1":19167,"PHASE1":19169,"PHASE2":19171,"PHASE3":19173,"PHASE4":19183,"NA":19185},{"trials":19168,"activeCount":104},[],{"trials":19170,"activeCount":104},[],{"trials":19172,"activeCount":104},[],{"trials":19174,"activeCount":104},[19175],{"nctId":19176,"briefTitle":19177,"status":328,"phases":19178,"primaryCompletion":19179,"completion":14006,"start":1156,"enrollment":19180,"conditions":19181,"interventions":19182},"NCT07320950","Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients",[94],"2025-08-30",333,[25],[19165],{"trials":19184,"activeCount":104},[],{"trials":19186,"activeCount":104},[],{"intervention":192,"totalTrials":100,"cells":19188},{"EARLY_PHASE1":19189,"PHASE1":19191,"PHASE2":19193,"PHASE3":19195,"PHASE4":19201,"NA":19203},{"trials":19190,"activeCount":104},[],{"trials":19192,"activeCount":104},[],{"trials":19194,"activeCount":104},[],{"trials":19196,"activeCount":104},[19197],{"nctId":185,"briefTitle":186,"status":174,"phases":19198,"primaryCompletion":178,"completion":178,"start":188,"enrollment":189,"conditions":19199,"interventions":19200},[94],[22],[192,160],{"trials":19202,"activeCount":104},[],{"trials":19204,"activeCount":104},[],{"intervention":17437,"totalTrials":100,"cells":19206},{"EARLY_PHASE1":19207,"PHASE1":19209,"PHASE2":19211,"PHASE3":19213,"PHASE4":19219,"NA":19221},{"trials":19208,"activeCount":104},[],{"trials":19210,"activeCount":104},[],{"trials":19212,"activeCount":104},[],{"trials":19214,"activeCount":104},[19215],{"nctId":17431,"briefTitle":17432,"status":174,"phases":19216,"primaryCompletion":2458,"completion":895,"start":17434,"enrollment":17,"conditions":19217,"interventions":19218},[94],[17426],[17412,17437],{"trials":19220,"activeCount":104},[],{"trials":19222,"activeCount":104},[],{"intervention":1570,"totalTrials":100,"cells":19224},{"EARLY_PHASE1":19225,"PHASE1":19227,"PHASE2":19229,"PHASE3":19231,"PHASE4":19237,"NA":19239},{"trials":19226,"activeCount":104},[],{"trials":19228,"activeCount":104},[],{"trials":19230,"activeCount":104},[],{"trials":19232,"activeCount":104},[19233],{"nctId":1563,"briefTitle":1564,"status":328,"phases":19234,"primaryCompletion":1566,"completion":1566,"start":1567,"enrollment":394,"conditions":19235,"interventions":19236},[94],[28],[444,1570],{"trials":19238,"activeCount":104},[],{"trials":19240,"activeCount":104},[],{"intervention":9017,"totalTrials":100,"cells":19242},{"EARLY_PHASE1":19243,"PHASE1":19245,"PHASE2":19247,"PHASE3":19249,"PHASE4":19255,"NA":19257},{"trials":19244,"activeCount":104},[],{"trials":19246,"activeCount":104},[],{"trials":19248,"activeCount":104},[],{"trials":19250,"activeCount":104},[19251],{"nctId":9009,"briefTitle":9010,"status":328,"phases":19252,"primaryCompletion":1337,"completion":1337,"start":9012,"enrollment":9013,"conditions":19253,"interventions":19254},[94],[9015],[9017,9018,9019],{"trials":19256,"activeCount":104},[],{"trials":19258,"activeCount":104},[],{"intervention":9019,"totalTrials":100,"cells":19260},{"EARLY_PHASE1":19261,"PHASE1":19263,"PHASE2":19265,"PHASE3":19267,"PHASE4":19273,"NA":19275},{"trials":19262,"activeCount":104},[],{"trials":19264,"activeCount":104},[],{"trials":19266,"activeCount":104},[],{"trials":19268,"activeCount":104},[19269],{"nctId":9009,"briefTitle":9010,"status":328,"phases":19270,"primaryCompletion":1337,"completion":1337,"start":9012,"enrollment":9013,"conditions":19271,"interventions":19272},[94],[9015],[9017,9018,9019],{"trials":19274,"activeCount":104},[],{"trials":19276,"activeCount":104},[],{"intervention":19278,"totalTrials":100,"cells":19279},"sequential IVM system",{"EARLY_PHASE1":19280,"PHASE1":19282,"PHASE2":19284,"PHASE3":19286,"PHASE4":19297,"NA":19299},{"trials":19281,"activeCount":104},[],{"trials":19283,"activeCount":104},[],{"trials":19285,"activeCount":104},[],{"trials":19287,"activeCount":104},[19288],{"nctId":19289,"briefTitle":19290,"status":174,"phases":19291,"primaryCompletion":176,"completion":428,"start":3953,"enrollment":189,"conditions":19292,"interventions":19295},"NCT03773263","New Application of Sequential in Vitro Muturation System for Infertility Patients With Polycystic Ovary Syndrome",[94],[19293,19294],"Polycystic Ovary Syndrome","Infertility",[19278,19296],"traditional IVM system",{"trials":19298,"activeCount":104},[],{"trials":19300,"activeCount":104},[],{"intervention":19296,"totalTrials":100,"cells":19302},{"EARLY_PHASE1":19303,"PHASE1":19305,"PHASE2":19307,"PHASE3":19309,"PHASE4":19315,"NA":19317},{"trials":19304,"activeCount":104},[],{"trials":19306,"activeCount":104},[],{"trials":19308,"activeCount":104},[],{"trials":19310,"activeCount":104},[19311],{"nctId":19289,"briefTitle":19290,"status":174,"phases":19312,"primaryCompletion":176,"completion":428,"start":3953,"enrollment":189,"conditions":19313,"interventions":19314},[94],[19293,19294],[19278,19296],{"trials":19316,"activeCount":104},[],{"trials":19318,"activeCount":104},[],{"intervention":3511,"totalTrials":100,"cells":19320},{"EARLY_PHASE1":19321,"PHASE1":19323,"PHASE2":19325,"PHASE3":19327,"PHASE4":19333,"NA":19335},{"trials":19322,"activeCount":104},[],{"trials":19324,"activeCount":104},[],{"trials":19326,"activeCount":104},[],{"trials":19328,"activeCount":104},[19329],{"nctId":3504,"briefTitle":3505,"status":174,"phases":19330,"primaryCompletion":1374,"completion":1374,"start":3507,"enrollment":3508,"conditions":19331,"interventions":19332},[94],[19],[3460,3511,3512],{"trials":19334,"activeCount":104},[],{"trials":19336,"activeCount":104},[],{"intervention":3512,"totalTrials":100,"cells":19338},{"EARLY_PHASE1":19339,"PHASE1":19341,"PHASE2":19343,"PHASE3":19345,"PHASE4":19351,"NA":19353},{"trials":19340,"activeCount":104},[],{"trials":19342,"activeCount":104},[],{"trials":19344,"activeCount":104},[],{"trials":19346,"activeCount":104},[19347],{"nctId":3504,"briefTitle":3505,"status":174,"phases":19348,"primaryCompletion":1374,"completion":1374,"start":3507,"enrollment":3508,"conditions":19349,"interventions":19350},[94],[19],[3460,3511,3512],{"trials":19352,"activeCount":104},[],{"trials":19354,"activeCount":104},[],{"intervention":19356,"totalTrials":100,"cells":19357},"Glucocorticoids",{"EARLY_PHASE1":19358,"PHASE1":19360,"PHASE2":19362,"PHASE3":19364,"PHASE4":19373,"NA":19375},{"trials":19359,"activeCount":104},[],{"trials":19361,"activeCount":104},[],{"trials":19363,"activeCount":104},[],{"trials":19365,"activeCount":104},[19366],{"nctId":19367,"briefTitle":19368,"status":174,"phases":19369,"primaryCompletion":3147,"completion":259,"start":19370,"enrollment":1304,"conditions":19371,"interventions":19372},"NCT04548284","Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO",[94],"2021-05",[14811],[19356],{"trials":19374,"activeCount":104},[],{"trials":19376,"activeCount":104},[],{"intervention":19378,"totalTrials":100,"cells":19379},"furosemide",{"EARLY_PHASE1":19380,"PHASE1":19382,"PHASE2":19384,"PHASE3":19386,"PHASE4":19395,"NA":19397},{"trials":19381,"activeCount":104},[],{"trials":19383,"activeCount":104},[],{"trials":19385,"activeCount":104},[],{"trials":19387,"activeCount":104},[19388],{"nctId":19389,"briefTitle":19390,"status":904,"phases":19391,"primaryCompletion":3332,"completion":7636,"start":15668,"enrollment":104,"conditions":19392,"interventions":19394},"NCT00936923","Effect of Diuretics on Fluid Status Control and Residual Renal Function in Peritoneal Dialysis Patients",[94],[19393],"Renal Function Disorder",[19378],{"trials":19396,"activeCount":104},[],{"trials":19398,"activeCount":104},[],{"intervention":19400,"totalTrials":100,"cells":19401},"Serplulimab combined with bevacizumab and first-line chemotherapy",{"EARLY_PHASE1":19402,"PHASE1":19404,"PHASE2":19406,"PHASE3":19408,"PHASE4":19420,"NA":19422},{"trials":19403,"activeCount":104},[],{"trials":19405,"activeCount":104},[],{"trials":19407,"activeCount":104},[],{"trials":19409,"activeCount":104},[19410],{"nctId":19411,"briefTitle":19412,"status":328,"phases":19413,"primaryCompletion":19414,"completion":19415,"start":19416,"enrollment":492,"conditions":19417,"interventions":19419},"NCT05807893","Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases",[93,94],"2024-03-22","2024-05-15","2023-05-14",[19418,272,318,1830],"Non-small Cell Lung Cancer Stage II",[19400],{"trials":19421,"activeCount":104},[],{"trials":19423,"activeCount":104},[],{"intervention":19425,"totalTrials":100,"cells":19426},"6-month Icotinib",{"EARLY_PHASE1":19427,"PHASE1":19429,"PHASE2":19431,"PHASE3":19433,"PHASE4":19445,"NA":19447},{"trials":19428,"activeCount":104},[],{"trials":19430,"activeCount":104},[],{"trials":19432,"activeCount":104},[],{"trials":19434,"activeCount":104},[19435],{"nctId":19436,"briefTitle":19437,"status":1091,"phases":19438,"primaryCompletion":289,"completion":19439,"start":19440,"enrollment":19441,"conditions":19442,"interventions":19443},"NCT01996098","Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation",[94],"2024-02-15","2014-01-01",251,[2210],[19425,19444],"12-month icotinib",{"trials":19446,"activeCount":104},[],{"trials":19448,"activeCount":104},[],{"intervention":19444,"totalTrials":100,"cells":19450},{"EARLY_PHASE1":19451,"PHASE1":19453,"PHASE2":19455,"PHASE3":19457,"PHASE4":19463,"NA":19465},{"trials":19452,"activeCount":104},[],{"trials":19454,"activeCount":104},[],{"trials":19456,"activeCount":104},[],{"trials":19458,"activeCount":104},[19459],{"nctId":19436,"briefTitle":19437,"status":1091,"phases":19460,"primaryCompletion":289,"completion":19439,"start":19440,"enrollment":19441,"conditions":19461,"interventions":19462},[94],[2210],[19425,19444],{"trials":19464,"activeCount":104},[],{"trials":19466,"activeCount":104},[],{"intervention":19468,"totalTrials":100,"cells":19469},"s-1 plus cisplatin",{"EARLY_PHASE1":19470,"PHASE1":19472,"PHASE2":19474,"PHASE3":19476,"PHASE4":19485,"NA":19487},{"trials":19471,"activeCount":104},[],{"trials":19473,"activeCount":104},[],{"trials":19475,"activeCount":104},[],{"trials":19477,"activeCount":104},[19478],{"nctId":19479,"briefTitle":19480,"status":174,"phases":19481,"primaryCompletion":3332,"completion":3332,"start":15560,"enrollment":13782,"conditions":19482,"interventions":19483},"NCT01198392","Trial of S-1 Plus Cisplatin in Gastric Cancer",[94],[539],[19468,19484],"5-Fu plus cisplatin",{"trials":19486,"activeCount":104},[],{"trials":19488,"activeCount":104},[],{"intervention":19484,"totalTrials":100,"cells":19490},{"EARLY_PHASE1":19491,"PHASE1":19493,"PHASE2":19495,"PHASE3":19497,"PHASE4":19503,"NA":19505},{"trials":19492,"activeCount":104},[],{"trials":19494,"activeCount":104},[],{"trials":19496,"activeCount":104},[],{"trials":19498,"activeCount":104},[19499],{"nctId":19479,"briefTitle":19480,"status":174,"phases":19500,"primaryCompletion":3332,"completion":3332,"start":15560,"enrollment":13782,"conditions":19501,"interventions":19502},[94],[539],[19468,19484],{"trials":19504,"activeCount":104},[],{"trials":19506,"activeCount":104},[],{"intervention":19508,"totalTrials":100,"cells":19509},"Lucentis® (Raibizumab) double-dose",{"EARLY_PHASE1":19510,"PHASE1":19512,"PHASE2":19514,"PHASE3":19516,"PHASE4":19528,"NA":19530},{"trials":19511,"activeCount":104},[],{"trials":19513,"activeCount":104},[],{"trials":19515,"activeCount":104},[],{"trials":19517,"activeCount":104},[19518],{"nctId":19519,"briefTitle":19520,"status":1091,"phases":19521,"primaryCompletion":19522,"completion":19523,"start":16451,"enrollment":161,"conditions":19524,"interventions":19526},"NCT02769169","Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy",[93,94],"2018-09-12","2018-12-15",[19525],"Polypoidal Choroidal Vasculopathy",[19508,19527],"Lucentis® (Raibizumab) regular-dose",{"trials":19529,"activeCount":104},[],{"trials":19531,"activeCount":104},[],{"intervention":19527,"totalTrials":100,"cells":19533},{"EARLY_PHASE1":19534,"PHASE1":19536,"PHASE2":19538,"PHASE3":19540,"PHASE4":19546,"NA":19548},{"trials":19535,"activeCount":104},[],{"trials":19537,"activeCount":104},[],{"trials":19539,"activeCount":104},[],{"trials":19541,"activeCount":104},[19542],{"nctId":19519,"briefTitle":19520,"status":1091,"phases":19543,"primaryCompletion":19522,"completion":19523,"start":16451,"enrollment":161,"conditions":19544,"interventions":19545},[93,94],[19525],[19508,19527],{"trials":19547,"activeCount":104},[],{"trials":19549,"activeCount":104},[],{"intervention":4071,"totalTrials":100,"cells":19551},{"EARLY_PHASE1":19552,"PHASE1":19554,"PHASE2":19556,"PHASE3":19558,"PHASE4":19564,"NA":19566},{"trials":19553,"activeCount":104},[],{"trials":19555,"activeCount":104},[],{"trials":19557,"activeCount":104},[],{"trials":19559,"activeCount":104},[19560],{"nctId":4064,"briefTitle":4065,"status":174,"phases":19561,"primaryCompletion":460,"completion":657,"start":4067,"enrollment":189,"conditions":19562,"interventions":19563},[94],[4037,4069,4025],[1767,4071],{"trials":19565,"activeCount":104},[],{"trials":19567,"activeCount":104},[],{"intervention":19569,"totalTrials":100,"cells":19570},"Recombinant Human Adenovirus Type 5",{"EARLY_PHASE1":19571,"PHASE1":19573,"PHASE2":19575,"PHASE3":19577,"PHASE4":19585,"NA":19587},{"trials":19572,"activeCount":104},[],{"trials":19574,"activeCount":104},[],{"trials":19576,"activeCount":104},[],{"trials":19578,"activeCount":104},[19579],{"nctId":19580,"briefTitle":19581,"status":174,"phases":19582,"primaryCompletion":15865,"completion":15865,"start":14741,"enrollment":628,"conditions":19583,"interventions":19584},"NCT01869088","TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma",[94],[19],[19569],{"trials":19586,"activeCount":104},[],{"trials":19588,"activeCount":104},[],{"intervention":19590,"totalTrials":100,"cells":19591},"TACE+sorafenib",{"EARLY_PHASE1":19592,"PHASE1":19594,"PHASE2":19596,"PHASE3":19598,"PHASE4":19608,"NA":19610},{"trials":19593,"activeCount":104},[],{"trials":19595,"activeCount":104},[],{"trials":19597,"activeCount":104},[],{"trials":19599,"activeCount":104},[19600],{"nctId":19601,"briefTitle":19602,"status":328,"phases":19603,"primaryCompletion":721,"completion":721,"start":19604,"enrollment":4473,"conditions":19605,"interventions":19607},"NCT04103398","TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma",[94],"2019-10-02",[19,999,19606],"Transarterial Chemoembolization",[19590],{"trials":19609,"activeCount":104},[],{"trials":19611,"activeCount":104},[],{"intervention":19613,"totalTrials":100,"cells":19614},"TPC",{"EARLY_PHASE1":19615,"PHASE1":19617,"PHASE2":19619,"PHASE3":19621,"PHASE4":19633,"NA":19635},{"trials":19616,"activeCount":104},[],{"trials":19618,"activeCount":104},[],{"trials":19620,"activeCount":104},[],{"trials":19622,"activeCount":104},[19623],{"nctId":19624,"briefTitle":19625,"status":1091,"phases":19626,"primaryCompletion":19627,"completion":19627,"start":19628,"enrollment":911,"conditions":19629,"interventions":19631},"NCT03055312","Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer",[94],"2020-11-15","2016-12-20",[19630],"Metastatic Triple Negative Breast Cancer",[19613,19632],"Bicalutamide 150 mg",{"trials":19634,"activeCount":104},[],{"trials":19636,"activeCount":104},[],{"intervention":19632,"totalTrials":100,"cells":19638},{"EARLY_PHASE1":19639,"PHASE1":19641,"PHASE2":19643,"PHASE3":19645,"PHASE4":19651,"NA":19653},{"trials":19640,"activeCount":104},[],{"trials":19642,"activeCount":104},[],{"trials":19644,"activeCount":104},[],{"trials":19646,"activeCount":104},[19647],{"nctId":19624,"briefTitle":19625,"status":1091,"phases":19648,"primaryCompletion":19627,"completion":19627,"start":19628,"enrollment":911,"conditions":19649,"interventions":19650},[94],[19630],[19613,19632],{"trials":19652,"activeCount":104},[],{"trials":19654,"activeCount":104},[],{"intervention":19656,"totalTrials":100,"cells":19657},"Zoledronic acid",{"EARLY_PHASE1":19658,"PHASE1":19660,"PHASE2":19662,"PHASE3":19664,"PHASE4":19672,"NA":19674},{"trials":19659,"activeCount":104},[],{"trials":19661,"activeCount":104},[],{"trials":19663,"activeCount":104},[],{"trials":19665,"activeCount":104},[19666],{"nctId":19667,"briefTitle":19668,"status":174,"phases":19669,"primaryCompletion":1459,"completion":895,"start":2857,"enrollment":898,"conditions":19670,"interventions":19671},"NCT05866172","HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC",[94],[19],[19656],{"trials":19673,"activeCount":104},[],{"trials":19675,"activeCount":104},[],{"intervention":19677,"totalTrials":100,"cells":19678},"S-1 plus oxaliplatin",{"EARLY_PHASE1":19679,"PHASE1":19681,"PHASE2":19683,"PHASE3":19685,"PHASE4":19696,"NA":19698},{"trials":19680,"activeCount":104},[],{"trials":19682,"activeCount":104},[],{"trials":19684,"activeCount":104},[],{"trials":19686,"activeCount":104},[19687],{"nctId":19688,"briefTitle":19689,"status":174,"phases":19690,"primaryCompletion":3747,"completion":549,"start":19691,"enrollment":19692,"conditions":19693,"interventions":19694},"NCT01795027","Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer",[94],"2011-09",724,[539],[19677,19695],"S-1 single",{"trials":19697,"activeCount":104},[],{"trials":19699,"activeCount":104},[],{"intervention":19695,"totalTrials":100,"cells":19701},{"EARLY_PHASE1":19702,"PHASE1":19704,"PHASE2":19706,"PHASE3":19708,"PHASE4":19714,"NA":19716},{"trials":19703,"activeCount":104},[],{"trials":19705,"activeCount":104},[],{"trials":19707,"activeCount":104},[],{"trials":19709,"activeCount":104},[19710],{"nctId":19688,"briefTitle":19689,"status":174,"phases":19711,"primaryCompletion":3747,"completion":549,"start":19691,"enrollment":19692,"conditions":19712,"interventions":19713},[94],[539],[19677,19695],{"trials":19715,"activeCount":104},[],{"trials":19717,"activeCount":104},[],{"intervention":19719,"totalTrials":100,"cells":19720},"Tenofovir disoproxil fumarate 300mg",{"EARLY_PHASE1":19721,"PHASE1":19723,"PHASE2":19725,"PHASE3":19727,"PHASE4":19741,"NA":19743},{"trials":19722,"activeCount":104},[],{"trials":19724,"activeCount":104},[],{"trials":19726,"activeCount":104},[],{"trials":19728,"activeCount":104},[19729],{"nctId":19730,"briefTitle":19731,"status":174,"phases":19732,"primaryCompletion":19733,"completion":19734,"start":19735,"enrollment":19736,"conditions":19737,"interventions":19739},"NCT04392700","A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection",[94],"2021-07-25","2024-07-25","2019-07-25",706,[19738],"Hepatocellular Carcinoma Recurrent",[19719,19740],"Entecavir 0.5 mg",{"trials":19742,"activeCount":104},[],{"trials":19744,"activeCount":104},[],{"intervention":19740,"totalTrials":100,"cells":19746},{"EARLY_PHASE1":19747,"PHASE1":19749,"PHASE2":19751,"PHASE3":19753,"PHASE4":19759,"NA":19761},{"trials":19748,"activeCount":104},[],{"trials":19750,"activeCount":104},[],{"trials":19752,"activeCount":104},[],{"trials":19754,"activeCount":104},[19755],{"nctId":19730,"briefTitle":19731,"status":174,"phases":19756,"primaryCompletion":19733,"completion":19734,"start":19735,"enrollment":19736,"conditions":19757,"interventions":19758},[94],[19738],[19719,19740],{"trials":19760,"activeCount":104},[],{"trials":19762,"activeCount":104},[],{"intervention":5461,"totalTrials":100,"cells":19764},{"EARLY_PHASE1":19765,"PHASE1":19767,"PHASE2":19769,"PHASE3":19771,"PHASE4":19777,"NA":19779},{"trials":19766,"activeCount":104},[],{"trials":19768,"activeCount":104},[],{"trials":19770,"activeCount":104},[],{"trials":19772,"activeCount":104},[19773],{"nctId":5455,"briefTitle":5456,"status":174,"phases":19774,"primaryCompletion":5458,"completion":5458,"start":2165,"enrollment":586,"conditions":19775,"interventions":19776},[94],[3293],[5438,5461],{"trials":19778,"activeCount":104},[],{"trials":19780,"activeCount":104},[],{"intervention":3181,"totalTrials":2627,"cells":19782},{"EARLY_PHASE1":19783,"PHASE1":19785,"PHASE2":19787,"PHASE3":19815,"PHASE4":19817,"NA":19819},{"trials":19784,"activeCount":104},[],{"trials":19786,"activeCount":104},[],{"trials":19788,"activeCount":104},[19789,19800,19807,19811],{"nctId":19790,"briefTitle":19791,"status":174,"phases":19792,"primaryCompletion":3177,"completion":721,"start":19793,"enrollment":1018,"conditions":19794,"interventions":19797},"NCT04254640","Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML",[93],"2021-03-01",[19795,19796,14287],"Acute Myeloid Leukemia","Elderly Patients",[4767,19798,3181,19799],"Aclarubicin","cytarabine",{"nctId":19801,"briefTitle":19802,"status":174,"phases":19803,"primaryCompletion":967,"completion":967,"start":4763,"enrollment":1727,"conditions":19804,"interventions":19806},"NCT03181815","Cladribine in Combination With CAG in Patients With Refractory\u002FRelapsed Acute Myeloid Leukemia",[93],[19795,19805],"Relapse Leukemia",[4767,3181,19798,4753],{"nctId":4760,"briefTitle":4761,"status":174,"phases":19808,"primaryCompletion":967,"completion":3355,"start":4763,"enrollment":205,"conditions":19809,"interventions":19810},[93],[4765],[4767,3181,4753,1205],{"nctId":3173,"briefTitle":3174,"status":174,"phases":19812,"primaryCompletion":3176,"completion":3177,"start":3178,"enrollment":3179,"conditions":19813,"interventions":19814},[93],[1240,3181],[268,3181],{"trials":19816,"activeCount":104},[],{"trials":19818,"activeCount":104},[],{"trials":19820,"activeCount":104},[],{"intervention":4753,"totalTrials":2627,"cells":19822},{"EARLY_PHASE1":19823,"PHASE1":19825,"PHASE2":19827,"PHASE3":19845,"PHASE4":19847,"NA":19849},{"trials":19824,"activeCount":104},[],{"trials":19826,"activeCount":104},[],{"trials":19828,"activeCount":104},[19829,19833,19837,19841],{"nctId":19790,"briefTitle":19791,"status":174,"phases":19830,"primaryCompletion":3177,"completion":721,"start":19793,"enrollment":1018,"conditions":19831,"interventions":19832},[93],[19795,19796,14287],[4767,19798,3181,19799],{"nctId":19801,"briefTitle":19802,"status":174,"phases":19834,"primaryCompletion":967,"completion":967,"start":4763,"enrollment":1727,"conditions":19835,"interventions":19836},[93],[19795,19805],[4767,3181,19798,4753],{"nctId":4745,"briefTitle":4746,"status":174,"phases":19838,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":19839,"interventions":19840},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"nctId":4760,"briefTitle":4761,"status":174,"phases":19842,"primaryCompletion":967,"completion":3355,"start":4763,"enrollment":205,"conditions":19843,"interventions":19844},[93],[4765],[4767,3181,4753,1205],{"trials":19846,"activeCount":104},[],{"trials":19848,"activeCount":104},[],{"trials":19850,"activeCount":104},[],{"intervention":4767,"totalTrials":1861,"cells":19852},{"EARLY_PHASE1":19853,"PHASE1":19855,"PHASE2":19857,"PHASE3":19871,"PHASE4":19873,"NA":19875},{"trials":19854,"activeCount":104},[],{"trials":19856,"activeCount":104},[],{"trials":19858,"activeCount":104},[19859,19863,19867],{"nctId":19790,"briefTitle":19791,"status":174,"phases":19860,"primaryCompletion":3177,"completion":721,"start":19793,"enrollment":1018,"conditions":19861,"interventions":19862},[93],[19795,19796,14287],[4767,19798,3181,19799],{"nctId":19801,"briefTitle":19802,"status":174,"phases":19864,"primaryCompletion":967,"completion":967,"start":4763,"enrollment":1727,"conditions":19865,"interventions":19866},[93],[19795,19805],[4767,3181,19798,4753],{"nctId":4760,"briefTitle":4761,"status":174,"phases":19868,"primaryCompletion":967,"completion":3355,"start":4763,"enrollment":205,"conditions":19869,"interventions":19870},[93],[4765],[4767,3181,4753,1205],{"trials":19872,"activeCount":104},[],{"trials":19874,"activeCount":104},[],{"trials":19876,"activeCount":104},[],{"intervention":19878,"totalTrials":1861,"cells":19879},"Conserved therapy",{"EARLY_PHASE1":19880,"PHASE1":19882,"PHASE2":19884,"PHASE3":19907,"PHASE4":19909,"NA":19911},{"trials":19881,"activeCount":104},[],{"trials":19883,"activeCount":104},[],{"trials":19885,"activeCount":104},[19886,19894,19901],{"nctId":19887,"briefTitle":19888,"status":174,"phases":19889,"primaryCompletion":8149,"completion":8149,"start":19890,"enrollment":996,"conditions":19891,"interventions":19893},"NCT01223664","Allogenic Bone Marrow Stem Cells Transplantation in Patients With Liver Cirrhosis",[93],"2010-10",[19892],"Liver Cirrhosis",[19878],{"nctId":19895,"briefTitle":19896,"status":174,"phases":19897,"primaryCompletion":19890,"completion":4334,"start":19898,"enrollment":996,"conditions":19899,"interventions":19900},"NCT00993941","Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein",[93],"2009-10",[19892],[19878],{"nctId":19902,"briefTitle":19903,"status":174,"phases":19904,"primaryCompletion":8149,"completion":8149,"start":19890,"enrollment":996,"conditions":19905,"interventions":19906},"NCT01221454","Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure",[93],[5153],[19878],{"trials":19908,"activeCount":104},[],{"trials":19910,"activeCount":104},[],{"trials":19912,"activeCount":104},[],{"intervention":4755,"totalTrials":1255,"cells":19914},{"EARLY_PHASE1":19915,"PHASE1":19917,"PHASE2":19919,"PHASE3":19929,"PHASE4":19931,"NA":19933},{"trials":19916,"activeCount":104},[],{"trials":19918,"activeCount":104},[],{"trials":19920,"activeCount":104},[19921,19925],{"nctId":7424,"briefTitle":7425,"status":174,"phases":19922,"primaryCompletion":217,"completion":3355,"start":7427,"enrollment":7428,"conditions":19923,"interventions":19924},[93],[7430],[981,7432,2308,2197,4755],{"nctId":4745,"briefTitle":4746,"status":174,"phases":19926,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":19927,"interventions":19928},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":19930,"activeCount":104},[],{"trials":19932,"activeCount":104},[],{"trials":19934,"activeCount":104},[],{"intervention":19798,"totalTrials":1255,"cells":19936},{"EARLY_PHASE1":19937,"PHASE1":19939,"PHASE2":19941,"PHASE3":19951,"PHASE4":19953,"NA":19955},{"trials":19938,"activeCount":104},[],{"trials":19940,"activeCount":104},[],{"trials":19942,"activeCount":104},[19943,19947],{"nctId":19790,"briefTitle":19791,"status":174,"phases":19944,"primaryCompletion":3177,"completion":721,"start":19793,"enrollment":1018,"conditions":19945,"interventions":19946},[93],[19795,19796,14287],[4767,19798,3181,19799],{"nctId":19801,"briefTitle":19802,"status":174,"phases":19948,"primaryCompletion":967,"completion":967,"start":4763,"enrollment":1727,"conditions":19949,"interventions":19950},[93],[19795,19805],[4767,3181,19798,4753],{"trials":19952,"activeCount":104},[],{"trials":19954,"activeCount":104},[],{"trials":19956,"activeCount":104},[],{"intervention":1662,"totalTrials":1255,"cells":19958},{"EARLY_PHASE1":19959,"PHASE1":19961,"PHASE2":19963,"PHASE3":19973,"PHASE4":19975,"NA":19977},{"trials":19960,"activeCount":104},[],{"trials":19962,"activeCount":104},[],{"trials":19964,"activeCount":104},[19965,19969],{"nctId":1654,"briefTitle":1655,"status":174,"phases":19966,"primaryCompletion":1657,"completion":1657,"start":1658,"enrollment":492,"conditions":19967,"interventions":19968},[93],[1660],[1662,353,483],{"nctId":1752,"briefTitle":1753,"status":904,"phases":19970,"primaryCompletion":1737,"completion":1737,"start":217,"enrollment":104,"conditions":19971,"interventions":19972},[93],[1660],[1662,483,269],{"trials":19974,"activeCount":104},[],{"trials":19976,"activeCount":104},[],{"trials":19978,"activeCount":104},[],{"intervention":4323,"totalTrials":1255,"cells":19980},{"EARLY_PHASE1":19981,"PHASE1":19983,"PHASE2":19993,"PHASE3":19999,"PHASE4":20001,"NA":20003},{"trials":19982,"activeCount":104},[],{"trials":19984,"activeCount":104},[19985],{"nctId":19986,"briefTitle":19987,"status":174,"phases":19988,"primaryCompletion":2106,"completion":967,"start":19989,"enrollment":1464,"conditions":19990,"interventions":19991},"NCT03527251","Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC",[92],"2018-05-15",[1831],[19992,4323],"Ipilimumab",{"trials":19994,"activeCount":104},[19995],{"nctId":4313,"briefTitle":4314,"status":328,"phases":19996,"primaryCompletion":4316,"completion":4317,"start":4318,"enrollment":1289,"conditions":19997,"interventions":19998},[93],[4320,4321],[4323,269],{"trials":20000,"activeCount":104},[],{"trials":20002,"activeCount":104},[],{"trials":20004,"activeCount":104},[],{"intervention":20006,"totalTrials":1255,"cells":20007},"Erlotinib",{"EARLY_PHASE1":20008,"PHASE1":20010,"PHASE2":20012,"PHASE3":20028,"PHASE4":20030,"NA":20032},{"trials":20009,"activeCount":104},[],{"trials":20011,"activeCount":104},[],{"trials":20013,"activeCount":104},[20014,20020],{"nctId":20015,"briefTitle":20016,"status":174,"phases":20017,"primaryCompletion":1500,"completion":204,"start":3955,"enrollment":996,"conditions":20018,"interventions":20019},"NCT02066038","Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed\u002FCarboplatin in Ⅲb\u002FIV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation",[93],[1936],[20006],{"nctId":20021,"briefTitle":20022,"status":1091,"phases":20023,"primaryCompletion":15524,"completion":15524,"start":5352,"enrollment":3748,"conditions":20024,"interventions":20026},"NCT02556593","IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases",[93],[20025],"Non-Small Cell Lung Carcinoma",[20027],"erlotinib",{"trials":20029,"activeCount":104},[],{"trials":20031,"activeCount":104},[],{"trials":20033,"activeCount":104},[],{"intervention":7705,"totalTrials":1255,"cells":20035},{"EARLY_PHASE1":20036,"PHASE1":20038,"PHASE2":20040,"PHASE3":20054,"PHASE4":20056,"NA":20058},{"trials":20037,"activeCount":104},[],{"trials":20039,"activeCount":104},[],{"trials":20041,"activeCount":104},[20042,20046],{"nctId":7695,"briefTitle":7696,"status":328,"phases":20043,"primaryCompletion":7698,"completion":6749,"start":7699,"enrollment":333,"conditions":20044,"interventions":20045},[92,93],[2042,7701,7702,7703,2045],[7705,1122],{"nctId":20047,"briefTitle":20048,"status":174,"phases":20049,"primaryCompletion":13596,"completion":13596,"start":20050,"enrollment":205,"conditions":20051,"interventions":20053},"NCT05327621","Pamiparib in mCRPC With HRD or BRCA1\u002F2 Mutation",[93],"2022-05-01",[20052],"Metastatic Castration-resistant Prostate Cancer",[7705],{"trials":20055,"activeCount":104},[],{"trials":20057,"activeCount":104},[],{"trials":20059,"activeCount":104},[],{"intervention":295,"totalTrials":1255,"cells":20061},{"EARLY_PHASE1":20062,"PHASE1":20064,"PHASE2":20066,"PHASE3":20076,"PHASE4":20078,"NA":20080},{"trials":20063,"activeCount":104},[],{"trials":20065,"activeCount":104},[],{"trials":20067,"activeCount":104},[20068,20072],{"nctId":286,"briefTitle":287,"status":174,"phases":20069,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":20070,"interventions":20071},[93],[16],[295,225,296],{"nctId":519,"briefTitle":520,"status":174,"phases":20073,"primaryCompletion":522,"completion":53,"start":523,"enrollment":29,"conditions":20074,"interventions":20075},[93],[16,525],[295,225,527],{"trials":20077,"activeCount":104},[],{"trials":20079,"activeCount":104},[],{"trials":20081,"activeCount":104},[],{"intervention":20083,"totalTrials":1255,"cells":20084},"neoadjuvant SCRT followed by Sintilimab plus CAPOX",{"EARLY_PHASE1":20085,"PHASE1":20087,"PHASE2":20089,"PHASE3":20103,"PHASE4":20105,"NA":20107},{"trials":20086,"activeCount":104},[],{"trials":20088,"activeCount":104},[],{"trials":20090,"activeCount":104},[20091,20097],{"nctId":20092,"briefTitle":20093,"status":328,"phases":20094,"primaryCompletion":11744,"completion":1227,"start":1459,"enrollment":978,"conditions":20095,"interventions":20096},"NCT06608537","A Clinical Study Based on FAPI-PET\u002FCT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer",[93],[34],[20083],{"nctId":20098,"briefTitle":20099,"status":904,"phases":20100,"primaryCompletion":379,"completion":379,"start":9919,"enrollment":104,"conditions":20101,"interventions":20102},"NCT06895577","Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-",[93],[34],[20083],{"trials":20104,"activeCount":104},[],{"trials":20106,"activeCount":104},[],{"trials":20108,"activeCount":104},[],{"intervention":14259,"totalTrials":1255,"cells":20110},{"EARLY_PHASE1":20111,"PHASE1":20113,"PHASE2":20115,"PHASE3":20125,"PHASE4":20127,"NA":20129},{"trials":20112,"activeCount":104},[],{"trials":20114,"activeCount":104},[],{"trials":20116,"activeCount":104},[20117,20121],{"nctId":14253,"briefTitle":14254,"status":904,"phases":20118,"primaryCompletion":3953,"completion":657,"start":459,"enrollment":104,"conditions":20119,"interventions":20120},[93],[3957],[14258,14259,183],{"nctId":14281,"briefTitle":14282,"status":174,"phases":20122,"primaryCompletion":1227,"completion":1227,"start":14284,"enrollment":205,"conditions":20123,"interventions":20124},[93],[14286,14287,154],[14289,14259,183],{"trials":20126,"activeCount":104},[],{"trials":20128,"activeCount":104},[],{"trials":20130,"activeCount":104},[],{"intervention":20132,"totalTrials":1255,"cells":20133},"Camrelizumab in Combination With Neoadjuvant Chemotherapy",{"EARLY_PHASE1":20134,"PHASE1":20136,"PHASE2":20138,"PHASE3":20157,"PHASE4":20159,"NA":20161},{"trials":20135,"activeCount":104},[],{"trials":20137,"activeCount":104},[],{"trials":20139,"activeCount":104},[20140,20148],{"nctId":20141,"briefTitle":20142,"status":174,"phases":20143,"primaryCompletion":20144,"completion":12408,"start":20145,"enrollment":1007,"conditions":20146,"interventions":20147},"NCT04606108","Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma",[93],"2021-10-19","2020-10-19",[4686],[20132],{"nctId":20149,"briefTitle":20150,"status":174,"phases":20151,"primaryCompletion":20152,"completion":20153,"start":20154,"enrollment":16816,"conditions":20155,"interventions":20156},"NCT04294511","Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma",[93],"2021-03-16","2023-09-16","2019-12-26",[12092],[20132],{"trials":20158,"activeCount":104},[],{"trials":20160,"activeCount":104},[],{"trials":20162,"activeCount":104},[],{"intervention":4815,"totalTrials":1255,"cells":20164},{"EARLY_PHASE1":20165,"PHASE1":20167,"PHASE2":20169,"PHASE3":20179,"PHASE4":20181,"NA":20183},{"trials":20166,"activeCount":104},[],{"trials":20168,"activeCount":104},[],{"trials":20170,"activeCount":104},[20171,20175],{"nctId":7938,"briefTitle":7939,"status":328,"phases":20172,"primaryCompletion":5303,"completion":5303,"start":830,"enrollment":7941,"conditions":20173,"interventions":20174},[93],[539],[4815,541],{"nctId":4807,"briefTitle":4808,"status":174,"phases":20176,"primaryCompletion":4810,"completion":4810,"start":4811,"enrollment":29,"conditions":20177,"interventions":20178},[93],[4813],[4815,398],{"trials":20180,"activeCount":104},[],{"trials":20182,"activeCount":104},[],{"trials":20184,"activeCount":104},[],{"intervention":2648,"totalTrials":1255,"cells":20186},{"EARLY_PHASE1":20187,"PHASE1":20189,"PHASE2":20195,"PHASE3":20201,"PHASE4":20203,"NA":20205},{"trials":20188,"activeCount":104},[],{"trials":20190,"activeCount":104},[20191],{"nctId":2639,"briefTitle":2640,"status":328,"phases":20192,"primaryCompletion":2642,"completion":2643,"start":2644,"enrollment":1615,"conditions":20193,"interventions":20194},[92],[2646],[2402,2648],{"trials":20196,"activeCount":104},[20197],{"nctId":2758,"briefTitle":2759,"status":328,"phases":20198,"primaryCompletion":2761,"completion":721,"start":2762,"enrollment":1501,"conditions":20199,"interventions":20200},[93],[22],[1958,2765],{"trials":20202,"activeCount":104},[],{"trials":20204,"activeCount":104},[],{"trials":20206,"activeCount":104},[],{"intervention":484,"totalTrials":1255,"cells":20208},{"EARLY_PHASE1":20209,"PHASE1":20211,"PHASE2":20219,"PHASE3":20225,"PHASE4":20227,"NA":20229},{"trials":20210,"activeCount":104},[],{"trials":20212,"activeCount":104},[20213],{"nctId":20214,"briefTitle":20215,"status":174,"phases":20216,"primaryCompletion":479,"completion":1064,"start":1679,"enrollment":911,"conditions":20217,"interventions":20218},"NCT04850235","Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study",[92],[396],[484],{"trials":20220,"activeCount":104},[20221],{"nctId":476,"briefTitle":477,"status":328,"phases":20222,"primaryCompletion":479,"completion":479,"start":480,"enrollment":205,"conditions":20223,"interventions":20224},[93],[463],[483,484,225],{"trials":20226,"activeCount":104},[],{"trials":20228,"activeCount":104},[],{"trials":20230,"activeCount":104},[],{"intervention":20232,"totalTrials":100,"cells":20233},"Unity-based MR-Linac guided FSRT",{"EARLY_PHASE1":20234,"PHASE1":20236,"PHASE2":20238,"PHASE3":20246,"PHASE4":20248,"NA":20250},{"trials":20235,"activeCount":104},[],{"trials":20237,"activeCount":104},[],{"trials":20239,"activeCount":104},[20240],{"nctId":20241,"briefTitle":20242,"status":328,"phases":20243,"primaryCompletion":9117,"completion":9117,"start":2644,"enrollment":280,"conditions":20244,"interventions":20245},"NCT04946019","MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer",[93],[22],[20232],{"trials":20247,"activeCount":104},[],{"trials":20249,"activeCount":104},[],{"trials":20251,"activeCount":104},[],{"intervention":20253,"totalTrials":100,"cells":20254},"Paclitaxel , carboplatin, endostatin",{"EARLY_PHASE1":20255,"PHASE1":20257,"PHASE2":20259,"PHASE3":20269,"PHASE4":20271,"NA":20273},{"trials":20256,"activeCount":104},[],{"trials":20258,"activeCount":104},[],{"trials":20260,"activeCount":104},[20261],{"nctId":20262,"briefTitle":20263,"status":174,"phases":20264,"primaryCompletion":828,"completion":4644,"start":17342,"enrollment":492,"conditions":20265,"interventions":20267},"NCT01347424","Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography",[93],[1831,396,20266],"Liver Metastasis",[20253,20268],"Paclitaxel and Carboplatin",{"trials":20270,"activeCount":104},[],{"trials":20272,"activeCount":104},[],{"trials":20274,"activeCount":104},[],{"intervention":20268,"totalTrials":100,"cells":20276},{"EARLY_PHASE1":20277,"PHASE1":20279,"PHASE2":20281,"PHASE3":20287,"PHASE4":20289,"NA":20291},{"trials":20278,"activeCount":104},[],{"trials":20280,"activeCount":104},[],{"trials":20282,"activeCount":104},[20283],{"nctId":20262,"briefTitle":20263,"status":174,"phases":20284,"primaryCompletion":828,"completion":4644,"start":17342,"enrollment":492,"conditions":20285,"interventions":20286},[93],[1831,396,20266],[20253,20268],{"trials":20288,"activeCount":104},[],{"trials":20290,"activeCount":104},[],{"trials":20292,"activeCount":104},[],{"intervention":7569,"totalTrials":100,"cells":20294},{"EARLY_PHASE1":20295,"PHASE1":20297,"PHASE2":20299,"PHASE3":20305,"PHASE4":20307,"NA":20309},{"trials":20296,"activeCount":104},[],{"trials":20298,"activeCount":104},[],{"trials":20300,"activeCount":104},[20301],{"nctId":7563,"briefTitle":7564,"status":328,"phases":20302,"primaryCompletion":289,"completion":289,"start":7566,"enrollment":29,"conditions":20303,"interventions":20304},[92,93],[1020],[823,54,7569],{"trials":20306,"activeCount":104},[],{"trials":20308,"activeCount":104},[],{"trials":20310,"activeCount":104},[],{"intervention":20312,"totalTrials":100,"cells":20313},"Preoperative systematic therapy",{"EARLY_PHASE1":20314,"PHASE1":20316,"PHASE2":20318,"PHASE3":20332,"PHASE4":20334,"NA":20336},{"trials":20315,"activeCount":104},[],{"trials":20317,"activeCount":104},[],{"trials":20319,"activeCount":104},[20320],{"nctId":20321,"briefTitle":20322,"status":174,"phases":20323,"primaryCompletion":2788,"completion":2788,"start":897,"enrollment":1402,"conditions":20324,"interventions":20330},"NCT05353582","Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases",[93],[1341,25,1020,20325,20326,20327,2430,20328,20329],"Peritoneal Metastases","Peritoneal Cancer","Peritoneal Neoplasms","Cytoreductive Surgery","Hyperthermic Intraperitoneal Chemotherapy",[20312,20331,20331],"Postoperative chemotherapy",{"trials":20333,"activeCount":104},[],{"trials":20335,"activeCount":104},[],{"trials":20337,"activeCount":104},[],{"intervention":20331,"totalTrials":100,"cells":20339},{"EARLY_PHASE1":20340,"PHASE1":20342,"PHASE2":20344,"PHASE3":20350,"PHASE4":20352,"NA":20354},{"trials":20341,"activeCount":104},[],{"trials":20343,"activeCount":104},[],{"trials":20345,"activeCount":104},[20346],{"nctId":20321,"briefTitle":20322,"status":174,"phases":20347,"primaryCompletion":2788,"completion":2788,"start":897,"enrollment":1402,"conditions":20348,"interventions":20349},[93],[1341,25,1020,20325,20326,20327,2430,20328,20329],[20312,20331,20331],{"trials":20351,"activeCount":104},[],{"trials":20353,"activeCount":104},[],{"trials":20355,"activeCount":104},[],{"intervention":20357,"totalTrials":100,"cells":20358},"PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin",{"EARLY_PHASE1":20359,"PHASE1":20361,"PHASE2":20363,"PHASE3":20374,"PHASE4":20376,"NA":20378},{"trials":20360,"activeCount":104},[],{"trials":20362,"activeCount":104},[],{"trials":20364,"activeCount":104},[20365],{"nctId":20366,"briefTitle":20367,"status":174,"phases":20368,"primaryCompletion":20369,"completion":1551,"start":20370,"enrollment":1066,"conditions":20371,"interventions":20373},"NCT03830385","Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck",[93],"2021-02-15","2019-02-15",[20372],"Squamous Cell Carcinoma Of The Head And Neck",[20357],{"trials":20375,"activeCount":104},[],{"trials":20377,"activeCount":104},[],{"trials":20379,"activeCount":104},[],{"intervention":20381,"totalTrials":100,"cells":20382},"Treprilimab",{"EARLY_PHASE1":20383,"PHASE1":20385,"PHASE2":20387,"PHASE3":20395,"PHASE4":20397,"NA":20399},{"trials":20384,"activeCount":104},[],{"trials":20386,"activeCount":104},[],{"trials":20388,"activeCount":104},[20389],{"nctId":20390,"briefTitle":20391,"status":174,"phases":20392,"primaryCompletion":7514,"completion":6596,"start":4713,"enrollment":492,"conditions":20393,"interventions":20394},"NCT04534855","A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation",[93],[16],[20381],{"trials":20396,"activeCount":104},[],{"trials":20398,"activeCount":104},[],{"trials":20400,"activeCount":104},[],{"intervention":20402,"totalTrials":100,"cells":20403},"gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab",{"EARLY_PHASE1":20404,"PHASE1":20406,"PHASE2":20408,"PHASE3":20419,"PHASE4":20421,"NA":20423},{"trials":20405,"activeCount":104},[],{"trials":20407,"activeCount":104},[],{"trials":20409,"activeCount":104},[20410],{"nctId":20411,"briefTitle":20412,"status":174,"phases":20413,"primaryCompletion":20414,"completion":12555,"start":20415,"enrollment":1727,"conditions":20416,"interventions":20418},"NCT04021992","GVD±R Regimen for ASCT-eligible Patients With Refractory\u002FRelapsed DLBCL",[93],"2023-07-15","2019-07-15",[20417],"Lymphoma, Large B-Cell, Diffuse",[20402],{"trials":20420,"activeCount":104},[],{"trials":20422,"activeCount":104},[],{"trials":20424,"activeCount":104},[],{"intervention":20426,"totalTrials":100,"cells":20427},"Epalrestat",{"EARLY_PHASE1":20428,"PHASE1":20430,"PHASE2":20432,"PHASE3":20440,"PHASE4":20442,"NA":20444},{"trials":20429,"activeCount":104},[],{"trials":20431,"activeCount":104},[],{"trials":20433,"activeCount":104},[20434],{"nctId":20435,"briefTitle":20436,"status":1091,"phases":20437,"primaryCompletion":217,"completion":217,"start":18464,"enrollment":3748,"conditions":20438,"interventions":20439},"NCT03244358","Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer",[93],[1068],[20426],{"trials":20441,"activeCount":104},[],{"trials":20443,"activeCount":104},[],{"trials":20445,"activeCount":104},[],{"intervention":20447,"totalTrials":100,"cells":20448},"Local triamcinolone injection combined with fibrin glue spray",{"EARLY_PHASE1":20449,"PHASE1":20451,"PHASE2":20453,"PHASE3":20466,"PHASE4":20468,"NA":20470},{"trials":20450,"activeCount":104},[],{"trials":20452,"activeCount":104},[],{"trials":20454,"activeCount":104},[20455],{"nctId":20456,"briefTitle":20457,"status":328,"phases":20458,"primaryCompletion":20459,"completion":20459,"start":20460,"enrollment":239,"conditions":20461,"interventions":20465},"NCT06840561","Local Triamcinolone Injection Combined With Fibrin Glue Spray in Preventing Esophageal Stricture After Big-range Endoscopic Submucosal Dissection for Esophageal Early Cancer",[93],"2024-12-10","2021-11-24",[20462,20463,20464],"Esophageal Stricture","Endoscopic Submucosal Dissection","Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection",[20447],{"trials":20467,"activeCount":104},[],{"trials":20469,"activeCount":104},[],{"trials":20471,"activeCount":104},[],{"intervention":20473,"totalTrials":100,"cells":20474},"RX-af01",{"EARLY_PHASE1":20475,"PHASE1":20477,"PHASE2":20479,"PHASE3":20490,"PHASE4":20492,"NA":20494},{"trials":20476,"activeCount":104},[],{"trials":20478,"activeCount":104},[],{"trials":20480,"activeCount":104},[20481],{"nctId":20482,"briefTitle":20483,"status":174,"phases":20484,"primaryCompletion":1064,"completion":1064,"start":2418,"enrollment":996,"conditions":20485,"interventions":20487},"NCT05576961","Safety and Efficacy of RX-af01 Combined With PD-1 Antibody",[92,93],[1111,3401,20486],"Intestinal Flora",[20473,20488,20489],"Mixed bacteria","High dose RX-af01",{"trials":20491,"activeCount":104},[],{"trials":20493,"activeCount":104},[],{"trials":20495,"activeCount":104},[],{"intervention":20488,"totalTrials":100,"cells":20497},{"EARLY_PHASE1":20498,"PHASE1":20500,"PHASE2":20502,"PHASE3":20508,"PHASE4":20510,"NA":20512},{"trials":20499,"activeCount":104},[],{"trials":20501,"activeCount":104},[],{"trials":20503,"activeCount":104},[20504],{"nctId":20482,"briefTitle":20483,"status":174,"phases":20505,"primaryCompletion":1064,"completion":1064,"start":2418,"enrollment":996,"conditions":20506,"interventions":20507},[92,93],[1111,3401,20486],[20473,20488,20489],{"trials":20509,"activeCount":104},[],{"trials":20511,"activeCount":104},[],{"trials":20513,"activeCount":104},[],{"intervention":20489,"totalTrials":100,"cells":20515},{"EARLY_PHASE1":20516,"PHASE1":20518,"PHASE2":20520,"PHASE3":20526,"PHASE4":20528,"NA":20530},{"trials":20517,"activeCount":104},[],{"trials":20519,"activeCount":104},[],{"trials":20521,"activeCount":104},[20522],{"nctId":20482,"briefTitle":20483,"status":174,"phases":20523,"primaryCompletion":1064,"completion":1064,"start":2418,"enrollment":996,"conditions":20524,"interventions":20525},[92,93],[1111,3401,20486],[20473,20488,20489],{"trials":20527,"activeCount":104},[],{"trials":20529,"activeCount":104},[],{"trials":20531,"activeCount":104},[],{"intervention":5298,"totalTrials":100,"cells":20533},{"EARLY_PHASE1":20534,"PHASE1":20536,"PHASE2":20538,"PHASE3":20544,"PHASE4":20546,"NA":20548},{"trials":20535,"activeCount":104},[],{"trials":20537,"activeCount":104},[],{"trials":20539,"activeCount":104},[20540],{"nctId":5291,"briefTitle":5292,"status":328,"phases":20541,"primaryCompletion":657,"completion":657,"start":5294,"enrollment":5295,"conditions":20542,"interventions":20543},[93],[1368],[5298,5273],{"trials":20545,"activeCount":104},[],{"trials":20547,"activeCount":104},[],{"trials":20549,"activeCount":104},[],{"intervention":7920,"totalTrials":100,"cells":20551},{"EARLY_PHASE1":20552,"PHASE1":20554,"PHASE2":20556,"PHASE3":20562,"PHASE4":20564,"NA":20566},{"trials":20553,"activeCount":104},[],{"trials":20555,"activeCount":104},[],{"trials":20557,"activeCount":104},[20558],{"nctId":7914,"briefTitle":7915,"status":328,"phases":20559,"primaryCompletion":3291,"completion":3507,"start":7917,"enrollment":26,"conditions":20560,"interventions":20561},[93],[539],[541,7920],{"trials":20563,"activeCount":104},[],{"trials":20565,"activeCount":104},[],{"trials":20567,"activeCount":104},[],{"intervention":20569,"totalTrials":100,"cells":20570},"Pucotenlimab Combined With Lenvatinib",{"EARLY_PHASE1":20571,"PHASE1":20573,"PHASE2":20575,"PHASE3":20585,"PHASE4":20587,"NA":20589},{"trials":20572,"activeCount":104},[],{"trials":20574,"activeCount":104},[],{"trials":20576,"activeCount":104},[20577],{"nctId":20578,"briefTitle":20579,"status":174,"phases":20580,"primaryCompletion":379,"completion":379,"start":20581,"enrollment":360,"conditions":20582,"interventions":20584},"NCT06129955","Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma",[93],"2023-11-11",[20583],"Renal Cell Carcinoma",[20569],{"trials":20586,"activeCount":104},[],{"trials":20588,"activeCount":104},[],{"trials":20590,"activeCount":104},[],{"intervention":20592,"totalTrials":100,"cells":20593},"anti-PD-1+Albumin-Bound Paclitaxel",{"EARLY_PHASE1":20594,"PHASE1":20596,"PHASE2":20598,"PHASE3":20609,"PHASE4":20611,"NA":20613},{"trials":20595,"activeCount":104},[],{"trials":20597,"activeCount":104},[],{"trials":20599,"activeCount":104},[20600],{"nctId":20601,"briefTitle":20602,"status":328,"phases":20603,"primaryCompletion":20604,"completion":20605,"start":20606,"enrollment":2059,"conditions":20607,"interventions":20608},"NCT04341883","Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer",[93],"2022-05-22","2024-04-26","2020-01-13",[265],[20592],{"trials":20610,"activeCount":104},[],{"trials":20612,"activeCount":104},[],{"trials":20614,"activeCount":104},[],{"intervention":20616,"totalTrials":100,"cells":20617},"AC0010",{"EARLY_PHASE1":20618,"PHASE1":20620,"PHASE2":20622,"PHASE3":20630,"PHASE4":20632,"NA":20634},{"trials":20619,"activeCount":104},[],{"trials":20621,"activeCount":104},[],{"trials":20623,"activeCount":104},[20624],{"nctId":20625,"briefTitle":20626,"status":174,"phases":20627,"primaryCompletion":203,"completion":460,"start":17318,"enrollment":1339,"conditions":20628,"interventions":20629},"NCT02274337","Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer",[92,93],[252],[20616],{"trials":20631,"activeCount":104},[],{"trials":20633,"activeCount":104},[],{"trials":20635,"activeCount":104},[],{"intervention":20637,"totalTrials":100,"cells":20638},"Combinations treatment",{"EARLY_PHASE1":20639,"PHASE1":20641,"PHASE2":20643,"PHASE3":20655,"PHASE4":20657,"NA":20659},{"trials":20640,"activeCount":104},[],{"trials":20642,"activeCount":104},[],{"trials":20644,"activeCount":104},[20645],{"nctId":20646,"briefTitle":20647,"status":174,"phases":20648,"primaryCompletion":20649,"completion":20650,"start":20651,"enrollment":1366,"conditions":20652,"interventions":20654},"NCT03736330","A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma",[93],"2020-10-08","2021-11-08","2018-09-08",[20653],"Renal Cancer Metastatic",[20637],{"trials":20656,"activeCount":104},[],{"trials":20658,"activeCount":104},[],{"trials":20660,"activeCount":104},[],{"intervention":20662,"totalTrials":100,"cells":20663},"Apatinib + Fluzoparib",{"EARLY_PHASE1":20664,"PHASE1":20666,"PHASE2":20668,"PHASE3":20678,"PHASE4":20680,"NA":20682},{"trials":20665,"activeCount":104},[],{"trials":20667,"activeCount":104},[],{"trials":20669,"activeCount":104},[20670],{"nctId":20671,"briefTitle":20672,"status":174,"phases":20673,"primaryCompletion":17457,"completion":4009,"start":20674,"enrollment":996,"conditions":20675,"interventions":20676},"NCT05932264","Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer",[93],"2023-07",[7985,22],[20662,20677],"Apatinib + Fluzoparib + Adebrelimab",{"trials":20679,"activeCount":104},[],{"trials":20681,"activeCount":104},[],{"trials":20683,"activeCount":104},[],{"intervention":20677,"totalTrials":100,"cells":20685},{"EARLY_PHASE1":20686,"PHASE1":20688,"PHASE2":20690,"PHASE3":20696,"PHASE4":20698,"NA":20700},{"trials":20687,"activeCount":104},[],{"trials":20689,"activeCount":104},[],{"trials":20691,"activeCount":104},[20692],{"nctId":20671,"briefTitle":20672,"status":174,"phases":20693,"primaryCompletion":17457,"completion":4009,"start":20674,"enrollment":996,"conditions":20694,"interventions":20695},[93],[7985,22],[20662,20677],{"trials":20697,"activeCount":104},[],{"trials":20699,"activeCount":104},[],{"trials":20701,"activeCount":104},[],{"intervention":20703,"totalTrials":100,"cells":20704},"cisplatin and 5-Fu combined with nimotuzumab",{"EARLY_PHASE1":20705,"PHASE1":20707,"PHASE2":20709,"PHASE3":20718,"PHASE4":20720,"NA":20722},{"trials":20706,"activeCount":104},[],{"trials":20708,"activeCount":104},[],{"trials":20710,"activeCount":104},[20711],{"nctId":20712,"briefTitle":20713,"status":328,"phases":20714,"primaryCompletion":764,"completion":764,"start":16922,"enrollment":26,"conditions":20715,"interventions":20717},"NCT01616849","Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma",[93],[20716],"Stage IV Nasopharyngeal Carcinoma",[20703],{"trials":20719,"activeCount":104},[],{"trials":20721,"activeCount":104},[],{"trials":20723,"activeCount":104},[],{"intervention":20725,"totalTrials":100,"cells":20726},"Tolipalimab",{"EARLY_PHASE1":20727,"PHASE1":20729,"PHASE2":20731,"PHASE3":20740,"PHASE4":20742,"NA":20744},{"trials":20728,"activeCount":104},[],{"trials":20730,"activeCount":104},[],{"trials":20732,"activeCount":104},[20733],{"nctId":20734,"briefTitle":20735,"status":174,"phases":20736,"primaryCompletion":1737,"completion":1365,"start":20737,"enrollment":959,"conditions":20738,"interventions":20739},"NCT03854838","IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.",[93],"2019-05-01",[16,441,566,567],[20725],{"trials":20741,"activeCount":104},[],{"trials":20743,"activeCount":104},[],{"trials":20745,"activeCount":104},[],{"intervention":20747,"totalTrials":100,"cells":20748},"R-CHOP\u002FR-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）",{"EARLY_PHASE1":20749,"PHASE1":20751,"PHASE2":20753,"PHASE3":20762,"PHASE4":20764,"NA":20766},{"trials":20750,"activeCount":104},[],{"trials":20752,"activeCount":104},[],{"trials":20754,"activeCount":104},[20755],{"nctId":20756,"briefTitle":20757,"status":174,"phases":20758,"primaryCompletion":9234,"completion":8254,"start":20759,"enrollment":360,"conditions":20760,"interventions":20761},"NCT04736914","Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma",[93],"2021-01-31",[11993],[20747],{"trials":20763,"activeCount":104},[],{"trials":20765,"activeCount":104},[],{"trials":20767,"activeCount":104},[],{"intervention":20769,"totalTrials":100,"cells":20770},"avatrombopag",{"EARLY_PHASE1":20771,"PHASE1":20773,"PHASE2":20775,"PHASE3":20787,"PHASE4":20789,"NA":20791},{"trials":20772,"activeCount":104},[],{"trials":20774,"activeCount":104},[],{"trials":20776,"activeCount":104},[20777],{"nctId":20778,"briefTitle":20779,"status":174,"phases":20780,"primaryCompletion":20781,"completion":20674,"start":20782,"enrollment":461,"conditions":20783,"interventions":20786},"NCT04797182","Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma",[93],"2023-04","2021-04",[20784,20785,15199],"Thrombocytopenia","Cytarabine Causing Adverse Effects in Therapeutic Use",[20769],{"trials":20788,"activeCount":104},[],{"trials":20790,"activeCount":104},[],{"trials":20792,"activeCount":104},[],{"intervention":20794,"totalTrials":100,"cells":20795},"Mirtazapine",{"EARLY_PHASE1":20796,"PHASE1":20798,"PHASE2":20800,"PHASE3":20809,"PHASE4":20811,"NA":20813},{"trials":20797,"activeCount":104},[],{"trials":20799,"activeCount":104},[],{"trials":20801,"activeCount":104},[20802],{"nctId":20803,"briefTitle":20804,"status":174,"phases":20805,"primaryCompletion":549,"completion":3954,"start":1934,"enrollment":800,"conditions":20806,"interventions":20808},"NCT02650544","Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression",[93],[2437,20807],"Depression",[20794],{"trials":20810,"activeCount":104},[],{"trials":20812,"activeCount":104},[],{"trials":20814,"activeCount":104},[],{"intervention":20816,"totalTrials":100,"cells":20817},"D-CIK and anti-PD-1 antibody",{"EARLY_PHASE1":20818,"PHASE1":20820,"PHASE2":20822,"PHASE3":20831,"PHASE4":20833,"NA":20835},{"trials":20819,"activeCount":104},[],{"trials":20821,"activeCount":104},[],{"trials":20823,"activeCount":104},[20824],{"nctId":20825,"briefTitle":20826,"status":174,"phases":20827,"primaryCompletion":20828,"completion":489,"start":829,"enrollment":205,"conditions":20829,"interventions":20830},"NCT02886897","A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors",[92,93],"2019-09",[19,20583,8231,25,7374,28],[20816],{"trials":20832,"activeCount":104},[],{"trials":20834,"activeCount":104},[],{"trials":20836,"activeCount":104},[],{"intervention":3102,"totalTrials":100,"cells":20838},{"EARLY_PHASE1":20839,"PHASE1":20841,"PHASE2":20843,"PHASE3":20849,"PHASE4":20851,"NA":20853},{"trials":20840,"activeCount":104},[],{"trials":20842,"activeCount":104},[],{"trials":20844,"activeCount":104},[20845],{"nctId":3095,"briefTitle":3096,"status":174,"phases":20846,"primaryCompletion":1026,"completion":3098,"start":3099,"enrollment":1007,"conditions":20847,"interventions":20848},[93],[252],[268,3102],{"trials":20850,"activeCount":104},[],{"trials":20852,"activeCount":104},[],{"trials":20854,"activeCount":104},[],{"intervention":5156,"totalTrials":100,"cells":20856},{"EARLY_PHASE1":20857,"PHASE1":20859,"PHASE2":20861,"PHASE3":20867,"PHASE4":20869,"NA":20871},{"trials":20858,"activeCount":104},[],{"trials":20860,"activeCount":104},[],{"trials":20862,"activeCount":104},[20863],{"nctId":5147,"briefTitle":5148,"status":328,"phases":20864,"primaryCompletion":5150,"completion":449,"start":5151,"enrollment":1450,"conditions":20865,"interventions":20866},[93],[5153],[5155,5156],{"trials":20868,"activeCount":104},[],{"trials":20870,"activeCount":104},[],{"trials":20872,"activeCount":104},[],{"intervention":1671,"totalTrials":100,"cells":20874},{"EARLY_PHASE1":20875,"PHASE1":20877,"PHASE2":20879,"PHASE3":20885,"PHASE4":20887,"NA":20889},{"trials":20876,"activeCount":104},[],{"trials":20878,"activeCount":104},[],{"trials":20880,"activeCount":104},[20881],{"nctId":1664,"briefTitle":1665,"status":174,"phases":20882,"primaryCompletion":1667,"completion":1668,"start":1657,"enrollment":29,"conditions":20883,"interventions":20884},[93],[1651],[483,981,1671,1672],{"trials":20886,"activeCount":104},[],{"trials":20888,"activeCount":104},[],{"trials":20890,"activeCount":104},[],{"intervention":1672,"totalTrials":100,"cells":20892},{"EARLY_PHASE1":20893,"PHASE1":20895,"PHASE2":20897,"PHASE3":20903,"PHASE4":20905,"NA":20907},{"trials":20894,"activeCount":104},[],{"trials":20896,"activeCount":104},[],{"trials":20898,"activeCount":104},[20899],{"nctId":1664,"briefTitle":1665,"status":174,"phases":20900,"primaryCompletion":1667,"completion":1668,"start":1657,"enrollment":29,"conditions":20901,"interventions":20902},[93],[1651],[483,981,1671,1672],{"trials":20904,"activeCount":104},[],{"trials":20906,"activeCount":104},[],{"trials":20908,"activeCount":104},[],{"intervention":20910,"totalTrials":100,"cells":20911},"Weekly DP chemotherapy concurrent with thoracic radiotherapy",{"EARLY_PHASE1":20912,"PHASE1":20914,"PHASE2":20916,"PHASE3":20926,"PHASE4":20928,"NA":20930},{"trials":20913,"activeCount":104},[],{"trials":20915,"activeCount":104},[],{"trials":20917,"activeCount":104},[20918],{"nctId":20919,"briefTitle":20920,"status":328,"phases":20921,"primaryCompletion":370,"completion":1647,"start":20922,"enrollment":1376,"conditions":20923,"interventions":20925},"NCT03673657","Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer",[93],"2018-08-10",[20924],"Local Advanced Non-small Cell Lung Cancer",[20910],{"trials":20927,"activeCount":104},[],{"trials":20929,"activeCount":104},[],{"trials":20931,"activeCount":104},[],{"intervention":20933,"totalTrials":100,"cells":20934},"Pemigatinib",{"EARLY_PHASE1":20935,"PHASE1":20937,"PHASE2":20939,"PHASE3":20948,"PHASE4":20950,"NA":20952},{"trials":20936,"activeCount":104},[],{"trials":20938,"activeCount":104},[],{"trials":20940,"activeCount":104},[20941],{"nctId":20942,"briefTitle":20943,"status":174,"phases":20944,"primaryCompletion":1238,"completion":369,"start":1566,"enrollment":35,"conditions":20945,"interventions":20947},"NCT05997459","A Single Arm, Phase II Exploratory Clinical Study of Pemitinib in Advanced Gastric Cancer With Previous Standard Therapy Failure the FGFR Variant",[93],[20946],"Locally Advanced Unresectable Gastric Cancer",[20933],{"trials":20949,"activeCount":104},[],{"trials":20951,"activeCount":104},[],{"trials":20953,"activeCount":104},[],{"intervention":20955,"totalTrials":100,"cells":20956},"Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy",{"EARLY_PHASE1":20957,"PHASE1":20959,"PHASE2":20961,"PHASE3":20970,"PHASE4":20972,"NA":20974},{"trials":20958,"activeCount":104},[],{"trials":20960,"activeCount":104},[],{"trials":20962,"activeCount":104},[20963],{"nctId":20964,"briefTitle":20965,"status":328,"phases":20966,"primaryCompletion":20967,"completion":20967,"start":8200,"enrollment":2184,"conditions":20968,"interventions":20969},"NCT04380480","Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma",[93],"2022-03-15",[463],[20955],{"trials":20971,"activeCount":104},[],{"trials":20973,"activeCount":104},[],{"trials":20975,"activeCount":104},[],{"intervention":20977,"totalTrials":100,"cells":20978},"Intensity-modulated radiotherapy concurrent with capecitabine",{"EARLY_PHASE1":20979,"PHASE1":20981,"PHASE2":20983,"PHASE3":20993,"PHASE4":20995,"NA":20997},{"trials":20980,"activeCount":104},[],{"trials":20982,"activeCount":104},[],{"trials":20984,"activeCount":104},[20985],{"nctId":20986,"briefTitle":20987,"status":174,"phases":20988,"primaryCompletion":7506,"completion":3262,"start":20989,"enrollment":5618,"conditions":20990,"interventions":20992},"NCT05512520","Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）",[93],"2022-09-20",[20991],"Metastatic Esophageal Squamous Cell Carcinoma",[20977],{"trials":20994,"activeCount":104},[],{"trials":20996,"activeCount":104},[],{"trials":20998,"activeCount":104},[],{"intervention":21000,"totalTrials":100,"cells":21001},"Anti-PD-1 Antibody Plus Chidamide and Rituximab",{"EARLY_PHASE1":21002,"PHASE1":21004,"PHASE2":21006,"PHASE3":21015,"PHASE4":21017,"NA":21019},{"trials":21003,"activeCount":104},[],{"trials":21005,"activeCount":104},[],{"trials":21007,"activeCount":104},[21008],{"nctId":21009,"briefTitle":21010,"status":174,"phases":21011,"primaryCompletion":1827,"completion":260,"start":897,"enrollment":2059,"conditions":21012,"interventions":21014},"NCT05115409","Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)",[93],[21013],"Relapsed or Refractory DLBCL",[21000],{"trials":21016,"activeCount":104},[],{"trials":21018,"activeCount":104},[],{"trials":21020,"activeCount":104},[],{"intervention":21022,"totalTrials":100,"cells":21023},"Sindilimab +paclitaxel+ cisplantin",{"EARLY_PHASE1":21024,"PHASE1":21026,"PHASE2":21028,"PHASE3":21040,"PHASE4":21042,"NA":21044},{"trials":21025,"activeCount":104},[],{"trials":21027,"activeCount":104},[],{"trials":21029,"activeCount":104},[21030],{"nctId":21031,"briefTitle":21032,"status":328,"phases":21033,"primaryCompletion":21034,"completion":21035,"start":21036,"enrollment":360,"conditions":21037,"interventions":21039},"NCT04799639","Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer",[93],"2024-06-17","2024-06-24","2021-03-18",[700,2430,21038,4554],"Programmed Cell Death 1 Receptor \u002F Antagonists & Inhibitors",[21022],{"trials":21041,"activeCount":104},[],{"trials":21043,"activeCount":104},[],{"trials":21045,"activeCount":104},[],{"intervention":21047,"totalTrials":100,"cells":21048},"Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab",{"EARLY_PHASE1":21049,"PHASE1":21051,"PHASE2":21053,"PHASE3":21062,"PHASE4":21064,"NA":21066},{"trials":21050,"activeCount":104},[],{"trials":21052,"activeCount":104},[],{"trials":21054,"activeCount":104},[21055],{"nctId":21056,"briefTitle":21057,"status":174,"phases":21058,"primaryCompletion":1668,"completion":1227,"start":4517,"enrollment":1712,"conditions":21059,"interventions":21060},"NCT05341193","PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma",[92,93],[16],[21047,21061],"Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab",{"trials":21063,"activeCount":104},[],{"trials":21065,"activeCount":104},[],{"trials":21067,"activeCount":104},[],{"intervention":21061,"totalTrials":100,"cells":21069},{"EARLY_PHASE1":21070,"PHASE1":21072,"PHASE2":21074,"PHASE3":21080,"PHASE4":21082,"NA":21084},{"trials":21071,"activeCount":104},[],{"trials":21073,"activeCount":104},[],{"trials":21075,"activeCount":104},[21076],{"nctId":21056,"briefTitle":21057,"status":174,"phases":21077,"primaryCompletion":1668,"completion":1227,"start":4517,"enrollment":1712,"conditions":21078,"interventions":21079},[92,93],[16],[21047,21061],{"trials":21081,"activeCount":104},[],{"trials":21083,"activeCount":104},[],{"trials":21085,"activeCount":104},[],{"intervention":21087,"totalTrials":100,"cells":21088},"Nivolumab",{"EARLY_PHASE1":21089,"PHASE1":21091,"PHASE2":21093,"PHASE3":21103,"PHASE4":21105,"NA":21107},{"trials":21090,"activeCount":104},[],{"trials":21092,"activeCount":104},[],{"trials":21094,"activeCount":104},[21095],{"nctId":21096,"briefTitle":21097,"status":174,"phases":21098,"primaryCompletion":1348,"completion":1348,"start":21099,"enrollment":898,"conditions":21100,"interventions":21102},"NCT04085250","Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy",[93],"2019-11-28",[21101],"Stage III Non-small-cell Lung Cancer",[21087],{"trials":21104,"activeCount":104},[],{"trials":21106,"activeCount":104},[],{"trials":21108,"activeCount":104},[],{"intervention":21110,"totalTrials":100,"cells":21111},"Neo-MASCT",{"EARLY_PHASE1":21112,"PHASE1":21114,"PHASE2":21116,"PHASE3":21128,"PHASE4":21130,"NA":21132},{"trials":21113,"activeCount":104},[],{"trials":21115,"activeCount":104},[],{"trials":21117,"activeCount":104},[21118],{"nctId":21119,"briefTitle":21120,"status":174,"phases":21121,"primaryCompletion":2642,"completion":2642,"start":21122,"enrollment":11931,"conditions":21123,"interventions":21127},"NCT03067493","RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial",[93],"2017-07-25",[21124,21125,318,21126],"Primary Liver Cancer","Radiofrequency Ablation","Hepatectomy",[21110],{"trials":21129,"activeCount":104},[],{"trials":21131,"activeCount":104},[],{"trials":21133,"activeCount":104},[],{"intervention":21135,"totalTrials":100,"cells":21136},"FOLFOX4",{"EARLY_PHASE1":21137,"PHASE1":21139,"PHASE2":21141,"PHASE3":21149,"PHASE4":21151,"NA":21153},{"trials":21138,"activeCount":104},[],{"trials":21140,"activeCount":104},[],{"trials":21142,"activeCount":104},[21143],{"nctId":21144,"briefTitle":21145,"status":174,"phases":21146,"primaryCompletion":1336,"completion":7887,"start":2303,"enrollment":1066,"conditions":21147,"interventions":21148},"NCT02452853","HR Combined With FOLFOX4 for HCC With PVTT",[93],[19],[21135],{"trials":21150,"activeCount":104},[],{"trials":21152,"activeCount":104},[],{"trials":21154,"activeCount":104},[],{"intervention":21156,"totalTrials":100,"cells":21157},"Tislelizumab, Carboplatin, Pemetrexed",{"EARLY_PHASE1":21158,"PHASE1":21160,"PHASE2":21162,"PHASE3":21173,"PHASE4":21175,"NA":21177},{"trials":21159,"activeCount":104},[],{"trials":21161,"activeCount":104},[],{"trials":21163,"activeCount":104},[21164],{"nctId":21165,"briefTitle":21166,"status":328,"phases":21167,"primaryCompletion":21168,"completion":7735,"start":21169,"enrollment":911,"conditions":21170,"interventions":21172},"NCT04507217","Tislelizumab Combined With Pemetrexed\u002F Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC",[93],"2022-11-15","2020-09-15",[21171,1830,1418],"NSCLC Stage IV",[21156],{"trials":21174,"activeCount":104},[],{"trials":21176,"activeCount":104},[],{"trials":21178,"activeCount":104},[],{"intervention":21180,"totalTrials":100,"cells":21181},"Autologous CIK Transfusion plus Chemotherapy",{"EARLY_PHASE1":21182,"PHASE1":21184,"PHASE2":21186,"PHASE3":21196,"PHASE4":21198,"NA":21200},{"trials":21183,"activeCount":104},[],{"trials":21185,"activeCount":104},[],{"trials":21187,"activeCount":104},[21188],{"nctId":21189,"briefTitle":21190,"status":904,"phases":21191,"primaryCompletion":460,"completion":658,"start":21192,"enrollment":104,"conditions":21193,"interventions":21194},"NCT01533727","CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)",[93],"2011-08",[22],[21180,21195],"chemotherapy alone",{"trials":21197,"activeCount":104},[],{"trials":21199,"activeCount":104},[],{"trials":21201,"activeCount":104},[],{"intervention":21195,"totalTrials":100,"cells":21203},{"EARLY_PHASE1":21204,"PHASE1":21206,"PHASE2":21208,"PHASE3":21214,"PHASE4":21216,"NA":21218},{"trials":21205,"activeCount":104},[],{"trials":21207,"activeCount":104},[],{"trials":21209,"activeCount":104},[21210],{"nctId":21189,"briefTitle":21190,"status":904,"phases":21211,"primaryCompletion":460,"completion":658,"start":21192,"enrollment":104,"conditions":21212,"interventions":21213},[93],[22],[21180,21195],{"trials":21215,"activeCount":104},[],{"trials":21217,"activeCount":104},[],{"trials":21219,"activeCount":104},[],{"intervention":21221,"totalTrials":100,"cells":21222},"Toripalimab and Anlotinib",{"EARLY_PHASE1":21223,"PHASE1":21225,"PHASE2":21227,"PHASE3":21236,"PHASE4":21238,"NA":21240},{"trials":21224,"activeCount":104},[],{"trials":21226,"activeCount":104},[],{"trials":21228,"activeCount":104},[21229],{"nctId":21230,"briefTitle":21231,"status":328,"phases":21232,"primaryCompletion":2643,"completion":1459,"start":21233,"enrollment":492,"conditions":21234,"interventions":21235},"NCT04996758","Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)",[93],"2021-10-30",[16,7081],[21221],{"trials":21237,"activeCount":104},[],{"trials":21239,"activeCount":104},[],{"trials":21241,"activeCount":104},[],{"intervention":21243,"totalTrials":100,"cells":21244},"5-Fu, oxaliplatin , leucovorin",{"EARLY_PHASE1":21245,"PHASE1":21247,"PHASE2":21249,"PHASE3":21258,"PHASE4":21260,"NA":21262},{"trials":21246,"activeCount":104},[],{"trials":21248,"activeCount":104},[],{"trials":21250,"activeCount":104},[21251],{"nctId":21252,"briefTitle":21253,"status":174,"phases":21254,"primaryCompletion":2526,"completion":21255,"start":3747,"enrollment":3705,"conditions":21256,"interventions":21257},"NCT02987699","Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil",[93],"2017-05",[181],[21243,21243,21243],{"trials":21259,"activeCount":104},[],{"trials":21261,"activeCount":104},[],{"trials":21263,"activeCount":104},[],{"intervention":21265,"totalTrials":100,"cells":21266},"pegylated recombinant human granulocyte-colony stimulating factor",{"EARLY_PHASE1":21267,"PHASE1":21269,"PHASE2":21271,"PHASE3":21280,"PHASE4":21282,"NA":21284},{"trials":21268,"activeCount":104},[],{"trials":21270,"activeCount":104},[],{"trials":21272,"activeCount":104},[21273],{"nctId":21274,"briefTitle":21275,"status":174,"phases":21276,"primaryCompletion":347,"completion":2857,"start":21277,"enrollment":1450,"conditions":21278,"interventions":21279},"NCT04547829","Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy",[93],"2020-10-10",[1617],[21265],{"trials":21281,"activeCount":104},[],{"trials":21283,"activeCount":104},[],{"trials":21285,"activeCount":104},[],{"intervention":21287,"totalTrials":100,"cells":21288},"Surufatinib+Sintilimab",{"EARLY_PHASE1":21289,"PHASE1":21291,"PHASE2":21293,"PHASE3":21302,"PHASE4":21304,"NA":21306},{"trials":21290,"activeCount":104},[],{"trials":21292,"activeCount":104},[],{"trials":21294,"activeCount":104},[21295],{"nctId":21296,"briefTitle":21297,"status":174,"phases":21298,"primaryCompletion":3517,"completion":696,"start":21299,"enrollment":226,"conditions":21300,"interventions":21301},"NCT05235906","A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer",[93],"2022-08-16",[11414],[21287],{"trials":21303,"activeCount":104},[],{"trials":21305,"activeCount":104},[],{"trials":21307,"activeCount":104},[],{"intervention":21309,"totalTrials":100,"cells":21310},"PD-1 antibody + cox inhibitor",{"EARLY_PHASE1":21311,"PHASE1":21313,"PHASE2":21315,"PHASE3":21325,"PHASE4":21327,"NA":21329},{"trials":21312,"activeCount":104},[],{"trials":21314,"activeCount":104},[],{"trials":21316,"activeCount":104},[21317],{"nctId":21318,"briefTitle":21319,"status":174,"phases":21320,"primaryCompletion":21321,"completion":1648,"start":21322,"enrollment":333,"conditions":21323,"interventions":21324},"NCT03638297","PD-1 Antibody Combined With COX Inhibitor in MSI-H\u002FdMMR or High TMB Colorectal Cancer",[93],"2022-08-20","2018-08-23",[25],[21309],{"trials":21326,"activeCount":104},[],{"trials":21328,"activeCount":104},[],{"trials":21330,"activeCount":104},[],{"intervention":21332,"totalTrials":100,"cells":21333},"Endostatin",{"EARLY_PHASE1":21334,"PHASE1":21336,"PHASE2":21338,"PHASE3":21347,"PHASE4":21349,"NA":21351},{"trials":21335,"activeCount":104},[],{"trials":21337,"activeCount":104},[],{"trials":21339,"activeCount":104},[21340],{"nctId":21341,"briefTitle":21342,"status":174,"phases":21343,"primaryCompletion":1427,"completion":1934,"start":21344,"enrollment":205,"conditions":21345,"interventions":21346},"NCT01218594","Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer",[93],"2009-05",[22],[21332],{"trials":21348,"activeCount":104},[],{"trials":21350,"activeCount":104},[],{"trials":21352,"activeCount":104},[],{"intervention":21354,"totalTrials":100,"cells":21355},"Niraparib in Combination With Anti-PD1 Antibody",{"EARLY_PHASE1":21356,"PHASE1":21358,"PHASE2":21360,"PHASE3":21369,"PHASE4":21371,"NA":21373},{"trials":21357,"activeCount":104},[],{"trials":21359,"activeCount":104},[],{"trials":21361,"activeCount":104},[21362],{"nctId":21363,"briefTitle":21364,"status":174,"phases":21365,"primaryCompletion":3107,"completion":3177,"start":722,"enrollment":29,"conditions":21366,"interventions":21368},"NCT04885413","An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent\u002F Advanced Stage Endometrial Cancer Patients",[93],[21367],"Recurrent\u002F Advanced Stage Endometrial Cancer Patients",[21354],{"trials":21370,"activeCount":104},[],{"trials":21372,"activeCount":104},[],{"trials":21374,"activeCount":104},[],{"intervention":21376,"totalTrials":100,"cells":21377},"Sintilimab; Bevacizumab Biosimilar",{"EARLY_PHASE1":21378,"PHASE1":21380,"PHASE2":21382,"PHASE3":21391,"PHASE4":21393,"NA":21395},{"trials":21379,"activeCount":104},[],{"trials":21381,"activeCount":104},[],{"trials":21383,"activeCount":104},[21384],{"nctId":21385,"briefTitle":21386,"status":174,"phases":21387,"primaryCompletion":1647,"completion":1963,"start":21388,"enrollment":1018,"conditions":21389,"interventions":21390},"NCT04796025","TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study",[93],"2021-09-23",[19],[21376],{"trials":21392,"activeCount":104},[],{"trials":21394,"activeCount":104},[],{"trials":21396,"activeCount":104},[],{"intervention":21398,"totalTrials":100,"cells":21399},"pegylated interferon (Peg IFN)α-2b",{"EARLY_PHASE1":21400,"PHASE1":21402,"PHASE2":21404,"PHASE3":21415,"PHASE4":21417,"NA":21419},{"trials":21401,"activeCount":104},[],{"trials":21403,"activeCount":104},[],{"trials":21405,"activeCount":104},[21406],{"nctId":21407,"briefTitle":21408,"status":174,"phases":21409,"primaryCompletion":331,"completion":4684,"start":21410,"enrollment":2591,"conditions":21411,"interventions":21413},"NCT03969017","Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients",[93],"2019-06-17",[21412],"Cirrhosis of Liver Due to Hepatitis B (Disorder)",[21398,21414],"Nucleoside （acid）analogue",{"trials":21416,"activeCount":104},[],{"trials":21418,"activeCount":104},[],{"trials":21420,"activeCount":104},[],{"intervention":21414,"totalTrials":100,"cells":21422},{"EARLY_PHASE1":21423,"PHASE1":21425,"PHASE2":21427,"PHASE3":21433,"PHASE4":21435,"NA":21437},{"trials":21424,"activeCount":104},[],{"trials":21426,"activeCount":104},[],{"trials":21428,"activeCount":104},[21429],{"nctId":21407,"briefTitle":21408,"status":174,"phases":21430,"primaryCompletion":331,"completion":4684,"start":21410,"enrollment":2591,"conditions":21431,"interventions":21432},[93],[21412],[21398,21414],{"trials":21434,"activeCount":104},[],{"trials":21436,"activeCount":104},[],{"trials":21438,"activeCount":104},[],{"intervention":21440,"totalTrials":100,"cells":21441},"umbilical cord blood mesenchymal stem cells",{"EARLY_PHASE1":21442,"PHASE1":21444,"PHASE2":21446,"PHASE3":21455,"PHASE4":21457,"NA":21459},{"trials":21443,"activeCount":104},[],{"trials":21445,"activeCount":104},[],{"trials":21447,"activeCount":104},[21448],{"nctId":21449,"briefTitle":21450,"status":174,"phases":21451,"primaryCompletion":203,"completion":549,"start":1374,"enrollment":21452,"conditions":21453,"interventions":21454},"NCT02812121","UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure",[93],261,[5153],[21440],{"trials":21456,"activeCount":104},[],{"trials":21458,"activeCount":104},[],{"trials":21460,"activeCount":104},[],{"intervention":21462,"totalTrials":100,"cells":21463},"TACE combined with Lenvatinib",{"EARLY_PHASE1":21464,"PHASE1":21466,"PHASE2":21468,"PHASE3":21479,"PHASE4":21481,"NA":21483},{"trials":21465,"activeCount":104},[],{"trials":21467,"activeCount":104},[],{"trials":21469,"activeCount":104},[21470],{"nctId":21471,"briefTitle":21472,"status":174,"phases":21473,"primaryCompletion":818,"completion":21474,"start":21475,"enrollment":461,"conditions":21476,"interventions":21478},"NCT05555316","TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma",[93],"2023-11","2019-11-10",[21477],"Liver Tumor",[21462],{"trials":21480,"activeCount":104},[],{"trials":21482,"activeCount":104},[],{"trials":21484,"activeCount":104},[],{"intervention":21486,"totalTrials":100,"cells":21487},"RC48+Tislelizumab+carboplatin",{"EARLY_PHASE1":21488,"PHASE1":21490,"PHASE2":21492,"PHASE3":21507,"PHASE4":21509,"NA":21511},{"trials":21489,"activeCount":104},[],{"trials":21491,"activeCount":104},[],{"trials":21493,"activeCount":104},[21494],{"nctId":21495,"briefTitle":21496,"status":174,"phases":21497,"primaryCompletion":21498,"completion":21499,"start":19097,"enrollment":21500,"conditions":21501,"interventions":21504},"NCT05847764","Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations",[93],"2024-10","2025-05",95,[1831,21502,21503,2188],"ERBB2 Mutation-Related Tumors","RC48",[21486,21505,21506],"RC48+Furmonertinib, 1L","RC48+Furmonertinib, 2L+",{"trials":21508,"activeCount":104},[],{"trials":21510,"activeCount":104},[],{"trials":21512,"activeCount":104},[],{"intervention":21505,"totalTrials":100,"cells":21514},{"EARLY_PHASE1":21515,"PHASE1":21517,"PHASE2":21519,"PHASE3":21525,"PHASE4":21527,"NA":21529},{"trials":21516,"activeCount":104},[],{"trials":21518,"activeCount":104},[],{"trials":21520,"activeCount":104},[21521],{"nctId":21495,"briefTitle":21496,"status":174,"phases":21522,"primaryCompletion":21498,"completion":21499,"start":19097,"enrollment":21500,"conditions":21523,"interventions":21524},[93],[1831,21502,21503,2188],[21486,21505,21506],{"trials":21526,"activeCount":104},[],{"trials":21528,"activeCount":104},[],{"trials":21530,"activeCount":104},[],{"intervention":21506,"totalTrials":100,"cells":21532},{"EARLY_PHASE1":21533,"PHASE1":21535,"PHASE2":21537,"PHASE3":21543,"PHASE4":21545,"NA":21547},{"trials":21534,"activeCount":104},[],{"trials":21536,"activeCount":104},[],{"trials":21538,"activeCount":104},[21539],{"nctId":21495,"briefTitle":21496,"status":174,"phases":21540,"primaryCompletion":21498,"completion":21499,"start":19097,"enrollment":21500,"conditions":21541,"interventions":21542},[93],[1831,21502,21503,2188],[21486,21505,21506],{"trials":21544,"activeCount":104},[],{"trials":21546,"activeCount":104},[],{"trials":21548,"activeCount":104},[],{"intervention":21550,"totalTrials":100,"cells":21551},"lapatinib and capecitabine or vinorelbine",{"EARLY_PHASE1":21552,"PHASE1":21554,"PHASE2":21556,"PHASE3":21567,"PHASE4":21569,"NA":21571},{"trials":21553,"activeCount":104},[],{"trials":21555,"activeCount":104},[],{"trials":21557,"activeCount":104},[21558],{"nctId":21559,"briefTitle":21560,"status":328,"phases":21561,"primaryCompletion":18183,"completion":18183,"start":21562,"enrollment":21563,"conditions":21564,"interventions":21566},"NCT02362958","A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer",[93],"2015-01-09",159,[21565],"HER2 Positive Breast Cancer",[21550],{"trials":21568,"activeCount":104},[],{"trials":21570,"activeCount":104},[],{"trials":21572,"activeCount":104},[],{"intervention":1732,"totalTrials":100,"cells":21574},{"EARLY_PHASE1":21575,"PHASE1":21577,"PHASE2":21579,"PHASE3":21585,"PHASE4":21587,"NA":21589},{"trials":21576,"activeCount":104},[],{"trials":21578,"activeCount":104},[],{"trials":21580,"activeCount":104},[21581],{"nctId":1722,"briefTitle":1723,"status":174,"phases":21582,"primaryCompletion":1725,"completion":259,"start":1726,"enrollment":1727,"conditions":21583,"interventions":21584},[93],[1729,1730],[483,981,1732],{"trials":21586,"activeCount":104},[],{"trials":21588,"activeCount":104},[],{"trials":21590,"activeCount":104},[],{"intervention":5390,"totalTrials":100,"cells":21592},{"EARLY_PHASE1":21593,"PHASE1":21595,"PHASE2":21597,"PHASE3":21603,"PHASE4":21605,"NA":21607},{"trials":21594,"activeCount":104},[],{"trials":21596,"activeCount":104},[],{"trials":21598,"activeCount":104},[21599],{"nctId":5381,"briefTitle":5382,"status":174,"phases":21600,"primaryCompletion":5384,"completion":923,"start":5385,"enrollment":5386,"conditions":21601,"interventions":21602},[93],[241],[5389,5390,5391],{"trials":21604,"activeCount":104},[],{"trials":21606,"activeCount":104},[],{"trials":21608,"activeCount":104},[],{"intervention":21610,"totalTrials":100,"cells":21611},"Tislelizumab, paclitaxel, Carboplatin",{"EARLY_PHASE1":21612,"PHASE1":21614,"PHASE2":21616,"PHASE3":21626,"PHASE4":21628,"NA":21630},{"trials":21613,"activeCount":104},[],{"trials":21615,"activeCount":104},[],{"trials":21617,"activeCount":104},[21618],{"nctId":21619,"briefTitle":21620,"status":174,"phases":21621,"primaryCompletion":53,"completion":1027,"start":21622,"enrollment":23,"conditions":21623,"interventions":21625},"NCT05207904","Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases",[93],"2021-06-17",[21624,1830],"Non-Small Cell Squamous Lung Cancer",[21610],{"trials":21627,"activeCount":104},[],{"trials":21629,"activeCount":104},[],{"trials":21631,"activeCount":104},[],{"intervention":338,"totalTrials":100,"cells":21633},{"EARLY_PHASE1":21634,"PHASE1":21636,"PHASE2":21638,"PHASE3":21644,"PHASE4":21646,"NA":21648},{"trials":21635,"activeCount":104},[],{"trials":21637,"activeCount":104},[],{"trials":21639,"activeCount":104},[21640],{"nctId":326,"briefTitle":327,"status":328,"phases":21641,"primaryCompletion":330,"completion":331,"start":332,"enrollment":333,"conditions":21642,"interventions":21643},[93],[335],[337,338,225,339,340],{"trials":21645,"activeCount":104},[],{"trials":21647,"activeCount":104},[],{"trials":21649,"activeCount":104},[],{"intervention":21651,"totalTrials":100,"cells":21652},"S1 80-120 mg\u002Fd",{"EARLY_PHASE1":21653,"PHASE1":21655,"PHASE2":21657,"PHASE3":21668,"PHASE4":21670,"NA":21672},{"trials":21654,"activeCount":104},[],{"trials":21656,"activeCount":104},[],{"trials":21658,"activeCount":104},[21659],{"nctId":21660,"briefTitle":21661,"status":174,"phases":21662,"primaryCompletion":21663,"completion":657,"start":1934,"enrollment":15285,"conditions":21664,"interventions":21665},"NCT02631460","S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC",[93],"2018-09",[7985],[21651,21666,21667],"pemetrexed 500 mg\u002Fm2","carboplatin AUC=5",{"trials":21669,"activeCount":104},[],{"trials":21671,"activeCount":104},[],{"trials":21673,"activeCount":104},[],{"intervention":21666,"totalTrials":100,"cells":21675},{"EARLY_PHASE1":21676,"PHASE1":21678,"PHASE2":21680,"PHASE3":21686,"PHASE4":21688,"NA":21690},{"trials":21677,"activeCount":104},[],{"trials":21679,"activeCount":104},[],{"trials":21681,"activeCount":104},[21682],{"nctId":21660,"briefTitle":21661,"status":174,"phases":21683,"primaryCompletion":21663,"completion":657,"start":1934,"enrollment":15285,"conditions":21684,"interventions":21685},[93],[7985],[21651,21666,21667],{"trials":21687,"activeCount":104},[],{"trials":21689,"activeCount":104},[],{"trials":21691,"activeCount":104},[],{"intervention":21667,"totalTrials":100,"cells":21693},{"EARLY_PHASE1":21694,"PHASE1":21696,"PHASE2":21698,"PHASE3":21704,"PHASE4":21706,"NA":21708},{"trials":21695,"activeCount":104},[],{"trials":21697,"activeCount":104},[],{"trials":21699,"activeCount":104},[21700],{"nctId":21660,"briefTitle":21661,"status":174,"phases":21701,"primaryCompletion":21663,"completion":657,"start":1934,"enrollment":15285,"conditions":21702,"interventions":21703},[93],[7985],[21651,21666,21667],{"trials":21705,"activeCount":104},[],{"trials":21707,"activeCount":104},[],{"trials":21709,"activeCount":104},[],{"intervention":21711,"totalTrials":100,"cells":21712},"Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus AI",{"EARLY_PHASE1":21713,"PHASE1":21715,"PHASE2":21717,"PHASE3":21726,"PHASE4":21728,"NA":21730},{"trials":21714,"activeCount":104},[],{"trials":21716,"activeCount":104},[],{"trials":21718,"activeCount":104},[21719],{"nctId":21720,"briefTitle":21721,"status":174,"phases":21722,"primaryCompletion":73,"completion":2788,"start":21723,"enrollment":4035,"conditions":21724,"interventions":21725},"NCT04941885","Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+\u002FHR+ Breast Cancer",[93],"2021-06-25",[28],[21711],{"trials":21727,"activeCount":104},[],{"trials":21729,"activeCount":104},[],{"trials":21731,"activeCount":104},[],{"intervention":21733,"totalTrials":100,"cells":21734},"Monosialotetrahexosylganglioside",{"EARLY_PHASE1":21735,"PHASE1":21737,"PHASE2":21739,"PHASE3":21747,"PHASE4":21749,"NA":21751},{"trials":21736,"activeCount":104},[],{"trials":21738,"activeCount":104},[],{"trials":21740,"activeCount":104},[21741],{"nctId":21742,"briefTitle":21743,"status":174,"phases":21744,"primaryCompletion":2526,"completion":5304,"start":5211,"enrollment":1339,"conditions":21745,"interventions":21746},"NCT02093910","Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy",[93],[7889],[21733],{"trials":21748,"activeCount":104},[],{"trials":21750,"activeCount":104},[],{"trials":21752,"activeCount":104},[],{"intervention":1000,"totalTrials":100,"cells":21754},{"EARLY_PHASE1":21755,"PHASE1":21757,"PHASE2":21759,"PHASE3":21765,"PHASE4":21767,"NA":21769},{"trials":21756,"activeCount":104},[],{"trials":21758,"activeCount":104},[],{"trials":21760,"activeCount":104},[21761],{"nctId":991,"briefTitle":992,"status":174,"phases":21762,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":21763,"interventions":21764},[93],[19],[284,999,1000],{"trials":21766,"activeCount":104},[],{"trials":21768,"activeCount":104},[],{"trials":21770,"activeCount":104},[],{"intervention":21772,"totalTrials":100,"cells":21773},"P-CHOP",{"EARLY_PHASE1":21774,"PHASE1":21776,"PHASE2":21778,"PHASE3":21786,"PHASE4":21788,"NA":21790},{"trials":21775,"activeCount":104},[],{"trials":21777,"activeCount":104},[],{"trials":21779,"activeCount":104},[21780],{"nctId":21781,"briefTitle":21782,"status":1091,"phases":21783,"primaryCompletion":460,"completion":15865,"start":1338,"enrollment":3748,"conditions":21784,"interventions":21785},"NCT02520479","\"Sandwich\" Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL",[93],[2195],[21772,21772],{"trials":21787,"activeCount":104},[],{"trials":21789,"activeCount":104},[],{"trials":21791,"activeCount":104},[],{"intervention":21793,"totalTrials":100,"cells":21794},"Apatinib plus Camrelizumab",{"EARLY_PHASE1":21795,"PHASE1":21797,"PHASE2":21799,"PHASE3":21811,"PHASE4":21813,"NA":21815},{"trials":21796,"activeCount":104},[],{"trials":21798,"activeCount":104},[],{"trials":21800,"activeCount":104},[21801],{"nctId":21802,"briefTitle":21803,"status":174,"phases":21804,"primaryCompletion":21805,"completion":21806,"start":21807,"enrollment":3414,"conditions":21808,"interventions":21810},"NCT04586088","Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure",[93],"2022-06-02","2023-09-05","2020-05-05",[16,3305,3887,2430,318,21809],"Molecular Targeted Therapy",[21793],{"trials":21812,"activeCount":104},[],{"trials":21814,"activeCount":104},[],{"trials":21816,"activeCount":104},[],{"intervention":1354,"totalTrials":100,"cells":21818},{"EARLY_PHASE1":21819,"PHASE1":21821,"PHASE2":21823,"PHASE3":21829,"PHASE4":21831,"NA":21833},{"trials":21820,"activeCount":104},[],{"trials":21822,"activeCount":104},[],{"trials":21824,"activeCount":104},[21825],{"nctId":1344,"briefTitle":1345,"status":174,"phases":21826,"primaryCompletion":1347,"completion":1348,"start":1349,"enrollment":1350,"conditions":21827,"interventions":21828},[93],[1352],[1354,444],{"trials":21830,"activeCount":104},[],{"trials":21832,"activeCount":104},[],{"trials":21834,"activeCount":104},[],{"intervention":21836,"totalTrials":100,"cells":21837},"anlotinib and anti PD-1 antibody",{"EARLY_PHASE1":21838,"PHASE1":21840,"PHASE2":21842,"PHASE3":21851,"PHASE4":21853,"NA":21855},{"trials":21839,"activeCount":104},[],{"trials":21841,"activeCount":104},[],{"trials":21843,"activeCount":104},[21844],{"nctId":21845,"briefTitle":21846,"status":174,"phases":21847,"primaryCompletion":3355,"completion":479,"start":21848,"enrollment":35,"conditions":21849,"interventions":21850},"NCT04157491","Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer",[92,93],"2019-10-18",[2896],[21836],{"trials":21852,"activeCount":104},[],{"trials":21854,"activeCount":104},[],{"trials":21856,"activeCount":104},[],{"intervention":2529,"totalTrials":100,"cells":21858},{"EARLY_PHASE1":21859,"PHASE1":21861,"PHASE2":21863,"PHASE3":21869,"PHASE4":21871,"NA":21873},{"trials":21860,"activeCount":104},[],{"trials":21862,"activeCount":104},[],{"trials":21864,"activeCount":104},[21865],{"nctId":2522,"briefTitle":2523,"status":174,"phases":21866,"primaryCompletion":2525,"completion":2526,"start":1500,"enrollment":1084,"conditions":21867,"interventions":21868},[93],[19],[542,2529],{"trials":21870,"activeCount":104},[],{"trials":21872,"activeCount":104},[],{"trials":21874,"activeCount":104},[],{"intervention":21876,"totalTrials":100,"cells":21877},"Rego+Tori+Cele",{"EARLY_PHASE1":21878,"PHASE1":21880,"PHASE2":21882,"PHASE3":21892,"PHASE4":21894,"NA":21896},{"trials":21879,"activeCount":104},[],{"trials":21881,"activeCount":104},[],{"trials":21883,"activeCount":104},[21884],{"nctId":21885,"briefTitle":21886,"status":174,"phases":21887,"primaryCompletion":3312,"completion":4583,"start":21888,"enrollment":2040,"conditions":21889,"interventions":21891},"NCT05933980","Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer",[93],"2023-12-19",[25,2098,21890],"MSS",[21876],{"trials":21893,"activeCount":104},[],{"trials":21895,"activeCount":104},[],{"trials":21897,"activeCount":104},[],{"intervention":21899,"totalTrials":100,"cells":21900},"GELOX",{"EARLY_PHASE1":21901,"PHASE1":21903,"PHASE2":21905,"PHASE3":21913,"PHASE4":21915,"NA":21917},{"trials":21902,"activeCount":104},[],{"trials":21904,"activeCount":104},[],{"trials":21906,"activeCount":104},[21907],{"nctId":21908,"briefTitle":21909,"status":174,"phases":21910,"primaryCompletion":459,"completion":427,"start":3507,"enrollment":492,"conditions":21911,"interventions":21912},"NCT02080234","Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE\u002FIIE ENKTL",[93],[2235],[21899],{"trials":21914,"activeCount":104},[],{"trials":21916,"activeCount":104},[],{"trials":21918,"activeCount":104},[],{"intervention":21920,"totalTrials":100,"cells":21921},"Anlotinib plus Sintilimab",{"EARLY_PHASE1":21922,"PHASE1":21924,"PHASE2":21926,"PHASE3":21936,"PHASE4":21938,"NA":21940},{"trials":21923,"activeCount":104},[],{"trials":21925,"activeCount":104},[],{"trials":21927,"activeCount":104},[21928],{"nctId":21929,"briefTitle":21930,"status":174,"phases":21931,"primaryCompletion":1238,"completion":1238,"start":21932,"enrollment":348,"conditions":21933,"interventions":21935},"NCT05220267","Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma",[93],"2022-02-28",[21934],"Non Clear Cell Renal Carcinoma",[21920],{"trials":21937,"activeCount":104},[],{"trials":21939,"activeCount":104},[],{"trials":21941,"activeCount":104},[],{"intervention":21943,"totalTrials":100,"cells":21944},"PD-1 combined with SBRT",{"EARLY_PHASE1":21945,"PHASE1":21947,"PHASE2":21949,"PHASE3":21959,"PHASE4":21961,"NA":21963},{"trials":21946,"activeCount":104},[],{"trials":21948,"activeCount":104},[],{"trials":21950,"activeCount":104},[21951],{"nctId":21952,"briefTitle":21953,"status":174,"phases":21954,"primaryCompletion":238,"completion":1801,"start":21955,"enrollment":492,"conditions":21956,"interventions":21958},"NCT05626569","Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC",[93],"2022-12-10",[463,21957],"Oligometastatic Disease",[21943],{"trials":21960,"activeCount":104},[],{"trials":21962,"activeCount":104},[],{"trials":21964,"activeCount":104},[],{"intervention":21966,"totalTrials":100,"cells":21967},"TMZ",{"EARLY_PHASE1":21968,"PHASE1":21970,"PHASE2":21972,"PHASE3":21982,"PHASE4":21984,"NA":21986},{"trials":21969,"activeCount":104},[],{"trials":21971,"activeCount":104},[],{"trials":21973,"activeCount":104},[21974],{"nctId":21975,"briefTitle":21976,"status":174,"phases":21977,"primaryCompletion":203,"completion":460,"start":829,"enrollment":5386,"conditions":21978,"interventions":21981},"NCT02832635","A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases",[93],[21979,21980],"Brain Metastasis","Radiation Therapy Complication",[21966],{"trials":21983,"activeCount":104},[],{"trials":21985,"activeCount":104},[],{"trials":21987,"activeCount":104},[],{"intervention":21989,"totalTrials":100,"cells":21990},"Pegaspargase combined with concurrent radiotherapy.",{"EARLY_PHASE1":21991,"PHASE1":21993,"PHASE2":21995,"PHASE3":22005,"PHASE4":22007,"NA":22009},{"trials":21992,"activeCount":104},[],{"trials":21994,"activeCount":104},[],{"trials":21996,"activeCount":104},[21997],{"nctId":21998,"briefTitle":21999,"status":174,"phases":22000,"primaryCompletion":840,"completion":840,"start":22001,"enrollment":406,"conditions":22002,"interventions":22004},"NCT06406556","Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL",[93],"2016-03-01",[22003],"Extranodal NK\u002FT-cell Lymphoma",[21989],{"trials":22006,"activeCount":104},[],{"trials":22008,"activeCount":104},[],{"trials":22010,"activeCount":104},[],{"intervention":14258,"totalTrials":100,"cells":22012},{"EARLY_PHASE1":22013,"PHASE1":22015,"PHASE2":22017,"PHASE3":22023,"PHASE4":22025,"NA":22027},{"trials":22014,"activeCount":104},[],{"trials":22016,"activeCount":104},[],{"trials":22018,"activeCount":104},[22019],{"nctId":14253,"briefTitle":14254,"status":904,"phases":22020,"primaryCompletion":3953,"completion":657,"start":459,"enrollment":104,"conditions":22021,"interventions":22022},[93],[3957],[14258,14259,183],{"trials":22024,"activeCount":104},[],{"trials":22026,"activeCount":104},[],{"trials":22028,"activeCount":104},[],{"intervention":22030,"totalTrials":100,"cells":22031},"Sapropterin Dihydrochloride",{"EARLY_PHASE1":22032,"PHASE1":22034,"PHASE2":22036,"PHASE3":22045,"PHASE4":22047,"NA":22049},{"trials":22033,"activeCount":104},[],{"trials":22035,"activeCount":104},[],{"trials":22037,"activeCount":104},[22038],{"nctId":22039,"briefTitle":22040,"status":174,"phases":22041,"primaryCompletion":8229,"completion":8229,"start":368,"enrollment":239,"conditions":22042,"interventions":22044},"NCT06396637","PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC",[93],[22043],"Pancreatic Adenocarcinoma Metastatic",[22030],{"trials":22046,"activeCount":104},[],{"trials":22048,"activeCount":104},[],{"trials":22050,"activeCount":104},[],{"intervention":22052,"totalTrials":100,"cells":22053},"Chidamide Plus Toripalimab Plus Paclitaxel",{"EARLY_PHASE1":22054,"PHASE1":22056,"PHASE2":22058,"PHASE3":22066,"PHASE4":22068,"NA":22070},{"trials":22055,"activeCount":104},[],{"trials":22057,"activeCount":104},[],{"trials":22059,"activeCount":104},[22060],{"nctId":22061,"briefTitle":22062,"status":174,"phases":22063,"primaryCompletion":4865,"completion":12208,"start":8339,"enrollment":1084,"conditions":22064,"interventions":22065},"NCT05749575","Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.",[93],[28],[22052],{"trials":22067,"activeCount":104},[],{"trials":22069,"activeCount":104},[],{"trials":22071,"activeCount":104},[],{"intervention":22073,"totalTrials":100,"cells":22074},"ABX + DDP",{"EARLY_PHASE1":22075,"PHASE1":22077,"PHASE2":22079,"PHASE3":22087,"PHASE4":22089,"NA":22091},{"trials":22076,"activeCount":104},[],{"trials":22078,"activeCount":104},[],{"trials":22080,"activeCount":104},[22081],{"nctId":22082,"briefTitle":22083,"status":174,"phases":22084,"primaryCompletion":3507,"completion":1428,"start":16195,"enrollment":2710,"conditions":22085,"interventions":22086},"NCT01735409","Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma",[92,93],[441],[22073,22073,22073],{"trials":22088,"activeCount":104},[],{"trials":22090,"activeCount":104},[],{"trials":22092,"activeCount":104},[],{"intervention":22094,"totalTrials":100,"cells":22095},"Chidamide combined with Zimberelimab",{"EARLY_PHASE1":22096,"PHASE1":22098,"PHASE2":22100,"PHASE3":22108,"PHASE4":22110,"NA":22112},{"trials":22097,"activeCount":104},[],{"trials":22099,"activeCount":104},[],{"trials":22101,"activeCount":104},[22102],{"nctId":22103,"briefTitle":22104,"status":328,"phases":22105,"primaryCompletion":10907,"completion":5936,"start":17434,"enrollment":360,"conditions":22106,"interventions":22107},"NCT05632848","Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients",[93],[1068],[22094],{"trials":22109,"activeCount":104},[],{"trials":22111,"activeCount":104},[],{"trials":22113,"activeCount":104},[],{"intervention":22115,"totalTrials":100,"cells":22116},"Camrelizumab; Apatinib",{"EARLY_PHASE1":22117,"PHASE1":22119,"PHASE2":22121,"PHASE3":22129,"PHASE4":22131,"NA":22133},{"trials":22118,"activeCount":104},[],{"trials":22120,"activeCount":104},[],{"trials":22122,"activeCount":104},[22123],{"nctId":22124,"briefTitle":22125,"status":174,"phases":22126,"primaryCompletion":1647,"completion":1963,"start":4740,"enrollment":1018,"conditions":22127,"interventions":22128},"NCT04724226","Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma",[93],[19],[22115],{"trials":22130,"activeCount":104},[],{"trials":22132,"activeCount":104},[],{"trials":22134,"activeCount":104},[],{"intervention":22136,"totalTrials":100,"cells":22137},"anti-PD1 antibody-activated TILs",{"EARLY_PHASE1":22138,"PHASE1":22140,"PHASE2":22142,"PHASE3":22151,"PHASE4":22153,"NA":22155},{"trials":22139,"activeCount":104},[],{"trials":22141,"activeCount":104},[],{"trials":22143,"activeCount":104},[22144],{"nctId":22145,"briefTitle":22146,"status":174,"phases":22147,"primaryCompletion":967,"completion":289,"start":22148,"enrollment":239,"conditions":22149,"interventions":22150},"NCT03903887","A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer",[92,93],"2019-02-19",[22],[22136],{"trials":22152,"activeCount":104},[],{"trials":22154,"activeCount":104},[],{"trials":22156,"activeCount":104},[],{"intervention":22158,"totalTrials":100,"cells":22159},"Regorafenib and PD-1 antibody in Combination with Radiotherapy",{"EARLY_PHASE1":22160,"PHASE1":22162,"PHASE2":22164,"PHASE3":22175,"PHASE4":22177,"NA":22179},{"trials":22161,"activeCount":104},[],{"trials":22163,"activeCount":104},[],{"trials":22165,"activeCount":104},[22166],{"nctId":22167,"briefTitle":22168,"status":174,"phases":22169,"primaryCompletion":22170,"completion":22171,"start":22172,"enrollment":1084,"conditions":22173,"interventions":22174},"NCT04030260","Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR\u002FMSS Metastatic Colorectal Cancer",[93],"2023-02-20","2023-07-19","2019-07-19",[1020,21890],[22158],{"trials":22176,"activeCount":104},[],{"trials":22178,"activeCount":104},[],{"trials":22180,"activeCount":104},[],{"intervention":22182,"totalTrials":100,"cells":22183},"Dalpiciclib Isetionate Tablets, Camrelizumab",{"EARLY_PHASE1":22184,"PHASE1":22186,"PHASE2":22188,"PHASE3":22196,"PHASE4":22198,"NA":22200},{"trials":22185,"activeCount":104},[],{"trials":22187,"activeCount":104},[],{"trials":22189,"activeCount":104},[22190],{"nctId":22191,"briefTitle":22192,"status":174,"phases":22193,"primaryCompletion":3125,"completion":21498,"start":7514,"enrollment":1712,"conditions":22194,"interventions":22195},"NCT05724355","CDK4\u002F6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R\u002FM NPC",[93],[16],[22182],{"trials":22197,"activeCount":104},[],{"trials":22199,"activeCount":104},[],{"trials":22201,"activeCount":104},[],{"intervention":22203,"totalTrials":100,"cells":22204},"EP\u002FEC+PD-1",{"EARLY_PHASE1":22205,"PHASE1":22207,"PHASE2":22209,"PHASE3":22220,"PHASE4":22222,"NA":22224},{"trials":22206,"activeCount":104},[],{"trials":22208,"activeCount":104},[],{"trials":22210,"activeCount":104},[22211],{"nctId":22212,"briefTitle":22213,"status":174,"phases":22214,"primaryCompletion":22215,"completion":22216,"start":22217,"enrollment":1350,"conditions":22218,"interventions":22219},"NCT05760053","Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma",[93],"2025-02-18","2026-02-18","2023-02-18",[284,9770],[22203],{"trials":22221,"activeCount":104},[],{"trials":22223,"activeCount":104},[],{"trials":22225,"activeCount":104},[],{"intervention":22227,"totalTrials":100,"cells":22228},"Fluzoparib+ Dalpiciclib",{"EARLY_PHASE1":22229,"PHASE1":22231,"PHASE2":22233,"PHASE3":22241,"PHASE4":22243,"NA":22245},{"trials":22230,"activeCount":104},[],{"trials":22232,"activeCount":104},[],{"trials":22234,"activeCount":104},[22235],{"nctId":22236,"briefTitle":22237,"status":174,"phases":22238,"primaryCompletion":1459,"completion":302,"start":73,"enrollment":205,"conditions":22239,"interventions":22240},"NCT05952128","Phase Ib\u002FII Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma",[93],[7724],[22227],{"trials":22242,"activeCount":104},[],{"trials":22244,"activeCount":104},[],{"trials":22246,"activeCount":104},[],{"intervention":22248,"totalTrials":100,"cells":22249},"Amifostine every-other-day regimen",{"EARLY_PHASE1":22250,"PHASE1":22252,"PHASE2":22254,"PHASE3":22266,"PHASE4":22268,"NA":22270},{"trials":22251,"activeCount":104},[],{"trials":22253,"activeCount":104},[],{"trials":22255,"activeCount":104},[22256],{"nctId":22257,"briefTitle":22258,"status":174,"phases":22259,"primaryCompletion":3954,"completion":657,"start":14741,"enrollment":5429,"conditions":22260,"interventions":22264},"NCT01762514","A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens",[93],[441,22261,22262,22263],"Salivary Gland Diseases","Bone Marrow Diseases","Mucositis",[22248,22265],"Amifostine everyday regimen",{"trials":22267,"activeCount":104},[],{"trials":22269,"activeCount":104},[],{"trials":22271,"activeCount":104},[],{"intervention":22265,"totalTrials":100,"cells":22273},{"EARLY_PHASE1":22274,"PHASE1":22276,"PHASE2":22278,"PHASE3":22284,"PHASE4":22286,"NA":22288},{"trials":22275,"activeCount":104},[],{"trials":22277,"activeCount":104},[],{"trials":22279,"activeCount":104},[22280],{"nctId":22257,"briefTitle":22258,"status":174,"phases":22281,"primaryCompletion":3954,"completion":657,"start":14741,"enrollment":5429,"conditions":22282,"interventions":22283},[93],[441,22261,22262,22263],[22248,22265],{"trials":22285,"activeCount":104},[],{"trials":22287,"activeCount":104},[],{"trials":22289,"activeCount":104},[],{"intervention":22291,"totalTrials":100,"cells":22292},"Abraxane combined with liposomal doxorubicin",{"EARLY_PHASE1":22293,"PHASE1":22295,"PHASE2":22297,"PHASE3":22307,"PHASE4":22309,"NA":22311},{"trials":22294,"activeCount":104},[],{"trials":22296,"activeCount":104},[],{"trials":22298,"activeCount":104},[22299],{"nctId":22300,"briefTitle":22301,"status":174,"phases":22302,"primaryCompletion":1876,"completion":2734,"start":22303,"enrollment":2710,"conditions":22304,"interventions":22306},"NCT04859465","Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma",[93],"2021-05-21",[22305],"Angiosarcoma Metastatic",[22291],{"trials":22308,"activeCount":104},[],{"trials":22310,"activeCount":104},[],{"trials":22312,"activeCount":104},[],{"intervention":22314,"totalTrials":100,"cells":22315},"Camrelizumab, nab-paclitaxel, cisplatin",{"EARLY_PHASE1":22316,"PHASE1":22318,"PHASE2":22320,"PHASE3":22328,"PHASE4":22330,"NA":22332},{"trials":22317,"activeCount":104},[],{"trials":22319,"activeCount":104},[],{"trials":22321,"activeCount":104},[22322],{"nctId":22323,"briefTitle":22324,"status":174,"phases":22325,"primaryCompletion":4826,"completion":7492,"start":957,"enrollment":1316,"conditions":22326,"interventions":22327},"NCT04826679","Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC",[93],[1474],[22314],{"trials":22329,"activeCount":104},[],{"trials":22331,"activeCount":104},[],{"trials":22333,"activeCount":104},[],{"intervention":5166,"totalTrials":100,"cells":22335},{"EARLY_PHASE1":22336,"PHASE1":22338,"PHASE2":22340,"PHASE3":22346,"PHASE4":22348,"NA":22350},{"trials":22337,"activeCount":104},[],{"trials":22339,"activeCount":104},[],{"trials":22341,"activeCount":104},[22342],{"nctId":5158,"briefTitle":5159,"status":174,"phases":22343,"primaryCompletion":368,"completion":1064,"start":5161,"enrollment":5162,"conditions":22344,"interventions":22345},[93],[5164],[5138,5166],{"trials":22347,"activeCount":104},[],{"trials":22349,"activeCount":104},[],{"trials":22351,"activeCount":104},[],{"intervention":22353,"totalTrials":100,"cells":22354},"Cisplatin+Toripalimab",{"EARLY_PHASE1":22355,"PHASE1":22357,"PHASE2":22359,"PHASE3":22370,"PHASE4":22372,"NA":22374},{"trials":22356,"activeCount":104},[],{"trials":22358,"activeCount":104},[],{"trials":22360,"activeCount":104},[22361],{"nctId":22362,"briefTitle":22363,"status":174,"phases":22364,"primaryCompletion":22365,"completion":3125,"start":22366,"enrollment":1389,"conditions":22367,"interventions":22368},"NCT03925090","Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients",[93],"2021-12-06","2019-12-08",[16],[22353,22369],"Cisplatin+placebo",{"trials":22371,"activeCount":104},[],{"trials":22373,"activeCount":104},[],{"trials":22375,"activeCount":104},[],{"intervention":22369,"totalTrials":100,"cells":22377},{"EARLY_PHASE1":22378,"PHASE1":22380,"PHASE2":22382,"PHASE3":22388,"PHASE4":22390,"NA":22392},{"trials":22379,"activeCount":104},[],{"trials":22381,"activeCount":104},[],{"trials":22383,"activeCount":104},[22384],{"nctId":22362,"briefTitle":22363,"status":174,"phases":22385,"primaryCompletion":22365,"completion":3125,"start":22366,"enrollment":1389,"conditions":22386,"interventions":22387},[93],[16],[22353,22369],{"trials":22389,"activeCount":104},[],{"trials":22391,"activeCount":104},[],{"trials":22393,"activeCount":104},[],{"intervention":22395,"totalTrials":100,"cells":22396},"Abraxane,Cyclophosphamide,Carboplatin",{"EARLY_PHASE1":22397,"PHASE1":22399,"PHASE2":22401,"PHASE3":22411,"PHASE4":22413,"NA":22415},{"trials":22398,"activeCount":104},[],{"trials":22400,"activeCount":104},[],{"trials":22402,"activeCount":104},[22403],{"nctId":22404,"briefTitle":22405,"status":1091,"phases":22406,"primaryCompletion":9095,"completion":9095,"start":22407,"enrollment":2272,"conditions":22408,"interventions":22410},"NCT02183805","Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer",[93],"2014-06-17",[22409],"Carcinoma Breast Stage IV",[22395],{"trials":22412,"activeCount":104},[],{"trials":22414,"activeCount":104},[],{"trials":22416,"activeCount":104},[],{"intervention":22418,"totalTrials":100,"cells":22419},"anlotinib and toripalimab",{"EARLY_PHASE1":22420,"PHASE1":22422,"PHASE2":22424,"PHASE3":22434,"PHASE4":22436,"NA":22438},{"trials":22421,"activeCount":104},[],{"trials":22423,"activeCount":104},[],{"trials":22425,"activeCount":104},[22426],{"nctId":22427,"briefTitle":22428,"status":174,"phases":22429,"primaryCompletion":746,"completion":19415,"start":22430,"enrollment":1076,"conditions":22431,"interventions":22433},"NCT04172805","Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma",[93],"2020-03-13",[22432],"Sarcoma,Soft Tissue",[22418],{"trials":22435,"activeCount":104},[],{"trials":22437,"activeCount":104},[],{"trials":22439,"activeCount":104},[],{"intervention":22441,"totalTrials":100,"cells":22442},"Cadonilimab+regorafenib",{"EARLY_PHASE1":22443,"PHASE1":22445,"PHASE2":22447,"PHASE3":22455,"PHASE4":22457,"NA":22459},{"trials":22444,"activeCount":104},[],{"trials":22446,"activeCount":104},[],{"trials":22448,"activeCount":104},[22449],{"nctId":22450,"briefTitle":22451,"status":174,"phases":22452,"primaryCompletion":405,"completion":2662,"start":573,"enrollment":32,"conditions":22453,"interventions":22454},"NCT05773105","A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC",[92,93],[1230],[22441],{"trials":22456,"activeCount":104},[],{"trials":22458,"activeCount":104},[],{"trials":22460,"activeCount":104},[],{"intervention":22462,"totalTrials":100,"cells":22463},"cisplatin, dexamethasone,vitamin B12, folic acid",{"EARLY_PHASE1":22464,"PHASE1":22466,"PHASE2":22468,"PHASE3":22479,"PHASE4":22481,"NA":22483},{"trials":22465,"activeCount":104},[],{"trials":22467,"activeCount":104},[],{"trials":22469,"activeCount":104},[22470],{"nctId":22471,"briefTitle":22472,"status":328,"phases":22473,"primaryCompletion":7637,"completion":16009,"start":22474,"enrollment":22475,"conditions":22476,"interventions":22477},"NCT01194453","Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer",[93],"2009-11",288,[22,1279],[22462,22478],"cisplatin, gemcitabine",{"trials":22480,"activeCount":104},[],{"trials":22482,"activeCount":104},[],{"trials":22484,"activeCount":104},[],{"intervention":22478,"totalTrials":100,"cells":22486},{"EARLY_PHASE1":22487,"PHASE1":22489,"PHASE2":22491,"PHASE3":22497,"PHASE4":22499,"NA":22501},{"trials":22488,"activeCount":104},[],{"trials":22490,"activeCount":104},[],{"trials":22492,"activeCount":104},[22493],{"nctId":22471,"briefTitle":22472,"status":328,"phases":22494,"primaryCompletion":7637,"completion":16009,"start":22474,"enrollment":22475,"conditions":22495,"interventions":22496},[93],[22,1279],[22462,22478],{"trials":22498,"activeCount":104},[],{"trials":22500,"activeCount":104},[],{"trials":22502,"activeCount":104},[],{"intervention":352,"totalTrials":100,"cells":22504},{"EARLY_PHASE1":22505,"PHASE1":22507,"PHASE2":22509,"PHASE3":22515,"PHASE4":22517,"NA":22519},{"trials":22506,"activeCount":104},[],{"trials":22508,"activeCount":104},[],{"trials":22510,"activeCount":104},[22511],{"nctId":342,"briefTitle":343,"status":174,"phases":22512,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":22513,"interventions":22514},[93],[350],[352,353,49,225],{"trials":22516,"activeCount":104},[],{"trials":22518,"activeCount":104},[],{"trials":22520,"activeCount":104},[],{"intervention":15412,"totalTrials":100,"cells":22522},{"EARLY_PHASE1":22523,"PHASE1":22525,"PHASE2":22527,"PHASE3":22533,"PHASE4":22535,"NA":22537},{"trials":22524,"activeCount":104},[],{"trials":22526,"activeCount":104},[],{"trials":22528,"activeCount":104},[22529],{"nctId":15406,"briefTitle":15407,"status":328,"phases":22530,"primaryCompletion":15409,"completion":217,"start":1934,"enrollment":4430,"conditions":22531,"interventions":22532},[93],[22],[14310,15412],{"trials":22534,"activeCount":104},[],{"trials":22536,"activeCount":104},[],{"trials":22538,"activeCount":104},[],{"intervention":22540,"totalTrials":100,"cells":22541},"C225",{"EARLY_PHASE1":22542,"PHASE1":22544,"PHASE2":22546,"PHASE3":22555,"PHASE4":22557,"NA":22559},{"trials":22543,"activeCount":104},[],{"trials":22545,"activeCount":104},[],{"trials":22547,"activeCount":104},[22548],{"nctId":22549,"briefTitle":22550,"status":328,"phases":22551,"primaryCompletion":22552,"completion":22552,"start":16324,"enrollment":1339,"conditions":22553,"interventions":22554},"NCT00700440","Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy",[93],"2009-04",[16],[22540],{"trials":22556,"activeCount":104},[],{"trials":22558,"activeCount":104},[],{"trials":22560,"activeCount":104},[],{"intervention":22562,"totalTrials":100,"cells":22563},"FSRT combined with Bevacizumab",{"EARLY_PHASE1":22564,"PHASE1":22566,"PHASE2":22568,"PHASE3":22576,"PHASE4":22578,"NA":22580},{"trials":22565,"activeCount":104},[],{"trials":22567,"activeCount":104},[],{"trials":22569,"activeCount":104},[22570],{"nctId":22571,"briefTitle":22572,"status":328,"phases":22573,"primaryCompletion":2642,"completion":2642,"start":670,"enrollment":1339,"conditions":22574,"interventions":22575},"NCT04345146","Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC",[93],[22],[22562],{"trials":22577,"activeCount":104},[],{"trials":22579,"activeCount":104},[],{"trials":22581,"activeCount":104},[],{"intervention":22583,"totalTrials":100,"cells":22584},"Unity-based MR-Linac guided Radiotherapy",{"EARLY_PHASE1":22585,"PHASE1":22587,"PHASE2":22589,"PHASE3":22599,"PHASE4":22601,"NA":22603},{"trials":22586,"activeCount":104},[],{"trials":22588,"activeCount":104},[],{"trials":22590,"activeCount":104},[22591],{"nctId":22592,"briefTitle":22593,"status":174,"phases":22594,"primaryCompletion":10550,"completion":10550,"start":22595,"enrollment":514,"conditions":22596,"interventions":22598},"NCT05163509","MR-linac Guided Adaptive Radiotherapy for Inoperable Mediastinal Tumor",[93],"2021-10-01",[22597],"Mediastinal Tumor",[22583],{"trials":22600,"activeCount":104},[],{"trials":22602,"activeCount":104},[],{"trials":22604,"activeCount":104},[],{"intervention":22606,"totalTrials":100,"cells":22607},"Levofloxacin",{"EARLY_PHASE1":22608,"PHASE1":22610,"PHASE2":22612,"PHASE3":22626,"PHASE4":22628,"NA":22630},{"trials":22609,"activeCount":104},[],{"trials":22611,"activeCount":104},[],{"trials":22613,"activeCount":104},[22614],{"nctId":22615,"briefTitle":22616,"status":174,"phases":22617,"primaryCompletion":1428,"completion":17318,"start":7636,"enrollment":32,"conditions":22618,"interventions":22623},"NCT02148016","Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation",[92,93],[22619,22620,22621,22622],"Corneal Disease","Pterygium","Myopia","Hyperopia",[22606,22624,22625],"Betamethasone","Limbal stem cells",{"trials":22627,"activeCount":104},[],{"trials":22629,"activeCount":104},[],{"trials":22631,"activeCount":104},[],{"intervention":22624,"totalTrials":100,"cells":22633},{"EARLY_PHASE1":22634,"PHASE1":22636,"PHASE2":22638,"PHASE3":22644,"PHASE4":22646,"NA":22648},{"trials":22635,"activeCount":104},[],{"trials":22637,"activeCount":104},[],{"trials":22639,"activeCount":104},[22640],{"nctId":22615,"briefTitle":22616,"status":174,"phases":22641,"primaryCompletion":1428,"completion":17318,"start":7636,"enrollment":32,"conditions":22642,"interventions":22643},[92,93],[22619,22620,22621,22622],[22606,22624,22625],{"trials":22645,"activeCount":104},[],{"trials":22647,"activeCount":104},[],{"trials":22649,"activeCount":104},[],{"intervention":22625,"totalTrials":100,"cells":22651},{"EARLY_PHASE1":22652,"PHASE1":22654,"PHASE2":22656,"PHASE3":22662,"PHASE4":22664,"NA":22666},{"trials":22653,"activeCount":104},[],{"trials":22655,"activeCount":104},[],{"trials":22657,"activeCount":104},[22658],{"nctId":22615,"briefTitle":22616,"status":174,"phases":22659,"primaryCompletion":1428,"completion":17318,"start":7636,"enrollment":32,"conditions":22660,"interventions":22661},[92,93],[22619,22620,22621,22622],[22606,22624,22625],{"trials":22663,"activeCount":104},[],{"trials":22665,"activeCount":104},[],{"trials":22667,"activeCount":104},[],{"intervention":4743,"totalTrials":100,"cells":22669},{"EARLY_PHASE1":22670,"PHASE1":22672,"PHASE2":22674,"PHASE3":22680,"PHASE4":22682,"NA":22684},{"trials":22671,"activeCount":104},[],{"trials":22673,"activeCount":104},[],{"trials":22675,"activeCount":104},[22676],{"nctId":4736,"briefTitle":4737,"status":174,"phases":22677,"primaryCompletion":4739,"completion":1064,"start":4740,"enrollment":32,"conditions":22678,"interventions":22679},[93],[2249],[1205,4743],{"trials":22681,"activeCount":104},[],{"trials":22683,"activeCount":104},[],{"trials":22685,"activeCount":104},[],{"intervention":22687,"totalTrials":100,"cells":22688},"Tislelizumab & Fruquintinib",{"EARLY_PHASE1":22689,"PHASE1":22691,"PHASE2":22693,"PHASE3":22702,"PHASE4":22704,"NA":22706},{"trials":22690,"activeCount":104},[],{"trials":22692,"activeCount":104},[],{"trials":22694,"activeCount":104},[22695],{"nctId":22696,"briefTitle":22697,"status":904,"phases":22698,"primaryCompletion":763,"completion":763,"start":763,"enrollment":104,"conditions":22699,"interventions":22701},"NCT05690035","Tislelizumab Combined With Fruquintinib for Metastatic pMMR\u002FMSS Colorectal Cancer",[93],[1368,22700],"mCRC",[22687],{"trials":22703,"activeCount":104},[],{"trials":22705,"activeCount":104},[],{"trials":22707,"activeCount":104},[],{"intervention":22709,"totalTrials":100,"cells":22710},"Fruquintinib plus Tislelizumab",{"EARLY_PHASE1":22711,"PHASE1":22713,"PHASE2":22715,"PHASE3":22724,"PHASE4":22726,"NA":22728},{"trials":22712,"activeCount":104},[],{"trials":22714,"activeCount":104},[],{"trials":22716,"activeCount":104},[22717],{"nctId":22718,"briefTitle":22719,"status":174,"phases":22720,"primaryCompletion":907,"completion":22721,"start":3843,"enrollment":1727,"conditions":22722,"interventions":22723},"NCT04989855","Fruquintinib Plus PD-1 Antibody in pMMR \u002F MSS Locally Advanced Rectal Cancer (LARC) With High Immune Score",[93],"2024-02",[1352],[22709],{"trials":22725,"activeCount":104},[],{"trials":22727,"activeCount":104},[],{"trials":22729,"activeCount":104},[],{"intervention":22731,"totalTrials":100,"cells":22732},"Almonertinib combine with Pyrrolitinib",{"EARLY_PHASE1":22733,"PHASE1":22735,"PHASE2":22737,"PHASE3":22746,"PHASE4":22748,"NA":22750},{"trials":22734,"activeCount":104},[],{"trials":22736,"activeCount":104},[],{"trials":22738,"activeCount":104},[22739],{"nctId":22740,"briefTitle":22741,"status":174,"phases":22742,"primaryCompletion":259,"completion":259,"start":3355,"enrollment":911,"conditions":22743,"interventions":22745},"NCT04785729","Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification\u002FMutation After EGFR-TKI Resistance",[93],[22744],"Safety",[22731],{"trials":22747,"activeCount":104},[],{"trials":22749,"activeCount":104},[],{"trials":22751,"activeCount":104},[],{"intervention":22753,"totalTrials":100,"cells":22754},"Aumolertinib",{"EARLY_PHASE1":22755,"PHASE1":22757,"PHASE2":22759,"PHASE3":22767,"PHASE4":22769,"NA":22771},{"trials":22756,"activeCount":104},[],{"trials":22758,"activeCount":104},[],{"trials":22760,"activeCount":104},[22761],{"nctId":22762,"briefTitle":22763,"status":904,"phases":22764,"primaryCompletion":7492,"completion":6571,"start":1907,"enrollment":104,"conditions":22765,"interventions":22766},"NCT06227897","Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).",[93],[2210],[22753],{"trials":22768,"activeCount":104},[],{"trials":22770,"activeCount":104},[],{"trials":22772,"activeCount":104},[],{"intervention":22774,"totalTrials":100,"cells":22775},"Cadonilimab Combined With Lenvatinib",{"EARLY_PHASE1":22776,"PHASE1":22778,"PHASE2":22780,"PHASE3":22789,"PHASE4":22791,"NA":22793},{"trials":22777,"activeCount":104},[],{"trials":22779,"activeCount":104},[],{"trials":22781,"activeCount":104},[22782],{"nctId":22783,"briefTitle":22784,"status":328,"phases":22785,"primaryCompletion":22786,"completion":379,"start":88,"enrollment":26,"conditions":22787,"interventions":22788},"NCT06138496","Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC",[93],"2024-12-09",[12473],[22774],{"trials":22790,"activeCount":104},[],{"trials":22792,"activeCount":104},[],{"trials":22794,"activeCount":104},[],{"intervention":4751,"totalTrials":100,"cells":22796},{"EARLY_PHASE1":22797,"PHASE1":22799,"PHASE2":22801,"PHASE3":22807,"PHASE4":22809,"NA":22811},{"trials":22798,"activeCount":104},[],{"trials":22800,"activeCount":104},[],{"trials":22802,"activeCount":104},[22803],{"nctId":4745,"briefTitle":4746,"status":174,"phases":22804,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":22805,"interventions":22806},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":22808,"activeCount":104},[],{"trials":22810,"activeCount":104},[],{"trials":22812,"activeCount":104},[],{"intervention":4752,"totalTrials":100,"cells":22814},{"EARLY_PHASE1":22815,"PHASE1":22817,"PHASE2":22819,"PHASE3":22825,"PHASE4":22827,"NA":22829},{"trials":22816,"activeCount":104},[],{"trials":22818,"activeCount":104},[],{"trials":22820,"activeCount":104},[22821],{"nctId":4745,"briefTitle":4746,"status":174,"phases":22822,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":22823,"interventions":22824},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":22826,"activeCount":104},[],{"trials":22828,"activeCount":104},[],{"trials":22830,"activeCount":104},[],{"intervention":4754,"totalTrials":100,"cells":22832},{"EARLY_PHASE1":22833,"PHASE1":22835,"PHASE2":22837,"PHASE3":22843,"PHASE4":22845,"NA":22847},{"trials":22834,"activeCount":104},[],{"trials":22836,"activeCount":104},[],{"trials":22838,"activeCount":104},[22839],{"nctId":4745,"briefTitle":4746,"status":174,"phases":22840,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":22841,"interventions":22842},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":22844,"activeCount":104},[],{"trials":22846,"activeCount":104},[],{"trials":22848,"activeCount":104},[],{"intervention":4757,"totalTrials":100,"cells":22850},{"EARLY_PHASE1":22851,"PHASE1":22853,"PHASE2":22855,"PHASE3":22861,"PHASE4":22863,"NA":22865},{"trials":22852,"activeCount":104},[],{"trials":22854,"activeCount":104},[],{"trials":22856,"activeCount":104},[22857],{"nctId":4745,"briefTitle":4746,"status":174,"phases":22858,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":22859,"interventions":22860},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":22862,"activeCount":104},[],{"trials":22864,"activeCount":104},[],{"trials":22866,"activeCount":104},[],{"intervention":4758,"totalTrials":100,"cells":22868},{"EARLY_PHASE1":22869,"PHASE1":22871,"PHASE2":22873,"PHASE3":22879,"PHASE4":22881,"NA":22883},{"trials":22870,"activeCount":104},[],{"trials":22872,"activeCount":104},[],{"trials":22874,"activeCount":104},[22875],{"nctId":4745,"briefTitle":4746,"status":174,"phases":22876,"primaryCompletion":491,"completion":491,"start":3759,"enrollment":1339,"conditions":22877,"interventions":22878},[93],[4749],[2306,4751,1205,2309,4752,2308,4753,4754,4755,411,4756,4757,4758],{"trials":22880,"activeCount":104},[],{"trials":22882,"activeCount":104},[],{"trials":22884,"activeCount":104},[],{"intervention":22886,"totalTrials":100,"cells":22887},"Tocilizumab",{"EARLY_PHASE1":22888,"PHASE1":22890,"PHASE2":22892,"PHASE3":22901,"PHASE4":22903,"NA":22905},{"trials":22889,"activeCount":104},[],{"trials":22891,"activeCount":104},[],{"trials":22893,"activeCount":104},[22894],{"nctId":22895,"briefTitle":22896,"status":904,"phases":22897,"primaryCompletion":22898,"completion":22898,"start":22898,"enrollment":104,"conditions":22899,"interventions":22900},"NCT06087731","Efficacy and Safety of Tocilizumab for TAO",[93],"2023-09-23",[22886,14811],[22886],{"trials":22902,"activeCount":104},[],{"trials":22904,"activeCount":104},[],{"trials":22906,"activeCount":104},[],{"intervention":22908,"totalTrials":100,"cells":22909},"Paclitaxel and Carboplatin regimen",{"EARLY_PHASE1":22910,"PHASE1":22912,"PHASE2":22914,"PHASE3":22923,"PHASE4":22925,"NA":22927},{"trials":22911,"activeCount":104},[],{"trials":22913,"activeCount":104},[],{"trials":22915,"activeCount":104},[22916],{"nctId":22917,"briefTitle":22918,"status":1091,"phases":22919,"primaryCompletion":22920,"completion":22920,"start":204,"enrollment":1066,"conditions":22921,"interventions":22922},"NCT02737709","Paclitaxel Detection in NSCLC Treated With TC Regimen",[93],"2018-10-25",[22],[22908],{"trials":22924,"activeCount":104},[],{"trials":22926,"activeCount":104},[],{"trials":22928,"activeCount":104},[],{"intervention":22930,"totalTrials":100,"cells":22931},"Transarterial Chemoinfusion (TAI) Combine Toripalimab",{"EARLY_PHASE1":22932,"PHASE1":22934,"PHASE2":22936,"PHASE3":22945,"PHASE4":22947,"NA":22949},{"trials":22933,"activeCount":104},[],{"trials":22935,"activeCount":104},[],{"trials":22937,"activeCount":104},[22938],{"nctId":22939,"briefTitle":22940,"status":174,"phases":22941,"primaryCompletion":2663,"completion":19793,"start":22942,"enrollment":8569,"conditions":22943,"interventions":22944},"NCT03851939","The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)",[93],"2019-02-26",[19],[22930],{"trials":22946,"activeCount":104},[],{"trials":22948,"activeCount":104},[],{"trials":22950,"activeCount":104},[],{"intervention":22952,"totalTrials":100,"cells":22953},"Deferoxamine Plus Chemotherapy",{"EARLY_PHASE1":22954,"PHASE1":22956,"PHASE2":22958,"PHASE3":22968,"PHASE4":22970,"NA":22972},{"trials":22955,"activeCount":104},[],{"trials":22957,"activeCount":104},[],{"trials":22959,"activeCount":104},[22960],{"nctId":22961,"briefTitle":22962,"status":1091,"phases":22963,"primaryCompletion":22964,"completion":22964,"start":22965,"enrollment":959,"conditions":22966,"interventions":22967},"NCT05300958","Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer",[93],"2025-07-21","2022-03-21",[1068],[22952],{"trials":22969,"activeCount":104},[],{"trials":22971,"activeCount":104},[],{"trials":22973,"activeCount":104},[],{"intervention":22975,"totalTrials":100,"cells":22976},"albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin",{"EARLY_PHASE1":22977,"PHASE1":22979,"PHASE2":22981,"PHASE3":22993,"PHASE4":22995,"NA":22997},{"trials":22978,"activeCount":104},[],{"trials":22980,"activeCount":104},[],{"trials":22982,"activeCount":104},[22983],{"nctId":22984,"briefTitle":22985,"status":174,"phases":22986,"primaryCompletion":22987,"completion":22988,"start":22989,"enrollment":348,"conditions":22990,"interventions":22992},"NCT04581265","Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor.",[93],"2023-11-10","2024-05-10","2020-11-10",[22991],"Extracranial Germ Cell Tumor, Pediatric",[22975],{"trials":22994,"activeCount":104},[],{"trials":22996,"activeCount":104},[],{"trials":22998,"activeCount":104},[],{"intervention":14271,"totalTrials":100,"cells":23000},{"EARLY_PHASE1":23001,"PHASE1":23003,"PHASE2":23005,"PHASE3":23011,"PHASE4":23013,"NA":23015},{"trials":23002,"activeCount":104},[],{"trials":23004,"activeCount":104},[],{"trials":23006,"activeCount":104},[23007],{"nctId":14265,"briefTitle":14266,"status":174,"phases":23008,"primaryCompletion":549,"completion":549,"start":178,"enrollment":1192,"conditions":23009,"interventions":23010},[93],[14269],[14271,4756],{"trials":23012,"activeCount":104},[],{"trials":23014,"activeCount":104},[],{"trials":23016,"activeCount":104},[],{"intervention":7950,"totalTrials":100,"cells":23018},{"EARLY_PHASE1":23019,"PHASE1":23021,"PHASE2":23023,"PHASE3":23029,"PHASE4":23031,"NA":23033},{"trials":23020,"activeCount":104},[],{"trials":23022,"activeCount":104},[],{"trials":23024,"activeCount":104},[23025],{"nctId":7945,"briefTitle":7946,"status":328,"phases":23026,"primaryCompletion":906,"completion":906,"start":764,"enrollment":3050,"conditions":23027,"interventions":23028},[93],[463],[7950,541],{"trials":23030,"activeCount":104},[],{"trials":23032,"activeCount":104},[],{"trials":23034,"activeCount":104},[],{"intervention":23036,"totalTrials":100,"cells":23037},"nedaplatin and gemcitabine",{"EARLY_PHASE1":23038,"PHASE1":23040,"PHASE2":23042,"PHASE3":23051,"PHASE4":23053,"NA":23055},{"trials":23039,"activeCount":104},[],{"trials":23041,"activeCount":104},[],{"trials":23043,"activeCount":104},[23044],{"nctId":23045,"briefTitle":23046,"status":1091,"phases":23047,"primaryCompletion":23048,"start":1374,"enrollment":996,"conditions":23049,"interventions":23050},"NCT02789189","Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and\u002For Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail",[93],"2019-09-04",[15176],[23036],{"trials":23052,"activeCount":104},[],{"trials":23054,"activeCount":104},[],{"trials":23056,"activeCount":104},[],{"intervention":23058,"totalTrials":100,"cells":23059},"anti-PD-1 antibody-activated TILs",{"EARLY_PHASE1":23060,"PHASE1":23062,"PHASE2":23064,"PHASE3":23072,"PHASE4":23074,"NA":23076},{"trials":23061,"activeCount":104},[],{"trials":23063,"activeCount":104},[],{"trials":23065,"activeCount":104},[23066],{"nctId":23067,"briefTitle":23068,"status":174,"phases":23069,"primaryCompletion":967,"completion":289,"start":22148,"enrollment":239,"conditions":23070,"interventions":23071},"NCT03904537","A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer",[92,93],[1330],[23058],{"trials":23073,"activeCount":104},[],{"trials":23075,"activeCount":104},[],{"trials":23077,"activeCount":104},[],{"intervention":23079,"totalTrials":100,"cells":23080},"Combination of Bortezomib, Fludarabine and Cyclophosphamide",{"EARLY_PHASE1":23081,"PHASE1":23083,"PHASE2":23085,"PHASE3":23094,"PHASE4":23096,"NA":23098},{"trials":23082,"activeCount":104},[],{"trials":23084,"activeCount":104},[],{"trials":23086,"activeCount":104},[23087],{"nctId":23088,"briefTitle":23089,"status":174,"phases":23090,"primaryCompletion":188,"completion":188,"start":16010,"enrollment":492,"conditions":23091,"interventions":23093},"NCT01322776","Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma",[92,93],[23092],"Mantle Cell Lymphoma Recurrent",[23079],{"trials":23095,"activeCount":104},[],{"trials":23097,"activeCount":104},[],{"trials":23099,"activeCount":104},[],{"intervention":23101,"totalTrials":100,"cells":23102},"Chemotherapy plus radiotherapy and Toripalimab",{"EARLY_PHASE1":23103,"PHASE1":23105,"PHASE2":23107,"PHASE3":23115,"PHASE4":23117,"NA":23119},{"trials":23104,"activeCount":104},[],{"trials":23106,"activeCount":104},[],{"trials":23108,"activeCount":104},[23109],{"nctId":23110,"briefTitle":23111,"status":174,"phases":23112,"primaryCompletion":862,"completion":860,"start":3863,"enrollment":7736,"conditions":23113,"interventions":23114},"NCT04398056","Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma",[93],[16],[23101],{"trials":23116,"activeCount":104},[],{"trials":23118,"activeCount":104},[],{"trials":23120,"activeCount":104},[],{"intervention":23122,"totalTrials":100,"cells":23123},"Toripalimab + Chidamide",{"EARLY_PHASE1":23124,"PHASE1":23126,"PHASE2":23128,"PHASE3":23140,"PHASE4":23142,"NA":23144},{"trials":23125,"activeCount":104},[],{"trials":23127,"activeCount":104},[],{"trials":23129,"activeCount":104},[23130],{"nctId":23131,"briefTitle":23132,"status":1091,"phases":23133,"primaryCompletion":23134,"completion":23134,"start":23135,"enrollment":161,"conditions":23136,"interventions":23139},"NCT04651127","Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer",[92,93],"2023-01-26","2020-11-09",[700,23137,23138],"Cervix Cancer","Cervix Neoplasm",[23122],{"trials":23141,"activeCount":104},[],{"trials":23143,"activeCount":104},[],{"trials":23145,"activeCount":104},[],{"intervention":23147,"totalTrials":100,"cells":23148},"chidamide and toripalimab",{"EARLY_PHASE1":23149,"PHASE1":23151,"PHASE2":23153,"PHASE3":23162,"PHASE4":23164,"NA":23166},{"trials":23150,"activeCount":104},[],{"trials":23152,"activeCount":104},[],{"trials":23154,"activeCount":104},[23155],{"nctId":23156,"briefTitle":23157,"status":174,"phases":23158,"primaryCompletion":290,"completion":1238,"start":23159,"enrollment":2001,"conditions":23160,"interventions":23161},"NCT04025931","Chidamide Combined With Toripalimab in Sarcoma",[93],"2020-01-19",[7724],[23147],{"trials":23163,"activeCount":104},[],{"trials":23165,"activeCount":104},[],{"trials":23167,"activeCount":104},[],{"intervention":23169,"totalTrials":100,"cells":23170},"Endostatins",{"EARLY_PHASE1":23171,"PHASE1":23173,"PHASE2":23175,"PHASE3":23183,"PHASE4":23185,"NA":23187},{"trials":23172,"activeCount":104},[],{"trials":23174,"activeCount":104},[],{"trials":23176,"activeCount":104},[23177],{"nctId":23178,"briefTitle":23179,"status":174,"phases":23180,"primaryCompletion":428,"completion":1575,"start":638,"enrollment":3272,"conditions":23181,"interventions":23182},"NCT02636231","Endostar for Locally Recurrent Nasopharyngeal Carcinoma",[93],[16],[23169],{"trials":23184,"activeCount":104},[],{"trials":23186,"activeCount":104},[],{"trials":23188,"activeCount":104},[],{"intervention":2728,"totalTrials":100,"cells":23190},{"EARLY_PHASE1":23191,"PHASE1":23193,"PHASE2":23195,"PHASE3":23201,"PHASE4":23203,"NA":23205},{"trials":23192,"activeCount":104},[],{"trials":23194,"activeCount":104},[],{"trials":23196,"activeCount":104},[23197],{"nctId":2721,"briefTitle":2722,"status":174,"phases":23198,"primaryCompletion":2724,"completion":2724,"start":1247,"enrollment":2725,"conditions":23199,"interventions":23200},[93],[16],[2402,2728],{"trials":23202,"activeCount":104},[],{"trials":23204,"activeCount":104},[],{"trials":23206,"activeCount":104},[],{"intervention":23208,"totalTrials":100,"cells":23209},"Probiotic",{"EARLY_PHASE1":23210,"PHASE1":23212,"PHASE2":23214,"PHASE3":23224,"PHASE4":23226,"NA":23228},{"trials":23211,"activeCount":104},[],{"trials":23213,"activeCount":104},[],{"trials":23215,"activeCount":104},[23216],{"nctId":23217,"briefTitle":23218,"status":174,"phases":23219,"primaryCompletion":20759,"completion":2599,"start":23220,"enrollment":996,"conditions":23221,"interventions":23223},"NCT03521297","Probiotics in PBC Patients of Poor Response to UDCA",[93],"2020-01-20",[23222],"Primary Biliary Cholangitis (PBC)",[23208],{"trials":23225,"activeCount":104},[],{"trials":23227,"activeCount":104},[],{"trials":23229,"activeCount":104},[],{"intervention":23231,"totalTrials":100,"cells":23232},"Tisleizumab",{"EARLY_PHASE1":23233,"PHASE1":23235,"PHASE2":23237,"PHASE3":23246,"PHASE4":23248,"NA":23250},{"trials":23234,"activeCount":104},[],{"trials":23236,"activeCount":104},[],{"trials":23238,"activeCount":104},[23239],{"nctId":23240,"briefTitle":23241,"status":174,"phases":23242,"primaryCompletion":3281,"completion":379,"start":22898,"enrollment":492,"conditions":23243,"interventions":23245},"NCT06262581","Neoadjuvant Tisleizumab(BGB-A317) for dMMR\u002FMSI-H Non-late Stage CRC Patients Before Surgery",[93],[1414,23244,318],"Anti PD-1",[23231],{"trials":23247,"activeCount":104},[],{"trials":23249,"activeCount":104},[],{"trials":23251,"activeCount":104},[],{"intervention":23253,"totalTrials":100,"cells":23254},"Fulvestrant plus Anlotinib",{"EARLY_PHASE1":23255,"PHASE1":23257,"PHASE2":23259,"PHASE3":23267,"PHASE4":23269,"NA":23271},{"trials":23256,"activeCount":104},[],{"trials":23258,"activeCount":104},[],{"trials":23260,"activeCount":104},[23261],{"nctId":23262,"briefTitle":23263,"status":174,"phases":23264,"primaryCompletion":3177,"completion":895,"start":1270,"enrollment":226,"conditions":23265,"interventions":23266},"NCT04936295","Fulvestrant Plus Anlotinib in HR(+)\u002FHER2(-) Metastatic Breast Cancer With FGFR Mutation",[93],[28],[23253],{"trials":23268,"activeCount":104},[],{"trials":23270,"activeCount":104},[],{"trials":23272,"activeCount":104},[],{"intervention":23274,"totalTrials":100,"cells":23275},"Docetaxel and Cisplatin and Nimotuzumab",{"EARLY_PHASE1":23276,"PHASE1":23278,"PHASE2":23280,"PHASE3":23290,"PHASE4":23292,"NA":23294},{"trials":23277,"activeCount":104},[],{"trials":23279,"activeCount":104},[],{"trials":23281,"activeCount":104},[23282],{"nctId":23283,"briefTitle":23284,"status":174,"phases":23285,"primaryCompletion":23286,"completion":1347,"start":23287,"enrollment":1727,"conditions":23288,"interventions":23289},"NCT03708822","Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma",[93],"2022-07-20","2018-10-15",[16],[23274],{"trials":23291,"activeCount":104},[],{"trials":23293,"activeCount":104},[],{"trials":23295,"activeCount":104},[],{"intervention":23297,"totalTrials":100,"cells":23298},"GC chemotherapy plus CIK cells",{"EARLY_PHASE1":23299,"PHASE1":23301,"PHASE2":23303,"PHASE3":23312,"PHASE4":23314,"NA":23316},{"trials":23300,"activeCount":104},[],{"trials":23302,"activeCount":104},[],{"trials":23304,"activeCount":104},[23305],{"nctId":23306,"briefTitle":23307,"status":174,"phases":23308,"primaryCompletion":14788,"completion":4810,"start":4045,"enrollment":492,"conditions":23309,"interventions":23310},"NCT01655628","GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma",[93],[20716],[23297,23311],"GC chemotherapy",{"trials":23313,"activeCount":104},[],{"trials":23315,"activeCount":104},[],{"trials":23317,"activeCount":104},[],{"intervention":23311,"totalTrials":100,"cells":23319},{"EARLY_PHASE1":23320,"PHASE1":23322,"PHASE2":23324,"PHASE3":23330,"PHASE4":23332,"NA":23334},{"trials":23321,"activeCount":104},[],{"trials":23323,"activeCount":104},[],{"trials":23325,"activeCount":104},[23326],{"nctId":23306,"briefTitle":23307,"status":174,"phases":23327,"primaryCompletion":14788,"completion":4810,"start":4045,"enrollment":492,"conditions":23328,"interventions":23329},[93],[20716],[23297,23311],{"trials":23331,"activeCount":104},[],{"trials":23333,"activeCount":104},[],{"trials":23335,"activeCount":104},[],{"intervention":23337,"totalTrials":100,"cells":23338},"steroid & Cyclosporin",{"EARLY_PHASE1":23339,"PHASE1":23341,"PHASE2":23343,"PHASE3":23355,"PHASE4":23357,"NA":23359},{"trials":23340,"activeCount":104},[],{"trials":23342,"activeCount":104},[],{"trials":23344,"activeCount":104},[23345],{"nctId":23346,"briefTitle":23347,"status":174,"phases":23348,"primaryCompletion":459,"completion":459,"start":1428,"enrollment":2459,"conditions":23349,"interventions":23354},"NCT02173106","A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy",[93],[23350,23351,23352,9004,23353],"Idiopathic Membranous Nephropathy","Proteinuria","Spontaneous Remission","Cyclosporin Overdose",[23337],{"trials":23356,"activeCount":104},[],{"trials":23358,"activeCount":104},[],{"trials":23360,"activeCount":104},[],{"intervention":23362,"totalTrials":100,"cells":23363},"Fosaprepitant,ondansetron, dexamethasone",{"EARLY_PHASE1":23364,"PHASE1":23366,"PHASE2":23368,"PHASE3":23377,"PHASE4":23379,"NA":23381},{"trials":23365,"activeCount":104},[],{"trials":23367,"activeCount":104},[],{"trials":23369,"activeCount":104},[23370],{"nctId":23371,"briefTitle":23372,"status":328,"phases":23373,"primaryCompletion":23374,"completion":23374,"start":1964,"enrollment":1450,"conditions":23375,"interventions":23376},"NCT04508400","Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients",[93],"2023-06-22",[1617],[23362],{"trials":23378,"activeCount":104},[],{"trials":23380,"activeCount":104},[],{"trials":23382,"activeCount":104},[],{"intervention":23384,"totalTrials":100,"cells":23385},"Regorafenib and Toripalimab Combination",{"EARLY_PHASE1":23386,"PHASE1":23388,"PHASE2":23390,"PHASE3":23400,"PHASE4":23402,"NA":23404},{"trials":23387,"activeCount":104},[],{"trials":23389,"activeCount":104},[],{"trials":23391,"activeCount":104},[23392],{"nctId":23393,"briefTitle":23394,"status":174,"phases":23395,"primaryCompletion":23396,"completion":1347,"start":23397,"enrollment":1712,"conditions":23398,"interventions":23399},"NCT05485909","Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM",[93],"2023-07-30","2022-07-25",[5620],[23384],{"trials":23401,"activeCount":104},[],{"trials":23403,"activeCount":104},[],{"trials":23405,"activeCount":104},[],{"intervention":23407,"totalTrials":100,"cells":23408},"Cisplatin combine with IMRT",{"EARLY_PHASE1":23409,"PHASE1":23411,"PHASE2":23413,"PHASE3":23422,"PHASE4":23424,"NA":23426},{"trials":23410,"activeCount":104},[],{"trials":23412,"activeCount":104},[],{"trials":23414,"activeCount":104},[23415],{"nctId":23416,"briefTitle":23417,"status":174,"phases":23418,"primaryCompletion":23419,"completion":2771,"start":178,"enrollment":800,"conditions":23420,"interventions":23421},"NCT02871518","Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma",[93],"2018-07",[16],[23407,23407],{"trials":23423,"activeCount":104},[],{"trials":23425,"activeCount":104},[],{"trials":23427,"activeCount":104},[],{"intervention":23429,"totalTrials":100,"cells":23430},"pembrolizumab or nivolumab or JS001",{"EARLY_PHASE1":23431,"PHASE1":23433,"PHASE2":23435,"PHASE3":23444,"PHASE4":23446,"NA":23448},{"trials":23432,"activeCount":104},[],{"trials":23434,"activeCount":104},[],{"trials":23436,"activeCount":104},[23437],{"nctId":23438,"briefTitle":23439,"status":328,"phases":23440,"primaryCompletion":23441,"completion":23441,"start":3003,"enrollment":205,"conditions":23442,"interventions":23443},"NCT03939975","Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC",[93],"2019-07-31",[1888],[23429],{"trials":23445,"activeCount":104},[],{"trials":23447,"activeCount":104},[],{"trials":23449,"activeCount":104},[],{"intervention":23451,"totalTrials":100,"cells":23452},"Pemetrexed disodium",{"EARLY_PHASE1":23453,"PHASE1":23455,"PHASE2":23457,"PHASE3":23465,"PHASE4":23467,"NA":23469},{"trials":23454,"activeCount":104},[],{"trials":23456,"activeCount":104},[],{"trials":23458,"activeCount":104},[23459],{"nctId":23460,"briefTitle":23461,"status":328,"phases":23462,"primaryCompletion":1427,"completion":1428,"start":7637,"enrollment":1018,"conditions":23463,"interventions":23464},"NCT01953419","Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy",[93],[539],[23451],{"trials":23466,"activeCount":104},[],{"trials":23468,"activeCount":104},[],{"trials":23470,"activeCount":104},[],{"intervention":23472,"totalTrials":100,"cells":23473},"Durvalumab",{"EARLY_PHASE1":23474,"PHASE1":23476,"PHASE2":23478,"PHASE3":23488,"PHASE4":23490,"NA":23492},{"trials":23475,"activeCount":104},[],{"trials":23477,"activeCount":104},[],{"trials":23479,"activeCount":104},[23480],{"nctId":23481,"briefTitle":23482,"status":328,"phases":23483,"primaryCompletion":23484,"completion":23484,"start":23485,"enrollment":32,"conditions":23486,"interventions":23487},"NCT04945720","Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma",[93],"2024-07-05","2022-04-11",[19],[23472],{"trials":23489,"activeCount":104},[],{"trials":23491,"activeCount":104},[],{"trials":23493,"activeCount":104},[],{"intervention":23495,"totalTrials":100,"cells":23496},"DCX",{"EARLY_PHASE1":23497,"PHASE1":23499,"PHASE2":23501,"PHASE3":23510,"PHASE4":23512,"NA":23514},{"trials":23498,"activeCount":104},[],{"trials":23500,"activeCount":104},[],{"trials":23502,"activeCount":104},[23503],{"nctId":23504,"briefTitle":23505,"status":174,"phases":23506,"primaryCompletion":5181,"start":4297,"enrollment":942,"conditions":23507,"interventions":23509},"NCT02915965","A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma",[93],[23508],"Stage II and III Esophageal Squamous Cell Carcinoma",[23495],{"trials":23511,"activeCount":104},[],{"trials":23513,"activeCount":104},[],{"trials":23515,"activeCount":104},[],{"intervention":23517,"totalTrials":100,"cells":23518},"Erlotinib 100mg qd",{"EARLY_PHASE1":23519,"PHASE1":23521,"PHASE2":23523,"PHASE3":23534,"PHASE4":23536,"NA":23538},{"trials":23520,"activeCount":104},[],{"trials":23522,"activeCount":104},[],{"trials":23524,"activeCount":104},[23525],{"nctId":23526,"briefTitle":23527,"status":174,"phases":23528,"primaryCompletion":1374,"start":3291,"enrollment":23529,"conditions":23530,"interventions":23532},"NCT01955421","Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc",[93],224,[23531],"Advanced Stage Non Small Cell Lung Cancer",[23517,23533],"Gefitinib 250mg qd",{"trials":23535,"activeCount":104},[],{"trials":23537,"activeCount":104},[],{"trials":23539,"activeCount":104},[],{"intervention":23533,"totalTrials":100,"cells":23541},{"EARLY_PHASE1":23542,"PHASE1":23544,"PHASE2":23546,"PHASE3":23552,"PHASE4":23554,"NA":23556},{"trials":23543,"activeCount":104},[],{"trials":23545,"activeCount":104},[],{"trials":23547,"activeCount":104},[23548],{"nctId":23526,"briefTitle":23527,"status":174,"phases":23549,"primaryCompletion":1374,"start":3291,"enrollment":23529,"conditions":23550,"interventions":23551},[93],[23531],[23517,23533],{"trials":23553,"activeCount":104},[],{"trials":23555,"activeCount":104},[],{"trials":23557,"activeCount":104},[],{"intervention":23559,"totalTrials":100,"cells":23560},"Camrelizumab and Apatinib Plus GP",{"EARLY_PHASE1":23561,"PHASE1":23563,"PHASE2":23565,"PHASE3":23575,"PHASE4":23577,"NA":23579},{"trials":23562,"activeCount":104},[],{"trials":23564,"activeCount":104},[],{"trials":23566,"activeCount":104},[23567],{"nctId":23568,"briefTitle":23569,"status":174,"phases":23570,"primaryCompletion":290,"completion":1238,"start":6504,"enrollment":1727,"conditions":23571,"interventions":23574},"NCT05742750","A Phase Ib\u002FII Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer",[92,93],[23572,23573],"Locally Advanced Biliary Tract Cancer","Metastatic Biliary Tract Cancer",[23559],{"trials":23576,"activeCount":104},[],{"trials":23578,"activeCount":104},[],{"trials":23580,"activeCount":104},[],{"intervention":433,"totalTrials":100,"cells":23582},{"EARLY_PHASE1":23583,"PHASE1":23585,"PHASE2":23587,"PHASE3":23593,"PHASE4":23595,"NA":23597},{"trials":23584,"activeCount":104},[],{"trials":23586,"activeCount":104},[],{"trials":23588,"activeCount":104},[23589],{"nctId":424,"briefTitle":425,"status":174,"phases":23590,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":23591,"interventions":23592},[93],[16],[433,225],{"trials":23594,"activeCount":104},[],{"trials":23596,"activeCount":104},[],{"trials":23598,"activeCount":104},[],{"intervention":23600,"totalTrials":100,"cells":23601},"Pamiparib\u002FTamoxifen",{"EARLY_PHASE1":23602,"PHASE1":23604,"PHASE2":23606,"PHASE3":23614,"PHASE4":23616,"NA":23618},{"trials":23603,"activeCount":104},[],{"trials":23605,"activeCount":104},[],{"trials":23607,"activeCount":104},[23608],{"nctId":23609,"briefTitle":23610,"status":174,"phases":23611,"primaryCompletion":860,"completion":1459,"start":2761,"enrollment":461,"conditions":23612,"interventions":23613},"NCT05669768","Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy",[93],[2042],[23600],{"trials":23615,"activeCount":104},[],{"trials":23617,"activeCount":104},[],{"trials":23619,"activeCount":104},[],{"intervention":23621,"totalTrials":100,"cells":23622},"Surufatinib,Etoposide,Cisplatin,Toripalimab",{"EARLY_PHASE1":23623,"PHASE1":23625,"PHASE2":23627,"PHASE3":23638,"PHASE4":23640,"NA":23642},{"trials":23624,"activeCount":104},[],{"trials":23626,"activeCount":104},[],{"trials":23628,"activeCount":104},[23629],{"nctId":23630,"briefTitle":23631,"status":174,"phases":23632,"primaryCompletion":721,"completion":1064,"start":23633,"enrollment":9272,"conditions":23634,"interventions":23636},"NCT04996771","Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer",[92,93],"2021-11-09",[23635],"Small Cell Lung Carcinoma",[23621,23637],"Surufatinib,Etoposide,Cisplatin",{"trials":23639,"activeCount":104},[],{"trials":23641,"activeCount":104},[],{"trials":23643,"activeCount":104},[],{"intervention":23637,"totalTrials":100,"cells":23645},{"EARLY_PHASE1":23646,"PHASE1":23648,"PHASE2":23650,"PHASE3":23656,"PHASE4":23658,"NA":23660},{"trials":23647,"activeCount":104},[],{"trials":23649,"activeCount":104},[],{"trials":23651,"activeCount":104},[23652],{"nctId":23630,"briefTitle":23631,"status":174,"phases":23653,"primaryCompletion":721,"completion":1064,"start":23633,"enrollment":9272,"conditions":23654,"interventions":23655},[92,93],[23635],[23621,23637],{"trials":23657,"activeCount":104},[],{"trials":23659,"activeCount":104},[],{"trials":23661,"activeCount":104},[],{"intervention":8799,"totalTrials":100,"cells":23663},{"EARLY_PHASE1":23664,"PHASE1":23666,"PHASE2":23668,"PHASE3":23674,"PHASE4":23676,"NA":23678},{"trials":23665,"activeCount":104},[],{"trials":23667,"activeCount":104},[],{"trials":23669,"activeCount":104},[23670],{"nctId":8792,"briefTitle":8793,"status":174,"phases":23671,"primaryCompletion":798,"completion":798,"start":957,"enrollment":3050,"conditions":23672,"interventions":23673},[93],[8796,8797],[3054,8799],{"trials":23675,"activeCount":104},[],{"trials":23677,"activeCount":104},[],{"trials":23679,"activeCount":104},[],{"intervention":23681,"totalTrials":100,"cells":23682},"Anti-HER2 ADC",{"EARLY_PHASE1":23683,"PHASE1":23685,"PHASE2":23687,"PHASE3":23697,"PHASE4":23699,"NA":23701},{"trials":23684,"activeCount":104},[],{"trials":23686,"activeCount":104},[],{"trials":23688,"activeCount":104},[23689],{"nctId":23690,"briefTitle":23691,"status":174,"phases":23692,"primaryCompletion":23693,"completion":3015,"start":23694,"enrollment":333,"conditions":23695,"interventions":23696},"NCT05578287","RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer",[93],"2024-12-15","2023-07-18",[25],[23681],{"trials":23698,"activeCount":104},[],{"trials":23700,"activeCount":104},[],{"trials":23702,"activeCount":104},[],{"intervention":23704,"totalTrials":100,"cells":23705},"Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab",{"EARLY_PHASE1":23706,"PHASE1":23708,"PHASE2":23710,"PHASE3":23721,"PHASE4":23723,"NA":23725},{"trials":23707,"activeCount":104},[],{"trials":23709,"activeCount":104},[],{"trials":23711,"activeCount":104},[23712],{"nctId":23713,"briefTitle":23714,"status":174,"phases":23715,"primaryCompletion":2761,"completion":3177,"start":23716,"enrollment":32,"conditions":23717,"interventions":23720},"NCT05214339","A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)",[93],"2022-03-16",[23718,23719],"Unresectable Hepatocellular Carcinoma","Hepatocellular Carcinoma by BCLC Stage",[23704],{"trials":23722,"activeCount":104},[],{"trials":23724,"activeCount":104},[],{"trials":23726,"activeCount":104},[],{"intervention":23728,"totalTrials":100,"cells":23729},"Bevacizumab Biosimilar QL 1101",{"EARLY_PHASE1":23730,"PHASE1":23732,"PHASE2":23734,"PHASE3":23742,"PHASE4":23744,"NA":23746},{"trials":23731,"activeCount":104},[],{"trials":23733,"activeCount":104},[],{"trials":23735,"activeCount":104},[23736],{"nctId":23737,"briefTitle":23738,"status":174,"phases":23739,"primaryCompletion":14352,"completion":2788,"start":3177,"enrollment":1109,"conditions":23740,"interventions":23741},"NCT05883176","TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria",[93],[23719],[23728],{"trials":23743,"activeCount":104},[],{"trials":23745,"activeCount":104},[],{"trials":23747,"activeCount":104},[],{"intervention":23749,"totalTrials":100,"cells":23750},"Osimertinib Mesylate",{"EARLY_PHASE1":23751,"PHASE1":23753,"PHASE2":23755,"PHASE3":23763,"PHASE4":23765,"NA":23767},{"trials":23752,"activeCount":104},[],{"trials":23754,"activeCount":104},[],{"trials":23756,"activeCount":104},[23757],{"nctId":23758,"briefTitle":23759,"status":174,"phases":23760,"primaryCompletion":658,"completion":658,"start":4360,"enrollment":1339,"conditions":23761,"interventions":23762},"NCT03460275","Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer",[93],[22],[23749],{"trials":23764,"activeCount":104},[],{"trials":23766,"activeCount":104},[],{"trials":23768,"activeCount":104},[],{"intervention":23770,"totalTrials":100,"cells":23771},"Concurrent chemotherapy twice a week",{"EARLY_PHASE1":23772,"PHASE1":23774,"PHASE2":23776,"PHASE3":23786,"PHASE4":23788,"NA":23790},{"trials":23773,"activeCount":104},[],{"trials":23775,"activeCount":104},[],{"trials":23777,"activeCount":104},[23778],{"nctId":23779,"briefTitle":23780,"status":174,"phases":23781,"primaryCompletion":23782,"completion":1093,"start":1094,"enrollment":734,"conditions":23783,"interventions":23784},"NCT04524299","Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC",[93],"2022-05-31",[22],[23770,23785],"Concurrent chemotherapy once a week",{"trials":23787,"activeCount":104},[],{"trials":23789,"activeCount":104},[],{"trials":23791,"activeCount":104},[],{"intervention":23785,"totalTrials":100,"cells":23793},{"EARLY_PHASE1":23794,"PHASE1":23796,"PHASE2":23798,"PHASE3":23804,"PHASE4":23806,"NA":23808},{"trials":23795,"activeCount":104},[],{"trials":23797,"activeCount":104},[],{"trials":23799,"activeCount":104},[23800],{"nctId":23779,"briefTitle":23780,"status":174,"phases":23801,"primaryCompletion":23782,"completion":1093,"start":1094,"enrollment":734,"conditions":23802,"interventions":23803},[93],[22],[23770,23785],{"trials":23805,"activeCount":104},[],{"trials":23807,"activeCount":104},[],{"trials":23809,"activeCount":104},[],{"intervention":23811,"totalTrials":100,"cells":23812},"TAI combine SBRT",{"EARLY_PHASE1":23813,"PHASE1":23815,"PHASE2":23817,"PHASE3":23826,"PHASE4":23828,"NA":23830},{"trials":23814,"activeCount":104},[],{"trials":23816,"activeCount":104},[],{"trials":23818,"activeCount":104},[23819],{"nctId":23820,"briefTitle":23821,"status":174,"phases":23822,"primaryCompletion":4267,"completion":23823,"start":535,"enrollment":1350,"conditions":23824,"interventions":23825},"NCT03851887","The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)",[93],"2022-01-31",[19],[23811],{"trials":23827,"activeCount":104},[],{"trials":23829,"activeCount":104},[],{"trials":23831,"activeCount":104},[],{"intervention":23833,"totalTrials":100,"cells":23834},"R2-CHOP",{"EARLY_PHASE1":23835,"PHASE1":23837,"PHASE2":23839,"PHASE3":23848,"PHASE4":23850,"NA":23852},{"trials":23836,"activeCount":104},[],{"trials":23838,"activeCount":104},[],{"trials":23840,"activeCount":104},[23841],{"nctId":23842,"briefTitle":23843,"status":174,"phases":23844,"primaryCompletion":290,"completion":290,"start":23845,"enrollment":942,"conditions":23846,"interventions":23847},"NCT04842487","R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study",[93],"2021-04-10",[3150],[23833],{"trials":23849,"activeCount":104},[],{"trials":23851,"activeCount":104},[],{"trials":23853,"activeCount":104},[],{"intervention":23855,"totalTrials":100,"cells":23856},"etoposide and cisplatin",{"EARLY_PHASE1":23857,"PHASE1":23859,"PHASE2":23861,"PHASE3":23870,"PHASE4":23872,"NA":23874},{"trials":23858,"activeCount":104},[],{"trials":23860,"activeCount":104},[],{"trials":23862,"activeCount":104},[23863],{"nctId":23864,"briefTitle":23865,"status":174,"phases":23866,"primaryCompletion":7533,"completion":1575,"start":819,"enrollment":3508,"conditions":23867,"interventions":23869},"NCT02337712","Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer",[93],[23868],"Small Cell Lung Cancer",[23855],{"trials":23871,"activeCount":104},[],{"trials":23873,"activeCount":104},[],{"trials":23875,"activeCount":104},[],{"intervention":23877,"totalTrials":100,"cells":23878},"inetetamab",{"EARLY_PHASE1":23879,"PHASE1":23881,"PHASE2":23883,"PHASE3":23893,"PHASE4":23895,"NA":23897},{"trials":23880,"activeCount":104},[],{"trials":23882,"activeCount":104},[],{"trials":23884,"activeCount":104},[23885],{"nctId":23886,"briefTitle":23887,"status":174,"phases":23888,"primaryCompletion":733,"completion":2662,"start":23889,"enrollment":1727,"conditions":23890,"interventions":23891},"NCT05016544","Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer",[92,93],"2021-07-28",[22],[23877,23892],"Pytotinib",{"trials":23894,"activeCount":104},[],{"trials":23896,"activeCount":104},[],{"trials":23898,"activeCount":104},[],{"intervention":23892,"totalTrials":100,"cells":23900},{"EARLY_PHASE1":23901,"PHASE1":23903,"PHASE2":23905,"PHASE3":23911,"PHASE4":23913,"NA":23915},{"trials":23902,"activeCount":104},[],{"trials":23904,"activeCount":104},[],{"trials":23906,"activeCount":104},[23907],{"nctId":23886,"briefTitle":23887,"status":174,"phases":23908,"primaryCompletion":733,"completion":2662,"start":23889,"enrollment":1727,"conditions":23909,"interventions":23910},[92,93],[22],[23877,23892],{"trials":23912,"activeCount":104},[],{"trials":23914,"activeCount":104},[],{"trials":23916,"activeCount":104},[],{"intervention":23918,"totalTrials":100,"cells":23919},"Pyrotinib combine with SHR6390",{"EARLY_PHASE1":23920,"PHASE1":23922,"PHASE2":23924,"PHASE3":23933,"PHASE4":23935,"NA":23937},{"trials":23921,"activeCount":104},[],{"trials":23923,"activeCount":104},[],{"trials":23925,"activeCount":104},[23926],{"nctId":23927,"briefTitle":23928,"status":174,"phases":23929,"primaryCompletion":23930,"completion":1679,"start":5385,"enrollment":239,"conditions":23931,"interventions":23932},"NCT03993964","Study to Evaluate the Efficacy and Safety of CDK4\u002F6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer",[93],"2020-10-30",[241],[23918],{"trials":23934,"activeCount":104},[],{"trials":23936,"activeCount":104},[],{"trials":23938,"activeCount":104},[],{"intervention":9447,"totalTrials":100,"cells":23940},{"EARLY_PHASE1":23941,"PHASE1":23943,"PHASE2":23945,"PHASE3":23951,"PHASE4":23953,"NA":23955},{"trials":23942,"activeCount":104},[],{"trials":23944,"activeCount":104},[],{"trials":23946,"activeCount":104},[23947],{"nctId":9440,"briefTitle":9441,"status":174,"phases":23948,"primaryCompletion":9443,"completion":9443,"start":429,"enrollment":205,"conditions":23949,"interventions":23950},[93],[9445],[9447,9448,9449,9421,9450,9451,9452],{"trials":23952,"activeCount":104},[],{"trials":23954,"activeCount":104},[],{"trials":23956,"activeCount":104},[],{"intervention":9448,"totalTrials":100,"cells":23958},{"EARLY_PHASE1":23959,"PHASE1":23961,"PHASE2":23963,"PHASE3":23969,"PHASE4":23971,"NA":23973},{"trials":23960,"activeCount":104},[],{"trials":23962,"activeCount":104},[],{"trials":23964,"activeCount":104},[23965],{"nctId":9440,"briefTitle":9441,"status":174,"phases":23966,"primaryCompletion":9443,"completion":9443,"start":429,"enrollment":205,"conditions":23967,"interventions":23968},[93],[9445],[9447,9448,9449,9421,9450,9451,9452],{"trials":23970,"activeCount":104},[],{"trials":23972,"activeCount":104},[],{"trials":23974,"activeCount":104},[],{"intervention":9449,"totalTrials":100,"cells":23976},{"EARLY_PHASE1":23977,"PHASE1":23979,"PHASE2":23981,"PHASE3":23987,"PHASE4":23989,"NA":23991},{"trials":23978,"activeCount":104},[],{"trials":23980,"activeCount":104},[],{"trials":23982,"activeCount":104},[23983],{"nctId":9440,"briefTitle":9441,"status":174,"phases":23984,"primaryCompletion":9443,"completion":9443,"start":429,"enrollment":205,"conditions":23985,"interventions":23986},[93],[9445],[9447,9448,9449,9421,9450,9451,9452],{"trials":23988,"activeCount":104},[],{"trials":23990,"activeCount":104},[],{"trials":23992,"activeCount":104},[],{"intervention":9450,"totalTrials":100,"cells":23994},{"EARLY_PHASE1":23995,"PHASE1":23997,"PHASE2":23999,"PHASE3":24005,"PHASE4":24007,"NA":24009},{"trials":23996,"activeCount":104},[],{"trials":23998,"activeCount":104},[],{"trials":24000,"activeCount":104},[24001],{"nctId":9440,"briefTitle":9441,"status":174,"phases":24002,"primaryCompletion":9443,"completion":9443,"start":429,"enrollment":205,"conditions":24003,"interventions":24004},[93],[9445],[9447,9448,9449,9421,9450,9451,9452],{"trials":24006,"activeCount":104},[],{"trials":24008,"activeCount":104},[],{"trials":24010,"activeCount":104},[],{"intervention":9451,"totalTrials":100,"cells":24012},{"EARLY_PHASE1":24013,"PHASE1":24015,"PHASE2":24017,"PHASE3":24023,"PHASE4":24025,"NA":24027},{"trials":24014,"activeCount":104},[],{"trials":24016,"activeCount":104},[],{"trials":24018,"activeCount":104},[24019],{"nctId":9440,"briefTitle":9441,"status":174,"phases":24020,"primaryCompletion":9443,"completion":9443,"start":429,"enrollment":205,"conditions":24021,"interventions":24022},[93],[9445],[9447,9448,9449,9421,9450,9451,9452],{"trials":24024,"activeCount":104},[],{"trials":24026,"activeCount":104},[],{"trials":24028,"activeCount":104},[],{"intervention":9452,"totalTrials":100,"cells":24030},{"EARLY_PHASE1":24031,"PHASE1":24033,"PHASE2":24035,"PHASE3":24041,"PHASE4":24043,"NA":24045},{"trials":24032,"activeCount":104},[],{"trials":24034,"activeCount":104},[],{"trials":24036,"activeCount":104},[24037],{"nctId":9440,"briefTitle":9441,"status":174,"phases":24038,"primaryCompletion":9443,"completion":9443,"start":429,"enrollment":205,"conditions":24039,"interventions":24040},[93],[9445],[9447,9448,9449,9421,9450,9451,9452],{"trials":24042,"activeCount":104},[],{"trials":24044,"activeCount":104},[],{"trials":24046,"activeCount":104},[],{"intervention":24048,"totalTrials":100,"cells":24049},"Apatinib Mesylate, doxorubicin, ifosfamide",{"EARLY_PHASE1":24050,"PHASE1":24052,"PHASE2":24054,"PHASE3":24063,"PHASE4":24065,"NA":24067},{"trials":24051,"activeCount":104},[],{"trials":24053,"activeCount":104},[],{"trials":24055,"activeCount":104},[24056],{"nctId":24057,"briefTitle":24058,"status":174,"phases":24059,"primaryCompletion":63,"completion":721,"start":24060,"enrollment":1450,"conditions":24061,"interventions":24062},"NCT04012827","Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma",[93],"2019-08-20",[4686],[24048],{"trials":24064,"activeCount":104},[],{"trials":24066,"activeCount":104},[],{"trials":24068,"activeCount":104},[],{"intervention":2251,"totalTrials":100,"cells":24070},{"EARLY_PHASE1":24071,"PHASE1":24073,"PHASE2":24075,"PHASE3":24081,"PHASE4":24083,"NA":24085},{"trials":24072,"activeCount":104},[],{"trials":24074,"activeCount":104},[],{"trials":24076,"activeCount":104},[24077],{"nctId":2245,"briefTitle":2246,"status":174,"phases":24078,"primaryCompletion":618,"completion":906,"start":2165,"enrollment":32,"conditions":24079,"interventions":24080},[93],[2249],[2251,49,542,1205,183],{"trials":24082,"activeCount":104},[],{"trials":24084,"activeCount":104},[],{"trials":24086,"activeCount":104},[],{"intervention":5357,"totalTrials":100,"cells":24088},{"EARLY_PHASE1":24089,"PHASE1":24091,"PHASE2":24093,"PHASE3":24099,"PHASE4":24101,"NA":24103},{"trials":24090,"activeCount":104},[],{"trials":24092,"activeCount":104},[],{"trials":24094,"activeCount":104},[24095],{"nctId":5349,"briefTitle":5350,"status":328,"phases":24096,"primaryCompletion":5352,"completion":3759,"start":1429,"enrollment":5353,"conditions":24097,"interventions":24098},[93],[5355],[5357,834],{"trials":24100,"activeCount":104},[],{"trials":24102,"activeCount":104},[],{"trials":24104,"activeCount":104},[],{"intervention":24106,"totalTrials":100,"cells":24107},"Chidamide, Rituximab, Gemcitabine,Oxaliplatin",{"EARLY_PHASE1":24108,"PHASE1":24110,"PHASE2":24112,"PHASE3":24123,"PHASE4":24125,"NA":24127},{"trials":24109,"activeCount":104},[],{"trials":24111,"activeCount":104},[],{"trials":24113,"activeCount":104},[24114],{"nctId":24115,"briefTitle":24116,"status":328,"phases":24117,"primaryCompletion":24118,"completion":24119,"start":24120,"enrollment":3705,"conditions":24121,"interventions":24122},"NCT04022005","Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed\u002FRefractory DLBCL",[93],"2022-11-16","2023-03-11","2019-06-19",[20417],[24106],{"trials":24124,"activeCount":104},[],{"trials":24126,"activeCount":104},[],{"trials":24128,"activeCount":104},[],{"intervention":5314,"totalTrials":100,"cells":24130},{"EARLY_PHASE1":24131,"PHASE1":24133,"PHASE2":24135,"PHASE3":24141,"PHASE4":24143,"NA":24145},{"trials":24132,"activeCount":104},[],{"trials":24134,"activeCount":104},[],{"trials":24136,"activeCount":104},[24137],{"nctId":5308,"briefTitle":5309,"status":328,"phases":24138,"primaryCompletion":1247,"completion":670,"start":5311,"enrollment":4430,"conditions":24139,"interventions":24140},[93],[1368],[5314,5273],{"trials":24142,"activeCount":104},[],{"trials":24144,"activeCount":104},[],{"trials":24146,"activeCount":104},[],{"intervention":24148,"totalTrials":100,"cells":24149},"Combined anti-PD-1 and R-CHOP",{"EARLY_PHASE1":24150,"PHASE1":24152,"PHASE2":24154,"PHASE3":24163,"PHASE4":24165,"NA":24167},{"trials":24151,"activeCount":104},[],{"trials":24153,"activeCount":104},[],{"trials":24155,"activeCount":104},[24156],{"nctId":24157,"briefTitle":24158,"status":174,"phases":24159,"primaryCompletion":1508,"completion":1508,"start":1907,"enrollment":1712,"conditions":24160,"interventions":24162},"NCT06412068","A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment",[93],[24161],"Primary Mediastinal Large B Cell Lymphoma",[24148],{"trials":24164,"activeCount":104},[],{"trials":24166,"activeCount":104},[],{"trials":24168,"activeCount":104},[],{"intervention":24170,"totalTrials":100,"cells":24171},"Moderately hypofractionated conformal radiation combined With S-1",{"EARLY_PHASE1":24172,"PHASE1":24174,"PHASE2":24176,"PHASE3":24186,"PHASE4":24188,"NA":24190},{"trials":24173,"activeCount":104},[],{"trials":24175,"activeCount":104},[],{"trials":24177,"activeCount":104},[24178],{"nctId":24179,"briefTitle":24180,"status":328,"phases":24181,"primaryCompletion":24182,"completion":24182,"start":24183,"enrollment":3414,"conditions":24184,"interventions":24185},"NCT03660449","Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma",[93],"2022-07-30","2017-10-01",[463],[24170],{"trials":24187,"activeCount":104},[],{"trials":24189,"activeCount":104},[],{"trials":24191,"activeCount":104},[],{"intervention":454,"totalTrials":100,"cells":24193},{"EARLY_PHASE1":24194,"PHASE1":24196,"PHASE2":24198,"PHASE3":24204,"PHASE4":24206,"NA":24208},{"trials":24195,"activeCount":104},[],{"trials":24197,"activeCount":104},[],{"trials":24199,"activeCount":104},[24200],{"nctId":446,"briefTitle":447,"status":174,"phases":24201,"primaryCompletion":449,"completion":449,"start":450,"enrollment":430,"conditions":24202,"interventions":24203},[93],[452,16],[454,225,270],{"trials":24205,"activeCount":104},[],{"trials":24207,"activeCount":104},[],{"trials":24209,"activeCount":104},[],{"intervention":24211,"totalTrials":100,"cells":24212},"Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy",{"EARLY_PHASE1":24213,"PHASE1":24215,"PHASE2":24217,"PHASE3":24227,"PHASE4":24229,"NA":24231},{"trials":24214,"activeCount":104},[],{"trials":24216,"activeCount":104},[],{"trials":24218,"activeCount":104},[24219],{"nctId":24220,"briefTitle":24221,"status":174,"phases":24222,"primaryCompletion":4739,"completion":1459,"start":24223,"enrollment":1289,"conditions":24224,"interventions":24226},"NCT05527912","A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy",[93],"2023-02-24",[24225],"Double Express Diffuse Large B-cell Lymphoma",[24211],{"trials":24228,"activeCount":104},[],{"trials":24230,"activeCount":104},[],{"trials":24232,"activeCount":104},[],{"intervention":24234,"totalTrials":100,"cells":24235},"Tamoxifen Oral Product",{"EARLY_PHASE1":24236,"PHASE1":24238,"PHASE2":24240,"PHASE3":24249,"PHASE4":24251,"NA":24253},{"trials":24237,"activeCount":104},[],{"trials":24239,"activeCount":104},[],{"trials":24241,"activeCount":104},[24242],{"nctId":24243,"briefTitle":24244,"status":328,"phases":24245,"primaryCompletion":5428,"completion":5428,"start":18795,"enrollment":32,"conditions":24246,"interventions":24248},"NCT03045653","Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer",[93],[24247],"Breast Cancer Metastatic",[24234],{"trials":24250,"activeCount":104},[],{"trials":24252,"activeCount":104},[],{"trials":24254,"activeCount":104},[],{"intervention":3295,"totalTrials":100,"cells":24256},{"EARLY_PHASE1":24257,"PHASE1":24259,"PHASE2":24261,"PHASE3":24267,"PHASE4":24269,"NA":24271},{"trials":24258,"activeCount":104},[],{"trials":24260,"activeCount":104},[],{"trials":24262,"activeCount":104},[24263],{"nctId":3288,"briefTitle":3289,"status":174,"phases":24264,"primaryCompletion":1934,"completion":1934,"start":3291,"enrollment":239,"conditions":24265,"interventions":24266},[93],[3293],[3295,3296],{"trials":24268,"activeCount":104},[],{"trials":24270,"activeCount":104},[],{"trials":24272,"activeCount":104},[],{"intervention":1182,"totalTrials":100,"cells":24274},{"EARLY_PHASE1":24275,"PHASE1":24277,"PHASE2":24279,"PHASE3":24290,"PHASE4":24292,"NA":24294},{"trials":24276,"activeCount":104},[],{"trials":24278,"activeCount":104},[],{"trials":24280,"activeCount":104},[24281],{"nctId":24282,"briefTitle":24283,"status":174,"phases":24284,"primaryCompletion":3125,"completion":24285,"start":7371,"enrollment":996,"conditions":24286,"interventions":24289},"NCT04588987","Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma",[93],"2024-05",[4554,24287,269,24288],"Carilizumab","Recurrent High-Grade Glioma",[1182],{"trials":24291,"activeCount":104},[],{"trials":24293,"activeCount":104},[],{"trials":24295,"activeCount":104},[],{"intervention":24297,"totalTrials":100,"cells":24298},"fruquintinib plus TAS-102",{"EARLY_PHASE1":24299,"PHASE1":24301,"PHASE2":24303,"PHASE3":24314,"PHASE4":24316,"NA":24318},{"trials":24300,"activeCount":104},[],{"trials":24302,"activeCount":104},[],{"trials":24304,"activeCount":104},[24305],{"nctId":24306,"briefTitle":24307,"status":174,"phases":24308,"primaryCompletion":24309,"completion":24310,"start":24311,"enrollment":3705,"conditions":24312,"interventions":24313},"NCT05004831","Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC",[93],"2023-09","2024-09","2022-03-11",[1368],[24297],{"trials":24315,"activeCount":104},[],{"trials":24317,"activeCount":104},[],{"trials":24319,"activeCount":104},[],{"intervention":24321,"totalTrials":100,"cells":24322},"Gemcitabine, Vinorelbine, or Eribulin",{"EARLY_PHASE1":24323,"PHASE1":24325,"PHASE2":24327,"PHASE3":24338,"PHASE4":24340,"NA":24342},{"trials":24324,"activeCount":104},[],{"trials":24326,"activeCount":104},[],{"trials":24328,"activeCount":104},[24329],{"nctId":24330,"briefTitle":24331,"status":328,"phases":24332,"primaryCompletion":6548,"completion":24333,"start":24334,"enrollment":1464,"conditions":24335,"interventions":24337},"NCT06533722","Adaptive Therapy for Post-Second-Line Advanced Breast Cancer",[93],"2025-05-28","2024-08-04",[24336],"HER2-negative Metastatic Breast Cancer",[24321],{"trials":24339,"activeCount":104},[],{"trials":24341,"activeCount":104},[],{"trials":24343,"activeCount":104},[],{"intervention":24345,"totalTrials":100,"cells":24346},"Iron Isomaltoside 1000",{"EARLY_PHASE1":24347,"PHASE1":24349,"PHASE2":24351,"PHASE3":24363,"PHASE4":24365,"NA":24367},{"trials":24348,"activeCount":104},[],{"trials":24350,"activeCount":104},[],{"trials":24352,"activeCount":104},[24353],{"nctId":24354,"briefTitle":24355,"status":174,"phases":24356,"primaryCompletion":4684,"completion":3587,"start":24357,"enrollment":820,"conditions":24358,"interventions":24361},"NCT05913414","Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma",[93],"2023-05-05",[16,24359,24360],"Iron-deficiency","Anemia",[24345,24362],"Polysaccharide Iron Complex Pill",{"trials":24364,"activeCount":104},[],{"trials":24366,"activeCount":104},[],{"trials":24368,"activeCount":104},[],{"intervention":24362,"totalTrials":100,"cells":24370},{"EARLY_PHASE1":24371,"PHASE1":24373,"PHASE2":24375,"PHASE3":24381,"PHASE4":24383,"NA":24385},{"trials":24372,"activeCount":104},[],{"trials":24374,"activeCount":104},[],{"trials":24376,"activeCount":104},[24377],{"nctId":24354,"briefTitle":24355,"status":174,"phases":24378,"primaryCompletion":4684,"completion":3587,"start":24357,"enrollment":820,"conditions":24379,"interventions":24380},[93],[16,24359,24360],[24345,24362],{"trials":24382,"activeCount":104},[],{"trials":24384,"activeCount":104},[],{"trials":24386,"activeCount":104},[],{"intervention":24388,"totalTrials":100,"cells":24389},"Chidamide, Lenalidomide",{"EARLY_PHASE1":24390,"PHASE1":24392,"PHASE2":24394,"PHASE3":24406,"PHASE4":24408,"NA":24410},{"trials":24391,"activeCount":104},[],{"trials":24393,"activeCount":104},[],{"trials":24395,"activeCount":104},[24396],{"nctId":24397,"briefTitle":24398,"status":174,"phases":24399,"primaryCompletion":24400,"completion":24401,"start":24402,"enrollment":2040,"conditions":24403,"interventions":24405},"NCT04329130","Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma",[93],"2022-03-26","2025-03-26","2020-03-27",[24404],"Relapsed or Refractory Peripheral T-cell Lymphoma",[24388],{"trials":24407,"activeCount":104},[],{"trials":24409,"activeCount":104},[],{"trials":24411,"activeCount":104},[],{"intervention":9132,"totalTrials":100,"cells":24413},{"EARLY_PHASE1":24414,"PHASE1":24416,"PHASE2":24418,"PHASE3":24424,"PHASE4":24426,"NA":24428},{"trials":24415,"activeCount":104},[],{"trials":24417,"activeCount":104},[],{"trials":24419,"activeCount":104},[24420],{"nctId":9126,"briefTitle":9127,"status":174,"phases":24421,"primaryCompletion":2106,"completion":1337,"start":1934,"enrollment":9129,"conditions":24422,"interventions":24423},[93],[1936],[9132,9083],{"trials":24425,"activeCount":104},[],{"trials":24427,"activeCount":104},[],{"trials":24429,"activeCount":104},[],{"intervention":24431,"totalTrials":100,"cells":24432},"Moxifloxacin Hydrochloride 400mg",{"EARLY_PHASE1":24433,"PHASE1":24435,"PHASE2":24437,"PHASE3":24449,"PHASE4":24451,"NA":24453},{"trials":24434,"activeCount":104},[],{"trials":24436,"activeCount":104},[],{"trials":24438,"activeCount":104},[24439],{"nctId":24440,"briefTitle":24441,"status":328,"phases":24442,"primaryCompletion":24443,"completion":24443,"start":1247,"enrollment":1109,"conditions":24444,"interventions":24448},"NCT03405168","Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer",[93],"2018-07-30",[24445,24446,24447],"Advanced Breast Cancer","Antibiotic","Stable Disease With a Trend of Progression",[24431],{"trials":24450,"activeCount":104},[],{"trials":24452,"activeCount":104},[],{"trials":24454,"activeCount":104},[],{"intervention":7667,"totalTrials":100,"cells":24456},{"EARLY_PHASE1":24457,"PHASE1":24459,"PHASE2":24461,"PHASE3":24467,"PHASE4":24469,"NA":24471},{"trials":24458,"activeCount":104},[],{"trials":24460,"activeCount":104},[],{"trials":24462,"activeCount":104},[24463],{"nctId":7661,"briefTitle":7662,"status":174,"phases":24464,"primaryCompletion":1064,"completion":379,"start":733,"enrollment":1350,"conditions":24465,"interventions":24466},[93],[1368,823,7665],[7667,823],{"trials":24468,"activeCount":104},[],{"trials":24470,"activeCount":104},[],{"trials":24472,"activeCount":104},[],{"intervention":24474,"totalTrials":100,"cells":24475},"Orelabrutinib and Gemox",{"EARLY_PHASE1":24476,"PHASE1":24478,"PHASE2":24480,"PHASE3":24488,"PHASE4":24490,"NA":24492},{"trials":24477,"activeCount":104},[],{"trials":24479,"activeCount":104},[],{"trials":24481,"activeCount":104},[24482],{"nctId":24483,"briefTitle":24484,"status":174,"phases":24485,"primaryCompletion":259,"completion":4009,"start":9102,"enrollment":2754,"conditions":24486,"interventions":24487},"NCT05381506","Study of Orelabrutinib in Combination With Gemox in Refractory \u002F Relapsed Diffuse Large B-cell Lymphoma",[93],[3150],[24474],{"trials":24489,"activeCount":104},[],{"trials":24491,"activeCount":104},[],{"trials":24493,"activeCount":104},[],{"intervention":24495,"totalTrials":100,"cells":24496},"Mitoxantrone liposome combine with Chidamide",{"EARLY_PHASE1":24497,"PHASE1":24499,"PHASE2":24501,"PHASE3":24511,"PHASE4":24513,"NA":24515},{"trials":24498,"activeCount":104},[],{"trials":24500,"activeCount":104},[],{"trials":24502,"activeCount":104},[24503],{"nctId":24504,"briefTitle":24505,"status":174,"phases":24506,"primaryCompletion":4739,"completion":1459,"start":24507,"enrollment":4035,"conditions":24508,"interventions":24510},"NCT05527275","A Phase I\u002FII Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed\u002FRefractory Peripheral T-cell Lymphoma",[92,93],"2022-10-01",[24509],"Relapsed and Refractory Peripheral T-cell Lymphoma",[24495],{"trials":24512,"activeCount":104},[],{"trials":24514,"activeCount":104},[],{"trials":24516,"activeCount":104},[],{"intervention":24518,"totalTrials":100,"cells":24519},"Sintilimab and Bevacizumab Combined with Radiotherapy",{"EARLY_PHASE1":24520,"PHASE1":24522,"PHASE2":24524,"PHASE3":24532,"PHASE4":24534,"NA":24536},{"trials":24521,"activeCount":104},[],{"trials":24523,"activeCount":104},[],{"trials":24525,"activeCount":104},[24526],{"nctId":24527,"briefTitle":24528,"status":174,"phases":24529,"primaryCompletion":24309,"completion":24309,"start":627,"enrollment":461,"conditions":24530,"interventions":24531},"NCT05010434","Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma",[93],[19],[24518],{"trials":24533,"activeCount":104},[],{"trials":24535,"activeCount":104},[],{"trials":24537,"activeCount":104},[],{"intervention":24539,"totalTrials":100,"cells":24540},"Niraparib，Sintilimab",{"EARLY_PHASE1":24541,"PHASE1":24543,"PHASE2":24545,"PHASE3":24554,"PHASE4":24556,"NA":24558},{"trials":24542,"activeCount":104},[],{"trials":24544,"activeCount":104},[],{"trials":24546,"activeCount":104},[24547],{"nctId":24548,"briefTitle":24549,"status":174,"phases":24550,"primaryCompletion":1027,"completion":1268,"start":24551,"enrollment":2742,"conditions":24552,"interventions":24553},"NCT05162872","Niraparib And Sintilimab In Recurrent\u002FMetastatic Nasopharyngeal Carcinoma",[93],"2021-08-05",[16],[24539],{"trials":24555,"activeCount":104},[],{"trials":24557,"activeCount":104},[],{"trials":24559,"activeCount":104},[],{"intervention":24561,"totalTrials":100,"cells":24562},"physiological (1.25 mmol\u002FL ) calcium dialysate",{"EARLY_PHASE1":24563,"PHASE1":24565,"PHASE2":24567,"PHASE3":24578,"PHASE4":24580,"NA":24582},{"trials":24564,"activeCount":104},[],{"trials":24566,"activeCount":104},[],{"trials":24568,"activeCount":104},[24569],{"nctId":24570,"briefTitle":24571,"status":328,"phases":24572,"primaryCompletion":3333,"completion":3333,"start":24573,"enrollment":2459,"conditions":24574,"interventions":24577},"NCT00744302","Study of 1.25 mmol\u002FL Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.",[93],"2006-04",[24575,24576],"Hyperparathyroidism","Hypercalcemia",[24561],{"trials":24579,"activeCount":104},[],{"trials":24581,"activeCount":104},[],{"trials":24583,"activeCount":104},[],{"intervention":24585,"totalTrials":100,"cells":24586},"GP combine with Tislelizumab neoadjuvant therapy+CCRT",{"EARLY_PHASE1":24587,"PHASE1":24589,"PHASE2":24591,"PHASE3":24601,"PHASE4":24603,"NA":24605},{"trials":24588,"activeCount":104},[],{"trials":24590,"activeCount":104},[],{"trials":24592,"activeCount":104},[24593],{"nctId":24594,"briefTitle":24595,"status":328,"phases":24596,"primaryCompletion":24597,"completion":24597,"start":24598,"enrollment":2184,"conditions":24599,"interventions":24600},"NCT04833257","Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC",[93],"2025-05-30","2021-04-14",[16],[24585],{"trials":24602,"activeCount":104},[],{"trials":24604,"activeCount":104},[],{"trials":24606,"activeCount":104},[],{"intervention":24608,"totalTrials":100,"cells":24609},"Radiotherapy+anti-PD-1 antibody",{"EARLY_PHASE1":24610,"PHASE1":24612,"PHASE2":24614,"PHASE3":24623,"PHASE4":24625,"NA":24627},{"trials":24611,"activeCount":104},[],{"trials":24613,"activeCount":104},[],{"trials":24615,"activeCount":104},[24616],{"nctId":24617,"briefTitle":24618,"status":174,"phases":24619,"primaryCompletion":1313,"completion":1313,"start":24620,"enrollment":911,"conditions":24621,"interventions":24622},"NCT03898895","COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer",[93],"2019-12-10",[3253,505,318],[24608],{"trials":24624,"activeCount":104},[],{"trials":24626,"activeCount":104},[],{"trials":24628,"activeCount":104},[],{"intervention":24630,"totalTrials":100,"cells":24631},"erlotinib in combination with capecitabine",{"EARLY_PHASE1":24632,"PHASE1":24634,"PHASE2":24636,"PHASE3":24644,"PHASE4":24646,"NA":24648},{"trials":24633,"activeCount":104},[],{"trials":24635,"activeCount":104},[],{"trials":24637,"activeCount":104},[24638],{"nctId":24639,"briefTitle":24640,"status":328,"phases":24641,"primaryCompletion":7899,"completion":16010,"start":15546,"enrollment":1007,"conditions":24642,"interventions":24643},"NCT00816868","A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung",[93],[22],[24630],{"trials":24645,"activeCount":104},[],{"trials":24647,"activeCount":104},[],{"trials":24649,"activeCount":104},[],{"intervention":24651,"totalTrials":100,"cells":24652},"S-1 maintenance",{"EARLY_PHASE1":24653,"PHASE1":24655,"PHASE2":24657,"PHASE3":24666,"PHASE4":24668,"NA":24670},{"trials":24654,"activeCount":104},[],{"trials":24656,"activeCount":104},[],{"trials":24658,"activeCount":104},[24659],{"nctId":24660,"briefTitle":24661,"status":174,"phases":24662,"primaryCompletion":3953,"completion":3953,"start":4763,"enrollment":1192,"conditions":24663,"interventions":24665},"NCT03701373","Maintenance Treatment With S-1 in Gastric Cancer Patients",[93],[3877,24664],"Cancer of Stomach",[24651],{"trials":24667,"activeCount":104},[],{"trials":24669,"activeCount":104},[],{"trials":24671,"activeCount":104},[],{"intervention":24673,"totalTrials":100,"cells":24674},"Adalimumab plus Methotrexate",{"EARLY_PHASE1":24675,"PHASE1":24677,"PHASE2":24679,"PHASE3":24687,"PHASE4":24689,"NA":24691},{"trials":24676,"activeCount":104},[],{"trials":24678,"activeCount":104},[],{"trials":24680,"activeCount":104},[24681],{"nctId":24682,"briefTitle":24683,"status":174,"phases":24684,"primaryCompletion":721,"completion":721,"start":8200,"enrollment":32,"conditions":24685,"interventions":24686},"NCT04588818","Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis",[93],[9227],[24673],{"trials":24688,"activeCount":104},[],{"trials":24690,"activeCount":104},[],{"trials":24692,"activeCount":104},[],{"intervention":24694,"totalTrials":100,"cells":24695},"Gefitinib 500mg\u002FGefitinib 250mg",{"EARLY_PHASE1":24696,"PHASE1":24698,"PHASE2":24700,"PHASE3":24708,"PHASE4":24710,"NA":24712},{"trials":24697,"activeCount":104},[],{"trials":24699,"activeCount":104},[],{"trials":24701,"activeCount":104},[24702],{"nctId":24703,"briefTitle":24704,"status":328,"phases":24705,"primaryCompletion":2233,"completion":1427,"start":21344,"enrollment":3272,"conditions":24706,"interventions":24707},"NCT01017679","Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg",[93],[22],[24694],{"trials":24709,"activeCount":104},[],{"trials":24711,"activeCount":104},[],{"trials":24713,"activeCount":104},[],{"intervention":1454,"totalTrials":100,"cells":24715},{"EARLY_PHASE1":24716,"PHASE1":24718,"PHASE2":24720,"PHASE3":24726,"PHASE4":24728,"NA":24730},{"trials":24717,"activeCount":104},[],{"trials":24719,"activeCount":104},[],{"trials":24721,"activeCount":104},[24722],{"nctId":1444,"briefTitle":1445,"status":174,"phases":24723,"primaryCompletion":1447,"completion":1448,"start":1449,"enrollment":1450,"conditions":24724,"interventions":24725},[93],[539,1452],[385,542,1454,444],{"trials":24727,"activeCount":104},[],{"trials":24729,"activeCount":104},[],{"trials":24731,"activeCount":104},[],{"intervention":7739,"totalTrials":100,"cells":24733},{"EARLY_PHASE1":24734,"PHASE1":24736,"PHASE2":24738,"PHASE3":24744,"PHASE4":24746,"NA":24748},{"trials":24735,"activeCount":104},[],{"trials":24737,"activeCount":104},[],{"trials":24739,"activeCount":104},[24740],{"nctId":7731,"briefTitle":7732,"status":328,"phases":24741,"primaryCompletion":696,"completion":7734,"start":7735,"enrollment":7736,"conditions":24742,"interventions":24743},[93],[1714],[1122,7739],{"trials":24745,"activeCount":104},[],{"trials":24747,"activeCount":104},[],{"trials":24749,"activeCount":104},[],{"intervention":4870,"totalTrials":100,"cells":24751},{"EARLY_PHASE1":24752,"PHASE1":24754,"PHASE2":24756,"PHASE3":24762,"PHASE4":24764,"NA":24766},{"trials":24753,"activeCount":104},[],{"trials":24755,"activeCount":104},[],{"trials":24757,"activeCount":104},[24758],{"nctId":4862,"briefTitle":4863,"status":174,"phases":24759,"primaryCompletion":4865,"completion":4865,"start":4866,"enrollment":1987,"conditions":24760,"interventions":24761},[93],[4868],[4870,4152],{"trials":24763,"activeCount":104},[],{"trials":24765,"activeCount":104},[],{"trials":24767,"activeCount":104},[],{"intervention":24769,"totalTrials":100,"cells":24770},"Bacillus Cereus",{"EARLY_PHASE1":24771,"PHASE1":24773,"PHASE2":24775,"PHASE3":24785,"PHASE4":24787,"NA":24789},{"trials":24772,"activeCount":104},[],{"trials":24774,"activeCount":104},[],{"trials":24776,"activeCount":104},[24777],{"nctId":24778,"briefTitle":24779,"status":1091,"phases":24780,"primaryCompletion":480,"completion":3355,"start":2548,"enrollment":3748,"conditions":24781,"interventions":24784},"NCT03486587","A Study Evaluating Bacillus Cereus in the Prevention of Afatinib-associated Diarrhea",[93],[24782,24783],"Diarrhea","Treatment Side Effects",[24769],{"trials":24786,"activeCount":104},[],{"trials":24788,"activeCount":104},[],{"trials":24790,"activeCount":104},[],{"intervention":24792,"totalTrials":100,"cells":24793},"Pyrotinib 320mg + Vinorelbine",{"EARLY_PHASE1":24794,"PHASE1":24796,"PHASE2":24798,"PHASE3":24811,"PHASE4":24813,"NA":24815},{"trials":24795,"activeCount":104},[],{"trials":24797,"activeCount":104},[],{"trials":24799,"activeCount":104},[24800],{"nctId":24801,"briefTitle":24802,"status":174,"phases":24803,"primaryCompletion":733,"completion":500,"start":24804,"enrollment":3042,"conditions":24805,"interventions":24808},"NCT04605575","Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer",[93],"2020-05-22",[28,5389,24806,768,24807],"Breast Diseases","HER2-positive Breast Cancer",[24792,24809,24810],"Pyrotinib 400mg + Vinorelbine","Pyrotinib plus Vinorelbine",{"trials":24812,"activeCount":104},[],{"trials":24814,"activeCount":104},[],{"trials":24816,"activeCount":104},[],{"intervention":24809,"totalTrials":100,"cells":24818},{"EARLY_PHASE1":24819,"PHASE1":24821,"PHASE2":24823,"PHASE3":24829,"PHASE4":24831,"NA":24833},{"trials":24820,"activeCount":104},[],{"trials":24822,"activeCount":104},[],{"trials":24824,"activeCount":104},[24825],{"nctId":24801,"briefTitle":24802,"status":174,"phases":24826,"primaryCompletion":733,"completion":500,"start":24804,"enrollment":3042,"conditions":24827,"interventions":24828},[93],[28,5389,24806,768,24807],[24792,24809,24810],{"trials":24830,"activeCount":104},[],{"trials":24832,"activeCount":104},[],{"trials":24834,"activeCount":104},[],{"intervention":24810,"totalTrials":100,"cells":24836},{"EARLY_PHASE1":24837,"PHASE1":24839,"PHASE2":24841,"PHASE3":24847,"PHASE4":24849,"NA":24851},{"trials":24838,"activeCount":104},[],{"trials":24840,"activeCount":104},[],{"trials":24842,"activeCount":104},[24843],{"nctId":24801,"briefTitle":24802,"status":174,"phases":24844,"primaryCompletion":733,"completion":500,"start":24804,"enrollment":3042,"conditions":24845,"interventions":24846},[93],[28,5389,24806,768,24807],[24792,24809,24810],{"trials":24848,"activeCount":104},[],{"trials":24850,"activeCount":104},[],{"trials":24852,"activeCount":104},[],{"intervention":24854,"totalTrials":100,"cells":24855},"Bifidobacterium Bifidum Oral Product",{"EARLY_PHASE1":24856,"PHASE1":24858,"PHASE2":24860,"PHASE3":24870,"PHASE4":24872,"NA":24874},{"trials":24857,"activeCount":104},[],{"trials":24859,"activeCount":104},[],{"trials":24861,"activeCount":104},[24862],{"nctId":24863,"briefTitle":24864,"status":174,"phases":24865,"primaryCompletion":721,"completion":24866,"start":24867,"enrollment":32,"conditions":24868,"interventions":24869},"NCT05620004","Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy",[92,93],"2024-10-31","2021-11-01",[1230],[24854],{"trials":24871,"activeCount":104},[],{"trials":24873,"activeCount":104},[],{"trials":24875,"activeCount":104},[],{"intervention":2267,"totalTrials":100,"cells":24877},{"EARLY_PHASE1":24878,"PHASE1":24880,"PHASE2":24882,"PHASE3":24888,"PHASE4":24890,"NA":24892},{"trials":24879,"activeCount":104},[],{"trials":24881,"activeCount":104},[],{"trials":24883,"activeCount":104},[24884],{"nctId":2261,"briefTitle":2262,"status":174,"phases":24885,"primaryCompletion":459,"completion":2264,"start":1375,"enrollment":32,"conditions":24886,"interventions":24887},[93],[2249],[2267,49,1205,183],{"trials":24889,"activeCount":104},[],{"trials":24891,"activeCount":104},[],{"trials":24893,"activeCount":104},[],{"intervention":24895,"totalTrials":100,"cells":24896},"Sorafenib plus Cisplatin and 5-fluorouracil",{"EARLY_PHASE1":24897,"PHASE1":24899,"PHASE2":24901,"PHASE3":24910,"PHASE4":24912,"NA":24914},{"trials":24898,"activeCount":104},[],{"trials":24900,"activeCount":104},[],{"trials":24902,"activeCount":104},[24903],{"nctId":24904,"briefTitle":24905,"status":328,"phases":24906,"primaryCompletion":24907,"completion":8149,"start":15546,"enrollment":3705,"conditions":24908,"interventions":24909},"NCT00747799","Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)",[93],"2011-05",[441],[24895],{"trials":24911,"activeCount":104},[],{"trials":24913,"activeCount":104},[],{"trials":24915,"activeCount":104},[],{"intervention":24917,"totalTrials":100,"cells":24918},"Toripalimab plus gemcitabine",{"EARLY_PHASE1":24919,"PHASE1":24921,"PHASE2":24923,"PHASE3":24932,"PHASE4":24934,"NA":24936},{"trials":24920,"activeCount":104},[],{"trials":24922,"activeCount":104},[],{"trials":24924,"activeCount":104},[24925],{"nctId":24926,"briefTitle":24927,"status":174,"phases":24928,"primaryCompletion":2966,"completion":19097,"start":24929,"enrollment":38,"conditions":24930,"interventions":24931},"NCT04405622","Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.",[93],"2020-05-30",[16,3305,3887,2430,318],[24917],{"trials":24933,"activeCount":104},[],{"trials":24935,"activeCount":104},[],{"trials":24937,"activeCount":104},[],{"intervention":24939,"totalTrials":100,"cells":24940},"NY-ESO-1",{"EARLY_PHASE1":24941,"PHASE1":24943,"PHASE2":24945,"PHASE3":24954,"PHASE4":24956,"NA":24958},{"trials":24942,"activeCount":104},[],{"trials":24944,"activeCount":104},[],{"trials":24946,"activeCount":104},[24947],{"nctId":24948,"briefTitle":24949,"status":174,"phases":24950,"primaryCompletion":4739,"completion":4739,"start":24951,"enrollment":1076,"conditions":24952,"interventions":24953},"NCT05549921","Phase II Study of TAEST16001 in Soft Tissue Sarcoma",[93],"2022-07-08",[4686],[24939],{"trials":24955,"activeCount":104},[],{"trials":24957,"activeCount":104},[],{"trials":24959,"activeCount":104},[],{"intervention":24961,"totalTrials":100,"cells":24962},"Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant",{"EARLY_PHASE1":24963,"PHASE1":24965,"PHASE2":24967,"PHASE3":24976,"PHASE4":24978,"NA":24980},{"trials":24964,"activeCount":104},[],{"trials":24966,"activeCount":104},[],{"trials":24968,"activeCount":104},[24969],{"nctId":24970,"briefTitle":24971,"status":174,"phases":24972,"primaryCompletion":290,"completion":1064,"start":24973,"enrollment":1018,"conditions":24974,"interventions":24975},"NCT04334330","Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER\u002FPR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China",[93],"2020-12-04",[28,1830],[24961],{"trials":24977,"activeCount":104},[],{"trials":24979,"activeCount":104},[],{"trials":24981,"activeCount":104},[],{"intervention":8344,"totalTrials":100,"cells":24983},{"EARLY_PHASE1":24984,"PHASE1":24986,"PHASE2":24988,"PHASE3":24994,"PHASE4":24996,"NA":24998},{"trials":24985,"activeCount":104},[],{"trials":24987,"activeCount":104},[],{"trials":24989,"activeCount":104},[24990],{"nctId":8336,"briefTitle":8337,"status":174,"phases":24991,"primaryCompletion":1952,"completion":8339,"start":8340,"enrollment":5071,"conditions":24992,"interventions":24993},[92,93],[8342],[8344,8308,183,8344,8308,183,8344,8308,183,8344,8308,183],{"trials":24995,"activeCount":104},[],{"trials":24997,"activeCount":104},[],{"trials":24999,"activeCount":104},[],{"intervention":25001,"totalTrials":100,"cells":25002},"Fludarabine and Pegylated liposomal doxorubicin",{"EARLY_PHASE1":25003,"PHASE1":25005,"PHASE2":25007,"PHASE3":25016,"PHASE4":25018,"NA":25020},{"trials":25004,"activeCount":104},[],{"trials":25006,"activeCount":104},[],{"trials":25008,"activeCount":104},[25009],{"nctId":25010,"briefTitle":25011,"status":174,"phases":25012,"primaryCompletion":1575,"completion":1827,"start":18464,"enrollment":17,"conditions":25013,"interventions":25014},"NCT03335241","Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant\u002FRefractory Ovarian Cancer",[93],[2042],[25001,25015],"Pegylated liposomal doxorubicin",{"trials":25017,"activeCount":104},[],{"trials":25019,"activeCount":104},[],{"trials":25021,"activeCount":104},[],{"intervention":25015,"totalTrials":100,"cells":25023},{"EARLY_PHASE1":25024,"PHASE1":25026,"PHASE2":25028,"PHASE3":25034,"PHASE4":25036,"NA":25038},{"trials":25025,"activeCount":104},[],{"trials":25027,"activeCount":104},[],{"trials":25029,"activeCount":104},[25030],{"nctId":25010,"briefTitle":25011,"status":174,"phases":25031,"primaryCompletion":1575,"completion":1827,"start":18464,"enrollment":17,"conditions":25032,"interventions":25033},[93],[2042],[25001,25015],{"trials":25035,"activeCount":104},[],{"trials":25037,"activeCount":104},[],{"trials":25039,"activeCount":104},[],{"intervention":3316,"totalTrials":100,"cells":25041},{"EARLY_PHASE1":25042,"PHASE1":25044,"PHASE2":25046,"PHASE3":25052,"PHASE4":25054,"NA":25056},{"trials":25043,"activeCount":104},[],{"trials":25045,"activeCount":104},[],{"trials":25047,"activeCount":104},[25048],{"nctId":3308,"briefTitle":3309,"status":174,"phases":25049,"primaryCompletion":3311,"completion":3312,"start":3313,"enrollment":2591,"conditions":25050,"interventions":25051},[93],[16],[3316,3317,3318,726],{"trials":25053,"activeCount":104},[],{"trials":25055,"activeCount":104},[],{"trials":25057,"activeCount":104},[],{"intervention":3317,"totalTrials":100,"cells":25059},{"EARLY_PHASE1":25060,"PHASE1":25062,"PHASE2":25064,"PHASE3":25070,"PHASE4":25072,"NA":25074},{"trials":25061,"activeCount":104},[],{"trials":25063,"activeCount":104},[],{"trials":25065,"activeCount":104},[25066],{"nctId":3308,"briefTitle":3309,"status":174,"phases":25067,"primaryCompletion":3311,"completion":3312,"start":3313,"enrollment":2591,"conditions":25068,"interventions":25069},[93],[16],[3316,3317,3318,726],{"trials":25071,"activeCount":104},[],{"trials":25073,"activeCount":104},[],{"trials":25075,"activeCount":104},[],{"intervention":3318,"totalTrials":100,"cells":25077},{"EARLY_PHASE1":25078,"PHASE1":25080,"PHASE2":25082,"PHASE3":25088,"PHASE4":25090,"NA":25092},{"trials":25079,"activeCount":104},[],{"trials":25081,"activeCount":104},[],{"trials":25083,"activeCount":104},[25084],{"nctId":3308,"briefTitle":3309,"status":174,"phases":25085,"primaryCompletion":3311,"completion":3312,"start":3313,"enrollment":2591,"conditions":25086,"interventions":25087},[93],[16],[3316,3317,3318,726],{"trials":25089,"activeCount":104},[],{"trials":25091,"activeCount":104},[],{"trials":25093,"activeCount":104},[],{"intervention":19992,"totalTrials":100,"cells":25095},{"EARLY_PHASE1":25096,"PHASE1":25098,"PHASE2":25104,"PHASE3":25106,"PHASE4":25108,"NA":25110},{"trials":25097,"activeCount":104},[],{"trials":25099,"activeCount":104},[25100],{"nctId":19986,"briefTitle":19987,"status":174,"phases":25101,"primaryCompletion":2106,"completion":967,"start":19989,"enrollment":1464,"conditions":25102,"interventions":25103},[92],[1831],[19992,4323],{"trials":25105,"activeCount":104},[],{"trials":25107,"activeCount":104},[],{"trials":25109,"activeCount":104},[],{"trials":25111,"activeCount":104},[],{"intervention":25113,"totalTrials":100,"cells":25114},"LMP2 Antigen-specific TCR T cells",{"EARLY_PHASE1":25115,"PHASE1":25117,"PHASE2":25126,"PHASE3":25128,"PHASE4":25130,"NA":25132},{"trials":25116,"activeCount":104},[],{"trials":25118,"activeCount":104},[25119],{"nctId":25120,"briefTitle":25121,"status":174,"phases":25122,"primaryCompletion":216,"completion":1964,"start":25123,"enrollment":2059,"conditions":25124,"interventions":25125},"NCT03925896","Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients",[92],"2019-08-07",[16],[25113],{"trials":25127,"activeCount":104},[],{"trials":25129,"activeCount":104},[],{"trials":25131,"activeCount":104},[],{"trials":25133,"activeCount":104},[],{"intervention":25135,"totalTrials":100,"cells":25136},"NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）",{"EARLY_PHASE1":25137,"PHASE1":25139,"PHASE2":25149,"PHASE3":25151,"PHASE4":25153,"NA":25155},{"trials":25138,"activeCount":104},[],{"trials":25140,"activeCount":104},[25141],{"nctId":25142,"briefTitle":25143,"status":174,"phases":25144,"primaryCompletion":19439,"completion":19415,"start":25145,"enrollment":239,"conditions":25146,"interventions":25148},"NCT03462316","NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma",[92],"2018-05-21",[25147,4686],"Bone Sarcoma",[25135],{"trials":25150,"activeCount":104},[],{"trials":25152,"activeCount":104},[],{"trials":25154,"activeCount":104},[],{"trials":25156,"activeCount":104},[],{"intervention":25158,"totalTrials":100,"cells":25159},"CCRT+TIL",{"EARLY_PHASE1":25160,"PHASE1":25162,"PHASE2":25170,"PHASE3":25172,"PHASE4":25174,"NA":25176},{"trials":25161,"activeCount":104},[],{"trials":25163,"activeCount":104},[25164],{"nctId":25165,"briefTitle":25166,"status":174,"phases":25167,"primaryCompletion":289,"completion":479,"start":1449,"enrollment":1464,"conditions":25168,"interventions":25169},"NCT04443296","Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma",[92],[2859],[25158],{"trials":25171,"activeCount":104},[],{"trials":25173,"activeCount":104},[],{"trials":25175,"activeCount":104},[],{"trials":25177,"activeCount":104},[],{"intervention":25179,"totalTrials":100,"cells":25180},"PEDylated Recombinant Human Endostatin",{"EARLY_PHASE1":25181,"PHASE1":25183,"PHASE2":25193,"PHASE3":25195,"PHASE4":25197,"NA":25199},{"trials":25182,"activeCount":104},[],{"trials":25184,"activeCount":104},[25185],{"nctId":25186,"briefTitle":25187,"status":328,"phases":25188,"primaryCompletion":17342,"completion":17342,"start":15547,"enrollment":239,"conditions":25189,"interventions":25192},"NCT01260025","Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor",[92],[25190,25191,21332],"Tolerability","Pharmacokinetics",[25179],{"trials":25194,"activeCount":104},[],{"trials":25196,"activeCount":104},[],{"trials":25198,"activeCount":104},[],{"trials":25200,"activeCount":104},[],{"intervention":25202,"totalTrials":100,"cells":25203},"pegylated liposomal doxorubicin, cyclophosphamide, vincristine,",{"EARLY_PHASE1":25204,"PHASE1":25206,"PHASE2":25217,"PHASE3":25219,"PHASE4":25221,"NA":25223},{"trials":25205,"activeCount":104},[],{"trials":25207,"activeCount":104},[25208],{"nctId":25209,"briefTitle":25210,"status":174,"phases":25211,"primaryCompletion":25212,"completion":18463,"start":25213,"enrollment":38,"conditions":25214,"interventions":25216},"NCT04213612","DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors",[92],"2020-08-30","2019-12-30",[25215],"Unrecognized Condition",[25202],{"trials":25218,"activeCount":104},[],{"trials":25220,"activeCount":104},[],{"trials":25222,"activeCount":104},[],{"trials":25224,"activeCount":104},[],{"intervention":25226,"totalTrials":100,"cells":25227},"CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells",{"EARLY_PHASE1":25228,"PHASE1":25230,"PHASE2":25239,"PHASE3":25241,"PHASE4":25243,"NA":25245},{"trials":25229,"activeCount":104},[],{"trials":25231,"activeCount":104},[25232],{"nctId":25233,"briefTitle":25234,"status":174,"phases":25235,"primaryCompletion":1575,"completion":1827,"start":25236,"enrollment":528,"conditions":25237,"interventions":25238},"NCT04153799","Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer",[92],"2019-11-01",[1831],[25226],{"trials":25240,"activeCount":104},[],{"trials":25242,"activeCount":104},[],{"trials":25244,"activeCount":104},[],{"trials":25246,"activeCount":104},[],{"intervention":25248,"totalTrials":100,"cells":25249},"TAEST16001 cells",{"EARLY_PHASE1":25250,"PHASE1":25252,"PHASE2":25261,"PHASE3":25263,"PHASE4":25265,"NA":25267},{"trials":25251,"activeCount":104},[],{"trials":25253,"activeCount":104},[25254],{"nctId":25255,"briefTitle":25256,"status":174,"phases":25257,"primaryCompletion":1677,"completion":8897,"start":25258,"enrollment":3748,"conditions":25259,"interventions":25260},"NCT04318964","TAEST16001 in the Treatment of Soft Tissue Sarcoma",[92],"2020-03-19",[4686],[25248],{"trials":25262,"activeCount":104},[],{"trials":25264,"activeCount":104},[],{"trials":25266,"activeCount":104},[],{"trials":25268,"activeCount":104},[],{"intervention":25270,"totalTrials":100,"cells":25271},"CAR-T cells to treat advanced lung cancer",{"EARLY_PHASE1":25272,"PHASE1":25274,"PHASE2":25285,"PHASE3":25287,"PHASE4":25289,"NA":25291},{"trials":25273,"activeCount":104},[],{"trials":25275,"activeCount":104},[25276],{"nctId":25277,"briefTitle":25278,"status":1091,"phases":25279,"primaryCompletion":25280,"completion":25280,"start":25281,"enrollment":100,"conditions":25282,"interventions":25284},"NCT03330834","CAR-T Cell Immunotherapy for Advanced Lung Cancer",[92],"2020-04-14","2017-11-20",[25283],"Advanced Lung Cancer",[25270],{"trials":25286,"activeCount":104},[],{"trials":25288,"activeCount":104},[],{"trials":25290,"activeCount":104},[],{"trials":25292,"activeCount":104},[],{"intervention":25294,"totalTrials":100,"cells":25295},"fosaprepitant",{"EARLY_PHASE1":25296,"PHASE1":25298,"PHASE2":25308,"PHASE3":25310,"PHASE4":25312,"NA":25314},{"trials":25297,"activeCount":104},[],{"trials":25299,"activeCount":104},[25300],{"nctId":25301,"briefTitle":25302,"status":328,"phases":25303,"primaryCompletion":25304,"completion":25304,"start":25305,"enrollment":1339,"conditions":25306,"interventions":25307},"NCT04636632","Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma",[92],"2022-11-04","2020-11-24",[16],[25294],{"trials":25309,"activeCount":104},[],{"trials":25311,"activeCount":104},[],{"trials":25313,"activeCount":104},[],{"trials":25315,"activeCount":104},[],{"intervention":25317,"totalTrials":100,"cells":25318},"Gemcitabine combined with Aptinib and Toripalimab",{"EARLY_PHASE1":25319,"PHASE1":25321,"PHASE2":25330,"PHASE3":25332,"PHASE4":25334,"NA":25336},{"trials":25320,"activeCount":104},[],{"trials":25322,"activeCount":104},[25323],{"nctId":25324,"briefTitle":25325,"status":174,"phases":25326,"primaryCompletion":1156,"completion":8003,"start":25327,"enrollment":23,"conditions":25328,"interventions":25329},"NCT04073784","Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.",[92],"2019-06-08",[16],[25317],{"trials":25331,"activeCount":104},[],{"trials":25333,"activeCount":104},[],{"trials":25335,"activeCount":104},[],{"trials":25337,"activeCount":104},[],{"intervention":25339,"totalTrials":100,"cells":25340},"tumor infiltrating lymphocytes, IL-2",{"EARLY_PHASE1":25341,"PHASE1":25343,"PHASE2":25353,"PHASE3":25355,"PHASE4":25357,"NA":25359},{"trials":25342,"activeCount":104},[],{"trials":25344,"activeCount":104},[25345],{"nctId":25346,"briefTitle":25347,"status":174,"phases":25348,"primaryCompletion":25349,"completion":4810,"start":19691,"enrollment":239,"conditions":25350,"interventions":25352},"NCT01462903","A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors",[92],"2014-11",[16,19,25351],"Breast Carcinoma",[25339],{"trials":25354,"activeCount":104},[],{"trials":25356,"activeCount":104},[],{"trials":25358,"activeCount":104},[],{"trials":25360,"activeCount":104},[],{"intervention":25362,"totalTrials":100,"cells":25363},"Individualized neoantigen peptides vaccine",{"EARLY_PHASE1":25364,"PHASE1":25366,"PHASE2":25374,"PHASE3":25376,"PHASE4":25378,"NA":25380},{"trials":25365,"activeCount":104},[],{"trials":25367,"activeCount":104},[25368],{"nctId":25369,"briefTitle":25370,"status":174,"phases":25371,"primaryCompletion":331,"completion":53,"start":24929,"enrollment":239,"conditions":25372,"interventions":25373},"NCT04397926","Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer",[92],[1831],[25362],{"trials":25375,"activeCount":104},[],{"trials":25377,"activeCount":104},[],{"trials":25379,"activeCount":104},[],{"trials":25381,"activeCount":104},[],{"intervention":25383,"totalTrials":100,"cells":25384},"Antangiogenesis",{"EARLY_PHASE1":25385,"PHASE1":25387,"PHASE2":25399,"PHASE3":25401,"PHASE4":25403,"NA":25405},{"trials":25386,"activeCount":104},[],{"trials":25388,"activeCount":104},[25389],{"nctId":25390,"briefTitle":25391,"status":174,"phases":25392,"completion":25393,"start":25394,"enrollment":239,"conditions":25395,"interventions":25397},"NCT00262327","Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor",[92],"2006-02","2005-05",[25396],"Advanced Solid Tumor",[25383,25398],"endostatin gene",{"trials":25400,"activeCount":104},[],{"trials":25402,"activeCount":104},[],{"trials":25404,"activeCount":104},[],{"trials":25406,"activeCount":104},[],{"intervention":25398,"totalTrials":100,"cells":25408},{"EARLY_PHASE1":25409,"PHASE1":25411,"PHASE2":25417,"PHASE3":25419,"PHASE4":25421,"NA":25423},{"trials":25410,"activeCount":104},[],{"trials":25412,"activeCount":104},[25413],{"nctId":25390,"briefTitle":25391,"status":174,"phases":25414,"completion":25393,"start":25394,"enrollment":239,"conditions":25415,"interventions":25416},[92],[25396],[25383,25398],{"trials":25418,"activeCount":104},[],{"trials":25420,"activeCount":104},[],{"trials":25422,"activeCount":104},[],{"trials":25424,"activeCount":104},[],{"intervention":25426,"totalTrials":1255,"cells":25427},"conbercept",{"EARLY_PHASE1":25428,"PHASE1":25446,"PHASE2":25448,"PHASE3":25450,"PHASE4":25452,"NA":25454},{"trials":25429,"activeCount":104},[25430,25438],{"nctId":25431,"briefTitle":25432,"status":174,"phases":25433,"primaryCompletion":670,"completion":670,"start":25434,"enrollment":205,"conditions":25435,"interventions":25437},"NCT03973125","Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma",[91],"2014-08-28",[25436],"Circumscribed Choroidal Haemangioma",[25426],{"nctId":25439,"briefTitle":25440,"status":174,"phases":25441,"primaryCompletion":25442,"completion":25442,"start":25443,"enrollment":205,"conditions":25444,"interventions":25445},"NCT03571282","Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma",[91],"2019-06-06","2018-06-06",[25436],[25426],{"trials":25447,"activeCount":104},[],{"trials":25449,"activeCount":104},[],{"trials":25451,"activeCount":104},[],{"trials":25453,"activeCount":104},[],{"trials":25455,"activeCount":104},[],{"intervention":25457,"totalTrials":100,"cells":25458},"Rifaximin 200 mg",{"EARLY_PHASE1":25459,"PHASE1":25472,"PHASE2":25474,"PHASE3":25476,"PHASE4":25478,"NA":25480},{"trials":25460,"activeCount":104},[25461],{"nctId":25462,"briefTitle":25463,"status":174,"phases":25464,"primaryCompletion":1363,"completion":9270,"start":8775,"enrollment":1056,"conditions":25465,"interventions":25471},"NCT05786859","The Efficacy and Safety of Rifaximin Treatment",[91],[25466,25467,25468,5213,25469,25470],"Liver Failure, Acute on Chronic","Hepatic Encephalopathy","HBV","Rifaximin","Effect of Drug",[25457],{"trials":25473,"activeCount":104},[],{"trials":25475,"activeCount":104},[],{"trials":25477,"activeCount":104},[],{"trials":25479,"activeCount":104},[],{"trials":25481,"activeCount":104},[],{"intervention":25483,"totalTrials":100,"cells":25484},"ACM-1",{"EARLY_PHASE1":25485,"PHASE1":25494,"PHASE2":25496,"PHASE3":25498,"PHASE4":25500,"NA":25502},{"trials":25486,"activeCount":104},[25487],{"nctId":25488,"briefTitle":25489,"status":174,"phases":25490,"primaryCompletion":438,"completion":1374,"start":4810,"enrollment":1464,"conditions":25491,"interventions":25493},"NCT02448732","Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases",[91],[25492],"Neovascularization, Pathologic",[25483],{"trials":25495,"activeCount":104},[],{"trials":25497,"activeCount":104},[],{"trials":25499,"activeCount":104},[],{"trials":25501,"activeCount":104},[],{"trials":25503,"activeCount":104},[],{"intervention":25505,"totalTrials":100,"cells":25506},"Continuous oxygen",{"EARLY_PHASE1":25507,"PHASE1":25520,"PHASE2":25522,"PHASE3":25524,"PHASE4":25526,"NA":25528},{"trials":25508,"activeCount":104},[25509],{"nctId":25510,"briefTitle":25511,"status":174,"phases":25512,"primaryCompletion":4008,"completion":4008,"start":2303,"enrollment":25513,"conditions":25514,"interventions":25515},"NCT02465749","Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa",[91],404,[9237],[25505,25516,25517,25518,25519],"Compound thrombosis capsule sig: 1.5g\u002Ftid","Ginkgo biloba pills sig: 300mg\u002Ftid;","Vitamin B sig: 10mg\u002Ftid","Vitamin AD sig: 1 tablet\u002Ftid",{"trials":25521,"activeCount":104},[],{"trials":25523,"activeCount":104},[],{"trials":25525,"activeCount":104},[],{"trials":25527,"activeCount":104},[],{"trials":25529,"activeCount":104},[],{"intervention":25516,"totalTrials":100,"cells":25531},{"EARLY_PHASE1":25532,"PHASE1":25538,"PHASE2":25540,"PHASE3":25542,"PHASE4":25544,"NA":25546},{"trials":25533,"activeCount":104},[25534],{"nctId":25510,"briefTitle":25511,"status":174,"phases":25535,"primaryCompletion":4008,"completion":4008,"start":2303,"enrollment":25513,"conditions":25536,"interventions":25537},[91],[9237],[25505,25516,25517,25518,25519],{"trials":25539,"activeCount":104},[],{"trials":25541,"activeCount":104},[],{"trials":25543,"activeCount":104},[],{"trials":25545,"activeCount":104},[],{"trials":25547,"activeCount":104},[],{"intervention":25517,"totalTrials":100,"cells":25549},{"EARLY_PHASE1":25550,"PHASE1":25556,"PHASE2":25558,"PHASE3":25560,"PHASE4":25562,"NA":25564},{"trials":25551,"activeCount":104},[25552],{"nctId":25510,"briefTitle":25511,"status":174,"phases":25553,"primaryCompletion":4008,"completion":4008,"start":2303,"enrollment":25513,"conditions":25554,"interventions":25555},[91],[9237],[25505,25516,25517,25518,25519],{"trials":25557,"activeCount":104},[],{"trials":25559,"activeCount":104},[],{"trials":25561,"activeCount":104},[],{"trials":25563,"activeCount":104},[],{"trials":25565,"activeCount":104},[],{"intervention":25518,"totalTrials":100,"cells":25567},{"EARLY_PHASE1":25568,"PHASE1":25574,"PHASE2":25576,"PHASE3":25578,"PHASE4":25580,"NA":25582},{"trials":25569,"activeCount":104},[25570],{"nctId":25510,"briefTitle":25511,"status":174,"phases":25571,"primaryCompletion":4008,"completion":4008,"start":2303,"enrollment":25513,"conditions":25572,"interventions":25573},[91],[9237],[25505,25516,25517,25518,25519],{"trials":25575,"activeCount":104},[],{"trials":25577,"activeCount":104},[],{"trials":25579,"activeCount":104},[],{"trials":25581,"activeCount":104},[],{"trials":25583,"activeCount":104},[],{"intervention":25519,"totalTrials":100,"cells":25585},{"EARLY_PHASE1":25586,"PHASE1":25592,"PHASE2":25594,"PHASE3":25596,"PHASE4":25598,"NA":25600},{"trials":25587,"activeCount":104},[25588],{"nctId":25510,"briefTitle":25511,"status":174,"phases":25589,"primaryCompletion":4008,"completion":4008,"start":2303,"enrollment":25513,"conditions":25590,"interventions":25591},[91],[9237],[25505,25516,25517,25518,25519],{"trials":25593,"activeCount":104},[],{"trials":25595,"activeCount":104},[],{"trials":25597,"activeCount":104},[],{"trials":25599,"activeCount":104},[],{"trials":25601,"activeCount":104},[],{"intervention":25603,"totalTrials":100,"cells":25604},"Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis",{"EARLY_PHASE1":25605,"PHASE1":25614,"PHASE2":25616,"PHASE3":25618,"PHASE4":25620,"NA":25622},{"trials":25606,"activeCount":104},[25607],{"nctId":25608,"briefTitle":25609,"status":174,"phases":25610,"primaryCompletion":658,"start":1576,"enrollment":1339,"conditions":25611,"interventions":25613},"NCT02985346","Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis",[91],[25612],"Idiopathic Pulmonary Hemosiderosis",[25603],{"trials":25615,"activeCount":104},[],{"trials":25617,"activeCount":104},[],{"trials":25619,"activeCount":104},[],{"trials":25621,"activeCount":104},[],{"trials":25623,"activeCount":104},[],{"intervention":25625,"totalTrials":100,"cells":25626},"dexamethasone acetate",{"EARLY_PHASE1":25627,"PHASE1":25638,"PHASE2":25640,"PHASE3":25642,"PHASE4":25644,"NA":25646},{"trials":25628,"activeCount":104},[25629],{"nctId":25630,"briefTitle":25631,"status":328,"phases":25632,"primaryCompletion":3759,"completion":204,"start":2525,"enrollment":996,"conditions":25633,"interventions":25635},"NCT02837614","Evaluation of Preoperative Submucosal Dexamethasone in Third Molar Surgery",[91],[25634],"Impacted Third Molar Tooth",[25625,25636,25637],"submucosal dexamethasone","Amoxicillin and paracetamol",{"trials":25639,"activeCount":104},[],{"trials":25641,"activeCount":104},[],{"trials":25643,"activeCount":104},[],{"trials":25645,"activeCount":104},[],{"trials":25647,"activeCount":104},[],{"intervention":25636,"totalTrials":100,"cells":25649},{"EARLY_PHASE1":25650,"PHASE1":25656,"PHASE2":25658,"PHASE3":25660,"PHASE4":25662,"NA":25664},{"trials":25651,"activeCount":104},[25652],{"nctId":25630,"briefTitle":25631,"status":328,"phases":25653,"primaryCompletion":3759,"completion":204,"start":2525,"enrollment":996,"conditions":25654,"interventions":25655},[91],[25634],[25625,25636,25637],{"trials":25657,"activeCount":104},[],{"trials":25659,"activeCount":104},[],{"trials":25661,"activeCount":104},[],{"trials":25663,"activeCount":104},[],{"trials":25665,"activeCount":104},[],{"intervention":25637,"totalTrials":100,"cells":25667},{"EARLY_PHASE1":25668,"PHASE1":25674,"PHASE2":25676,"PHASE3":25678,"PHASE4":25680,"NA":25682},{"trials":25669,"activeCount":104},[25670],{"nctId":25630,"briefTitle":25631,"status":328,"phases":25671,"primaryCompletion":3759,"completion":204,"start":2525,"enrollment":996,"conditions":25672,"interventions":25673},[91],[25634],[25625,25636,25637],{"trials":25675,"activeCount":104},[],{"trials":25677,"activeCount":104},[],{"trials":25679,"activeCount":104},[],{"trials":25681,"activeCount":104},[],{"trials":25683,"activeCount":104},[],{"intervention":999,"totalTrials":3737,"cells":25685},{"EARLY_PHASE1":25686,"PHASE1":25688,"PHASE2":25690,"PHASE3":25712,"PHASE4":25749,"NA":25762},{"trials":25687,"activeCount":104},[],{"trials":25689,"activeCount":104},[],{"trials":25691,"activeCount":104},[25692,25696,25700,25704,25708],{"nctId":3860,"briefTitle":3861,"status":904,"phases":25693,"primaryCompletion":217,"completion":1657,"start":3863,"enrollment":104,"conditions":25694,"interventions":25695},[93],[19],[517,999],{"nctId":17035,"briefTitle":17036,"status":904,"phases":25697,"primaryCompletion":17038,"completion":17038,"start":218,"enrollment":104,"conditions":25698,"interventions":25699},[93],[19],[17026,999],{"nctId":991,"briefTitle":992,"status":174,"phases":25701,"primaryCompletion":994,"completion":994,"start":995,"enrollment":996,"conditions":25702,"interventions":25703},[93],[19],[284,999,1000],{"nctId":9159,"briefTitle":9160,"status":174,"phases":25705,"primaryCompletion":966,"completion":966,"start":9162,"enrollment":1339,"conditions":25706,"interventions":25707},[93],[19],[2906,999,9165],{"nctId":17042,"briefTitle":17043,"status":174,"phases":25709,"primaryCompletion":9151,"completion":9151,"start":17045,"enrollment":1389,"conditions":25710,"interventions":25711},[93],[19],[999,17026,17048],{"trials":25713,"activeCount":104},[25714,25718,25726,25730,25739,25743],{"nctId":17052,"briefTitle":17053,"status":174,"phases":25715,"primaryCompletion":17055,"completion":17056,"start":17057,"enrollment":189,"conditions":25716,"interventions":25717},[94],[19],[999,17026,17048],{"nctId":25719,"briefTitle":25720,"status":1091,"phases":25721,"primaryCompletion":25722,"completion":4267,"start":25723,"enrollment":1168,"conditions":25724,"interventions":25725},"NCT02867280","Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection",[94],"2019-08-31","2016-06-01",[19,15784],[999],{"nctId":2950,"briefTitle":2951,"status":174,"phases":25727,"primaryCompletion":1657,"completion":1657,"start":2953,"enrollment":2954,"conditions":25728,"interventions":25729},[94],[19],[353,999],{"nctId":25731,"briefTitle":25732,"status":174,"phases":25733,"primaryCompletion":25734,"completion":8700,"start":25735,"enrollment":25736,"conditions":25737,"interventions":25738},"NCT04143191","Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC",[94],"2021-09-15","2019-09-15",158,[19],[999],{"nctId":16989,"briefTitle":16990,"status":328,"phases":25740,"primaryCompletion":5478,"completion":3842,"start":1336,"enrollment":16992,"conditions":25741,"interventions":25742},[94],[19],[999,2906],{"nctId":25744,"briefTitle":25745,"status":1091,"phases":25746,"primaryCompletion":23419,"completion":23419,"start":4810,"enrollment":16961,"conditions":25747,"interventions":25748},"NCT02220088","The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial",[93,94],[19],[999],{"trials":25750,"activeCount":104},[25751,25755],{"nctId":15706,"briefTitle":15707,"status":328,"phases":25752,"primaryCompletion":829,"completion":829,"start":764,"enrollment":430,"conditions":25753,"interventions":25754},[95],[19],[15693,999],{"nctId":25756,"briefTitle":25757,"status":328,"phases":25758,"primaryCompletion":203,"completion":15865,"start":17342,"enrollment":2459,"conditions":25759,"interventions":25760},"NCT01409499","Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)",[95],[21126,19,999],[25761],"sorafenib",{"trials":25763,"activeCount":104},[25764,25768],{"nctId":2999,"briefTitle":3000,"status":174,"phases":25765,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":1192,"conditions":25766,"interventions":25767},[],[3005,3006,3007,3008,3009],[999,353],{"nctId":25769,"briefTitle":25770,"status":328,"phases":25771,"primaryCompletion":2953,"completion":2427,"start":25772,"enrollment":2419,"conditions":25773,"interventions":25774},"NCT05121571","The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study",[96],"2016-04-21",[19],[999],{"intervention":25776,"totalTrials":2627,"cells":25777},"Thymosin alpha 1",{"EARLY_PHASE1":25778,"PHASE1":25780,"PHASE2":25782,"PHASE3":25788,"PHASE4":25800,"NA":25811},{"trials":25779,"activeCount":104},[],{"trials":25781,"activeCount":104},[],{"trials":25783,"activeCount":104},[25784],{"nctId":2775,"briefTitle":2776,"status":328,"phases":25785,"primaryCompletion":2778,"completion":2778,"start":2691,"enrollment":2710,"conditions":25786,"interventions":25787},[93],[22],[2402,2781],{"trials":25789,"activeCount":104},[25790],{"nctId":25791,"briefTitle":25792,"status":328,"phases":25793,"primaryCompletion":25794,"completion":25795,"start":25796,"enrollment":25797,"conditions":25798,"interventions":25799},"NCT02867267","The Efficacy and Safety of Ta1 for Sepsis",[94],"2021-01-22","2021-03-23","2016-09-06",1106,[5808],[25776],{"trials":25801,"activeCount":104},[25802],{"nctId":25803,"briefTitle":25804,"status":328,"phases":25805,"primaryCompletion":25806,"completion":25807,"start":25808,"enrollment":239,"conditions":25809,"interventions":25810},"NCT02883595","Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis",[95],"2016-09-30","2016-12-31","2016-03-31",[5808],[2781],{"trials":25812,"activeCount":104},[25813],{"nctId":25814,"briefTitle":25815,"status":328,"phases":25816,"primaryCompletion":449,"completion":17342,"start":25817,"enrollment":25818,"conditions":25819,"interventions":25821},"NCT00711620","Efficacy of Thymosin alpha1 for Severe Sepsis",[96],"2008-05",366,[25820],"Severe Sepsis",[25776],{"intervention":25823,"totalTrials":1861,"cells":25824},"Ranibizumab",{"EARLY_PHASE1":25825,"PHASE1":25827,"PHASE2":25829,"PHASE3":25838,"PHASE4":25840,"NA":25851},{"trials":25826,"activeCount":104},[],{"trials":25828,"activeCount":104},[],{"trials":25830,"activeCount":104},[25831],{"nctId":25832,"briefTitle":25833,"status":174,"phases":25834,"primaryCompletion":670,"completion":670,"start":5311,"enrollment":1339,"conditions":25835,"interventions":25837},"NCT03973138","Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab",[92,93],[25836],"Diabetic Macular Edema",[25823],{"trials":25839,"activeCount":104},[],{"trials":25841,"activeCount":104},[25842],{"nctId":25843,"briefTitle":25844,"status":174,"phases":25845,"primaryCompletion":4317,"completion":4317,"start":18882,"enrollment":1339,"conditions":25846,"interventions":25850},"NCT04062370","Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion",[95],[25847,25848,25849,25823],"Retinal Vein Occlusion","Treatment","Photocoagulation Burn to Retina",[25823],{"trials":25852,"activeCount":104},[25853],{"nctId":25854,"briefTitle":25855,"status":328,"phases":25856,"primaryCompletion":25857,"completion":25857,"start":14788,"enrollment":406,"conditions":25858,"interventions":25860},"NCT02857491","Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy",[96],"2017-09-30",[25859],"Proliferative Diabetic Retinopathy",[25861],"ranibizumab",{"intervention":18388,"totalTrials":1861,"cells":25863},{"EARLY_PHASE1":25864,"PHASE1":25866,"PHASE2":25868,"PHASE3":25870,"PHASE4":25882,"NA":25884},{"trials":25865,"activeCount":104},[],{"trials":25867,"activeCount":104},[],{"trials":25869,"activeCount":104},[],{"trials":25871,"activeCount":104},[25872,25878],{"nctId":25873,"briefTitle":25874,"status":328,"phases":25875,"primaryCompletion":15560,"completion":15560,"start":754,"enrollment":226,"conditions":25876,"interventions":25877},"NCT00615667","Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)",[94],[18383,17351,18384],[18388],{"nctId":18377,"briefTitle":18378,"status":328,"phases":25879,"primaryCompletion":15560,"completion":15560,"start":18380,"enrollment":18381,"conditions":25880,"interventions":25881},[94],[18383,16697,18384,18385,18386],[18388,18366],{"trials":25883,"activeCount":104},[],{"trials":25885,"activeCount":104},[25886],{"nctId":25887,"briefTitle":25888,"status":174,"phases":25889,"primaryCompletion":7636,"start":25890,"enrollment":996,"conditions":25891,"interventions":25893},"NCT01068067","Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Recipients",[96],"2010-03",[25892],"Renal Transplantation",[18388],{"intervention":7904,"totalTrials":1255,"cells":25895},{"EARLY_PHASE1":25896,"PHASE1":25898,"PHASE2":25900,"PHASE3":25902,"PHASE4":25904,"NA":25906},{"trials":25897,"activeCount":104},[],{"trials":25899,"activeCount":104},[],{"trials":25901,"activeCount":104},[],{"trials":25903,"activeCount":104},[],{"trials":25905,"activeCount":104},[],{"trials":25907,"activeCount":104},[25908,25916],{"nctId":25909,"briefTitle":25910,"status":174,"phases":25911,"primaryCompletion":2085,"completion":3291,"start":15780,"enrollment":1389,"conditions":25912,"interventions":25914},"NCT01172626","Exploration of Genotype Based Personalized Prescription of Valproate Sodium in Anti-epileptic Treatment",[],[25913,7902],"Epilepsy",[25915,7904],"valproate sodium",{"nctId":7896,"briefTitle":7897,"status":328,"phases":25917,"primaryCompletion":2578,"completion":2578,"start":7899,"enrollment":314,"conditions":25918,"interventions":25919},[],[7901,7902],[7904,2308],{"intervention":25921,"totalTrials":1255,"cells":25922},"Nalbuphine",{"EARLY_PHASE1":25923,"PHASE1":25925,"PHASE2":25927,"PHASE3":25929,"PHASE4":25931,"NA":25933},{"trials":25924,"activeCount":104},[],{"trials":25926,"activeCount":104},[],{"trials":25928,"activeCount":104},[],{"trials":25930,"activeCount":104},[],{"trials":25932,"activeCount":104},[],{"trials":25934,"activeCount":104},[25935,25945],{"nctId":25936,"briefTitle":25937,"status":328,"phases":25938,"primaryCompletion":20651,"completion":16793,"start":25939,"enrollment":2184,"conditions":25940,"interventions":25942},"NCT03562611","Postoperative Pain and Discomfort After Orbital Decompression",[96],"2018-06-08",[1183,25941,16878],"Anesthesia",[25921,25943,25944],"Flurbiprofen Axetil","Nalbuphine and Flurbiprofen Axetil",{"nctId":25946,"briefTitle":25947,"status":328,"phases":25948,"primaryCompletion":25949,"completion":16793,"start":25950,"enrollment":16406,"conditions":25951,"interventions":25952},"NCT03422887","Nalbuphine and Flurbiprofen for Oculoplastic Surgery",[96],"2018-08-31","2018-01-18",[1183,25941,16878],[25921,25943,25944],{"intervention":25943,"totalTrials":1255,"cells":25954},{"EARLY_PHASE1":25955,"PHASE1":25957,"PHASE2":25959,"PHASE3":25961,"PHASE4":25963,"NA":25965},{"trials":25956,"activeCount":104},[],{"trials":25958,"activeCount":104},[],{"trials":25960,"activeCount":104},[],{"trials":25962,"activeCount":104},[],{"trials":25964,"activeCount":104},[],{"trials":25966,"activeCount":104},[25967,25971],{"nctId":25936,"briefTitle":25937,"status":328,"phases":25968,"primaryCompletion":20651,"completion":16793,"start":25939,"enrollment":2184,"conditions":25969,"interventions":25970},[96],[1183,25941,16878],[25921,25943,25944],{"nctId":25946,"briefTitle":25947,"status":328,"phases":25972,"primaryCompletion":25949,"completion":16793,"start":25950,"enrollment":16406,"conditions":25973,"interventions":25974},[96],[1183,25941,16878],[25921,25943,25944],{"intervention":25944,"totalTrials":1255,"cells":25976},{"EARLY_PHASE1":25977,"PHASE1":25979,"PHASE2":25981,"PHASE3":25983,"PHASE4":25985,"NA":25987},{"trials":25978,"activeCount":104},[],{"trials":25980,"activeCount":104},[],{"trials":25982,"activeCount":104},[],{"trials":25984,"activeCount":104},[],{"trials":25986,"activeCount":104},[],{"trials":25988,"activeCount":104},[25989,25993],{"nctId":25936,"briefTitle":25937,"status":328,"phases":25990,"primaryCompletion":20651,"completion":16793,"start":25939,"enrollment":2184,"conditions":25991,"interventions":25992},[96],[1183,25941,16878],[25921,25943,25944],{"nctId":25946,"briefTitle":25947,"status":328,"phases":25994,"primaryCompletion":25949,"completion":16793,"start":25950,"enrollment":16406,"conditions":25995,"interventions":25996},[96],[1183,25941,16878],[25921,25943,25944],{"intervention":17964,"totalTrials":1255,"cells":25998},{"EARLY_PHASE1":25999,"PHASE1":26001,"PHASE2":26003,"PHASE3":26005,"PHASE4":26011,"NA":26013},{"trials":26000,"activeCount":104},[],{"trials":26002,"activeCount":104},[],{"trials":26004,"activeCount":104},[],{"trials":26006,"activeCount":104},[26007],{"nctId":17956,"briefTitle":17957,"status":1091,"phases":26008,"primaryCompletion":17372,"completion":17372,"start":17959,"enrollment":1066,"conditions":26009,"interventions":26010},[94],[1830,3458,17961,17962,28],[17945,17964],{"trials":26012,"activeCount":104},[],{"trials":26014,"activeCount":104},[26015],{"nctId":26016,"briefTitle":26017,"status":328,"phases":26018,"primaryCompletion":4644,"completion":4644,"start":15560,"enrollment":1192,"conditions":26019,"interventions":26020},"NCT00721773","Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients",[96],[19393],[26021,26022,26023,17964],"Benazepril","Valsartan","Benazepril+Valsartan",{"intervention":26025,"totalTrials":1255,"cells":26026},"proparacaine",{"EARLY_PHASE1":26027,"PHASE1":26029,"PHASE2":26031,"PHASE3":26033,"PHASE4":26035,"NA":26037},{"trials":26028,"activeCount":104},[],{"trials":26030,"activeCount":104},[],{"trials":26032,"activeCount":104},[],{"trials":26034,"activeCount":104},[],{"trials":26036,"activeCount":104},[],{"trials":26038,"activeCount":104},[26039,26046],{"nctId":26040,"briefTitle":26041,"status":328,"phases":26042,"primaryCompletion":7636,"completion":7636,"start":4067,"enrollment":8569,"conditions":26043,"interventions":26044},"NCT02609997","Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens",[96],[31],[26045,26025],"Subconjunctival dexamethasone",{"nctId":26047,"briefTitle":26048,"status":174,"phases":26049,"primaryCompletion":428,"completion":48,"start":2525,"enrollment":1228,"conditions":26050,"interventions":26052},"NCT02613013","Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure",[96],[26051],"Glaucoma, Angle-Closure",[26053,26054],"Pilocarpine","Proparacaine",{"intervention":18231,"totalTrials":1255,"cells":26056},{"EARLY_PHASE1":26057,"PHASE1":26059,"PHASE2":26061,"PHASE3":26063,"PHASE4":26069,"NA":26071},{"trials":26058,"activeCount":104},[],{"trials":26060,"activeCount":104},[],{"trials":26062,"activeCount":104},[],{"trials":26064,"activeCount":104},[26065],{"nctId":18223,"briefTitle":18224,"status":328,"phases":26066,"primaryCompletion":18226,"completion":18226,"start":2232,"enrollment":18227,"conditions":26067,"interventions":26068},[94],[3035,18229],[18212,18231,18232],{"trials":26070,"activeCount":104},[],{"trials":26072,"activeCount":104},[26073],{"nctId":26074,"briefTitle":26075,"status":328,"phases":26076,"primaryCompletion":429,"completion":1500,"start":4644,"enrollment":1192,"conditions":26077,"interventions":26078},"NCT02552745","Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization",[],[19],[18231],{"intervention":18232,"totalTrials":1255,"cells":26080},{"EARLY_PHASE1":26081,"PHASE1":26083,"PHASE2":26085,"PHASE3":26087,"PHASE4":26093,"NA":26095},{"trials":26082,"activeCount":104},[],{"trials":26084,"activeCount":104},[],{"trials":26086,"activeCount":104},[],{"trials":26088,"activeCount":104},[26089],{"nctId":18223,"briefTitle":18224,"status":328,"phases":26090,"primaryCompletion":18226,"completion":18226,"start":2232,"enrollment":18227,"conditions":26091,"interventions":26092},[94],[3035,18229],[18212,18231,18232],{"trials":26094,"activeCount":104},[],{"trials":26096,"activeCount":104},[26097],{"nctId":26098,"briefTitle":26099,"status":174,"phases":26100,"primaryCompletion":7887,"completion":549,"start":1336,"enrollment":1076,"conditions":26101,"interventions":26102},"NCT03045484","Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy",[96],[16],[26103],"Controlled-release oxycodone",{"intervention":26105,"totalTrials":1255,"cells":26106},"Subconjunctival dexamethasone and general anesthesia",{"EARLY_PHASE1":26107,"PHASE1":26109,"PHASE2":26111,"PHASE3":26113,"PHASE4":26115,"NA":26117},{"trials":26108,"activeCount":104},[],{"trials":26110,"activeCount":104},[],{"trials":26112,"activeCount":104},[],{"trials":26114,"activeCount":104},[],{"trials":26116,"activeCount":104},[],{"trials":26118,"activeCount":104},[26119,26127],{"nctId":26120,"briefTitle":26121,"status":174,"phases":26122,"primaryCompletion":3953,"completion":3953,"start":3759,"enrollment":15309,"conditions":26123,"interventions":26125},"NCT02593669","The Effect of Cataract Surgery on Sleep Quality",[96],[31,26124],"Sleep",[26105,26126],"Viscoelastic materials",{"nctId":26128,"briefTitle":26129,"status":328,"phases":26130,"primaryCompletion":1427,"completion":1427,"start":17342,"enrollment":226,"conditions":26131,"interventions":26132},"NCT02581046","Effect of the Timing of Cataract Surgery on Complications in Patients With Bilateral Congenital Cataracts",[96],[31],[26105],{"intervention":26134,"totalTrials":1255,"cells":26135},"atorvastatin",{"EARLY_PHASE1":26136,"PHASE1":26138,"PHASE2":26140,"PHASE3":26142,"PHASE4":26144,"NA":26154},{"trials":26137,"activeCount":104},[],{"trials":26139,"activeCount":104},[],{"trials":26141,"activeCount":104},[],{"trials":26143,"activeCount":104},[],{"trials":26145,"activeCount":104},[26146],{"nctId":26147,"briefTitle":26148,"status":174,"phases":26149,"primaryCompletion":1980,"start":1428,"enrollment":32,"conditions":26150,"interventions":26153},"NCT02023892","Single Dose of Atorvastatin and Circulating Endothelial Microparticles",[95],[26151,26152],"Endothelium","Hydroxymethylglutaryl-CoA Reductase Inhibitors",[26134],{"trials":26155,"activeCount":104},[26156],{"nctId":26157,"briefTitle":26158,"status":174,"phases":26159,"primaryCompletion":819,"completion":3759,"start":3382,"enrollment":1248,"conditions":26160,"interventions":26162},"NCT00818103","Characteristic Study on Chinese Patients With Multiple Sclerosis",[96],[26161],"Multiple Sclerosis",[26134,26163,26164],"β-interferon","EPO",{"intervention":26166,"totalTrials":1255,"cells":26167},"PEG-rhG-CSF",{"EARLY_PHASE1":26168,"PHASE1":26170,"PHASE2":26179,"PHASE3":26181,"PHASE4":26183,"NA":26185},{"trials":26169,"activeCount":104},[],{"trials":26171,"activeCount":104},[26172],{"nctId":26173,"briefTitle":26174,"status":174,"phases":26175,"primaryCompletion":710,"completion":733,"start":3178,"enrollment":959,"conditions":26176,"interventions":26178},"NCT05222009","G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma",[92],[26177,1240],"Granulocyte Colony-Stimulating Factor",[26166,26166],{"trials":26180,"activeCount":104},[],{"trials":26182,"activeCount":104},[],{"trials":26184,"activeCount":104},[],{"trials":26186,"activeCount":104},[26187],{"nctId":26188,"briefTitle":26189,"status":174,"phases":26190,"primaryCompletion":1827,"completion":818,"start":1575,"enrollment":942,"conditions":26191,"interventions":26192},"NCT05156554","PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation",[96],[15199],[26166,26193],"rhG-CSF",{"intervention":26195,"totalTrials":100,"cells":26196},"allopurinol",{"EARLY_PHASE1":26197,"PHASE1":26199,"PHASE2":26201,"PHASE3":26203,"PHASE4":26205,"NA":26207},{"trials":26198,"activeCount":104},[],{"trials":26200,"activeCount":104},[],{"trials":26202,"activeCount":104},[],{"trials":26204,"activeCount":104},[],{"trials":26206,"activeCount":104},[],{"trials":26208,"activeCount":104},[26209],{"nctId":26210,"briefTitle":26211,"status":328,"phases":26212,"primaryCompletion":26213,"completion":26213,"start":16217,"enrollment":492,"conditions":26214,"interventions":26215},"NCT00793585","A Controlled Study of Uric Acid on the Progression of IgA Nephropathy",[96],"2009-06",[9015],[26195],{"intervention":26217,"totalTrials":100,"cells":26218},"Bisphosphonates",{"EARLY_PHASE1":26219,"PHASE1":26221,"PHASE2":26223,"PHASE3":26225,"PHASE4":26227,"NA":26229},{"trials":26220,"activeCount":104},[],{"trials":26222,"activeCount":104},[],{"trials":26224,"activeCount":104},[],{"trials":26226,"activeCount":104},[],{"trials":26228,"activeCount":104},[],{"trials":26230,"activeCount":104},[26231],{"nctId":26232,"briefTitle":26233,"status":174,"phases":26234,"primaryCompletion":26235,"completion":63,"start":26236,"enrollment":14982,"conditions":26237,"interventions":26238},"NCT03543072","A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Postmenopausal Breast Cancer Patients",[],"2021-06-15","2018-06-15",[28],[26217],{"intervention":26240,"totalTrials":100,"cells":26241},"cyclophosphamide , methotrexate , vinorelbine ,capecitabine",{"EARLY_PHASE1":26242,"PHASE1":26244,"PHASE2":26246,"PHASE3":26248,"PHASE4":26250,"NA":26252},{"trials":26243,"activeCount":104},[],{"trials":26245,"activeCount":104},[],{"trials":26247,"activeCount":104},[],{"trials":26249,"activeCount":104},[],{"trials":26251,"activeCount":104},[],{"trials":26253,"activeCount":104},[26254],{"nctId":26255,"briefTitle":26256,"status":328,"phases":26257,"primaryCompletion":8568,"completion":8568,"start":2761,"enrollment":26258,"conditions":26259,"interventions":26260},"NCT06373744","Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients",[],597,[28],[26240],{"intervention":26262,"totalTrials":100,"cells":26263},"oral chloral hydrate",{"EARLY_PHASE1":26264,"PHASE1":26266,"PHASE2":26268,"PHASE3":26270,"PHASE4":26272,"NA":26274},{"trials":26265,"activeCount":104},[],{"trials":26267,"activeCount":104},[],{"trials":26269,"activeCount":104},[],{"trials":26271,"activeCount":104},[],{"trials":26273,"activeCount":104},[],{"trials":26275,"activeCount":104},[26276],{"nctId":26277,"briefTitle":26278,"status":328,"phases":26279,"primaryCompletion":5478,"completion":5478,"start":1576,"enrollment":820,"conditions":26280,"interventions":26282},"NCT03242629","Comparison Between Oral and Enema of Chloral Hydrate",[96],[26281],"Congenital Cataract",[26262,26283],"enema chloral hydrate",{"intervention":26283,"totalTrials":100,"cells":26285},{"EARLY_PHASE1":26286,"PHASE1":26288,"PHASE2":26290,"PHASE3":26292,"PHASE4":26294,"NA":26296},{"trials":26287,"activeCount":104},[],{"trials":26289,"activeCount":104},[],{"trials":26291,"activeCount":104},[],{"trials":26293,"activeCount":104},[],{"trials":26295,"activeCount":104},[],{"trials":26297,"activeCount":104},[26298],{"nctId":26277,"briefTitle":26278,"status":328,"phases":26299,"primaryCompletion":5478,"completion":5478,"start":1576,"enrollment":820,"conditions":26300,"interventions":26301},[96],[26281],[26262,26283],{"intervention":26303,"totalTrials":100,"cells":26304},"verteporfin",{"EARLY_PHASE1":26305,"PHASE1":26307,"PHASE2":26309,"PHASE3":26311,"PHASE4":26313,"NA":26315},{"trials":26306,"activeCount":104},[],{"trials":26308,"activeCount":104},[],{"trials":26310,"activeCount":104},[],{"trials":26312,"activeCount":104},[],{"trials":26314,"activeCount":104},[],{"trials":26316,"activeCount":104},[26317],{"nctId":26318,"briefTitle":26319,"status":328,"phases":26320,"primaryCompletion":26321,"completion":26321,"start":26322,"enrollment":996,"conditions":26323,"interventions":26324},"NCT03459144","Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen",[96],"2015-07-30","2012-12-01",[19525],[26303,26325],"verteporfin and ranibizumab",{"intervention":26325,"totalTrials":100,"cells":26327},{"EARLY_PHASE1":26328,"PHASE1":26330,"PHASE2":26332,"PHASE3":26334,"PHASE4":26336,"NA":26338},{"trials":26329,"activeCount":104},[],{"trials":26331,"activeCount":104},[],{"trials":26333,"activeCount":104},[],{"trials":26335,"activeCount":104},[],{"trials":26337,"activeCount":104},[],{"trials":26339,"activeCount":104},[26340],{"nctId":26318,"briefTitle":26319,"status":328,"phases":26341,"primaryCompletion":26321,"completion":26321,"start":26322,"enrollment":996,"conditions":26342,"interventions":26343},[96],[19525],[26303,26325],{"intervention":26345,"totalTrials":100,"cells":26346},"Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate",{"EARLY_PHASE1":26347,"PHASE1":26349,"PHASE2":26351,"PHASE3":26353,"PHASE4":26355,"NA":26357},{"trials":26348,"activeCount":104},[],{"trials":26350,"activeCount":104},[],{"trials":26352,"activeCount":104},[],{"trials":26354,"activeCount":104},[],{"trials":26356,"activeCount":104},[],{"trials":26358,"activeCount":104},[26359],{"nctId":26360,"briefTitle":26361,"status":328,"phases":26362,"primaryCompletion":26363,"completion":26364,"start":26365,"enrollment":11675,"conditions":26366,"interventions":26368},"NCT04238429","Whitening Efficacy of Dentifrice Containing 10% High Cleaning Silica, 0.5% Sodium Phytate and 0.5% Sodium Pyrophosphate",[96],"2018-09-28","2018-10-05","2018-05-07",[26367],"Tooth Bleaching",[26345,26369],"Control toothpaste",{"intervention":26369,"totalTrials":100,"cells":26371},{"EARLY_PHASE1":26372,"PHASE1":26374,"PHASE2":26376,"PHASE3":26378,"PHASE4":26380,"NA":26382},{"trials":26373,"activeCount":104},[],{"trials":26375,"activeCount":104},[],{"trials":26377,"activeCount":104},[],{"trials":26379,"activeCount":104},[],{"trials":26381,"activeCount":104},[],{"trials":26383,"activeCount":104},[26384],{"nctId":26360,"briefTitle":26361,"status":328,"phases":26385,"primaryCompletion":26363,"completion":26364,"start":26365,"enrollment":11675,"conditions":26386,"interventions":26387},[96],[26367],[26345,26369],{"intervention":25915,"totalTrials":100,"cells":26389},{"EARLY_PHASE1":26390,"PHASE1":26392,"PHASE2":26394,"PHASE3":26396,"PHASE4":26398,"NA":26400},{"trials":26391,"activeCount":104},[],{"trials":26393,"activeCount":104},[],{"trials":26395,"activeCount":104},[],{"trials":26397,"activeCount":104},[],{"trials":26399,"activeCount":104},[],{"trials":26401,"activeCount":104},[26402],{"nctId":25909,"briefTitle":25910,"status":174,"phases":26403,"primaryCompletion":2085,"completion":3291,"start":15780,"enrollment":1389,"conditions":26404,"interventions":26405},[],[25913,7902],[25915,7904],{"intervention":26407,"totalTrials":100,"cells":26408},"Thymosin-α1",{"EARLY_PHASE1":26409,"PHASE1":26411,"PHASE2":26413,"PHASE3":26415,"PHASE4":26417,"NA":26419},{"trials":26410,"activeCount":104},[],{"trials":26412,"activeCount":104},[],{"trials":26414,"activeCount":104},[],{"trials":26416,"activeCount":104},[],{"trials":26418,"activeCount":104},[],{"trials":26420,"activeCount":104},[26421],{"nctId":26422,"briefTitle":26423,"status":328,"phases":26424,"primaryCompletion":26425,"completion":3099,"start":26426,"enrollment":820,"conditions":26427,"interventions":26428},"NCT03082885","The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF",[96],"2019-06-02","2017-04-10",[5153],[26407],{"intervention":26430,"totalTrials":100,"cells":26431},"Dentifrice Containing Ilex Rotunda Thunb",{"EARLY_PHASE1":26432,"PHASE1":26434,"PHASE2":26436,"PHASE3":26438,"PHASE4":26440,"NA":26442},{"trials":26433,"activeCount":104},[],{"trials":26435,"activeCount":104},[],{"trials":26437,"activeCount":104},[],{"trials":26439,"activeCount":104},[],{"trials":26441,"activeCount":104},[],{"trials":26443,"activeCount":104},[26444],{"nctId":26445,"briefTitle":26446,"status":328,"phases":26447,"primaryCompletion":25349,"completion":25349,"start":2085,"enrollment":1339,"conditions":26448,"interventions":26451},"NCT02313558","Efficacy of a Commercial Dentifrice Containing Ilex Rotunda Thunb Extract for Dental Plaque and Gingivitis",[96],[26449,26450],"Gingivitis","Dental Plaque",[26430,26452],"Control dentifrice",{"intervention":26452,"totalTrials":100,"cells":26454},{"EARLY_PHASE1":26455,"PHASE1":26457,"PHASE2":26459,"PHASE3":26461,"PHASE4":26463,"NA":26465},{"trials":26456,"activeCount":104},[],{"trials":26458,"activeCount":104},[],{"trials":26460,"activeCount":104},[],{"trials":26462,"activeCount":104},[],{"trials":26464,"activeCount":104},[],{"trials":26466,"activeCount":104},[26467],{"nctId":26445,"briefTitle":26446,"status":328,"phases":26468,"primaryCompletion":25349,"completion":25349,"start":2085,"enrollment":1339,"conditions":26469,"interventions":26470},[96],[26449,26450],[26430,26452],{"intervention":26472,"totalTrials":100,"cells":26473},"prophylactic HPV vaccine",{"EARLY_PHASE1":26474,"PHASE1":26476,"PHASE2":26478,"PHASE3":26480,"PHASE4":26482,"NA":26484},{"trials":26475,"activeCount":104},[],{"trials":26477,"activeCount":104},[],{"trials":26479,"activeCount":104},[],{"trials":26481,"activeCount":104},[],{"trials":26483,"activeCount":104},[],{"trials":26485,"activeCount":104},[26486],{"nctId":26487,"briefTitle":26488,"status":174,"phases":26489,"primaryCompletion":1093,"completion":1064,"start":26490,"enrollment":1248,"conditions":26491,"interventions":26494},"NCT05838157","The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age",[],"2023-05-04",[26492,26493],"Menstrual Disorder","Premature Ovarian Failure",[26472],{"intervention":26045,"totalTrials":100,"cells":26496},{"EARLY_PHASE1":26497,"PHASE1":26499,"PHASE2":26501,"PHASE3":26503,"PHASE4":26505,"NA":26507},{"trials":26498,"activeCount":104},[],{"trials":26500,"activeCount":104},[],{"trials":26502,"activeCount":104},[],{"trials":26504,"activeCount":104},[],{"trials":26506,"activeCount":104},[],{"trials":26508,"activeCount":104},[26509],{"nctId":26040,"briefTitle":26041,"status":328,"phases":26510,"primaryCompletion":7636,"completion":7636,"start":4067,"enrollment":8569,"conditions":26511,"interventions":26512},[96],[31],[26045,26025],{"intervention":26514,"totalTrials":100,"cells":26515},"autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm",{"EARLY_PHASE1":26516,"PHASE1":26518,"PHASE2":26520,"PHASE3":26522,"PHASE4":26524,"NA":26526},{"trials":26517,"activeCount":104},[],{"trials":26519,"activeCount":104},[],{"trials":26521,"activeCount":104},[],{"trials":26523,"activeCount":104},[],{"trials":26525,"activeCount":104},[],{"trials":26527,"activeCount":104},[26528],{"nctId":26529,"briefTitle":26530,"status":174,"phases":26531,"primaryCompletion":658,"completion":26532,"start":21663,"enrollment":205,"conditions":26533,"interventions":26535},"NCT03639506","Clinical Application of Autologous Mitochondria Transplantation for Improving Oocyte Quality.",[96],"2021-09",[26534],"Repetition Failure",[26514,26536],"intracytoplasmic sperm",{"intervention":26536,"totalTrials":100,"cells":26538},{"EARLY_PHASE1":26539,"PHASE1":26541,"PHASE2":26543,"PHASE3":26545,"PHASE4":26547,"NA":26549},{"trials":26540,"activeCount":104},[],{"trials":26542,"activeCount":104},[],{"trials":26544,"activeCount":104},[],{"trials":26546,"activeCount":104},[],{"trials":26548,"activeCount":104},[],{"trials":26550,"activeCount":104},[26551],{"nctId":26529,"briefTitle":26530,"status":174,"phases":26552,"primaryCompletion":658,"completion":26532,"start":21663,"enrollment":205,"conditions":26553,"interventions":26554},[96],[26534],[26514,26536],{"intervention":26556,"totalTrials":100,"cells":26557},"Montelukast",{"EARLY_PHASE1":26558,"PHASE1":26560,"PHASE2":26562,"PHASE3":26564,"PHASE4":26566,"NA":26568},{"trials":26559,"activeCount":104},[],{"trials":26561,"activeCount":104},[],{"trials":26563,"activeCount":104},[],{"trials":26565,"activeCount":104},[],{"trials":26567,"activeCount":104},[],{"trials":26569,"activeCount":104},[26570],{"nctId":26571,"briefTitle":26572,"status":174,"phases":26573,"primaryCompletion":658,"start":19890,"enrollment":1389,"conditions":26574,"interventions":26576},"NCT02505113","Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis",[],[26575],"Portal Vein, Cavernous Transformation Of",[26556],{"intervention":26578,"totalTrials":100,"cells":26579},"Strabismus diagnostic system.",{"EARLY_PHASE1":26580,"PHASE1":26582,"PHASE2":26584,"PHASE3":26586,"PHASE4":26588,"NA":26590},{"trials":26581,"activeCount":104},[],{"trials":26583,"activeCount":104},[],{"trials":26585,"activeCount":104},[],{"trials":26587,"activeCount":104},[],{"trials":26589,"activeCount":104},[],{"trials":26591,"activeCount":104},[26592],{"nctId":26593,"briefTitle":26594,"status":174,"phases":26595,"primaryCompletion":26596,"completion":26596,"start":9151,"enrollment":1510,"conditions":26597,"interventions":26600},"NCT04416776","Validation of the Utility of Strabismus Intelligent Diagnostic System",[],"2020-06-10",[26598,26599],"Ophthalmological Disorder","Strabismus",[26578],{"intervention":26602,"totalTrials":100,"cells":26603},"noncorticosteroid systemic immunomodulatory therapy",{"EARLY_PHASE1":26604,"PHASE1":26606,"PHASE2":26608,"PHASE3":26610,"PHASE4":26612,"NA":26614},{"trials":26605,"activeCount":104},[],{"trials":26607,"activeCount":104},[],{"trials":26609,"activeCount":104},[],{"trials":26611,"activeCount":104},[],{"trials":26613,"activeCount":104},[],{"trials":26615,"activeCount":104},[26616],{"nctId":26617,"briefTitle":26618,"status":174,"phases":26619,"primaryCompletion":26620,"completion":26621,"start":26622,"enrollment":1192,"conditions":26623,"interventions":26625},"NCT05120687","Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH",[],"2024-10-06","2025-10-06","2021-10-15",[26624],"Vogt Koyanagi Harada Disease (VKH)",[26602],{"intervention":26627,"totalTrials":100,"cells":26628},"EEN",{"EARLY_PHASE1":26629,"PHASE1":26631,"PHASE2":26633,"PHASE3":26635,"PHASE4":26637,"NA":26639},{"trials":26630,"activeCount":104},[],{"trials":26632,"activeCount":104},[],{"trials":26634,"activeCount":104},[],{"trials":26636,"activeCount":104},[],{"trials":26638,"activeCount":104},[],{"trials":26640,"activeCount":104},[26641],{"nctId":26642,"briefTitle":26643,"status":328,"phases":26644,"primaryCompletion":2525,"start":3291,"enrollment":1727,"conditions":26645,"interventions":26647},"NCT02887287","Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease",[],[26646],"Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease With Complications or Failure of Medical Treatment",[26627],{"intervention":26649,"totalTrials":100,"cells":26650},"Standard medical therapy",{"EARLY_PHASE1":26651,"PHASE1":26653,"PHASE2":26655,"PHASE3":26657,"PHASE4":26659,"NA":26661},{"trials":26652,"activeCount":104},[],{"trials":26654,"activeCount":104},[],{"trials":26656,"activeCount":104},[],{"trials":26658,"activeCount":104},[],{"trials":26660,"activeCount":104},[],{"trials":26662,"activeCount":104},[26663],{"nctId":26664,"briefTitle":26665,"status":328,"phases":26666,"primaryCompletion":26667,"completion":26668,"start":26669,"enrollment":1389,"conditions":26670,"interventions":26672},"NCT03106116","Efficacy of Enhanced External Counterpulsation on Ventricular Function",[96],"2018-12-30","2019-03-30","2017-03-15",[26671],"Coronary Heart Disease",[26649],{"intervention":26674,"totalTrials":100,"cells":26675},"exenatide",{"EARLY_PHASE1":26676,"PHASE1":26678,"PHASE2":26680,"PHASE3":26682,"PHASE4":26684,"NA":26686},{"trials":26677,"activeCount":104},[],{"trials":26679,"activeCount":104},[],{"trials":26681,"activeCount":104},[],{"trials":26683,"activeCount":104},[],{"trials":26685,"activeCount":104},[],{"trials":26687,"activeCount":104},[26688],{"nctId":26689,"briefTitle":26690,"status":328,"phases":26691,"primaryCompletion":16009,"completion":7636,"start":15780,"enrollment":7224,"conditions":26692,"interventions":26693},"NCT01147627","Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients",[96],[15450,14287],[26674,26694,26695],"Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R","Pioglitazone",{"intervention":26694,"totalTrials":100,"cells":26697},{"EARLY_PHASE1":26698,"PHASE1":26700,"PHASE2":26702,"PHASE3":26704,"PHASE4":26706,"NA":26708},{"trials":26699,"activeCount":104},[],{"trials":26701,"activeCount":104},[],{"trials":26703,"activeCount":104},[],{"trials":26705,"activeCount":104},[],{"trials":26707,"activeCount":104},[],{"trials":26709,"activeCount":104},[26710],{"nctId":26689,"briefTitle":26690,"status":328,"phases":26711,"primaryCompletion":16009,"completion":7636,"start":15780,"enrollment":7224,"conditions":26712,"interventions":26713},[96],[15450,14287],[26674,26694,26695],{"intervention":26695,"totalTrials":100,"cells":26715},{"EARLY_PHASE1":26716,"PHASE1":26718,"PHASE2":26720,"PHASE3":26722,"PHASE4":26724,"NA":26726},{"trials":26717,"activeCount":104},[],{"trials":26719,"activeCount":104},[],{"trials":26721,"activeCount":104},[],{"trials":26723,"activeCount":104},[],{"trials":26725,"activeCount":104},[],{"trials":26727,"activeCount":104},[26728],{"nctId":26689,"briefTitle":26690,"status":328,"phases":26729,"primaryCompletion":16009,"completion":7636,"start":15780,"enrollment":7224,"conditions":26730,"interventions":26731},[96],[15450,14287],[26674,26694,26695],{"intervention":26733,"totalTrials":100,"cells":26734},"photodynamic therapy",{"EARLY_PHASE1":26735,"PHASE1":26737,"PHASE2":26739,"PHASE3":26741,"PHASE4":26743,"NA":26745},{"trials":26736,"activeCount":104},[],{"trials":26738,"activeCount":104},[],{"trials":26740,"activeCount":104},[],{"trials":26742,"activeCount":104},[],{"trials":26744,"activeCount":104},[],{"trials":26746,"activeCount":104},[26747],{"nctId":26748,"briefTitle":26749,"status":328,"phases":26750,"primaryCompletion":26751,"completion":24929,"start":26752,"enrollment":1218,"conditions":26753,"interventions":26754},"NCT04429139","Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study",[96],"2018-05-30","2011-02-01",[3293],[26733],{"intervention":26053,"totalTrials":100,"cells":26756},{"EARLY_PHASE1":26757,"PHASE1":26759,"PHASE2":26761,"PHASE3":26763,"PHASE4":26765,"NA":26767},{"trials":26758,"activeCount":104},[],{"trials":26760,"activeCount":104},[],{"trials":26762,"activeCount":104},[],{"trials":26764,"activeCount":104},[],{"trials":26766,"activeCount":104},[],{"trials":26768,"activeCount":104},[26769],{"nctId":26047,"briefTitle":26048,"status":174,"phases":26770,"primaryCompletion":428,"completion":48,"start":2525,"enrollment":1228,"conditions":26771,"interventions":26772},[96],[26051],[26053,26054],{"intervention":223,"totalTrials":100,"cells":26774},{"EARLY_PHASE1":26775,"PHASE1":26777,"PHASE2":26779,"PHASE3":26781,"PHASE4":26783,"NA":26785},{"trials":26776,"activeCount":104},[],{"trials":26778,"activeCount":104},[],{"trials":26780,"activeCount":104},[],{"trials":26782,"activeCount":104},[],{"trials":26784,"activeCount":104},[],{"trials":26786,"activeCount":104},[26787],{"nctId":213,"briefTitle":214,"status":174,"phases":26788,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":26789,"interventions":26790},[96],[221],[223,160],{"intervention":26792,"totalTrials":100,"cells":26793},"Corticosteroids, immunosuppressors, biological agents",{"EARLY_PHASE1":26794,"PHASE1":26796,"PHASE2":26798,"PHASE3":26800,"PHASE4":26802,"NA":26804},{"trials":26795,"activeCount":104},[],{"trials":26797,"activeCount":104},[],{"trials":26799,"activeCount":104},[],{"trials":26801,"activeCount":104},[],{"trials":26803,"activeCount":104},[],{"trials":26805,"activeCount":104},[26806],{"nctId":26807,"briefTitle":26808,"status":174,"phases":26809,"primaryCompletion":26810,"completion":10905,"start":26811,"enrollment":26812,"conditions":26813,"interventions":26817},"NCT04849819","the SDMEAI Study: a Multi-center Epidemiological Study",[],"2025-04-22","2021-04-22",1000,[26814,26815,26816],"Eye Involvement of Systemic Diseaes","Adverse Drug Effect on Eye","Artificial Intelligence",[26792],{"intervention":26819,"totalTrials":100,"cells":26820},"contrast",{"EARLY_PHASE1":26821,"PHASE1":26823,"PHASE2":26825,"PHASE3":26827,"PHASE4":26829,"NA":26831},{"trials":26822,"activeCount":104},[],{"trials":26824,"activeCount":104},[],{"trials":26826,"activeCount":104},[],{"trials":26828,"activeCount":104},[],{"trials":26830,"activeCount":104},[],{"trials":26832,"activeCount":104},[26833],{"nctId":26834,"briefTitle":26835,"status":328,"phases":26836,"primaryCompletion":5352,"completion":5352,"start":188,"enrollment":26837,"conditions":26838,"interventions":26840},"NCT02650336","Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial",[],592,[26839],"Contrast Induced Nephropathy",[26819],{"intervention":26842,"totalTrials":100,"cells":26843},"part1:teprenone",{"EARLY_PHASE1":26844,"PHASE1":26846,"PHASE2":26848,"PHASE3":26850,"PHASE4":26852,"NA":26854},{"trials":26845,"activeCount":104},[],{"trials":26847,"activeCount":104},[],{"trials":26849,"activeCount":104},[],{"trials":26851,"activeCount":104},[],{"trials":26853,"activeCount":104},[],{"trials":26855,"activeCount":104},[26856],{"nctId":26857,"briefTitle":26858,"status":174,"phases":26859,"primaryCompletion":25349,"start":26860,"enrollment":14742,"conditions":26861,"interventions":26863},"NCT01547559","Research for Prevention and Treatment of NSAIDs Related Gastrointestinal Side Effects",[96],"2007-06",[26862],"Non-steroidal Anti-inflammatory Drug Adverse Reaction",[26842,26864,26865,26842,26866],"part1:EAC-T","part1:EA-EMC-T","part2:GGA group",{"intervention":26864,"totalTrials":100,"cells":26868},{"EARLY_PHASE1":26869,"PHASE1":26871,"PHASE2":26873,"PHASE3":26875,"PHASE4":26877,"NA":26879},{"trials":26870,"activeCount":104},[],{"trials":26872,"activeCount":104},[],{"trials":26874,"activeCount":104},[],{"trials":26876,"activeCount":104},[],{"trials":26878,"activeCount":104},[],{"trials":26880,"activeCount":104},[26881],{"nctId":26857,"briefTitle":26858,"status":174,"phases":26882,"primaryCompletion":25349,"start":26860,"enrollment":14742,"conditions":26883,"interventions":26884},[96],[26862],[26842,26864,26865,26842,26866],{"intervention":26865,"totalTrials":100,"cells":26886},{"EARLY_PHASE1":26887,"PHASE1":26889,"PHASE2":26891,"PHASE3":26893,"PHASE4":26895,"NA":26897},{"trials":26888,"activeCount":104},[],{"trials":26890,"activeCount":104},[],{"trials":26892,"activeCount":104},[],{"trials":26894,"activeCount":104},[],{"trials":26896,"activeCount":104},[],{"trials":26898,"activeCount":104},[26899],{"nctId":26857,"briefTitle":26858,"status":174,"phases":26900,"primaryCompletion":25349,"start":26860,"enrollment":14742,"conditions":26901,"interventions":26902},[96],[26862],[26842,26864,26865,26842,26866],{"intervention":26866,"totalTrials":100,"cells":26904},{"EARLY_PHASE1":26905,"PHASE1":26907,"PHASE2":26909,"PHASE3":26911,"PHASE4":26913,"NA":26915},{"trials":26906,"activeCount":104},[],{"trials":26908,"activeCount":104},[],{"trials":26910,"activeCount":104},[],{"trials":26912,"activeCount":104},[],{"trials":26914,"activeCount":104},[],{"trials":26916,"activeCount":104},[26917],{"nctId":26857,"briefTitle":26858,"status":174,"phases":26918,"primaryCompletion":25349,"start":26860,"enrollment":14742,"conditions":26919,"interventions":26920},[96],[26862],[26842,26864,26865,26842,26866],{"intervention":26922,"totalTrials":100,"cells":26923},"PTX 175mg\u002Fm2, DOC 75mg\u002Fm2",{"EARLY_PHASE1":26924,"PHASE1":26926,"PHASE2":26928,"PHASE3":26930,"PHASE4":26932,"NA":26934},{"trials":26925,"activeCount":104},[],{"trials":26927,"activeCount":104},[],{"trials":26929,"activeCount":104},[],{"trials":26931,"activeCount":104},[],{"trials":26933,"activeCount":104},[],{"trials":26935,"activeCount":104},[26936],{"nctId":26937,"briefTitle":26938,"status":174,"phases":26939,"primaryCompletion":1374,"completion":459,"start":1338,"enrollment":189,"conditions":26940,"interventions":26942},"NCT01891123","Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy",[96],[22,28,26941],"Nasal Cancer",[26922],{"intervention":26944,"totalTrials":100,"cells":26945},"α-Keto Acid with restricted protein diet",{"EARLY_PHASE1":26946,"PHASE1":26948,"PHASE2":26950,"PHASE3":26952,"PHASE4":26954,"NA":26956},{"trials":26947,"activeCount":104},[],{"trials":26949,"activeCount":104},[],{"trials":26951,"activeCount":104},[],{"trials":26953,"activeCount":104},[],{"trials":26955,"activeCount":104},[],{"trials":26957,"activeCount":104},[26958],{"nctId":26959,"briefTitle":26960,"status":328,"phases":26961,"primaryCompletion":1427,"completion":1427,"start":25890,"enrollment":734,"conditions":26962,"interventions":26963},"NCT01255020","Renal Protective Effects of Restricted Protein Dietary With α-keto Acid in CAPD Patients",[96],[19393],[26944],{"intervention":26965,"totalTrials":100,"cells":26966},"detection and monitoring of cirulating tumor DNA",{"EARLY_PHASE1":26967,"PHASE1":26969,"PHASE2":26971,"PHASE3":26973,"PHASE4":26975,"NA":26977},{"trials":26968,"activeCount":104},[],{"trials":26970,"activeCount":104},[],{"trials":26972,"activeCount":104},[],{"trials":26974,"activeCount":104},[],{"trials":26976,"activeCount":104},[],{"trials":26978,"activeCount":104},[26979],{"nctId":26980,"briefTitle":26981,"status":174,"phases":26982,"primaryCompletion":721,"completion":721,"start":24507,"enrollment":492,"conditions":26983,"interventions":26985},"NCT05778955","Study on Dynamic CtDNA Analysis in Pediatric Soft Tissue Sarcoma",[],[26984],"Pediatric Soft Tissue Sarcoma",[26965],{"intervention":26987,"totalTrials":100,"cells":26988},"0.1% bromfenac ophthalmic solution",{"EARLY_PHASE1":26989,"PHASE1":26991,"PHASE2":26993,"PHASE3":26995,"PHASE4":26997,"NA":26999},{"trials":26990,"activeCount":104},[],{"trials":26992,"activeCount":104},[],{"trials":26994,"activeCount":104},[],{"trials":26996,"activeCount":104},[],{"trials":26998,"activeCount":104},[],{"trials":27000,"activeCount":104},[27001],{"nctId":27002,"briefTitle":27003,"status":328,"phases":27004,"primaryCompletion":1934,"completion":1934,"start":4644,"enrollment":996,"conditions":27005,"interventions":27006},"NCT02681679","Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery",[96],[31],[26987],{"intervention":27008,"totalTrials":100,"cells":27009},"Erlotinib or Gefitinib",{"EARLY_PHASE1":27010,"PHASE1":27012,"PHASE2":27014,"PHASE3":27016,"PHASE4":27018,"NA":27020},{"trials":27011,"activeCount":104},[],{"trials":27013,"activeCount":104},[],{"trials":27015,"activeCount":104},[],{"trials":27017,"activeCount":104},[],{"trials":27019,"activeCount":104},[],{"trials":27021,"activeCount":104},[27022],{"nctId":27023,"briefTitle":27024,"status":174,"phases":27025,"primaryCompletion":21255,"completion":460,"start":1427,"enrollment":205,"conditions":27026,"interventions":27027},"NCT02013089","A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study",[96],[5201],[27008,27028,27029,27030,27031],"Everolimus","Imatinib","Sorafenib or Sunitinib","Vandetanib",{"intervention":27028,"totalTrials":100,"cells":27033},{"EARLY_PHASE1":27034,"PHASE1":27036,"PHASE2":27038,"PHASE3":27040,"PHASE4":27042,"NA":27044},{"trials":27035,"activeCount":104},[],{"trials":27037,"activeCount":104},[],{"trials":27039,"activeCount":104},[],{"trials":27041,"activeCount":104},[],{"trials":27043,"activeCount":104},[],{"trials":27045,"activeCount":104},[27046],{"nctId":27023,"briefTitle":27024,"status":174,"phases":27047,"primaryCompletion":21255,"completion":460,"start":1427,"enrollment":205,"conditions":27048,"interventions":27049},[96],[5201],[27008,27028,27029,27030,27031],{"intervention":27029,"totalTrials":100,"cells":27051},{"EARLY_PHASE1":27052,"PHASE1":27054,"PHASE2":27056,"PHASE3":27058,"PHASE4":27060,"NA":27062},{"trials":27053,"activeCount":104},[],{"trials":27055,"activeCount":104},[],{"trials":27057,"activeCount":104},[],{"trials":27059,"activeCount":104},[],{"trials":27061,"activeCount":104},[],{"trials":27063,"activeCount":104},[27064],{"nctId":27023,"briefTitle":27024,"status":174,"phases":27065,"primaryCompletion":21255,"completion":460,"start":1427,"enrollment":205,"conditions":27066,"interventions":27067},[96],[5201],[27008,27028,27029,27030,27031],{"intervention":27030,"totalTrials":100,"cells":27069},{"EARLY_PHASE1":27070,"PHASE1":27072,"PHASE2":27074,"PHASE3":27076,"PHASE4":27078,"NA":27080},{"trials":27071,"activeCount":104},[],{"trials":27073,"activeCount":104},[],{"trials":27075,"activeCount":104},[],{"trials":27077,"activeCount":104},[],{"trials":27079,"activeCount":104},[],{"trials":27081,"activeCount":104},[27082],{"nctId":27023,"briefTitle":27024,"status":174,"phases":27083,"primaryCompletion":21255,"completion":460,"start":1427,"enrollment":205,"conditions":27084,"interventions":27085},[96],[5201],[27008,27028,27029,27030,27031],{"intervention":27031,"totalTrials":100,"cells":27087},{"EARLY_PHASE1":27088,"PHASE1":27090,"PHASE2":27092,"PHASE3":27094,"PHASE4":27096,"NA":27098},{"trials":27089,"activeCount":104},[],{"trials":27091,"activeCount":104},[],{"trials":27093,"activeCount":104},[],{"trials":27095,"activeCount":104},[],{"trials":27097,"activeCount":104},[],{"trials":27099,"activeCount":104},[27100],{"nctId":27023,"briefTitle":27024,"status":174,"phases":27101,"primaryCompletion":21255,"completion":460,"start":1427,"enrollment":205,"conditions":27102,"interventions":27103},[96],[5201],[27008,27028,27029,27030,27031],{"intervention":27105,"totalTrials":100,"cells":27106},"Tropicamide",{"EARLY_PHASE1":27107,"PHASE1":27109,"PHASE2":27111,"PHASE3":27113,"PHASE4":27115,"NA":27117},{"trials":27108,"activeCount":104},[],{"trials":27110,"activeCount":104},[],{"trials":27112,"activeCount":104},[],{"trials":27114,"activeCount":104},[],{"trials":27116,"activeCount":104},[],{"trials":27118,"activeCount":104},[27119],{"nctId":27120,"briefTitle":27121,"status":328,"phases":27122,"primaryCompletion":799,"completion":799,"start":1980,"enrollment":492,"conditions":27123,"interventions":27124},"NCT02895074","Subfoveal Choroidal Thickness After Surgery for Age-related Cataracts",[96],[31],[27105,27125],"Proparacaine hydrochloride",{"intervention":27125,"totalTrials":100,"cells":27127},{"EARLY_PHASE1":27128,"PHASE1":27130,"PHASE2":27132,"PHASE3":27134,"PHASE4":27136,"NA":27138},{"trials":27129,"activeCount":104},[],{"trials":27131,"activeCount":104},[],{"trials":27133,"activeCount":104},[],{"trials":27135,"activeCount":104},[],{"trials":27137,"activeCount":104},[],{"trials":27139,"activeCount":104},[27140],{"nctId":27120,"briefTitle":27121,"status":328,"phases":27141,"primaryCompletion":799,"completion":799,"start":1980,"enrollment":492,"conditions":27142,"interventions":27143},[96],[31],[27105,27125],{"intervention":27145,"totalTrials":100,"cells":27146},"Taxane",{"EARLY_PHASE1":27147,"PHASE1":27149,"PHASE2":27151,"PHASE3":27153,"PHASE4":27155,"NA":27157},{"trials":27148,"activeCount":104},[],{"trials":27150,"activeCount":104},[],{"trials":27152,"activeCount":104},[],{"trials":27154,"activeCount":104},[],{"trials":27156,"activeCount":104},[],{"trials":27158,"activeCount":104},[27159],{"nctId":27160,"briefTitle":27161,"status":174,"phases":27162,"primaryCompletion":637,"completion":637,"start":638,"enrollment":996,"conditions":27163,"interventions":27164},"NCT02624531","Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005\u002FCSEM009)",[96],[700],[27145],{"intervention":27166,"totalTrials":100,"cells":27167},"Guideline-driven standard medical therapy",{"EARLY_PHASE1":27168,"PHASE1":27170,"PHASE2":27172,"PHASE3":27174,"PHASE4":27176,"NA":27178},{"trials":27169,"activeCount":104},[],{"trials":27171,"activeCount":104},[],{"trials":27173,"activeCount":104},[],{"trials":27175,"activeCount":104},[],{"trials":27177,"activeCount":104},[],{"trials":27179,"activeCount":104},[27180],{"nctId":27181,"briefTitle":27182,"status":174,"phases":27183,"primaryCompletion":7637,"completion":17319,"start":15560,"enrollment":27184,"conditions":27185,"interventions":27187},"NCT01198405","Study of Enahnced External Counterpulsation to Treat Coronary Heart Disease",[96],1050,[27186],"Coronary Artery Disease",[27166],{"intervention":27189,"totalTrials":100,"cells":27190},"Atezolizumab combined with Bevacizumab",{"EARLY_PHASE1":27191,"PHASE1":27193,"PHASE2":27195,"PHASE3":27197,"PHASE4":27199,"NA":27201},{"trials":27192,"activeCount":104},[],{"trials":27194,"activeCount":104},[],{"trials":27196,"activeCount":104},[],{"trials":27198,"activeCount":104},[],{"trials":27200,"activeCount":104},[],{"trials":27202,"activeCount":104},[27203],{"nctId":27204,"briefTitle":27205,"status":328,"phases":27206,"primaryCompletion":2680,"completion":2680,"start":27207,"enrollment":3189,"conditions":27208,"interventions":27209},"NCT06199297","Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma",[],"2021-03-02",[19],[27189,27210],"Sintilimab combined with Bevacizumab",{"intervention":27210,"totalTrials":100,"cells":27212},{"EARLY_PHASE1":27213,"PHASE1":27215,"PHASE2":27217,"PHASE3":27219,"PHASE4":27221,"NA":27223},{"trials":27214,"activeCount":104},[],{"trials":27216,"activeCount":104},[],{"trials":27218,"activeCount":104},[],{"trials":27220,"activeCount":104},[],{"trials":27222,"activeCount":104},[],{"trials":27224,"activeCount":104},[27225],{"nctId":27204,"briefTitle":27205,"status":328,"phases":27226,"primaryCompletion":2680,"completion":2680,"start":27207,"enrollment":3189,"conditions":27227,"interventions":27228},[],[19],[27189,27210],{"intervention":27230,"totalTrials":100,"cells":27231},"intranasal dexmedetomidine",{"EARLY_PHASE1":27232,"PHASE1":27234,"PHASE2":27236,"PHASE3":27238,"PHASE4":27240,"NA":27242},{"trials":27233,"activeCount":104},[],{"trials":27235,"activeCount":104},[],{"trials":27237,"activeCount":104},[],{"trials":27239,"activeCount":104},[],{"trials":27241,"activeCount":104},[],{"trials":27243,"activeCount":104},[27244],{"nctId":27245,"briefTitle":27246,"status":174,"phases":27247,"primaryCompletion":203,"completion":203,"start":5294,"enrollment":996,"conditions":27248,"interventions":27250},"NCT02077712","Intranasal Dexmedetomidine Sedation for Ophthalmic Examinations in Children",[96],[27249],"Sniffs Drugs",[27230],{"intervention":26126,"totalTrials":100,"cells":27252},{"EARLY_PHASE1":27253,"PHASE1":27255,"PHASE2":27257,"PHASE3":27259,"PHASE4":27261,"NA":27263},{"trials":27254,"activeCount":104},[],{"trials":27256,"activeCount":104},[],{"trials":27258,"activeCount":104},[],{"trials":27260,"activeCount":104},[],{"trials":27262,"activeCount":104},[],{"trials":27264,"activeCount":104},[27265],{"nctId":26120,"briefTitle":26121,"status":174,"phases":27266,"primaryCompletion":3953,"completion":3953,"start":3759,"enrollment":15309,"conditions":27267,"interventions":27268},[96],[31,26124],[26105,26126],{"intervention":27270,"totalTrials":100,"cells":27271},"TTFields",{"EARLY_PHASE1":27272,"PHASE1":27274,"PHASE2":27276,"PHASE3":27278,"PHASE4":27280,"NA":27282},{"trials":27273,"activeCount":104},[],{"trials":27275,"activeCount":104},[],{"trials":27277,"activeCount":104},[],{"trials":27279,"activeCount":104},[],{"trials":27281,"activeCount":104},[],{"trials":27283,"activeCount":104},[27284],{"nctId":27285,"briefTitle":27286,"status":174,"phases":27287,"primaryCompletion":722,"completion":862,"start":2342,"enrollment":492,"conditions":27288,"interventions":27290},"NCT04689087","A Prospective, Open-label, Single-arm Clinical Study",[96],[27289],"Recurrent Glioblastoma Multiforme",[27270],{"intervention":27292,"totalTrials":100,"cells":27293},"interferon α plus nucleoside analogue",{"EARLY_PHASE1":27294,"PHASE1":27296,"PHASE2":27298,"PHASE3":27300,"PHASE4":27302,"NA":27304},{"trials":27295,"activeCount":104},[],{"trials":27297,"activeCount":104},[],{"trials":27299,"activeCount":104},[],{"trials":27301,"activeCount":104},[],{"trials":27303,"activeCount":104},[],{"trials":27305,"activeCount":104},[27306],{"nctId":27307,"briefTitle":27308,"status":174,"phases":27309,"primaryCompletion":3333,"completion":27310,"start":439,"enrollment":205,"conditions":27311,"interventions":27312},"NCT00860626","Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B",[96],"2010-02",[16099],[27292,27313,27313],"interferon α",{"intervention":27313,"totalTrials":100,"cells":27315},{"EARLY_PHASE1":27316,"PHASE1":27318,"PHASE2":27320,"PHASE3":27322,"PHASE4":27324,"NA":27326},{"trials":27317,"activeCount":104},[],{"trials":27319,"activeCount":104},[],{"trials":27321,"activeCount":104},[],{"trials":27323,"activeCount":104},[],{"trials":27325,"activeCount":104},[],{"trials":27327,"activeCount":104},[27328],{"nctId":27307,"briefTitle":27308,"status":174,"phases":27329,"primaryCompletion":3333,"completion":27310,"start":439,"enrollment":205,"conditions":27330,"interventions":27331},[96],[16099],[27292,27313,27313],{"intervention":27333,"totalTrials":100,"cells":27334},"IOP lowering eye drops",{"EARLY_PHASE1":27335,"PHASE1":27337,"PHASE2":27339,"PHASE3":27341,"PHASE4":27343,"NA":27345},{"trials":27336,"activeCount":104},[],{"trials":27338,"activeCount":104},[],{"trials":27340,"activeCount":104},[],{"trials":27342,"activeCount":104},[],{"trials":27344,"activeCount":104},[],{"trials":27346,"activeCount":104},[27347],{"nctId":27348,"briefTitle":27349,"status":174,"phases":27350,"primaryCompletion":21498,"completion":21498,"start":27351,"enrollment":898,"conditions":27352,"interventions":27354},"NCT04296916","Effect of Lowering IOP in Glaucoma Suspects With HM",[96],"2020-04-17",[27353,15334],"Glaucoma, Suspect",[27333],{"intervention":27356,"totalTrials":100,"cells":27357},"DNA extraction and genetic characterization",{"EARLY_PHASE1":27358,"PHASE1":27360,"PHASE2":27362,"PHASE3":27364,"PHASE4":27366,"NA":27368},{"trials":27359,"activeCount":104},[],{"trials":27361,"activeCount":104},[],{"trials":27363,"activeCount":104},[],{"trials":27365,"activeCount":104},[],{"trials":27367,"activeCount":104},[],{"trials":27369,"activeCount":104},[27370],{"nctId":27371,"briefTitle":27372,"status":174,"phases":27373,"primaryCompletion":27374,"completion":27375,"start":19989,"enrollment":15087,"conditions":27376,"interventions":27377},"NCT03515863","Natural History and Risk Factors of TAO",[],"2021-05-09","2022-05-09",[14811],[27356],{"intervention":27379,"totalTrials":100,"cells":27380},"High-dose MTX based chemotherapy",{"EARLY_PHASE1":27381,"PHASE1":27383,"PHASE2":27385,"PHASE3":27387,"PHASE4":27389,"NA":27391},{"trials":27382,"activeCount":104},[],{"trials":27384,"activeCount":104},[],{"trials":27386,"activeCount":104},[],{"trials":27388,"activeCount":104},[],{"trials":27390,"activeCount":104},[],{"trials":27392,"activeCount":104},[27393],{"nctId":27394,"briefTitle":27395,"status":328,"phases":27396,"primaryCompletion":1953,"completion":1953,"start":27397,"enrollment":27398,"conditions":27399,"interventions":27401},"NCT04283955","A Retrospective Cohort Study: The Influence of MTHFR C677T and A1298C on the High-dose Methotrexate-Related Toxicities in Pediatric Patients With Non-Hodgkin Lymphoma",[],"2014-03-01",93,[27400],"Pediatric NHL",[27379],{"intervention":27403,"totalTrials":100,"cells":27404},"GnRH analogue",{"EARLY_PHASE1":27405,"PHASE1":27407,"PHASE2":27409,"PHASE3":27411,"PHASE4":27413,"NA":27415},{"trials":27406,"activeCount":104},[],{"trials":27408,"activeCount":104},[],{"trials":27410,"activeCount":104},[],{"trials":27412,"activeCount":104},[],{"trials":27414,"activeCount":104},[],{"trials":27416,"activeCount":104},[27417],{"nctId":27418,"briefTitle":27419,"status":174,"phases":27420,"primaryCompletion":26235,"completion":63,"start":26236,"enrollment":14982,"conditions":27421,"interventions":27422},"NCT03543059","A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients",[],[28],[27403],{"intervention":27424,"totalTrials":100,"cells":27425},"Liposic",{"EARLY_PHASE1":27426,"PHASE1":27428,"PHASE2":27430,"PHASE3":27432,"PHASE4":27434,"NA":27436},{"trials":27427,"activeCount":104},[],{"trials":27429,"activeCount":104},[],{"trials":27431,"activeCount":104},[],{"trials":27433,"activeCount":104},[],{"trials":27435,"activeCount":104},[],{"trials":27437,"activeCount":104},[27438],{"nctId":27439,"briefTitle":27440,"status":174,"phases":27441,"primaryCompletion":21255,"completion":203,"start":459,"enrollment":205,"conditions":27442,"interventions":27444},"NCT02992392","Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome",[96],[27443],"Dry Eye",[27424,27445],"Tears Naturale Forte",{"intervention":27445,"totalTrials":100,"cells":27447},{"EARLY_PHASE1":27448,"PHASE1":27450,"PHASE2":27452,"PHASE3":27454,"PHASE4":27456,"NA":27458},{"trials":27449,"activeCount":104},[],{"trials":27451,"activeCount":104},[],{"trials":27453,"activeCount":104},[],{"trials":27455,"activeCount":104},[],{"trials":27457,"activeCount":104},[],{"trials":27459,"activeCount":104},[27460],{"nctId":27439,"briefTitle":27440,"status":174,"phases":27461,"primaryCompletion":21255,"completion":203,"start":459,"enrollment":205,"conditions":27462,"interventions":27463},[96],[27443],[27424,27445],{"intervention":27465,"totalTrials":100,"cells":27466},"Take probiotics",{"EARLY_PHASE1":27467,"PHASE1":27469,"PHASE2":27471,"PHASE3":27473,"PHASE4":27475,"NA":27477},{"trials":27468,"activeCount":104},[],{"trials":27470,"activeCount":104},[],{"trials":27472,"activeCount":104},[],{"trials":27474,"activeCount":104},[],{"trials":27476,"activeCount":104},[],{"trials":27478,"activeCount":104},[27479],{"nctId":27480,"briefTitle":27481,"status":174,"phases":27482,"primaryCompletion":4865,"completion":12208,"start":27483,"enrollment":1339,"conditions":27484,"interventions":27485},"NCT05773391","Mechanism Exploration of Anti-HER-2 Small-molecule Tyrosine Kinase Inhibitor-related Diarrhea and Establishment of Prevention and Treatment Model(Measure)",[96],"2023-04-12",[28],[27465],{"intervention":27487,"totalTrials":100,"cells":27488},"Human Insulin",{"EARLY_PHASE1":27489,"PHASE1":27491,"PHASE2":27493,"PHASE3":27495,"PHASE4":27497,"NA":27499},{"trials":27490,"activeCount":104},[],{"trials":27492,"activeCount":104},[],{"trials":27494,"activeCount":104},[],{"trials":27496,"activeCount":104},[],{"trials":27498,"activeCount":104},[],{"trials":27500,"activeCount":104},[27501],{"nctId":27502,"briefTitle":27503,"status":328,"phases":27504,"primaryCompletion":27505,"completion":27505,"start":27506,"enrollment":27507,"conditions":27508,"interventions":27509},"NCT00147836","Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients",[96],"2007-10","2004-09",436,[15670],[27487,27510,27511,27512,27513],"Novolin-R","Human Insulin NPH","Gliclazide","Diamicron and Glucophage",{"intervention":27510,"totalTrials":100,"cells":27515},{"EARLY_PHASE1":27516,"PHASE1":27518,"PHASE2":27520,"PHASE3":27522,"PHASE4":27524,"NA":27526},{"trials":27517,"activeCount":104},[],{"trials":27519,"activeCount":104},[],{"trials":27521,"activeCount":104},[],{"trials":27523,"activeCount":104},[],{"trials":27525,"activeCount":104},[],{"trials":27527,"activeCount":104},[27528],{"nctId":27502,"briefTitle":27503,"status":328,"phases":27529,"primaryCompletion":27505,"completion":27505,"start":27506,"enrollment":27507,"conditions":27530,"interventions":27531},[96],[15670],[27487,27510,27511,27512,27513],{"intervention":27511,"totalTrials":100,"cells":27533},{"EARLY_PHASE1":27534,"PHASE1":27536,"PHASE2":27538,"PHASE3":27540,"PHASE4":27542,"NA":27544},{"trials":27535,"activeCount":104},[],{"trials":27537,"activeCount":104},[],{"trials":27539,"activeCount":104},[],{"trials":27541,"activeCount":104},[],{"trials":27543,"activeCount":104},[],{"trials":27545,"activeCount":104},[27546],{"nctId":27502,"briefTitle":27503,"status":328,"phases":27547,"primaryCompletion":27505,"completion":27505,"start":27506,"enrollment":27507,"conditions":27548,"interventions":27549},[96],[15670],[27487,27510,27511,27512,27513],{"intervention":27512,"totalTrials":100,"cells":27551},{"EARLY_PHASE1":27552,"PHASE1":27554,"PHASE2":27556,"PHASE3":27558,"PHASE4":27560,"NA":27562},{"trials":27553,"activeCount":104},[],{"trials":27555,"activeCount":104},[],{"trials":27557,"activeCount":104},[],{"trials":27559,"activeCount":104},[],{"trials":27561,"activeCount":104},[],{"trials":27563,"activeCount":104},[27564],{"nctId":27502,"briefTitle":27503,"status":328,"phases":27565,"primaryCompletion":27505,"completion":27505,"start":27506,"enrollment":27507,"conditions":27566,"interventions":27567},[96],[15670],[27487,27510,27511,27512,27513],{"intervention":27513,"totalTrials":100,"cells":27569},{"EARLY_PHASE1":27570,"PHASE1":27572,"PHASE2":27574,"PHASE3":27576,"PHASE4":27578,"NA":27580},{"trials":27571,"activeCount":104},[],{"trials":27573,"activeCount":104},[],{"trials":27575,"activeCount":104},[],{"trials":27577,"activeCount":104},[],{"trials":27579,"activeCount":104},[],{"trials":27581,"activeCount":104},[27582],{"nctId":27502,"briefTitle":27503,"status":328,"phases":27583,"primaryCompletion":27505,"completion":27505,"start":27506,"enrollment":27507,"conditions":27584,"interventions":27585},[96],[15670],[27487,27510,27511,27512,27513],{"intervention":5270,"totalTrials":100,"cells":27587},{"EARLY_PHASE1":27588,"PHASE1":27590,"PHASE2":27592,"PHASE3":27594,"PHASE4":27596,"NA":27598},{"trials":27589,"activeCount":104},[],{"trials":27591,"activeCount":104},[],{"trials":27593,"activeCount":104},[],{"trials":27595,"activeCount":104},[],{"trials":27597,"activeCount":104},[],{"trials":27599,"activeCount":104},[27600],{"nctId":5263,"briefTitle":5264,"status":174,"phases":27601,"primaryCompletion":658,"completion":1827,"start":1934,"enrollment":610,"conditions":27602,"interventions":27603},[96],[441],[5268,5269,5270,5271],{"intervention":5271,"totalTrials":100,"cells":27605},{"EARLY_PHASE1":27606,"PHASE1":27608,"PHASE2":27610,"PHASE3":27612,"PHASE4":27614,"NA":27616},{"trials":27607,"activeCount":104},[],{"trials":27609,"activeCount":104},[],{"trials":27611,"activeCount":104},[],{"trials":27613,"activeCount":104},[],{"trials":27615,"activeCount":104},[],{"trials":27617,"activeCount":104},[27618],{"nctId":5263,"briefTitle":5264,"status":174,"phases":27619,"primaryCompletion":658,"completion":1827,"start":1934,"enrollment":610,"conditions":27620,"interventions":27621},[96],[441],[5268,5269,5270,5271],{"intervention":26193,"totalTrials":100,"cells":27623},{"EARLY_PHASE1":27624,"PHASE1":27626,"PHASE2":27628,"PHASE3":27630,"PHASE4":27632,"NA":27634},{"trials":27625,"activeCount":104},[],{"trials":27627,"activeCount":104},[],{"trials":27629,"activeCount":104},[],{"trials":27631,"activeCount":104},[],{"trials":27633,"activeCount":104},[],{"trials":27635,"activeCount":104},[27636],{"nctId":26188,"briefTitle":26189,"status":174,"phases":27637,"primaryCompletion":1827,"completion":818,"start":1575,"enrollment":942,"conditions":27638,"interventions":27639},[96],[15199],[26166,26193],{"intervention":27641,"totalTrials":100,"cells":27642},"MSC",{"EARLY_PHASE1":27643,"PHASE1":27645,"PHASE2":27647,"PHASE3":27649,"PHASE4":27651,"NA":27653},{"trials":27644,"activeCount":104},[],{"trials":27646,"activeCount":104},[],{"trials":27648,"activeCount":104},[],{"trials":27650,"activeCount":104},[],{"trials":27652,"activeCount":104},[],{"trials":27654,"activeCount":104},[27655],{"nctId":27656,"briefTitle":27657,"status":328,"phases":27658,"primaryCompletion":4810,"completion":4810,"start":27659,"enrollment":820,"conditions":27660,"interventions":27661},"NCT01709656","A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis",[96],"2012-03",[15928],[27641,27662],"\"celecoxib\", \"Celebrex®\"",{"intervention":27662,"totalTrials":100,"cells":27664},{"EARLY_PHASE1":27665,"PHASE1":27667,"PHASE2":27669,"PHASE3":27671,"PHASE4":27673,"NA":27675},{"trials":27666,"activeCount":104},[],{"trials":27668,"activeCount":104},[],{"trials":27670,"activeCount":104},[],{"trials":27672,"activeCount":104},[],{"trials":27674,"activeCount":104},[],{"trials":27676,"activeCount":104},[27677],{"nctId":27656,"briefTitle":27657,"status":328,"phases":27678,"primaryCompletion":4810,"completion":4810,"start":27659,"enrollment":820,"conditions":27679,"interventions":27680},[96],[15928],[27641,27662],{"intervention":27682,"totalTrials":100,"cells":27683},"Genotype Detection",{"EARLY_PHASE1":27684,"PHASE1":27686,"PHASE2":27688,"PHASE3":27690,"PHASE4":27692,"NA":27694},{"trials":27685,"activeCount":104},[],{"trials":27687,"activeCount":104},[],{"trials":27689,"activeCount":104},[],{"trials":27691,"activeCount":104},[],{"trials":27693,"activeCount":104},[],{"trials":27695,"activeCount":104},[27696],{"nctId":27697,"briefTitle":27698,"status":328,"phases":27699,"primaryCompletion":1427,"completion":3507,"start":17308,"enrollment":2601,"conditions":27700,"interventions":27702},"NCT01689350","A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment",[96],[27701],"Systemic Lupus Erythematosus",[27682],{"intervention":27704,"totalTrials":100,"cells":27705},"Chemotherapy drug",{"EARLY_PHASE1":27706,"PHASE1":27708,"PHASE2":27710,"PHASE3":27712,"PHASE4":27714,"NA":27716},{"trials":27707,"activeCount":104},[],{"trials":27709,"activeCount":104},[],{"trials":27711,"activeCount":104},[],{"trials":27713,"activeCount":104},[],{"trials":27715,"activeCount":104},[],{"trials":27717,"activeCount":104},[27718],{"nctId":27719,"briefTitle":27720,"status":174,"phases":27721,"primaryCompletion":1827,"completion":1827,"start":1336,"enrollment":27722,"conditions":27723,"interventions":27725},"NCT02964260","RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma",[96],410,[27724],"Hepatocellular Carcinoma, Adult",[27704,27726],"Embolic agents",{"intervention":27726,"totalTrials":100,"cells":27728},{"EARLY_PHASE1":27729,"PHASE1":27731,"PHASE2":27733,"PHASE3":27735,"PHASE4":27737,"NA":27739},{"trials":27730,"activeCount":104},[],{"trials":27732,"activeCount":104},[],{"trials":27734,"activeCount":104},[],{"trials":27736,"activeCount":104},[],{"trials":27738,"activeCount":104},[],{"trials":27740,"activeCount":104},[27741],{"nctId":27719,"briefTitle":27720,"status":174,"phases":27742,"primaryCompletion":1827,"completion":1827,"start":1336,"enrollment":27722,"conditions":27743,"interventions":27744},[96],[27724],[27704,27726],{"intervention":5215,"totalTrials":100,"cells":27746},{"EARLY_PHASE1":27747,"PHASE1":27749,"PHASE2":27751,"PHASE3":27753,"PHASE4":27755,"NA":27757},{"trials":27748,"activeCount":104},[],{"trials":27750,"activeCount":104},[],{"trials":27752,"activeCount":104},[],{"trials":27754,"activeCount":104},[],{"trials":27756,"activeCount":104},[],{"trials":27758,"activeCount":104},[27759],{"nctId":5208,"briefTitle":5209,"status":174,"phases":27760,"primaryCompletion":5211,"completion":5211,"start":4045,"enrollment":996,"conditions":27761,"interventions":27762},[96],[5213],[5138,5215],{"intervention":27764,"totalTrials":100,"cells":27765},"immunosuppressive agent",{"EARLY_PHASE1":27766,"PHASE1":27768,"PHASE2":27770,"PHASE3":27772,"PHASE4":27774,"NA":27776},{"trials":27767,"activeCount":104},[],{"trials":27769,"activeCount":104},[],{"trials":27771,"activeCount":104},[],{"trials":27773,"activeCount":104},[],{"trials":27775,"activeCount":104},[],{"trials":27777,"activeCount":104},[27778],{"nctId":27779,"briefTitle":27780,"status":174,"phases":27781,"primaryCompletion":1459,"completion":302,"start":26622,"enrollment":3748,"conditions":27782,"interventions":27783},"NCT05110040","Multi-model Image of Immunosuppressive Agents in TAO",[96],[14811],[27764],{"intervention":1253,"totalTrials":100,"cells":27785},{"EARLY_PHASE1":27786,"PHASE1":27788,"PHASE2":27790,"PHASE3":27792,"PHASE4":27794,"NA":27796},{"trials":27787,"activeCount":104},[],{"trials":27789,"activeCount":104},[],{"trials":27791,"activeCount":104},[],{"trials":27793,"activeCount":104},[],{"trials":27795,"activeCount":104},[],{"trials":27797,"activeCount":104},[27798],{"nctId":1244,"briefTitle":1245,"status":328,"phases":27799,"primaryCompletion":923,"completion":73,"start":1247,"enrollment":1248,"conditions":27800,"interventions":27801},[],[19,1250,1251],[353,1253,268,1254,284,483,69],{"intervention":1254,"totalTrials":100,"cells":27803},{"EARLY_PHASE1":27804,"PHASE1":27806,"PHASE2":27808,"PHASE3":27810,"PHASE4":27812,"NA":27814},{"trials":27805,"activeCount":104},[],{"trials":27807,"activeCount":104},[],{"trials":27809,"activeCount":104},[],{"trials":27811,"activeCount":104},[],{"trials":27813,"activeCount":104},[],{"trials":27815,"activeCount":104},[27816],{"nctId":1244,"briefTitle":1245,"status":328,"phases":27817,"primaryCompletion":923,"completion":73,"start":1247,"enrollment":1248,"conditions":27818,"interventions":27819},[],[19,1250,1251],[353,1253,268,1254,284,483,69],{"intervention":27821,"totalTrials":100,"cells":27822},"ctDNA detection",{"EARLY_PHASE1":27823,"PHASE1":27825,"PHASE2":27827,"PHASE3":27829,"PHASE4":27831,"NA":27833},{"trials":27824,"activeCount":104},[],{"trials":27826,"activeCount":104},[],{"trials":27828,"activeCount":104},[],{"trials":27830,"activeCount":104},[],{"trials":27832,"activeCount":104},[],{"trials":27834,"activeCount":104},[27835],{"nctId":27836,"briefTitle":27837,"status":328,"phases":27838,"primaryCompletion":8200,"completion":8200,"start":4459,"enrollment":1339,"conditions":27839,"interventions":27841},"NCT03172156","ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS",[],[27840],"Non-small Cell Lung Cancer Stage I",[27821],{"intervention":26021,"totalTrials":100,"cells":27843},{"EARLY_PHASE1":27844,"PHASE1":27846,"PHASE2":27848,"PHASE3":27850,"PHASE4":27852,"NA":27854},{"trials":27845,"activeCount":104},[],{"trials":27847,"activeCount":104},[],{"trials":27849,"activeCount":104},[],{"trials":27851,"activeCount":104},[],{"trials":27853,"activeCount":104},[],{"trials":27855,"activeCount":104},[27856],{"nctId":26016,"briefTitle":26017,"status":328,"phases":27857,"primaryCompletion":4644,"completion":4644,"start":15560,"enrollment":1192,"conditions":27858,"interventions":27859},[96],[19393],[26021,26022,26023,17964],{"intervention":26022,"totalTrials":100,"cells":27861},{"EARLY_PHASE1":27862,"PHASE1":27864,"PHASE2":27866,"PHASE3":27868,"PHASE4":27870,"NA":27872},{"trials":27863,"activeCount":104},[],{"trials":27865,"activeCount":104},[],{"trials":27867,"activeCount":104},[],{"trials":27869,"activeCount":104},[],{"trials":27871,"activeCount":104},[],{"trials":27873,"activeCount":104},[27874],{"nctId":26016,"briefTitle":26017,"status":328,"phases":27875,"primaryCompletion":4644,"completion":4644,"start":15560,"enrollment":1192,"conditions":27876,"interventions":27877},[96],[19393],[26021,26022,26023,17964],{"intervention":26023,"totalTrials":100,"cells":27879},{"EARLY_PHASE1":27880,"PHASE1":27882,"PHASE2":27884,"PHASE3":27886,"PHASE4":27888,"NA":27890},{"trials":27881,"activeCount":104},[],{"trials":27883,"activeCount":104},[],{"trials":27885,"activeCount":104},[],{"trials":27887,"activeCount":104},[],{"trials":27889,"activeCount":104},[],{"trials":27891,"activeCount":104},[27892],{"nctId":26016,"briefTitle":26017,"status":328,"phases":27893,"primaryCompletion":4644,"completion":4644,"start":15560,"enrollment":1192,"conditions":27894,"interventions":27895},[96],[19393],[26021,26022,26023,17964],{"intervention":27897,"totalTrials":100,"cells":27898},"Hylo-Comod eye drop",{"EARLY_PHASE1":27899,"PHASE1":27901,"PHASE2":27903,"PHASE3":27905,"PHASE4":27907,"NA":27909},{"trials":27900,"activeCount":104},[],{"trials":27902,"activeCount":104},[],{"trials":27904,"activeCount":104},[],{"trials":27906,"activeCount":104},[],{"trials":27908,"activeCount":104},[],{"trials":27910,"activeCount":104},[27911],{"nctId":27912,"briefTitle":27913,"status":174,"phases":27914,"primaryCompletion":3747,"completion":3747,"start":1374,"enrollment":942,"conditions":27915,"interventions":27917},"NCT02817191","Effects of Holy-Comod and Tears Naturale Forte in Patients After Phaco+IOL",[96],[27916],"Age-related Cataract",[27897,27918],"Tears Naturale Forte eye drop",{"intervention":27918,"totalTrials":100,"cells":27920},{"EARLY_PHASE1":27921,"PHASE1":27923,"PHASE2":27925,"PHASE3":27927,"PHASE4":27929,"NA":27931},{"trials":27922,"activeCount":104},[],{"trials":27924,"activeCount":104},[],{"trials":27926,"activeCount":104},[],{"trials":27928,"activeCount":104},[],{"trials":27930,"activeCount":104},[],{"trials":27932,"activeCount":104},[27933],{"nctId":27912,"briefTitle":27913,"status":174,"phases":27934,"primaryCompletion":3747,"completion":3747,"start":1374,"enrollment":942,"conditions":27935,"interventions":27936},[96],[27916],[27897,27918],{"intervention":27938,"totalTrials":100,"cells":27939},"Nucleotide Analog",{"EARLY_PHASE1":27940,"PHASE1":27942,"PHASE2":27944,"PHASE3":27946,"PHASE4":27948,"NA":27950},{"trials":27941,"activeCount":104},[],{"trials":27943,"activeCount":104},[],{"trials":27945,"activeCount":104},[],{"trials":27947,"activeCount":104},[],{"trials":27949,"activeCount":104},[],{"trials":27951,"activeCount":104},[27952],{"nctId":27953,"briefTitle":27954,"status":174,"phases":27955,"primaryCompletion":290,"completion":1238,"start":535,"enrollment":15087,"conditions":27956,"interventions":27957},"NCT03771677","To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr \u002FISGs.",[96],[5213],[27938,27958],"Interferon Alfa-2A",{"intervention":27958,"totalTrials":100,"cells":27960},{"EARLY_PHASE1":27961,"PHASE1":27963,"PHASE2":27965,"PHASE3":27967,"PHASE4":27969,"NA":27971},{"trials":27962,"activeCount":104},[],{"trials":27964,"activeCount":104},[],{"trials":27966,"activeCount":104},[],{"trials":27968,"activeCount":104},[],{"trials":27970,"activeCount":104},[],{"trials":27972,"activeCount":104},[27973],{"nctId":27953,"briefTitle":27954,"status":174,"phases":27974,"primaryCompletion":290,"completion":1238,"start":535,"enrollment":15087,"conditions":27975,"interventions":27976},[96],[5213],[27938,27958],{"intervention":27978,"totalTrials":100,"cells":27979},"intravitreal injection of conbercept",{"EARLY_PHASE1":27980,"PHASE1":27982,"PHASE2":27984,"PHASE3":27986,"PHASE4":27988,"NA":27990},{"trials":27981,"activeCount":104},[],{"trials":27983,"activeCount":104},[],{"trials":27985,"activeCount":104},[],{"trials":27987,"activeCount":104},[],{"trials":27989,"activeCount":104},[],{"trials":27991,"activeCount":104},[27992],{"nctId":27993,"briefTitle":27994,"status":174,"phases":27995,"primaryCompletion":1827,"completion":1827,"start":1449,"enrollment":5763,"conditions":27996,"interventions":27997},"NCT02911311","Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy",[96],[25859],[27978],{"intervention":26163,"totalTrials":100,"cells":27999},{"EARLY_PHASE1":28000,"PHASE1":28002,"PHASE2":28004,"PHASE3":28006,"PHASE4":28008,"NA":28010},{"trials":28001,"activeCount":104},[],{"trials":28003,"activeCount":104},[],{"trials":28005,"activeCount":104},[],{"trials":28007,"activeCount":104},[],{"trials":28009,"activeCount":104},[],{"trials":28011,"activeCount":104},[28012],{"nctId":26157,"briefTitle":26158,"status":174,"phases":28013,"primaryCompletion":819,"completion":3759,"start":3382,"enrollment":1248,"conditions":28014,"interventions":28015},[96],[26161],[26134,26163,26164],{"intervention":26164,"totalTrials":100,"cells":28017},{"EARLY_PHASE1":28018,"PHASE1":28020,"PHASE2":28022,"PHASE3":28024,"PHASE4":28026,"NA":28028},{"trials":28019,"activeCount":104},[],{"trials":28021,"activeCount":104},[],{"trials":28023,"activeCount":104},[],{"trials":28025,"activeCount":104},[],{"trials":28027,"activeCount":104},[],{"trials":28029,"activeCount":104},[28030],{"nctId":26157,"briefTitle":26158,"status":174,"phases":28031,"primaryCompletion":819,"completion":3759,"start":3382,"enrollment":1248,"conditions":28032,"interventions":28033},[96],[26161],[26134,26163,26164],{"intervention":28035,"totalTrials":100,"cells":28036},"Medical therapy",{"EARLY_PHASE1":28037,"PHASE1":28039,"PHASE2":28041,"PHASE3":28043,"PHASE4":28045,"NA":28047},{"trials":28038,"activeCount":104},[],{"trials":28040,"activeCount":104},[],{"trials":28042,"activeCount":104},[],{"trials":28044,"activeCount":104},[],{"trials":28046,"activeCount":104},[],{"trials":28048,"activeCount":104},[28049],{"nctId":28050,"briefTitle":28051,"status":328,"phases":28052,"primaryCompletion":9404,"completion":3790,"start":28053,"enrollment":1460,"conditions":28054,"interventions":28055},"NCT03102502","Impact of Enhanced External Counterpulsation on Vascular Hemodynamics and Status",[96],"2017-03-10",[26671],[28035],{"intervention":14382,"totalTrials":100,"cells":28057},{"EARLY_PHASE1":28058,"PHASE1":28060,"PHASE2":28062,"PHASE3":28064,"PHASE4":28066,"NA":28068},{"trials":28059,"activeCount":104},[],{"trials":28061,"activeCount":104},[],{"trials":28063,"activeCount":104},[],{"trials":28065,"activeCount":104},[],{"trials":28067,"activeCount":104},[],{"trials":28069,"activeCount":104},[28070],{"nctId":14375,"briefTitle":14376,"status":174,"phases":28071,"primaryCompletion":290,"completion":1238,"start":14378,"enrollment":1228,"conditions":28072,"interventions":28073},[96],[14380,19],[14382,13412],{"intervention":28075,"totalTrials":100,"cells":28076},"ICI",{"EARLY_PHASE1":28077,"PHASE1":28079,"PHASE2":28081,"PHASE3":28083,"PHASE4":28085,"NA":28087},{"trials":28078,"activeCount":104},[],{"trials":28080,"activeCount":104},[],{"trials":28082,"activeCount":104},[],{"trials":28084,"activeCount":104},[],{"trials":28086,"activeCount":104},[],{"trials":28088,"activeCount":104},[28089],{"nctId":28090,"briefTitle":28091,"status":174,"phases":28092,"primaryCompletion":721,"completion":721,"start":28093,"enrollment":15152,"conditions":28094,"interventions":28095},"NCT04680598","Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study",[],"2020-12-25",[19],[28075,28096],"Antiviral Prophylaxis",{"intervention":28096,"totalTrials":100,"cells":28098},{"EARLY_PHASE1":28099,"PHASE1":28101,"PHASE2":28103,"PHASE3":28105,"PHASE4":28107,"NA":28109},{"trials":28100,"activeCount":104},[],{"trials":28102,"activeCount":104},[],{"trials":28104,"activeCount":104},[],{"trials":28106,"activeCount":104},[],{"trials":28108,"activeCount":104},[],{"trials":28110,"activeCount":104},[28111],{"nctId":28090,"briefTitle":28091,"status":174,"phases":28112,"primaryCompletion":721,"completion":721,"start":28093,"enrollment":15152,"conditions":28113,"interventions":28114},[],[19],[28075,28096]]